0000950170-24-12340310-Q Sight Sciences, Inc. 20241107202411071624351624351624351

results, revised expectations, or the occurrence of unanticipated events, except as required by law. We may not actually achieve the plans, intentions or expectations disclosed in our forward-looking statements, and you should not place undue reliance on our forward-looking statements. Â Â 4 Â PART 1. FINANCIAL INFORMATION Â Item 1. Financial Statements Â SIGHT SCIENCES, INC. Condensed Consolidated Balance Sheets (Unaudited) (in thousands, except share and per share data) Â Â Â September 30, Â Â December 31, Â Â Â 2024 Â Â 2023 Â Assets Â Â Â Â Â Â Current assets: Â Â Â Â Â Â Cash and cash equivalents Â $ 118,564 Â Â $ 138,129 Â Accounts receivable, net of allowance for credit losses of $824Â and $1,186Â at September 30, 2024 and December 31, 2023, respectively Â Â 12,929 Â Â Â 14,289 Â Inventory, net Â Â 6,091 Â Â Â 7,849 Â Prepaid expenses and other current assets Â Â 2,885 Â Â Â 2,604 Â Total current assets Â Â 140,469 Â Â Â 162,871 Â Property and equipment, net Â Â 1,448 Â Â Â 1,640 Â Operating lease right-of-use assets Â Â 1,100 Â Â Â 1,458 Â Other noncurrent assets Â Â 580 Â Â Â 682 Â Total assets Â $ 143,597 Â Â $ 166,651 Â Liabilities and stockholdersâ€™ equity Â Â Â Â Â Â Current liabilities: Â Â Â Â Â Â Accounts payable Â $ 1,297 Â Â $ 1,731 Â Accrued compensation Â Â 7,889 Â Â Â 4,528 Â Accrued and other current liabilities Â Â 4,613 Â Â Â 3,774 Â Current portion - long-term debt, net Â Â â€” Â Â Â 2,219 Â Total current liabilities Â Â 13,799 Â Â Â 12,252 Â Â Â Â Â Â Long-term debt, net Â Â 34,152 Â Â Â 31,708 Â Other noncurrent liabilities Â Â 689 Â Â Â 2,476 Â Total liabilities Â Â 48,640 Â Â Â 46,436 Â Commitments and contingencies (Note 6) Â Â Â Â Â Â Stockholdersâ€™ equity: Â Â Â Â Â Â Preferred stock, par value $0.001Â per share; 10,000,000Â shares authorized; noÂ shares issued and outstanding as of September 30, 2024 and December 31, 2023 Â Â â€” Â Â Â â€” Â Common stock, par value $0.001Â per share; 200,000,000Â shares authorized; 50,398,148Â and 49,131,363Â shares issued and outstanding as of September 30, 2024 and December 31, 2023, respectively Â Â 50 Â Â Â 49 Â Additional paid-in-capital Â Â 429,358 Â Â Â 414,956 Â Accumulated deficit Â Â (334,451) Â Â (294,790) Total stockholdersâ€™ equity Â Â 94,957 Â Â Â 120,215 Â Total liabilities and stockholdersâ€™ equity Â $ 143,597 Â Â $ 166,651 Â Â The accompanying notes are an integral part of these condensed consolidated financial statements. Â 5 Â SIGHT SCIENCES, INC. Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) (in thousands, except share and per share data) Â Â Â Three Months Ended September 30, Â Â Nine Months Ended September 30, Â Â Â 2024 Â Â 2023 Â Â 2024 Â Â 2023 Â Revenue Â $ 20,157 Â Â $ 20,009 Â Â $ 60,792 Â Â $ 62,305 Â Cost of goods sold Â Â 3,250 Â Â Â 2,677 Â Â Â 9,068 Â Â Â 9,105 Â Gross profit Â Â 16,907 Â Â Â 17,332 Â Â Â 51,724 Â Â Â 53,200 Â Operating expenses: Â Â Â Â Â Â Â Â Â Â Â Â Research and development Â Â 4,746 Â Â Â 4,239 Â Â Â 13,698 Â Â Â 14,129 Â Selling, general and administrative Â Â 23,390 Â Â Â 26,504 Â Â Â 76,629 Â Â Â 85,235 Â Total operating expenses Â Â 28,136 Â Â Â 30,743 Â Â Â 90,327 Â Â Â 99,364 Â Loss from operations Â Â (11,229) Â Â (13,411) Â Â (38,603) Â Â (46,164) Investment income Â Â 1,454 Â Â Â 1,897 Â Â Â 4,628 Â Â Â 5,499 Â Interest expense Â Â (1,151) Â Â (1,432) Â Â (3,501) Â Â (4,057) Loss on debt extinguishment Â Â â€” Â Â Â â€” Â Â Â (1,962) Â Â â€” Â Other income (expense), net Â Â 26 Â Â Â (11) Â Â Â (25) Â Â Â (34) Loss before income taxes Â Â (10,900) Â Â (12,957) Â Â (39,463) Â Â (44,756) Provision for income taxes Â Â 166 Â Â Â 78 Â Â Â 198 Â Â Â 100 Â Net loss and comprehensive loss Â $ (11,066) Â $ (13,035) Â $ (39,661) Â $ (44,856) Net loss per share attributable to common stockholders, basic and diluted Â $ (0.22) Â $ (0.27) Â $ (0.79) Â $ (0.92) Weighted-average shares used in computing net loss per share attributable to common stockholders, basic and diluted Â Â 50,340,603 Â Â Â 48,671,049 Â Â Â 49,911,655 Â Â Â 48,538,517 Â Â The accompanying notes are an integral part of these condensed consolidated financial statements. Â 6 Â SIGHT SCIENCES, INC. Condensed Consolidated Statements of Stockholdersâ€™ Equity (Unaudited) (in thousands, except share data) Â Â Â Three Months Ended September 30, 2024 Â Â Â Common Stock Â Â AdditionalPaid-In Â Â Accumulated Â Â TotalStockholdersâ€™ Â Â Â Shares Â Â Amount Â Â Capital Â Â Deficit Â Â Equity Â Balance at June 30, 2024 Â Â 50,136,131 Â Â Â $ 50 Â Â Â $ 424,973 Â Â Â $ (323,385) Â $ 101,638 Â Issuance of common stock upon exercise of stock options Â Â 38,936 Â Â Â â€” Â Â Â 77 Â Â Â â€” Â Â Â 77 Â Issuance of common stock upon vesting of restricted stock units Â Â 223,081 Â Â Â â€” Â Â Â â€” Â Â Â â€” Â Â Â â€” Â Stock-based compensation expense Â Â â€” Â Â Â 4,308 Â Â Â â€” Â Â Â 4,308 Â Net loss Â Â â€” Â Â Â â€” Â Â Â â€” Â Â Â (11,066) Â Â (11,066) Balance at September 30, 2024 Â Â 50,398,148 Â Â Â 50 Â Â Â 429,358 Â Â Â (334,451) Â Â 94,957 Â Â Â Â Nine Months Ended September 30, 2024 Â Â Â Common Stock Â Â AdditionalPaid-In Â Â Accumulated Â Â TotalStockholdersâ€™ Â Â Â Shares Â Â Amount Â Â Capital Â Â Deficit Â Â Equity Â Balance at December 31, 2023 Â Â 49,131,363 Â Â Â $ 49 Â Â Â $ 414,956 Â Â Â $ (294,790) Â $ 120,215 Â Issuance of common stock upon exercise of stock options Â Â 194,119 Â Â Â â€” Â Â Â 233 Â Â Â â€” Â Â Â 233 Â Issuance of common stock upon vesting of restricted stock units Â Â 840,376 Â Â Â 1 Â Â Â (1) Â Â â€” Â Â Â â€” Â Withholding taxes on net share settlement of restricted stock units Â Â â€” Â Â Â â€” Â Â Â (20) Â Â â€” Â Â Â (20) Warrant issuance Â Â â€” Â Â Â â€” Â Â Â 609 Â Â Â â€” Â Â Â 609 Â Employee stock purchase plan purchases Â Â 232,290 Â Â Â â€” Â Â Â 450 Â Â Â â€” Â Â Â 450 Â Stock-based compensation expense Â Â â€” Â Â Â â€” Â Â Â 13,131 Â Â Â â€” Â Â Â 13,131 Â Net loss Â Â â€” Â Â Â â€” Â Â Â â€” Â Â Â (39,661) Â Â (39,661) Balance at September 30, 2024 Â Â 50,398,148 Â Â Â 50 Â Â Â 429,358 Â Â Â (334,451) Â Â 94,957 Â Â Â The accompanying notes are an integral part of these condensed consolidated financial statements. Â Â Â Â 7 Â Â Â Three Months Ended September 30, 2023 Â Â Â Common Stock Â Â AdditionalPaid-In Â Â Accumulated Â Â TotalStockholdersâ€™ Â Â Â Shares Â Â Amount Â Â Capital Â Â Deficit Â Â Equity Â Balance at June 30, 2023 Â Â 48,649,343 Â Â Â $ 49 Â Â Â $ 407,146 Â Â Â $ (271,064) Â $ 136,131 Â Issuance of common stock upon exercise of stock options Â Â 60,738 Â Â Â â€” Â Â Â 117 Â Â Â â€” Â Â Â 117 Â Issuance of common stock upon vesting of restricted stock units Â Â 12,138 Â Â Â â€” Â Â Â â€” Â Â Â â€” Â Â Â â€” Â Stock-based compensation expense Â Â â€” Â Â Â 3,856 Â Â Â â€” Â Â Â 3,856 Â Net loss Â Â â€” Â Â Â â€” Â Â Â â€” Â Â Â (13,035) Â Â (13,035) Balance at September 30, 2023 Â Â 48,722,219 Â Â Â 49 Â Â Â 411,119 Â Â Â (284,099) Â Â 127,069 Â Â Â Â Nine Months Ended September 30, 2023 Â Â Â Common Stock Â Â AdditionalPaid-In Â Â Accumulated Â Â TotalStockholdersâ€™ Â Â Â Shares Â Â Amount Â Â Capital Â Â Deficit Â Â Equity Â Balance at December 31, 2022 Â Â 48,298,138 Â Â Â $ 48 Â Â Â $ 399,271 Â Â Â $ (239,243) Â $ 160,076 Â Issuance of common stock upon exercise of stock options Â Â 163,940 Â Â Â â€” Â Â Â 288 Â Â Â â€” Â Â Â 288 Â Issuance of common stock upon vesting of restricted stock units Â Â 181,607 Â Â Â 1 Â Â Â â€” Â Â Â â€” Â Â Â 1 Â Withholding taxes of net share settlement of restricted stock units Â Â â€” Â Â Â â€” Â Â Â (222) Â Â â€” Â Â Â (222) Employee stock purchase plan purchases Â Â 78,534 Â Â Â â€” Â Â Â 661 Â Â Â â€” Â Â Â 661 Â Stock-based compensation expense Â Â â€” Â Â Â â€” Â Â Â 11,121 Â Â Â â€” Â Â Â 11,121 Â Net loss Â Â â€” Â Â Â â€” Â Â Â â€” Â Â Â (44,856) Â Â (44,856) Balance at September 30, 2023 Â Â 48,722,219 Â Â Â 49 Â Â Â 411,119 Â Â Â (284,099) Â Â 127,069 Â Â The accompanying notes are an integral part of these condensed consolidated financial statements. Â 8 Â SIGHT SCIENCES, INC. Condensed Consolidated Statements of Cash Flows (Unaudited) (in thousands) Â Â Â Nine Months Ended Â Â Â September 30, Â Â Â 2024 Â Â 2023 Â Cash flows from operating activities Â Â Â Â Â Â Net loss Â $ (39,661) Â $ (44,856) Adjustments to reconcile net loss to net cash used in operating activities: Â Â Â Â Â Â Depreciation and amortization Â Â 536 Â Â Â 455 Â Accretion of debt discount and debt issuance costs Â Â 550 Â Â Â 452 Â Stock-based compensation expense Â Â 13,131 Â Â Â 11,121 Â Allowance for credit losses Â Â (68) Â Â 416 Â Provision (benefit) for excess and obsolete inventories Â Â (105) Â Â 219 Â Noncash operating lease expense Â Â 481 Â Â Â 743 Â Loss on disposal of property and equipment Â Â 23 Â Â Â 66 Â Noncash loss on debt extinguishment Â Â 1,033 Â Â Â â€” Â Changes in operating assets and liabilities: Â Â Â Â Â Â Accounts receivable Â Â 1,427 Â Â Â (2,187) Inventory Â Â 1,863 Â Â Â (3,345) Prepaid expenses and other current assets Â Â (280) Â Â 517 Â Other noncurrent assets Â Â (35) Â Â (444) Accounts payable Â Â (41) Â Â 841 Â Accrued compensation Â Â 3,360 Â Â Â (1,851) Accrued and other current liabilities Â Â 418 Â Â Â (3,089) Other noncurrent liabilities Â Â (1,524) Â Â 242 Â Net cash used in operating activities Â Â (18,892) Â Â (40,700) Cash flows from investing activities Â Â Â Â Â Â Purchases of property and equipment Â Â (248) Â Â (527) Net cash used in investing activities Â Â (248) Â Â (527) Cash flows from financing activities Â Â Â Â Â Â Net proceeds from Hercules Loan Agreement Â Â 34,526 Â Â Â â€” Â Repayment of MidCap Loan Agreement Â Â (35,375) Â Â â€” Â Debt issuance costs Â Â (238) Â Â â€” Â Proceeds from employee stock purchase plan purchases Â Â 450 Â Â Â 289 Â Taxes paid on net share settlement of restricted stock units Â Â (20) Â Â (222) Proceeds from exercise of common stock options Â Â 232 Â Â Â 661 Â Net cash (used in) provided by financing activities Â Â (425) Â Â 728 Â Net change in cash and cash equivalents Â Â (19,565) Â Â (40,499) Cash and cash equivalents at beginning of period Â Â 138,129 Â Â Â 185,000 Â Cash and cash equivalents at end of period Â $ 118,564 Â Â $ 144,501 Â Â Â Â Â Â Â Â Supplemental disclosure of cash flow information Â Â Â Â Â Â Cash paid for interest Â $ 3,023 Â Â $ 3,167 Â Supplemental noncash disclosure of investing and financing activities Â Â Â Â Â Â Acquisition of property and equipment included in accounts payable and accrued liabilities Â $ 43 Â Â $ 81 Â Common stock warrants issued upon execution of Hercules Loan Agreement Â $ 609 Â Â $ â€” Â Â The accompanying notes are an integral part of these condensed consolidated financial statements. Â 9 Â SIGHT SCIENCES, INC. Notes to Condensed Consolidated Financial Statements (Unaudited) Â Note 1. Company and Nature of BusinessÂ Description of BusinessSight Sciences, Inc. (the â€œCompanyâ€) was incorporated in the State of Delaware in 2010 and is headquartered in Menlo Park, California. The Company is an ophthalmic medical device company focused on the development and commercialization of surgical and nonsurgical technologies for the treatment of prevalent eye diseases. The Companyâ€™s mission is to develop transformative, interventional technologies that allow eyecare providers to procedurally elevate the standards of care â€” empowering people to keep seeing. The Company's product portfolio aligns with its two reportable operating segments: Surgical Glaucoma and Dry Eye. The products for the Surgical Glaucoma segment include the OMNIÂ® Surgical System ("OMNI"), which is an implant-free, handheld, single-use, therapeutic technology that enables ophthalmic surgeons to perform a comprehensive procedure (i) indicated in the United States to reduce intraocular pressure in adult patients with primary open-angle glaucoma, and (ii) CE Marked for the catheterization and transluminal viscodilation of Schlemmâ€™s canal and cutting of the trabecular meshwork to reduce intraocular pressure in adult patients with open-angle glaucoma; and the SIONÂ® Surgical Instrument ("SION"), a bladeless, manually operated device used in ophthalmic surgical procedures to excise trabecular meshwork. The product portfolio for the Dry Eye segment consists of the TearCareÂ® System ("TearCare") for ophthalmologists and optometrists. TearCare is a proprietary, interventional, dry eye device designed to melt and facilitate the comprehensive removal of meibomian gland obstructions and restore gland functionality and healthy oil production for adult patients with evaporative dry eye disease due to meibomian gland dysfunction (â€œMGDâ€) when used in conjunction with manual expression of the meibomian glands, enabling clearance of gland obstructions by physicians to address the leading cause of dry eye disease.Significant Risks and UncertaintiesSince inception, the Company has incurred losses and negative cash flows from operations. As of September 30, 2024, the Company had an accumulated deficit of $334.5 million since inception and recorded a net loss of $39.7 million for the nine months then ended and expects to incur additional losses in the future. If the Companyâ€™s revenue levels from its products are not sufficient or if the Company is unable to secure additional funding when desired, the Company may need to delay the development of its products, scale back its business and operations, or change its business strategy.The Company believes that its existing sources of liquidity will satisfy its working capital and capital requirements for at least 12 months from the issuance of its unaudited condensed consolidated financial statements. Any failure to generate increased revenue, achieve improved gross margins, or control operating costs could require the Company to raise additional capital through equity or debt financing. Such additional financing may not be available on acceptable terms, or at all, and could require the Company to modify, delay, or abandon some of its planned future expansion or expenditures or reduce some of its ongoing operating costs, which could harm its business, operating results, financial condition, and ability to achieve its intended business objectives. Note 2. Summary of Significant Accounting PoliciesBasis of PresentationThe condensed consolidated financial statements and accompanying notes thereto are unaudited and have been prepared in accordance with accounting principles generally accepted in the United States of America ("US GAAP") applicable to interim periods and pursuant to the instructions to Form 10-Q and Article 10 of Regulation S-X. The Companyâ€™s condensed consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries, Sight Sciences UK, Ltd and Sight Sciences GmbH. All intercompany balances and transactions have been eliminated in consolidation. The unaudited condensed consolidated financial statements have been prepared on a basis consistent with the audited consolidated financial statements. In the opinion of management, the unaudited condensed consolidated financial statements reflect all adjustments, which include only normal recurring adjustments, necessary for the fair Â 10 Â presentation of the Company's financial information contained herein. The condensed consolidated balance sheet as of December 31, 2023 is derived from the Company's consolidated audited financial statements as of that date. These interim condensed consolidated financial statements do not include all disclosures required by US GAAP and should be read in conjunction with the Company's audited consolidated financial statements and the accompanying notes thereto for the fiscal year ended December 31, 2023, which are contained in the Annual Report. The Company's results of operations for the nine months ended September 30, 2024 are not necessarily indicative of the results to be expected for the year ending December 31, 2024 or for any other interim period. Use of EstimatesThe preparation of the unaudited condensed consolidated financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent liabilities at the date of the financial statements, and the reported amounts of revenues and expense during the reporting period. The most significant estimates related to the provision for credit losses, inventory excess and obsolescence, determination of the fair value of stock option grants, and provisions for income taxes and contingencies. Management evaluates its estimates and assumptions on an ongoing basis using historical experience and other factors, including the current economic environment, and makes adjustments when facts and circumstances dictate. These estimates are based on information available as of the date of the financial statements. Actual results could differ from these estimates and such differences could be material to the Companyâ€™s financial position and results of operations.New Accounting PronouncementsAccounting Standards Recently AdoptedDuring the nine-month period ended September 30, 2024, there were no significant Accounting Standard Updates ("ASUs") issued that were adopted. Accounting Standards Not Yet AdoptedIn November 2023, the Financial Accounting Standards Board ("FASB") issued ASU No. 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures. The ASU updates reportable segment disclosure requirements, primarily through requiring enhanced disclosures about significant segment expenses and information used to assess segment performance. The ASU is effective on a retrospective basis for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024, with early adoption permitted. The Company is currently evaluating the impact of adopting this ASU on its disclosures. In December 2023, the FASB issued ASU No. 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures. The ASU includes amendments requiring enhanced income tax disclosures, primarily related to standardization and disaggregation of rate reconciliation categories and income taxes paid by jurisdiction. The guidance is effective for fiscal years beginning after December 15, 2024, with early adoption permitted, and should be applied either prospectively or retrospectively. The Company is currently evaluating the impact of adopting this ASU on its disclosures.As of September 30, 2024, there are no additional ASUs issued and not yet adopted that are expected to have a material impact on the Company's financial statements and related disclosures. Note 3. Fair Value MeasurementsThe Company reports all financial assets and liabilities and nonfinancial assets and liabilities that are recognized or disclosed at fair value in the financial statements on a recurring basis. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. The authoritative guidance establishes a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to measurements involving significant unobservable inputs (Level 3 measurements). The three levels of the fair value hierarchy are as follows:Level 1â€”Inputs are quoted prices (unadjusted) in active markets for identical assets or liabilities that the Company has the ability to access at the measurement date. Â 11 Â Level 2â€”Inputs are observable, unadjusted quoted prices in active markets for similar assets or liabilities, unadjusted quoted prices for identical or similar assets or liabilities in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the related assets or liabilities.Level 3â€”Inputs are unobservable inputs for the asset or liability. The level in the fair value hierarchy within which a fair value measurement in its entirety is based on the lowest-level input that is significant to the fair value measurement in its entirety.The Company's cash and cash equivalents included Level 1 investments in treasury securities of $100.5 million and $129.1 million as of September 30, 2024 and December 31, 2023, respectively. These securities are classified as held-to-maturity and all have been purchased with original maturities of 90 days or less. Held-to-maturity debt securities are recorded at amortized cost in the financial statements.Â Â Â September 30, 2024 Â Â Â Amortized Cost Â Â Unrealized Gains Â Â Unrealized Losses Â Â Aggregate Fair Value Â U.S. treasury securities Â $ 100,488 Â Â $ 24 Â Â $ (1) Â $ 100,511 Â Â Â Â December 31, 2023 Â Â Â Amortized Cost Â Â Unrealized Gains Â Â Unrealized Losses Â Â Aggregate Fair Value Â U.S. treasury securities Â $ 129,113 Â Â $ 28 Â Â $ â€” Â Â $ 129,141 Â The Company measures the fair value of outstanding debt for disclosure purposes on a recurring basis. As of September 30, 2024 and December 31, 2023, total debt of $34.2 million and $33.9 million is reported at amortized cost, respectively. This outstanding debt is classified as Level 2 as it is not actively traded. The amortized cost of the outstanding debt approximates the fair value.The Company measures the fair

value of the unissued common stock warrants to be issued pursuant to the Hercules Loan Agreement (as defined in Note 5, Debt) using the Black-Scholes option pricing method. These are classified as Level 3 liabilities, with an overall value of less than $0.1 million as of September 30, 2024. The unissued warrants are remeasured at each reporting date following execution of the Hercules Loan Agreement. See Note 5, Debt, and Note 7, Stockholders' Equity, for additional information regarding the common stock warrants. The financial statements as of September 30, 2024 and December 31, 2023 do not include any assets or liabilities that are measured at fair value on a nonrecurring basis. Note 4. Balance Sheet ComponentsProperty and Equipment, NetProperty and equipment, net consist of the following (in thousands):Â Â Â As of September 30, Â Â As of December 31, Â Â Â 2024 Â Â 2023 Â Tools and equipment Â $ 1,991 Â Â $ 2,010 Â Computer equipment and software Â Â 37 Â Â Â 37 Â Furniture and fixtures Â Â 286 Â Â Â 323 Â Leasehold improvements Â Â 38 Â Â Â 38 Â Construction in process Â Â 1,071 Â Â Â 859 Â Â Â 3,423 Â Â Â 3,267 Â Less: Accumulated depreciation Â Â (1,975) Â Â (1,627) Property and equipment, net Â $ 1,448 Â Â $ 1,640 Â Â Â 12 Â Depreciation expense was $0.1 million and $0.4 million for the three and nine months ended September 30, 2024, respectively. Depreciation expense was $0.2 million and $0.5 million for the three and nine months ended September 30, 2023, respectively. Accrued and Other Current LiabilitiesAccrued and other current liabilities consist of the following (in thousands):Â Â Â As of September 30, Â Â As of December 31, Â Â Â 2024 Â Â 2023 Â Accrued expenses Â $ 2,447 Â Â $ 1,639 Â Current portion of lease liabilities Â Â 519 Â Â Â 573 Â Short-term interest payable Â Â 311 Â Â Â 375 Â Other accrued liabilities Â Â 1,336 Â Â Â 1,187 Â Total accrued and other current liabilities Â $ 4,613 Â Â $ 3,774 Â Â Other Noncurrent LiabilitiesOther noncurrent liabilities consist of the following (in thousands):Â Â Â As of September 30, Â Â As of December 31, Â Â Â 2024 Â Â 2023 Â Noncurrent portion of lease liabilities Â $ 614 Â Â $ 914 Â Other noncurrent liabilities Â Â 75 Â Â Â 38 Â Long-term interest payable Â Â â€” Â Â Â 1,524 Â Total other noncurrent liabilities Â $ 689 Â Â $ 2,476 Â Â Note 5. DebtHercules Capital Loan AgreementIn January 2024, the Company entered into a Loan and Security Agreement (the â€œHercules Loan Agreementâ€), with Hercules Capital, Inc. (â€œHercules â€) and certain of its affiliates (collective with Hercules, the â€œLendersâ€), which provides for a senior secured term loan facility in the aggregate principal amount of up to $65.0 million. An initial tranche of $35.0 million (the â€œInitial Loanâ€) was funded under the Hercules Loan Agreement on January 22, 2024. In addition to the Initial Loan, the Hercules Loan Agreement provides for additional tranches as follows: $5.0 million available in a single draw through December 15, 2024, $10.0 million available to draw upon the achievement of certain performance milestones through September 15, 2025, and $15.0 million available for the Company to draw on through the interest-only period in increments of $5.0 million, subject to the sole approval of Hercules' investment committee (such tranche loans together with the Initial Loan, the â€œTerm Loansâ€).The Hercules Loan Agreement includes a maturity date of July 1, 2028, with an interest only period running for the first 30 months of the agreement term, extendable for an additional six months for a total of 36 months upon the achievement of certain milestones. The Term Loans accrue interest at a floating annual rate of the greater of 10.35% or the Wall Street Journal prime rate plus 2.35%, with the interest rate under the Term Loans equal to 10.35% at September 30, 2024. The final payment fee is set at 5.95% of the funded balance, which is recognized as a debt discount and is being accreted into the amortization of debt issuance costs using the effective interest rate method over the term of the loan. In conjunction with the funding of the Initial Loan, the Company issued warrants to the Lenders to purchase up to an aggregate of 135,686 shares of its common stock at an exercise price of $5.159 per share, which were recorded and classified as equity. Each warrant is exercisable for a period of seven years from the date of issuance. See Note 7, Stockholders' Equity, for additional information regarding these common stock warrants.The obligations under the Hercules Loan Agreement are guaranteed by the Company and its future subsidiaries, subject to exceptions for certain foreign subsidiaries. The obligations under the agreement are secured by substantially all of the Company's assets, including its material intellectual property. Additionally, the Company Â 13 Â is subject to customary affirmative and negative covenants, including covenants that limit or restrict the ability of the Company to, among other things, incur indebtedness, grant liens, merge or consolidate, make investments, dispose of assets, make acquisitions, pay dividends or make distributions, repurchase stock and enter into certain transactions with affiliates, in each case subject to certain exceptions. The Company is also subject to certain minimum cash and revenue covenants under the Hercules Loan Agreement. The Company was in compliance with all covenants as of September 30, 2024.MidCap Loan AgreementThe Company had credit and security agreements with certain entities affiliated with MidCap Financial Services (such entities collectively, â€œMidCapâ€), which provided for a $35.0 million senior secured term loan (the â€œMidCap Term Loanâ€). In January 2024, the Company terminated the Amended and Restated Credit and Security Agreement (Term Loan) (the â€œMidCap Term Loan Agreementâ€) evidencing the MidCap Term Loan and paid off in full the secured obligations thereunder in connection with its entry into the Hercules Loan Agreement. The Company recorded a loss on debt extinguishment of $2.0 million during the nine months ended September 30, 2024.The commitment obligations under the MidCap Term Loan Agreement were guaranteed by the Companyâ€™s current and future subsidiaries, subject to exceptions for certain foreign subsidiaries, and secured by substantially all assets of the Company, including material intellectual property. The MidCap Term Loan Agreement had a maturity date of November 1, 2025, and principal payments under the Term Loan were scheduled to commence in December 2024. In addition, the MidCap Term Loan Agreement included a stated floating interest rate that was reserve-adjusted Secured Overnight Finance Rate, plus 7.00%, and a provision for a final payment fee of 6.0% of the $35.0 million MidCap Term Loan balance, which was recorded as a long-term interest payable as of December 31, 2023. Maturities ScheduleLong-term and short-term debt as of September 30, 2024 and December 31, 2023, respectively, was as follows (in thousands):Â Â Â As of September 30, Â Â As of December 31, Â Â Â 2024 Â Â 2023 Â Hercules Initial Loan Â $ 35,000 Â Â $ â€” Â MidCap Term Loan Â Â â€” Â Â Â 35,000 Â Total principal payments due Â Â 35,000 Â Â Â 35,000 Â Less: unamortized discount and debt issuance costs Â Â (848) Â Â (1,073) Total amounts outstanding Â Â 34,152 Â Â Â 33,927 Â Less: current portion Â Â â€” Â Â Â (2,219) Long-term debt, net Â $ 34,152 Â Â $ 31,708 Â The repayment schedule relating to the Hercules Initial Loan as of September 30, 2024, is as follows (in thousands):Â Â Â Amount Â 2024 (remainder) Â $ â€” Â 2025 Â Â â€” Â 2026 Â Â 6,680 Â 2027 Â Â 17,294 Â Thereafter Â Â 11,026 Â Total principal payments Â $ 35,000 Â Final fee due at maturity Â Â 2,083 Â Total repayments Â $ 37,083 Â Â Â 14 Â Note 6. Commitments and ContingenciesOperating Lease ObligationsThe Companyâ€™s leases include facility leases and equipment leases. In determining the present value of lease payments, the Company uses its incremental borrowing rate based on the information available at the lease commencement date if the rate implicit in the lease is not readily determinable. The Companyâ€™s incremental borrowing rate represents the interest rate that the Company would expect to incur at lease commencement to borrow an amount equal to the lease payments on a collateralized basis with similar terms and payments, in an economic environment where the leased asset is located. In determining the lease term, the Company includes all renewal options that are reasonably probable to be executed. The Company leases its corporate headquarters in Menlo Park, California. The lease commenced in August 2021 and was originally for a term of 37 months from the commencement date. In December 2023, the Company entered into an amendment to the lease, extending the lease term an additional 26 months. Upon signing the amendment, the Company recorded an aggregate lease right-of-use ("ROU") asset and lease liability of $1.2 million. The lease ROU asset and corresponding liability were estimated using a weighted-average incremental borrowing rate of 11.40%. Total base rent for the remaining 34 months under the amended lease agreement is approximately $1.5 million. During the fourth quarter of 2022, the Company entered into a supply agreement that was expected to last approximately 18 months. In January 2024, the term was extended through December 31, 2024. The supply agreement contained provisions that, when evaluated, indicated an embedded lease was present within the agreement and the Company recorded an aggregate lease ROU asset and lease liability of $0.7 million. The lease ROU asset and corresponding lease liability were estimated using a weighted-average incremental borrowing rate of 10.75%. Total base rent under the agreement is approximately $0.7 million. The Company recognizes rent expense on a straight-line basis over the noncancelable lease term. The Companyâ€™s rent expense was $0.2 million and $0.3 million for the three months ended September 30, 2024 and 2023, respectively. The Companyâ€™s rent expense was $0.6 million and $0.9 million for the nine months ended September 30, 2024 and 2023, respectively. As of September 30, 2024, the weighted average remaining lease term for the leases was 2.0 years.Operating lease expense and supplemental cash flow information related to operating leases for the three months ended September 30, 2024 and 2023 were as follows (in thousands):Â Â Â Three Months Ended September 30, Â Â Nine Months Ended September 30, Â Â Â 2024 Â Â 2023 Â Â 2024 Â Â 2023 Â Operating lease expense Â $ 196 Â Â $ 288 Â Â $ 587 Â Â $ 869 Â Cash paid for operating leases Â Â 162 Â Â Â 295 Â Â Â 582 Â Â Â 885 Â Aggregate future minimum lease payments as of September 30, 2024, under these noncancelable operating leases were as follows (in thousands):Â Â Â As of September 30, Â Â Â 2024 Â Â 2024 (remainder) Â $ 158 Â Â 2025 Â Â 618 Â Â 2026 Â Â 497 Â Â Total future minimum lease payments Â $ 1,273 Â Â Less: imputed interest Â Â (140) Â Present value of future minimum lease payments Â $ 1,133 Â Â Less: current portion of operating lease liability Â Â (519) Â Noncurrent portion of lease liabilities Â $ 614 Â Â Â Â 15 Â Legal ProceedingsOn September 16, 2021, the Company filed suit in the U.S. District Court for the District of Delaware (C.A. No. 1:21-cv-01317) (the â€œCourtâ€) alleging that Ivantis, Inc. (â€œIvantisâ€) directly and indirectly infringes the Companyâ€™s U.S. Patent Nos. 8,287,482, 9,370,443, 9,486,361, and 10,314,742 by making, using, selling, and offering for sale the HydrusÂ® Microstent. The Companyâ€™s complaint seeks money damages and injunctive relief. On January 24, 2022, Ivantis asserted counterclaims requesting declaratory judgments that the Company's asserted patents-in-suit are not infringed and/or invalid. On August 1, 2022, the Company filed an amended complaint alleging that Alcon Inc., Alcon Vision, LLC and Alcon Research, LLC (collectively, â€œAlconâ€) infringe the four originally asserted patents by making, using, selling, and offering for sale the HydrusÂ® Microstent, and that all defendants also infringe U.S. Patent No. 11,389,328. The defendants asserted counterclaims requesting declaratory judgments that the Companyâ€™s asserted patents-in-suit are not infringed and/or are invalid. In September 2022, Ivantis and Alcon filed petitions with the U.S. Patent Office seeking inter partes review of U.S. Patent Nos. 8,287,482, 9,370,443, 9,486,361, and 10,314,742 (IPR2022-01529, IPR2022-01530, IPR2022-01533, IPR2022-01540), each of which the U.S. Patent Office denied for raising prior art references and invalidity arguments that were cumulative of those previously considered by the U.S. Patent Office. On April 26, 2024, at the conclusion of a five-day jury trial, the Company was awarded a positive jury trial verdict of $34 million, comprised of $5.5 million in lost profits damages and $28.5 million in royalty damages for commercial sales of the Hydrus Microstent for the period between its commercial launch through trial. The patents at issue were U.S. Patent Nos. 8,287,482, 9,370,443, and 11,389,328. The parties have submitted their post-trial briefings and the Court will hold an in-person hearing in December 2024 to hear the partiesâ€™ oral arguments on these briefings. The Court will enter its final judgement after the hearing, with such entry currently expected in late fourth quarter 2024 or in first quarter 2025. The Court's final judgment will be subject to appeal. The Company is presently unable to predict the outcome of this lawsuit or to reasonably estimate the potential financial impact of the lawsuit on the Company, if any.In addition to the foregoing, from time to time, the Company is subject to legal claims, regulatory matters and contingencies in the ordinary course of business. Accruals for these matters are reflected in the financial statements based on managementâ€™s assessment, including the advice of legal counsel, of the expected outcome of these matters. Liabilities for estimated losses are accrued if the potential losses from any legal proceedings, regulatory matters or contingencies are considered probable and the amounts can be reasonably estimated. Significant judgment is required in both the determination of probability of loss and the determination as to whether the amount can be reasonably estimated. Accruals are based only on information available at the time of the assessment due to the uncertain nature of such matters. As additional information becomes available, management reassesses potential liabilities related to legal claims, regulatory matters and contingencies, and may revise its previous estimates, which could materially affect the Companyâ€™s results of operations in a given period. Except as described above, as of September 30, 2024 and December 31, 2023, the Company was not a party to any legal proceedings, regulatory matters, or other disputes or claims which, if determined adversely, would, individually or taken together, have a material adverse effect on the Companyâ€™s business, financial condition, operating results, liquidity, or future prospects.IndemnificationIn the normal course of business, the Company enters into contracts and agreements that contain a variety of representations and warranties and provide for general indemnifications. The Companyâ€™s exposure under these agreements is unknown because it involves claims that may be made against the Company in the future, but that have not yet been made. To date, the Company has not paid any claims or been required to defend any action related to its indemnification obligations. However, the Company may record charges in the future as a result of these indemnification obligations.The Company indemnifies each of its directors and officers for certain events or occurrences, subject to certain limits, while the director is or was serving at the Companyâ€™s request in such capacity, as permitted under Delaware law and in accordance with its certificate of incorporation and bylaws. The term of the indemnification period lasts as long as a director or officer may be subject to any proceeding arising out of acts or omissions of such director or officer in such capacity. The maximum amount of potential future indemnification is unlimited; however, the Company currently holds director and officer liability insurance. This insurance allows the transfer of risk associated with the Companyâ€™s exposure and may enable it to recover a portion of any future amounts paid. The Â 16 Â Company believes the fair value of these indemnification obligations is minimal. Accordingly, the Company has not recognized any liabilities relating to these obligations as of September 30, 2024 and December 31, 2023. Â Note 7. Stockholders' EquityCommon StockThe Companyâ€™s certificate of incorporation provides for 200,000,000 authorized shares of common stock, par value $0.001 per share, and 10,000,000 authorized shares of preferred stock, par value $0.001 per share. The holders of common stock are entitled to receive dividends whenever funds are legally available, when and if declared by the board of directors. As of September 30, 2024, no dividends have been declared. Each share of common stock is entitled to one vote.At September 30, 2024 and December 31, 2023, the Company had reserved common stock for future issuances as follows: Â Â September 30, Â Â December 31, Â Â Â 2024 Â Â 2023 Â Common stock available for future grants Â Â 5,956,636 Â Â Â 6,033,176 Â Common stock options issued and outstanding Â Â 4,583,289 Â Â Â 4,980,190 Â Restricted stock units outstanding Â Â 4,574,045 Â Â Â 2,721,361 Â Shares available for future purchase under employee stock purchase plan Â Â 1,747,250 Â Â Â 1,488,227 Â Total Â Â 16,861,220 Â Â Â 15,222,954 Â Â Common Stock WarrantsIn conjunction with the funding of the Initial Loan under the Hercules Loan Agreement, the Company issued common stock warrants to the Lenders to purchase up to an aggregate of 135,686 shares of our common stock at an exercise price of $5.159 per share. Each warrant is exercisable for up to seven years from the date of issuance. The warrants are classified as equity. During the nine months ended September 30, 2024, the fair value of the issued warrants recorded was $0.6 million, which was calculated using the Black-Scholes option pricing model. These warrants were recorded at fair value upon their issuance in additional paid-in capital in the condensed consolidated balance sheet. The issued warrants are not remeasured after the issuance date.If the additional Term Loans are funded, the Company will be obligated to issue to the Lenders additional warrants to purchase common stock in an amount equal to 2.0% of the funded balance of each tranche, divided by the exercise price on the date the Company draws funds from such tranche, or the issuance date. The exercise price will be calculated using the five-day volume-weighted average stock price as of such date.The unissued warrants do not meet the requirements for classification in equity, and are recorded as liabilities in other noncurrent liabilities in the financial statements. The fair value of the unissued common stock warrants was calculated using the Black-Scholes option pricing method and they were recorded at fair value upon the funding of the Hercules Loan Agreement. The unissued warrants are remeasured at each reporting date after the issuance date. According to the fair value measurement criteria, the unissued warrants are considered Level 3 liabilities, with an overall value of less than $0.1 million as of September 30, 2024. Note 8. Equity Incentive Plans2011 Stock Option Plan and 2021 Incentive Award PlanIn 2011, the Company established its 2011 Stock Option Plan (the â€œ2011 Planâ€) that provided for the granting of stock options to employees and nonemployees of the Company. In July 2021, the board of directors and stockholders adopted and approved the 2021 Incentive Award Plan, (the â€œ2021 Planâ€). Under the 2021 Plan, the Company has the ability to issue incentive stock options ("ISOs"), nonqualified stock options ("NSOs"), stock appreciation rights, dividend equivalent rights, restricted stock awards, and restricted stock unit awards ("RSUs"). Options under the 2021 Plan can typically be granted for periods of up to Â 17 Â ten years. For stock options granted to a grantee who, at the time the option is granted, owned stock representing more than 10% of the voting power of all classes of stock of the Company (or any parent or subsidiary of the Company), the term of the stock option may be granted for periods of up to five years. The ISOs and NSOs will be granted at a price per share not less than the fair value at the date of grant. The exercise price of a stock option granted to a 10% stockholder shall be not less than 110% of the grant date fair value of the shares. Options granted to new hires generally vest over a four-year period, with 25% of the shares vesting on the first anniversary of the grant date and the remaining shares vesting in 36 equal monthly installments thereafter; options granted as merit awards generally vest in 48 equal monthly installments following the grant date. RSUs granted generally vest over a four-year period with straight-line vesting in equal amounts (either in annual or quarterly installments). The Company initially reserved 5,200,000 shares of common stock for future issuance under the 2021 Plan. This initial reserve is subject to annual increase on the first day of each calendar year beginning on January 1, 2022 and ending on and including January 1, 2031. These annual increases are equal to the lesser of (i) 5% of the aggregate number of shares of common stock outstanding on the final day of the immediately preceding calendar year and (ii) such smaller number of shares of common stock as determined by the Board, subject to certain limitations. Pursuant to the evergreen provision, the initial share reserve was increased by 2,456,568 shares and 2,414,907 shares on January 1, 2024 and 2023, respectively. The

2011 Plan was superseded by the 2021 Plan at the time of the initial public offering of the Company's common stock, which closed on July 15, 2021, and no further grants have been made under the 2011 Plan from the date the 2021 Plan became effective. The terms under the 2011 Plan are consistent with those described above for the 2021 Plan. As of September 30, 2024 and December 31, 2023 there were 5,956,636 shares and 6,033,176 shares, respectively, of common stock available for issuance under the 2021 Plan.Stock Option AwardsThe following table summarizes stock option activity under the 2021 Plan during the periods presented: Â Â Â Number ofShares Â Â Weighted-Average Exercise Price Â Â Weighted-AverageContractualÂ Term (in years) Â Â Average Intrinsic Value (in thousands) Â Balances as of December 31, 2023 Â Â 4,980,190 Â Â $ 9.00 Â Â Â 7.4 Â Â $ 5,924 Â Grants Â Â 7,377 Â Â Â 4.43 Â Â Â Â Â Â Forfeited/cancelled Â Â (210,159) Â Â 10.15 Â Â Â Â Â Â Â Exercised/released Â Â (194,119) Â Â 1.20 Â Â Â Â Â Â Â Balances as of September 30, 2024 Â Â 4,583,289 Â Â $ 9.28 Â Â Â 7.0 Â Â $ 6,558 Â Vested and exercisable as of September 30, 2024 Â Â 3,163,058 Â Â $ 9.32 Â Â Â 6.4 Â Â $ 4,635 Â Vested and expected to vest as of September 30, 2024 Â Â 4,583,289 Â Â $ 9.28 Â Â Â 7.0 Â Â $ 6,558 Â Â During the three months ended September 30, 2024 and 2023, the Company recorded stock-based compensation expense of $1.9 million and $2.1 million related to stock option awards, respectively. During the nine months ended September 30, 2024 and 2023, the Company recorded stock-based compensation expense of $5.7 million and $6.6 million related to stock option awards, respectively. The weighted-average grant-date fair values of options granted during the nine months ended September 30, 2024 and 2023 was $2.71 and $6.92 per share, respectively. The aggregate intrinsic value of options exercised was $0.2 million and $0.8 million during the three and nine months ended September 30, 2024, respectively. The aggregate intrinsic value was calculated as the difference between the exercise prices of the underlying options and the estimated fair value of the common stock on the date of exercise. As of September 30, 2024, the unrecognized stock-based compensation expense relating to unvested options was $8.1 million, which is expected to be recognized over a weighted-average period of 1.3 years. Â 18 Â Determination of Fair ValueThe Company estimated the grant date fair value of stock options using the Black-Scholes option-pricing model, which requires the use of highly subjective and complex valuation assumptions to determine the fair value of stock-based awards, including the optionâ€™s expected term, the expected volatility of the underlying stock, the risk-free interest rate, and the expected dividend yield. For the purposes of the Black-Scholes valuation model, the Company used the simplified method for determining the expected term of the granted options. The simplified method was used since the Company does not have adequate historical data to utilize in calculating the expected term of options. The fair value for options granted was calculated using the following weighted average assumptions: Â Â Â Three Months Ended September 30, Â Nine Months Ended September 30, Â Â 2024 Â 2023 Â 2024 Â 2023 Expected term (in years) Â N/A Â 5.99Â â€“ 6.01 Â 6.13 Â 5.60Â â€“ 6.07 Expected volatility Â N/A Â 79.82% Â 61.67% Â 78.53% â€“ 79.82% Risk-free interest rate Â N/A Â 4.04% Â 4.28% Â 3.48% â€“ 4.04% Dividend yield Â N/A Â â€“ Â â€“ Â â€“ Restricted Stock UnitsRSUs are share awards that entitle the holder to receive shares of common stock upon vesting. The RSUs cannot be transferred, and the awards are subject to forfeiture if the holderâ€™s employment terminates prior to the release of the vesting restrictions. The RSUs generally vest either (i) annually over a four-year period with straight-line vesting in equal amounts, or (ii) quarterly over a four-year period with straight-line vesting in equal amounts, in each case provided the holder provides continuous services to the Company. The fair value of the RSUs is equal to the closing price of the Companyâ€™s common stock on the grant date.The following table summarizes restricted share award activity: Â Â Number ofShares Â Â Weighted-Average Grant Date Fair Value Per Share Â Outstanding, December 31, 2023 Â Â 2,721,361 Â Â $ 7.61 Â Grants Â Â 2,949,065 Â Â Â 4.46 Â Forfeited/cancelled Â Â (213,175) Â Â 6.54 Â Vested Â Â (883,206) Â Â 7.58 Â Outstanding, September 30, 2024 Â Â 4,574,045 Â Â $ 5.62 Â During the three months ended September 30, 2024 and 2023, the Company recorded stock-based compensation expense of $2.2 million and $1.6 million, respectively, related to the RSUs. During the nine months ended September 30, 2024 and 2023, the Company recorded stock-based compensation expense of $6.9 million and $4.2 million, respectively, related to the RSUs. As of September 30, 2024, there was $21.2 million of total unrecognized stock-based compensation expense relating to the RSUs that is expected to be recognized over a weighted-average period of 2.7 years. Employee Stock Purchase PlanIn July 2021, the board of directors and stockholders adopted and approved the 2021 Employee Stock Purchase Plan (the â€œESPPâ€). The Company initially reserved 850,000 shares of common stock for future issuance under the ESPP. This initial reserve is subject to annual increase on the first day of each calendar year beginning on January 1, 2022 and ending on and including January 1, 2031. These annual increases shall be equal to the lesser of (i) 1% of the aggregate number of shares of common stock outstanding on the final day of the immediately preceding calendar year and (ii) such smaller number of shares of common stock as determined by the Board, subject to certain limitations. Pursuant to the evergreen provision, the initial share reserve was increased by 491,313 and 482,981 shares on January 1, 2024 and 2023, respectively. Â 19 Â The Company has two offering periods annually, running for six months, with the first offering period beginning in the second quarter, and the second offering period beginning in the fourth quarter. The purchase of shares for participants in the ESPP occurs at the conclusion of each offering period. During the nine months ended, September 30, 2024, participants in the ESPP purchased 232,290 shares for a total of $0.5 million. As of September 30, 2024, the Company has collected payroll withholdings of $0.4 million in the current offering period for the purchase of shares under the ESPP. The Company recorded stock-based compensation expense associated with the ESPP of $0.1 million for both the three months ended September 30, 2024 and 2023. The Company recorded stock-based compensation expense associated with the ESPP of $0.5 million and $0.4 million for the nine months ended September 30, 2024 and 2023, respectively. As of September 30, 2024, there were 1,747,250 shares of common stock available for issuance under the ESPP. The fair value of shares to be issued under the ESPP was estimated using the Black-Scholes valuation model with the following assumptions for the three and nine months ended September 30, 2024 and 2023:Â Â Â Three Months Ended September 30, Â Nine Months Ended September 30, Â Â 2024 Â 2023 Â 2024 Â 2023 Expected term (in years) Â 0.49 â€“ 0.50 Â 0.48 â€“ 0.50 Â 0.49Â â€“ 0.50 Â 0.48Â â€“ 0.50 Expected volatility Â 100.00% â€“ 197.51% Â 66.72% â€“ 97.38% Â 100.00% â€“ 197.51% Â 66.72% â€“ 97.38% Risk-free interest rate Â 5.37% â€“ 5.40% Â 4.62% â€“ 5.32% Â 5.37% â€“ 5.40% Â 4.62% â€“ 5.32% Dividend yield Â â€“ Â â€“ Â â€“ Â â€“ Stock-Based CompensationThe following is a summary of stock-based compensation expense by function (in thousands):Â Â Â Three Months Ended September 30, Â Â Nine Months Ended September 30, Â Â Â 2024 Â Â 2023 Â Â 2024 Â Â 2023 Â Cost of goods sold Â $ 83 Â Â $ 77 Â Â $ 283 Â Â $ 206 Â Research and development Â Â 588 Â Â Â 549 Â Â Â 1,787 Â Â Â 1,664 Â Selling, general and administrative Â Â 3,637 Â Â Â 3,230 Â Â Â 11,061 Â Â Â 9,251 Â Total stock-based compensation expense Â $ 4,308 Â Â $ 3,856 Â Â $ 13,131 Â Â $ 11,121 Â Â Note 9. Net Loss per Share Attributable to Common StockholdersBasic net loss per share is computed by dividing the net loss by the weighted-average number of common shares outstanding for the period. As the Company reported a net loss for the three and nine months ended September 30, 2024 and 2023, basic net loss per share is the same as diluted net loss per share for each of the reported periods. Â 20 Â The following table sets forth the computation of basic and diluted net loss per share attributable to common stockholders for the periods presented (in thousands, except share and per share data):Â Â Â Three Months Ended September 30, Â Â Nine Months Ended September 30, Â Â Â 2024 Â Â 2023 Â Â 2024 Â Â 2023 Â Numerator: Â Â Â Â Â Â Â Â Â Â Â Â Net loss attributable to common stockholders Â $ (11,066) Â $ (13,035) Â $ (39,661) Â $ (44,856) Denominator: Â Â Â Â Â Â Â Â Â Â Â Â Weighted-average shares of common stockÂ Â Â outstandingâ€”basic and diluted Â Â 50,340,603 Â Â Â 48,671,049 Â Â Â 49,911,655 Â Â Â 48,538,517 Â Net loss per share attributable to commonÂ Â stockholdersâ€”basic and diluted Â $ (0.22) Â $ (0.27) Â $ (0.79) Â $ (0.92) Â The following potentially dilutive issued and outstanding securities were excluded from the computation of diluted net loss per share attributable to common stockholders for the period presented because including them would have been antidilutive as a result of the net loss position:Â Â Â September 30, Â Â Â 2024 Â Â 2023 Â Stock option awards Â Â 4,583,289 Â Â Â 4,705,390 Â Restricted stock units Â Â 4,574,045 Â Â Â 1,853,657 Â Common stock warrants Â Â 135,686 Â Â Â â€” Â Total Â Â 9,293,020 Â Â Â 6,559,047 Â Â Note 10. Segment InformationThe Company has two reportable operating segments which are determined on the basis of the product portfolio: Surgical Glaucoma and Dry Eye. The operating and reportable segments were determined based on how the Companyâ€™s Chief Executive Officer, its Chief Operating Decision Maker (â€œCODMâ€), views and evaluates the Companyâ€™s operations. The CODM allocates resources to and evaluates the financial performance of each operating segment primarily based on gross profit and gross profit margin.The Surgical Glaucoma segment includes sales of the Companyâ€™s OMNI Surgical System and SION Surgical Instrument for use in minimally invasive glaucoma procedures. The Dry Eye segment includes sales of the Companyâ€™s TearCare System and related components. Â 21 Â The following table summarizes select operating results information for each reportable segment (in thousands):Â Â Â Three Months Ended September 30, Â Â Nine Months Ended September 30, Â Â Â 2024 Â Â 2023 Â Â 2024 Â Â 2023 Â Revenue Â Â Â Â Â Â Â Â Â Â Â Â Surgical Glaucoma Â $ 18,632 Â Â $ 18,425 Â Â $ 57,132 Â Â $ 57,158 Â Dry Eye Â Â 1,525 Â Â Â 1,584 Â Â Â 3,660 Â Â Â 5,147 Â Total Â Â 20,157 Â Â Â 20,009 Â Â Â 60,792 Â Â Â 62,305 Â Cost of goods sold Â Â Â Â Â Â Â Â Â Â Â Â Surgical Glaucoma Â Â 2,453 Â Â Â 2,002 Â Â Â 7,084 Â Â Â 6,808 Â Dry Eye Â Â 797 Â Â Â 675 Â Â Â 1,984 Â Â Â 2,297 Â Total Â Â 3,250 Â Â Â 2,677 Â Â Â 9,068 Â Â Â 9,105 Â Gross profit Â Â Â Â Â Â Â Â Â Â Â Â Surgical Glaucoma Â Â 16,179 Â Â Â 16,423 Â Â Â 50,048 Â Â Â 50,350 Â Dry Eye Â Â 728 Â Â Â 909 Â Â Â 1,676 Â Â Â 2,850 Â Total Â Â 16,907 Â Â Â 17,332 Â Â Â 51,724 Â Â Â 53,200 Â Operating expenses Â Â 28,136 Â Â Â 30,743 Â Â Â 90,327 Â Â Â 99,364 Â Loss from operations Â Â (11,229) Â Â (13,411) Â Â (38,603) Â Â (46,164) Investment income Â Â 1,454 Â Â Â 1,897 Â Â Â 4,628 Â Â Â 5,499 Â Interest expense Â Â (1,151) Â Â (1,432) Â Â (3,501) Â Â (4,057) Loss on debt extinguishment Â Â â€” Â Â Â â€” Â Â Â (1,962) Â Â â€” Â Other income (expense), net Â Â 26 Â Â Â (11) Â Â (25) Â Â (34) Loss before income taxes Â $ (10,900) Â $ (12,957) Â $ (39,463) Â $ (44,756) Â The Company does not allocate any income and expenses beyond revenue and cost of goods sold to the reportable operating segments in its reporting to the CODM. No asset information is provided for reportable operating segments because they are not reviewed by the CODM on a segment basis. Substantially all of the Companyâ€™s revenue is generated from sales in the United States. Â Â 22 Â Item 2. Managementâ€™s Discussion and Analysis of Financial Condition and Results of Operations. The following discussion and analysis of our financial condition and results of operations should be read in conjunction with our condensed consolidated financial statements and the related notes and other financial information included in Park I, Item 1, â€œFinancial Statements,â€ within this Quarterly Report and our audited consolidated financial statements and related notes included in Part II, Item 8, â€œFinancial Statements and Supplementary Data,â€ in our Annual Report. Certain statements included in this discussion and analysis constitute â€œforward-looking statementsâ€ that are subject to considerable risks and uncertainties. Please see the information under the heading â€œSpecial Note Regarding Forward-Looking Statementsâ€ in this Quarterly Report. Overview Sight Sciencesâ€™ mission is to develop transformative, interventional technologies that allow eyecare providers to procedurally elevate the standards of care â€“ empowering people to keep seeing. We are passionate about improving patientsâ€™ lives by helping them preserve their sight. Our objective is to develop and market products for use in new treatment paradigms and to create an interventional mindset in eyecare whereby our products may be used in procedures which supplant conventional outdated approaches. Our business philosophy is grounded in the following principles: â€¢comprehensively understanding disease physiology; â€¢developing products that are intended to preserve, protect and restore natural physiological functionality to diseased eyes; â€¢developing and marketing products with proven clinical evidence that achieve superior effectiveness versus current treatment paradigms while minimizing complications or side effects; â€¢providing intuitive, patient-friendly, interventional solutions to ophthalmologists and optometrists (together, "ECPs"); and â€¢delivering compelling economic value to all stakeholders, including patients, providers and third-party payors such as Medicare and commercial insurers. Our initial product development has focused on the treatment of two of the worldâ€™s most prevalent and underserved eye diseases, glaucoma and dry eye disease (â€œDEDâ€). We have commercialized products in each of our two reportable operating segments, Surgical Glaucoma and Dry Eye. Our Surgical Glaucoma revenues consist of sales of the OMNIÂ® Surgical System ("OMNI") and the SIONÂ® Surgical Instrument ("SION"), while our Dry Eye revenues are comprised of sales of the TearCareÂ® System ("TearCare"), and related components and accessories. Each product is primarily sold through a highly involved direct sales model that offers intensive education, training and customer service. We believe this philosophy and model not only enable us to differentiate our products and company from competitors, but also expand our addressable market by educating ECPs, patients and other stakeholders on our products and evolving treatment paradigms. Outside of the U.S., we have established direct commercial operations in the United Kingdom and Germany. We sell OMNI in several other countries through distributors. We sell OMNI and SION to facilities where ophthalmic surgeons perform outpatient procedures, such as ambulatory surgery centers ("ASCs") and hospital outpatient departments ("HOPDs"), which are typically reimbursed by Medicare or private payors for procedures using our products. We sell TearCare to ECPs. Currently, there is no meaningful reimbursement coverage by Medicare or private payors for DED procedures, including TearCare, and patients typically pay out-of-pocket for TearCare, although some payors may agree to provide case-based coverage outside of a formal policy. We are continuing our controlled commercial launch and are focused on our comprehensive, clinical data-driven long-term market development plan that aims to improve awareness and patient access to TearCare. We have dedicated meaningful resources to execute our commercial strategy as we reduce operating expenses and improve cost efficiencies to better align our operating structure for long-term, profitable growth. The overall success of our approach to eyecare to date is evidenced by over 275,000 estimated uses of Surgical Glaucoma products and their predicates in over 2,000 hospitals and ASCs in the U.S. and Europe, and over 65,000 estimated uses of TearCare in over 1,500 eyecare facilities in the U.S. through September 30, 2024. We do not currently operate any manufacturing facilities and instead contract with third parties for our production requirements. We believe our suppliers will be able to meet our current and anticipated manufacturing Â 23 Â needs across all of our product lines. We plan to continue to utilize third party contract manufacturers for our products and any related components. Revenue in our Surgical Glaucoma segment for the nine-months ended September 30, 2024 and 2023 was $57.1 million and $57.2 million, respectively, with gross margins for the same periods of 87.6% and 88.1%, respectively. Revenue in our Dry Eye segment for the nine-months ended September 30, 2024 and 2023 was $3.7 million and $5.1 million, respectively, with gross margins for the same periods of 45.8% and 55.4%, respectively. Given the earlier stage of TearCareâ€™s commercial development, we expect our Dry Eye segmentâ€™s gross margins to be lower than our Surgical Glaucoma segmentâ€™s gross margins for the near and medium-term due to the allocation of fixed labor and overhead costs to the segment's cost of goods sold. In addition, we expect lower demand and related gross margin in the Dry Eye segment in the fourth quarter of 2024 due to our increase in dry eye pricing which took effect on October 1, 2024, which we believe will have a significant impact on cash-pay volumes. We expect TearCare procedure revenues will return to a growth trajectory upon receipt of positive payor coverage determinations that provide for sufficient and equitable reimbursement. We currently anticipate that we and our customers will begin receiving coverage and payment determinations with respect to the TearCare procedure in 2025, though there is no guarantee that such determinations will be made in accordance with this time frame. In the first three quarters of 2024, approximately 95% of our revenue was generated from customers in the U.S. We believe in the importance of continued strategic investment in initiatives that: â€¢further demonstrate our productsâ€™ clinical effectiveness and safety to potential customers, patients, payors and regulators including establishing OMNI and SION as standards of care of interventional glaucoma treatment among MIGS-trained surgeons, developing the standalone MIGS market, and pursuing coverage and equitable reimbursement for TearCare; â€¢enhance our commercial capabilities and expertise, including resources dedicated to sales, marketing and education; â€¢ensure the broadest possible patient access to the treatment alternatives that our products are cleared to offer; â€¢enhance and improve upon our existing product technologies; â€¢develop our existing international markets and expand into new international markets; and â€¢allow us to create transformational and interventional technology innovation with new products, devices or drugs, in glaucoma and ocular surface disease or in new eye disease areas. As a result, we intend to continue to invest in clinical studies, sales and marketing, education initiatives, market access, and product development. However, we are also focused on disciplined expenditures, and seek to grow our operating expenses at a lower rate than revenue. Because of these and other factors, we expect to continue to incur net losses for at least the next several years, and we may seek additional debt and equity financing to fund our operations and planned growth. To date, our primary sources of capital have been private placements of redeemable convertible preferred stock, debt financing agreements, the sale of common stock in our IPO, and revenue from the sale of our products. As of September 30, 2024, we had an outstanding term loan balance of $35.0 million (excluding unamortized debt discount and debt issuance costs), cash and cash equivalents of $118.6 million and an accumulated deficit of $334.5 million. Factors Affecting Our Business and Results of Operations We believe there are several important factors that have impacted and that will continue to impact our business, financial condition, and results of operations. Except as described in Part II, Item 1A, "Risk Factors," of this Quarterly Report, and except as described below, there have been no material changes to such factors from those described in Part II, Item 7, â€œManagementâ€™s Discussion and Analysis of Financial Condition and Results of Operationsâ€ in our Annual Report under the heading "Factors Affecting Our Business and Results of Operations." The availability of sufficient coverage and reimbursement for procedures involving our OMNI technology is fundamental to our business and prospects, with Medicare providing reimbursement for procedures that account for a majority of our revenue. As such, our business and results of operation are in material part dependent upon Â 24 Â Medicare coverage and reimbursement policies applicable to OMNI procedures. Recent occurrences that could reasonably be expected to

materially impact Medicare coverage and reimbursement for OMNI procedures include the publication in September and October 2024, by five of the seven Medicare Administrative Contractors (â€œMACsâ€), of final local coverage determinations and related final local coverage articles (collectively, the â€œFinal LCDsâ€) that, once effective, will establish new Medicare coverage policies for phacoemulsification / intraocular lens placement procedures (each, a â€œcataract surgeryâ€) performed with a single minimally invasive glaucoma surgical ("MIGS") procedure in these MACs' jurisdictions, including both canaloplasty and goniotomy procedures. Unlike the local coverage determinations previously published and later withdrawn by these MACs in 2023, the Final LCDs do not characterize the OMNI procedure as investigational. Accordingly, Medicare coverage for canaloplasty and goniotomy procedures for single MIGS procedures will continue in the states administered by these MACs. The anticipated effective date of the Final LCDs is November 17, 2024. Each of the Final LCDs would adopt a non-coverage policy when an aqueous shunt or stent procedure is performed with another surgical MIGS procedure, such as canaloplasty or goniotomy, at the same time in the same patient eye. We expect that this non-coverage policy for multiple MIGS procedures will reduce overall MIGS procedure volumes in the near-term. Our estimate is that approximately 10% of total MIGS codes billed were done in combination with another MIGS code in the six months ended June 30, 2024. Given OMNI's comprehensive treatment of the conventional outflow pathway, we believe OMNI provides an effective single MIGS procedure option for cases that were previously treated with a combination of MIGS procedures, but we cannot assure you that the Final LCDs will not have an adverse impact on future OMNI sales and therefore adversely affect our business, financial condition and results of operations. Our business and results of operations have also been impacted by recent elevated customer trialing of alternative MIGS products and technologies that are less proven and generally available at lower average selling prices than our OMNI technology. While we believe that the effects of this current customer trialing are transitory, we believe trialing activities in the marketplace will continue and are indicative of increasing competition in the MIGS segment. If we are unable to successfully differentiate and compete against new alternative products, our business and results of operations will be adversely affected. Components of Our Results of Operations Revenue We currently derive the majority of our U.S. revenue from the sale of our OMNI and SION products to ASCs and HOPDs and our TearCare products to ECPs. To date, the revenue from our Surgical Glaucoma segment has accounted for over 90% of our total revenue, substantially all of which was generated from sales within the U.S. Our Surgical Glaucoma customers place orders based on their expected procedure volume and reorder as needed, typically on a biweekly, monthly or bimonthly basis. Our TearCare customers typically purchase a TearCare System which consists of one or more TearCare SmartHubsÂ® (â€œSmartHubsâ€), multiple single-use TearCare SmartLidsÂ® (â€œSmartLidsâ€) and other accessories. After utilizing their initial inventory, customers can reorder SmartLids as needed. No single customer accounted for 10% or more of our revenue for the nine months ended September 30, 2024 and 2023. The growth in our revenue is driven by the demand for elective surgery and treatment utilizing our products in the United States and Europe. Such demand is often lower during summer months because of ECP vacations and in winter months because of fewer business or surgery days due to holidays and adverse weather conditions. Cost of Goods Sold Our components and products are produced by third-party suppliers and manufacturers. Our cost of goods sold consists primarily of amounts paid for our products to third-party manufacturers, and our manufacturing overhead costs, which consist primarily of personnel expenses, including salaries, benefits and stock-based compensation, and reserves for excess, obsolete and non-sellable inventory. Cost of goods sold also includes depreciation expenses for production equipment which we provide to our third-party manufacturers and certain direct costs, such as shipping and handling costs. Â 25 Â Gross Profit and Gross Margin We calculate gross margin as gross profit divided by revenue. Our gross margin has been and we believe it will continue to be, affected by a variety of factors, including differences in segment gross margins, changes in average selling prices, product sales mix, production and ordering volumes, manufacturing costs, product yields, and headcount. In general, we expect our gross margins to increase over the long term to the extent our production and ordering volumes increase and as we spread the fixed portion of our overhead costs over a larger number of units produced. We intend to use our design, engineering and manufacturing know-how and capabilities to further advance and improve the efficiency of our suppliersâ€™ manufacturing processes, which we believe will reduce costs and increase our gross margins. Our gross margins could fluctuate from quarter to quarter as our product mix varies, we transition to new suppliers, introduce new products, and adopt new manufacturing processes and technologies. Research and Development Expenses Research and development ("R&D") expenses consist primarily of costs associated with engineering, product development, clinical studies to develop and support our products, including clinical trial design, clinical trial site initiation and study costs, internal and external costs associated with our regulatory compliance and quality assurance functions, medical affairs, cost of products used for clinical trials and other costs associated with products and technologies â€“ either new or enhancements of existing platforms â€“ that are in development. These expenses also include personnel expenses, including salaries, benefits and stock-based compensation, supplies, consulting, prototyping, testing, materials, travel expenses, depreciation expenses for equipment and an allocation of information technology ("IT") and facility overhead expenses. Our R&D expenses as a percentage of revenue may vary over time depending on the level and timing of new product development efforts, as well as clinical development, clinical trial and other related activities. We expect our R&D expenses to increase for the next several years as we continue to invest in our active clinical trial programs, develop new products, and improve our existing products. Selling, General and Administrative Expenses Selling, general and administrative ("SG&A") expenses consist primarily of personnel expenses, including salaries, benefits and stock-based compensation related to selling, marketing and corporate functions, allocation of IT and facility overhead expenses, bad debt expense, finance, legal and human resource costs. Other SG&A expenses include training, travel expenses, promotional activities, marketing initiatives, market research and analysis, conferences and trade shows, professional services fees (including external legal, audit, consulting and tax fees), insurance costs, and general corporate expenses. Investment Income Investment income primarily consists of interest and amortization on held-to-maturity investments in treasury securities. Interest Expense Interest expense consists primarily of interest incurred on our outstanding indebtedness and non-cash interest related to the accretion of debt discount and amortization of debt issuance costs associated with our term loan agreements. Loss on Debt Extinguishment The loss on debt extinguishment is associated with our termination and settlement of the MidCap Term Loan. Other Income (Expense), Net Other income (expense), net primarily consists of income and expenses that do not originate from our primary business. Â 26 Â Results of Operations Comparison of the Three Months Ended September 30, 2024 and 2023 (dollars in thousands) Â Â Â Three Months Ended September 30, Â Â Change Â Â Â 2024 Â Â 2023 Â Â $ Â Â % Â Â Â (unaudited) Â Â Â Â Â Â Â Revenue Â Â Â Â Â Â Â Â Â Â Surgical Glaucoma Â $ 18,632 Â Â $ 18,425 Â Â Â $ 207 Â Â Â 1.1 % Percentage of total revenue Â Â 92.4 % Â Â 92.1 % Â Â Â Â Â Â Dry Eye Â Â 1,525 Â Â Â 1,584 Â Â Â (59) Â Â (3.7) Percentage of total revenue Â Â 7.6 % Â Â 7.9 % Â Â Â Â Â Â Total Â Â 20,157 Â Â Â 20,009 Â Â Â 148 Â Â Â 0.7 Â Cost of goods sold Â Â Â Â Â Â Â Â Â Â Â Surgical Glaucoma Â Â 2,453 Â Â Â 2,002 Â Â Â 451 Â Â Â 22.5 Â Dry Eye Â Â 797 Â Â Â 675 Â Â Â 122 Â Â Â 18.1 Â Total Â Â 3,250 Â Â Â 2,677 Â Â Â 573 Â Â Â 21.4 Â Gross profit Â Â Â Â Â Â Â Â Â Â Â Surgical Glaucoma Â Â 16,179 Â Â Â 16,423 Â Â Â (244) Â Â (1.5) Dry Eye Â Â 728 Â Â Â 909 Â Â Â (181) Â Â (19.9) Total Â Â 16,907 Â Â Â 17,332 Â Â Â (425) Â Â (2.5) Gross margin Â Â Â Â Â Â Â Â Â Â Surgical Glaucoma Â Â 86.8 % Â Â 89.1 % Â Â Â Â Â Dry Eye Â Â 47.7 % Â Â 57.4 % Â Â Â Â Â Total Â Â 83.9 % Â Â 86.6 % Â Â Â Â Â Â Operating expenses Â Â Â Â Â Â Â Â Â Â Research and development Â Â 4,746 Â Â Â 4,239 Â Â Â 507 Â Â Â 12.0 Â Selling, general and administrative Â Â 23,390 Â Â Â 26,504 Â Â Â (3,114) Â Â (11.7) Total operating expenses Â Â 28,136 Â Â Â 30,743 Â Â Â (2,607) Â Â (8.5) Loss from operations Â Â (11,229) Â Â (13,411) Â Â 2,182 Â Â Â 16.3 Â Investment income Â Â 1,454 Â Â Â 1,897 Â Â Â (443) Â Â (23.4) Interest expense Â Â (1,151) Â Â (1,432) Â Â 281 Â Â Â 19.6 Â Loss on debt extinguishment Â Â â€” Â Â Â â€” Â Â Â â€” Â Â n.m. Â Other income (expense), net Â Â 26 Â Â Â (11) Â Â 37 Â Â Â 336.4 Â Â Â Â Â Â Â Â Â Â Â Loss before income taxes Â Â (10,900) Â Â (12,957) Â Â 2,057 Â Â Â 15.9 Â Provision for income taxes Â Â 166 Â Â Â 78 Â Â Â 88 Â Â Â 112.8 Â Net loss and comprehensive loss Â $ (11,066) Â $ (13,035) Â $ 1,969 Â Â Â 15.1 % Â Revenue. Our Surgical Glaucoma revenue for the three months ended September 30, 2024 was $18.6 million, an increase of $0.2 million, or 1.1%, from the prior year comparable period. The overall increase in Surgical Glaucoma revenue was primarily attributable to an increase in the number of OMNI units sold in the three months ended September 30, 2024. This increase in units sold was primarily driven by an increase in unit utilization per ordering facility. Our Dry Eye revenue decreased 3.7% in the three months ended September 30, 2024 compared to the prior year comparable period primarily due to fewer new customers added in the period, which led to lower SmartHub revenue, partially offset by increased SmartLids purchased prior to our October 1, 2024 price increase. The primary reason that fewer new customers were added was the Companyâ€™s focus on the next phase of its commercial strategy for its Dry Eye segment which involves achieving reimbursed market access instead of adding customers pursuing a cash pay model for its TearCare products. Cost of Goods Sold. Cost of goods sold was $3.3 million during the three months ended September 30, 2024, an increase of $0.6 million from $2.7 million in the prior year comparable period. Our Surgical Glaucoma cost of goods sold increased $0.5 million as compared to the prior year comparable period. The increase was primarily driven by higher sales volumes and higher overhead costs per unit from lower production volumes. Our Dry Eye Â 27 Â cost of goods sold increased $0.1 million in the three months ended September 30, 2024 compared to the comparable period in 2023, primarily driven by higher costs per unit from lower production volumes. Gross Profit and Gross Margin. Our total gross profit was $16.9 million in the three months ended September 30, 2024, a decrease of $0.4 million from the prior year comparable period. Our gross margin for the three months ended September 30, 2024 decreased to 83.9%, from 86.6% in the prior year comparable period, with lower gross margin in both our Surgical Glaucoma and Dry Eye segments, primarily due to higher overhead costs per unit in the current period as a result of lower production volumes in both segments. Gross margin in our Surgical Glaucoma segment was 86.8% for the quarter ended September 30, 2024, a decrease from 89.1% for the prior year comparable period. In our Dry Eye segment, gross margin decreased from 57.4% in the third quarter of 2023 to 47.7% in the third quarter of 2024. Research and Development Expenses. R&D expenses during the three months ended September 30, 2024 increased $0.5 million, or 12.0%, to $4.7 million. The increase was primarily driven by a $0.2 million increase in personnel expenses, including corporate bonus and stock-based compensation expenses, as well as a $0.1 million increase in consulting expenses. Selling, General, and Administrative Expenses. SG&A expenses were $23.4 million for the three months ended September 30, 2024, a decrease of $3.1 million from the prior year comparable period. The decrease was primarily driven by a $2.3 million decrease in legal expenses, a $0.7 million decrease in marketing expenses, including sales training, and a $0.1 million decrease in facilities expenses. Investment Income. Investment income was $1.5 million for the three months ended September 30, 2024, a decline of $0.4 million from the prior year comparable period. The decline was primarily due to lower investment balances during the current year. Interest Expense. Interest expense decreased $0.3 million during the three months ended September 30, 2024 compared to the three months ended September 30, 2023, due to lower lending rates associated with the Hercules Loan Agreement. Loss on Debt Extinguishment. Loss on debt extinguishment was $0.0 million for both the three months ended September 30, 2024 and 2023. Other Income (Expense), Net. Other income (expense), net was income of less than $0.1 million for the three months ended September 30, 2024, compared to expense of less than $0.1 million for the three months ended September 30, 2023. Â 28 Â Comparison of the Nine Months Ended September 30, 2024 and 2023 (dollars in thousands) Â Â Â Nine Months Ended September 30, Â Â Change Â Â Â 2024 Â Â 2023 Â Â $ Â Â % Â Â Â (unaudited) Â Â Â Â Â Â Â Revenue Â Â Â Â Â Â Â Â Â Â Surgical Glaucoma Â $ 57,132 Â Â $ 57,158 Â Â $ (26) Â Â (0.0)% Percentage of total revenue Â Â 94.0 % Â Â 91.7 % Â Â Â Â Â Â Dry Eye Â Â 3,660 Â Â Â 5,147 Â Â Â (1,487) Â Â (28.9) Percentage of total revenue Â Â 6.0 % Â Â 8.3 % Â Â Â Â Â Â Total Â Â 60,792 Â Â Â 62,305 Â Â Â (1,513) Â Â (2.4) Cost of goods sold Â Â Â Â Â Â Â Â Â Â Â Surgical Glaucoma Â Â 7,084 Â Â Â 6,808 Â Â Â 276 Â Â Â 4.1 Â Dry Eye Â Â 1,984 Â Â Â 2,297 Â Â Â (313) Â Â (13.6) Total Â Â 9,068 Â Â Â 9,105 Â Â Â (37) Â Â (0.4) Gross profit Â Â Â Â Â Â Â Â Â Â Â Surgical Glaucoma Â Â 50,048 Â Â Â 50,350 Â Â Â (302) Â Â (0.6) Dry Eye Â Â 1,676 Â Â Â 2,850 Â Â Â (1,174) Â Â (41.2) Total Â Â 51,724 Â Â Â 53,200 Â Â Â (1,476) Â Â (2.8) Gross margin Â Â Â Â Â Â Â Â Â Â Surgical Glaucoma Â Â 87.6 % Â Â 88.1 % Â Â Â Â Â Dry Eye Â Â 45.8 % Â Â 55.4 % Â Â Â Â Â Total Â Â 85.1 % Â Â 85.4 % Â Â Â Â Â Â Operating expenses Â Â Â Â Â Â Â Â Â Â Research and development Â Â 13,698 Â Â Â 14,129 Â Â Â (431) Â Â (3.1) Selling, general and administrative Â Â 76,629 Â Â Â 85,235 Â Â Â (8,606) Â Â (10.1) Total operating expenses Â Â 90,327 Â Â Â 99,364 Â Â Â (9,037) Â Â (9.1) Loss from operations Â Â (38,603) Â Â (46,164) Â Â 7,561 Â Â Â 16.4 Â Investment income Â Â 4,628 Â Â Â 5,499 Â Â Â (871) Â Â (15.8) Interest expense Â Â (3,501) Â Â (4,057) Â Â 556 Â Â Â 13.7 Â Loss on debt extinguishment Â Â (1,962) Â Â â€” Â Â Â (1,962) Â Â n.m. Â Other expense, net Â Â (25) Â Â (34) Â Â 9 Â Â Â 26.5 Â Â Â Â Â Â Â Â Â Â Â Loss before income taxes Â Â (39,463) Â Â (44,756) Â Â 5,293 Â Â Â 11.8 Â Provision for income taxes Â $ 198 Â Â $ 100 Â Â Â 98 Â Â Â 98.0 Â Net loss and comprehensive loss Â Â (39,661) Â Â (44,856) Â $ 5,195 Â Â Â 11.6 % Â Revenue. Our Surgical Glaucoma revenue for the nine months ended September 30, 2024 was $57.1 million, a decrease of less than $0.1 million, or less than 0.1%, from the prior year comparable period. The overall decrease in Surgical Glaucoma revenue was primarily attributable to a decrease in the number of OMNI units sold during the nine months ended September 30, 2024. This decline in units sold was primarily driven by a decrease in unit utilization per ordering facility and a lower average selling price primarily due to product mix. Our Dry Eye revenue decreased $1.5 million, or 28.9%, in the nine months ended September 30, 2024 versus the prior year comparable period primarily due to fewer new customers added in the period, which led to lower SmartHub revenue and fewer SmartLids purchased, partially offset by a higher average selling price for SmartHubs. The primary reason that fewer new customers were added was the Companyâ€™s focus on the next phase of its commercial strategy for its Dry Eye segment which involves achieving reimbursed market access instead of adding customers pursuing a cash pay model for its TearCare products. Cost of Goods Sold. Cost of goods sold was $9.1 million during the nine months ended September 30, 2024, a decrease of less than $0.1 million from $9.1 million in the prior year comparable period. Our Surgical Glaucoma cost of goods sold increased $0.3 million as compared to the prior year comparable period. The increase was primarily driven by product sales mix and higher per unit cost, partially offset by higher prior year scrap charges. Our Dry Eye cost of goods sold decreased $0.3 million in the nine months ended September 30, 2024 compared to the prior year comparable period, primarily driven by lower sales volumes and product mix. Â 29 Â Gross Profit and Gross Margin. Our gross profit was $51.7 million in the nine months ended September 30, 2024, a decrease of $1.5 million from the prior year comparable period. Our total gross margin for the nine months ended September 30, 2024 decreased to 85.1%, from 85.4% in the prior year comparable period. Gross margin in our Surgical Glaucoma segment was 87.6% for the nine months ended September 30, 2024, a decrease from 88.1% for the prior year comparable period, primarily due to product sales mix and higher cost per unit, partially offset by higher prior year comparable period scrap charges. In our Dry Eye segment, gross margin decreased from 55.4% in the nine months ended September 30, 2023 to 45.8% in the nine months ended September 30, 2024, primarily due to higher overhead costs per unit due to lower volumes. Research and Development Expenses. R&D expenses during the nine months ended September 30, 2024 decreased $0.4 million, or 3.1%, to $13.7 million. The decrease was primarily driven by a $0.8 million decrease in clinical studies and general research and development expenses, as well as $0.5 million decrease in payroll expenses. These were partially offset by a $0.4 million increase in professional and outside services, as well as a $0.2 million increase in legal expenses and stock-based compensation expenses. Selling, General, and Administrative Expenses. SG&A expenses were $76.6 million for the nine months ended September 30, 2024, a decrease of $8.6 million from the prior year comparable period. The decrease was primarily driven by a $5.8 million decrease in personnel expenses, including lower commissions during the current period. In addition, there was a $2.9 million decrease in marketing expenses, including sales training and demos, a $1.2 million decrease in travel and entertainment expenses, and a $0.7 million decrease in facilities expenses. These decreases were partially offset by a $1.8 million increase in stock-based compensation expenses, as well as a $1.1 million increase in accounting and legal expenses. Investment Income. Investment income was $4.6 million for the nine months ended September 30, 2024, a decline of $0.9 million from the prior year comparable period. The decline was primarily due to lower investment balances during the current year. Interest Expense. Interest expense decreased $0.6 million, due to lower lending rates associated with the Hercules Loan Agreement during the nine months ended September 30, 2024 compared to the nine months ended September 30, 2023. Loss on Debt Extinguishment. Loss on debt extinguishment was $2.0 million for the nine months ended September 30, 2024 compared to $0.0 million in the nine months ended September 30, 2023. The increase in the current year is driven by our loss on the termination and settlement of the MidCap Term Loan. Other Expense, Net. Other expense, net was expense of less than $0.1 million for both the nine months ended September 30, 2024 and 2023. Cash Flows The following table summarizes our cash flows for the periods indicated (in thousands): Â Â Â Nine Months Ended September 30, Â Â Â 2024 Â Â 2023 Â Â Â Â Â Â Â Net cash used in operating activities Â $ (18,892) Â $ (40,700) Net cash used in investing activities Â Â (248) Â Â (527) Net cash (used in) provided by financing activities Â Â (425) Â Â 728 Â Net change in cash and cash equivalents Â $ (19,565) Â $ (40,499) Â Net Cash Used in Operating Activities. Net cash used in operating activities for the nine months ended September 30, 2024 was $18.9 million, consisting of a net loss of $39.7 million, partially offset by non-cash charges of $15.6 million as well as a net change in our operating assets and liabilities of $5.2 million. The net change in our operating assets and liabilities was Â 30 Â primarily due to a $1.4 million decrease in accounts receivable, a $1.9 million decrease in our inventory

balance, and a $3.4 million increase in accrued compensation. These were partially offset by a $1.5 million decrease in other noncurrent liabilities. The non-cash charges primarily consisted of $13.1 million related to stock-based compensation expense, $1.0 million of noncash loss on debt extinguishment, $0.5 million of depreciation and amortization, $0.5 million of noncash operating lease expense, and $0.5 million of accretion of debt discount and debt issuance costs. Net cash used in operating activities for the nine months ended September 30, 2023 was $40.7 million, consisting primarily of a net loss of $44.9 million and a net change in our operating assets and liabilities of $9.3 million, partially offset by non-cash charges of $13.5 million. The net change in our operating assets and liabilities was primarily due to a $2.2 million increase in accounts receivable and a $3.3 million increase in inventory to support the continued growth of our operations and increase stocking levels. We had a $0.9 million increase in accounts payable, while accrued compensation and accrued and other current liabilities decreased by an aggregate of $4.9 million, primarily driven by the timing of payments on invoices and bonuses. The non-cash charges primarily consisted of $11.1 million related to stock-based compensation, $0.7 million of noncash operating lease expense, $0.5 million of depreciation, and $0.5 million of accretion of debt discount and debt issuance costs. Net Cash Used in Investing Activities. Net cash used in investing activities for the nine months ended September 30, 2024 and 2023 was $0.2 million and $0.5 million, respectively, in both cases for purchases of property and equipment. Net Cash (Used in) Provided by Financing Activities. Net cash used in financing activities for the nine months ended September 30, 2024 was $0.4 million, consisting primarily of the costs associated with our term loan agreement with Hercules Capital, Inc. ("Hercules"). Net cash provided by financing activities for the nine months ended September 30, 2023 of $0.7 million, which primarily relates to the exercise of common stock options and proceeds from employee stock plan purchases, partially offset by taxes paid on the net share settlement of restricted stock units. Liquidity and Capital Resources Sources of Liquidity To date, our primary sources of capital have been private placements of redeemable convertible preferred stock, debt financing agreements, the sale of common stock in our IPO, and revenue from the sale of our products. Since our inception, we have raised an aggregate of approximately $402.4 million in net proceeds from sales of our redeemable convertible preferred stock and common stock and borrowed $32.9 million of net proceeds under our term loans. In January 2024, we entered into a Loan and Security Agreement (the â€œHercules Loan Agreementâ€) with Hercules and certain of its affiliates (collectively with Hercules, the â€œLendersâ€), which provides for a senior secured term loan facility in the aggregate principal amount of up to $65.0 million. We used the proceeds from an initial $35.0 million tranche (the "Initial Loan") funded under the Hercules Loan Agreement to discharge our indebtedness under our prior secured credit facility with MidCap Financial Services and certain of its affiliates (the â€œPrior Lendersâ€). While our indebtedness to Lenders remains outstanding, we are required to use commercially reasonable efforts to grant the Lenders the option to invest up to $3.0 million in our next round of equity financing, if any, broadly marketed to multiple investors on the same terms, conditions and pricing offered to investors in such subsequent equity financing. As of September 30, 2024, we had cash and cash equivalents of $118.6 million, an accumulated deficit of $334.5 million and $35.0 million outstanding under the Hercules Term Loan Agreement (before debt discount). Based on our current planned operations, we expect our cash and cash equivalents and additional borrowings available under the Hercules Loan Agreement will enable us to fund our operations for at least the next 12 months and the foreseeable future. Hercules Capital Loan Agreement The Hercules Loan Agreement provides for a senior secured term loan facility in the aggregate principal amount of up to $65.0 million, and the Initial Loan was funded on January 22, 2024. In addition to the Initial Loan, the Hercules Loan Agreement provides for the following tranches: $5.0 million available in a single draw through Â 31 Â December 15, 2024, $10.0 million available to draw upon the achievement of certain performance milestones through September 15, 2025, and $15.0 million available for us to draw on through the interest-only period in increments of $5.0 million, subject to the sole approval of Hercules' investment committee (such tranche loans, together with the Initial Loan, the â€œTerm Loansâ€). The Hercules Loan Agreement includes a maturity date of July 1, 2028, with an interest only period running for 30 months, extendable for an additional six months for a total of 36 months upon the achievement of certain milestones. The Term Loans accurate interest at a floating annual rate of the greater of 10.35% or the Wall Street Journal prime rate plus 2.35%, with an interest rate under the Term Loans equal to 10.35% as of September 30, 2024. The final payment fee is set at 5.95% of the funded balance. In conjunction with the funding of the Initial Loan, we issued warrants to the Lenders to purchase up to an aggregate of 135,686 shares of our common stock at an exercise price of $5.159 per share. Each warrant is exercisable for a period of seven years from the date of issuance and is tradeable in accordance with the provisions of Rule 144 of the Securities Act. Our obligations under the Hercules Loan Agreement are guaranteed by us and our future subsidiaries, subject to exceptions for certain foreign subsidiaries and secured by substantially all of our assets, including our material intellectual property. Additionally, we are subject to customary affirmative and negative covenants, including covenants that limit or restrict the ability of us to, among other things, incur indebtedness, grant liens, merge or consolidate, make investments, dispose of assets, make acquisitions, pay dividends or make distributions, repurchase stock and enter into certain transactions with affiliates, in each case subject to certain exceptions. We are also subject to certain minimum cash and revenue covenants under the Hercules Loan Agreement. MidCap Loan Agreements In January 2019, we entered into credit and security agreements with the Prior Lenders. These agreements were amended and restated in November 2020, providing for a maximum $40.0 million credit facility consisting of a $35.0 million senior secured term loan (the "2020 Term Loan") and a $5.0 million revolving loan (the "2020 Revolverâ€ and together with the 2020 Term Loan, the â€œMidCap Credit Facilityâ€). In July 2023, we terminated the 2020 Revolver. In January 2024, we terminated the Amended and Restated Credit and Security Agreement (Term Loan) (the â€œMidCap Term Loan Agreementâ€) and paid off in full the secured obligations thereunder in connection with our entry into the Hercules Loan Agreement. The MidCap Term Loan Agreement extended the maturity date of the 2020 Term Loan to November 1, 2025 and adjusted the stated floating interest rate to reserve-adjusted SOFR, plus 7.00%. Principal payments under the MidCap Term Loan Agreement were extended and scheduled to begin in December 2024. The final payment fee was amended to 6.0%. Our obligations under the MidCap Term Loan Agreement were guaranteed by us and our future subsidiaries, subject to exceptions for certain foreign subsidiaries. Our obligations under the agreements were secured by substantially all of our assets, including our material intellectual property. Additionally, we were subject to customary affirmative and negative covenants, including covenants that limited or restricted our ability to, among other things, incur indebtedness, grant liens, merge or consolidate, make investments, dispose of assets, make acquisitions, pay dividends or make distributions, repurchase stock and enter into certain transactions with affiliates, in each case subject to certain exceptions. The MidCap Credit Term Loan Agreement contained events of default that included, among others, non-payment of principal, interest or fees, breach of covenants, inaccuracy of representations and warranties, cross-defaults and bankruptcy and insolvency events. Leases Our corporate headquarters are located in Menlo Park, California, where we lease approximately 11,000 square feet of office, research and development, engineering and laboratory space pursuant to a lease that commenced on August 1, 2021, and expires on October 31, 2026. Off-Balance Sheet Arrangements We do not have any off-balance sheet arrangements. Â 32 Â Critical Accounting Estimates Our unaudited condensed consolidated financial statements included elsewhere in this Quarterly Report have been prepared in accordance with U.S. generally accepted accounting principles. The preparation of these condensed consolidated financial statements requires us to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenue, expenses and related disclosures. Our estimates are based on our historical experience and various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions and any such differences may be material. An accounting estimate is deemed to be critical if it requires an accounting estimate to be made based on assumptions about matters that are highly uncertain at the time the estimate is made, if different estimates reasonably could have been used, or if changes in the estimate that are reasonably possible could materially impact the financial statements. There have been no material changes to our critical accounting estimates as compared to the critical accounting estimates described in Part II, Item 7, â€œManagementâ€™s Discussion and Analysis of Financial Condition and Results of Operationsâ€ in our Annual Report under the heading â€œCritical Accounting Estimatesâ€. JOBS Act Accounting Election The JOBS Act permits an â€œemerging growth companyâ€ such as us to take advantage of an extended transition period to comply with new or revised accounting standards applicable to public companies. We have elected to use this extended transition period under the JOBS Act. As a result, our financial statements may not be comparable to the financial statements of issuers who are required to comply with the effective dates for new or revised accounting standards that are applicable to public companies, which may make comparison of our financial statements to those of other public companies more difficult. Recently Issued Accounting Pronouncements See Note 2, Summary of Significant Accounting Policies, in the notes to our unaudited condensed consolidated financial statements in this Quarterly Report for recent accounting pronouncements not yet adopted as of the date hereof. Item 3. Quantitative and Qualitative Disclosures About Market Risk. We are exposed to market risks in the ordinary course of our business. These risks primarily include interest rate risk. There have been no material changes to such risks from those described in our Annual Report under the heading "Quantitative and Qualitative Disclosures About Market Risk." Item 4. Controls and Procedures. Evaluation of Disclosure Controls and Procedures Our management, with the participation and supervision of our principal executive officer and our principal financial and accounting officer, evaluated our disclosure controls and procedures. The term "disclosure controls and procedures," (as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act) means controls and other procedures of a company that are designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the SEC's rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is accumulated and communicated to the Company's management, including its principal executive officer, and principal financial and accounting officer, as appropriate to allow timely decisions regarding required disclosure. Based on this evaluation, our principal executive officer and principal financial and accounting officer concluded that, as of the end of the period covered by this Quarterly Report, our disclosure controls and procedures were effective at a reasonable assurance level. Â 33 Â Changes in Internal Control Over Financial Reporting There were no changes in our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) during the quarter ended September 30, 2024 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting. PART IIâ€”OTHER INFORMATION Item 1. Legal Proceedings. Except as set forth in Note 6, Commitments and Contingencies, in the notes to the unaudited condensed consolidated financial statements in this Quarterly Report, we do not believe we are currently a party to any legal proceedings, regulatory matters, or other disputes or claims which, if determined adversely to us, would, individually or taken together, have a material adverse effect on our business, financial condition, operating results, liquidity or future prospects. However, we may, in the ordinary course of business, face various claims brought by third parties, and we may, from time to time, make claims or take legal actions to assert our rights, including intellectual property rights as well as claims relating to employment matters and the safety or effectiveness of our products. Any of these claims could subject us to costly litigation, and, while we generally believe that we have adequate insurance to cover many different types of liabilities, our insurance carriers may deny coverage, may be inadequately capitalized to pay on valid claims, or our policy limits may be inadequate to fully satisfy any damage awards or settlements. If this were to happen, the payment of any such awards could have a material adverse effect on our business, financial condition and results of operations. Additionally, any such claims, whether or not successful, could damage our reputation and business, and may have an adverse impact on us as a result of defense and settlement costs, diversion of management time and resources, and other factors. Item 1A. Risk Factors. Except as set forth below, we are not aware of any material changes to the risks and uncertainties described under the heading "Risk Factors" in our Annual Report or Quarterly Report on Form 10-Q for the three months ended March 31, 2024, which are incorporated herein by reference. The risks described below and in our Annual Report and our Quarterly Report on Form 10-Q for the three months ended March 31, 2024 are not the only ones we face. Additional risks we currently do not know about or that we currently believe to be immaterial may also impair our business, financial condition, operating results, liquidity, and future prospects. We may not be able to incrementally secure or maintain adequate levels of third-party coverage and reimbursement for procedures in which our Surgical Glaucoma or Dry Eye products are used, and third parties may rescind or modify their coverage or delay payments related to these products, which will adversely affect our business, financial condition, and results of operations. We derive revenue from sales of OMNI and SION to physicians, ASCs, and HOPDs, which typically bill all or a portion of the costs and fees associated with our products to various third-party payors, including Medicare, Medicaid, foreign governmental payers, private commercial insurance companies, health maintenance organizations and other healthcare-related organizations, and then bill patients for any applicable deductibles or co-payments. As a result, access to adequate coverage and reimbursement for procedures in which our Surgical Glaucoma products are used by third-party payors is essential to their acceptance and adoption by patients and ECPs. Internationally, medical reimbursement systems vary significantly from country to country, with some countries limiting medical centersâ€™ spending through fixed budgets, regardless of levels of patient treatment, and other countries requiring application for, and approval of, government or third-party reimbursement. For example, in the third quarter of 2024, certain reimbursement guidance in the United Kingdom has caused a shift in perspectives regarding appropriate coding for procedures performed with our OMNI technology. This shift may result in disadvantageous reimbursement for OMNI procedures as compared to historic reimbursement levels, which in turn could materially affect our business, results of operations and prospects in the United Kingdom. These third-party payors continually review new and existing technologies for possible coverage and can deny or reverse coverage for new or existing products and procedures, and there can be no assurance that third-party payor policies provide coverage, or will continue to provide coverage, for procedures in which OMNI or our other products are used. For example, in the U.S., CMS, MACs or commercial payors could require or issue coverage policies that could restrict or eliminate coverage for the patient populations eligible for treatment with our products or that are otherwise unfavorable to our business. In June 2023, for instance, five MACs published proposed local Â 34 Â coverage determinations (the â€œPrior LCDsâ€)that proposed to identify certain non-implantable MIGS procedures as investigational and not reasonable and necessary in the jurisdictions where these MACS administer Medicare Part B benefits, including but not limited to adult canaloplasty in combination with trabeculotomy ab interno, a procedure performed with OMNI and for which it is indicated. The Prior LCDs may also have categorized our SION technology as investigational and thus non-covered with respect to goniotomy procedures. The Prior LCDs were withdrawn in late December 2023, prior to becoming effective, and then replaced with updated LCDs issued in late September and early October 2024 (the â€œFinal LCDsâ€) that are scheduled to become effective in November 2024. The Final LCDs allow for continued coverage of canaloplasty and goniotomy procedures performed with our OMNI and SION technologies in these five MAC jurisdictions. However, each of the Final LCDs will adopt a non-coverage policy when an aqueous shunt or stent procedure is performed with another surgical MIGS procedure, such as canaloplasty or goniotomy, at the same time in the same patient eye. We estimate that approximately 10% of total MIGS codes billed in the six months ended June 30, 2024 were done in combination with another MIGS code and expect the non-coverage determination for multiple MIGS procedures will reduce overall MIGS procedure volumes. In the future, governmental or private payers may issue coverage policies or guidance that may establish non-coverage, materially restrict coverage, or reduce reimbursement levels for one or more of our products. Any such policies, determinations or guidance could in turn influence coverage determinations by other third-party payors. If we are not successful in reversing any proposed non-coverage policies, or if third-party payors that currently cover or reimburse procedures in which our products are used reverse or limit their coverage in the future, or if other third-party payors issue similar policies, it would have a material adverse effect on our business, financial condition, and results of operations. Moreover, any uncertainty with respect to coverage or coding may impact managementâ€™s ability to accurately forecast results. We also derive revenue from sales of TearCare to ECPs and eye care clinics, which bill all or a portion of the costs and fees associated with treatments and products to patients or, on a limited basis, to third-party payors. We believe that access to adequate coverage and reimbursement for procedures in which TearCare is used by third-party payors is important to the broad acceptance and adoption of TearCare. Currently, no MACs have formal policies establishing coverage for the TearCare procedure; however, MACs from time to time may include, and we are currently aware of three MACs that have included, low payment rates for TearCare procedures in their fee schedules that, if not removed or increased to what we believe is an appropriate reimbursement level, could adversely impact our efforts to achieve reimbursement for TearCare that is sufficient to support its broad commercial growth and adoption. Further, commercial payors may from time to time make â€œno coverageâ€ or similar determinations with respect to our TearCare product that could hamper our efforts to drive broad commercial adoption of TearCare. We are pursuing a comprehensive long-term market development and patient access plan for TearCare and focusing our efforts on partnering with key strategic accounts to pursue prior authorization approvals and reimbursement claims for procedures in which TearCare is used, but there is no guarantee that we will be successful. If patients are not willing to pay for procedures in which TearCare is used, or if third-party payors continue to refuse to provide coverage and reimbursement, or provide insufficient levels of coverage and reimbursement, it could have a negative impact on ECPsâ€™ adoption of TearCare and sales of TearCare, which could adversely affect our business. Third-party payors, whether foreign or domestic, or governmental or commercial, are developing increasingly sophisticated

methods of controlling healthcare costs. In addition, no uniform policy of coverage and reimbursement for procedures using our products exists among third-party payors. Therefore, coverage and reimbursement for procedures using our products can differ significantly from payor to payor. Obtaining and maintaining coverage and reimbursement can be a time-consuming process that could require us to provide supporting scientific, clinical and cost-effectiveness data for the use of our products. We may not be able to provide data sufficient to satisfy governmental and third-party payors that procedures using our products should be covered and reimbursed. With regard to our international sales efforts, even if and as we succeed in bringing our products to market in foreign countries, uncertainties regarding future healthcare policy, legislation and regulation, as well as private market practices, could affect our ability to sell our products in commercially acceptable quantities at acceptable prices. In the United States, the AMA generally assigns specific billing codes for procedures under a coding system known as Current Procedure Terminology (â€œCPTâ€), which surgeons use to bill third-party payors and receive reimbursement. Once a permanent CPT code ("Category I CPT code") is established for a service, CMS establishes payment levels under Medicare, while other payors may establish rates and coverage rules independently. Canaloplasty followed by trabeculotomy procedures using OMNI are typically billed using the Category I CPT code 66174, which describes canaloplasty. Coding for ophthalmic surgical procedures is complex, and changes to the codes used to report services performed with our products may result in significant changes in reimbursement, Â 35 Â which could negatively impact our revenue. For example, in 2021 the RVS Update Committee ("RUC") of the AMA reevaluated the physician work associated with CPT code 66174. As a result of this RUC review and further conversion factor reductions, CMS reduced the Medicare Physician Fee Schedule amount associated with this service from approximately $950 in 2021, to $761 in 2022, to $622 in 2023, to $608 in 2024 and to $600 in 2025. Many of the factors considered by the RUC, and many of the factors evaluated by payors and other payor advisory bodies, in assessing the costs of, and payments with respect to, procedures associated with our products are not within our control. For instance, with respect to determination of hospital, ASC and physician payment associated with CPT code 66174, evaluation of procedure costs may include the costs of competitive products that are priced well below our products, and may also reflect reduced physician work with respect to procedures that are less comprehensive than the procedures performed with OMNI. This, in turn, may adversely affect our ability to obtain and maintain adequate and appropriate levels of reimbursement for the comprehensive procedure enabled by our OMNI technology, which could adversely affect our financial condition and results of operations. The AMA maintains a subset of temporary CPT codes ("Category III CPT codes") used for new and emerging technologies. For example, TearCare was assigned a Category III CPT code effective beginning January 1, 2020. Coverage for Category III CPT codes is often limited. Medicare does not generally establish national payment rates for Category III CPT codes on the Medicare Physician Fee Schedule ("MPFS"). As a result, individual Medicare contractors and private payors may establish their own payment rates for services described by Category III CPT codes, as has been the case with TearCare, which payment rates are subject to change, may be variable across Medicare contractors, may be materially below the final reimbursement rates that we are currently targeting, or may determine not to reimburse services described by Category III CPT codes. Further, we believe that future coverage and reimbursement may be subject to increased restrictions, such as additional prior authorization requirements, both in the United States and in international markets. Third-party coverage and reimbursement for procedures using our products or any of our products in development for which we may receive regulatory clearance, certification or approval may not be available or adequate in either the United States or international markets. Further, other devices or treatments that compete with our products may be more widely covered or subject to different co-pay policies and requirements, which could impact demand for our products. If hospital, surgical center, ECP and/or patient demand for our products is adversely affected by third-party reimbursement policies and decisions, it could have a material adverse effect on our business, financial condition and results of operations. The market for our products is highly competitive. Our competitors may have longer operating histories, more established products and greater resources than we do, and may be able to develop or market treatments that are safer, more effective or gain greater acceptance in the marketplace than our products. The medical device industry is highly competitive, subject to rapid change and significantly affected by the introduction of new products and technologies and the other activities of industry participants. We compete, or plan to compete, with medical device and pharmaceutical companies that develop and commercialize products for eye conditions, including Glaukos, AbbVie/Allergan, Novartis, Alcon, Johnson & Johnson, Nova Eye Medical, and New World Medical. These companies, or other entrants into the market, may have or develop competing technologies, other products that are in or that enter clinical trials, new devices or additional indications for existing devices that could demonstrate better safety, effectiveness, clinical results, lower costs or greater ECP and market acceptance than our products. For example, there has been a recent increase in ECP trialing of alternative products that are offered at lower prices than OMNI, which we believe has had a near-term adverse impact on utilization of OMNI. Though in the past, we viewed such ECP trialing and use of alternative devices as temporary and not material to the continued growth of OMNI sales, we cannot guarantee that this has continued or will continue to remain the case. Sustained increases in ECP use of alternative MIGS devices could result in reduced OMNI sales and revenue growth or even loss of market share, which would adversely impact our competitive position, business and results of operations. In addition, despite what we believe to be the strong safety profile of our products for their intended uses, patients may experience adverse events following canaloplasty or trabeculotomy with OMNI, including, but not limited to, hyphema, mild anterior chamber inflammation and spikes in intraocular pressure. Similarly, patients may experience adverse events following use of the SION surgical instrument, including anterior chamber shallowing and prolonged, or persistent intraocular inflammation, or application of localized heat with TearCare, including discomfort, pain or erythema of the eyelids. Any failure to meet customer and patient expectations and any resulting negative perceptions or publicity could harm our reputation and future sales and therefore adversely affect our business, financial condition and results of operations. Â 36 Â We compete, or may compete in the future, against other companies which have longer, more established operating histories and significantly greater financial, technical, marketing, sales, distribution and other resources, which may prevent us from achieving significant market penetration or improved operating results. These companies may enjoy several competitive advantages, including: â€¢Established treatment patterns pursuant to which prescription medications, traditional glaucoma surgery or more conventional MIGS procedures are generally first-line therapies for the treatment of glaucoma and eye drops or warm-compresses are first-line therapies for the treatment of MGD; â€¢Established relationships with ECPs who are familiar with their products and procedures for the treatment of glaucoma or MGD; â€¢Established relationships with key stakeholders, including hospital outpatient departments, ambulatory surgery centers, optometrists and ophthalmologists, general practitioners and administrators; â€¢Greater financial and human capital resources; â€¢Significantly greater name recognition; â€¢Additional lines of products, and the ability to offer rebates or bundle products to offer greater discounts or incentives to gain a competitive advantage; and â€¢Established sales, marketing and worldwide distribution networks. One of the major hurdles to adoption of our products will be overcoming established treatment patterns, which will require educating ECPs and supportive clinical data. However, because of the size of the market opportunity for devices used in procedures to address MIGS and MGD, we believe current and potential future competitors will dedicate significant resources to aggressively promote their products or develop new products or treatments, such as Glaukosâ€™ iStentÂ® technologies, iPRIMEâ„¢ Viscodelivery System, and iDoseÂ® TR intraocular implant; Alconâ€™s HydrusÂ® MicroStent; and various canaloplasty devices including Nova Eyeâ€™s iTrackâ„¢ Advance. Further, new treatment options may be developed that could compete more effectively with our products due to the prevalence of glaucoma and MGD, and the research and technological progress that exist within the market. Also, even if competitor products do not have indications for use or clinical data that are comparable to ours, ECPs can still choose these competitor products for a variety of reasons, including those set forth above. For instance, competitors may seek to bundle their products in a manner that is attractive to ECPs, which may result in decreased use or adoption of our products by ECPs, notwithstanding that our products may offer superior efficacy. We rely on third parties to manufacture and supply our products, many of which are single-source providers and certain of which are located outside the U.S., and we are subject to numerous risks relating to our reliance on these parties. Our business strategy depends on our ability to manufacture our current and future products in sufficient quantities, on terms that are acceptable to us, and on a timely basis to meet customer demand, while adhering to product quality standards, complying with regulatory quality system requirements, and managing manufacturing costs. We do not have any internal manufacturing capabilities or infrastructure and rely on a limited number of third-party manufacturers, many of which are single-source suppliers, and certain of which are located outside the U.S., for the components, accessories, materials and assembly that we utilize in our products. These items are critical and, for certain items, there are relatively few or no readily available alternative sources of supply. These single-source suppliers may be unwilling or unable to supply these items reliably and at the levels we anticipate or that are required by the market, or we may be unable to purchase these items on terms that are acceptable to us, or at all. Our ability to obtain products and components in sufficient quantities from these suppliers may be limited for several reasons, including their financial difficulties, damage to their manufacturing equipment or facilities, inability to obtain components, problems with their own suppliers, our relative importance as a customer to each manufacturer. In addition, geopolitical or trade tensions between China and Taiwan or China and the United States, or potential tariffs, could increase the cost of our products or components, and materially and adversely affect our business operations and financial condition. For example, a significant portion of our OMNI and SION products, and certain of our TearCare system components, are produced and assembled by a single Taiwan-based manufacturer in China, and there is currently significant uncertainty about the future relationship between the U.S. Â 37 Â and China with respect to trade policies, government regulations, and tariffs, and such uncertainty could continue in future periods. There has been increasing discussion from U.S. and foreign leaders regarding the possibility of instituting tariffs against foreign imports of certain materials. The institution of trade tariffs between the U.S. and China specifically could cause a significant increase in the cost of our products and the components for our products, which could materially and adversely affect our business, results of operations, and financial condition. To mitigate these risks, we have also contracted with a U.S.-based manufacturer to produce and assemble OMNI products, and have supply arrangements with other suppliers for the production of certain TearCare system components. However, for our business strategy to be successful, our suppliers must be able to provide us with products in sufficient quantities, in compliance with regulatory requirements, including the FDAâ€™s QSR or other applicable laws or regulations enforced by the FDA, state and foreign regulatory authorities, in accordance with agreed-upon specifications, at acceptable costs and on a timely basis, and tariffs or a trade war could materially and adversely impact our ability to do so. If we are unable to meet our demand requirements on a timely basis, we may not have a sufficient number of our products available for delivery to support ECPs that utilize our products as part of their treatment. For instance, if our supply of OMNI products from our manufacturer in China was interrupted or suspended for any significant period, or tariffs that affect our products or components were imposed by the United States, we may be unable to meet customer demand for our OMNI products during that time. Any shortfall in the supply of products may result in lower adoption and usage rates of our products and have a material adverse effect on our business, financial condition and results of operations. The process of identifying and qualifying alternative manufacturing facilities for any other reason could be time-consuming and expensive, may result in interruptions in our operations and product delivery, and could affect the performance specifications of our products. We cannot assure you that we will be able to identify and engage alternative contract manufacturers on terms similar to our current arrangements, or without delay. Furthermore, our contract manufacturers could require that their manufacture and assembly of our products be moved to another of their production facilities. The occurrence of any of these events could harm our ability to meet the demand for our products in a timely and cost-effective manner, which could have a material adverse effect on our business, financial condition and results of operations. We are also subject to numerous other risks relating to our reliance on third parties, including potential quality issues at our suppliers' manufacturing facilities with respect to our products, and our potential inability to renew or extend contracts and arrangements with such third parties or renew any such contracts or arrangements on terms that are favorable to us, and price fluctuations due to a lack of long-term supply agreements with certain of our suppliers. These risks are likely to be exacerbated by our limited experience with our current products and manufacturing processes. As demand for our products increases, we will have to invest additional resources to manage the manufacturing process. If we fail to secure increased production capacity efficiently, we may not be able to fill customer orders on a timely basis, our sales may not increase in line with our expectations and our operating margins could fluctuate or decline. In addition, the manufacture of future products may require modification of the current production processes or unique production processes, the identification of new suppliers for specific components, sub-assemblies and materials or the development of new manufacturing technologies. It may not be possible for our current third-party manufacturers to produce these products at a cost or in quantities sufficient to make these products commercially viable or to maintain current operating margins, all of which could have a material adverse effect on our business, financial condition and results of operations. Â 38 Â Item 2. Unregistered Sales of Equity Securities and Use of Proceeds. Use of Proceeds On July 14, 2021, our registration statement on Form S-1 (File No. 333-257320) relating to our IPO became effective. The IPO closed on July 15, 2021, at which time we issued 11,500,000 shares of our common stock at a price of $24.00 per share. There has been no material change in the planned use of proceeds from our IPO as described in our final prospectus dated July 14, 2021 and filed with the SEC on July 15, 2021 pursuant to Rule 424(b) under the Securities Act. Recent Sales of Unregistered Securities None. Issuer Repurchases of Equity Securities None. Item 3. Defaults Upon Senior Securities. None. Item 4. Mine Safety Disclosures. Not applicable. Item 5. Other Information. Trading PlansOur directors and officers may enter into trading plans or other arrangements with financial institutions to purchase or sell shares of our common stock, which plans or arrangements are intended to comply with the affirmative defense provisions of Rule 10b5-1 of the Exchange Act or which may represent a non-Rule 10b5-1 trading arrangement as defined under Item 408(a) of Regulation S-K.Set forth below is a summary of the adoption, modification, and termination activity of our directors and executive officers in respect of their Rule 10b5-1 trading plans during the quarter ended September 30, 2024: Name & Title Adoption Date Termination Date Contract End Date Aggregate Shares Covered(in ones) Jeremy B. Hayden, Chief Legal Officer August 28, 2024 August 25, 2025 August 25, 2025 48,000 Â Â 39 Â Item 6. Exhibits. The following exhibits are filed or furnished as a part of, or incorporated by reference into, this Quarterly Report. Â Â Â Â Â Incorporated by Reference Â Â Â Â Â Â Â Â Â Â Â Â Exhibit Number Â Exhibit Description Â Form Â File No. Â Exhibit Â Filing Date Â Filed/Furnished Herewith 3.1 Â Restated Certificate of Incorporation of Sight Sciences, Inc. Â 8-K Â 001-40587 Â 3.1 Â 7/19/21 Â Â 3.2 Â Amended and Restated Bylaws of Sight Sciences, Inc. Â 8-K Â 001-40587 Â 3.2 Â 7/19/21 Â Â 31.1 Certification of the Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 Â Â Â Â Â Â Â Â Â * 31.2 Certification of the Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 Â Â Â Â Â Â Â Â Â Â * 32.1 Certification of the Chief Executive Officer pursuant to 18 U.S.C Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 Â Â Â Â Â Â Â Â Â Â ** 32.2 Certification of the Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 Â Â Â Â Â Â Â Â ** 101.INS Inline XBRL Instance Document Â Â Â Â Â Â Â Â * 101.SCH Inline XBRL Taxonomy Extension Schema Document Â Â Â Â Â Â Â Â * 101.CAL Inline XBRL Taxonomy Extension Calculation Linkbase Document Â Â Â Â Â Â Â Â * 101.DEF Inline XBRL Taxonomy Extension Definition Linkbase Document Â Â Â Â Â Â Â Â * 101.LAB Inline XBRL Taxonomy Extension Label Linkbase Document Â Â Â Â Â Â Â Â * 101.PRE Inline XBRL Taxonomy Extension Presentation Linkbase Document Â Â Â Â Â Â Â Â * 104 Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101) Â Â Â Â Â Â Â Â Â * Â * Filed herewith. ** Furnished herewith. Â Â 40 Â SIGNATURES Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this Report to be signed on its behalf by the undersigned, thereunto duly authorized. Â SIGHT SCIENCES, INC Date: November 7, 2024 By: /s/ Alison Bauerlein Â Alison Bauerlein Chief Financial Officer (Principal Financial Officer and Â Â Principal Accounting Officer) Â Â 41 EX-31.1 2 sght-ex31_1.htm EX-31.1 EX-31.1 Â Â Exhibit 31.1 CERTIFICATION OF CHIEF EXECUTIVE OFFICER PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 Â I, Paul Badawi, certify that: Â 1.I have reviewed this Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2024 of Sight Sciences, Inc.; Â 2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; Â 3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; Â 4.The registrantâ€™s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have: Â a)Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; b)Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; Â c)Evaluated the effectiveness of the

registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and d)Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and Â 5.The registrantâ€™s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrantâ€™s auditors and the audit committee of the registrantâ€™s board of directors (or persons performing the equivalent functions): a)all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrantâ€™s ability to record, process, summarize and report financial information; and b)any fraud, whether or not material, that involves management or other employees who have a significant role in the registrantâ€™s internal control over financial reporting. Â Â Â Â Â Date: November 7, 2024 /s/ Paul Badawi Paul BadawiChief Executive Officer(Principal Executive Officer) Â Â Â Â Â Â Â | Â Â Â Â Â | EX-31.2 3 sght-ex31_2.htm EX-31.2 EX-31.2 Â Exhibit 31.2 CERTIFICATION OF CHIEF FINANCIAL OFFICER PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 Â I, Alison Bauerlein, certify that: Â 1.I have reviewed this Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2024 of Sight Sciences, Inc.; Â 2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; Â 3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; Â 4.The registrantâ€™s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have: Â a.Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; b.Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; Â c.Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and d.Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and Â 5.The registrantâ€™s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrantâ€™s auditors and the audit committee of the registrantâ€™s board of directors (or persons performing the equivalent functions): Â a.all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrantâ€™s ability to record, process, summarize and report financial information; and b.any fraud, whether or not material, that involves management or other employees who have a significant role in the registrantâ€™s internal control over financial reporting. Â Date: November 7, 2024 Â /s/ Alison Bauerlein Alison BauerleinChief Financial Officer(Principal Financial Officer and Principal Accounting Officer) Â Â Â Â Â | Â Â Â Â Â | EX-32.1 4 sght-ex32_1.htm EX-32.1 EX-32.1 Â Â Exhibit 32.1 CERTIFICATION OF CHIEF EXECUTIVE OFFICER PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 Â Pursuant to 18 U.S.C. Â§ 1350, as created by Section 906 of the Sarbanes-Oxley Act of 2002, the undersigned officer of Sight Sciences, Inc. (the â€œCompanyâ€) hereby certifies that, to his knowledge: Â 1.the Quarterly Report on Form 10-Q of the Company for the quarterly period ended September 30, 2024 (the â€œReportâ€) fully complies with the requirements of Section 13(a) or Section 15(d), as applicable, of the Securities Exchange Act of 1934, as amended; and Â 2.the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. Â Â Â Dated: November 7, 2024 /s/ Paul Badawi Paul Badawi Chief Executive Officer (Principal Executive Officer) Â The foregoing certification is being furnished solely to accompany the Report pursuant to 18 U.S.C. Â§ 1350, and is not being filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and is not to be incorporated by reference into any filing of the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing. Â A signed original of this written statement required by Section 906, or other document authenticating, acknowledging, or otherwise adopting the signature that appears in typed form within the electronic version of this written statement required by Section 906, has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request. Â Â Â Â Â EX-32.2 5 sght-ex32_2.htm EX-32.2 EX-32.2 Â Â Exhibit 32.2 CERTIFICATION OF CHIEF FINANCIAL OFFICER PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 Â Pursuant to 18 U.S.C. Â§ 1350, as created by Section 906 of the Sarbanes-Oxley Act of 2002, the undersigned officer of Sight Sciences, Inc. (the â€œCompanyâ€) hereby certifies that, to her knowledge: Â 1.the Quarterly Report on Form 10-Q of the Company for the quarterly period ended September 30, 2024 (the â€œReportâ€) fully complies with the requirements of Section 13(a) or Section 15(d), as applicable, of the Securities Exchange Act of 1934, as amended; and Â 2.the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. Â Â Â Dated: November 7, 2024 /s/ Alison Bauerlein Alison Bauerlein Chief Financial Officer (Principal Financial Officer and Principal Accounting Officer) Â Â The foregoing certification is being furnished solely to accompany the Report pursuant to 18 U.S.C. Â§ 1350, and is not being filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and is not to be incorporated by reference into any filing of the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing. Â A signed original of this written statement required by Section 906, or other document authenticating, acknowledging, or otherwise adopting the signature that appears in typed form within the electronic version of this written statement required by Section 906, has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request. Â EX-101.SCH 6 sght-20240930.xsd XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT 100000 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink 100010 - Statement - Condensed Consolidated Balance Sheets (Unaudited) link:presentationLink link:calculationLink link:definitionLink 100020 - Disclosure - Balance Sheet Components - Summary of Accrued and Other Current Liabilities (Details) 2 link:presentationLink link:calculationLink link:definitionLink 100030 - Disclosure - Commitments and Contingencies - Schedule of Aggregate Future Minimum Lease Payments (Details) 2 link:presentationLink link:calculationLink link:definitionLink 100040 - Disclosure - Debt - Schedule of Long-term and Short-term Debt (Details) 2 link:presentationLink link:calculationLink link:definitionLink 100050 - Statement - Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 100060 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) link:presentationLink link:calculationLink link:definitionLink 100070 - Statement - Condensed Consolidated Statements of Redeemable Convertible Preferred Stock and Stockholders' Equity (Unaudited) link:presentationLink link:calculationLink link:definitionLink 100080 - Statement - Condensed Consolidated Statements of Redeemable Convertible Preferred Stock and Stockholders' Equity (Unaudited) (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 100090 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) link:presentationLink link:calculationLink link:definitionLink 995455 - Disclosure - Company and Nature of Business link:presentationLink link:calculationLink link:definitionLink 995465 - Disclosure - Summary of Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 995475 - Disclosure - Fair Value Measurements link:presentationLink link:calculationLink link:definitionLink 995485 - Disclosure - Balance Sheet Components link:presentationLink link:calculationLink link:definitionLink 995495 - Disclosure - Debt link:presentationLink link:calculationLink link:definitionLink 995505 - Disclosure - Commitments and Contingencies link:presentationLink link:calculationLink link:definitionLink 995515 - Disclosure - Stockholders' Equity link:presentationLink link:calculationLink link:definitionLink 995525 - Disclosure - Equity Incentive Plans link:presentationLink link:calculationLink link:definitionLink 995535 - Disclosure - Net Loss per Share Attributable to Common Stockholders link:presentationLink link:calculationLink link:definitionLink 995545 - Disclosure - Defined Contribution Plan link:presentationLink link:calculationLink link:definitionLink 995555 - Disclosure - Segment Information link:presentationLink link:calculationLink link:definitionLink 995565 - Disclosure - Subsequent Events link:presentationLink link:calculationLink link:definitionLink 995575 - Disclosure - Summary of Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 995585 - Disclosure - Fair Value Measurements (Tables) link:presentationLink link:calculationLink link:definitionLink 995595 - Disclosure - Balance Sheet Components (Tables) link:presentationLink link:calculationLink link:definitionLink 995605 - Disclosure - Debt (Tables) link:presentationLink link:calculationLink link:definitionLink 995615 - Disclosure - Commitments and Contingencies (Tables) link:presentationLink link:calculationLink link:definitionLink 995625 - Disclosure - Stockholders' Equity (Tables) link:presentationLink link:calculationLink link:definitionLink 995635 - Disclosure - Equity Incentive Plans (Tables) link:presentationLink link:calculationLink link:definitionLink 995645 - Disclosure - Net Loss per Share Attributable to Common Stockholders (Tables) link:presentationLink link:calculationLink link:definitionLink 995655 - Disclosure - Segment Information (Tables) link:presentationLink link:calculationLink link:definitionLink 995665 - Disclosure - Company and Nature of Business - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 995675 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 995685 - Disclosure - Fair Value Measurements - Summary of Fair Value Measurement Liabilities Measured On Recurring Basis (Details) link:presentationLink link:calculationLink link:definitionLink 995695 - Disclosure - Fair value Measurement - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 995705 - Disclosure - Fair Value Measurement - Held-to-maturity debt securities at amortized cost (Details) link:presentationLink link:calculationLink link:definitionLink 995715 - Disclosure - Balance Sheet Components - Summary of Property and Equipment, Net (Details) link:presentationLink link:calculationLink link:definitionLink 995725 - Disclosure - Balance Sheet Components - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 995735 - Disclosure - Balance Sheet Components - Summary of Accrued and Other Current Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 995745 - Disclosure - Balance Sheet Components - Summary of Other Noncurrent Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 995755 - Disclosure - Debt - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 995765 - Disclosure - Debt - Schedule of Long-term and Short-term Debt (Details) link:presentationLink link:calculationLink link:definitionLink 995775 - Disclosure - Debt - Schedule Relating to the Company's Debt (Details) link:presentationLink link:calculationLink link:definitionLink 995785 - Disclosure - Commitments and Contingencies - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 995795 - Disclosure - Commitments and Contingencies - Schedule of Operating Lease Expense Recognized and Supplemental Cash Flow (Details) link:presentationLink link:calculationLink link:definitionLink 995805 - Disclosure - Commitments and Contingencies - Schedule of Aggregate Future Minimum Lease Payments (Details) link:presentationLink link:calculationLink link:definitionLink 995815 - Disclosure - Stockholder's Equity - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 995825 - Disclosure - Stockholder's Equity - Schedule of Reserved Common Stock for Future Issuances (Details) link:presentationLink link:calculationLink link:definitionLink 995835 - Disclosure - Equity Incentive Plans - Additional Information (Detail) link:presentationLink link:calculationLink link:definitionLink 995845 - Disclosure - Equity Incentive Plans - Summary of Company Stock Option Activity (Detail) link:presentationLink link:calculationLink link:definitionLink 995855 - Disclosure - Equity Incentive Plans - Summary of Stock Based Compensation Fair Value Assumptions (Details) link:presentationLink link:calculationLink link:definitionLink 995865 - Disclosure - Equity Incentive Plans - Summary of Share-Based Compensation Expense By Function (Details) link:presentationLink link:calculationLink link:definitionLink 995875 - Disclosure - Equity Incentive Plans - Summarizes restricted share award activity under the 2021 Plan (Details) link:presentationLink link:calculationLink link:definitionLink 995885 - Disclosure - Net Loss Per Share Attributable to Common Stockholders - Schedule of Computation of Basic and Diluted Net Loss per Share Attributable to Common Stockholders (Details) link:presentationLink link:calculationLink link:definitionLink 995895 - Disclosure - Net Loss Per Share Attributable to Common Stockholders - Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share (Details) link:presentationLink link:calculationLink link:definitionLink 995905 - Disclosure - Defined Contribution Plan - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 995915 - Disclosure - Segment Information - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 995925 - Disclosure - Segment Information - Summary of Operating Result Information for Each Reportable Segment (Details) link:presentationLink link:calculationLink link:definitionLink 995935 - Disclosure - Subsequent Events - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink Gain Contingency, Unrecorded Amount Gain Contingency, Unrecorded Amount Statement [Line Items] Statement [Line Items] Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract] Interest Rate During Period Debt Instrument, Interest Rate During Period Debt Instrument Debt Instrument [Axis] Fair Value Of The Unissued Common Stock Warrants Fair Value Of The Unissued Common Stock Warrants Fair value of the unissued common stock warrants Redeemable preferred stock warrants liabilities Redeemable Preferred Stock Warrants Liabilities Non Current Redeemable preferred stock warrants liabilities non current. Accounts receivable Increase (Decrease) in Accounts Receivable Plan Name Plan Name [Domain] Lease Commencement Date Lease Commencement Date Lease commencement date Repayments of Long-Term Loans from Vendors Repayment of MidCap Loan Agreement Hercules Credit Agreement [Member] Hercules Credit Agreement [Member] Entity Address, Postal Zip Code Entity Address, Postal Zip Code Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table] Fair Value, Recurring and Nonrecurring [Table] Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Restructuring Charges, Total Restructuring Charges Revenue Revenues [Abstract] Cash paid for interest Interest Paid, Excluding Capitalized Interest, Operating Activities Subsidiary or Equity Method Investee, Sale of Stock, Type [Table] Debt Instrument, Covenant Description Debt Instrument, Covenant Description Share-Based Payment Arrangement, Tranche One [Member] At the End of One Year Vested and expected to vest as of September 30, 2024 Weighted-Average Exercise Price, Expected to vest as of March 31, 2022 Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price Exercise of options under stock plan. Exercise of Options Under Stock Plan [Member] Exercise of Options under Stock Plan Shares available for future purchase under ESPP. Shares Available For Future Purchase Under E S P P [Member] Shares available for future purchase under employee stock purchase plan Shares, Outstanding Beginning Balance, shares Ending Balance, shares Issuance of common stock upon vesting of restricted stock units, shares Issuance of common stock upon vesting of restricted stock units, shares Issuance of common stock upon vesting of restricted stock units, shares Fair Value Hierarchy and NAV Fair Value Hierarchy and NAV [Axis] Revolving Credit Facility Two Thousand Nineteen [Member] Revolving credit facility 2019. Revolver 2019 Redeemable convertible preferred stock, shares issued Temporary Equity, Shares Issued Shares Issued Fair Value, Inputs, Level 2 Fair Value, Inputs, Level 2 [Member] Share Based Compensation Arrangement By Share Based Payment Award [Line Items] Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] 2020 Warrants [Member] Two Thousand Twenty Warrants [Member] 2020 Warrants Two thousand Twenty warrant. Long-Term Debt, Type [Domain] Schedule of Stock by Class [Table Text Block] Reserved Common Stock for Future Issuances 2011 Plan and 2021 Plan Two Thousand Eleven Plan And Two Thousand Twenty One Plan [Member] Two Thousand Eleven Plan And Two Thousand Twenty One Plan Less: current portion Current portion - long-term debt, net Less: current portion Long-Term Debt, Current Maturities Long-term Debt, Current Maturities, Total Schedule of Aggregate Future Minimum Lease Payments Schedule Of Future Minimum Rental Payments Noncancelable For Operating Leases [Table Text Block] Schedule Of Future Minimum Rental Payments Noncancelable For Operating Leases [Table Text Block] Commitments and Contingencies Commitments and Contingencies Disclosure [Text Block] Summary of Changes in Level 3 Fair Value Instruments Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block] Two Thousand Twenty One Employee Stock Purchase Plan [Member] Two thousand twenty one employee stock purchase plan. 2021 Employee Stock Purchase Plan I S O [Member] ISO ISO Lender Name [Axis] Depreciation and amortization Depreciation, Depletion and Amortization Depreciation, Depletion and Amortization, Total Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Percentage Vesting percentage Jeremy B. Hayden [Member] Jeremy B. Hayden [Member] Jeremy B. Hayden [Member] Senior Secured Twenty Twenty Term Loan [Member] Senior secured 2020 term loan. Senior Secured 2020 Term Loan Stockholders' Equity Equity [Text Block] Tools and Equipment Tools, Dies and Molds [Member] Class of Warrant or Right Class of

Warrant or Right [Axis] Sale of Stock Sale of Stock [Domain] Cash and Cash Equivalents [Domain] Long-Term Debt, Gross Total principal payments due Line of Credit Facility, Remaining Borrowing Capacity Line of credit facility, remaining borrowing capacity Entity Central Index Key Entity Central Index Key Common stock warrants Warrants Warrant [Member] Percentage of long term debt fee payable Long-Term Debt, Percentage Bearing Fixed Interest, Percentage Rate Number of Shares, Forfeited/cancelled Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period Shares Available for Grant, Options forfeited/cancelled Changes in operating assets and liabilities: Increase (Decrease) in Operating Capital [Abstract] Common stock, shares issued Common Stock, Shares, Issued Common Stock, Shares, Issued, Total Issuance of options under stock plan. Issuance of Options Under Stock Plan [Member] Issuance of Options under Plan Prepaid expenses and other current assets Increase (Decrease) in Prepaid Expense and Other Assets Increase (Decrease) in Prepaid Expense and Other Assets, Total Remaining lease term Lessee, Operating Lease, Remaining Lease Term Percentage of voting power required to own Percentage of Voting Power Required to Own Percentage of voting power required to own Income Statement [Abstract] Entity Address, State or Province Entity Address, State or Province Debt Instrument, Fair Value Disclosure Debt Instrument, Fair Value Disclosure, Total Fair value of outstanding debt Loss before income taxes Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Loss before income tax Loss before income taxes Supply Commitment [Member] Supply agreement [Member] Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized Shares Available for Grant, Additional shares reserved Restricted stock units outstanding. Restricted Stock Units Outstanding [Member] Restricted stock units outstanding Average Intrinsic Value, Vested and exercisable as of September 30, 2024 Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value Tranche One Loans Tranche One Loans [Member] Tranche one loans. Debt issuance costs Payments of Debt Issuance Costs Series F Series F Preferred Stock [Member] Cover [Abstract] Subsequent Event [Line Items] Series A redeemable convertible preferred stock. Series A Redeemable Convertible Preferred Stock [Member] Series A Series A Redeemable Convertible Preferred Stock Net loss per share attributable to common stockholders-basic Earnings Per Share, Basic Earnings Per Share, Basic, Total Net loss per share attributable to common stockholders-basic Extending the lease term Lessee, Operating Lease, Option to Extend Operating expenses: Operating Expenses [Abstract] Total stock-based compensation expense Share-Based Payment Arrangement, Expense Long-term Debt Long-Term Debt Term Loan Total repayments Total repayments Total repayments Retained Earnings (Accumulated Deficit), Total Retained Earnings (Accumulated Deficit), Beginning Balance Retained Earnings (Accumulated Deficit), Ending Balance Accumulated deficit Retained Earnings (Accumulated Deficit) Accumulated deficit Denominator: Denominator: Plan Name Plan Name [Axis] Segment Reporting [Abstract] Number of Shares Number of Shares Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number Current assets: Assets, Current [Abstract] Common stock reserved for future issuance Common Stock, Capital Shares Reserved for Future Issuance Common stock reserved for future issuance Debt Instrument Covenant Minimum Revenue Debt instrument covenant minimum revenue. Debt instrument covenant minimum revenue Net cash used in operating activities Net Cash Provided by (Used in) Operating Activities Replacement cost of device Replacement cost of Device Weighted- Average Grant Date Fair Value Per Share, Forfeited/cancelled Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value Number of Shares, Vested and expected to vest as of September 30, 2024 Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number Operating lease term Lessee, Operating Lease, Term of Contract Debt Instrument [Line Items] Debt Instrument [Line Items] Property and equipment, net Property and equipment, net Property, Plant and Equipment, Net Property, Plant and Equipment, Net, Beginning Balance Property, Plant and Equipment, Net, Ending Balance 2027 Lessee, Operating Lease, Liability, to be Paid, Year Four Cash flows from operating activities Net Cash Provided by (Used in) Operating Activities [Abstract] Fair Value, Recurring Fair Value, Recurring [Member] MidCap Term Loan [Member] MidCap Term Loan [Member] Vesting [Axis] Common stock, par value Common Stock, Par or Stated Value Per Share Accounts Payable and Other Accrued Liabilities, Current Accrued and other current liabilities Total accrued and other current liabilities Stock option awards Description of Transaction of Future issuance Sale of Stock, Description of Transaction Preferred stock par value of $0.001 per share; 10,000,000 shares authorized; no shares issued and outstanding as of March 31, 2022 and December 31, 2021, respectively Convertible preferred stock par value of $0.001 per share; 10,000,000 shares authorized; no shares issued and outstanding as of March 31, 2022 and December 31, 2021, respectively Carrying Value Beginning Balance Ending Balance Temporary Equity, Carrying Amount, Attributable to Parent Statement of Cash Flows [Abstract] Class of Warrant or Right, Unissued Accrued Accretion On Maturity Payments Accrued accretion on maturity payments. Accrued amount related accretion on maturity payments Antidilutive Securities, Name Antidilutive Securities, Name [Domain] Withholding taxes on net share settlement of restricted stock units Taxes paid on the net share settlement of restricted stock units Taxes paid on the net share settlement of restricted stock units Taxes paid on net share settlement of restricted stock units Litigation Status [Axis] 2021 Plan Two Thousand And Twenty One Plan [Member] Two thousand and twenty one plan. Class of Warrant or Right, Number of Securities Called by Warrants or Rights Warrants issued to purchase shares of convertible preferred stock Warrants to purchase common stock Other noncurrent liabilities Increase (Decrease) in Other Noncurrent Liabilities Selling, General and Administrative Selling, General and Administrative Expenses Selling, General and Administrative Expenses [Member] Restricted Stock [Member] Equity Components Equity Components [Axis] Entity Address, Address Line One Entity Address, Address Line One Schedule of Computation of Basic and Diluted Net Loss per Share Attributable to Common Stockholders Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] Accrued compensation Employee-related Liabilities, Current Employee-related Liabilities, Current, Total Two Thousand And Eleven Plan [Member] 2011 Plan Two thousand and Eleven plan. Number of Shares, Grants Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period Computer Equipment and Software Computer Equipment [Member] Property Plant And Equipment [Line Items] Property, Plant and Equipment [Line Items] Subsequent Event Type Subsequent Event Type [Axis] Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] Line of Credit Facility, Maximum Borrowing Capacity Maximum borrowing capacity Risk-free interest rate Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items] Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items] Organization consolidation and presentation of financial statements disclosure. Lost profits damages Gain (Loss) from Litigation Settlement Number of Shares, Outstanding, December 31, 2023 Number of Shares, Outstanding, September 30, 2024 Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number Amendment Flag Amendment Flag Term loan. Term Loan [Member] Term Loan Noncurrent portion of lease liabilities Operating Lease, Liability, Noncurrent Noncurrent portion of lease liabilities Debt Instrument, Name Debt Instrument, Name [Domain] Additional paid-in-capital Additional Paid in Capital, Common Stock Additional Paid in Capital, Common Stock, Beginning Balance Additional Paid in Capital, Common Stock, Ending Balance Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration] SOFR [Member] Secured Overnight Financing Rate (SOFR) Overnight Index Swap Rate [Member] Net loss Net loss and comprehensive loss Net loss attributable to common stockholders Summary of Accrued and Other Current Liabilities Accrued And Other Current Liabilities [Table Text Block] Accrued and other current liabilities. Exercise of stock options, Shares Number of Shares, Exercised/released Exercise of options under stock plan Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period Variable Rate Variable Rate [Domain] Research and Development Research and Development Expenses Research and Development Expense [Member] Schedule of Long-term and Short-term Debt Schedule of Debt [Table Text Block] Series E Series E Preferred Stock [Member] Equity Component Equity Component [Domain] Statistical Measurement Statistical Measurement [Domain] Balance Sheet Components Supplemental Balance Sheet Disclosures [Text Block] Interest Expense, Debt Interest Expense, Debt, Total Interest expense, debt Other income (expense), net Other income (expense), net Other Nonoperating Income (Expense) Other Nonoperating Income (Expense), Total Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period Stock option grant period Furniture and Fixtures Furniture and Fixtures [Member] Net loss Net loss Net Income (Loss), Including Portion Attributable to Noncontrolling Interest Net Income (Loss), Including Portion Attributable to Noncontrolling Interest, Total Preferred Stock, Shares Issued Preferred Stock, Shares Issued Preferred Stock, Shares Issued, Total Cash paid for operating leases Operating Lease, Payments Tranche Three Loans Tranche Three Loans [Member] Tranche three loans. Proceeds from exercise of common stock options Proceeds from Stock Options Exercised Debt Securities, Held-to-Maturity, Fair Value Aggregate Fair Value Aggregate Fair Value Less: unamortized discount and debt issuance costs Debt Instrument, Unamortized Discount Debt Instrument, Unamortized Discount, Total Operating lease, discount rate Lessee, Operating Lease, Discount Rate Net proceeds from Hercules Loan Agreement Payments for (Proceeds from) Deposit on Loan Allowance for credit losses Accounts Receivable, Credit Loss Expense (Reversal) Operating Lease, Expense Operating leases, rent expense Operating lease expense Prepaid expenses and other current assets Prepaid Expense and Other Assets, Current Warrant issuance Issuance of Warrant Issuance of Warrant Weighted-Average Exercise Price, Forfeited/cancelled Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price Proceeds from employee stock purchase plan purchases Proceeds from employee stock purchase plan purchases Proceeds from employee stock purchase plan purchases Options Granted To New Hires [Member] Options granted to new hires. Options Granted to New Hires Class of Stock Class of Stock [Domain] ESPP purchase, Shares Stock Issued During Period, Shares, Purchase of Assets Common stock, shares outstanding Common Stock, Shares, Outstanding Common Stock, Shares, Outstanding, Beginning Balance Common Stock, Shares, Outstanding, Ending Balance Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward] Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward] Line of Credit Facility, Current Borrowing Capacity Line of credit facility, current borrowing capacity Other noncurrent liabilities Other Non Current Liabilities Other non current liabilities. Preferred stock par value Preferred Stock, Par or Stated Value Per Share Antidilutive Securities Antidilutive Securities [Axis] Cost of goods sold Cost of Goods and Services Sold [Abstract] Line of Credit Facility, Commitment Fee Description Line of credit facility, commitment fee description Series F redeemable convertible preferred stock issuance cost Redeemable Convertible Preferred Stock Issuance Cost Value redeemable convertible preferred stock issuance cost value. Rule 10b5-1 Arrangement Modified [Flag] Rule 10b5-1 Arrangement Modified Rule 10b5-1 Arr Modified [Flag] Share-based Payment Arrangement, Restricted Stock Unit, Activity Share-Based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block] Entity Interactive Data Current Entity Interactive Data Current Lease expiration date Lease Expiration Date Cost of Goods Sold Cost of Sales [Member] Document Quarterly Report Document Quarterly Report Weighted- Average Grant Date Fair Value Per Share, Vested Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Total Cash and cash equivalents at beginning of period Cash and cash equivalents at end of period Statistical Measurement Statistical Measurement [Axis] Total Cost of goods sold Cost of Goods and Services Sold Cost of Goods and Services Sold, Total Repayment Schedule Relating to the Company's Debt Schedule of Extinguishment of Debt [Table Text Block] Weighted average exercise price Class Of Warrant Or Right Weighted Average Exercise Price Class of warrant or right weighted average exercise price. Lost Profits [Member] Lost Profits [Member] Shares Available for Grant Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant Common stock available for issuance Shares Available for Grant Weighted- Average Grant Date Fair Value Per Share, Grants Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition Weighted-average period expected to recognize Loss Contingency, Nature [Domain] Final fee due at maturity Final Fee Due at Maturity Final Fee Due at Maturity Income Statement Location Statement of Income Location, Balance [Axis] Cash and Cash Equivalents [Axis] Total assets Assets Expected term (in years) Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term Exercise of common stock warrants, shares Exercise of Common Stock Warrants, Shares Exercise of common stock warrants shares. Debt Instrument [Table] Schedule of Long-Term Debt Instruments [Table] Number of Shares, Vested Number of Shares, Vested Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period Conversion of redeemable convertible preferred stock warrants to common stock warrants upon initial public offering Conversion and Reclassification of Preferred Stock Warrants to Common Stock Warrants Upon Initial Public Offering Conversion and reclassification of preferred stock warrants to common stock warrants upon initial public offering. Warrants expiration date Warrants Expiration Term Warrants Expiration Term. New Accounting Pronouncements New Accounting Pronouncements, Policy [Policy Text Block] Entity Address, City or Town Entity Address, City or Town Equity [Abstract] Revolving Credit Facility Two Thousand Twenty [Member] Revolving credit facility 2020. Revolving 2020 Segments Segments [Axis] Accounting for Payroll Protection Program Accounting For Payroll Protection Program [Policy Text Block] Accounting for payroll protection program. Number of Shares, Forfeited/cancelled Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period Debt Instrument Percentage of Prepayment Premium Year One Percentage of prepayment premium year one Debt instrument percentage of prepayment premium year one. Depreciation and amortization Depreciation Depreciation, Total Depreciation expense Lenders [Member] Lenders [Member] Schedule of Segment Reporting Information, by Segment [Table] Equity Incentive Plans Share-Based Payment Arrangement [Text Block] Construction In Process Construction in Progress [Member] Lease, borrowing rate Operating Lease, Weighted Average Discount Rate, Percent Fair Value Disclosures [Abstract] ssuance of common stock in connection with initial public offering, net of underwriting discounts and commissions and other offering costs of $23.8 million Stock Issued During Period, Value, New Issues Schedule of Aggregate Future Minimum Lease Payments Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block] Exercise of stock options, Amount Stock Issued During Period, Value, Stock Options Exercised Common stock warrants, net exercised Current liabilities: Liabilities, Current [Abstract] Document Type Document Type Series F Redeemable Convertible Preferred Stock [Member] Series F Series F Redeemable Convertible Preferred Stock Series F redeemable convertible preferred stock. Debt instrument interest payment extended term. Debt Instrument Interest Payment Extended Term Debt instrument interest payment extended term Title of 12(b) Security Title of 12(b) Security Cash and cash equivalents Cash and cash equivalents at beginning of period Cash and cash equivalents at end of period Cash and Cash Equivalents, at Carrying Value Cash and Cash Equivalents, at Carrying Value, Total Schedule of Operating Lease Expense Recognized and Supplemental Cash Flow Lease, Cost [Table Text Block] Shares Available for Grant, Granted Share-based compensation arrangement by share-based payment award, number of shares available for grant, granted in period. Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant, Granted in Period Statement of Stockholders' Equity [Abstract] Document Fiscal Period Focus Document Fiscal Period Focus Aggregate intrinsic value of options exercised Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value Research and Development Expense Research and Development Expense, Total Research and development Long-Term Debt, Excluding Current Maturities Total accrued and other current liabilities Long-term debt, net Long-term debt, net CALIFORNIA California [Member] Number of Shares, Grants Issuance of options under plan Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross Shares Available for Grant, Option granted Property, Plant and Equipment, Gross Property, Plant and Equipment, Gross, Total Property, Plant and Equipment, Gross, Beginning Balance Property, Plant and Equipment, Gross, Ending Balance Property and equipment, gross Subsequent Event Type Subsequent Event Type [Domain] Summary of Weighted Average Valuation Assumptions Used to Estimate Fair Value of Employee Stock Options Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block] Series F redeemable convertible preferred stock and warrants. Series F Redeemable Convertible Preferred Stock and Warrants [Member] Series F Redeemable Convertible Preferred Stock and Warrants Series F Redeemable Convertible Preferred Stock and Warrants Supply Commitment [Line Items] Class of Warrant or Right, Exercise Price of Warrants or Rights Class of warrant exercise price Financial Instruments [Domain] Investment income Investment Income, Net, Total Investment Income, Net Investment income Sale of Stock Sale of Stock [Axis] Cash flows from investing activities Net Cash Provided by (Used in) Investing Activities [Abstract] Revenue Revenue from Contract with Customer, Excluding Assessed Tax Revenue from Contract with Customer, Excluding Assessed Tax, Total Issuance of common stock upon exercise of stock options Issuance of common stock upon exercise of stock options, Shares Issuance of common stock upon exercise of stock options, Shares Selling, general and administrative Selling, General and Administrative Expense Selling, General and Administrative Expense, Total Credit Facility Credit Facility [Domain] Debt Instrument, Frequency of Periodic Payment Debt instrument, frequency of periodic payment Other accrued liabilities Other Accrued Liabilities, Current Accounts payable Increase (Decrease) in Accounts Payable Increase (Decrease) in Accounts Payable, Total Subsidiary or Equity Method Investee, Sale of Stock [Table] Entity Address, Address Line Two Entity Address, Address Line Two Subsequent Event, Description Subsequent event, Description Liabilities and stockholders' equity Liabilities and Equity [Abstract] Acquisition of property and equipment included in accounts payable and accrued liabilities Noncash or Part Noncash Acquisition, Fixed Assets Acquired Document Period

End Date Document Period End Date Tranche Two Loans Tranche Two Loans [Member] Tranche two loans. Net Cash Provided by (Used in) Financing Activities Net cash (used in) provided by financing activities Stock based compensation Employee Benefits and Share-Based Compensation Redeemable convertible preferred stock Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Accrued Liabilities, Current Accrued Liabilities, Current, Total Accrued expenses Provision for income taxes Income Tax Expense (Benefit) Income Tax Expense (Benefit), Total Debt Securities, Held-to-Maturity, Amortized Cost, after Allowance for Credit Loss Amortized Cost Amortized Cost Loss on disposal of property and equipment Gain (Loss) on Disposition of Property Plant Equipment Gain (Loss) on Disposition of Property Plant Equipment, Total Trading Symbol Trading Symbol Variable Rate Variable Rate [Axis] Beginning Balance Ending Balance Equity, Attributable to Parent Total stockholders' equity Conversion and reclassification of preferred stock warrants to common stock warrants upon initial public offering, shares Conversion and Reclassification of Preferred Stock Warrants to Common Stock Warrants Upon Initial Public Offering, Shares Conversion and Reclassification of Preferred Stock Warrants to Common Stock Warrants Upon Initial Public Offering, Shares Long-Lived Tangible Asset Long-Lived Tangible Asset [Axis] Class of Warrant or Right, Outstanding Warrant outstanding Total other noncurrent liabilities Other noncurrent liabilities Other Liabilities, Noncurrent Restricted Stock Units Restricted Stock Units (RSUs) [Member] Restricted Stock Units RSU Conversion of Stock, Shares Issued Share of common stock issued upon warrant exercised Redeemable convertible preferred stock, shares authorized Temporary Equity, Shares Authorized Shares Authorized Schedule Of Property Plant And Equipment [Table] Property, Plant and Equipment [Table] Unrecognized stock-based compensation of unvested options Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block] Summary of Stock-Based Compensation Expense by Function Company and Nature of Business Nature of Operations [Text Block] Geographical [Axis] Average Intrinsic Value, Vested and expected as of September 30, 2024 Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value Weighted average contractual term, vested and expected Line Of Credit Facility Collateral Fees Percentage Line of credit facility collateral fees. Line of credit facility collateral fees Operating lease office space Area of Land Use of Estimates Use of Estimates, Policy [Policy Text Block] Defined contribution plan, maximum annual contributions per employee Defined Contribution Plan, Maximum Annual Contributions Per Employee, Percent Conversion of redeemable convertible preferred stock to common stock upon initial public offering Common Stock issued on conversion of convertible preferred stock Stock Issued During Period, Value, Conversion of Convertible Securities Fair Value Measurements Fair Value Measurement and Measurement Inputs, Recurring and Nonrecurring [Text Block] Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration] Loan agreement initiation Date Line of Credit Facility, Initiation Date Dividend yield Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate Security Exchange Name Security Exchange Name Dividends declared Dividends, Common Stock Dividends, Common Stock, Total Noncash operating lease expense Noncash Operating Lease Cost Noncash Operating Lease Cost Operating expense Operating expense Total operating expenses Operating Expenses Operating expenses Long-Lived Tangible Asset Long-Lived Tangible Asset [Domain] Loss Contingency Nature [Axis] Class of Stock Class of Stock [Axis] Less: Accumulated depreciation Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Total Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Beginning Balance Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Ending Balance Line of Credit [Member] 2026 Lessee, Operating Lease, Liability, to be Paid, Year Three Weighted-average grant-date fair values of options granted Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value Issuance costs Temporary equity, issuance costs. Temporary Equity, Issuance Costs Subsequent Event Subsequent Event [Member] Maximum [Member] Maximum Maximum [Member] Liabilities and Equity Total liabilities and stockholders' equity Loss on debt extinguishment Noncash loss on extinguishment of debt Gain (Loss) on Extinguishment of Debt Gain (Loss) on Extinguishment of Debt, Total Operating lease right-of-use assets Operating Lease, Right-of-Use Asset Supplemental disclosure of cash flow information Supplemental Cash Flow Information [Abstract] Total liabilities measured at fair value Financial Liabilities Fair Value Disclosure Financial Liabilities Fair Value Disclosure, Total Net loss per share attributable to common stockholders-diluted Earnings Per Share, Diluted Earnings Per Share, Diluted, Total Net loss per share attributable to common stockholders-diluted Leasehold Improvements Leasehold Improvements [Member] Exercise price percentage of an ISO granted Share Based Compensation Arrangement By Share Based Payment Exercise Price Percentage Granted Share based compensation arrangement by share based payment exercise price percentage granted. Entity Ex Transition Period Entity Ex Transition Period Total liabilities Liabilities Series C Redeemable Convertible Preferred Stock [Member] Series C Series C Redeemable Convertible Preferred Stock Series C redeemable convertible preferred stock. Fair Value Hierarchy and NAV Fair Value Hierarchy and NAV [Domain] Line of Credit Facility, Commitment Fee Amount Line of credit facility commitment fee amount Total current assets Assets, Current Net cash used in investing activities Net Cash Provided by (Used in) Investing Activities Thereafter Thereafter Long-Term Debt, Maturity, after Year Three Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing after third fiscal year following current fiscal year. ssuance of common stock in connection with initial public offering, net of underwriting discounts and commissions and other offering costs of $23.8 million, Shares Stock Issued During Period, Shares, New Issues Interest in increments period Interest On period Increments Interest On period Increments Share-Based Compensation Arrangement by Share-Based Payment Award, Additional General Disclosures [Abstract] Stock Option Granted For period Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period Vesting period ESPP purchase Stock Issued During Period, Value, Purchase of Assets Entity Filer Category Entity Filer Category Mid Cap Financial Services [Member] Mid Cap Financial Services. Mid Cap Financial Services Revolver Agreement [Member] Revolver Agreement [Member] Organization Consolidation And Presentation Of Financial Statements Disclosure [Table] Organization Consolidation And Presentation Of Financial Statements Disclosure [Table] Organization consolidation and presentation of financial statements disclosure. Shares Available for Grant, Forfeited/cancelled Share-based compensation arrangement by share-based payment award, number of shares available for grant, forfeited in period. Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant, Forfeited in Period Summary of Other Noncurrent Liabilities Other Noncurrent Liabilities [Table Text Block] Current Fiscal Year End Date Current Fiscal Year End Date Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Less: imputed interest Lessee, Operating Lease, Liability, Undiscounted Excess Amount Redeemable convertible preferred stock, par value Temporary Equity, Par or Stated Value Per Share Stock-based compensation expense Share-Based Payment Arrangement, Noncash Expense Share-based Payment Arrangement, Noncash Expense, Total Average Intrinsic Value Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value Common Stock, Shares Subscribed but Unissued Common Stock, Shares Subscribed but Unissued Entity Registrant Name Entity Registrant Name Gross profit Surgical Glaucoma Gross Profit Number of Reportable Segments Number of Reportable Segments Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table] Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table] Net Loss per Share Attributable to Common Stockholders Earnings Per Share [Text Block] Maturity date Debt Instrument, Maturity Date Entity Emerging Growth Company Entity Emerging Growth Company Weighted-average shares used in computing net loss per share attributable to common stockholders-basic Weighted Average Number of Shares Outstanding, Basic Weighted Average Number of Shares Outstanding, Basic, Total Weighted-average shares of common stock outstanding-basic Vesting [Domain] Stock issuance costs Temporary Equity, Stock Issued During Period, Value, New Issues Issuance of Series E convertible preferred stock Common stock, shares authorized Common Stock, Shares Authorized Deferred Offering Costs Deferred Offering Costs [Policy Text Block] Deferred offering costs. Interest Payable, Current Short-term interest payable Proceeds from Issuance of Common Stock Proceeds from issuance of common stock Fair Value, Inputs, Level 1 Fair Value, Inputs, Level 1 [Member] Debt Disclosure [Abstract] Vested and exercisable as of September 30, 2024 Weighted-Average Exercise Price, Vested and exercisable as of March 31, 2022 Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price Litigation Status [Domain] Restricted Stock, Value, Shares Issued Net of Tax Withholdings Withholding taxes on net share settlement of restricted stock units Weighted-Average Exercise Price, Granted Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price Financial Instrument [Axis] Exercise of common stock warrants Exercise of Common Stock Warrants Exercise of common stock warrants. Weighted Average Remaining Contractual Term Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term Debt Instrument Covenant Maximum Revenue Debt instrument covenant maximum revenue. Debt instrument covenant maximum revenue Share-Based Payment Arrangement [Abstract] Share of common stock purchased Stock-based compensation expense Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture, Total Accounting Policies [Abstract] Share-Based Payment Arrangement, Option, Activity [Table Text Block] Summary of Stock Option Activity Supply Commitment [Axis] Series B Series B redeemable convertible preferred stock. Series B Redeemable Convertible Preferred Stock Equity, Attributable to Parent [Abstract] Stockholders' equity: Supply Commitment Arrangement [Domain] Supplemental noncash disclosure of investing and financing activities Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract] Statement [Table] Statement [Table] Summary of Property and Equipment, Net Property, Plant and Equipment [Table Text Block] Royalty Damages [Member] Royalty Damages [Member] Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term Weighted average contractual term, vested and expected Provision (benefit) for excess and obsolete inventories Inventory Write-down Subsequent Event [Table] Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Weighted Average Exercise Price Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract] Preferred stock, shares authorized Preferred Stock, Shares Authorized Total principal payments Total Principal Payments Total Principal Payments Securities Act File Number Segment Information Segment Reporting Disclosure [Text Block] Net change in cash and cash equivalents Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Earnings Per Share [Abstract] Interest Payable Non Current Interest payable non current. Long-term interest payable 2024 (remainder) 2022 (remainder) Long-Term Debt, Maturity, Remainder of Fiscal Year Statement of Financial Position [Abstract] Interest Expense, Operating and Nonoperating Interest Expense, Total Interest expense IPO [Member] IPO [Member] Loss from operations Operating Income (Loss) Loss from operations 2025 2023 Long-Term Debt, Maturity, Year One Expected volatility Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate Entity Shell Company Entity Shell Company Debt Instrument, Interest Rate, Effective Percentage Debt instrument, effective interest rate Redeemable convertible preferred stock outstanding redeemable convertible preferred stock outstanding. Entity Tax Identification Number Entity Tax Identification Number Assets Assets [Abstract] Incentive Stock Option [Member] Incentive stock option. Incentive Stock Option Class of Warrant or Right Class of Warrant or Right [Domain] Fair Value of Financial Instruments Fair Value of Financial Instruments, Policy [Policy Text Block] Entity Current Reporting Status Entity Current Reporting Status Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term Weighted average contractual term, vested and exercisable Fair Value, Liabilities Measured on Recurring Basis [Table Text Block] Summary of Fair Value Measurement of Liabilities of Measured on Recurring Basis Reduction in workforce Reduction in workforce Long-Term Debt, Type [Axis] Subsequent Events [Abstract] Issuance of options and restricted stock units under stock plan Issuance of options and restricted stock units under stock plan [Member] Issuance of options and restricted stock units under stock plan [Member] Geographical [Domain] Document Fiscal Year Focus Document Fiscal Year Focus Preferred stock, par value $0.001 per share; 10,000,000 shares authorized; no shares issued and outstanding as of September 30, 2024 and December 31, 2023 Preferred Stock, Value, Issued Preferred Stock, Value, Issued, Ending Balance Preferred Stock, Value, Issued, Beginning Balance Preferred Stock, Value, Issued, Total 2019 Warrants [Member] 2019 Warrants Two Thousand Nineteen Warrants [Member] Two thousand Nineteen warrants. MidCap Credit Facility Agreements [Member] MidCap Credit Facility Agreements City Area Code City Area Code Total amounts outstanding Debt, Long-Term and Short-Term, Combined Amount Total current liabilities Liabilities, Current Total accrued and other current liabilities Accrued Liabilities and Other Liabilities Line of Credit Facility, Lender [Domain] Line of Credit Facility, Unused Capacity, Commitment Fee Percentage Line of credit facility, unused capacity, commitment fee percentage Tranche One And Two Loans [Member] Tranche one and two loans. Tranche One and Two Loans Inventory, Net, Total Inventory, net Inventory, Net Debt Securities, Available-for-Sale and Held-to-Maturity, Cumulative Unrecognized Gain Unrealized Gains Unrealized Gains Defined Contribution Plan Defined Contribution Plan [Text Block] Conversion of redeemable convertible preferred stock to common stock upon initial public offering, Shares Conversion of redeemable convertible preferred stock Stock Issued During Period, Shares, Conversion of Convertible Securities Organization, Consolidation and Presentation of Financial Statements [Abstract] Local Phone Number Local Phone Number Settled Litigation Settled Litigation [Member] Preferred Stock, Shares Outstanding Preferred Stock, Shares Outstanding Preferred Stock, Shares Outstanding, Ending Balance Preferred Stock, Shares Outstanding, Beginning Balance Common stock options issued and outstanding. Common Stock Options Issued And Outstanding [Member] Common stock options issued and outstanding Subsidiary, Sale of Stock [Line Items] Conversion of preferred stock warrants to common stock warrants upon the closing of the IPO Stock and Warrants Issued During Period, Value, Preferred Stock and Warrants Common stock warrants issued upon execution of Hercules Loan Agreement Deferred costs, current Deferred Costs, Total Deferred Costs, Current Commitments and Contingencies Disclosure [Abstract] Liabilities: Financial Liabilities Fair Value Disclosure [Abstract] Series D redeemable convertible preferred stock. Series D Redeemable Convertible Preferred Stock [Member] Series D Series D Redeemable Convertible Preferred Stock Less: current portion of operating lease liability Current portion of lease liabilities Operating Lease, Liability, Current Common stock available for future grant. Common Stock Available For Future Grant [Member] Common stock available for future grants Debt instrument, Initial interest rate Debt Instrument, Interest Rate, Stated Percentage Retained Earnings [Member] Accumulated Deficit Accretion of debt discount and debt issuance costs Amortization of Debt Issuance Costs and Discounts Amortization of Debt Issuance Costs and Discounts, Total Over-Allotment Option [Member] Underwriters' Option Purchases of property and equipment Payments to Acquire Property, Plant, and Equipment Payments to Acquire Property, Plant, and Equipment, Total Document Transition Report Document Transition Report Line of credit achievement of certain performance milestones LineOfCreditAchievementOfCertainPerformanceMilestones Line Of Credit Achievement Of Certain Performance Milestones Series E Series E redeemable convertible preferred stock. Series E Redeemable Convertible Preferred Stock [Member] Series E Redeemable Convertible Preferred Stock Additional warrants to purchase common stock Share-Based Compensation Arrangement by Share-Based Payment Award, Purchase Price of Common Stock, Percent 2025 Lessee, Operating Lease, Liability, to be Paid, Year Two Postemployment Benefits [Abstract] Non-Rule 10b5-1 Arrangement Modified [Flag] Non-Rule 10b5-1 Arrangement Modified Non-Rule 10b5-1 Arr Modified [Flag] Total base rent under lease agreement Total base rent under lease agreement Total base rent under lease agreement. Proceeds from Stock Plans Collected withholdings under plan Weighted-Average Exercise Price, Exercised/released Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price Minimum [Member] Minimum Numerator: Earnings Per Share Reconciliation [Abstract] Common Stock Common Stock [Member] 2026 2024 Long-Term Debt, Maturity, Year Two Issuance of common stock upon vesting of restricted stock units Issuance of common stock upon vesting of restricted stock units Issuance of common stock upon vesting of restricted stock units Weighted- Average Grant Date Fair Value Per Share, Outstanding, September 30, 2024 Weighted- Average Grant Date Fair Value Per Share, Outstanding, December 31, 2023 Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value Increase (Decrease) in Other Noncurrent Assets Other noncurrent assets Additional Paid-in Capital [Member] Additional Paid-In Capital Proceeds from Short-Term Debt Proceeds from Short-term Debt, Total Loan received Gross Profit [Abstract] Gross profit Adjustments to reconcile net loss to net cash used in operating activities: Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Income Statement Location Statement of Income Location, Balance [Domain] 2024 (remainder) Lessee, Operating Lease, Liability, to be Paid, Year One Other noncurrent assets Other Assets, Noncurrent, Total Other Assets, Noncurrent Segments Segments [Domain] Interest Income, Securities, US Treasury Treasury bills Redeemable Convertible Preferred Stock Warrants Redeemable Convertible Preferred Stock Warrants [Member] Redeemable convertible preferred stock warrants liabilities. Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Senior Secured Two Thousand Nineteen Term Loan [Member] Senior secured 2019 term loan. Senior Secured 2019 Term Loan Basis of Presentation Basis of Accounting, Policy [Policy Text Block] Warrants and Rights Outstanding Unused warrants value Common stock, par value $0.001 per share; 200,000,000 shares authorized; 50,398,148 and 49,131,363 shares issued and outstanding as of September 30, 2024 and December

31, 2023, respectively Common Stock, Value, Issued Common Stock, Value, Issued, Total Common Stock, Value, Issued, Beginning Balance Common Stock, Value, Issued, Ending Balance Accrued compensation Increase (Decrease) in Employee Related Liabilities Increase (Decrease) in Employee Related Liabilities, Total Unrealized Losses Debt Securities, Available-for-Sale and Held-to-Maturity, Cumulative Unrecognized Loss Unrealized Losses Unrealized Losses Number of votes entitled per share of common stock Common Stock Vote for Each Share Common stock, vote for each share. 2027 2025 Long-Term Debt, Maturity, Year Three Temporary equity, stock issued during period shares, new issues. Temporary Equity Stock Issued During Period Shares New Issues Issuance of Series E convertible preferred stock, shares Present value of future minimum lease payments Present value of future minimum lease payments Operating Lease, Liability Measurement Frequency Measurement Frequency [Axis] Commitments and contingencies (Note 6) Commitments and Contingencies Weighted-average shares used in computing net loss per share attributable to common stockholders-diluted Weighted Average Number of Shares Outstanding, Diluted Weighted Average Number of Shares Outstanding, Diluted, Total Weighted-average shares of common stock outstanding-diluted Summary of Significant Accounting Policies Significant Accounting Policies [Text Block] Schedule of Segment Reporting Information Schedule of Segment Reporting Information, by Segment [Table Text Block] Redeemable Convertible Preferred Stock Redeemable Convertible Preferred Stock [Member] Accounts receivable, net of allowance for credit losses of $824 and $1,186 at September 30, 2024 and December 31, 2023, respectively Accounts Receivable, after Allowance for Credit Loss, Current Accounts Receivable, after Allowance for Credit Loss, Current, Total Number of Shares Vested and exercisable as of September 30, 2024 Vested and exercisable as of June 30, 2021 Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number Total future minimum lease payments Lessee, Operating Lease, Liability, to be Paid Inventory Increase (Decrease) in Inventories Increase (Decrease) in Inventories, Total Entity Small Business Entity Small Business Segment Reporting Information [Line Items] Debt Instrument, Basis Spread on Variable Rate Debt instrument, variable rate Debt Debt Disclosure [Text Block] US Treasury Securities [Member] US Treasury Securities [Member] Series C redeemable convertible preferred stock and warrants. Series C Redeemable Convertible Preferred Stock and Warrants [Member] Series C Redeemable Convertible Preferred Stock and Warrants Series C Redeemable Convertible Preferred Stock and Warrants Fair Value, by Balance Sheet Grouping [Table Text Block] Summary of Held-to-maturity debt securities at amortized cost in the financial statements. Credit Facility [Axis] Credit Facility Dry Eye [Member] Dry eye. Dry Eye Noncash loss on debt extinguishment Noncash Loss On Extinguishment Of Debt Noncash Loss On Extinguishment Of Debt Cash flows from financing activities Net Cash Provided by (Used in) Financing Activities [Abstract] Balances as of June 30, 2021 Weighted-Average Exercise Price Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price Weighted-Average Exercise Price Supply Commitment [Table] Issuance of common stock upon exercise of stock options Issuance of common stock upon exercise of stock options Issuance of common stock upon exercise of stock options Debt Instrument Fair Value, Amount Debt Instrument Fair Value Amount Debt Instrument, Fair Value Amount Defined contribution plan, maximum annual contributions per employee amount Defined Contribution Plan, Maximum Annual Contributions Per Employee, Amount New operating lease assets obtained in exchange for operating lease liabilities Right-of-Use Asset Obtained in Exchange for Operating Lease Liability Line of Credit Facility, Commitment Fee Percentage Percentage of final payment fee Surgical Glaucoma [Member] Surgical Glaucoma. Surgical Glaucoma Measurement Frequency Measurement Frequency [Domain] Redeemable convertible preferred stock, shares outstanding Temporary Equity, Shares Outstanding Shares Outstanding Beginning Balance, shares Ending Balance, shares Options Granted Merit Awards [Member] Options Granted Merit Awards Options granted merit awards. Fair Value, Inputs, Level 3 Fair Value, Inputs, Level 3 [Member] PPP Loan Paycheck Protection Program Loan [Member] Paycheck Protection Program loan. Subsequent Events Subsequent Events [Text Block] Accounts Payable, Current, Total Accounts payable Accounts Payable, Current Deferred initial public offering cost recorded to additional paid in capital Total deferred costs Deferred Offering Costs Deferred offering costs Accounts receivable, net of allowance for credit losses Accounts Receivable, Allowance for Credit Loss, Current Fair Value Of Warrants Fair value of warrants. Fair value of warrants Accrued and other current liabilities Increase (Decrease) in Accrued Liabilities Increase (Decrease) in Accrued Liabilities, Total Deferred costs, current Accounts Receivable, Allowance for Credit Loss Accounts Receivable, Allowance for Credit Loss, Ending Balance Accounts Receivable, Allowance for Credit Loss, Beginning Balance XML 8 R1.htm IDEA: XBRL DOCUMENT v3.24.3 Document and Entity Information - shares 9 Months Ended Sep. 30, 2024 Nov. 01, 2024 Cover [Abstract] Â Â Document Type 10-Q Â Amendment Flag false Â Document Quarterly Report true Â Document Transition Report false Â Document Period End Date Sep. 30, 2024 Â Document Fiscal Year Focus 2024 Â Document Fiscal Period Focus Q3 Â Current Fiscal Year End Date --12-31 Â Entity Registrant Name SIGHT SCIENCES, INC. Â Entity Central Index Key 0001531177 Â Securities Act File Number 001-40587 Â Entity Incorporation, State or Country Code DE Â Entity Tax Identification Number 80-0625749 Â Entity Address, Address Line One 4040 Campbell Ave Â Entity Address, Address Line Two Suite 100 Â Entity Address, City or Town Menlo Park Â Entity Address, State or Province CA Â Entity Address, Postal Zip Code 94025 Â City Area Code 877 Â Local Phone Number 266-1144 Â Title of 12(b) Security Common Stock, par value $0.001 per share Â Trading Symbol SGHT Â Entity Current Reporting Status Yes Â Entity Interactive Data Current Yes Â Security Exchange Name NASDAQ Â Entity Filer Category Non-accelerated Filer Â Entity Emerging Growth Company true Â Entity Ex Transition Period false Â Entity Small Business true Â Entity Shell Company false Â Entity Common Stock, Shares Outstanding Â 50,754,616 X - DefinitionBoolean flag that is true when the XBRL content amends previously-filed or accepted submission. + ReferencesNo definition available. + Details Name: dei_AmendmentFlag Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionArea code of city + ReferencesNo definition available. + Details Name: dei_CityAreaCode Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionCover page. + ReferencesNo definition available. + Details Name: dei_CoverAbstract Namespace Prefix: dei_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionEnd date of current fiscal year in the format --MM-DD. + ReferencesNo definition available. + Details Name: dei_CurrentFiscalYearEndDate Namespace Prefix: dei_ Data Type: xbrli:gMonthDayItemType Balance Type: na Period Type: duration X - DefinitionFiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY. + ReferencesNo definition available. + Details Name: dei_DocumentFiscalPeriodFocus Namespace Prefix: dei_ Data Type: dei:fiscalPeriodItemType Balance Type: na Period Type: duration X - DefinitionThis is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006. + ReferencesNo definition available. + Details Name: dei_DocumentFiscalYearFocus Namespace Prefix: dei_ Data Type: xbrli:gYearItemType Balance Type: na Period Type: duration X - DefinitionFor the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD. + ReferencesNo definition available. + Details Name: dei_DocumentPeriodEndDate Namespace Prefix: dei_ Data Type: xbrli:dateItemType Balance Type: na Period Type: duration X - DefinitionBoolean flag that is true only for a form used as an quarterly report. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Form 10-Q -Number 240 -Section 308 -Subsection a + Details Name: dei_DocumentQuarterlyReport Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionBoolean flag that is true only for a form used as a transition report. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Forms 10-K, 10-Q, 20-F -Number 240 -Section 13 -Subsection a-1 + Details Name: dei_DocumentTransitionReport Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionThe type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'. + ReferencesNo definition available. + Details Name: dei_DocumentType Namespace Prefix: dei_ Data Type: dei:submissionTypeItemType Balance Type: na Period Type: duration X - DefinitionAddress Line 1 such as Attn, Building Name, Street Name + ReferencesNo definition available. + Details Name: dei_EntityAddressAddressLine1 Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionAddress Line 2 such as Street or Suite number + ReferencesNo definition available. + Details Name: dei_EntityAddressAddressLine2 Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionName of the City or Town + ReferencesNo definition available. + Details Name: dei_EntityAddressCityOrTown Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionCode for the postal or zip code + ReferencesNo definition available. + Details Name: dei_EntityAddressPostalZipCode Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionName of the state or province. + ReferencesNo definition available. + Details Name: dei_EntityAddressStateOrProvince Namespace Prefix: dei_ Data Type: dei:stateOrProvinceItemType Balance Type: na Period Type: duration X - DefinitionA unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityCentralIndexKey Namespace Prefix: dei_ Data Type: dei:centralIndexKeyItemType Balance Type: na Period Type: duration X - DefinitionIndicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument. + ReferencesNo definition available. + Details Name: dei_EntityCommonStockSharesOutstanding Namespace Prefix: dei_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionIndicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure. + ReferencesNo definition available. + Details Name: dei_EntityCurrentReportingStatus Namespace Prefix: dei_ Data Type: dei:yesNoItemType Balance Type: na Period Type: duration X - DefinitionIndicate if registrant meets the emerging growth company criteria. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityEmergingGrowthCompany Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionIndicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Securities Act -Number 7A -Section B -Subsection 2 + Details Name: dei_EntityExTransitionPeriod Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionCommission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen. + ReferencesNo definition available. + Details Name: dei_EntityFileNumber Namespace Prefix: dei_ Data Type: dei:fileNumberItemType Balance Type: na Period Type: duration X - DefinitionIndicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityFilerCategory Namespace Prefix: dei_ Data Type: dei:filerCategoryItemType Balance Type: na Period Type: duration X - DefinitionTwo-character EDGAR code representing the state or country of incorporation. + ReferencesNo definition available. + Details Name: dei_EntityIncorporationStateCountryCode Namespace Prefix: dei_ Data Type: dei:edgarStateCountryItemType Balance Type: na Period Type: duration X - DefinitionBoolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-T -Number 232 -Section 405 + Details Name: dei_EntityInteractiveDataCurrent Namespace Prefix: dei_ Data Type: dei:yesNoItemType Balance Type: na Period Type: duration X - DefinitionThe exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityRegistrantName Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionBoolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityShellCompany Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionIndicates that the company is a Smaller Reporting Company (SRC). + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntitySmallBusiness Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionThe Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityTaxIdentificationNumber Namespace Prefix: dei_ Data Type: dei:employerIdItemType Balance Type: na Period Type: duration X - DefinitionLocal phone number for entity. + ReferencesNo definition available. + Details Name: dei_LocalPhoneNumber Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionTitle of a 12(b) registered security. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b + Details Name: dei_Security12bTitle Namespace Prefix: dei_ Data Type: dei:securityTitleItemType Balance Type: na Period Type: duration X - DefinitionName of the Exchange on which a security is registered. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection d1-1 + Details Name: dei_SecurityExchangeName Namespace Prefix: dei_ Data Type: dei:edgarExchangeCodeItemType Balance Type: na Period Type: duration X - DefinitionTrading symbol of an instrument as listed on an exchange. + ReferencesNo definition available. + Details Name: dei_TradingSymbol Namespace Prefix: dei_ Data Type: dei:tradingSymbolItemType Balance Type: na Period Type: duration XML 9 R2.htm IDEA: XBRL DOCUMENT v3.24.3 Condensed Consolidated Balance Sheets (Unaudited) - USD ($) $ in Thousands Sep. 30, 2024 Dec. 31, 2023 Current assets: Â Â Cash and cash equivalents $ 118,564 $ 138,129 Accounts receivable, net of allowance for credit losses of $824 and $1,186 at September 30, 2024 and December 31, 2023, respectively 12,929 14,289 Inventory, net 6,091 7,849 Prepaid expenses and other current assets 2,885 2,604 Total current assets 140,469 162,871 Property and equipment, net 1,448 1,640 Operating lease right-of-use assets 1,100 1,458 Other noncurrent assets 580 682 Total assets 143,597 166,651 Current liabilities: Â Â Accounts payable 1,297 1,731 Accrued compensation 7,889 4,528 Accrued and other current liabilities 4,613 3,774 Current portion - long-term debt, net 0 2,219 Total current liabilities 13,799 12,252 Long-term debt, net 34,152 31,708 Other noncurrent liabilities 689 2,476 Total liabilities 48,640 46,436 Commitments and contingencies (Note 6) Stockholders' equity: Â Â Preferred stock, par value $0.001 per share; 10,000,000 shares authorized; no shares issued and outstanding as of September 30, 2024 and December 31, 2023 0 0 Common stock, par value $0.001 per share; 200,000,000 shares authorized; 50,398,148 and 49,131,363 shares issued and outstanding as of September 30, 2024 and December 31, 2023, respectively 50 49 Additional paid-in-capital 429,358 414,956 Accumulated deficit (334,451) (294,790) Total stockholders' equity 94,957 120,215 Total liabilities and stockholders' equity $ 143,597 $ 166,651 X - DefinitionAmount of liabilities incurred to vendors for goods and services received, and accrued liabilities classified as other, payable within one year or the normal operating cycle, if longer. + ReferencesNo definition available. + Details Name: us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionCarrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(19)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10 + Details Name: us-gaap_AccountsPayableCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 310 -SubTopic 10 -Name Accounting Standards

Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481990/310-10-45-2 + Details Name: us-gaap_AccountsReceivableNetCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionValue received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)(a)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_AdditionalPaidInCapitalCommonStock Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of asset recognized for present right to economic benefit. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 49 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 12: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 13: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(12)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 18: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 19: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7Reference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 30: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(11)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1 + Details Name: us-gaap_Assets Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of asset recognized for present right to economic benefit, classified as current. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 6: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 10: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 11: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 20: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7 + Details Name: us-gaap_AssetsCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_AssetsCurrentAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4 + Details Name: us-gaap_CashAndCashEquivalentsAtCarryingValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionRepresents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(17)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(15)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1 + Details Name: us-gaap_CommitmentsAndContingencies Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1 + Details Name: us-gaap_CommonStockValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionTotal of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_EmployeeRelatedLiabilitiesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(6)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_InventoryNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)) -SubTopic 10 -Topic 210 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(24)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(19)) -

Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(26)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(21)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 15: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(14)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 18: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 27: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7Reference 28: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7Reference 29: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30 + Details Name: us-gaap_Liabilities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(32)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_LiabilitiesAndStockholdersEquity Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionTotal obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(21)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 8: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-5Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 11: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 20: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7Reference 21: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7 + Details Name: us-gaap_LiabilitiesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_LiabilitiesCurrentAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as current. Excludes lease obligation. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_LongTermDebtCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_LongTermDebtNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's right to use underlying asset under operating lease. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap_OperatingLeaseRightOfUseAsset Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of noncurrent assets classified as other. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(17)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_OtherAssetsNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of liabilities classified as other, due after one year or the normal operating cycle, if longer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(24)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_OtherLiabilitiesNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(21)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1 + Details Name: us-gaap_PreferredStockValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_PrepaidExpenseAndOtherAssetsCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -SubTopic 10 -Topic 360 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7AReference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 360 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1 + Details Name: us-gaap_PropertyPlantAndEquipmentNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of accumulated undistributed earnings (deficit). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)(a)(3)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(2)(i) -Publisher FASB -URI

https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (h)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(23)(a)(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(17)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_RetainedEarningsAccumulatedDeficit Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(31)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 5: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(6)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 4.E) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2 + Details Name: us-gaap_StockholdersEquity Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_StockholdersEquityAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 10 R3.htm IDEA: XBRL DOCUMENT v3.24.3 Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) - USD ($) $ in Thousands Sep. 30, 2024 Dec. 31, 2023 Accounts receivable, net of allowance for credit losses $ 824 $ 1,186 Preferred stock par value $ 0.001 $ 0.001 Preferred stock, shares authorized 10,000,000 10,000,000 Preferred Stock, Shares Issued 0 0 Preferred Stock, Shares Outstanding 0 0 Common stock, par value $ 0.001 $ 0.001 Common stock, shares authorized 200,000,000 200,000,000 Common stock, shares issued 50,398,148 49,131,363 Common stock, shares outstanding 50,398,148 49,131,363 X - DefinitionAmount of allowance for credit loss on accounts receivable, classified as current. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479344/326-20-45-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481962/310-10-50-4 + Details Name: us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionFace amount or stated value per share of common stock. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_CommonStockParOrStatedValuePerShare Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionThe maximum number of common shares permitted to be issued by an entity's charter and bylaws. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1 + Details Name: us-gaap_CommonStockSharesAuthorized Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionTotal number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_CommonStockSharesIssued Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionNumber of shares of common stock outstanding. Common stock represent the ownership interest in a corporation. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3 + Details Name: us-gaap_CommonStockSharesOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionFace amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13 + Details Name: us-gaap_PreferredStockParOrStatedValuePerShare Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionThe maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1 + Details Name: us-gaap_PreferredStockSharesAuthorized Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionNumber of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13 + Details Name: us-gaap_PreferredStockSharesIssued Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionAggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3 + Details Name: us-gaap_PreferredStockSharesOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant XML 11 R4.htm IDEA: XBRL DOCUMENT v3.24.3 Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($) $ in Thousands 3 Months Ended 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Income Statement [Abstract] Â Â Â Â Revenue $ 20,157 $ 20,009 $ 60,792 $ 62,305 Cost of goods sold 3,250 2,677 9,068 9,105 Gross profit 16,907 17,332 51,724 53,200 Operating expenses: Â Â Â Â Research and development 4,746 4,239 13,698 14,129 Selling, general and administrative 23,390 26,504 76,629 85,235 Total operating expenses 28,136 30,743 90,327 99,364 Loss from operations (11,229) (13,411) (38,603) (46,164) Investment income 1,454 1,897 4,628 5,499 Interest expense (1,151) (1,432) (3,501) (4,057) Loss on debt extinguishment 0 0 (1,962) 0 Other income (expense), net 26 (11) (25) (34) Loss before income taxes (10,900) (12,957) (39,463) (44,756) Provision for income taxes 166 78 198 100 Net loss and comprehensive loss $ (11,066) $ (13,035) $ (39,661) $ (44,856) Net loss per share attributable to common stockholders-basic $ (0.22) $ (0.27) $ (0.79) $ (0.92) Net loss per share attributable to common stockholders-diluted $ (0.22) $ (0.27) $ (0.79) $ (0.92) Weighted-average shares used in computing net loss per share attributable to common stockholders-basic 50,340,603 48,671,049 49,911,655 48,538,517 Weighted-average shares used in computing net loss per share attributable to common stockholders-diluted 50,340,603 48,671,049 49,911,655 48,538,517 X - DefinitionThe aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(2)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(2)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 924 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 11.L) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1 + Details Name: us-gaap_CostOfGoodsAndServicesSold Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 52 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (e)(4) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -

Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(27)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7 + Details Name: us-gaap_EarningsPerShareBasic Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionThe amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 52 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (e)(4) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(27)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7 + Details Name: us-gaap_EarningsPerShareDiluted Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionDifference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 470 -SubTopic 50 -Section 40 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481303/470-50-40-2Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 470 -SubTopic 50 -Section 40 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481303/470-50-40-4 + Details Name: us-gaap_GainsLossesOnExtinguishmentOfDebt Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 7: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 14: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 23: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 31 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31 + Details Name: us-gaap_GrossProfit Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 7: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(11)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 9: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 31 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 235 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-05(b)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(10)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(15)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1 + Details Name: us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_IncomeStatementAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 231 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 6.I.7) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Subparagraph (a) -SubTopic 20 -Topic 740 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(h)) -SubTopic 10 -Topic 235 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1 + Details Name: us-gaap_IncomeTaxExpenseBenefit Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of interest expense classified as operating and nonoperating. Includes, but is not limited to, cost of borrowing accounted for as interest expense. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48Reference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 49 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI

https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-24Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 835 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483013/835-20-50-1 + Details Name: us-gaap_InterestExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount after accretion (amortization) of discount (premium), and investment expense, of interest income and dividend income on nonoperating securities. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(7)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(7)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2 + Details Name: us-gaap_InvestmentIncomeNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 17: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 32: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 37: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1 + Details Name: us-gaap_NetIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionGenerally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense. + ReferencesNo definition available. + Details Name: us-gaap_OperatingExpenses Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_OperatingExpensesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe net result for the period of deducting operating expenses from operating revenues. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 7: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 31 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31 + Details Name: us-gaap_OperatingIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of income (expense) related to nonoperating activities, classified as other. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2 + Details Name: us-gaap_OtherNonoperatingIncomeExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 985 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 730 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 912 -SubTopic 730 -Name Accounting Standards Codification -Section 25 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1 + Details Name: us-gaap_ResearchAndDevelopmentExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 924 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 11.L) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4 + Details Name: us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2 + Details Name: us-gaap_SellingGeneralAndAdministrativeExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -

Section 45 -Paragraph 16 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16 + Details Name: us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionNumber of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10 + Details Name: us-gaap_WeightedAverageNumberOfSharesOutstandingBasic Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration XML 12 R5.htm IDEA: XBRL DOCUMENT v3.24.3 Condensed Consolidated Statements of Redeemable Convertible Preferred Stock and Stockholders' Equity (Unaudited) - USD ($) $ in Thousands Total Common Stock Additional Paid-In Capital Accumulated Deficit Beginning Balance at Dec. 31, 2022 $ 160,076 $ 48 $ 399,271 $ (239,243) Beginning Balance, shares at Dec. 31, 2022 Â 48,298,138 Â Â Issuance of common stock upon exercise of stock options Â 163,940 Â Â Issuance of common stock upon exercise of stock options 288 Â 288 Â Issuance of common stock upon vesting of restricted stock units 1 $ 1 Â Â Issuance of common stock upon vesting of restricted stock units, shares Â 181,607 Â Â Withholding taxes on net share settlement of restricted stock units (222) Â (222) Â ESPP purchase 661 Â 661 Â ESPP purchase, Shares Â 78,534 Â Â Stock-based compensation expense 11,121 Â 11,121 Â Net Income (Loss) (44,856) Â Â (44,856) Ending Balance at Sep. 30, 2023 127,069 $ 49 411,119 (284,099) Ending Balance, shares at Sep. 30, 2023 Â 48,722,219 Â Â Beginning Balance at Jun. 30, 2023 136,131 $ 49 407,146 (271,064) Beginning Balance, shares at Jun. 30, 2023 Â 48,649,343 Â Â Issuance of common stock upon exercise of stock options Â 60,738 Â Â Issuance of common stock upon exercise of stock options 117 Â 117 Â Issuance of common stock upon vesting of restricted stock units 0 $ 0 Â Â Issuance of common stock upon vesting of restricted stock units, shares Â 12,138 Â Â Stock-based compensation expense 3,856 Â 3,856 Â Net Income (Loss) (13,035) Â Â (13,035) Ending Balance at Sep. 30, 2023 127,069 $ 49 411,119 (284,099) Ending Balance, shares at Sep. 30, 2023 Â 48,722,219 Â Â Beginning Balance at Dec. 31, 2023 120,215 $ 49 414,956 (294,790) Beginning Balance, shares at Dec. 31, 2023 Â 49,131,363 Â Â Issuance of common stock upon exercise of stock options Â 194,119 Â Â Issuance of common stock upon exercise of stock options 233 Â 233 Â Issuance of common stock upon vesting of restricted stock units Â $ 1 (1) Â Issuance of common stock upon vesting of restricted stock units, shares Â 840,376 Â Â Warrant issuance 609 Â 609 Â Withholding taxes on net share settlement of restricted stock units (20) Â (20) Â ESPP purchase 450 Â 450 Â ESPP purchase, Shares Â 232,290 Â Â Stock-based compensation expense 13,131 Â 13,131 Â Net Income (Loss) (39,661) Â Â (39,661) Ending Balance at Sep. 30, 2024 94,957 $ 50 429,358 (334,451) Ending Balance, shares at Sep. 30, 2024 Â 50,398,148 Â Â Beginning Balance at Jun. 30, 2024 101,638 $ 50 424,973 (323,385) Beginning Balance, shares at Jun. 30, 2024 Â 50,136,131 Â Â Issuance of common stock upon exercise of stock options Â 38,936 Â Â Issuance of common stock upon exercise of stock options 77 Â 77 Â Issuance of common stock upon vesting of restricted stock units, shares Â 223,081 Â Â Stock-based compensation expense 4,308 Â 4,308 Â Net Income (Loss) (11,066) Â Â (11,066) Ending Balance at Sep. 30, 2024 $ 94,957 $ 50 $ 429,358 $ (334,451) Ending Balance, shares at Sep. 30, 2024 Â 50,398,148 Â Â X - DefinitionIssuance of common stock upon exercise of stock options + ReferencesNo definition available. + Details Name: sght_IssuanceOfCommonStockUponExerciseOfStockOptions Namespace Prefix: sght_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionIssuance of common stock upon exercise of stock options, Shares + ReferencesNo definition available. + Details Name: sght_IssuanceOfCommonStockUponExerciseOfStockOptionsShares Namespace Prefix: sght_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionIssuance of common stock upon vesting of restricted stock units + ReferencesNo definition available. + Details Name: sght_IssuanceOfCommonStockUponVestingOfRestrictedStockUnits Namespace Prefix: sght_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionIssuance of common stock upon vesting of restricted stock units, shares + ReferencesNo definition available. + Details Name: sght_IssuanceOfCommonStockUponVestingOfRestrictedStockUnitsShares Namespace Prefix: sght_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionIssuance of Warrant + ReferencesNo definition available. + Details Name: sght_IssuanceOfWarrant Namespace Prefix: sght_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 17: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 32: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 37: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1 + Details Name: us-gaap_NetIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionValue, after value of shares used to satisfy grantee's tax withholding obligation for award under share-based payment arrangement, of restricted shares issued. Excludes cash used to satisfy grantee's tax withholding obligation. + ReferencesNo definition available. + Details Name: us-gaap_RestrictedStockValueSharesIssuedNetOfTaxWithholdings Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionNumber of shares issued which are neither cancelled nor held in the treasury. + ReferencesNo definition available. + Details Name: us-gaap_SharesOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionNumber of shares of stock issued during the period as part of a transaction to acquire assets that do not qualify as a business combination. + ReferencesNo definition available. + Details Name: us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionValue of shares of stock issued during the period as part of a transaction to acquire assets that do not qualify as a business combination. + ReferencesNo definition available. + Details Name: us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionValue, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (d)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(31)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 5: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(6)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 4.E) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2 + Details Name: us-gaap_StockholdersEquity Namespace Prefix: us-

gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant XML 13 R6.htm IDEA: XBRL DOCUMENT v3.24.3 Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Cash flows from operating activities Â Â Net loss $ (39,661) $ (44,856) Adjustments to reconcile net loss to net cash used in operating activities: Â Â Depreciation and amortization 536 455 Accretion of debt discount and debt issuance costs 550 452 Stock-based compensation expense 13,131 11,121 Allowance for credit losses (68) 416 Provision (benefit) for excess and obsolete inventories (105) 219 Noncash operating lease expense 481 743 Loss on disposal of property and equipment 23 66 Noncash loss on debt extinguishment 1,033 0 Changes in operating assets and liabilities: Â Â Accounts receivable 1,427 (2,187) Inventory 1,863 (3,345) Prepaid expenses and other current assets (280) 517 Other noncurrent assets (35) (444) Accounts payable (41) 841 Accrued compensation 3,360 (1,851) Accrued and other current liabilities 418 (3,089) Other noncurrent liabilities (1,524) 242 Net cash used in operating activities (18,892) (40,700) Cash flows from investing activities Â Â Purchases of property and equipment (248) (527) Net cash used in investing activities (248) (527) Cash flows from financing activities Â Â Net proceeds from Hercules Loan Agreement 34,526 0 Repayment of MidCap Loan Agreement (35,375) 0 Debt issuance costs (238) 0 Proceeds from employee stock purchase plan purchases 450 289 Taxes paid on net share settlement of restricted stock units (20) (222) Proceeds from exercise of common stock options 232 661 Net cash (used in) provided by financing activities (425) 728 Net change in cash and cash equivalents (19,565) (40,499) Cash and cash equivalents at beginning of period 138,129 185,000 Cash and cash equivalents at end of period 118,564 144,501 Supplemental disclosure of cash flow information Â Â Cash paid for interest 3,023 3,167 Supplemental noncash disclosure of investing and financing activities Â Â Acquisition of property and equipment included in accounts payable and accrued liabilities 43 81 Common stock warrants issued upon execution of Hercules Loan Agreement $ 609 $ 0 X - DefinitionNoncash Loss On Extinguishment Of Debt + ReferencesNo definition available. + Details Name: sght_NoncashLossOnExtinguishmentOfDebt Namespace Prefix: sght_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionNoncash Operating Lease Cost + ReferencesNo definition available. + Details Name: sght_NoncashOperatingLeaseCost Namespace Prefix: sght_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionProceeds from employee stock purchase plan purchases + ReferencesNo definition available. + Details Name: sght_ProceedsFromEmployeeStockPurchasePlanPurchases Namespace Prefix: sght_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionTaxes paid on the net share settlement of restricted stock units + ReferencesNo definition available. + Details Name: sght_TaxesPaidOnTheNetShareSettlementOfRestrictedStockUnits Namespace Prefix: sght_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of amortization expense attributable to debt discount (premium) and debt issuance costs. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69E -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69EReference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69F -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69FReference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-3 + Details Name: us-gaap_AmortizationOfFinancingCostsAndDiscounts Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4 + Details Name: us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 1 -SubTopic 230 -Topic 830 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1 + Details Name: us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48Reference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 49 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22 + Details Name: us-gaap_DepreciationDepletionAndAmortization Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_GainLossOnSaleOfPropertyPlantEquipment Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IncreaseDecreaseInAccountsPayable Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IncreaseDecreaseInAccountsReceivable Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IncreaseDecreaseInAccruedLiabilities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe increase (decrease) during the reporting period in the aggregate amount of obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IncreaseDecreaseInInventories Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_IncreaseDecreaseInOperatingCapitalAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of increase (decrease) in noncurrent assets classified as other. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IncreaseDecreaseInOtherNoncurrentAssets Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of increase (decrease) in noncurrent operating liabilities classified as other. + ReferencesNo definition available. + Details Name: us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of increase (decrease) in prepaid expenses, and assets classified as other. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 17 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-17Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2 + Details Name: us-gaap_InterestPaidNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of loss from reductions in inventory due to subsequent measurement adjustments, including, but not limited to, physical deterioration, obsolescence, or changes in price levels. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 330 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483080/330-10-50-2 + Details Name: us-gaap_InventoryWriteDown Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24 + Details Name: us-gaap_NetCashProvidedByUsedInFinancingActivities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24 + Details Name: us-gaap_NetCashProvidedByUsedInInvestingActivities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25 + Details Name: us-gaap_NetCashProvidedByUsedInOperatingActivities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe amount of fixed assets that an Entity acquires in a noncash (or part noncash) acquisition. Noncash is defined as information about all investing and financing activities of an enterprise during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-4Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5 + Details Name: us-gaap_NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1 Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe net cash inflow or outflow from resulting from payment, receipt or drawdown of cash deposit to guarantee a loan during the period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 8 -

Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-8Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 9 -Subparagraph (c) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-9 + Details Name: us-gaap_PaymentsForProceedsFromDepositOnLoan Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 15 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15 + Details Name: us-gaap_PaymentsOfDebtIssuanceCosts Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 13 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13 + Details Name: us-gaap_PaymentsToAcquirePropertyPlantAndEquipment Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of cash inflow from exercise of option under share-based payment arrangement. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2A -Subparagraph (a) -SubTopic 10 -Topic 718 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2A + Details Name: us-gaap_ProceedsFromStockOptionsExercised Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 11: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 205 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(16)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 19 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 20: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 235 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-05(b)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1Reference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 31: http://www.xbrl.org/2003/role/exampleRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 4J -Publisher FASB -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4JReference 32: http://www.xbrl.org/2003/role/exampleRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 4K -Publisher FASB -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4KReference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 34: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-2Reference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1A -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1AReference 37: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1A -Subparagraph (c)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A + Details Name: us-gaap_ProfitLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of expense (reversal of expense) for expected credit loss on accounts receivable. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479319/326-20-50-13Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2 + Details Name: us-gaap_ProvisionForDoubtfulAccounts Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionCash outflows under financing arrangements with vendors (seller-financed debt), which had a maturity date at inception of more than one year (or more than one operating cycle, if longer); such debt may have arisen from purchases of property, plant and equipment or other productive assets. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Section 45 -Paragraph 15 -Subparagraph (c) -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15 + Details Name: us-gaap_RepaymentsOfLongtermLoansFromVendors Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of noncash expense for share-based payment arrangement. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_ShareBasedCompensation Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionValue of preferred stock and warrants for common stock issued. + ReferencesNo definition available. + Details Name: us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_SupplementalCashFlowInformationAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 14 R7.htm IDEA: XBRL DOCUMENT v3.24.3 Pay vs Performance Disclosure - USD ($) $ in Thousands 3 Months Ended 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Pay vs Performance Disclosure Â Â Â Â Net Income (Loss) $ (11,066) $ (13,035) $ (39,661) $ (44,856) X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 1 + Details Name: ecd_PvpTable Namespace Prefix: ecd_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 17: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 27:

http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 32: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 37: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1 + Details Name: us-gaap_NetIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration XML 15 R8.htm IDEA: XBRL DOCUMENT v3.24.3 Insider Trading Arrangements 3 Months Ended Sep. 30, 2024 shares Trading Arrangements, by Individual Â Material Terms of Trading Arrangement Trading PlansOur directors and officers may enter into trading plans or other arrangements with financial institutions to purchase or sell shares of our common stock, which plans or arrangements are intended to comply with the affirmative defense provisions of Rule 10b5-1 of the Exchange Act or which may represent a non-Rule 10b5-1 trading arrangement as defined under Item 408(a) of Regulation S-K.Set forth below is a summary of the adoption, modification, and termination activity of our directors and executive officers in respect of their Rule 10b5-1 trading plans during the quarter ended September 30, 2024: Name & Title Adoption Date Termination Date Contract End Date Aggregate Shares Covered(in ones) Jeremy B. Hayden, Chief Legal Officer August 28, 2024 August 25, 2025 August 25, 2025 48,000 Jeremy B. Hayden [Member] Â Trading Arrangements, by Individual Â Name Jeremy B. Hayden Title Chief Legal Officer Rule 10b5-1 Arrangement Adopted true Adoption Date August 28, 2024 Rule 10b5-1 Arrangement Terminated true Termination Date August 25, 2025 Expiration Date August 25, 2025 Aggregate Available 48,000 Rule 10b5-1 Arrangement Modified true X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 1 + Details Name: ecd_MtrlTermsOfTrdArrTextBlock Namespace Prefix: ecd_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 1 + Details Name: ecd_Rule10b51ArrAdoptedFlag Namespace Prefix: ecd_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 1 + Details Name: ecd_Rule10b51ArrTrmntdFlag Namespace Prefix: ecd_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 2 -Subparagraph A + Details Name: ecd_TradingArrByIndTable Namespace Prefix: ecd_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 2 -Subparagraph B + Details Name: ecd_TrdArrAdoptionDate Namespace Prefix: ecd_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 2 -Subparagraph C + Details Name: ecd_TrdArrExpirationDate Namespace Prefix: ecd_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 2 -Subparagraph A + Details Name: ecd_TrdArrIndName Namespace Prefix: ecd_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 2 -Subparagraph A + Details Name: ecd_TrdArrIndTitle Namespace Prefix: ecd_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 2 -Subparagraph D + Details Name: ecd_TrdArrSecuritiesAggAvailAmt Namespace Prefix: ecd_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 2 -Subparagraph B + Details Name: ecd_TrdArrTerminationDate Namespace Prefix: ecd_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionRule 10b5-1 Arr Modified [Flag] + ReferencesNo definition available. + Details Name: sght_Rule10B51ArrModifiedFlag Namespace Prefix: sght_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - Details Name: ecd_IndividualAxis=sght_JeremyBHaydenMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 16 R9.htm IDEA: XBRL DOCUMENT v3.24.3 Company and Nature of Business 9 Months Ended Sep. 30, 2024 Organization, Consolidation and Presentation of Financial Statements [Abstract] Â Company and Nature of Business Note 1. Company and Nature of BusinessÂ Description of BusinessSight Sciences, Inc. (the â€œCompanyâ€) was incorporated in the State of Delaware in 2010 and is headquartered in Menlo Park, California. The Company is an ophthalmic medical device company focused on the development and commercialization of surgical and nonsurgical technologies for the treatment of prevalent eye diseases. The Companyâ€™s mission is to develop transformative, interventional technologies that allow eyecare providers to procedurally elevate the standards of care â€” empowering people to keep seeing. The Company's product portfolio aligns with its two reportable operating segments: Surgical Glaucoma and Dry Eye. The products for the Surgical Glaucoma segment include the OMNIÂ® Surgical System ("OMNI"), which is an implant-free, handheld, single-use, therapeutic technology that enables ophthalmic surgeons to perform a comprehensive procedure (i) indicated in the United States to reduce intraocular pressure in adult patients with primary open-angle glaucoma, and (ii) CE Marked for the catheterization and transluminal viscodilation of Schlemmâ€™s canal and cutting of the trabecular meshwork to reduce intraocular pressure in adult patients with open-angle glaucoma; and the SIONÂ® Surgical Instrument ("SION"), a bladeless, manually operated device used in ophthalmic surgical procedures to excise trabecular meshwork. The product portfolio for the Dry Eye segment consists of the TearCareÂ® System ("TearCare") for ophthalmologists and optometrists. TearCare is a proprietary, interventional, dry eye device designed to melt and facilitate the comprehensive removal of meibomian gland obstructions and restore gland functionality and healthy oil production for adult patients with evaporative dry eye disease due to meibomian gland dysfunction (â€œMGDâ€) when used in conjunction with manual expression of the meibomian glands, enabling clearance of gland obstructions by physicians to address the leading cause of dry eye disease.Significant Risks and UncertaintiesSince inception, the Company has incurred losses and negative cash flows from operations. As of September 30, 2024, the Company had an accumulated deficit of $334.5 million since inception and recorded a net loss of $39.7 million for the nine months then ended and expects to incur additional losses in the future. If the Companyâ€™s revenue levels from its products are not sufficient or if the Company is unable to secure additional funding when desired, the Company may need to delay the development of its products, scale back its business and operations, or change its business strategy.The Company believes that its existing sources of liquidity will satisfy its working capital and capital requirements for at least 12 months from the issuance of its unaudited condensed consolidated financial statements. Any failure to generate increased revenue, achieve improved gross margins, or control operating costs could require the Company to raise additional capital through equity or debt financing. Such additional financing may not be available on acceptable terms, or at all, and could require the Company to modify, delay, or abandon some of its planned future expansion or expenditures or reduce some of its ongoing operating costs, which could harm its business, operating results, financial condition, and ability to achieve its intended business objectives. X - DefinitionThe entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Topic 275 -Publisher FASB -URI https://asc.fasb.org/275/tableOfContentReference 2: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -SubTopic 10 -Topic 275 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1 + Details Name: us-gaap_NatureOfOperations Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 17 R10.htm IDEA: XBRL DOCUMENT v3.24.3 Summary of Significant Accounting Policies 9 Months Ended Sep. 30, 2024 Accounting Policies [Abstract] Â Summary of Significant Accounting Policies Note 2. Summary of Significant Accounting PoliciesBasis of PresentationThe condensed consolidated financial statements and accompanying notes thereto are unaudited and have been prepared in accordance with accounting principles generally accepted in the United States of America ("US GAAP") applicable to interim periods and pursuant to the instructions to Form 10-Q and Article 10 of Regulation S-X. The Companyâ€™s condensed consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries, Sight Sciences UK, Ltd and Sight Sciences GmbH. All intercompany balances and transactions have been eliminated in consolidation. The unaudited condensed consolidated financial statements have been prepared on a basis consistent with the audited consolidated financial statements. In the opinion of management, the unaudited condensed consolidated financial statements reflect all adjustments, which include only normal recurring adjustments, necessary for the fair presentation of the Company's financial information contained herein. The condensed consolidated balance sheet as of December 31, 2023 is derived from the Company's consolidated audited financial statements as of that date. These interim condensed consolidated financial statements do not include all disclosures required by US GAAP and should be read in conjunction with the Company's audited consolidated financial statements and the accompanying notes thereto for the fiscal year ended December 31, 2023, which are contained in the Annual Report. The Company's results of operations for the nine months ended September 30, 2024 are not necessarily indicative of the results to be expected for the year ending December 31, 2024 or for any other interim period. Use of EstimatesThe preparation of the unaudited condensed consolidated financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent liabilities at the date of the financial statements, and the reported amounts of revenues and expense during the reporting period. The most significant estimates related to the provision for credit losses, inventory excess and obsolescence, determination of the fair value of stock option grants, and provisions for income taxes and contingencies. Management evaluates its estimates and assumptions on an ongoing basis using historical experience and other factors, including the current economic environment, and makes adjustments when facts and circumstances dictate. These estimates are based on information available as of the date of the financial statements. Actual results could differ from these estimates and such differences could be material to the Companyâ€™s financial position and results of operations.New Accounting PronouncementsAccounting Standards Recently AdoptedDuring the nine-month period ended September 30, 2024, there were no significant Accounting Standard Updates ("ASUs") issued that were adopted. Accounting Standards Not Yet AdoptedIn November 2023, the Financial Accounting Standards Board ("FASB") issued ASU No. 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures. The ASU updates reportable segment disclosure requirements, primarily through requiring enhanced disclosures about significant segment expenses and information used to assess segment performance. The ASU is effective on a retrospective basis for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024, with early adoption permitted. The Company is currently evaluating the impact of adopting this ASU on its disclosures. In December 2023, the FASB issued ASU No. 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures. The ASU includes amendments requiring enhanced income tax disclosures, primarily related to standardization and disaggregation of rate reconciliation categories and income taxes paid by jurisdiction. The guidance is effective for fiscal years beginning after December 15, 2024, with early adoption permitted, and should be applied either prospectively or retrospectively. The Company is currently evaluating the impact of adopting this ASU on its disclosures.As of September 30, 2024, there are no additional ASUs issued and not yet adopted that are expected to have a material impact on the Company's financial statements and related disclosures. X - ReferencesNo definition available. + Details Name: us-gaap_AccountingPoliciesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for all significant accounting policies of the reporting entity. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483426/235-10-50-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 235 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/235/tableOfContent + Details Name: us-gaap_SignificantAccountingPoliciesTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 18 R11.htm IDEA: XBRL DOCUMENT v3.24.3 Fair Value Measurements 9 Months Ended Sep. 30, 2024 Fair Value Disclosures [Abstract] Â Fair Value Measurements Note 3. Fair Value MeasurementsThe Company reports all financial assets and liabilities and nonfinancial assets and liabilities that are recognized or disclosed at fair value in the financial statements on a recurring basis. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. The authoritative guidance establishes a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to measurements involving significant unobservable inputs (Level 3 measurements). The three levels of the fair value hierarchy are as follows:Level 1â€”Inputs are quoted prices (unadjusted) in active markets for identical assets or liabilities that the Company has the ability to access at the measurement date.Level 2â€”Inputs are observable, unadjusted quoted prices in active markets for similar assets or liabilities, unadjusted quoted prices for identical or similar assets or liabilities in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the related assets or liabilities.Level 3â€”Inputs are unobservable inputs for the asset or liability. The level in the fair value hierarchy within which a fair value measurement in its entirety is based on the lowest-level input that is significant to the fair value measurement in its entirety.The Company's cash and cash equivalents included Level 1 investments in treasury securities of $100.5 million and $129.1 million as of September 30, 2024 and December 31, 2023, respectively. These securities are classified as held-to-maturity and all have been purchased with original maturities of 90 days or less. Â Held-to-maturity debt securities are recorded at amortized cost in the financial statements.Â Â Â September 30, 2024 Â Â Â Amortized Cost Â Â Unrealized Gains Â Â Unrealized Losses Â Â Aggregate Fair Value Â U.S. treasury securities Â $ 100,488 Â Â $ 24 Â Â $ (1) Â $ 100,511 Â Â Â Â December 31, 2023 Â Â Â Amortized Cost Â Â Unrealized Gains Â Â Unrealized Losses Â Â Aggregate Fair Value Â U.S. treasury securities Â $ 129,113 Â Â $ 28 Â Â $ â€” Â Â $ 129,141 Â The Company measures the fair value of outstanding debt for disclosure purposes on a recurring basis. As of September 30, 2024 and December 31, 2023, total debt of $34.2 million and $33.9 million is reported at amortized cost, respectively. This outstanding debt is classified as Level 2 as it is not actively traded. The amortized cost of the outstanding debt approximates the fair value.The Company measures the fair value of the unissued common stock warrants to be issued pursuant to the Hercules Loan Agreement (as defined in Note 5, Debt) using the Black-Scholes option pricing method. These are classified as Level 3 liabilities, with an overall value of less than $0.1 million as of September 30, 2024. The unissued warrants are remeasured at each reporting date following execution of the Hercules Loan Agreement. See Note 5, Debt, and Note 7, Stockholders' Equity, for additional information regarding the common stock warrants. The financial statements as of September 30, 2024 and December 31, 2023 do not include any assets or liabilities that are measured at fair value on a nonrecurring basis. X - ReferencesNo definition available. + Details Name: us-

gaap_FairValueDisclosuresAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure of the fair value measurement of assets and liabilities, which includes financial instruments measured at fair value that are classified in shareholders' equity, which may be measured on a recurring or nonrecurring basis. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 820 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/820/tableOfContent + Details Name: us-gaap_FairValueMeasurementInputsDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 19 R12.htm IDEA: XBRL DOCUMENT v3.24.3 Balance Sheet Components 9 Months Ended Sep. 30, 2024 Organization, Consolidation and Presentation of Financial Statements [Abstract] Â Balance Sheet Components Note 4. Balance Sheet ComponentsProperty and Equipment, NetProperty and equipment, net consist of the following (in thousands):Â Â Â As of September 30, Â Â As of December 31, Â Â Â 2024 Â Â 2023 Â Tools and equipment Â $ 1,991 Â Â $ 2,010 Â Computer equipment and software Â Â 37 Â Â Â 37 Â Furniture and fixtures Â Â 286 Â Â Â 323 Â Leasehold improvements Â Â 38 Â Â Â 38 Â Construction in process Â Â 1,071 Â Â Â 859 Â Â Â 3,423 Â Â Â 3,267 Â Less: Accumulated depreciation Â Â (1,975) Â Â (1,627) Property and equipment, net Â $ 1,448 Â Â $ 1,640 Â Â Depreciation expense was $0.1 million and $0.4 million for the three and nine months ended September 30, 2024, respectively. Depreciation expense was $0.2 million and $0.5 million for the three and nine months ended September 30, 2023, respectively. Accrued and Other Current LiabilitiesAccrued and other current liabilities consist of the following (in thousands):Â Â Â As of September 30, Â Â As of December 31, Â Â Â 2024 Â Â 2023 Â Accrued expenses Â $ 2,447 Â Â $ 1,639 Â Current portion of lease liabilities Â Â 519 Â Â Â 573 Â Short-term interest payable Â Â 311 Â Â Â 375 Â Other accrued liabilities Â Â 1,336 Â Â Â 1,187 Â Total accrued and other current liabilities Â $ 4,613 Â Â $ 3,774 Â Â Other Noncurrent LiabilitiesOther noncurrent liabilities consist of the following (in thousands):Â Â Â As of September 30, Â Â As of December 31, Â Â Â 2024 Â Â 2023 Â Noncurrent portion of lease liabilities Â $ 614 Â Â $ 914 Â Other noncurrent liabilities Â Â 75 Â Â Â 38 Â Long-term interest payable Â Â â€” Â Â Â 1,524 Â Total other noncurrent liabilities Â $ 689 Â Â $ 2,476 Â X - ReferencesNo definition available. + Details Name: us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/210/tableOfContent + Details Name: us-gaap_SupplementalBalanceSheetDisclosuresTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 20 R13.htm IDEA: XBRL DOCUMENT v3.24.3 Debt 9 Months Ended Sep. 30, 2024 Debt Disclosure [Abstract] Â Debt Note 5. DebtHercules Capital Loan AgreementIn January 2024, the Company entered into a Loan and Security Agreement (the â€œHercules Loan Agreementâ€), with Hercules Capital, Inc. (â€œHerculesâ€) and certain of its affiliates (collective with Hercules, the â€œLendersâ€), which provides for a senior secured term loan facility in the aggregate principal amount of up to $65.0 million. An initial tranche of $35.0 million (the â€œInitial Loanâ€) was funded under the Hercules Loan Agreement on January 22, 2024. In addition to the Initial Loan, the Hercules Loan Agreement provides for additional tranches as follows: $5.0 million available in a single draw through December 15, 2024, $10.0 million available to draw upon the achievement of certain performance milestones through September 15, 2025, and $15.0 million available for the Company to draw on through the interest-only period in increments of $5.0 million, subject to the sole approval of Hercules' investment committee (such tranche loans together with the Initial Loan, the â€œTerm Loansâ€).The Hercules Loan Agreement includes a maturity date of July 1, 2028, with an interest only period running for the first 30 months of the agreement term, extendable for an additional six months for a total of 36 months upon the achievement of certain milestones. The Term Loans accrue interest at a floating annual rate of the greater of 10.35% or the Wall Street Journal prime rate plus 2.35%, with the interest rate under the Term Loans equal to 10.35% at September 30, 2024. The final payment fee is set at 5.95% of the funded balance, which is recognized as a debt discount and is being accreted into the amortization of debt issuance costs using the effective interest rate method over the term of the loan. In conjunction with the funding of the Initial Loan, the Company issued warrants to the Lenders to purchase up to an aggregate of 135,686 shares of its common stock at an exercise price of $5.159 per share, which were recorded and classified as equity. Each warrant is exercisable for a period of seven years from the date of issuance. See Note 7, Stockholders' Equity, for additional information regarding these common stock warrants.The obligations under the Hercules Loan Agreement are guaranteed by the Company and its future subsidiaries, subject to exceptions for certain foreign subsidiaries. The obligations under the agreement are secured by substantially all of the Company's assets, including its material intellectual property. Additionally, the Company is subject to customary affirmative and negative covenants, including covenants that limit or restrict the ability of the Company to, among other things, incur indebtedness, grant liens, merge or consolidate, make investments, dispose of assets, make acquisitions, pay dividends or make distributions, repurchase stock and enter into certain transactions with affiliates, in each case subject to certain exceptions. The Company is also subject to certain minimum cash and revenue covenants under the Hercules Loan Agreement. The Company was in compliance with all covenants as of September 30, 2024.MidCap Loan AgreementThe Company had credit and security agreements with certain entities affiliated with MidCap Financial Services (such entities collectively, â€œMidCapâ€), which provided for a $35.0 million senior secured term loan (the â€œMidCap Term Loanâ€). In January 2024, the Company terminated the Amended and Restated Credit and Security Agreement (Term Loan) (the â€œMidCap Term Loan Agreementâ€) evidencing the MidCap Term Loan and paid off in full the secured obligations thereunder in connection with its entry into the Hercules Loan Agreement. The Company recorded a loss on debt extinguishment of $2.0 million during the nine months ended September 30, 2024.The commitment obligations under the MidCap Term Loan Agreement were guaranteed by the Companyâ€™s current and future subsidiaries, subject to exceptions for certain foreign subsidiaries, and secured by substantially all assets of the Company, including material intellectual property. The MidCap Term Loan Agreement had a maturity date of November 1, 2025, and principal payments under the Term Loan were scheduled to commence in December 2024. In addition, the MidCap Term Loan Agreement included a stated floating interest rate that was reserve-adjusted Secured Overnight Finance Rate, plus 7.00%, and a provision for a final payment fee of 6.0% of the $35.0 million MidCap Term Loan balance, which was recorded as a long-term interest payable as of December 31, 2023. Maturities ScheduleLong-term and short-term debt as of September 30, 2024 and December 31, 2023, respectively, was as follows (in thousands):Â Â Â As of September 30, Â Â As of December 31, Â Â Â 2024 Â Â 2023 Â Hercules Initial Loan Â $ 35,000 Â Â $ â€” Â MidCap Term Loan Â Â â€” Â Â Â 35,000 Â Total principal payments due Â Â 35,000 Â Â Â 35,000 Â Less: unamortized discount and debt issuance costs Â Â (848) Â Â (1,073) Total amounts outstanding Â Â 34,152 Â Â Â 33,927 Â Less: current portion Â Â â€” Â Â Â (2,219) Long-term debt, net Â $ 34,152 Â Â $ 31,708 Â The repayment schedule relating to the Hercules Initial Loan as of September 30, 2024, is as follows (in thousands):Â Â Â Amount Â 2024 (remainder) Â $ â€” Â 2025 Â Â â€” Â 2026 Â Â 6,680 Â 2027 Â Â 17,294 Â Thereafter Â Â 11,026 Â Total principal payments Â $ 35,000 Â Final fee due at maturity Â Â 2,083 Â Total repayments Â $ 37,083 Â X - ReferencesNo definition available. + Details Name: us-gaap_DebtDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481544/470-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481544/470-10-50-6Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 405 -SubTopic 40 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 405 -SubTopic 40 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 405 -SubTopic 40 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 405 -SubTopic 40 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 405 -SubTopic 40 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(c)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 470 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/470/tableOfContentReference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1C -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1CReference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1C -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1CReference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1C -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1CReference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1EReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1I -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1IReference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1I -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1IReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1I -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I + Details Name: us-gaap_DebtDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 21 R14.htm IDEA: XBRL DOCUMENT v3.24.3 Commitments and Contingencies 9 Months Ended Sep. 30, 2024 Commitments and Contingencies Disclosure [Abstract] Â Commitments and Contingencies Note 6. Commitments and ContingenciesOperating Lease ObligationsThe Companyâ€™s leases include facility leases and equipment leases. In determining the present value of lease payments, the Company uses its incremental borrowing rate based on the information available at the lease commencement date if the rate implicit in the lease is not readily determinable. The Companyâ€™s incremental borrowing rate represents the interest rate that the Company would expect to incur at lease commencement to borrow an amount equal to the lease payments on a collateralized basis with similar terms and payments, in an economic environment where the leased asset is located. In determining the lease term, the Company includes all renewal options that are reasonably probable to be executed. The Company leases its corporate headquarters in Menlo Park, California. The lease commenced in August 2021 and was originally for a term of 37 months from the commencement date. In December 2023, the Company entered into an amendment to the lease, extending the lease term an additional 26 months. Upon signing the amendment, the Company recorded an aggregate lease right-of-use ("ROU") asset and lease liability of $1.2 million. The lease ROU asset and corresponding liability were estimated using a weighted-average incremental borrowing rate of 11.40%. Total base rent for the remaining 34 months under the amended lease agreement is approximately $1.5 million. During the fourth quarter of 2022, the Company entered into a supply agreement that was expected to last approximately 18 months. In January 2024, the term was extended through December 31, 2024. The supply agreement contained provisions that, when evaluated, indicated an embedded lease was present within the agreement and the Company recorded an aggregate lease ROU asset and lease liability of $0.7 million. The lease ROU asset and corresponding lease liability were estimated using a weighted-average incremental borrowing rate of 10.75%. Total base rent under the agreement is approximately $0.7 million. The Company recognizes rent expense on a straight-line basis over the noncancelable lease term. The Companyâ€™s rent expense was $0.2 million and $0.3 million for the three months ended September 30, 2024 and 2023, respectively. The Companyâ€™s rent expense was $0.6 million and $0.9 million for the nine months ended September 30, 2024 and 2023, respectively. As of September 30, 2024, the weighted average remaining lease term for the leases was 2.0 years.Operating lease expense and supplemental cash flow information related to operating leases for the three months ended September 30, 2024 and 2023 were as follows (in thousands):Â Â Â Three Months Ended September 30, Â Â Nine Months Ended September 30, Â Â Â 2024 Â Â 2023 Â Â 2024 Â Â 2023 Â Operating lease expense Â $ 196 Â Â $ 288 Â Â $ 587 Â Â $ 869 Â Cash paid for operating leases Â Â 162 Â Â Â 295 Â Â Â 582 Â Â Â 885 Â Aggregate future minimum lease payments as of September 30, 2024, under these noncancelable operating leases were as follows (in thousands):Â Â Â As of September 30, Â Â Â Â 2024 Â Â 2024 (remainder) Â $ 158 Â Â 2025 Â Â 618 Â Â 2026 Â Â 497 Â Â Total future minimum lease payments Â $ 1,273 Â Â Less: imputed interest Â Â (140) Â Present value of future minimum lease payments Â $ 1,133 Â Â Less: current portion of operating lease liability Â Â (519) Â Noncurrent portion of lease liabilities Â $ 614 Â Â Â Legal ProceedingsOn September 16, 2021, the Company filed suit in the U.S. District Court for the District of Delaware (C.A. No. 1:21-cv-01317) (the â€œCourtâ€) alleging that Ivantis, Inc. (â€œIvantisâ€) directly and indirectly infringes the Companyâ€™s U.S. Patent Nos. 8,287,482, 9,370,443, 9,486,361, and 10,314,742 by making, using, selling, and offering for sale the HydrusÂ® Microstent. The Companyâ€™s complaint seeks money damages and injunctive relief. On January 24, 2022, Ivantis asserted counterclaims requesting declaratory judgments that the Company's asserted patents-in-suit are not infringed and/or invalid. On August 1, 2022, the Company filed an amended complaint alleging that Alcon Inc., Alcon Vision, LLC and Alcon Research, LLC (collectively, â€œAlconâ€) infringe the four originally asserted patents by making, using, selling, and offering for sale the HydrusÂ® Microstent, and that all defendants also infringe U.S. Patent No. 11,389,328. The defendants asserted counterclaims requesting declaratory judgments that the Companyâ€™s asserted patents-in-suit are not infringed and/or are invalid. In September 2022, Ivantis and Alcon filed petitions with the U.S. Patent Office seeking inter partes review of U.S. Patent Nos. 8,287,482, 9,370,443, 9,486,361, and 10,314,742 (IPR2022-01529, IPR2022-01530, IPR2022-01533, IPR2022-01540), each of which the U.S. Patent Office denied for raising prior art references and invalidity arguments that were cumulative of those previously considered by the U.S. Patent Office. On April 26, 2024, at the conclusion of a five-day jury trial, the Company was awarded a positive jury trial verdict of $34 million, comprised of $5.5 million in lost profits damages and $28.5 million in royalty damages for commercial sales of the Hydrus Microstent for the period between its commercial launch through trial. The patents at issue were U.S. Patent Nos. 8,287,482, 9,370,443, and 11,389,328. The parties have submitted their post-trial briefings and the Court will hold an in-person hearing in December 2024 to hear the partiesâ€™ oral arguments on these briefings. The Court will enter its final judgement after the hearing, with such entry currently expected in late fourth quarter 2024 or in first quarter 2025. The Court's final judgment will be subject to appeal. The Company is presently unable to predict the outcome of this lawsuit or to reasonably estimate the potential financial impact of the lawsuit on the Company, if any.In addition to the foregoing, from time to time, the Company is subject to legal claims, regulatory matters and contingencies in the ordinary course of business. Accruals for these matters are reflected in the financial statements based on managementâ€™s assessment, including the advice of legal counsel, of the expected outcome of these matters. Liabilities for estimated losses are accrued if the potential losses from any legal proceedings, regulatory matters or contingencies are considered probable and the amounts can be reasonably estimated. Significant judgment is required in both the determination of probability of loss and the determination as to whether the amount can be reasonably estimated. Accruals are based only on information available at the time of the assessment due to the uncertain nature of such matters. As additional

information becomes available, management reassesses potential liabilities related to legal claims, regulatory matters and contingencies, and may revise its previous estimates, which could materially affect the Companyâ€™s results of operations in a given period. Except as described above, as of September 30, 2024 and December 31, 2023, the Company was not a party to any legal proceedings, regulatory matters, or other disputes or claims which, if determined adversely, would, individually or taken together, have a material adverse effect on the Companyâ€™s business, financial condition, operating results, liquidity, or future prospects.IndemnificationIn the normal course of business, the Company enters into contracts and agreements that contain a variety of representations and warranties and provide for general indemnifications. The Companyâ€™s exposure under these agreements is unknown because it involves claims that may be made against the Company in the future, but that have not yet been made. To date, the Company has not paid any claims or been required to defend any action related to its indemnification obligations. However, the Company may record charges in the future as a result of these indemnification obligations.The Company indemnifies each of its directors and officers for certain events or occurrences, subject to certain limits, while the director is or was serving at the Companyâ€™s request in such capacity, as permitted under Delaware law and in accordance with its certificate of incorporation and bylaws. The term of the indemnification period lasts as long as a director or officer may be subject to any proceeding arising out of acts or omissions of such director or officer in such capacity. The maximum amount of potential future indemnification is unlimited; however, the Company currently holds director and officer liability insurance. This insurance allows the transfer of risk associated with the Companyâ€™s exposure and may enable it to recover a portion of any future amounts paid. The Company believes the fair value of these indemnification obligations is minimal. Accordingly, the Company has not recognized any liabilities relating to these obligations as of September 30, 2024 and December 31, 2023. X - ReferencesNo definition available. + Details Name: us-gaap_CommitmentsAndContingenciesDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for commitments and contingencies. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 405 -SubTopic 30 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/405-30/tableOfContentReference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 440 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 450 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/450/tableOfContentReference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 954 -SubTopic 440 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478522/954-440-50-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 440 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 440 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/440/tableOfContent + Details Name: us-gaap_CommitmentsAndContingenciesDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 22 R15.htm IDEA: XBRL DOCUMENT v3.24.3 Stockholders' Equity 9 Months Ended Sep. 30, 2024 Equity [Abstract] Â Stockholders' Equity Note 7. Stockholders' EquityCommon StockThe Companyâ€™s certificate of incorporation provides for 200,000,000 authorized shares of common stock, par value $0.001 per share, and 10,000,000 authorized shares of preferred stock, par value $0.001 per share. The holders of common stock are entitled to receive dividends whenever funds are legally available, when and if declared by the board of directors. As of September 30, 2024, no dividends have been declared. Each share of common stock is entitled to one vote.At September 30, 2024 and December 31, 2023, the Company had reserved common stock for future issuances as follows: Â Â September 30, Â Â December 31, Â Â Â 2024 Â Â 2023 Â Common stock available for future grants Â Â 5,956,636 Â Â Â 6,033,176 Â Common stock options issued and outstanding Â Â 4,583,289 Â Â Â 4,980,190 Â Restricted stock units outstanding Â Â 4,574,045 Â Â Â 2,721,361 Â Shares available for future purchase under employee stock purchase plan Â Â 1,747,250 Â Â Â 1,488,227 Â Total Â Â 16,861,220 Â Â Â 15,222,954 Â Â Common Stock WarrantsIn conjunction with the funding of the Initial Loan under the Hercules Loan Agreement, the Company issued common stock warrants to the Lenders to purchase up to an aggregate of 135,686 shares of our common stock at an exercise price of $5.159 per share. Each warrant is exercisable for up to seven years from the date of issuance. The warrants are classified as equity. During the nine months ended September 30, 2024, the fair value of the issued warrants recorded was $0.6 million, which was calculated using the Black-Scholes option pricing model. These warrants were recorded at fair value upon their issuance in additional paid-in capital in the condensed consolidated balance sheet. The issued warrants are not remeasured after the issuance date.If the additional Term Loans are funded, the Company will be obligated to issue to the Lenders additional warrants to purchase common stock in an amount equal to 2.0% of the funded balance of each tranche, divided by the exercise price on the date the Company draws funds from such tranche, or the issuance date. The exercise price will be calculated using the five-day volume-weighted average stock price as of such date.The unissued warrants do not meet the requirements for classification in equity, and are recorded as liabilities in other noncurrent liabilities in the financial statements. The fair value of the unissued common stock warrants was calculated using the Black-Scholes option pricing method and they were recorded at fair value upon the funding of the Hercules Loan Agreement. The unissued warrants are remeasured at each reporting date after the issuance date. According to the fair value measurement criteria, the unissued warrants are considered Level 3 liabilities, with an overall value of less than $0.1 million as of September 30, 2024. X - ReferencesNo definition available. + Details Name: us-gaap_EquityAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for equity. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 14 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 235 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 235 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478448/946-505-50-6Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480237/815-40-50-6Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(e)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/505/tableOfContentReference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 14 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 14 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 16 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-16Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18 + Details Name: us-gaap_StockholdersEquityNoteDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 23 R16.htm IDEA: XBRL DOCUMENT v3.24.3 Equity Incentive Plans 9 Months Ended Sep. 30, 2024 Share-Based Payment Arrangement [Abstract] Â Equity Incentive Plans Note 8. Equity Incentive Plans2011 Stock Option Plan and 2021 Incentive Award PlanIn 2011, the Company established its 2011 Stock Option Plan (the â€œ2011 Planâ€) that provided for the granting of stock options to employees and nonemployees of the Company. In July 2021, the board of directors and stockholders adopted and approved the 2021 Incentive Award Plan, (the â€œ2021 Planâ€). Under the 2021 Plan, the Company has the ability to issue incentive stock options ("ISOs"), nonqualified stock options ("NSOs"), stock appreciation rights, dividend equivalent rights, restricted stock awards, and restricted stock unit awards ("RSUs"). Options under the 2021 Plan can typically be granted for periods of up to ten years. For stock options granted to a grantee who, at the time the option is granted, owned stock representing more than 10% of the voting power of all classes of stock of the Company (or any parent or subsidiary of the Company), the term of the stock option may be granted for periods of up to five years. The ISOs and NSOs will be granted at a price per share not less than the fair value at the date of grant. The exercise price of a stock option granted to a 10% stockholder shall be not less than 110% of the grant date fair value of the shares. Options granted to new hires generally vest over a four-year period, with 25% of the shares vesting on the first anniversary of the grant date and the remaining shares vesting in 36 equal monthly installments thereafter; options granted as merit awards generally vest in 48 equal monthly installments following the grant date. RSUs granted generally vest over a four-year period with straight-line vesting in equal amounts (either in annual or quarterly installments). The Company initially reserved 5,200,000 shares of common stock for future issuance under the 2021 Plan. This initial reserve is subject to annual increase on the first day of each calendar year beginning on January 1, 2022 and ending on and including January 1, 2031. These annual increases are equal to the lesser of (i) 5% of the aggregate number of shares of common stock outstanding on the final day of the immediately preceding calendar year and (ii) such smaller number of shares of common stock as determined by the Board, subject to certain limitations. Pursuant to the evergreen provision, the initial share reserve was increased by 2,456,568 shares and 2,414,907 shares on January 1, 2024 and 2023, respectively. The 2011 Plan was superseded by the 2021 Plan at the time of the initial public offering of the Company's common stock, which closed on July 15, 2021, and no further grants have been made under the 2011 Plan from the date the 2021 Plan became effective. The terms under the 2011 Plan are consistent with those described above for the 2021 Plan. As of September 30, 2024 and December 31, 2023 there were 5,956,636 shares and 6,033,176 shares, respectively, of common stock available for issuance under the 2021 Plan.Stock Option AwardsThe following table summarizes stock option activity under the 2021 Plan during the periods presented: Â Â Â Number ofShares Â Â Weighted-Average Exercise Price Â Â Weighted-AverageContractualÂ Term (in years) Â Â Average Intrinsic Value (in thousands) Â Balances as of December 31, 2023 Â Â 4,980,190 Â Â $ 9.00 Â Â Â 7.4 Â Â $ 5,924 Â Grants Â Â 7,377 Â Â Â 4.43 Â Â Â Â Â Â Â Forfeited/cancelled Â Â (210,159) Â Â 10.15 Â Â Â Â Â Â Â Exercised/released Â Â (194,119) Â Â 1.20 Â Â Â Â Â Â Â Balances as of September 30, 2024 Â Â 4,583,289 Â Â $ 9.28 Â Â Â 7.0 Â Â $ 6,558 Â Vested and exercisable as of September 30, 2024 Â Â 3,163,058 Â Â $ 9.32 Â Â Â 6.4 Â Â $ 4,635 Â Vested and expected to vest as of September 30, 2024 Â Â 4,583,289 Â Â $ 9.28 Â Â Â 7.0 Â Â $ 6,558 Â Â During the three months ended September 30, 2024 and 2023, the Company recorded stock-based compensation expense of $1.9 million and $2.1 million related to stock option awards, respectively. During the nine months ended September 30, 2024 and 2023, the Company recorded stock-based compensation expense of $5.7 million and $6.6 million related to stock option awards, respectively. The weighted-average grant-date fair values of options granted during the nine months ended September 30, 2024 and 2023 was $2.71 and $6.92 per share, respectively. The aggregate intrinsic value of options exercised was $0.2 million and $0.8 million during the three and nine months ended September 30, 2024, respectively. The aggregate intrinsic value was calculated as the difference between the exercise prices of the underlying options and the estimated fair value of the common stock on the date of exercise. As of September 30, 2024, the unrecognized stock-based compensation expense relating to unvested options was $8.1 million, which is expected to be recognized over a weighted-average period of 1.3 years.Determination of Fair ValueThe Company estimated the grant date fair value of stock options using the Black-Scholes option-pricing model, which requires the use of highly subjective and complex valuation assumptions to determine the fair value of stock-based awards, including the optionâ€™s expected term, the expected volatility of the underlying stock, the risk-free interest rate, and the expected dividend yield. For the purposes of the Black-Scholes valuation model, the Company used the simplified method for determining the expected term of the granted options. The simplified method was used since the Company does not have adequate historical data to utilize in calculating the expected term of options. The fair value for options granted was calculated using the following weighted average assumptions: Â Â Â Three Months Ended September 30, Â Nine Months Ended September 30, Â Â Â 2024 Â 2023 Â 2024 Â 2023 Expected term (in years) Â N/A Â 5.99Â â€“ 6.01 Â 6.13 Â 5.60Â â€“ 6.07 Expected volatility Â N/A Â 79.82% Â 61.67% Â 78.53% â€“ 79.82% Risk-free interest rate Â N/A Â Â 4.04% Â 4.28% Â 3.48% â€“ 4.04% Dividend yield Â N/A Â Â â€“ Â Â â€“ Â Â â€“ Restricted Stock UnitsRSUs are share awards that entitle the holder to receive shares of common stock upon vesting. The RSUs cannot be transferred, and the awards are subject to forfeiture if the holderâ€™s employment terminates prior to the release of the vesting restrictions. The RSUs generally vest either (i) annually over a four-year period with straight-line vesting in equal amounts, or (ii) quarterly over a four-year period with straight-line vesting in equal amounts, in each case provided the holder provides continuous services to the Company. The fair value of the RSUs is equal to the closing price of the Companyâ€™s common stock on the grant date.The following table summarizes restricted share award activity: Â Â Number ofShares Â Â Weighted-Average Grant Date Fair Value Per Share Â Outstanding, December 31, 2023 Â Â 2,721,361 Â Â $ 7.61 Â Grants Â Â 2,949,065 Â Â Â 4.46 Â Forfeited/cancelled Â Â (213,175) Â Â 6.54 Â Vested Â Â (883,206) Â Â 7.58 Â Outstanding, September 30, 2024 Â Â 4,574,045 Â Â $ 5.62 Â During the three months ended September 30, 2024 and 2023, the Company recorded stock-based compensation expense of $2.2 million and $1.6 million, respectively, related to the RSUs. During the nine months ended September 30, 2024 and 2023, the Company recorded stock-based compensation expense of $6.9 million and $4.2 million, respectively, related to the RSUs. As of September 30, 2024, there was $21.2 million of total unrecognized stock-based compensation expense relating to the RSUs that is expected to be recognized over a weighted-average period of 2.7 years. Employee Stock Purchase PlanIn July 2021, the board of directors and stockholders adopted and approved the 2021 Employee Stock Purchase Plan (the â€œESPPâ€). The Company initially reserved 850,000 shares of common stock for future issuance under the ESPP. This initial reserve is subject to annual increase on the first day of each calendar year beginning on January 1, 2022 and ending on and including January 1, 2031. These annual increases shall be equal to the lesser of (i) 1% of the aggregate number of shares of common stock outstanding on the final day of the immediately preceding calendar year and (ii) such smaller number of shares of common stock as determined by the Board, subject to certain limitations. Pursuant to the evergreen provision, the initial share reserve was increased by 491,313 and 482,981 shares on January 1, 2024 and 2023, respectively.The Company has two offering periods annually, running for six months, with the first offering period beginning in the second quarter, and the second offering period beginning in the fourth quarter. The purchase of shares for participants in the ESPP occurs at the conclusion of each offering period. During the nine months ended, September 30, 2024, participants in the ESPP purchased 232,290 shares for a total of $0.5 million. As of September 30, 2024, the Company has collected payroll withholdings of $0.4 million in the current offering period for the purchase of shares under the ESPP. The Company recorded stock-based compensation expense associated with the ESPP of $0.1 million for both the three months ended September 30, 2024 and 2023. The Company recorded stock-based compensation expense associated with the ESPP of $0.5 million and $0.4 million for the nine months ended September 30, 2024 and 2023, respectively. As of September 30, 2024, there were 1,747,250 shares of common stock available for issuance under the ESPP. The fair value of shares to be issued under the ESPP was estimated using the Black-Scholes valuation model with the following assumptions for the three and nine months ended September 30, 2024 and 2023:Â Â Â Three Months Ended September 30, Â Nine Months Ended September 30, Â Â Â 2024 Â 2023 Â 2024 Â 2023 Expected term (in years) Â 0.49 â€“ 0.50 Â 0.48 â€“ 0.50 Â 0.49Â â€“ 0.50 Â 0.48Â â€“ 0.50 Expected volatility Â 100.00% â€“ 197.51% Â 66.72% â€“ 97.38% Â 100.00% â€“ 197.51% Â 66.72% â€“ 97.38% Risk-free

interest rate Â 5.37% â€“ 5.40% Â 4.62% â€“ 5.32% Â 5.37% â€“ 5.40% Â 4.62% â€“ 5.32% Dividend yield Â â€“ Â â€“ Â â€“ Â â€“ Stock-Based CompensationThe following is a summary of stock-based compensation expense by function (in thousands):Â Â Â Three Months Ended September 30, Â Â Nine Months Ended September 30, Â Â Â 2024 Â Â 2023 Â Â 2024 Â Â 2023 Â Cost of goods sold Â $ 83 Â Â $ 77 Â Â $ 283 Â Â $ 206 Â Research and development Â Â 588 Â Â Â 549 Â Â Â 1,787 Â Â Â 1,664 Â Selling, general and administrative Â Â 3,637 Â Â Â 3,230 Â Â Â 11,061 Â Â Â 9,251 Â Total stock-based compensation expense Â $ 4,308 Â Â $ 3,856 Â Â $ 13,131 Â Â $ 11,121 Â X - DefinitionThe entire disclosure for share-based payment arrangement. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/718/tableOfContentReference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (h)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (h)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (l) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 24 R17.htm IDEA: XBRL DOCUMENT v3.24.3 Net Loss per Share Attributable to Common Stockholders 9 Months Ended Sep. 30, 2024 Earnings Per Share [Abstract] Â Net Loss per Share Attributable to Common Stockholders Note 9. Net Loss per Share Attributable to Common StockholdersBasic net loss per share is computed by dividing the net loss by the weighted-average number of common shares outstanding for the period. As the Company reported a net loss for the three and nine months ended September 30, 2024 and 2023, basic net loss per share is the same as diluted net loss per share for each of the reported periods.The following table sets forth the computation of basic and diluted net loss per share attributable to common stockholders for the periods presented (in thousands, except share and per share data):Â Â Â Three Months Ended September 30, Â Â Nine Months Ended September 30, Â Â Â 2024 Â Â 2023 Â Â 2024 Â Â 2023 Â Numerator: Â Â Â Â Â Â Â Â Â Â Â Net loss attributable to common stockholders Â $ (11,066) Â $ (13,035) Â $ (39,661) Â $ (44,856) Denominator: Â Â Â Â Â Â Â Â Â Â Â Weighted-average shares of common stockÂ Â Â outstandingâ€”basic and diluted Â Â 50,340,603 Â Â Â 48,671,049 Â Â Â 49,911,655 Â Â Â 48,538,517 Â Net loss per share attributable to commonÂ Â Â stockholdersâ€”basic and diluted Â $ (0.22) Â $ (0.27) Â $ (0.79) Â $ (0.92) Â The following potentially dilutive issued and outstanding securities were excluded from the computation of diluted net loss per share attributable to common stockholders for the period presented because including them would have been antidilutive as a result of the net loss position:Â Â Â September 30, Â Â Â 2024 Â Â 2023 Â Stock option awards Â Â 4,583,289 Â Â Â 4,705,390 Â Restricted stock units Â Â 4,574,045 Â Â Â 1,853,657 Â Common stock warrants Â Â 135,686 Â Â Â â€” Â Total Â Â 9,293,020 Â Â Â 6,559,047 Â X - ReferencesNo definition available. + Details Name: us-gaap_EarningsPerShareAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for earnings per share. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/260/tableOfContentReference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-3 + Details Name: us-gaap_EarningsPerShareTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 25 R18.htm IDEA: XBRL DOCUMENT v3.24.3 Segment Information 9 Months Ended Sep. 30, 2024 Segment Reporting [Abstract] Â Segment Information Note 10. Segment InformationThe Company has two reportable operating segments which are determined on the basis of the product portfolio: Surgical Glaucoma and Dry Eye. The operating and reportable segments were determined based on how the Companyâ€™s Chief Executive Officer, its Chief Operating Decision Maker (â€œCODMâ€), views and evaluates the Companyâ€™s operations. The CODM allocates resources to and evaluates the financial performance of each operating segment primarily based on gross profit and gross profit margin.The Surgical Glaucoma segment includes sales of the Companyâ€™s OMNI Surgical System and SION Surgical Instrument for use in minimally invasive glaucoma procedures. The Dry Eye segment includes sales of the Companyâ€™s TearCare System and related components.The following table summarizes select operating results information for each reportable segment (in thousands):Â Â Â Three Months Ended September 30, Â Â Nine Months Ended September 30, Â Â Â 2024 Â Â 2023 Â Â 2024 Â Â 2023 Â Revenue Â Â Â Â Â Â Â Â Â Â Â Surgical Glaucoma Â $ 18,632 Â Â $ 18,425 Â Â $ 57,132 Â Â $ 57,158 Â Dry Eye Â Â 1,525 Â Â Â 1,584 Â Â Â 3,660 Â Â Â 5,147 Â Total Â Â 20,157 Â Â Â 20,009 Â Â Â 60,792 Â Â Â 62,305 Â Cost of goods sold Â Â Â Â Â Â Â Â Â Â Â Surgical Glaucoma Â Â 2,453 Â Â Â 2,002 Â Â Â 7,084 Â Â Â 6,808 Â Dry Eye Â Â 797 Â Â Â 675 Â Â Â 1,984 Â Â Â 2,297 Â Total Â Â 3,250 Â Â Â 2,677 Â Â Â 9,068 Â Â Â 9,105 Â Gross profit Â Â Â Â Â Â Â Â Â Â Â Surgical Glaucoma Â Â 16,179 Â Â Â 16,423 Â Â Â 50,048 Â Â Â 50,350 Â Dry Eye Â Â 728 Â Â Â 909 Â Â Â 1,676 Â Â Â 2,850 Â Total Â Â 16,907 Â Â Â 17,332 Â Â Â 51,724 Â Â Â 53,200 Â Operating expenses Â Â 28,136 Â Â Â 30,743 Â Â Â 90,327 Â Â Â 99,364 Â Loss from operations Â Â (11,229) Â Â (13,411) Â Â (38,603) Â Â (46,164) Investment income Â Â 1,454 Â Â Â 1,897 Â Â Â 4,628 Â Â Â 5,499 Â Interest expense Â Â (1,151) Â Â (1,432) Â Â (3,501) Â Â (4,057) Loss on debt extinguishment Â Â â€” Â Â Â â€” Â Â Â (1,962) Â Â â€” Â Other income (expense), net Â Â 26 Â Â Â (11) Â Â (25) Â Â (34) Loss before income taxes Â $ (10,900) Â $ (12,957) Â $ (39,463) Â $ (44,756) Â The Company does not allocate any income and expenses beyond revenue and cost of goods sold to the reportable operating segments in its reporting to the CODM. No asset information is provided for reportable operating segments because they are not reviewed by the CODM on a segment basis. Substantially all of the Companyâ€™s revenue is generated from sales in the United States. X - ReferencesNo definition available. + Details Name: us-gaap_SegmentReportingAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 54 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54Reference 7: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 47 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47Reference 8: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 54 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54Reference 9: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 47 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47Reference 10: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 54 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54Reference 11: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 47 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 31 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 34 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-34Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 26C -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26CReference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 26B -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26BReference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-15Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/280/tableOfContentReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 26 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 21 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-21Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 21 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-21Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32 + Details Name: us-gaap_SegmentReportingDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 26 R19.htm IDEA: XBRL DOCUMENT v3.24.3 Summary of Significant Accounting Policies (Policies) 9 Months Ended Sep. 30, 2024 Accounting Policies [Abstract] Â Basis of Presentation Basis of PresentationThe condensed consolidated financial statements and accompanying notes thereto are unaudited and have been prepared in accordance with accounting principles generally accepted in the United States of America ("US GAAP") applicable to interim periods and pursuant to the instructions to Form 10-Q and Article 10 of Regulation S-X. The Companyâ€™s condensed consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries, Sight Sciences UK, Ltd and Sight Sciences GmbH. All intercompany balances and transactions have been eliminated in consolidation. The unaudited condensed consolidated financial statements have been prepared on a basis consistent with the audited consolidated financial statements. In the opinion of management, the unaudited condensed consolidated financial statements reflect all adjustments, which include only normal recurring adjustments, necessary for the fair presentation of the Company's financial information contained herein. The condensed consolidated balance sheet as of December 31, 2023 is derived from the Company's consolidated audited financial statements as of that date. These interim condensed consolidated financial statements do not include all disclosures required by US GAAP and should be read in conjunction with the Company's audited consolidated financial statements and the accompanying notes thereto for the fiscal year ended December 31, 2023, which are contained in the Annual Report. The Company's results of operations for the nine months ended September 30, 2024 are not necessarily indicative of the results to be expected for the year ending December 31, 2024 or for any other interim period. Use of Estimates Use of EstimatesThe preparation of the unaudited condensed consolidated financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent liabilities at the date of the financial statements, and the reported amounts of revenues and expense during the reporting period. The most significant estimates related to the provision for credit losses, inventory excess and obsolescence, determination of the fair value of stock option grants, and provisions for income taxes and contingencies. Management evaluates its estimates and assumptions on an ongoing basis using historical experience and other factors, including the current economic environment, and makes adjustments when facts and circumstances dictate. These estimates are based on information available as of the date of the financial statements. Actual results could differ from these estimates and such differences could be material to the Companyâ€™s financial position and results of operations. New Accounting Pronouncements New Accounting PronouncementsAccounting Standards Recently AdoptedDuring the nine-month period ended September 30, 2024, there were no significant Accounting Standard Updates ("ASUs") issued that were adopted. Accounting Standards Not Yet AdoptedIn November 2023, the Financial Accounting Standards Board ("FASB") issued ASU No. 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures. The ASU updates reportable segment disclosure requirements, primarily through requiring enhanced disclosures about significant segment expenses and information used to assess segment performance. The ASU is effective on a retrospective basis for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024, with early adoption permitted. The Company is currently evaluating the impact of adopting this ASU on its disclosures. In December 2023, the FASB issued ASU No. 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures. The ASU includes amendments requiring enhanced income tax disclosures, primarily related to standardization and disaggregation of rate reconciliation categories and income taxes paid by jurisdiction. The guidance is effective for fiscal years beginning after December 15, 2024, with early adoption permitted, and should be applied either prospectively or retrospectively. The Company is currently evaluating the impact of adopting this ASU on its disclosures.As of September 30, 2024, there are no additional ASUs issued and not yet adopted that are expected to have a material impact on the Company's financial statements and related disclosures. X - ReferencesNo definition available. + Details Name: us-gaap_AccountingPoliciesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). + ReferencesNo definition available. + Details Name: us-gaap_BasisOfAccountingPolicyPolicyTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact. + ReferencesNo definition available. + Details Name: us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-9Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-4Reference 3:

http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b) -SubTopic 10 -Topic 275 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c) -SubTopic 10 -Topic 275 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 11 -SubTopic 10 -Topic 275 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-11Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 12 -SubTopic 10 -Topic 275 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-12Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-8 + Details Name: us-gaap_UseOfEstimates Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 27 R20.htm IDEA: XBRL DOCUMENT v3.24.3 Fair Value Measurements (Tables) 9 Months Ended Sep. 30, 2024 Summary of Held-to-maturity debt securities at amortized cost in the financial statements. These securities are classified as held-to-maturity and all have been purchased with original maturities of 90 days or less. Held-to-maturity debt securities are recorded at amortized cost in the financial statements.Â Â Â September 30, 2024 Â Â Â Amortized Cost Â Â Unrealized Gains Â Â Unrealized Losses Â Â Aggregate Fair Value Â U.S. treasury securities Â $ 100,488 Â Â $ 24 Â Â $ (1) Â $ 100,511 Â Â Â Â December 31, 2023 Â Â Â Amortized Cost Â Â Unrealized Gains Â Â Unrealized Losses Â Â Aggregate Fair Value Â U.S. treasury securities Â $ 129,113 Â Â $ 28 Â Â $ â€” Â Â $ 129,141 Â X - DefinitionTabular disclosure of the fair value of financial instruments, including financial assets and financial liabilities, and the measurements of those instruments, assets, and liabilities. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 825 -SubTopic 10 -Section 50 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-11 + Details Name: us-gaap_FairValueByBalanceSheetGroupingTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 28 R21.htm IDEA: XBRL DOCUMENT v3.24.3 Balance Sheet Components (Tables) 9 Months Ended Sep. 30, 2024 Organization, Consolidation and Presentation of Financial Statements [Abstract] Â Summary of Property and Equipment, Net Property and equipment, net consist of the following (in thousands):Â Â Â As of September 30, Â Â As of December 31, Â Â Â 2024 Â Â 2023 Â Tools and equipment Â $ 1,991 Â Â $ 2,010 Â Computer equipment and software Â Â 37 Â Â Â 37 Â Furniture and fixtures Â Â 286 Â Â Â 323 Â Leasehold improvements Â Â 38 Â Â Â 38 Â Construction in process Â Â 1,071 Â Â Â 859 Â Â Â 3,423 Â Â Â 3,267 Â Less: Accumulated depreciation Â Â (1,975) Â Â (1,627) Property and equipment, net Â $ 1,448 Â Â $ 1,640 Â Â Summary of Accrued and Other Current Liabilities Accrued and other current liabilities consist of the following (in thousands):Â Â Â As of September 30, Â Â As of December 31, Â Â Â 2024 Â Â 2023 Â Accrued expenses Â $ 2,447 Â Â $ 1,639 Â Current portion of lease liabilities Â Â 519 Â Â Â 573 Â Short-term interest payable Â Â 311 Â Â Â 375 Â Other accrued liabilities Â Â 1,336 Â Â Â 1,187 Â Total accrued and other current liabilities Â $ 4,613 Â Â $ 3,774 Â Summary of Other Noncurrent Liabilities Other noncurrent liabilities consist of the following (in thousands):Â Â Â As of September 30, Â Â As of December 31, Â Â Â 2024 Â Â 2023 Â Noncurrent portion of lease liabilities Â $ 614 Â Â $ 914 Â Other noncurrent liabilities Â Â 75 Â Â Â 38 Â Long-term interest payable Â Â â€” Â Â 1,524 Â Total other noncurrent liabilities Â $ 689 Â Â $ 2,476 Â X - DefinitionAccrued and other current liabilities. + ReferencesNo definition available. + Details Name: sght_AccruedAndOtherCurrentLiabilitiesTableTextBlock Namespace Prefix: sght_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of other noncurrent liabilities. + ReferencesNo definition available. + Details Name: us-gaap_OtherNoncurrentLiabilitiesTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -SubTopic 10 -Topic 360 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1 + Details Name: us-gaap_PropertyPlantAndEquipmentTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 29 R22.htm IDEA: XBRL DOCUMENT v3.24.3 Debt (Tables) 9 Months Ended Sep. 30, 2024 Debt Disclosure [Abstract] Â Schedule of Long-term and Short-term Debt Long-term and short-term debt as of September 30, 2024 and December 31, 2023, respectively, was as follows (in thousands):Â Â Â As of September 30, Â Â As of December 31, Â Â Â 2024 Â Â 2023 Â Hercules Initial Loan Â $ 35,000 Â Â $ â€” Â MidCap Term Loan Â Â â€” Â Â Â 35,000 Â Total principal payments due Â Â 35,000 Â Â Â 35,000 Â Less: unamortized discount and debt issuance costs Â Â (848) Â Â (1,073) Total amounts outstanding Â Â 34,152 Â Â Â 33,927 Â Less: current portion Â Â â€” Â Â Â (2,219) Long-term debt, net Â $ 34,152 Â Â $ 31,708 Â Repayment Schedule Relating to the Company's Debt The repayment schedule relating to the Hercules Initial Loan as of September 30, 2024, is as follows (in thousands):Â Â Â Amount Â 2024 (remainder) Â $ â€” Â 2025 Â Â â€” Â 2026 Â Â 6,680 Â 2027 Â Â 17,294 Â Thereafter Â Â 11,026 Â Total principal payments Â $ 35,000 Â Final fee due at maturity Â Â 2,083 Â Total repayments Â $ 37,083 Â X - ReferencesNo definition available. + Details Name: us-gaap_DebtDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of information pertaining to short-term and long-debt instruments or arrangements, including but not limited to identification of terms, features, collateral requirements and other information necessary to a fair presentation. + ReferencesNo definition available. + Details Name: us-gaap_ScheduleOfDebtTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of debt extinguished which may include, amount of gain (loss), the income tax effect and the per share amount of the aggregate gain (loss), net of the related income tax. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 470 -SubTopic 50 -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481244/470-50-50-1 + Details Name: us-gaap_ScheduleOfExtinguishmentOfDebtTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 30 R23.htm IDEA: XBRL DOCUMENT v3.24.3 Commitments and Contingencies (Tables) 9 Months Ended Sep. 30, 2024 Commitments and Contingencies Disclosure [Abstract] Â Schedule of Operating Lease Expense Recognized and Supplemental Cash Flow Operating lease expense and supplemental cash flow information related to operating leases for the three months ended September 30, 2024 and 2023 were as follows (in thousands):Â Â Â Three Months Ended September 30, Â Â Nine Months Ended September 30, Â Â Â 2024 Â Â 2023 Â Â 2024 Â Â 2023 Â Operating lease expense Â $ 196 Â Â $ 288 Â Â $ 587 Â Â $ 869 Â Cash paid for operating leases Â Â 162 Â Â Â 295 Â Â Â 582 Â Â Â 885 Â Schedule of Aggregate Future Minimum Lease Payments Aggregate future minimum lease payments as of September 30, 2024, under these noncancelable operating leases were as follows (in thousands):Â Â Â As of September 30, Â Â Â Â 2024 Â Â 2024 (remainder) Â $ 158 Â Â 2025 Â Â 618 Â Â 2026 Â Â 497 Â Â Total future minimum lease payments Â $ 1,273 Â Â Less: imputed interest Â Â (140) Â Present value of future minimum lease payments Â $ 1,133 Â Â Less: current portion of operating lease liability Â Â (519) Â Noncurrent portion of lease liabilities Â $ 614 Â Â X - DefinitionSchedule Of Future Minimum Rental Payments Noncancelable For Operating Leases [Table Text Block] + ReferencesNo definition available. + Details Name: sght_ScheduleOfFutureMinimumRentalPaymentsNoncancelableForOperatingLeasesTableTextBlock Namespace Prefix: sght_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_CommitmentsAndContingenciesDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4 + Details Name: us-gaap_LeaseCostTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 31 R24.htm IDEA: XBRL DOCUMENT v3.24.3 Stockholders' Equity (Tables) 9 Months Ended Sep. 30, 2024 Equity [Abstract] Â Reserved Common Stock for Future Issuances At September 30, 2024 and December 31, 2023, the Company had reserved common stock for future issuances as follows: Â Â September 30, Â Â December 31, Â Â Â 2024 Â Â 2023 Â Common stock available for future grants Â Â 5,956,636 Â Â Â 6,033,176 Â Common stock options issued and outstanding Â Â 4,583,289 Â Â Â 4,980,190 Â Restricted stock units outstanding Â Â 4,574,045 Â Â Â 2,721,361 Â Shares available for future purchase under employee stock purchase plan Â Â 1,747,250 Â Â Â 1,488,227 Â Total Â Â 16,861,220 Â Â Â 15,222,954 Â X - ReferencesNo definition available. + Details Name: us-gaap_EquityAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of an entity's stock, including par or stated value per share, number and dollar amount of share subscriptions, shares authorized, shares issued, shares outstanding, number and dollar amount of shares held in an employee trust, dividend per share, total dividends, share conversion features, par value plus additional paid in capital, the value of treasury stock and other information necessary to a fair presentation, and EPS information. Stock by class includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. Includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity. If more than one issue is outstanding, state the title of each issue and the corresponding dollar amount; dollar amount of any shares subscribed but unissued and the deduction of subscriptions receivable there from; number of shares authorized, issued, and outstanding. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(27)) -SubTopic 10 -Topic 210 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-4Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-5Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481142/505-10-45-2Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-10Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-8Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 480 -SubTopic 10 -Section S99 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-1Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-6Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-7 + Details Name: us-gaap_ScheduleOfStockByClassTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 32 R25.htm IDEA: XBRL DOCUMENT v3.24.3 Equity Incentive Plans (Tables) 9 Months Ended Sep. 30, 2024 Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Â Summary of Stock Option Activity The following table summarizes stock option activity under the 2021 Plan during the periods presented: Â Â Â Number ofShares Â Â Weighted-Average Exercise Price Â Â Weighted-AverageContractualÂ Term (in years) Â Â Average Intrinsic Value (in thousands) Â Balances as of December 31, 2023 Â Â 4,980,190 Â Â Â $ 9.00 Â Â Â 7.4 Â Â Â $ 5,924 Â Grants Â Â 7,377 Â Â Â 4.43 Â Â Â Â Â Â Â Forfeited/cancelled Â Â (210,159) Â Â 10.15 Â Â Â Â Â Â Â Exercised/released Â Â (194,119) Â Â 1.20 Â Â Â Â Â Â Â Balances as of September 30, 2024 Â Â 4,583,289 Â Â Â $ 9.28 Â Â Â Â 7.0 Â Â Â $ 6,558 Â Vested and exercisable as of September 30, 2024 Â Â 3,163,058 Â Â Â $ 9.32 Â Â Â 6.4 Â Â Â $ 4,635 Â Vested and expected to vest as of September 30, 2024 Â Â 4,583,289 Â Â Â $ 9.28 Â Â Â 7.0 Â Â Â $ 6,558 Â Summary of Weighted Average Valuation Assumptions Used to Estimate Fair Value of Employee Stock Options The fair value for options granted was calculated using the following weighted average assumptions: Â Â Â Three Months Ended September 30, Â Nine Months Ended September 30, Â Â 2024 Â 2023 Â 2024 Â 2023 Expected term (in years) Â N/A Â 5.99Â â€“ 6.01 Â 6.13 Â 5.60Â â€“ 6.07 Expected volatility Â N/A Â 79.82% Â 61.67% Â 78.53% â€“ 79.82% Risk-free interest rate Â N/A Â 4.04% Â 4.28% Â 3.48% â€“ 4.04% Dividend yield Â N/A Â â€“ Â â€“ Â â€“ Share-based Payment Arrangement, Restricted Stock Unit, Activity The following table summarizes restricted share award activity: Â Â Number ofShares Â Â Weighted-Average Grant Date Fair Value Per Share Â Outstanding, December 31, 2023 Â Â 2,721,361 Â Â Â $ 7.61 Â Grants Â Â 2,949,065 Â Â Â 4.46 Â Forfeited/cancelled Â Â (213,175) Â Â 6.54 Â Vested Â Â (883,206) Â Â 7.58 Â Outstanding, September 30, 2024 Â Â 4,574,045 Â Â Â $ 5.62 Â Summary of Stock-Based Compensation Expense by Function The following is a summary of stock-based compensation expense by function (in thousands):Â Â Â Three Months Ended September 30, Â Â Nine Months Ended September 30, Â Â Â 2024 Â Â 2023 Â Â 2024 Â Â 2023 Â Cost of goods sold Â $ 83 Â Â $ 77 Â Â $ 283 Â Â $ 206 Â Research and development Â Â 588 Â Â Â 549 Â Â Â 1,787 Â Â Â 1,664 Â Selling, general and administrative Â Â 3,637 Â Â Â 3,230 Â Â Â 11,061 Â Â Â 9,251 Â Total stock-based compensation expense Â $ 4,308 Â Â $ 3,856 Â Â $ 13,131 Â Â $ 11,121 Â 2021 Employee Stock Purchase Plan Â Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Â Summary of Weighted Average Valuation Assumptions Used to Estimate Fair Value of Employee Stock Options The fair value of shares to be issued under the ESPP was estimated using the Black-Scholes valuation model with the following assumptions for the three and nine months ended September 30, 2024 and 2023:Â Â Â Three Months Ended September 30, Â Nine Months Ended September 30, Â Â 2024 Â 2023 Â 2024 Â 2023 Expected term (in years) Â 0.49 â€“ 0.50 Â 0.48 â€“ 0.50 Â 0.49Â â€“ 0.50 Â 0.48Â â€“ 0.50 Expected volatility Â 100.00% â€“ 197.51% Â 66.72% â€“ 97.38% Â 100.00% â€“ 197.51% Â 66.72% â€“ 97.38% Risk-free interest rate Â 5.37% â€“ 5.40% Â 4.62% â€“ 5.32% Â 5.37% â€“ 5.40% Â 4.62% â€“ 5.32% Dividend yield Â â€“ Â â€“ Â â€“ Â â€“ X - DefinitionTabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (h)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d) -SubTopic 10 -Topic 718 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e) -SubTopic 10 -Topic 718 -Publisher FASB -URI

https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 718 -SubTopic 10 -Subparagraph (f)(2) -Name Accounting Standards Codification -Paragraph 2 -Section 50 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 1D -Publisher FASB -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1DReference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(v) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_PlanNameAxis=sght_TwoThousandTwentyOneEmployeeStockPurchasePlanMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 33 R26.htm IDEA: XBRL DOCUMENT v3.24.3 Net Loss per Share Attributable to Common Stockholders (Tables) 9 Months Ended Sep. 30, 2024 Earnings Per Share [Abstract] Â Schedule of Computation of Basic and Diluted Net Loss per Share Attributable to Common Stockholders The following table sets forth the computation of basic and diluted net loss per share attributable to common stockholders for the periods presented (in thousands, except share and per share data):Â Â Â Three Months Ended September 30, Â Â Nine Months Ended September 30, Â Â Â 2024 Â Â 2023 Â Â 2024 Â Â 2023 Â Numerator: Â Â Â Â Â Â Â Â Â Â Â Â Net loss attributable to common stockholders Â $ (11,066) Â $ (13,035) Â $ (39,661) Â $ (44,856) Denominator: Â Â Â Â Â Â Â Â Â Â Â Â Weighted-average shares of common stockÂ Â Â outstandingâ€”basic and diluted Â Â 50,340,603 Â Â Â 48,671,049 Â Â Â 49,911,655 Â Â Â 48,538,517 Â Net loss per share attributable to commonÂ Â Â stockholdersâ€”basic and diluted Â $ (0.22) Â $ (0.27) Â $ (0.79) Â $ (0.92) Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share The following potentially dilutive issued and outstanding securities were excluded from the computation of diluted net loss per share attributable to common stockholders for the period presented because including them would have been antidilutive as a result of the net loss position:Â Â Â September 30, Â Â Â 2024 Â Â 2023 Â Stock option awards Â Â 4,583,289 Â Â Â 4,705,390 Â Restricted stock units Â Â 4,574,045 Â Â Â 1,853,657 Â Common stock warrants Â Â 135,686 Â Â Â â€” Â Total Â Â 9,293,020 Â Â Â 6,559,047 Â X - ReferencesNo definition available. + Details Name: us-gaap_EarningsPerShareAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1 + Details Name: us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1 + Details Name: us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 34 R27.htm IDEA: XBRL DOCUMENT v3.24.3 Segment Information (Tables) 9 Months Ended Sep. 30, 2024 Segment Reporting [Abstract] Â Schedule of Segment Reporting Information The following table summarizes select operating results information for each reportable segment (in thousands):Â Â Â Three Months Ended September 30, Â Â Nine Months Ended September 30, Â Â Â 2024 Â Â 2023 Â Â 2024 Â Â 2023 Â Revenue Â Â Â Â Â Â Â Â Â Â Â Â Surgical Glaucoma Â $ 18,632 Â Â $ 18,425 Â Â $ 57,132 Â Â $ 57,158 Â Dry Eye Â Â 1,525 Â Â Â 1,584 Â Â Â 3,660 Â Â Â 5,147 Â Total Â Â 20,157 Â Â Â 20,009 Â Â Â 60,792 Â Â Â 62,305 Â Cost of goods sold Â Â Â Â Â Â Â Â Â Â Â Â Surgical Glaucoma Â Â 2,453 Â Â Â 2,002 Â Â Â 7,084 Â Â Â 6,808 Â Dry Eye Â Â 797 Â Â Â 675 Â Â Â 1,984 Â Â Â 2,297 Â Total Â Â 3,250 Â Â Â 2,677 Â Â Â 9,068 Â Â Â 9,105 Â Gross profit Â Â Â Â Â Â Â Â Â Â Â Â Surgical Glaucoma Â Â 16,179 Â Â Â 16,423 Â Â Â 50,048 Â Â Â 50,350 Â Dry Eye Â Â 728 Â Â Â 909 Â Â Â 1,676 Â Â Â 2,850 Â Total Â Â 16,907 Â Â Â 17,332 Â Â Â 51,724 Â Â Â 53,200 Â Operating expenses Â Â 28,136 Â Â Â 30,743 Â Â Â 90,327 Â Â Â 99,364 Â Loss from operations Â Â (11,229) Â Â (13,411) Â Â (38,603) Â Â (46,164) Investment income Â Â 1,454 Â Â Â 1,897 Â Â Â 4,628 Â Â Â 5,499 Â Interest expense Â Â (1,151) Â Â (1,432) Â Â (3,501) Â Â (4,057) Loss on debt extinguishment Â Â â€” Â Â Â â€” Â Â Â (1,962) Â Â â€” Â Other income (expense), net Â Â 26 Â Â Â (11) Â Â (25) Â Â (34) Loss before income taxes Â $ (10,900) Â $ (12,957) Â $ (39,463) Â $ (44,756) X - DefinitionTabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 25 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-25Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 30 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30 + Details Name: us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_SegmentReportingAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 35 R28.htm IDEA: XBRL DOCUMENT v3.24.3 Company and Nature of Business - Additional Information (Details) - USD ($) $ in Thousands 3 Months Ended 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Dec. 31, 2023 Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items] Â Â Â Â Â Â Accumulated deficit $ (334,451) Â $ (334,451) Â $ (294,790) Net Income (Loss) $ (11,066) $ (13,035) $ (39,661) $ (44,856) Â X - DefinitionOrganization consolidation and presentation of financial statements disclosure. + ReferencesNo definition available. + Details Name: sght_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems Namespace Prefix: sght_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 17: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 25:

http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 32: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 37: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1 + Details Name: us-gaap_NetIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of accumulated undistributed earnings (deficit). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)(a)(3)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (h)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(23)(a)(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(17)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_RetainedEarningsAccumulatedDeficit Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant XML 36 R29.htm IDEA: XBRL DOCUMENT v3.24.3 Fair value Measurement - Additional Information (Details) - Fair Value, Recurring - USD ($) $ in Millions 9 Months Ended 12 Months Ended Sep. 30, 2024 Dec. 31, 2023 Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items] Â Â Treasury bills $ 100.5 $ 129.1 Fair Value, Inputs, Level 2 Â Â Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items] Â Â Debt Instrument, Fair Value Amount 34.2 $ 33.9 Fair Value, Inputs, Level 3 Â Â Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items] Â Â Fair value of the unissued common stock warrants $ 0.1 Â X - DefinitionDebt Instrument Fair Value, Amount + ReferencesNo definition available. + Details Name: sght_DebtInstrumentFairValueAmount Namespace Prefix: sght_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionFair Value Of The Unissued Common Stock Warrants + ReferencesNo definition available. + Details Name: sght_FairValueOfTheUnissuedCommonStockWarrants Namespace Prefix: sght_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 100 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3 + Details Name: us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionInterest income on US treasury securities. US treasury securities are negotiable debt obligations of the US government, secured by its full faith and credit and issued at various schedules and maturities. The income from treasury securities is exempt from state and local, but not federal, taxes. There are three types of securities issued by the US treasury (bonds, bills, and notes), which are distinguished by the amount of time from the initial sale of the bond to maturity. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1 + Details Name: us-gaap_InterestIncomeSecuritiesUSTreasury Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - Details Name: us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member Namespace Prefix: Data Type: na Balance Type: Period Type: XML 37 R30.htm IDEA: XBRL DOCUMENT v3.24.3 Fair Value Measurement - Held-to-maturity debt securities at amortized cost (Details) - US Treasury Securities [Member] - USD ($) $ in Thousands Sep. 30, 2024 Dec. 31, 2023 Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items] Â Â Amortized Cost $ 100,488 $ 129,113 Unrealized Gains 24 28 Unrealized Losses (1) 0 Aggregate Fair Value $ 100,511 $ 129,141 X - DefinitionAmount of cumulative unrecognized gain on investment in debt security measured at amortized cost (held-to-maturity) and investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5A -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-5AReference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2 + Details Name: us-gaap_DebtSecuritiesAvailableForSaleAndHeldToMaturityCumulativeUnrecognizedGain Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of cumulative unrecognized loss on investment in debt security measured at amortized cost (held-to-maturity) and investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5A -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-5AReference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2 + Details Name: us-gaap_DebtSecuritiesAvailableForSaleAndHeldToMaturityCumulativeUnrecognizedLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount, after allowance for credit loss, of investment in debt security measured at amortized cost (held-to-maturity). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-5Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-5Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(6)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481830/320-10-45-1 + Details Name: us-gaap_DebtSecuritiesHeldToMaturityAmortizedCostAfterAllowanceForCreditLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 100 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3 + Details Name: us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionFair value of investment in debt security measured at amortized cost (held-to-maturity). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2E -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2EReference 3: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Subparagraph (aa) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-5Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-5AReference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(6)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1 + Details Name: us-gaap_HeldToMaturitySecuritiesFairValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - Details Name: us-gaap_CashAndCashEquivalentsAxis=us-gaap_USTreasurySecuritiesMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 38 R31.htm IDEA: XBRL DOCUMENT v3.24.3 Balance Sheet Components - Summary of Property and Equipment, Net (Details) - USD ($) $ in Thousands Sep. 30, 2024 Dec. 31, 2023 Property Plant And Equipment [Line Items] Â Â Property and equipment, gross $ 3,423 $ 3,267 Less: Accumulated depreciation (1,975) (1,627) Property and equipment, net 1,448 1,640 Tools and Equipment Â Â Property Plant And Equipment [Line Items] Â Â Property and equipment, gross 1,991 2,010 Computer Equipment and Software Â Â Property Plant And Equipment [Line Items] Â Â Property and equipment, gross 37 37 Furniture and Fixtures Â Â Property Plant And Equipment [Line Items] Â Â Property and equipment, gross 286 323 Leasehold Improvements Â Â Property Plant And Equipment [Line Items] Â Â Property and equipment, gross 38 38 Construction In Process Â Â Property Plant And Equipment [Line Items] Â Â Property and equipment, gross $ 1,071 $ 859 X - DefinitionAmount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(8)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(14)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 360 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1 + Details Name: us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(13)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1 + Details Name: us-gaap_PropertyPlantAndEquipmentGross Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A + Details Name: us-gaap_PropertyPlantAndEquipmentLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -SubTopic 10 -Topic 360 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7AReference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 4:

http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 360 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1 + Details Name: us-gaap_PropertyPlantAndEquipmentNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - Details Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ToolsDiesAndMoldsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 39 R32.htm IDEA: XBRL DOCUMENT v3.24.3 Balance Sheet Components - Additional Information (Details) - USD ($) $ in Millions 3 Months Ended 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Organization, Consolidation and Presentation of Financial Statements [Abstract] Â Â Â Â Â Depreciation expense $ 0.1 $ 0.2 $ 0.4 $ 0.5 X - DefinitionThe amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 360 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1 + Details Name: us-gaap_Depreciation Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 40 R33.htm IDEA: XBRL DOCUMENT v3.24.3 Balance Sheet Components - Summary of Accrued and Other Current Liabilities (Details) - USD ($) $ in Thousands Sep. 30, 2024 Dec. 31, 2023 Organization, Consolidation and Presentation of Financial Statements [Abstract] Â Â Accrued expenses $ 2,447 $ 1,639 Current portion of lease liabilities 519 573 Short-term interest payable 311 375 Other accrued liabilities 1,336 1,187 Total accrued and other current liabilities $ 4,613 $ 3,774 X - DefinitionAmount of expenses incurred but not yet paid nor invoiced, and liabilities classified as other. + ReferencesNo definition available. + Details Name: us-gaap_AccruedLiabilitiesAndOtherLiabilities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionCarrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_AccruedLiabilitiesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionCarrying value as of the balance sheet date of [accrued] interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_InterestPayableCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionPresent value of lessee's discounted obligation for lease payments from operating lease, classified as current. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap_OperatingLeaseLiabilityCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_OtherAccruedLiabilitiesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant XML 41 R34.htm IDEA: XBRL DOCUMENT v3.24.3 Balance Sheet Components - Summary of Other Noncurrent Liabilities (Details) - USD ($) $ in Thousands Sep. 30, 2024 Dec. 31, 2023 Organization, Consolidation and Presentation of Financial Statements [Abstract] Â Â Long-term interest payable $ 0 $ 1,524 Noncurrent portion of lease liabilities 614 914 Other noncurrent liabilities 75 38 Total other noncurrent liabilities $ 689 $ 2,476 X - DefinitionInterest payable non current. + ReferencesNo definition available. + Details Name: sght_InterestPayableNonCurrent Namespace Prefix: sght_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionOther non current liabilities. + ReferencesNo definition available. + Details Name: sght_OtherNonCurrentLiabilities Namespace Prefix: sght_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionPresent value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap_OperatingLeaseLiabilityNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of liabilities classified as other, due after one year or the normal operating cycle, if longer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(24)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_OtherLiabilitiesNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant XML 42 R35.htm IDEA: XBRL DOCUMENT v3.24.3 Debt - Additional Information (Details) - USD ($) $ / shares in Units, $ in Thousands 1 Months Ended 3 Months Ended 9 Months Ended Jan. 31, 2024 Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Jan. 22, 2024 Dec. 31, 2023 Debt Instrument [Line Items] Â Â Â Â Â Â Â Loss on debt extinguishment Â $ 0 $ 0 $ (1,962) $ 0 Â Â Â Fair value of warrants Â Â Â 600 Â Â Â Long-term debt, net Â $ 34,152 Â $ 34,152 Â Â $ 31,708 Hercules Credit Agreement [Member] Â Â Â Â Â Â Â Debt Instrument [Line Items] Â Â Â Â Â Â Â Maximum borrowing capacity $ 65,000 Â Â Â Â Â Â Line of credit achievement of certain performance milestones 10,000 Â Â Â Â Â Â Line of credit facility, remaining borrowing capacity $ 15,000 Â Â Â Â Â Â Maturity date Jul. 01, 2028 Â Â Â Â Â Â Interest in increments period $ 5,000 Â Â Â Â Â Â Debt instrument, frequency of periodic payment 30 months Â Â Â Â Â Â Debt instrument interest payment extended term 36 months Â Â Â Â Â Â Debt instrument, variable rate 10.35% Â Â Â Â Â Â Debt instrument, Initial interest rate Â 10.35% Â 10.35% Â Â Â Interest Rate During Period 5.95% Â Â Â Â Â Â Debt instrument, effective interest rate 2.35% Â Â Â Â Â Â Warrants issued to purchase shares of convertible preferred stock Â 135,686 Â 135,686 Â Â Â Class of warrant exercise price Â $ 5.159 Â $ 5.159 Â Â Â Line of credit facility, current borrowing capacity Â Â Â Â Â Â $ 35,000 Â Hercules Credit Agreement [Member] | Tranche Two Loans Â Â Â Â Â Â Â Debt Instrument [Line Items] Â Â Â Â Â Â Â Maximum borrowing capacity $ 5,000 Â Â Â Â Â Â Mid Cap Financial Services Â Â Â Â Â Â Â Debt Instrument [Line Items] Â Â Â Â Â Â Loss on debt extinguishment Â Â Â Â $ 2,000 Â Â Â Debt instrument, variable rate Â Â Â 7.00% Â Â Â Mid Cap Financial Services | Senior Secured 2019 Term Loan Â Â Â Â Â Â Â Debt Instrument [Line Items] Â Â Â Â Â Â Â Maximum borrowing capacity Â $ 35,000 Â $ 35,000 Â Â Â Lenders [Member] | Hercules Credit Agreement [Member] Â Â Â Â Â Â Â Debt Instrument [Line Items] Â Â Â Â Â Â Â Warrants Expiration Term 7 years Â Â Â Â Â Â Â Warrants issued to purchase shares of convertible preferred stock 135,686 Â Â Â Â Â Â Class of warrant exercise price $ 5.159 Â Â Â Â Â Â MidCap Credit Facility Agreements [Member] Â Â Â Â Â Â Â Debt Instrument [Line Items] Â Â Â Â Â Â Â Long-term debt, net Â $ 35,000 Â $ 35,000 Â Â Â Percentage of long term debt fee payable Â 6.00% Â 6.00% Â Â Â X - DefinitionDebt instrument interest payment extended term. + ReferencesNo definition available. + Details Name: sght_DebtInstrumentInterestPaymentExtendedTerm Namespace Prefix: sght_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionFair value of warrants. + ReferencesNo definition available. + Details Name: sght_FairValueOfWarrants Namespace Prefix: sght_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionInterest On period Increments + ReferencesNo definition available. + Details Name: sght_InterestOnPeriodIncrements Namespace Prefix: sght_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionLine Of Credit Achievement Of Certain Performance Milestones + ReferencesNo definition available. + Details Name: sght_Lineofcreditachievementofcertainperformancemilestones Namespace Prefix: sght_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionWarrants Expiration Term. + ReferencesNo definition available. + Details Name: sght_WarrantsExpirationTerm Namespace Prefix: sght_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionExercise price per share or per unit of warrants or rights outstanding. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3 + Details Name: us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionNumber of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3 + Details Name: us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionPercentage points added to the reference rate to compute the variable rate on the debt instrument. + ReferencesNo definition available. + Details Name: us-gaap_DebtInstrumentBasisSpreadOnVariableRate1 Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionDescription of the frequency of periodic payments (monthly, quarterly, annual). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)) -SubTopic 10 -Topic 210 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 942 -SubTopic 470 -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477734/942-470-50-3 + Details Name: us-gaap_DebtInstrumentFrequencyOfPeriodicPayment Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe average effective interest rate during the reporting period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)(a)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2 + Details Name: us-gaap_DebtInstrumentInterestRateDuringPeriod Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionEffective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)(a)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-6 + Details Name: us-gaap_DebtInstrumentInterestRateEffectivePercentage Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: instant X - DefinitionContractual interest rate for funds borrowed, under the debt agreement. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)(a)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B + Details Name: us-gaap_DebtInstrumentInterestRateStatedPercentage Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(f)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.12-04(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 5: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69B -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69BReference 6: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69C -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69CReference 7: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69E -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69EReference 8: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69F -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69FReference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 11: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 15:

http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1DReference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1DReference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1DReference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1EReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1EReference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1EReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (b)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1I -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1IReference 26: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2Reference 27: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1 + Details Name: us-gaap_DebtInstrumentLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionDate when the debt instrument is scheduled to be fully repaid, in YYYY-MM-DD format. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)(a)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B + Details Name: us-gaap_DebtInstrumentMaturityDate Namespace Prefix: us-gaap_ Data Type: xbrli:dateItemType Balance Type: na Period Type: duration X - DefinitionDifference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 470 -SubTopic 50 -Section 40 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481303/470-50-40-2Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 470 -SubTopic 50 -Section 40 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481303/470-50-40-4 + Details Name: us-gaap_GainsLossesOnExtinguishmentOfDebt Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of current borrowing capacity under the credit facility considering any current restrictions on the amount that could be borrowed (for example, borrowings may be limited by the amount of current assets), but without considering any amounts currently outstanding under the facility. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(19)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionMaximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(19)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of borrowing capacity currently available under the credit facility (current borrowing capacity less the amount of borrowings outstanding). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481544/470-10-50-6Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(19)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_LongTermDebtNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionThe interest rate applicable to the portion of the carrying amount of long-term borrowings outstanding as of the balance sheet date, including current maturities, which accrues interest at a set, unchanging rate. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)(a)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_LongTermDebtPercentageBearingFixedInterestRate Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: instant X - Details Name: us-gaap_CreditFacilityAxis=sght_HerculesCreditAgreementMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_LongtermDebtTypeAxis=sght_TrancheTwoLoansMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_LineOfCreditFacilityAxis=sght_MidCapFinancialServicesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DebtInstrumentAxis=sght_SeniorSecuredTwoThousandNineteenTermLoanMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_LineOfCreditFacilityAxis=sght_LendersMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_PlanNameAxis=sght_MidcapCreditFacilityAgreementsMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 43 R36.htm IDEA: XBRL DOCUMENT v3.24.3 Debt - Schedule of Long-term and Short-term Debt (Details) - USD ($) $ in Thousands Sep. 30, 2024 Dec. 31, 2023 Debt Instrument [Line Items] Â Â Total principal payments due $ 35,000 $ 35,000 Less: unamortized discount and debt issuance costs (848) (1,073) Total amounts outstanding 34,152 33,927 Less: current portion 0 (2,219) Long-term debt, net 34,152 31,708 Hercules Credit Agreement [Member] Â Â Debt Instrument [Line Items] Â Â Total principal payments due 35,000 0 MidCap Term Loan [Member] Â Â Debt Instrument [Line Items] Â Â Total principal payments due $ 0 $ 35,000 X - DefinitionAmount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)) -SubTopic 10 -Topic 210 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(16)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (b)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-4 + Details Name: us-gaap_DebtInstrumentCarryingAmount Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(f)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.12-04(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 5: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69B -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69BReference 6: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69C -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69CReference 7: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69E -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69EReference 8: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69F -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69FReference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 11: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1DReference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1DReference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1DReference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1EReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1EReference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1EReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (b)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1I -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1IReference 26: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2Reference 27: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1 + Details Name: us-gaap_DebtInstrumentLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount, after accumulated amortization, of debt discount. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-1AReference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D + Details Name: us-gaap_DebtInstrumentUnamortizedDiscount Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionRepresents the aggregate of total long-term debt, including current maturities and short-term debt. + ReferencesNo definition available. + Details Name: us-gaap_DebtLongtermAndShorttermCombinedAmount Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as current. Excludes lease obligation. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_LongTermDebtCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount, after deduction of unamortized

premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_LongTermDebtNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - Details Name: us-gaap_DebtInstrumentAxis=sght_HerculesCreditAgreementMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DebtInstrumentAxis=sght_MidcapTermLoanMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 44 R37.htm IDEA: XBRL DOCUMENT v3.24.3 Debt - Schedule Relating to the Company's Debt (Details) $ in Thousands Sep. 30, 2024 USD ($) Debt Disclosure [Abstract] Â 2024 (remainder) $ 0 2025 0 2026 6,680 2027 17,294 Thereafter 11,026 Total principal payments 35,000 Final fee due at maturity 2,083 Total repayments $ 37,083 X - DefinitionFinal Fee Due at Maturity + ReferencesNo definition available. + Details Name: sght_FinalFeeDueAtMaturity Namespace Prefix: sght_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing after third fiscal year following current fiscal year. + ReferencesNo definition available. + Details Name: sght_LongTermDebtMaturityAfterYearThree Namespace Prefix: sght_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionTotal Principal Payments + ReferencesNo definition available. + Details Name: sght_TotalPrincipalPayments Namespace Prefix: sght_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_DebtDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)) -SubTopic 10 -Topic 210 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(16)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69B -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69BReference 5: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69C -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69CReference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1DReference 7: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(16)(a)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (b)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-4 + Details Name: us-gaap_LongTermDebt Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.12-04(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1EReference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -SubTopic 10 -Topic 470 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481544/470-10-50-1 + Details Name: us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.12-04(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1EReference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -SubTopic 10 -Topic 470 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481544/470-10-50-1 + Details Name: us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.12-04(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1EReference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -SubTopic 10 -Topic 470 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481544/470-10-50-1 + Details Name: us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in remainder of current fiscal year. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.12-04(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3 + Details Name: us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant XML 45 R38.htm IDEA: XBRL DOCUMENT v3.24.3 Commitments and Contingencies - Additional Information (Details) - USD ($) $ in Thousands 3 Months Ended 9 Months Ended 12 Months Ended Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Dec. 31, 2022 Dec. 31, 2023 Supply Commitment [Line Items] Â Â Â Â Â Â Operating lease right-of-use assets $ 1,100 Â $ 1,100 Â Â $ 1,458 Remaining lease term 2 years Â 2 years Â Â Â Operating leases, rent expense $ 196 $ 288 $ 587 $ 869 Â Â Supply agreement [Member] Â Â Â Â Â Â Supply Commitment [Line Items] Â Â Â Â Â Â Extending the lease term Â Â 26 Â Â Â Operating lease right-of-use assets $ 1,200 Â $ 1,200 Â $ 700 Â Lease, borrowing rate 11.40% Â 11.40% Â 10.75% Â Operating lease term 37 months Â 37 months Â 18 months Â Remaining lease term 34 months Â 34 months Â Â Â Total base rent under lease agreement Â Â $ 1,500 Â $ 700 Â X - DefinitionTotal base rent under lease agreement. + ReferencesNo definition available. + Details Name: sght_TotalBaseRentUnderLeaseAgreement Namespace Prefix: sght_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionDescription of terms and conditions of option to extend lessee's operating lease. Includes, but is not limited to, information about option recognized as part of right-of-use asset and lease liability. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3 + Details Name: us-gaap_LesseeOperatingLeaseOptionToExtend Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionRemaining lease term of operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7A -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7AReference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3 + Details Name: us-gaap_LesseeOperatingLeaseRemainingLeaseTerm Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: instant X - DefinitionTerm of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3 + Details Name: us-gaap_LesseeOperatingLeaseTermOfContract Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: instant X - DefinitionAmount of operating lease expense. Excludes sublease income. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 4 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-4 + Details Name: us-gaap_OperatingLeaseExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of lessee's right to use underlying asset under operating lease. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap_OperatingLeaseRightOfUseAsset Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionWeighted average discount rate for operating lease calculated at point in time. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 53 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (g)(4) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4 + Details Name: us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesNo definition available. + Details Name: us-gaap_SupplyCommitmentLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_SupplyCommitmentAxis=us-gaap_SupplyCommitmentMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 46 R39.htm IDEA: XBRL DOCUMENT v3.24.3 Commitments and Contingencies - Schedule of Operating Lease Expense Recognized and Supplemental Cash Flow (Details) - USD ($) $ in Thousands 3 Months Ended 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Commitments and Contingencies Disclosure [Abstract] Â Â Â Â Operating lease expense $ 196 $ 288 $ 587 $ 869 Cash paid for operating leases $ 162 $ 295 $ 582 $ 885 X - ReferencesNo definition available. + Details Name: us-gaap_CommitmentsAndContingenciesDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of operating lease expense. Excludes sublease income. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 4 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-4 + Details Name: us-gaap_OperatingLeaseExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 5 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-5Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (g)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4 + Details Name: us-gaap_OperatingLeasePayments Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration XML 47 R40.htm IDEA: XBRL DOCUMENT v3.24.3 Commitments and Contingencies - Schedule of Aggregate Future Minimum Lease Payments (Details) - USD ($) $ in Thousands Sep. 30, 2024 Dec. 31, 2023 Commitments and Contingencies Disclosure [Abstract] Â Â 2024 (remainder) $ 158 Â 2025 618 Â 2026 497 Â Total future minimum lease payments 1,273 Â Less: imputed interest (140) Â Present value of future minimum lease payments 1,133 Â Less: current portion of operating lease liability (519) $ (573) Noncurrent portion of lease liabilities $ 614 $ 914 X - ReferencesNo definition available. + Details Name: us-gaap_CommitmentsAndContingenciesDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of lessee's undiscounted obligation for lease payment for operating lease. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6 + Details Name: us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6 + Details Name: us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6 + Details Name: us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6 + Details Name: us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6 + Details Name: us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionPresent value of lessee's discounted obligation for lease payments from operating lease. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap_OperatingLeaseLiability Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionPresent value of lessee's discounted obligation for lease payments from operating lease, classified as current. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap_OperatingLeaseLiabilityCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionPresent value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI

https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap_OperatingLeaseLiabilityNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant XML 48 R41.htm IDEA: XBRL DOCUMENT v3.24.3 Stockholder's Equity - Additional Information (Details) $ / shares in Units, $ in Thousands 9 Months Ended Sep. 30, 2024 USD ($) Vote $ / shares shares Dec. 31, 2023 $ / shares shares Subsidiary, Sale of Stock [Line Items] Â Â Common stock, shares authorized 200,000,000 200,000,000 Preferred stock, shares authorized 10,000,000 10,000,000 Common stock, par value | $ / shares $ 0.001 $ 0.001 Preferred stock par value | $ / shares $ 0.001 $ 0.001 Dividends declared | $ $ 0 Â Additional warrants to purchase common stock 2.00% Â Number of votes entitled per share of common stock | Vote 1 Â Fair value of warrants | $ $ 600 Â Common stock, shares issued 50,398,148 49,131,363 Hercules Credit Agreement [Member] Â Â Subsidiary, Sale of Stock [Line Items] Â Â Warrants to purchase common stock 135,686 Â Class of warrant exercise price | $ / shares $ 5.159 Â Maximum [Member] Â Â Subsidiary, Sale of Stock [Line Items] Â Â Unused warrants value | $ $ 100 Â IPO [Member] Â Â Subsidiary, Sale of Stock [Line Items] Â Â Common stock, shares authorized 200,000,000 Â Preferred stock, shares authorized 10,000,000 Â Common stock, par value | $ / shares $ 0.001 Â Preferred stock par value | $ / shares $ 0.001 Â X - DefinitionCommon stock, vote for each share. + ReferencesNo definition available. + Details Name: sght_CommonStockVoteForEachShare Namespace Prefix: sght_ Data Type: xbrli:integerItemType Balance Type: na Period Type: duration X - DefinitionFair value of warrants. + ReferencesNo definition available. + Details Name: sght_FairValueOfWarrants Namespace Prefix: sght_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionExercise price per share or per unit of warrants or rights outstanding. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3 + Details Name: us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionNumber of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3 + Details Name: us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionFace amount or stated value per share of common stock. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_CommonStockParOrStatedValuePerShare Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionThe maximum number of common shares permitted to be issued by an entity's charter and bylaws. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1 + Details Name: us-gaap_CommonStockSharesAuthorized Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionTotal number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_CommonStockSharesIssued Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionAmount of paid and unpaid common stock dividends declared with the form of settlement in cash, stock and payment-in-kind (PIK). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 2 -SubTopic 405 -Topic 942 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477787/942-405-45-2 + Details Name: us-gaap_DividendsCommonStock Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionFace amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13 + Details Name: us-gaap_PreferredStockParOrStatedValuePerShare Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionThe maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1 + Details Name: us-gaap_PreferredStockSharesAuthorized Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionPurchase price of common stock expressed as a percentage of its fair value. + ReferencesNo definition available. + Details Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesNo definition available. + Details Name: us-gaap_SubsidiarySaleOfStockLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionValue of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details Name: us-gaap_WarrantsAndRightsOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - Details Name: us-gaap_CreditFacilityAxis=sght_HerculesCreditAgreementMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RangeAxis=srt_MaximumMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 49 R42.htm IDEA: XBRL DOCUMENT v3.24.3 Stockholder's Equity - Schedule of Reserved Common Stock for Future Issuances (Details) - shares Sep. 30, 2024 Dec. 31, 2023 Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Â Â Common stock reserved for future issuance 16,861,220 15,222,954 Common stock available for future grants Â Â Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Â Â Common stock reserved for future issuance 5,956,636 6,033,176 Common stock options issued and outstanding Â Â Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Â Â Common stock reserved for future issuance 4,583,289 4,980,190 Restricted stock units outstanding Â Â Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Â Â Common stock reserved for future issuance 4,574,045 2,721,361 Shares available for future purchase under employee stock purchase plan Â Â Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Â Â Common stock reserved for future issuance 1,747,250 1,488,227 X - DefinitionAggregate number of common shares reserved for future issuance. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_CommonStockCapitalSharesReservedForFutureIssuance Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 1D -Publisher FASB -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1DReference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(v) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_StatementClassOfStockAxis=sght_CommonStockAvailableForFutureGrantMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementClassOfStockAxis=sght_CommonStockOptionsIssuedAndOutstandingMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementClassOfStockAxis=sght_RestrictedStockUnitsOutstandingMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementClassOfStockAxis=sght_SharesAvailableForFuturePurchaseUnderESPPMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 50 R43.htm IDEA: XBRL DOCUMENT v3.24.3 Equity Incentive Plans - Additional Information (Detail) - USD ($) $ / shares in Units, $ in Thousands 3 Months Ended 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Jan. 01, 2024 Dec. 31, 2023 Jan. 01, 2023 Jul. 31, 2021 Share Based Compensation Arrangement By Share Based Payment Award [Line Items] Â Â Â Â Â Â Â Â Weighted-average grant-date fair values of options granted Â Â $ 2.71 $ 6.92 Â Â Â Â Aggregate intrinsic value of options exercised $ 200 Â $ 800 Â Â Â Â Â Unrecognized stock-based compensation of unvested options $ 8,100 Â $ 8,100 Â Â Â Â Â Weighted-average period expected to recognize Â Â 1 year 3 months 18 days Â Â Â Â Â Common stock reserved for future issuance 16,861,220 Â 16,861,220 Â Â 15,222,954 Â Â Description of Transaction of Future issuance Â Â annual increases are equal to the lesser of (i) 5% of the aggregate number of shares of common stock outstanding on the final day of the immediately preceding calendar year and (ii) such smaller number of shares of common stock as determined by the Board, subject to certain limitations Â Â Â Â Â Number of Shares, Grants Â Â 7,377 Â Â Â Â Â Weighted-Average Exercise Price, Granted Â Â $ 4.43 Â Â Â Â Â Stock based compensation $ 1,900 $ 2,100 $ 5,700 $ 6,600 Â Â Â Â Share of common stock purchased 4,308 3,856 13,131 11,121 Â Â Â Â ESPP purchase Â Â 450 661 Â Â Â Â Restricted Stock Units RSU Â Â Â Â Â Â Â Â Share Based Compensation Arrangement By Share Based Payment Award [Line Items] Â Â Â Â Â Â Â Â Unrecognized stock-based compensation of unvested options 21,200 Â $ 21,200 Â Â Â Â Â Weighted-average period expected to recognize Â Â 2 years 8 months 12 days Â Â Â Â Â Stock based compensation $ 2,200 1,600 $ 6,900 4,200 Â Â Â Â 2021 Plan Â Â Â Â Â Â Â Â Share Based Compensation Arrangement By Share Based Payment Award [Line Items] Â Â Â Â Â Â Â Â Common stock available for issuance 5,956,636 Â 5,956,636 Â Â 6,033,176 Â Â Common stock reserved for future issuance 5,200,000 Â 5,200,000 Â 2,456,568 Â 2,414,907 Â 2021 Employee Stock Purchase Plan Â Â Â Â Â Â Â Â Share Based Compensation

Arrangement By Share Based Payment Award [Line Items] Â Â Â Â Â Â Â Â Â Collected withholdings under plan Â Â $ 400 Â Â Â Â Â Â Common stock reserved for future issuance 1,747,250 Â 1,747,250 Â 491,313 Â 482,981 850,000 Stock based compensation $ 100 $ 100 $ 500 $ 400 Â Â Â Â ESPP purchase, Shares Â Â 232,290 Â Â Â Â Â Â ESPP purchase Â Â $ 500 Â Â Â Â Â Â X - DefinitionAggregate number of common shares reserved for future issuance. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_CommonStockCapitalSharesReservedForFutureIssuance Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionAmount of expense for employee benefit and equity-based compensation. + ReferencesNo definition available. + Details Name: us-gaap_EmployeeBenefitsAndShareBasedCompensation Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of cost not yet recognized for nonvested award under share-based payment arrangement. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionWeighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionThe cash inflow associated with the amount received from the stock plan during the period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14 + Details Name: us-gaap_ProceedsFromStockPlans Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionDescription of stock transaction which may include details of the offering (IPO, private placement), a description of the stock sold, percentage of subsidiary's or equity investee's stock sold, a description of the investors and whether the stock was issued in a business combination. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 23 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-23Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 50 -Paragraph 1A -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1AReference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1B -SubTopic 10 -Topic 810 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1B + Details Name: us-gaap_SaleOfStockDescriptionOfTransaction Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 1D -Publisher FASB -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1DReference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(v) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionAmount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionGross number of share options (or share units) granted during the period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionThe weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionWeighted average per share amount at which grantees can acquire shares of common stock by exercise of options. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionNumber of shares of stock issued during the period as part of a transaction to acquire assets that do not qualify as a business combination. + ReferencesNo definition available. + Details Name: us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionValue of shares of stock issued during the period as part of a transaction to acquire assets that do not qualify as a business combination. + ReferencesNo definition available. + Details Name: us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionValue, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (d)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - Details Name: us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_PlanNameAxis=sght_TwoThousandAndTwentyOnePlanMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_PlanNameAxis=sght_TwoThousandTwentyOneEmployeeStockPurchasePlanMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 51 R44.htm IDEA: XBRL DOCUMENT v3.24.3 Equity Incentive Plans - Summary of Company Stock Option Activity (Detail) - USD ($) $ / shares in Units, $ in Thousands 9 Months Ended 12 Months Ended Sep. 30, 2024 Dec. 31, 2023 Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward] Â Â Number of Shares 4,980,190 Â Number of Shares, Grants 7,377 Â Number of Shares, Forfeited/cancelled (210,159) Â Number of Shares, Exercised/released (194,119) Â Number of Shares 4,583,289 4,980,190 Number of Shares Vested and exercisable as of September 30, 2024 3,163,058 Â Number of Shares, Vested and expected to vest as of September 30, 2024 4,583,289 Â Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Weighted Average Exercise Price Â Â Weighted-Average Exercise Price $ 9 Â Weighted-Average Exercise Price, Granted 4.43 Â Weighted-Average Exercise Price, Forfeited/cancelled 10.15 Â Weighted-Average Exercise Price, Exercised/released 1.2 Â Weighted-Average Exercise Price 9.28 $ 9 Vested and exercisable as of September 30, 2024 9.32 Â Vested and expected to vest as of September 30, 2024 $ 9.28 Â Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term Â Â Weighted Average Remaining Contractual Term 7 years 7 years 4 months 24 days Weighted average contractual term, vested and exercisable 6 years 4 months 24 days Â Weighted average contractual term, vested and expected 7 years Â Average Intrinsic Value $ 6,558 $ 5,924 Average Intrinsic Value, Vested and exercisable as of September 30, 2024 4,635 Â Average Intrinsic Value, Vested and expected as of September 30, 2024 $ 6,558 Â X - ReferencesNo definition available. + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionThe number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionGross number of share options (or share units) granted during the period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 +

Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionAmount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionNumber of options outstanding, including both vested and non-vested options. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionA roll forward is a reconciliation of a concept from the beginning of a period to the end of a period. + ReferencesNo definition available. + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionWeighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionNumber of fully vested and expected to vest exercisable options that may be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionNumber of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionWeighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionWeighted average price at which option holders acquired shares when converting their stock options into shares. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionWeighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionWeighted average per share amount at which grantees can acquire shares of common stock by exercise of options. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionAmount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1 Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionWeighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionWeighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 718 -SubTopic 10 -Subparagraph (e)(1) -Name Accounting Standards Codification -Paragraph 2 -Section 50 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionWeighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1 Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionNumber of share options (or share units) exercised during the current period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration XML 52 R45.htm IDEA: XBRL DOCUMENT v3.24.3 Equity Incentive Plans - Summary of Stock Based Compensation Fair Value Assumptions (Details) 3 Months Ended 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Â Â Â Â Â Expected term (in years) Â Â 6 years 1 month 17 days Â Expected volatility Â 79.82% 61.67% Â Risk-free interest rate Â 4.04% 4.28% Â Maximum Â Â Â Â Â Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Â Â Â Â Â Expected term (in years) Â 6 years 3 days Â 6 years 25 days Expected volatility Â Â Â 79.82% Risk-free interest rate Â Â Â 4.04% Maximum | 2021 Employee Stock Purchase Plan Â Â Â Â Â Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Â Â Â Â Â Expected term (in years) 6 months 6 months 6 months 6 months Expected volatility 197.51% 97.38% 197.51% 97.38% Risk-free interest rate 5.40% 5.32% 5.40% 5.32% Minimum Â Â Â Â Â Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Â Â Â Â Â Expected term (in years) Â 5 years 11 months 26 days Â 5 years 7 months 6 days Expected volatility Â Â Â 78.53% Risk-free interest rate Â Â Â 3.48% Minimum | 2021 Employee Stock Purchase Plan Â Â Â Â Â Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Â Â Â Â Â Expected term (in years) 5 months 26 days 5 months 23 days 5 months 26 days 5 months 23 days Expected volatility 100.00% 66.72% 100.00% 66.72% Risk-free interest rate 5.37% 4.62% 5.37% 4.62% X - DefinitionThe estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionThe risk-free interest rate assumption that is used in valuing an option on its own shares. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 1D -Publisher FASB -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1DReference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-

50-2Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(v) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionExpected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - Details Name: srt_RangeAxis=srt_MaximumMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_PlanNameAxis=sght_TwoThousandTwentyOneEmployeeStockPurchasePlanMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RangeAxis=srt_MinimumMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 53 R46.htm IDEA: XBRL DOCUMENT v3.24.3 Equity Incentive Plans - Summary of Share-Based Compensation Expense By Function (Details) - USD ($) $ in Thousands 3 Months Ended 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Share Based Compensation Arrangement By Share Based Payment Award [Line Items] Â Â Â Â Total stock-based compensation expense $ 4,308 $ 3,856 $ 13,131 $ 11,121 Cost of Goods Sold Â Â Â Â Share Based Compensation Arrangement By Share Based Payment Award [Line Items] Â Â Â Â Total stock-based compensation expense 83 77 283 206 Research and Development Â Â Â Â Share Based Compensation Arrangement By Share Based Payment Award [Line Items] Â Â Â Â Total stock-based compensation expense 588 549 1,787 1,664 Selling, General and Administrative Â Â Â Â Share Based Compensation Arrangement By Share Based Payment Award [Line Items] Â Â Â Â Total stock-based compensation expense $ 3,637 $ 3,230 $ 11,061 $ 9,251 X - DefinitionAmount of expense for award under share-based payment arrangement. Excludes amount capitalized. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 14.F) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (h)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_AllocatedShareBasedCompensationExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 1D -Publisher FASB -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1DReference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(v) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 54 R47.htm IDEA: XBRL DOCUMENT v3.24.3 Equity Incentive Plans - Summarizes restricted share award activity under the 2021 Plan (Details) - Restricted Stock [Member] 9 Months Ended Sep. 30, 2024 $ / shares shares Share Based Compensation Arrangement By Share Based Payment Award [Line Items] Â Number of Shares, Outstanding, December 31, 2023 | shares 2,721,361 Number of Shares, Grants | shares 2,949,065 Number of Shares, Forfeited/cancelled | shares (213,175) Number of Shares, Vested | shares (883,206) Number of Shares, Outstanding, September 30, 2024 | shares 4,574,045 Weighted- Average Grant Date Fair Value Per Share, Outstanding, December 31, 2023 | $ / shares $ 7.61 Weighted- Average Grant Date Fair Value Per Share, Grants | $ / shares 4.46 Weighted- Average Grant Date Fair Value Per Share, Forfeited/cancelled | $ / shares 6.54 Weighted- Average Grant Date Fair Value Per Share, Vested | $ / shares 7.58 Weighted- Average Grant Date Fair Value Per Share, Outstanding, September 30, 2024 | $ / shares $ 5.62 X - DefinitionThe number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionWeighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionThe number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionThe weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionThe number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionPer share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionThe number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionThe weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 1D -Publisher FASB -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1DReference 2:

http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(v) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 55 R48.htm IDEA: XBRL DOCUMENT v3.24.3 Net Loss Per Share Attributable to Common Stockholders - Schedule of Computation of Basic and Diluted Net Loss per Share Attributable to Common Stockholders (Details) - USD ($) $ / shares in Units, $ in Thousands 3 Months Ended 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Numerator: Â Â Â Â Net loss attributable to common stockholders $ (11,066) $ (13,035) $ (39,661) $ (44,856) Denominator: Â Â Â Â Weighted-average shares of common stock outstanding-basic 50,340,603 48,671,049 49,911,655 48,538,517 Weighted-average shares of common stock outstanding-diluted 50,340,603 48,671,049 49,911,655 48,538,517 Net loss per share attributable to common stockholders-basic $ (0.22) $ (0.27) $ (0.79) $ (0.92) Net loss per share attributable to common stockholders-diluted $ (0.22) $ (0.27) $ (0.79) $ (0.92) X - DefinitionDenominator: + ReferencesNo definition available. + Details Name: sght_Denominator Namespace Prefix: sght_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 52 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (e)(4) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(27)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7 + Details Name: us-gaap_EarningsPerShareDiluted Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_EarningsPerShareReconciliationAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -

Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 17: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 32: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 37: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1 + Details Name: us-gaap_NetIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 16 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16 + Details Name: us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionNumber of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10 + Details Name: us-gaap_WeightedAverageNumberOfSharesOutstandingBasic Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration XML 56 R49.htm IDEA: XBRL DOCUMENT v3.24.3 Net Loss Per Share Attributable to Common Stockholders - Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share (Details) - shares 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Redeemable convertible preferred stock 9,293,020 6,559,047 Stock option awards Â Â Redeemable convertible preferred stock 4,583,289 4,705,390 Restricted Stock Units Â Â Redeemable convertible preferred stock 4,574,045 1,853,657 Common stock warrants Â Â Redeemable convertible preferred stock 135,686 0 X - DefinitionSecurities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1 + Details Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_AwardTypeAxis=us-gaap_WarrantMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 57 R50.htm IDEA: XBRL DOCUMENT v3.24.3 Segment Information - Additional Information (Details) 9 Months Ended Sep. 30, 2024 Segment Segment Reporting [Abstract] Â Number of Reportable Segments 2 X - DefinitionNumber of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 47 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 54 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-18 + Details Name: us-gaap_NumberOfReportableSegments Namespace Prefix: us-gaap_ Data Type: xbrli:integerItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_SegmentReportingAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 58 R51.htm IDEA: XBRL DOCUMENT v3.24.3 Segment Information - Summary of Operating Result Information for Each Reportable Segment (Details) - USD ($) $ in Thousands 3 Months Ended 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Revenue Â Â Â Â Revenue $ 20,157 $ 20,009 $ 60,792 $ 62,305 Cost of goods sold Â Â Â Â Cost of goods sold 3,250 2,677 9,068 9,105 Gross profit Â Â Â Â Gross profit 16,907 17,332 51,724 53,200 Operating expenses 28,136 30,743 90,327 99,364 Loss from operations (11,229) (13,411) (38,603) (46,164) Investment income 1,454 1,897 4,628 5,499 Interest expense (1,151) (1,432) (3,501) (4,057) Loss on debt extinguishment 0 0 (1,962) 0 Other income (expense), net 26 (11) (25) (34) Loss before income taxes (10,900) (12,957) (39,463) (44,756) Surgical Glaucoma Â Â Â Â Revenue Â Â Â Â Revenue 18,632 18,425 57,132 57,158 Cost of goods sold Â Â Â Â Cost of goods sold 2,453 2,002 7,084 6,808 Gross profit Â Â Â Â Gross profit 16,179 16,423 50,048 50,350 Dry Eye Â Â Â Â Revenue Â Â Â Â Revenue 1,525 1,584 3,660 5,147 Cost of goods sold Â Â Â Â Cost of goods sold 797 675 1,984 2,297 Gross profit Â Â Â Â Gross profit $ 728 $ 909 $ 1,676 $ 2,850 X - DefinitionThe aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(2)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(2)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 924 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 11.L) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1 + Details Name: us-gaap_CostOfGoodsAndServicesSold Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_CostOfGoodsAndServicesSoldAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionDifference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 470 -SubTopic 50 -Section 40 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481303/470-50-40-2Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 470 -SubTopic 50 -Section 40 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481303/470-50-40-4 + Details Name: us-gaap_GainsLossesOnExtinguishmentOfDebt Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 7: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 14: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 23: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 31 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31 + Details Name: us-gaap_GrossProfit Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_GrossProfitAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -

SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 7: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(11)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 9: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 31 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 235 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-05(b)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(10)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(15)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1 + Details Name: us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of interest expense classified as operating and nonoperating. Includes, but is not limited to, cost of borrowing accounted for as interest expense. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48Reference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 49 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-24Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 835 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483013/835-20-50-1 + Details Name: us-gaap_InterestExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount after accretion (amortization) of discount (premium), and investment expense, of interest income and dividend income on nonoperating securities. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(7)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(7)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2 + Details Name: us-gaap_InvestmentIncomeNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionGenerally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense. + ReferencesNo definition available. + Details Name: us-gaap_OperatingExpenses Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe net result for the period of deducting operating expenses from operating revenues. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 7: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 31 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31 + Details Name: us-gaap_OperatingIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of income (expense) related to nonoperating activities, classified as other. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2 + Details Name: us-gaap_OtherNonoperatingIncomeExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 924 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 11.L) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4 + Details Name: us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_RevenuesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_StatementBusinessSegmentsAxis=sght_SurgicalGlaucomaMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementBusinessSegmentsAxis=sght_DryEyeMember Namespace Prefix: Data Type: na Balance Type: Period Type: EXCEL 59 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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{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
ALM=";\T/(9)H9\X[L{)>4KM:_)97KC+J:C@?,P\[:F*(+TH" GV M['-"3MUY#_>TC[:A,0BAU!!81G1U !9$=0 M(9]@4$=GQ_$%K];U=Q"IV>Y*=3A>;9^VWUK>UE\8K.=WY&9*@. =%[I/>+@1S9-
WE17X[60FQ?32;U5CQ=M9TV^02' M8339I%DQNKIHG[NNKB[*G+#]KJ2CR:'**MLPXLZ*XN@XK>7H]?H%:-QTZ%M\?7&'^JCXZ"9 MRJ>R -P\>+NZ'(7-B'C.EZ()DU
M*#==9SF"35;L_Z>/G1%''1 YT0%W'7#?#]3K0(P..#[1@78=]-GAU!RF78=V MZI/]W%OC%JE(KRZJ\B&HFM8R6G/0NM_VEGYE1;-0;D0E7\UD/W$U+XN53#M? M!?*H+O-LE0KYX$;(?
W(]B#HH;X-W?,7E^OR4\Z;5/:]$UAQ?RYSRJFJ;E\O/ M05IT1^LR7_&J_CE@_^PR\6_P[$.1[E:9#/P\& [M6G:L+R9"3J<9U&39#?W-?NCXQ-#?ER+-'=WF_F[S;7=X:ON"WV3(3>I")3.8AH_B04=Q&
MI2>BON%W65%DQ5WP)LW38LF#5,CPRY&,W-?M5O4V7_'(DBW+-JWL^NOKI!VG4+ZYEN \VU;S"R0P1TS%(50843#.? M'LRG7O/?
UO6N77&R9BSW[.ZK0R[K3SDC[Q:9G7[ZO[IIH<\3+]7']:6=7AFK-^Y=S #?5OT$&1 @IJWT<'; MZ!N\O>>U:(J/?%%*BRI;-L6]:U!DPNEQ9"]/P^'(KL[&VO4.>NC:!0JF^1L? M_(V?TM\OY=
[ELU=X:$V)[:3-9-O8R ND)@,*IN5E=LC+S)N7CYE8-^=UC?LB M?90?J#(=A229UN^@YD+D[1GCL+4_LVPB->3'M]]D"7U;2"-Y\.R/LJZ?._W# M=M&B=#8U\3')'T_!5AA!5;8#U9/N!WC5QY:
M9+"-8O)'(5B&![%L$U%Q 8)O_#0738# #'L M@!A$0C(U_0,%,=!H[/P<= <5B&%P$,,)00SW #%'+">(.=IY00PK$,-/!F+^ MR(.+86\0)5E4-%T_Q6(X:\ L>.+OF[K'2 FVR+K/=T#Q!RQ***)7>M<();0
M. E/K$$%8O@;0.R\%Z @AAT@EDC")9$)8J"Z#"J:G@(%8OB[@9A?:7 ^'!>M M$FI5R 6H*H.*IF=#D1C^,B2&;2S"A)AE I3$^D@R*$G=845B^+N3F%]Q\+JW MHJ^*;@C9^"N M[RT&_CB#BZF-
('N: .9V"*NZVGVY32 .\N"%VTN4 M08GJ=BHF)'XF[+6U16Q8&Y/$OK/(KS780%#P.S\'W4&%=,2/=/ZM+>KTTX:M MA"93\)-U^SXW-2L? M'*(H3,C7OBW6T&Q-"Z?
34_!5$$3]$]=O95%D3FP^LM>@'8MB MFL0FBSK:C8E$UMP][66J^(?Z^:?W+09.+_S!!W^CP$:<:>BZ?6,!JLN@HND M4)!# _9 #^04/2,R94]<5IH28Q DJRJ"BZE)]QO\2L/7OPV/6%,PIE5BD"_:
853<_.T5?- #CV-8A M'9?%]$_F0H(OZ>:L7(%#'-2N$PLB\=\"O-=@_R&CL_!QT M!Q5B43]B?04@4/M;72Y <#2S3LX<;9R X&CG!02J (D. :1!@."//+@8V@QT M A! =1E4M+W_DZ-O]#
<_V/!G6LF3WSH^<3(T,[Z,Y?RJ_6\@[!^(RJ!$I)]E?OY>4;-GB(PY@ M%&@D^?+ZW.>YI'7[+.H?5H>6N>/=3+6]&H@I?LH4:RV>UH_?J9%>+Y
H;A2/#@^^\:>MT@\FR]N*/K%'IKY7#S7<38Y:2B1#7;W(WNXYM5@O4" M(_$G9_RY!II4]9" - WO^9WHT@C8@7+E%9!X<^K5A1:$V XZ].Z>CXG7KA MZ?5!^_&>#!F325;B>
(_/%?;N]%\A'*VH4VAOHGG7UAG4*KU9:*0YG_TW,E& M(Y0U4HE=MQ@0['C9_J4OG2-.%H >]P+<+<##!8EG >D6$&-HB\R8]84JNKRM MQ3.JM31HTQ?&-V8U6,-+'<9'5<.G'-
:IY4J4.02%Y0BNI"AX3A7+E4YO&7"F]%JK-7%KU15^ M(RN:L;L1E+!D]9Z-EG _6SR-_NDR^4K*SAR0'1V0A+0O_PT-J1#:2:2[]#5S09U;,&("_P9@'5)QC&,WW,41[B+LZP(ZFG$DC!,(_Z\8&K&
MWV[FC@]K5K(-5Q\-8O:2,2APG1=B M#=S'%(/BWD,O$+6G(??=&9$'*4#*QQ2.%YXS#AAZCC<0Z$SZ2;4-Y^"0:J$ MDJ/3>.;/^3 W'$*SA'C0XAXM#J+]3?=.<#F47R4D+70]5K7&KEZ-R]E?#:]T
MXW4"Q[8'R1"W+3/UY4I/U'&0!H].+@[P=<-@+]K=#9=;+UYB%UA$+,2V5.0! MW!-KG(1'BRTMGY@C*/@QRHN[]N M]5+S..-[NB[<99':T4KP;!@M6VJ,X_G,$[&>2>,PE?[:M9A7)S2;$^/YU$HD
M6VI,2.+ASK@GSSC,G@\UJRC/#RVEZXUJRZ"]-W7-(N:U')"MQEQC.=#VG1(MI;'/ISUQQF'F_-U@+*%XWX9I<^&86!W<(90DB0=F3YCQ&XQYR,^*OGJ3T\&3
MB=6S;:%YXJ%SW!,E#A.E'IZ:P>SA@HAM?B-D.HRT0VHEP6MI M.W="3X,X3(,/39UMJ>[?[QJZL(OP$JM '%(I]G1PW+,B#K.BE7(71\[!A0[4 M#BD_ZIXP\>Q=Z;;A)6R(+@
=Y.%WI]N5M)T[H2=?'"9?'3K(LHRQO'/#+ZS. MF@+R[S=!2W3_5#/F33J;.6&0P<.C H>8KU?T;(S#;/P-AIU7C4N7R5>>KVAU M"6 '/Y.4S(8CA$/.@YCT!$W"!/WELN,+XF!>3(8EX9#R
>RYF82Y^>$L#=BN M*L0K8TCJ@PU4=6T)504X^7#GM0L!U=8)C$,(^XB:]$1-PD3]!WUA>D"#,1CV M? KH3VYI#38PI0IV2!>H(U7S3)^5M\8U)?<$PT'DV#+%)80]$Y.CIW#[#X(MQPN4)0?_
WX8\79o7HM=5'K25JM#:H;G'A-Z(B9A(C8FF VZ9C1CC&9A$\+??+LA.V@V7B13BW@#KDD2A:^.N@)F80)>>5#BZA": ;$RU([7T\8K.8B M=QKAV,V2>8P70R-@,1A&_O56/ -1T.X2ZY!/J5
MKP1Z9B7SX'CQV%15VW-H80ZR"R&;NBW@P^0!F=7^FNO9K)$@>; _[1Z0K:3MW M2$_9)$S9)IZF-^L#7%XJIANQTVR;?DEDG2&ZI.*I9RQ,>IY.HLOC5G9'BN?Q M.QEO(0TO;69)
<#YX;S"OI>W<2_VPD+RUD8=ZE/SP:XU[HP*.RHHF;_<=$'!^ MTOX2U9T'O+&A3APCQ3 =#)S3Q$G_4*1A >*U2G5/M.ZIMH"/<4!Z*8R/^^P MK#FXX1VS< ?%![^)3J-
A;W4(#=OJY.3]@1VKG\QK%1(97[> _N1^?'E _=N#?XYO5NT+&+V:]GV0K[0&QI"H8!M0&7V:@8_K]A6+]D:)RKREL!9*B9VY MW#*:LUH+P.<;(=3A1G_!\467Y?\!4$L#!!0 (Z#9UF"M(@NA (,,' M
8 >&PO=V]R:W-H965T&ULK55M3]LP$/XK5H8FD$;S MV@RZ-!)MBH8TIHJ.[;,;7!N+Q,YLIX5_/]M)0XM"A1A?$M_YGN?QG:V[:,OX M@\@']'HL"RK&5BYE-;)MD>908C%@%5"ULV*\Q%*9?
&V+B@/.#*@L;,.]Q0KO$ MA%IQ9'QS'D>LE@6A,.=(U&6)^=,$"K8=6ZZU<]R1=2ZUPXZC"J]A ?*^FG-E MV1U+1DJ@@C"*.*S&U14[F@4ZW@3\K 5>VND,UDR]J"-FVQL.?I 4$ J-0-6
MOPU,H2@TD3K&WY3ZB0U<'^]8[\N:M9+62',%VV;V.'00FDM)"M;L#!!26CSQX]M'?8 [FL KP5X+P'!*P" _M!?AO50A:0!/6A6$+,*G;3>ZF< F6.(XXVR*NHQ6;7ICJ&[2]%Z'ZG2PD5[M$
MX60\QT]H(] [M$!]X1PD74 V0[WQ! MGN,%/>>9OAWN]Z7S?^JS-CI?%,/O7H%O^/SWO(*^RV[H@GXZW=M&HL(IC"W5 MO 3P#5CQYT]NZ'SKJ_1'DB4?23;[(+*#.PFZ.PF.L<<_U9"XH2DK
9W^8$*< M]=U#0Q$:"CT2-O&YZSIA&-F;_0KWA?F./SP,2WK"_LP=_#9CUA07 Q?!9M M\K7WNE()?&W&@4 IJZELGF;G[2;.E6FT+_P3=S1U>_R)FE#-0'FF;\;+>9K
M0@4J8*6DG,%7U31Y,S(:0[+*],0EDZK#FF6NIBQP':#V5XS)G:$%NKD=_P-0 M2P,$% @ #H-G6?.A.:*(! ;0X !@ !X;"]W;W)K:.E8 M(B*1*DG9_?(76QD\H,5] OM@[%\YWO7$5.-
U(]ZA31P%.>"3WKI<84YT&@ MHQ1SDJD@8+>K*3*F2%1)8$N%++8*>59, C#TR!G7/3F4[=VJ^9369J,"[Q5 MH,L\9VI[@9GWXB^-&[SV#=64IY:.,5KN-9+[2,,,,/(6 A&?VN\Q"RS2,3C6PW:
M:VU:Q?WG!OTWYSPYLV0:+V7V-X]-NM->A#CBI69N9.;3U@[Y A,M/N%S;5 MWB%MCDIM9%XK$X.*WG+2, -KBF^,"AX4B[E(8*4PE2W(V>!H8LV'U!5*-= M5&B# VA#N)"'!IJN1(SQ<_V
F+7T!@V]BX$7\!Z+$QB&1S (!R/0*5.H/;## MUNNA@QT>@.WR]@B66[@6,5_SN&19E_,5Z*@;U/;/N2Y8A+,>-8A&M<;> _.TO M_=/PHX?RJ*4\]J'/;YA!Q5D&#ZAR#7+5E;
(NTG[8!N0V8T+#UU)!5!5UC%0: MF(C)SHI'2$+.MD 6J%2X,!),K5L;V 4B6;%%9<,!%9XEQHPTUI MFU$#012EBE]]**M-;9K5Z;6N2>(1R3RGMJ4.B!Z/8)/R*-U9>V:'M"PIM#5G
M@4FSR+:5>6(%C'RP#4SM;QN61@I"H>2::T>%[-V5&4(_7(Z/^U:T2E=/1(Y, MP"(RUF)%P$9!H4NO,,! 2'&\K]R$98\?,&VM4MQC*(7MM6N#.8S"R3OVWAG' MI,R8FU'WQW^< $U"H'%+Y)=V:
(G#YNIV;!CL2R7GS"J'2!:1/-[;35!5JWG3&NH,O%*A=QJ:Q@.7TKF;+U4>6! M.I?<7)+T6+FF8*'+ CI-J99$D M"A/[=%\5RZ5K8T\MC)X^_DT>0H#$-/(X_;1AY[.^X[?O_K^2TC2"-=#>,.?_ 5!+ M P04
" .@V=9O-T;+!8(!N$@ & 'AL+W=O>]J.E]N+D/$+@D M48, X!2=+_^GQ5(6G)=3Z=?; '$+O;EV6>7/\Z_Q!JHBB^-<:&BTD=8_MN
M/@^JID:&F6O)XDGI?",CEKZ:A]:3+))08^;+Q>*'>2.UG5R>I[U[?WGNNFBT MI7LO0M1X,FQ\UE4=>6-^>=[*BE84O[3W'JOYJ*70#=F@G16> MRHO)^^-
W5Z=\/AWX3=,V[/T6[,G:N0=>W!87DP4;1(949 T2_S9T3<:P(ICQ MM=F%8T&B_\MO?1S^BL"R%U@FN_-%R7EN7=;X?DT MM/&/Y&J2AG':.IAER\O'9-*^U.2%N(CS)VGH0KQ547<"Z$\WG$'7QR
MKGI]5UG?\D_T 23NG(UU$!]L0<6A_!RVC08N!P.OEB\]7%%[$R>+]5@NEJAE8HN)BW?Y$3@&RZ!.VI I&ZU0W13PB \VR<4]-@.]PPX">^3K%L6V]V^B"?-*)A:+B\SBR
M$Z#3#6>";0X1KDE?!+8YR26KEF>"FM9MR6M;B99<:XCU/!"U(A!A]\"5?P:^ MHNA4%$AZ+%&/#O;HR@:08:R%1L7%K4,/X.=R#75H2H 'ZP]4I9I\)U9#@'\Q MLD-*9(K\C=^)#SO*-
;W/(;]CS*]/@:AZ8KLZ*>[C[>HT+>G9X\"JUT &XBC M"3^RHR113@:JH#+T&EJ:LV,N6N@C8C?G8 MY6R092#/C(9/@04I8R0Y]P*F0#JJ>8FN:$Q4R2.]"MXP%C>JZ$O5O,JE5+2 M@TKI%%<2X
*$&^D9>B%TN;QD@=8F6L0YD5[*1>LU-V].@'TMV1M1];&;IG@? M:5Q]_4'(VV7"B&@=Z9"<: MTFO7:%0<\L5&<5ONTKR7K40(H _/4/RX[J[(9.N96AJYA8HWL:#/$D>''7C\' M$!?
ZDMLQNA'IF=1=)1].#2IV(7A6G'4-[V[7VX>&Q[<&L& !/T^'$X79O@ M @FZ?65P2)Y< Z0ESN"R4 ;)P,R2VN4S<5GO1%OO@D:_RG0BBX*U)[V0+9(2 M"9M8P1,W9]S2K2Z!4P#JLPX/.=!?
HC;/67&OZ=:YQ7>> M&[5Q :TM]TBJJF;@M]WT9^0\S M =F.,X06WT>&.^/8T[C\K(N@D9)=3;.$%_I &]=GEYH+&Q3)Q#:LPA03>E/ MJ.321(X.0]O('2*2ZQ4D)W=_F(@0IGV[T/7
:81W)_60'JR'X3#3R)#;*5NK MT"LK.CS&DW:D:G#GD.26 ?<< U@WEQHH1WZY(MG1;E7("T\J_^/8-[XOA*$<97"B";YTRI#6<$L:W(IH;!J/%<<>6 '085;/O
M/&9@4,.3RC,"T9@K/0021GJ\33X.2LHQ=2O7F6+P[R"QW#(E-YH]. SQB+5W M707^@QAB"?T%K>/@",]SJP[#SSZ0AD<9,(#E&IHW\"_/;ZDX46\9BN2;;':> M1*?]5/V"J0UFA1+=)4$PBZXAQ-
6,MC1B$.S'O267%M>BS)\3<)X+$V"/J>>A&%\'68\X9%#JS(GLIUSIU(^;A M(:TQI*Z9.&0L [?^G=(GC#![[CUQOO<- "\C5?K2D?)M8_X<,.Z.'U/>YV(MC\?
SEYB[C",@OH3H8O;VS43X_'4C+Z)KTQ>%M8L8 M)/?OTBSP?PO'1X:^P7 M?,'XB>GR_U:1+ P04 " .@V=9/VT9_E((" %@ &0 'AL+W=O+\.VKI(!MVXS];53,N=%53F=SV;?32NI
MS>CRG)]=N\MSVX12&W7MA&^2]KK[*U7:W<7H9-0^N-&;(M"#Z>5Y+3=JJ<)M M?>UP-^VTY+I2QFMKA%/KB]'BY/75&>AN!B]&HE< MK653AAN[^UDE?
UZ0OLR6GG_%+LJ>G8Y$UOA@[08%E3:Q'JYE^(P6/!J=F3! M/"V8L]UQ([;RK0SR\MS9G7 D#6UTP:[R:ABG#25E6I+S>;JP+E\N8#&'78]DW M1]JU)DT0BRRSC0G:;,2U+76FE3^?!NQ'JZ99TGT5=
<^/Z/Y>?+ F%%[\'*5 M[Z^?PL[.V'EK[-7\485+54_$Z6PLYK/YC/Z3COG3UG?Z1%]![P4_UJL?' MR[\.1SUG1W61P7TVM\KD,N%EK(TVF M92D\A!7*/7@A38YRS6Q52W-/^@TL\2(4RJE@A71*-
$8VN28-)%S(K1(KI8R M]37>YT(;5N%RJ%X-;S!D@QC MIQ:5_Y7EEZXH#,H.YG1CC=JTY0QB,OG_YAP)-_$N'S]U:OY MRQ9ZO6R%QN-=82DJ=F>@S3IW>5SW1+R/R+&U-I0S1+:2 M!LV-
7H_YU9\S&JV^^]@ 3H7,/Z,OV,DQJ2SHDNK-4B8H6Y58DG6.$=@WUM@ M%,+NJ9S1T=FBM=1.U,-Z0?$-WY@DS9Q$" QF!W0]F$S%:9.63GB5LJXB*.& M9-
2]A2W52CEQ>LE*]0UBAC#_VF@"T>I>)%9@4/O"-B6>*D&S4D+PY\;$8:3# M5N_<'T99K)E4P$R6=4-2%?QOS%D/$JGU&$PL?D_5:UH4] M^OF6/7>8?3C2&!*=C 7<;FV@1U1Q
(A;+XE=X]ZIA_.F%-T6E1KXU28'H=*P MU@*QW0B.(9[JKD8I4'#23JUW%(:'[IT)")$@L8ZE\#S@Z(FX];S1CS[HBIF> MO(SI8Q"HY7I- M=!"#0[FA@]@Z.H>\2D IM5SI4@?
F[1ZX)$791LQHVX&4D%$0^=2Z?LBS<8?# M0Q8XM56F2>93QA ND3?,1_T:;L4I#13UROH@_&#&Z,/@5,E!3DVT=G:K^61 MR6/@-P[3!YL&*X]0=X8J-L"MD2OF,^A(BH0 ";B^###,3;FI79L..8
MO;,O0#9+;-"C6I^[O2/8P0RV0DN5=\G=+JXTDWASZ[BI2S.]1@C^>8&A*L M,AM+$8J=J?%T7: Y61I"2HZJXS8; 6-PK]%'K>,8$%^UX:96P ; -EOI#.6R MT<-9JC>BMEY'NZ'P(---
Q$<<.H=3, **ZRQ5_N -1DB32X>!\ ,\9)8;I%; MGC7?]C5!C/F<&3,5Q5'>'$>B%SO%_+E7,@>V%;=USL%Y-EHL;SVF5@VP43$1 ME[2&PC9_ZX+WD$E5Y9,>39ZMUA>]2;
M(.B:L)KGLY>8+=6&:^6F8XAGGS!/96+^:O;M: &^HO)+(486HQCCJEWYMF / MD59HCR:%P/7R/LD/6#%11:(@3AKT M?0_<;[0Q/ FN ?^^1YZ\:$>
:-7^V85Z%;K7DU0!F=SB($P'JCRQ9TU<&QA? M@Q&" _$G$!.'C6TQ:(DeWPU$S8RW\& LH#L0L-)D-\PQ(=L8,(FL'4;:]V,L M8>+^Q,2=0;/R[!#(>LG#X$K#(;*+)7D[LO\&*GVG&-H^Q-
F@R_E4./H_LN,A MK)*;C5.;KFTY8E!'M)ZA?Z>Y',\VUND.;8/^5$O-H^IGT(XG$N].4YM&Q[/R M'L]>#*;?0\#XP73,YV=XK#3WK[J',YT]W3["R_O 'X 63. 'N3:.JE"6&ULO5A;
M;]LV%'[/KR#QCV0$NTQ842%9*RZ_WZ?8>4 M9/D2M]G#7FR).I?OW(]TL=#FWJ9^./8}4[F][*3.%>>]GHU3D7$;Z4+D>#+5 M)N,.MV;6LX41//%,F>H-^_V7O8S+O'-
UX<\^FZL+73HE<_'9,%MF&3?+&Z'T MXK(SZ-0'7^0L=730N[HH^$S<"?>U^&QPUVND)#(3N94Z9T9,+SO7@_.;,=%[
M@F]2+&SKFIEZWOZ>9#EEY[3#$C'EI7)?].*]J.PY(7FQ5M;_LD6@'8T[+"ZM MTUG%# 29S,,__U[YH<5PVG^$85@Q##WNH,BC?,,=O[HP>L$,44,:77A3/3? MR9R"-S9BYZ#
<"+IQ96@FR!H^(B@, 9) MYRZU[&V>B&2=0P=@G2@B-NIW;_ '.^1-VHL'7EYHQ];^D;: M6&DRUK(KR?6&23'7[ML#B+'NT52P9S;@L?BLH.*L,+,1>?JQ;/!R [K/8#'
M#>#Q/NE/"0;MA_J:=8*.(/:*% 9X*=]NS@N=+%%^A#3PGD[QT]382D-&#V*R4":P0 M3.",(B9(H7\AL8TFE,-S$Z3*XJ3"2N*'->G45#-@Q?YJ1 D7'8Z' Q??Z@2 43KKCE<.>WH/_K)A]RUZB_E
M(4:!Q'N&QU!F6478LI,E*(NH0CO<1KOR5O>I\;7(=\7-;M1[I*W;_"-!I+S6 MVO2(7+L*49?(-8PV31741*U$ VR@TT$B[4Q>J(-)T"399LH:"&'\6!?B5& MG$)W4>WVT[?5=64HJ?
51)5EO4,F2JS]&F[^U* MT85T*9XO4AFGZ_VCG1"@D%!' C<"V2.MWV,2:INKNCNNU0%;<"GHVH6&I-L MLD=)U)X?OO@$PZ:^T/V%>"@E1%15':L2&T-=7U3F@%.7/'/&:UDR2_T]9 B" M\9P-
^OWH!%U8*;_=03;.AF?18'7F*;%'8$Y,D"_U,N&)WXBX.AWXTU$7P;6% M\$FF@@%HZBVM%,=8(5KPB$\!E@J5'#M]C.6P]"V+!-.03#E*9R)$SHH2D?+> MIF
ARG*&":98Q5)9<]9'%BY#/J&L(_9^4W(B)FX3# U.DX1)R3-,:#]#8VW= MOFD9'6O[Y."Z8;\E]]\YO*[\ ;]8[&W[X*-&OEIV9L9,8/0U@9Q\#6ZBW9& MS(>K,SX]Q14"\)P=(M)'U?')8'"P%8[_
]+PK#L8C @2X:[JMGXP]SM0%6R MV\TBH/T U8R^D=!H\G&:KO88&K_(4@(3P-U[RO43T]11AX!Z1;X01N-HN%$' MHU%TUARACL,"MRM3MK,>Y%L&X6P]\ZOQ0I?
2/UXU:&]=AB,M]\UG/3&K/KJE M@1>%T5B]$+U-%T<_&P>_B.72VM)KRS(8CQ>H^)XMN#$\#QL39D)%@KC8LM7: MW@L3EZ@_Y!-FQS62*?
2V0UB)%SULU0D5EM^<3[H(S<0=8=#GNME_A,F)G_5(&Z MTV7NPQM\<[l\#;D.'P%6Y.%3RB=N9M0BE9B"M1^].NDP$SY/A!NG"_])8**= MTYF_3 5JUA !GD\U E7=D(+F&]'5OU!+ P04 "
.@V=9;9EY21L$!E M"@ &0 'AL+W=O.-M*]457 (8\U%SHN5\9TTS#4!<5U%0/9 ,"3]92U=3@4FU"W2B@ MI5.J>9A$T2BL*1/^8N;V[M1B)EO#F8 [171;UU0]7@*7V[D?^[N-3VQ3&;L1 M+F8-W<
2S* -G<)5N$<6"-WXVF/Z>Y-6\7"^0[]VL6,L*ZKA2O+?66FJ MN3_V20EKVG+S26Y_ACZ>H<4K)-?NGVQ[V<@G1:N-K'ME]*![FHAOI0\ #CR@D MO4+B _X,_2 _?
44,7.R6W1%EI1+.3%ZK31N>8L$E9&H6G#/7,XI)R*@H@2U0)N2#%*;2Y+THH7RN'Z)7>]>2G6N7R4G M)30#DD8!2(.D.X&7[D--'5[Z MY'M:&" _45M-008JM^2L7J)VQ2%*(FU)86\L?%2AN%M?
3G,88Z![+C#MC[-=4-+6#N-]:6N@=_ M\?I5/(K>G@@OVX>7G4+_1YD\B73B@EG5312_$#J?^N;'?V>WZT MJ]4LR[LDIA-OYW0CU:Y7<5N!S;P;QA,RS%-O6:'43UCA-18?#H ^-_21KC@6
M=QQC=0^]C@O:VSU$B8,T'>%_/[Q.AGLA?2'V#DC63"*4QS3(,^SGNU,*8HC MA'>'XNGP_^'YP)N33)Z149SA_R3.O).NXKW$^WXCQ>8%OE^_&B=Q\A,Y'"99 MSZ<\A8BFQ$,N__F('/M(A >?
_AK4QCUP+&NM,-TK8+^[?T-==$^') 'N ?:! MJ@T3&AE8HVHTR(<^4=VCIEL8V;B'Q$H:?):X:87O0%6\ ,7$K\1_<(:V+\L M%W\#4$L#!!0 (Z#9UFN D7JS@D .,9 9 >&PO=V]R:W-H965T M@--
Z)4\7H:ENV8[O*N=4DEKRWMCO;JV4%S^* MO'17@[7WU<5HY-*U*J0:FDJ5>+(TMI >EW8UGHT+J]6GNZ,;]^K.1*W2K_K^JS
MQ=6HE9+I0I5.FU)8M;P:W$PN7AW3>E[P;ZWN7>^[($6QGRGB_?9U6!.!JE< MI9XD2/R[4Z]5GL@F/%GE#EH5=+&_O=&^COV';XLI%.O3?Z'SOSZ:G V$)E:
MRCKW7\S];RKZUT/A!I[;PIXF984.@R_)<_(@Z]#6?C'1NF M<<.4[0Z*V,HWTLOK2VONA:75D$9?V%7>#>-T24&Y]9/-?;YZS=]X2]"\'+H M>]3&7: "KNF.7>?BDRG]VHFW9::RS?TC6-
":.6W.>#7=* !654,Q&R=B.IX> M[Y$W:]V:L;S9'K?$&^W2W+C:*O&?FX7S%BGPWVW.!EG'VV41+2Y<)5-U-4#> M.V7OU.#ZM!UU\FI^.7>RP]:BT]WB=]9P#V[MINT^_&*W$R%.S\;]F=:Z<>"TK
M[64N/AI9BIN550J<\N)]*3[(L@81&?-$^>42KTU1R?)!8(&R*A.Z]$:(L%66 MF;A5:6VU?^C),.)]O_YR-IV.7[8Z-W7QT\G+YPERVZ^?6); EG0HCAX):7;Q MXE19CPHCS%)H[X1<+G6NI8>0(S" *7ZG-
L4'CZ+0CP]):EW/DK5.UZ*RYDYG MD(+]C^=*C6^,/(2W@.#0N3DRE*FT > 80))E2OXMH)^2-!EJBO@*PM3 P]8 M6%<"L!V*TY/A5)S-BEEOU0::[^J K,%XUL" MV)I8)^C3LCD[F%^-IX-:0 B^S3'-
A)FTOZ)IV2MQ$[HIO,(D:%'.4]] MNX!O?=?DG=2Y7.2*0 36NESA>V;E/31:4Z_62-Q4%OLX-3E)8E8>BLEXJQ"8 MSGKRL28I&NM[]+CRS9C*F6Y=96I(BD*%;6$G8U*%!Z_H1.?
E'#0N]UX:&>3\"U/F#V2$-D0G_*66:70A^CTE"3KCXAM2N0F+,] G*\(< M$&-Y$Y5G$'.'X>QK:HI">Z^4.'(UB8B[V79HB+ZJ-BZ+)$,+:)+ M:;%B!EQ"CX&XP+E&,?
R>]'!ZG;F,BRGXL_VBV!VI[XP,&L]/FP<\R\\N6 M@$.'#*W:DMNZ"+"3^Q!*V=)W)$EN!<+FS$@E3 =EO9ND0^STI$/T3T]@^9YP*E MG0:P#Z;V9#V*2J'" BJOG9CRCJ2+8:N8UW2%H&>B^I-
L0"8U^F!CE^Q-]PV> M+35KE0\,P1*II!V](/MU,COG:X.?L?0L9Z:LHH5EN5FE6I \)#21F140_* MT("Y*!*CL&BA&!Z IWS373@ A:%>_R6Y)D$3:]:.U=<0-787NJQIFZXQ)
<8F0%G9]@H*_NPD.3T[%6XM87C3SHC"L ?)EG[G7"J1 MW6"==MQ@4M74BLG).;$F;& _0OP<&C+^ET'"WS*5S>]E#,))H.90O)6T.)A. MT8@]@8UA(0R!SZ4XD%)>+6TIF
W&W(WD1DBH93@J6.>((=A _KDA.0S\9:5 M)H_[A"[#.2*,]"MILQA5IS91:"_"6H6N5[Q+OQ7E*P/&S'D M7/3413U-AJBY3F=:6DTC0Z\"JQ\IZ.(JR8FF*N]OUR8)\^(^6&6)R#340JH",?
VBH<^HF8*$L"I46D**#"^HDF@&TRN>?6JN&3BH68KS30MW M_O X??L.AM,%#0WP2\U6&DHM[*T[47..$F(#<=J5("PB, MOJ@I%W%7?E>]7HAU*#F5<9RF#7]\2*9(2,>XX!9*'5;2)%-
FCJ3R&NR% XLZ M+K*]?7-D)]#AR3A4KB8CJ.$ZF8: AT[7CJ?DF5!$Q)3E]-"(N[LT"UG4BY7. MG=FV!<= 7=0%B5RS49;86O?"]7.2;"]CJ5)3<2PJV$U%-_B!I.QD2JY7VWK(
M)YUAEG],P[Z"M4150N+KT M<W M./N@0KHX_;0;NV,!L2T"..&'WCE- %]O@HY%\YZ&@/ZM'L]K^VTU0>\]9) R> MD'=T^Z9095/#OR"G^<'K#K9MQZ]6Y?.!]CT]C0G%^9\V;?7)#M)824W]8$G9
ML;R1#CR71BCZ!8_8K$+6<2*5I>HU62I:4&T?NI[_M_*RZVJ W#D:LGDVP.P' MLT'H=3,T'6)(ZF*6 ;;H%D9+U4Q\ =U=4U 8I(/ K:5\:Z:A!^_L.03Y9/X2
M25E;]^(\]'_L/TE'JEV])13#1^,6X7]5_UE6^[@> "+[E'/]JD1NRAK9'#B>;&N!XNF8V[&@,O?]*&]NKNM),5G=O#<01OV(QM<-F
M]_SBX&:+\)LGMA^P/A)_T!:6_AC/4"9CA..0*^1D^O+@"9SQ05QY\)6/C%MR M-4.KC=+BTH\86"Z0P_$@ _@WCC[;SC-'XNSX3*!H@QKC^4P\C_K":R0X6'NB M,'-S=IQ,3J9B-DO.I _HK"DE%6DTG?
%'8IL)^>0UP6-]">8ZCS!$&0=$FKS M\1GS&I-.S,*&;;B5!T(\+M<;]Z?,+CRYZ@LI,A:$=6T8\'H/_S7G"H6/0O M3L4I#DYC^CH7DWDR/3\^^$H]1RYI()L Q.GI[I UX3]XQZ0CLE$4P>ZV9$V3
M\=DL2F@!X9US>B*VO>L=]5Z\X1*R/R_0[OPCOXP[T"9->'"?+0_?WR2 M=]51ZW.UQ-;O<'XR$#,\! NO*GX-?["><SM_'6M)&"C!7B^-#B(QV9#V*2J'" BJOG9CRCJ2+8:N8UW2%H&>B^I-
&PO=V]R:W-H965T M:G5P\2=-] MV-D'B(0DU"2A]04]=?O=PY D+1EM^EV)N-()'!P+M^Y0B]VQMZZM5*5^%KD MI7LY6%?5YMGIJ4O7JI!N:#;JQ)NEL86L\-6N3MW&*IGQIB(_G8Q&YZ>%U.7@
MU0M^=F-?O3!UE>M2W5CAZJ*0=O]:Y6;W- \^Z=6ZH@>GKUYLY$I]5M67 MS8W%M]-()=.%*ITVI;!]^7)P-7[V>D;K><$O6NU)F(PFLT?H3:.\4Z8W_2ORBC?:I;EQM57B/U<+ M5UF YK^'M.
/F1T^A!SIF=O(5+T/7]=^/ST?-'1)A%$6:/4?]V MDSU.[H.IE#@?BLW>R'+ _7?SR?CB MN1,YK7)"EVE>9TH9.IS7>V;YW2 ^JW6&SHO/!R*MR43*M!E_6') M5N:U$F;IUXJ-
W#.G"2*AXN:CZSX6*MH@PJV5H!Z6*6)W!B<3SX]/'+X&F FG'+\JU7/@X IT\>/A M!#DQS\%05\W8V]F)(^$OX)!%:BGL"9P)%T0R! [Z+7$8V)$92=R"Y"OU&,N M"2;&X^%L)/Z!XPTO8%%
(IV0 #A.*2B/:,ITU-JR1'&VK*-6()Z$2;T^@7VX MS: _'>! PIZUPKZI:,/KI:DMO"\@D7B"Z2>/F1X5V&8#FNUQ[!@$0!\XL!+K M<@EX]KD8SZ/-
@:5_R1*!CDU^_8)IY.Y06UKUM:4JW6+R^G8YW)OL'N<($)4 MT1=VXMRM=M%O$PH4""&4",A@%%,RS0&"0PN(9ZTFB80\6>A MVH615 M+D.(,'U*[B\:PV-?TO8U$!](QITG1TR2R<5/
M1P^)BG!Z>8Z_D_D7>X7^DI / 89UXQ1Q[H."TIR3]V9P> MGXGS,7\X%[/+BR,?.QX7!7N3R<7TZ)UR[AG5OU0MM57IL1@C'SX]NKE;M \Q MU?&TH8J2E7T/A18C#MOO:*,3-X_%V?
@2)WXPY8%]_=74R3R!S#-T.2N(>F-- MJA2%8W0X94=WXW,VT+B?1I7P]O!J*#V8HQL\FXY-T>S(;3\<73\4Q:;'0.QD]9SK\>?S*56R:N6S M/;+TVZU$7X:2^FV9#L5QV!&>QCV91KRN*+.6&2?
*\!5^3(6#3^44RFZ.0SM$?CO*IN-9 M%/(6!R0^?R7"*81&^D KS7^IN&XA%3F9^[+_IWUF:[^OI@]%^]U:HTC#@['
M9%2]FQPXKD!9W3H*,0H=EBSD*K25NORU+CF:4]32:CDDT\9:99;$^BBHC/.S M)0RGU IFX)\0<'_MYJR,;C-%)X!?0;[?ZVS51&;L7[K]4.'U(9UZ$YT><)H M(CL=BMW)?];D9"$
M:DVRL#1S@PXDQ]7-D.@=N)W./I>[&O\GH$9??;GIZ$%N:D

EX4NN(*=:VT)?56 M)UZK"XM\P-F^[?\H9>^@&;$V,8=8>"X$>27XLT,D M0%#$.2T& _ : 1<(M'-WDMGLO-.2MO2=&4HTUH4I=5Z*$")TF8M-70*Q8 +;'D M 8ACZTY
X)*T/OA@OCGEX!P+H'1>G'68^]'+AY_0$9<+5NRO8:R(ME$UUHRC MM]AR@YNZ;{9J>,9()C%,70$@P0EIPB=W''0)3Z8[E6OZ8*]A0Y@@^Q%C)8,+ MA:?T[L%]3D.G[+I90]-:_,_AM9E<-
<.N8%BM#.O4C]1TP>S2_W=&BJXK>D<5B7;2G<X]Q%E)"LC;6QA(/Z M(U<9#.Y@SA8((JM5XPX(U:A?4% *,$B<E9SF(DV1GO9F?YVCULH@H5KCTTZ M &1)Z$0LZ)B\ YC./.';G5>>24&JD?
#U"CR@?4.&* M0C0]7-(AEM5YY3K=)0^=: L+<#[10$NPQ.CU)"2B 0$6 *VHO!YO 9*F%-GM]&"+!(&W M;W??+H"KO;&?7"F$9YKI=WU/J2^?CF9N+P4%7=C4PN-+UMC*^[Q:G<35UO!
MB[''H4I,L39>3BDL)NKD*8^_MS95IO)):O+?,-57%[>%.*+, 'DU'W< 'N2L] M#4QNKF]^$_?" U*_MWB;]"B%K(1VTFAFO?9Z=#M]>3>G^6'"KU+LW>"9D2<;
M8S[1R]OB>I02(:%$[@F!X^=!O!)*$1!H -5BCGJ3M'#XW*' $'R'+QONQ"NC M?I.%+Z]'ZQ$KQ)8WRG\P^O]%Z\'^"*C7/C/]G%N!HMYX[RIVL5XKZ2.O QS M&X?1@G7ZQ(*L79
%WM%08/F:>WYS969H--'H(KH;5("7>6WR56.=O M[KW)/Y5&%<*Z[]B:OQKI#U<3#V3Z/LE;E+N(DCV!5=;3NLF[F\Z!C[_7;CO(42_CCG8X28 MGX>@ZGCI:IZ+ZQ'D[X1]$*.;;
[^,+M/OGR$X[PG,GT/_SWEX'N5GXP5;C=DY M-/,*5!7](''OC'TM! S77AV^_6F?3U?>,Y<)ZN94Y!XC9,JES8VMC>2B?VIH' M60C'T B0E31)XQ_CC2^-E7^+@KF2(S*T-H^V'-
E*6.TM>`^"]$>QKEH{3=,IJ M8>/LA%=L_F_P"'@6V$MC?TKXCCXUCI_RH5A A/;2Z\ Y@WZ2B[0%E@ARX3M= M,+8OA18/0-LV]$H+E-AQI0Z,/W"I^$;!-&^O&#[#90@:R]]#8 [[2=,&T&QDL,+AL!['
YTS-[PO(RN?>&-=$?.&"W8 M R0 < Z,K<#W-1R.H],P.DL"YU8+(%"P5MW%L2W*^[;Q#6A(QD3X4 M.KM[>7%L<&CG(E@G8Q>OCI+1Q7,(OK-<>\<6R>5BF2QG2[9,TMDLF:Z6QXM-
M3;IT@0RXDF_8=)S'@]0[-D\6ZUF2K2_Q=+E.D^EE>O%!H/IE[CL=L49+F#I9 MMIHGZ7S!LF2539/9=%_-CIN M:WOIRY!!DBMY (W0ZUNX)@'!SL!R)$?#/PJ;-PK>A/';G14"6ZP_%D$;TJ/T
M[SO[T!G-?2=T*#"VL:@IE?@\AV =VT?FQ)57I:)3Z#G*1H M(4EAZ==L,9XN+H?%';JA)1/'T'Q?U>8D<'"I8LX/@8+BUI@[4BZZQM?*-G:)W MC H._><<>B)"MBA<8[9Z\929 E#H^.R*FYV%
('B;$V'?'#9];@\V)6U8>X-H M#L868<2%/K;$#]\4LDK]108_T96Y0L8XB;9Q'8T[Q?-/+^YSM#D*:=VV:)G3 MA,H40@7GW,"]O8! O4E$?$"PJ;$Y0;VLCUNN#@*O M3 /]02!8A+G9.&?7
='F.;/H@8%20:''PT#A3)VV[[[>+4]GK1[$._2DLW[MV M4PJ2=LT0U)R-W,M?7 A(/ MQ1QH/%[#2SW)=&%"HBNZ8I -2V5E0]N)IXFNZ/)XTD"$8^'%LP$_DJUC2O*- M5$@8A(^!! 6!G3>X("
G)QCUYIQ(2Z(?]\CY8CVR^+M.=_OOO]SXH4.-3$ M/0IS#_^!%D\:^A.=^ZFHQ[ )UI:/(K0")SI/L$%@3Y;<;4[D@G/FM)VUH&2= MY58"0?+D.'C'316M
8(G&N_0EO6;#9.4Q"T./AG2&,39YP/>HA)+?*+N..VZ M8RN\+OOO^-O!?#*X'%7"[L(5$$FD H[WI'ZTOV7>QLO5X_1X1?V)VYU$RU%B MBZ7I>+48,1NO??'%FSI&PO=V]R:W-H965TIBJ.R[.1A:Q]
8BAB MC8/& **57[]?l\S@X"'9CK.IK7V02 XP/7U\?0)/-V7U0:VDK,6G/"O4L^-5 M7:\?GY^KQ4KFL7++M2QP95E6>5SC9W5SKM:5C!/>E&?G@>>-S _X+8Z?/^6U
MJ^KYTI*IL[205Y5039['U=VES,K-LV/_V"Z\36]6-2V7;L$4,R MDXN:*,3XN)4O9)81(;#QT= \;H^DC?WOEOJ/+#MDF<=*OBBSW]*D7CT[GAZ+ M1"[C]OZ!EIM_2"//B.@MRDSQ?
['1]T:AL5@TJBYSLQD<+0^=2TPD.T)F)G\NB7BGQJDAD,MQ_#IY: MQ@++V&5P+\%KN79%Z#DB\(+H'GIA*VC(\,)#]%9Q)<\N8^GLY_)-64LQ=<7^0Z!\WQ?7=;GX('Y9LQO1NHB+A.SB]^Z_
MV,15HJ^^+GB?(^J5%" *?!T7=T*J.IYG*9";B+0^2/F$]OSPW30(O"=\"ZWR M;__)*0C&M5A7Y6T*D F$)#[B!E:LT^)&E$NAF&+)%)6H2R'S=5;>2:F8Z:(L MN@7E --D//(AJP1B;N,.?,=> M
ZKJ*EW4+>689,8%TLW.Q:9(.W,'CGY[1Y'NP8,"E=W=" *0OUNDBSF"F MN;&\0<):5FF9L%6;-6FDEH6XDW&E7(§ OB6KW8G[8O-#BVU!*\UGUHC]? 7 MO0/ZM7L<46Z*5HI*LC-1 .9E19O
IN\|LOBZ+?G:NMQ (*R!>;'{8]4T! U? M RR*$S!,GVL$+2B8V&_F*DU2),ZM>T\U-&I9Y?9*7U0DBX=5M23$&%V] P$" M"QN- (&,!(Y[)*"A&%Z8+B11$HHB*W!5BTPJI<4G+I9Q6@D@!+
T.DUB!!L< MRH3T2?*3K!:IDH8>J6?(_L!0I-6>\\'1FK7AZ7Y/^[Q?G]QCR"J*6%<=Z']' M%2@H5O!Z+,I"5HRX6T!8P+]A&^BQJC0DSILX.!FMI!6(
MQ$4!E5>J9\X>HZ1Y6JHDE56T>8M66HAP3!0<\BZ82PM$V"RC9,;! 27: M$]!XL@-YQ(X<++>^MR4?:$?3^V@ORPRE'+$Q9-L5Y,/M,9^G-JTURKP40\XH M9_6EU&S$>=G0R29,6A4'/3S%H
"\^UT0!HP3WFJOT M"^2SAA<&]X8^*T/);3;@XO!.ZY@")C@B))]AZB0]%1V8XYN;2MX0.(LFG^L[M#N@-I3_LT#*FY2OPA)&3%M(\EPAFM81%*,E(OGLH/$ETDH(+U4 O*H?Y<.Z#
MQP/>B:1HF%*0GM_Q>9>4R)V^11:RJN%<(DOSM(ZUA[CBJJG(TK55AP1J(3@R M"5<=U(KH<&O-K8.?-?HF5JUR^>S B49C9S2>6FZY:N!).*X3MDN8_5QF-6\87S>HQA987<(/=>W42RI_
M4P.E(KBM4D)G5I)@I2F4_)%CBB5=6\%=*G90C@$*90IT,B?MY7$R=!EXP:(J M\RXW#+F?RT4.QB589/FU|&1:M9<666(!.Z;JJ[3D):5>@6. 0BVJ=$[!;XY MU%:.,/2>^8"2AZZ@E
\RV'BS:2R!4KVK[A#K B@W]&SDSV'B,@-RS\=COPM#Q M)W9O:$=G%[6W<9JA0-\W1]O!E7SA0[BI)E>8&9*NM%.?P=+@Y3*G3"5C?MJ MK*Z1;&BW98(I<&3R^.A-ZWV_<;\KD[,+N
C:= '*9O(KSN0[U^WGZP)E((RT M$+]2*CZZC#,259'C@NZNJN$]4_O9Y[X7LO44D#@=/HD-2O5!&\ MRRJQY?#9G%4):*IEH73G0/P6B@/0]U#L3.2H)U.3LKX7@>NW*[!%;"0;(M;T
M$<-8V).@H+KAOR+ R)UL"3!VQU\I #GMQOI);/R#8^?95L'*%MXNY)*OE] 3 M!BE^XK-96F78.9 _Z MJ@9192Y%[U!3N>\ U13PX-UW0]L]OC2EEV8+UWXDK7"D'Q3DG=KN;=*&37NC M+&
NLQB*N%Z@#R0K\?4SLIGNPA.96=$]FE-05F9E:B]>01*4+Z8:I-Z7K$D* MS>0G/ERSCQZ]R;M14EM6;K>WEE%C&>OL73G>S1%HR.-/GO3U#9[. 9]9NBW)
MBCS9V06@*DO/&*RKK/@#>0<]KT$HE*O=>9<>X9:/ M4S3?&G^1E."3NG^N-5%EHID!BM"1U65%@R)"5GSTCH-??WPNWA#(^BM"_Y>+??4./TV3Y)
MS;CK5+PYOT">FLUXQ.C[3Q#?/1___!#+8Z^_/.FH]%!'!"8S=QJ(1V+LN^,) M/B=3=Q3BTVXVUX_>[@L0/5#JEZ_C*3=_^29D M:44/0C@+FU%_SWYFC1I4&KHV98/V!MTWYVNCL7:D_VXG4-
=63Y3S^I,/ZFUY M3FL'D3U"K;7V9?3^!.R!-JP__^^PVC9D]_97W.F(E^1:O9QZA;OYT=;1+]W8 MQ=G3107.!(UZ,/91 4SQH?[)ZHEQVA,1J[H\@V(R=B M2NV%-\;ZQ$7,V!A?
S\RB1PO&G$=/0[^HAXDV"E+ _:Z$WVI4>Q6]A?<>V'^D]^KZZJI[FO? "HZ^@-3:#KI?WH W3[!N6<* M[?]?3:&__1 ZFB'PH_8C4:(L OI[4_\K)\^#Y\Z;LIL=V5&A+#&QN-&XO(ORK]
M9$*D8Z>R%GI;%'] 2[71%*(#.#)51E=NF?4']U,U@A/-?BW&VGIN9S]^+(I; MT$&N.2^:[>1@HEPL&HH.M>G]">7*1$=VFBTN[D\0^U*C<_APRRRL$@9.,,//Z M++,!W?5?C!-]*0"!&4)1VU*
<$P!Y7H9]-; M%EAVK>6VDG?CUMCJS\SLIR=8NCD_=^.?0 M3&=K]M"+&VUYW1_/6-U]V22QU>*?T87#M%T'#LM[M#+=67GHGKT-NN]Y]"2D M:Z;]&2IPG]KUL3L)>A>P'E+7_<4[#C;V(S>
<]&X?N9''/?XX&*R&]/,+[MT> M!!P: MA/+L+,"WTO^]XX[,%0!L7VE=/M0=U>#T;"7#:%?F?TA&,=.DS@1)W^ M 9"*#G7B9N2LJ1",*5!;$B]V(1*;OZ*3NKH+9)XC,#)R$R0^:-RS<.!T70J M1@
+7'L+WT>CY8@;/ M]X_><>)X4!WT"KTZ)E4Z$Q'8VJ6T N&U$;"G(^R>-\KCN>]-U)S5"\WBVE M&C3Y^N74=K5]M?="O]':W:[?"_XYKI#2%6K");9ZIF1TK%\XLS_J&PO=V]R:W-
H965TB!31;UILMUS:0I"TV8 V")%T_#/M 2V>+B$1J)!4G_WY'RI:=PG&'H1\2 MD]3=<\^`]\'CSK50/ND0T\%170B^\TIAF-AKIO,2:Z;%L4-"7M50U,[15FY%N M%++'*=75* R"=%0S+KSEW)W=J.58
EAA;FO("O^'OS*]\H"$8U_=IA>;|(]'J_WZ)^=[^3+BFF\DM4W M7IARX4T]*'#-VLK]K% MX4AA&KRB$.X40L>[,^18?F2&+>=*;D%9)4*S"^>]TR9R7-BDW!E%7SGIF>4U MY?T/J34TJ."N9
KAPAC%5ZUAJPK]2+B2=4WDNS.R?RAE5:#2\Y$AVQ9AE._L M7'9VPE?L9/!%"E-J^"0*+%[JCXAS3SS<$[\.SP+>83.$*/ A#.+X#%[4!R)R M>-$K>)^8$EQL--ST@?CK8]6-
HKKY^Y2_'5Q\&L[>I9EN6(X+CRZ+1O6(WO+M MFW$:?#A#-N[)QN?0?V+6SMHY[<6U- C9$/X?";ADFN<@2+G:*VNGS#7DLFY: M@P6LGJ'@C[R@C(I\2!.'^Q^ZVX;%K^R1U34/$"T]8J0Y-
IB6)L.4P/U(6V8 M<$#4PIPRF>2R&,*%=ELBV3#Q3"VFDQ53*D0@+ M:B]6D9;RT"5 M-:!9WY>C$Z1%^.*AP3:I41C2UJ&ZNZ39&-FZ66$E#DXE;EC0* MHK(^]TMJ;1V&VN@'KJ7EQ5ZGIT?>@CWI96]
MJ,&Z>+GH:S2.OBF=4A=9YCHAX72T+,TSAMEWV=Q'ICB;+V-*VK9,A 5\QP5] MD;TF*IH'?,HI3GMD41S9*:AQO9\-[EV,C]L$7-M@'Y\,7'AM:*%?#:[;FHK M2#4;7.^]^"_+>)8W^;D-C@(PI);;BS
M]NWI*MP7W?J%/4@"/XH#/PTBB*=^.B&;<09QYF=D/DT2>YI$]#>>'#SX81XL MKV 8ACN*M)STRTG6+S,K\+)"&KK!PG!65<]=_NEAI(+4K2U^2LWQI=&8MXH; M3FYMD'&!#Q4V<&T+9-.
#UNFJ+YC/YE&?CBE M]F3/(&C+!C<(CT3/+CM'1ZT\78>-F'M+6V&Z M0:_[<>HBVYZ.(AW,|@7IC9<:

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

<%*UY"=2. M$%4[0HUM7.R9!2%[#'FQCTNUJ:.B[@_#T\54U\<'|_A+=?K>DCTQK0E-:T%I M=D5MJFDVF&B;H>IF':.T29,7CFO M%OWO*L/|^%P4ZCI!.0:49D)I%I1F0VD.E..B;$U5USX6G?
[LN2C4^X+2#"G_MA-(L*,V&TAPHS471FI=_[7U1]4^WEDD8EBNH+T&V7B=AOJ58D&WL\Y1LCG7L M4#L+2C-H^]=I206DVE.9 :2Z*UA1K{5}1M4OUL?ELVY729L9/=QK
MLE17HK<>3TQK0M-:'6DGBWPOU^%T%NHY=66=T\5<.YS-MLO-IXTY?E,AM4]$ MU5Y)GX7T"M78; F^N3FAD-%1; KN<|]%6AV3I6Y>[ZX$ZKA :2Z*UA1*[;A0 MM>/2V#)W5OWHH5,ET-
\R06D&;1$S=$SIHB4]Z.|QH#0;2G.@-!=%;SYIIS9Z MQF]CY1GUMG>KXQMJ$THR*INX3H2DM*,$TAPHS4712F$;.|QZ@%O%T53Q!3QPG^RM)5$ L2\B>9
M:G0^DWU96CZAKWR3)9OB\6V/298E42%RS9F\.Y,GV#TG\?[_M4$L#!!0 (Z#9UE?'*#*@4 #@:. 9 >&PO=V]R:W-H965T=?1"V-M $|LBTH"PK]??38V&$&[%^ERY% M%"9DQ !?
QC%FFP&)Z+I7@[7MQ&.XFPLU8?6["SPC8R*>%B,F1U:N)0ACDO"0 M)H"1::]V!V^`R%4">L5S2-9\YQHH*!.*7]3@(>C5;.41B8@OE HL?U9D2*)(
M:9)^ ,R4UG*;2G#W>]OJBP8OP4P5);. 0@#,> 5.C40D"E>1N*1KO\B&2#M MH$\CKO^#=:,6K@% R06_V'101PFZ2]^S0*Q(R'!5@N@3 =*^!D HX&FGJF M8=UC@?M=1M>
J=52F[K0L='2$DV8]#2.!9-W0RDG^I] +D.O 0^)3O(54#"* M<,+|#1BG>05T"H8T7N!D\;"^B @VT+' T[%7XE^O"<"A]$G*?,TO@II^@-3SWPE29B MSL'G)"!!A?S0+ ^108$EPY;'#FUC-T!&C6.R.
#'K@-DHV:50V;Q>^)+<.C% M'8,[3IY*1^MSWG)'1?Q&[>E-ITS6&DY3Q1A.9D06GP 3F<;==2.\T=-W:\R"-M>I9;F:QO2\&%$%.8S, _CS2*@"P:M>;?JL2E?C6K_5(T2U?8)_T:O*DX82M
M2*W _^V^P9?i1%;0+*=L+!83,/8=.DO?_W,IX0IO:\#E+E+DTUN%]#.B17_:;7 ML;%G=ZW5+@ZCI3-QN#D.lR0<=?"GW *B$H[@*?M4M-LE,$9S9X)IY6!;)X*1 M>W%*0D$"R\?RX{JBRO-@T#I
=H.@#5VO!,YH_DQP[1Q<^T1PGU\)\T 9C!:3 MS4Y5:16V]B$VZ#4A+&,S6C\36R?'UOGE:NH<5!/;<5"GC*.B7:GJ]EST\ MDUP$SX3+?07DT0=(F@@\B0C 7*\A"T&T@:'4'W@'KCJPY=ANIP3)Z-
F9J8%V-MT??M$S?>'O2%I%ER("A8R>F3\&>&W\^IV<-S([##?:.1 7)P9+\<&/OE#TT7 MY8*[%6&2_N95#$8L]$EEF. EN^:.EM.W'$A6O1.;=M,5 Z"RIE]I/F>]H;-,!8VF4T9X#;8#"
[H#S7SG781'=MK.S!Y: M:#>@6X9[#5($"U8$S;3H7:C'}=[.BCJ^"K0-5.9Z#G%DH07$.@0+?@3-!.EB'3T"[H_1 /JA6-^)&HEUGJ.78HG_X9JL421^ [87%E)"]$RK(@7X/B
MH8+B(3/%^\58O*.]#38$LRI2/SQ.$C1!G+Z004T0X TW@2Y8'3(RG0(TSD#[M.U"%A%K7]75XOE2&P&RK=120+'.;7(&BH(&CH.()V;%G2TZ@R)F9#IFUO#3J' M"CJ'S'1N6P4/$GB8\- 'SSA:5N?
=.>AJ+??@ :YBE>N!$[J ;&"E*$S*7O# MS_HEGDU1Q=NKEE.F:68'STU40=.0F;8=%X"L7YZ$WCTJK1$J07R_I12L1TH_@'(Z#9UE[8)+4Z M404 HH_9 >&PO=V]R:W-
H965TUYERCMSA*U-5@K??FTG'48LUCIL[%AB?FG960 M,=/F4CX[:B,Y6V9!<>00U_6=F(7)8#;.VN[E,"JV.@H3?B^1VL8QD_L,'HG= MU0 /#@T/X?:.IPW.;+IAS_R1ZS\W]])<.25E&<8\4:%
(D.2K]\$UQJ3$3P.R.M'M]"OE-'KU$ZE2M5B\H!M3CB6.B]BL4<6R*G]EH43?6 +3E MZ%J9L;9)6Q7Z$G# PDC],G6T23$=R%D4Z=SDZ9"G=#OTJQ*]5H@F2[ZTQ ?M M\1$,(K3VP'"8[1D>V4K
M4!5]6M*5,RE*.NI7B543F@029.[&M"]V00E7(83C?#}+`B >9>SZ?"]WHIL ML+6?C_UQO\%2]ZFGU_JY!?]IQ"]E[.5Y!R%B5G 7&DDF>8V#5M!?37T;=]X M0W=XHF%#/S(YT1 HN9J&XU+#
<:N&=^PMC+>Q3;/6P+Z;0<("?!@%@M74GY3J M3SYY1YU %A$2%D#"*!"L5L2+LH@78#MJ*ZEO.=K3.FR"7M/>%T F0[LE0T;6 M;&JJ8[>R+B[$]ME.Z;LY*"T I=&"UK;YUZ4^,;+R)Q-
Z(GSOQ^ZU^@_.QUVK;<^<=#@X^"T@^% MUH6L/"T&,;788C#Q^<5XA.OF;&[KZ)].WHF+"KH2:0=B?>Z5\5@AA3;S>%H M>#K|AG[>J6'O"*0=@/795TX2OV,EPZ3)2K9'lKZ-
@9!94!]%HMK4/E)_F& M$H.Z2E!:.$JC4+1Z*2M7B>%L93NJ=U':$QL=OETMOEXUKLYO0]B@F=&.F8T/ MB=GRJo\.5+ E-N(VVRE]*P%*"T!IE-C=YF3DV3<24KE-N8VVTF]Y09UFZ T
M2NQNTQLV/+60RFV2=]OFOF]-U&VVTWN7_1M@M(H%*U>]\IMDL]VFP34;8+2 M E :A;+52UFY30+G-M!!C=[?A.>=$7PFA#Q?I .7Q NO]E_4$L#!!0 (Z#9UD?Y&,_#P0 $H5 9 >&PO=V]R:W-
H965T MS'M MA9L8$C6QF6V@ ?,73M*0!#=J[SQ5E4IBSOG9Y_Q/#K$G1T+O6((0! =YAMG4 M2#C?79DFBQ*40W9)=@B+;S:$YI"+6[HUV8XB&!=.>68ZEN6;.4RQ.9L48RLZ MFY |SU*.5A2P?
9Y#^K! &3E,#=W*+A)MPF7 ^9LLH.;M$;\VVY%Q9U94^(T M1YBE! .*E-C;E^%MBL="HM_4W1DC6L@0[DEY$[>7,=3PY(K0AF*N$1 \7% M2Y1EDB36\;N*&O63(U1@:(T0;N.WY#CI]1 M%=!
\B*2L>(_.%:VE@&B/>.DKYS%"O(4EY_POD|$PT%PU.Y.Y>!T';PG'-S* MP7WN#%[EX#UWAD'E4(1NEK$7B0L@A[.))4=];6@R8LB^X6WR%>*9:&L.17? MIL*/S\)?^Y0_@&L<(2PE
ZL,8@8NP+JL'$ V8)U BBX60HX8+$DN:I3!0N7P M7EXCL'@*_>X5/YM@#A,. 9..+ZM _#VS3OP!J08?$W(GD$@\< MR_$4ZUD^W!U5A? fLX?_>_96,MRZA-
R"YS[%D^4!%.4QIQ3B+1)MA9YUZCB7EH)OW=K-V|Q_J=7N.>[W!=]AM-@HK0[6ZW>;< MRK8MO[L14IB-G4%W(V0VSH9R1+?%H1P3<>TQ+ ?X)6A\)#&ULK99M;^)&$,> RLBMJE9*\+.!
M%) @:N;M&NK0HJ+D7I[{8V -8L;W<[AHNU7WXSJZ-H<4XC2YOL'29F?G]QSN[-M,]IQ\237B]^YEDAQ]9;[<99GPWMEQK/W&?KM9*3]B3T8:M M<('JS\U0$"EV-KZE[-7%\;F!4/*>
[DT3MH*8^`N)2*Y[4Q$>1I43W9USH11P:^=\; MJPT\PUT%,I0W3+')2/ ="+V:O.D7(]58$UQ:Z*^R4(+^3\4&L) M[RAF\F]lFZ0W^KV]_IG7Z7"!FQ[XSH5&#^!'L"N)LGYT1/";#/LF@G\N@DG9
MC'9. M<\lW*2Se$J[1"L6"%M<06S9SA> V?/9GJ$OWY([F$6X6Y;$U9%3]H MCZ_+^DIN6(QCB^I6HMBB:?G!!S=R?NU0%$3]@B[OD]!+_26!+RM^>0%_E$HJ M5B1HL;J &XS-IP;?
-2GVX5MK9BLA5:C0A-+'R7;B]3W7C]R1O6UA#!O&\)6, M'RCS2G:RA*T++/U3EL' JYRHG670L R^9U-1S:IZ5^T+MPMR< (9A/W M"\%9S:'>W1EN6]W%YD)+^"[MI_A1+PS.X'L'?.^M9M2?
('8.R7N]\+!&>+##>9V7B'?O=5,"_8%*?!)9@][MD?@'!Q^1<[0&PO=V]R:W-H965T>2;SS,3V3(^,OXJ,$(F^%7DI9E8F936Q;;'-2(%(ZM("4]V MC!=8PI3O,5%Q@E-
M5.2VYSB176!:6O.I?GOF\RFK94Y+\LRIJL"\|\6)&?' MF>5:IX5O=+))M6#/IO7>DS61+]4SAYG=L:2T{*6@K$2<[&:6DSM9O0JO 7]0 M@9 (_9P&L-O*%'<.' ;PW6ST$K4%PJX>P-="AVTWL6K@$
M2SR?7F?$(EI+CZ OY=U@MZ_^X#>(1L)O2 0+=%+2:7X"(LP_CUC MM0"O8FI+4$;%9V!;%1:."MX%%7STF94R$VA5IB0UV"?7[>,K]C9DI$N+=TK+ MPKM*N";5(_*=C\ASO.#P/LO:S7U3./_
-^^I?>S\3P^]L91\ M8LJL8QN8;=4V.Q@5WI*9!?NH(/Q K/F//[B1\)Y-UGN2)? MX!][WB1R]?GBP4>[;3Y;T?MH32EJV'/-K@ZNP_S!=9THMF9V'OO@FF_XX3DL M,<#\.(K<<]C*
N"+46$U(RV(8O5F-XSV]\)UER3[+5GTJUVS="3[@$&ZPMWLG0-ZPDT3TVO\YV^Z;P^8[ZG MJ4 YV8$KB #*FS?=3#.1K-+7]0V3 P (@H !X;"]W;W)K&ULM59K],P%/TK5[
02+!D>;49,:6V&P*)H6G5X+.,W#:6$CO8 M3CO^/=#.%OK("LV+ZWMW*M\SCUQ?$=:(>]5#J#)0UEP.79RK:L+UU5I#B55 M9Z("CD]60I94XU2N755)H)E-*@O7[IS8+2GCSF1DUVID9"1J73 ..
Y*HNBRI_M_V#0FS'SKGSN'#+UKDV"^YD5-$U+$#?53<29VZ'DK$2N&*"$PFKL3,]0Y@G M)MX& &"P53MC8I0LA;@WDZ_9V/$,(2@@U0:!XM\&YE 4!@AI_&HQG6Y+D[@[M?
D3_;+6CEB55,!?%3Y,I?.P,'9+!BM:%OA7;+]#JB0Q>*@IE?\FVC?4?,<7Y9M0BMR)(N<2B!3K25,UIHN"R!:D+DH M2RSX0HOT/A=%!E*1CV2![U-68X18D2G7+&-%;1PA"TAKR30#1:X>TJ+.(",K
M*4]#4R&J=0^3K]CDC*]W=WYW"9]R0KU'?&56U,C5*.)0==-6T*P1Y#\A*"'7 M@NL<-^>X\WZ^B\7[*N0_5FCFGP1<0'5& N\#\3T [.$S__TX 2=H#,LL'CA M$WBWD $>9.-
*O@&I&9FC$=X!5)BK97QJ;IN#6YD<..CB]HB"?'P\'[_A!1.:=W2V76Z^Y)$/-NU 536'LH&(%<@/.MY.V.\|C[U&?-"X'MZ8TZO=$K&14=&1!&P\ ?)@=&]<0-O^(A(O'ZCXHYX__B M"C\
J4:*C6=WG,E>KT[B/->K%P+;DSSH)]>R:M!CU>#T NG Z^.X\Z'41!' M3QRJ84=\>))X^VVV] B>*4EYOU4G89YKU0N![2E..L7)*UF5'%L01/$P/G#J M..SP/+D[UVT)Z5,[1]=J;W?#]9GV
U_&PO=V]R:W-H965TQ@ M.\WR[_%'&KI2MUR2&7O>FS>3F22#5 ^Z 3#HL>5"[[@QIEL1HHL&6JIGL@-A M;RJI6FJLJV]B.P6T]*"6DSB*KDE+FT(M@I:)L*; M/HYl. '$\3. > 3$7G=
(Y%7>4D.S1,D!*1=MV9SA2_5H*X%)U'V1ME;9G$F MVT-M6VS0G0@2\'7]+5J7)7.FY4\N7MV"H8SKUPDQ-K=C(,689Q/RQ,_D^3#N M!3"-1I]$"}>53/+&:,)^'Q4?@FODBXAVZ&YM$;%$?O
HUE7."=3PV9>]IY?QJR M@TXJPT2-?]YS;90=GU_GR@YLB_L;J56NJ,%4[IL-CNC 9U)RI?'%U'7V\H'4Q M:5U<8L^>]FT."LEJ5$MS#L=6Z'-B]W2TIEU/61Q0@ZG"LC)*+6@:K\P&A6R
M%R9,U70Z[>0ZC.*_\+#0]U353&C$H;+0:/;.YE5A28)C9.<'.Y?&CKDW&_M? M >4'[*TEI3DZ+L'T\K^ E!+ P04 " .@V=93:OID"$& M)0 &0 M 'AL+W=OS9G>5XQJ?OXKR6=#=->L
D^WC^?P:.O%*S%TJ MV9G_V8KN;V>A\!.T8NOTD,M;.O G:P5Y%=^2YZ+^BQY:+)Z@4Y%(OFN#U1WL MLJ+YGSZV W$2H'C@ -H&4#W /1/@M '.B*;HJ>1=HT90-
MXFOT9<|*=;C8H%LFU.@/D&H+)>ER]\[M>2G3NYRA(^/KF,DTR\4;Q?=M$;/7 MK]Z@5R@KT-]:?A!IL1)74ZD45/|/<+3USMP[ZS NY%2@I5FP%Q.?F M^.@0/U4CUPT?/0[?
#342+MC^'7+P6T0Q=8'[F3_W('D_ K5DY^^^F PG*Z6 MG)K/.< WR^Y9<6!06IM %PZL)L +L4^7[*JB9CO!RGLVF?W^& 'Q'|"8VB2+ M.9(EEL@&H^]VH^^:V$VCWP3Z=6"U<#6]/QU6"(5Q-
$3%8Y/@&@. M40F H@[V.M1 H== "5E/2AO.50(+GT QPX]DL-9MDL4VRQ!+9(|%^ MEPC?6&K/2T3#X9W4@$,]K!7=&&$3\0*O,> R*L!'|]0> R+F*'$]A@;'B/I9< M'+0O^3]3D.3 9JW9)
(MMDB66R 8I"+L4A.9:>RH%X2CMQ(^P/K_((12;56: M@SC')403#>&&G=IL8A7\]IF0M4'.BB7?@>MURS$H5]=S M=2QI4"R%4NP172T$/ M. 1S/$QTO0#,Q2>6:"BX=\#$;/&:NE:-
T8K=5.*K! J0B6V5;U"[,IH-?8%\ M&A(#D L2^,HG.S(-]?:>DYA-YQ>Y965,R>AUF^4W;U'!8+TNL-SK@L>8B_%S M#("HIPL&0.ZY)[@WH<1HK9H4WS'5^K*C<)D^PO-U2S74@B,\2C*$HY%NT6.(
MYT2N/Y}^)SKGSN'#+UKDV"^YD5-$U+$#?53<29VZ'DK$2N&*"$PFKL3,]0Y@G M)MX& &"P53MC8I0LA;@WDZ_9V/$,(2@@U0:!XM\&YE 4!@AI_&HQG6Y+D[@[!M?
[XK*SR19;94MLL0U?._8&FIH-]//2 M0<MEK.(13&NK."4 $.]>8(0/DA/E-]M+?-E/Q2(TZ-KONE=6>5+:;* MEMAB&R:B=_34[.B?3,386!.?!']]L)H .S#V-6[%Q#F>&?<+>W=/#6[M^:C\@9(?X-
QNCGQQP5E]I6V5+;'%-LQ!WV%0]V<]#C7V)B_.@4VVV"I;8HMM MF(.^Y-'FEL>4@W&G03S=N\Q!E+YVQ #*\7VL/^QCE$?<,YT[[3L;ZEOP-]1] M:V.5+:;*EMAB&Z;C;VVHT;8_QW!V)/H;\#F
.@/=*<@$@T=C=C%*71N=KK M>P@:_IJL;8@+ZXZFVRQ5;;$%MLP$7V30\UOX9],1#3Z73/0WZ7. 5 T^AD5 M !$_\/5Z&Z-H./(UTV//W:LW-3?W0BTY(=*K_>=T>[;WO>UU^T:,=OR.6< M
.=CO7U)AJ0371+/RHWSA W)P]G[GXM<7[_S[/WDP\E) M\!^O1L_JX!SXCM%KPX0O0@"7!A 3#PZ3'R?.B;=.TAZCS(FW.\6;H7^1(R= MQ.!T@QJ<(N1>X""W3$OSZS(9#=)6V&>SO23U\!UCWP"
7HC'8 M>3PA8A14:Z;DC>E4@ZO@,\BKV_>KPCB<*;KJ=*](2ZAN)LDD5PE339H.68=& M\%2L*/X; YWG1<^@%KGF6DDG,YR22L/:T;=,+\)3)L0=/-X_TBWM9;JQ8]5^ MR:9I# 5 *V,
[H+^I9K4W92]?I.L5_#'7GQ=F.K+J0V&S6\52OJSZR[0Q@*EW M<':5:%&+U2?"9S)B=_,$)1P.ZYGGS7/$GDPU*96H"3!'OD2G-IYN1?XH6]VRI MU^6T3'/W2/T_&_7>
<8D4U1LFC:U_Y97^<6.PlYK6.Z^578-.SW6[^RW:O+] M&$0QxV#R*&]R?PPFXR.PV7NU:\W#389O87B=]3M0F%Y<)6[)D7'25.%(U/=.P6>L+"+O(376Y$8QC.3<"
M&)8'AX[0PQM8MBN#'K89Y P:6!S+]W5KCNXU7R/XZP/9T7X5@,\4K$9LIOM: MN-< &"LWFTL#S"P7<.>8!R)8PR!6G37:!0AJQ/! MQ[T_V%,2AG'L1@<]S.PA##(&G$4@_NO(_\]7O*,_l[.?H 4$L#
M!!0 (Z#9UF7BKL

-8?20$3;8T.P6BP^0"X99K>]9!:G MD-+[1^ON-]:>L^^U-GZ5[$,XG,_GOMK+ MFOO?[4$:V+.UKN8!-MUN[@]:C Z2 _62.D\5(P^:.M5@(X!/O(-3>59!%DAD!F)X3\.XL@+ 3R/(
H$L3@@YBN02@5R>$C*#/(.\0R#-:R#5_8@^>K:7K?MX.EDOE M*VU]XV2$^ 9!?$.+>&6\$M*O6\<%)$%VX1PWN_9F##XB?(L0QJ6^TO6!FZ^MA@3C7[*/_S10 MWL1LF#]28H'T-%!L57 <%
(=L#3??*'*8.%)B<]Q O]?6>W: W%SN.22]BQ"< MVC10Z.K8'2DFCY38'J7<==7KD9(5LT9*K TT)8^]F!031TILCB,IF;V^;:IS M:?#]FF#DR8G,
<2\W/G#$F9I",V"!MAAY']QL,A4Y,R&Y1\,LPR&;%]=E9)M+W9"@QQ63$BL'+_]'B M Z:;C%@W71Y_>)G'V8Q="*%&,X .IQ2RN;G,_ FI=# CK==C M3$PW^8DF+,^7/<;$!)03"PB-
YGAI#%T:(O80CADOZ>28@G)B!74UQC"NK>%Z MG#YC3$O!.;&"GC%+Z$HTNDN:U]L9D&Z&I)IC(DI*"=6T$O.;lU!9L>"06$? M%Y8Y9J& +.3$+Y?1K9<HQ1R.]P"Q4G&25;< .1!R"Q-H M<0-
_X.&]XKI:.]9^](]9BF6[++IMM/X$;7^9:\O%\(;$\';'AW\!4$L#!!0 M (Z#9UFAE^J4R0$ * > : >&PO7W)E;',O=V]R:V)O,VLN>&UL M+G)E;/'V;ENPD 4A>%707X AKN8+
()4:=)&O(%AD4LMCP3!=<"_IRK!1I MC4\O0O+&!*#.H:.B#.B17_;;7 ML;%G=ZW5+@ZCI3-QN#D.lR0<=?"GW *B$H[@*?M4M-LE,$9S9X)IY6!;)X*1 M>W%*0D$"R\?RX{JBRO-@T#I
=H.@#5VO!,YH_DQP[1Q<^T1PGU\)\T 9C!:3 MS4Y5:16V]B$VZ#4A+&,S6C\36R?'UOGE:NH<5!/;<5"GC*.B7:GJ]EST\ MDUP$SX3+?07DT0=(F@@\B0C 7*\A"T&T@:'4'W@'KCJPY=ANIP3)Z-
F9J8%V-MT??M$S?>'O2%I%ER("A8R>F3\&>&W\^IV<-S([##?:.1 7)P9+\<&/OE#TT7 MY8*[%6&2_N95#$8L]$EEF. EN^:.EM.W'$A6O1.;=M,5 Z"RIE]I/F>]H;-,!8VF4T9X#;8#"
[H#S7SG781'=MK.S!Y: M:#>@6X9[#5($"U8$S;3H7:C'}=[.BCJ^"K0-5.9Z#G%DH07$.@0+?@3-!.EB'3T"[H_1 /JA6-^)&HEUGJ.78HG_X9JL421^ [87%E)"]$RK(@7X/B
MH8+B(3/%^\58O*.]#38$LRI2/SQ.$C1!G+Z004T0X TW@2Y8'3(RG0(TSD#[M.U"%A%K7]75XOE2&P&RK=120+'.;7(&BH(&CH.()V;%G2TZ@R)F9#IFUO#3J' M"CJ'S'1N6P4/$GB8\- 'SSA:5N?
=.>AJ+??@ :YBE>N!$[J ;&"E*$S*7O# MS_HEGDU1Q=NKEE.F:68'STU40=.0F;8=%X"L7YZ$WCTJK1$J07R_I12L1TH_@'(Z#9UE[8)+4Z M404 HH_9 >&PO=V]R:W-
H965TUYERCMSA*U-5@K??FTG'48LUCIL[%AB?FG960 M,=/F4CX[:B,Y6V9!<>00U_6=F(7)8#;.VN[E,"JV.@H3?B^1VL8QD_L,'HG= MU0 /#@T/X?:.IPW.;+IAS_R1ZS\W]])<.25E&<8\4:%
(D.2K]\$UQJ3$3P.R.M'M]"OE-'KU$ZE2M5B\H!M3CB6.B]BL4<6R*G]EH43?6 +3E MZ%J9L;9)6Q7Z$G# PDC],G6T23$=R%D4Z=SDZ9"G=#OTJQ*]5H@F2[ZTQ ?M M\1$,(K3VP'"8[1D>V4K
M4!5]6M*5,RE*.NI7B543F@029.[&M"]V00E7(83C?#}+`B >9>SZ?"]WHIL ML+6?C_UQO\%2]ZFGU_JY!?]IQ"]E[.5Y!R%B5G 7&DDF>8V#5M!?37T;=]X M0W=XHF%#/S(YT1 HN9J&XU+#
<:N&=^PMC+>Q3;/6P+Z;0<("?!@%@M74GY3J M3SYY1YU %A$2%D#"*!"L5L2+LH@78#MJ*ZEO.=K3.FR"7M/>%T F0[LE0T;6 M;&JJ8[>R+B[$]ME.Z;LY*"T I=&"UK;YUZ4^,;+R)Q-
Z(GSOQ^ZU^@_.QUVK;<^<=#@X^"T@^% MUH6L/"T&,;788C#Q^<5XA.OF;&[KZ)].WHF+"KH2:0=B?>Z5\5@AA3;S>%H M>#K|AG[>J6'O"*0=@/795TX2OV,EPZ3)2K9'lKZ-
@9!94!]%HMK4/E)_F& M$H.Z2E!:.$JC4+1Z*2M7B>%L93NJ=U':$QL=OETMOEXUKLYO0]B@F=&.F8T/ MB=GRJo\.5+ E-N(VVRE]*P%*"T!IE-C=YF3DV3<24KE-N8VVTF]Y09UFZ T
M2NQNTQLV/+60RFV2=]OFOF]-U&VVTWN7_1M@M(H%*U>]\IMDL]VFP34;8+2 M E :A;+52UFY30+G-M!!C=[?A.>=$7PFA#Q?I .7Q NO]E_4$L#!!0 (Z#9UD?Y&,_#P0 $H5 9 >&PO=V]R:W-
H965T MS'M MA9L8$C6QF6V@ ?,73M*0!#=J[SQ5E4IBSOG9Y_Q/#K$G1T+O6((0! =YAMG4 M2#C?79DFBQ*40W9)=@B+;S:$YI"+6[HUV8XB&!=.>68ZEN6;.4RQ.9L48RLZ MFY |SU*.5A2P?
9Y#^K! &3E,#=W*+A)MPF7 ^9LLH.;M$;\VVY%Q9U94^(T M1YBE! .*E-C;E^%MBL="HM_4W1DC6L@0[DEY$[>7,=3PY(K0AF*N$1 \7% M2Y1EDB36\;N*&O63(U1@:(T0;N.WY#CI]1 M%=!
\B*2L>(_.%:VE@&B/>.DKYS%"O(4EY_POD|$PT%PU.Y.Y>!T';PG'-S* MP7WN#%[EX#UWAD'E4(1NEK$7B0L@A[.))4=];6@R8LB^X6WR%>*9:&L.17? MIL*/S\)?^Y0_@&L<(2PE
ZL,8@8NP+JL'$ V8)U BBX60HX8+$DN:I3!0N7P M7EXCL'@*_>X5/YM@#A,. 9..+ZM _#VS3OP!J08?$W(GD$@\< MR_$4ZUD^W!U5A? fLX?_>_96,MRZA-
R"YS[%D^4!%.4QIQ3B+1)MA9YUZCB7EH)OW=K-V|Q_J=7N.>[W!=]AM-@HK0[6ZW>;< MRK8MO[L14IB-G4%W(V0VSH9R1+?%H1P3<>TQ+ ?X)6A\)#&ULK99M;^)&$,> RLBMJE9*\+.!
M%) @:N;M&NK0HJ+D7I[{8V -8L;W<[AHNU7WXSJZ-H<4XC2YOL'29F?G]QSN[-M,]IQ\237B]^YEDAQ]9;[<99GPWMEQK/W&?KM9*3]B3T8:M M<('JS\U0$"EV-KZE[-7%\;F!4/*>
[DT3MH*8^`N)2*Y[4Q$>1I43W9USH11P:^=\; MJPT\PUT%,I0W3+')2/ ="+V:O.D7(]58$UQ:Z*^R4(+^3\4&L) M[RAF\F]lFZ0W^KV]_IG7Z7"!FQ[XSH5&#^!'L"N)LGYT1/";#/LF@G\N@DG9
MC'9. M<\lW*2Se$J[1"L6"%M<06S9SA> V?/9GJ$OWY([F$6X6Y;$U9%3]H MCZ_+^DIN6(QCB^I6HMBB:?G!!S=R?NU0%$3]@B[OD]!+_26!+RM^>0%_E$HJ M5B1HL;J &XS-IP;?
-2GVX5MK9BLA5:C0A-+'R7;B]3W7C]R1O6UA#!O&\)6, M'RCS2G:RA*T++/U3EL' JYRHG670L R^9U-1S:IZ5^T+MPMR< (9A/W M"\%9S:'>W1EN6]W%YD)+^"[MI_A1+PS.X'L'?.^M9M2?
('8.R7N]\+!&>+##>9V7B'?O=5,"_8%*?!)9@][MD?@'!Q^1<[0&PO=V]R:W-H965T>2;SS,3V3(^,OXJ,$(F^%7DI9E8F936Q;;'-2(%(ZM("4]V MC!=8PI3O,5%Q@E-
M5.2VYSB176!:6O.I?GOF\RFK94Y+\LRIJL"\|\6)&?' MF>5:IX5O=+))M6#/IO7>DS61+]4SAYG=L:2T{*6@K$2<[&:6DSM9O0JO 7]0 M@9 (_9P&L-O*%'<.' ;PW6ST$K4%PJX>P-="AVTWL6K@$
M2SR?7F?$(EI+CZ OY=U@MZ_^X#>(1L)O2 0+=%+2:7X"(LP_CUC MM0"O8FI+4$;%9V!;%1:."MX%%7STF94R$VA5IB0UV"?7[>,K]C9DI$N+=TK+ MPKM*N";5(_*=C\ASO.#P/LO:S7U3./_
-^^I?>S\3P^]L91\ M8LJL8QN8;=4V.Q@5WI*9!?NH(/Q K/F//[B1\)Y-UGN2)? MX!][WB1R]?GBP4>[;3Y;T?MH32EJV'/-K@ZNP_S!=9THMF9V'OO@FF_XX3DL M,<#\.(K<<]C*
N"+46$U(RV(8O5F-XSV]\)UER3[+5GTJUVS="3[@$&ZPMWLG0-ZPDT3TVO\YV^Z;P^8[ZG MJ4 YV8$KB #*FS?=3#.1K-+7]0V3 P (@H !X;"]W;W)K&ULM59K],P%/TK5[
02+!D>;49,:6V&P*)H6G5X+.,W#:6$CO8 M3CO^/=#.%OK("LV+ZWMW*M\SCUQ?$=:(>]5#J#)0UEP.79RK:L+UU5I#B55 M9Z("CD]60I94XU2N755)H)E-*@O7[IS8+2GCSF1DUVID9"1J73 ..
Y*HNBRI_M_V#0FS'SKGSN'#+UKDV"^YD5-$U+$#?53<29VZ'DK$2N&*"$PFKL3,]0Y@G M)MX& &"P53MC8I0LA;@WDZ_9V/$,(2@@U0:!XM\&YE 4!@AI_&HQG6Y+D[@[!M?
D3_;+6CEB55,!?%3Y,I?.P,'9+!BM:%OA7;+]#JB0Q>*@IE?\FVC?4?,<7Y9M0BMR)(N<2B!3K25,UIHN"R!:D+DH M2RSX0HOT/A=%!E*1CV2![U-68X18D2G7+&-%;1PA"TAKR30#1:X>TJ+.(",K
M*4]#4R&J=0^3K]CDC*]W=WYW"9]R0KU'?&56U,C5*.)0==-6T*P1Y#\A*"'7 M@NL<-^>X\WZ^B\7[*N0_5FCFGP1<0'5& N\#\3T [.$S__TX 2=H#,LL'CA M$WBWD $>9.-
*O@&I&9FC$=X!5)BK97QJ;IN#6YD<..CB]HB"?'P\'[_A!1.:=W2V76Z^Y)$/-NU 536'LH&(%<@/.MY.V.\|C[U&?-"X'MZ8TZO=$K&14=&1!&P\ ?)@=&]<0-O^(A(O'ZCXHYX__B M"C\
J4:*C6=WG,E>KT[B/->K%P+;DSSH)]>R:M!CU>#T NG Z^.X\Z'41!' M3QRJ84=\>))X^VVV] B>*4EYOU4G89YKU0N![2E..L7)*UF5'%L01/$P/G#J M..SP/+D[UVT)Z5,[1]=J;W?#]9GV
U_&PO=V]R:W-H965TQ@ M.\WR[_%'&KI2MUR2&7O>FS>3F22#5 ^Z 3#HL>5"[[@QIEL1HHL&6JIGL@-A M;RJI6FJLJV]B.P6T]*"6DSB*KDE+FT(M@I:)L*; M/HYl. '$\3. > 3$7G=
(Y%7>4D.S1,D!*1=MV9SA2_5H*X%)U'V1ME;9G$F MVT-M6VS0G0@2\'7]+5J7)7.FY4\N7MV"H8SKUPDQ-K=C(,689Q/RQ,_D^3#N M!3"-1I]$"}>53/+&:,)^'Q4?@FODBXAVZ&YM$;%$?O
HUE7."=3PV9>]IY?QJR M@TXJPT2-?]YS;90=GU_GR@YLB_L;J56NJ,%4[IL-CNC 9U)RI?'%U'7V\H'4Q M:5U<8L^>]FT."LEJ5$MS#L=6Z'-B]W2TIEU/61Q0@ZG"LC)*+6@:K\P&A6R
M%R9,U70Z[>0ZC.*_\+#0]U353&C$H;+0:/;.YE5A28)C9.<'.Y?&CKDW&_M? M >4'[*TEI3DZ+L'T\K^ E!+ P04 " .@V=93:OID"$& M)0 &0 M 'AL+W=OS9G>5XQJ?OXKR6=#=->L
D^WC^?P:.O%*S%TJ MV9G_V8KN;V>A\!.T8NOTD,M;.O G:P5Y%=^2YZ+^BQY:+)Z@4Y%(OFN#U1WL MLJ+YGSZV W$2H'C@ -H&4#W /1/@M '.B*;HJ>1=HT90-
MXFOT9<|*=;C8H%LFU.@/D&H+)>ER]\[M>2G3NYRA(^/KF,DTR\4;Q?=M$;/7 MK]Z@5R@KT-]:?A!IL1)74ZD45/|/<+3USMP[ZS NY%2@I5FP%Q.?F M^.@0/U4CUPT?/0[?
#342+MC^'7+P6T0Q=8'[F3_W('D_ K5DY^^^F PG*Z6 MG)K/.< WR^Y9<6!06IM %PZL)L +L4^7[*JB9CO!RGLVF?W^& 'Q'|"8VB2+ M.9(EEL@&H^]VH^^:V$VCWP3Z=6"U<#6]/QU6"(5Q-
$3%8Y/@&@. M40F H@[V.M1 H== "5E/2AO.50(+GT QPX]DL-9MDL4VRQ!+9(|%^ MEPC?6&K/2T3#X9W4@$,]K!7=&&$3\0*O,> R*L!'|]0> R+F*'$]A@;'B/I9< M'+0O^3]3D.3 9JW9)
(MMDB66R 8I"+L4A.9:>RH%X2CMQ(^P/K_((12;56: M@SC')403#>&&G=IL8A7\]IF0M4'.BB7?@>MURS$H5]=S M=2QI4"R%4NP172T$/ M. 1S/$QTO0#,Q2>6:"BX=\#$;/&:NE:-
T8K=5.*K! J0B6V5;U"[,IH-?8%\ M&A(#D L2^,HG.S(-]?:>DYA-YQ>Y965,R>AUF^4W;U'!8+TNL-SK@L>8B_%S M#("HIPL&0.ZY)[@WH<1HK9H4WS'5^K*C<)D^PO-U2S74@B,\2C*$HY%NT6.(
MYT2N/Y}^)SKGSN'#+UKDV"^YD5-$U+$#?53<29VZ'DK$2N&*"$PFKL3,]0Y@G M)MX& &"P53MC8I0LA;@WDZ_9V/$,(2@@U0:!XM\&YE 4!@AI_&HQG6Y+D[@[!M?
[XK*SR19;94MLL0U?._8&FIH-]//2 M0<MEK.(13&NK."4 $.]>8(0/DA/E-]M+?-E/Q2(TZ-KONE=6>5+:;* MEMAB&R:B=_34[.B?3,386!.?!']]L)H .S#V-6[%Q#F>&?<+>W=/#6[M^:C\@9(?X-
QNCGQQP5E]I6V5+;'%-LQ!WV%0]V<]#C7V)B_.@4VVV"I;8HMM MF(.^Y-'FEL>4@W&G03S=N\Q!E+YVQ #*\7VL/^QCE$?<,YT[[3L;ZEOP-]1] M:V.5+:;*EMAB&Z;C;VVHT;8_QW!V)/H;\#F
.@/=*<@$@T=C=C%*71N=KK M>P@:_IJL;8@+ZXZFVRQ5;;$%MLP$7V30\UOX9],1#3Z73/0WZ7. 5 T^AD5 M !$_\/5Z&Z-H./(UTV//W:LW-3?W0BTY(=*K_>=T>[;WO>UU^T:,=OR.6< M
.=CO7U)AJ0371+/RHWSA W)P]G[GXM<7[_S[/WDP\E) M\!^O1L_JX!SXCM%KPX0O0@"7!A 3#PZ3'R?.B;=.TAZCS(FW.\6;H7^1(R= MQ

http://www.sightsciences.com/20240930/taxonomy/role/Role_DisclosureCompanyAndNatureOfBusiness Company and Nature of Business Notes 9 false false R10.htm 995465 - Disclosure - Summary of Significant Accounting Policies Sheet http://www.sightsciences.com/20240930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies Summary of Significant Accounting Policies Notes 10 false false R11.htm 995475 - Disclosure - Fair Value Measurements Sheet
http://www.sightsciences.com/20240930/taxonomy/role/Role_DisclosureFairValueMeasurements Fair Value Measurements Notes 11 false false R12.htm 995485 - Disclosure - Balance Sheet Components Sheet http://www.sightsciences.com/20240930/taxonomy/role/Role_DisclosureBalanceSheetComponents Balance Sheet Components Notes 12 false false R13.htm 995495 - Disclosure - Debt Sheet http://www.sightsciences.com/20240930/taxonomy/role/Role_DisclosureDebt Debt Notes 13 false false R14.htm 995505 - Disclosure - Commitments and Contingencies Sheet http://www.sightsciences.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingencies Commitments and Contingencies Notes 14 false false R15.htm 995515 - Disclosure - Stockholders' Equity Sheet http://www.sightsciences.com/20240930/taxonomy/role/DisclosureStockholdersEquity1 Stockholders' Equity Notes 15 false false R16.htm 995525 - Disclosure - Equity Incentive Plans Sheet http://www.sightsciences.com/20240930/taxonomy/role/DisclosureEquityIncentivePlans1 Equity Incentive Plans Notes 16 false false R17.htm 995535 - Disclosure - Net Loss per Share Attributable to Common Stockholders Sheet
http://www.sightsciences.com/20240930/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToCommonStockholders Net Loss per Share Attributable to Common Stockholders Notes 17 false false R18.htm 995555 - Disclosure - Segment Information Sheet http://www.sightsciences.com/20240930/taxonomy/role/Role_DisclosureSegmentInformation Segment Information Notes 18 false false R19.htm 995575 - Disclosure - Summary of Significant Accounting Policies (Policies) Sheet
http://www.sightsciences.com/20240930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies Summary of Significant Accounting Policies (Policies) Policies
http://www.sightsciences.com/20240930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies 19 false false R20.htm 995585 - Disclosure - Fair Value Measurements (Tables) Sheet http://www.sightsciences.com/20240930/taxonomy/role/Role_DisclosureFairValueMeasurementsTables Fair Value Measurements (Tables) Tables
http://www.sightsciences.com/20240930/taxonomy/role/Role_DisclosureFairValueMeasurements 20 false false R21.htm 995595 - Disclosure - Balance Sheet Components (Tables) Sheet
http://www.sightsciences.com/20240930/taxonomy/role/Role_DisclosureBalanceSheetComponentsTables Balance Sheet Components (Tables) Tables
http://www.sightsciences.com/20240930/taxonomy/role/Role_DisclosureBalanceSheetComponents 21 false false R22.htm 995605 - Disclosure - Debt (Tables) Sheet
http://www.sightsciences.com/20240930/taxonomy/role/Role_DisclosureDebtTables Debt (Tables) Tables http://www.sightsciences.com/20240930/taxonomy/role/Role_DisclosureDebt 22 false false R23.htm 995615 - Disclosure - Commitments and Contingencies (Tables) Sheet
http://www.sightsciences.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesTables Commitments and Contingencies (Tables) Tables
http://www.sightsciences.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingencies 23 false false R24.htm 995625 - Disclosure - Stockholders' Equity (Tables) Sheet
http://www.sightsciences.com/20240930/taxonomy/role/DisclosureStockholdersEquityTables Stockholders' Equity (Tables) Tables
http://www.sightsciences.com/20240930/taxonomy/role/DisclosureStockholdersEquity1 24 false false R25.htm 995635 - Disclosure - Equity Incentive Plans (Tables) Sheet
http://www.sightsciences.com/20240930/taxonomy/role/DisclosureEquityIncentivePlansTables Equity Incentive Plans (Tables) Tables
http://www.sightsciences.com/20240930/taxonomy/role/DisclosureEquityIncentivePlans1 25 false false R26.htm 995645 - Disclosure - Net Loss per Share Attributable to Common Stockholders (Tables) Sheet http://www.sightsciences.com/20240930/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToCommonStockholdersTables Net Loss per Share Attributable to Common Stockholders (Tables) Tables http://www.sightsciences.com/20240930/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToCommonStockholders 26 false false R27.htm 995655 - Disclosure - Segment Information (Tables) Sheet http://www.sightsciences.com/20240930/taxonomy/role/Role_DisclosureSegmentInformationTables Segment Information (Tables) Tables
http://www.sightsciences.com/20240930/taxonomy/role/Role_DisclosureSegmentInformation 27 false false R28.htm 995665 - Disclosure - Company and Nature of Business - Additional Information (Details) Sheet http://www.sightsciences.com/20240930/taxonomy/role/Role_DisclosureCompanyAndNatureOfBusinessAdditionalInformationDetails Company and Nature of Business - Additional Information (Details) Details 28 false false R29.htm 995695 - Disclosure - Fair value Measurement - Additional Information (Details) Sheet
http://www.sightsciences.com/20240930/taxonomy/role/Role_DisclosureFairValueMeasurementAdditionalInformationDetails Fair value Measurement - Additional Information (Details) Details 29 false false R30.htm 995705 - Disclosure - Fair Value Measurement - Held-to-maturity debt securities at amortized cost (Details) Sheet
http://www.sightsciences.com/20240930/taxonomy/role/DisclosureFairValueMeasurementHeldtomaturityDebtSecuritiesAtAmortizedCostDetails Fair Value Measurement - Held-to-maturity debt securities at amortized cost (Details) Details 30 false false R31.htm 995715 - Disclosure - Balance Sheet Components - Summary of Property and Equipment, Net (Details) Sheet
http://www.sightsciences.com/20240930/taxonomy/role/Role_DisclosureBalanceSheetComponentsSummaryOfPropertyAndEquipmentNetDetails Balance Sheet Components - Summary of Property and Equipment, Net (Details) Details 31 false false R32.htm 995725 - Disclosure - Balance Sheet Components - Additional Information (Details) Sheet
http://www.sightsciences.com/20240930/taxonomy/role/Role_DisclosureBalanceSheetComponentsAdditionalInformationDetails Balance Sheet Components - Additional Information (Details) Details 32 false false R33.htm 995735 - Disclosure - Balance Sheet Components - Summary of Accrued and Other Current Liabilities (Details) Sheet
http://www.sightsciences.com/20240930/taxonomy/role/Role_DisclosureBalanceSheetComponentsSummaryOfAccruedAndOtherCurrentLiabilitiesDetails Balance Sheet Components - Summary of Accrued and Other Current Liabilities (Details) Details 33 false false R34.htm 995745 - Disclosure - Balance Sheet Components - Summary of Other Noncurrent Liabilities (Details) Sheet
http://www.sightsciences.com/20240930/taxonomy/role/Role_DisclosureBalanceSheetComponentsSummaryOfOtherNoncurrentLiabilitiesDetails Balance Sheet Components - Summary of Other Noncurrent Liabilities (Details) Details 34 false false R35.htm 995755 - Disclosure - Debt - Additional Information (Details) Sheet
http://www.sightsciences.com/20240930/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails Debt - Additional Information (Details) Details 35 false false R36.htm 995765 - Disclosure - Debt - Schedule of Long-term and Short-term Debt (Details) Sheet
http://www.sightsciences.com/20240930/taxonomy/role/Role_DisclosureDebtScheduleOfLongTermAndShortTermDebtDetails Debt - Schedule of Long-term and Short-term Debt (Details) Details 36 false false R37.htm 995775 - Disclosure - Debt - Schedule Relating to the Company's Debt (Details) Sheet
http://www.sightsciences.com/20240930/taxonomy/role/Role_DisclosureDebtScheduleRelatingToCompanySDebtDetails Debt - Schedule Relating to the Company's Debt (Details) Details 37 false false R38.htm 995785 - Disclosure - Commitments and Contingencies - Additional Information (Details) Sheet
http://www.sightsciences.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails Commitments and Contingencies - Additional Information (Details) Details 38 false false R39.htm 995795 - Disclosure - Commitments and Contingencies - Schedule of Operating Lease Expense Recognized and Supplemental Cash Flow (Details) Sheet
http://www.sightsciences.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfOperatingLeaseExpenseRecognizedAndSupplementalCashFlowDetails Commitments and Contingencies - Schedule of Operating Lease Expense Recognized and Supplemental Cash Flow (Details) Details 39 false false R40.htm 995805 - Disclosure - Commitments and Contingencies - Schedule of Aggregate Future Minimum Lease Payments (Details) Sheet
http://www.sightsciences.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfAggregateFutureMinimumLeasePaymentsDetails Commitments and Contingencies - Schedule of Aggregate Future Minimum Lease Payments (Details) Details 40 false false R41.htm 995815 - Disclosure - Stockholder's Equity - Additional Information (Details) Sheet http://www.sightsciences.com/20240930/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails Stockholder's Equity - Additional Information (Details) Details 41 false false R42.htm 995825 - Disclosure - Stockholder's Equity - Schedule of Reserved Common Stock for Future Issuances (Details) Sheet
http://www.sightsciences.com/20240930/taxonomy/role/DisclosureStockholdersEquityScheduleOfReservedCommonStockForFutureIssuancesDetails Stockholder's Equity - Schedule of Reserved Common Stock for Future Issuances (Details) Details 42 false false R43.htm 995835 - Disclosure - Equity Incentive Plans - Additional Information (Detail) Sheet
http://www.sightsciences.com/20240930/taxonomy/role/DisclosureEquityIncentivePlansAdditionalInformationDetail Equity Incentive Plans - Additional Information (Detail) Details 43 false false R44.htm 995845 - Disclosure - Equity Incentive Plans - Summary of Company Stock Option Activity (Detail) Sheet
http://www.sightsciences.com/20240930/taxonomy/role/DisclosureEquityIncentivePlansSummaryOfCompanyStockOptionActivityDetail Equity Incentive Plans - Summary of Company Stock Option Activity (Detail) Details 44 false false R45.htm 995855 - Disclosure - Equity Incentive Plans - Summary of Stock Based Compensation Fair Value Assumptions (Details) Sheet
http://www.sightsciences.com/20240930/taxonomy/role/DisclosureEquityIncentivePlansSummaryOfStockBasedCompensationFairValueAssumptionsDetails Equity Incentive Plans - Summary of Stock Based Compensation Fair Value Assumptions (Details) Details 45 false false R46.htm 995865 - Disclosure - Equity Incentive Plans - Summary of Share-Based Compensation Expense By Function (Details) Sheet http://www.sightsciences.com/20240930/taxonomy/role/DisclosureEquityIncentivePlansSummaryOfSharebasedCompensationExpenseByFunctionDetails Equity Incentive Plans - Summary of Share-Based Compensation Expense By Function (Details) Details 46 false false R47.htm 995875 - Disclosure - Equity Incentive Plans - Summarizes restricted share award activity under the 2021 Plan (Details) Sheet
http://www.sightsciences.com/20240930/taxonomy/role/DisclosureEquityIncentivePlansSummarizesRestrictedShareAwardActivityUnderThe2021PlanDetails Equity Incentive Plans - Summarizes restricted share award activity under the 2021 Plan (Details) Details 47 false false R48.htm 995885 - Disclosure - Net Loss Per Share Attributable to Common Stockholders - Schedule of Computation of Basic and Diluted Net Loss per Share Attributable to Common Stockholders (Details) Sheet
http://www.sightsciences.com/20240930/taxonomy/role/DisclosureNetLossPerShareAttributableToCommonStockholdersScheduleOfComputationOfBasicAndDilutedNetLossPerShareAttributableT Net Loss Per Share Attributable to Common Stockholders - Schedule of Computation of Basic and Diluted Net Loss per Share Attributable to Common Stockholders (Details) Details 48 false false R49.htm 995895 - Disclosure - Net Loss Per Share Attributable to Common Stockholders - Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share (Details) Sheet
http://www.sightsciences.com/20240930/taxonomy/role/DisclosureNetLossPerShareAttributableToCommonStockholdersScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPe Net Loss Per Share Attributable to Common Stockholders - Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share (Details) Details 49 false false R50.htm 995915 - Disclosure - Segment Information - Additional Information (Details) Sheet http://www.sightsciences.com/20240930/taxonomy/role/DisclosureSegmentInformationAdditionalInformationDetails Segment Information - Additional Information (Details) Details 50 false false R51.htm 995925 - Disclosure - Segment Information - Summary of Operating Result Information for Each Reportable Segment (Details) Sheet http://www.sightsciences.com/20240930/taxonomy/role/Role_DisclosureSegmentInformationSummaryOfOperatingResultInformationForEachReportableSegmentDetails Segment Information - Summary of Operating Result Information for Each Reportable Segment (Details) Details 51 false false All Reports Book All Reports sght-20240930.htm sght-20240930.xsd http://fasb.org/us-gaap/2024 http://xbrl.sec.gov/dei/2024 http://xbrl.sec.gov/ecd/2024 false false JSON 65 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "sght-20240930.htm": { "nsprefix": "sght", "nsuri": "http://www.sightsciences.com/20240930", "dts": { "inline": { "local": ["sght-20240930.htm"] }, "schema": { "local": ["sght-20240930.xsd"], "remote": ["http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/arcrole/esma-arcrole-2018-11-21.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/2023/calculation-1.1.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd", "https://xbrl.sec.gov/country/2024/country-2024.xsd", "https://xbrl.sec.gov/dei/2024/dei-2024.xsd", "https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd", "https://xbrl.sec.gov/ecd/2024/ecd-sub-2024.xsd", "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd"] } }, "keyStandard": 241, "keyCustom": 26, "axisStandard": 19, "axisCustom": 0, "memberStandard": 23, "memberCustom": 16, "hidden": { "total": 6, "http://xbrl.sec.gov/dei/2024": 4, "http://fasb.org/us-gaap/2024": 2 }, "contextCount": 145, "entityCount": 1, "segmentCount": 40, "elementCount": 634, "unitCount": 6, "baseTaxonomies": { "http://fasb.org/us-gaap/2024": 631, "http://xbrl.sec.gov/dei/2024": 31, "http://xbrl.sec.gov/ecd/2024": 9 }, "report": { "R1": { "role": "http://www.sightsciences.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation", "longName": "100000 - Document - Document and Entity Information", "shortName": "Document and Entity Information", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "C_65414eb4-cf20-46fb-8a2e-a0aa6d34f146", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "p", "body", "html"], "reportCount": 1, "baseRef": "sght-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_65414eb4-cf20-46fb-8a2e-a0aa6d34f146", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "p", "body", "html"], "reportCount": 1, "baseRef": "sght-20240930.htm", "first": true, "unique": true } }, "R2": { "role": "http://www.sightsciences.com/20240930/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited", "longName": "100010 - Statement - Condensed Consolidated Balance Sheets (Unaudited)", "shortName": "Condensed Consolidated Balance Sheets (Unaudited)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "2", "firstAnchor": { "contextRef": "C_27bdb57f-fb7b-4248-88fc-b11e5858c198", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "body", "html"], "reportCount": 1, "baseRef": "sght-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_27bdb57f-fb7b-4248-88fc-b11e5858c198", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "body", "html"], "reportCount": 1, "baseRef": "sght-20240930.htm", "first": true, "unique": true } }, "R3": { "role": "http://www.sightsciences.com/20240930/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnauditedParenthetical", "longName": "100050 - Statement - Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical)", "shortName": "Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical)", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "3", "firstAnchor": { "contextRef": "C_27bdb57f-fb7b-4248-88fc-b11e5858c198", "name": "us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "body", "html"], "reportCount": 1, "baseRef": "sght-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_27bdb57f-fb7b-4248-88fc-b11e5858c198", "name": "us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "body", "html"], "reportCount": 1, "baseRef": "sght-20240930.htm", "first": true, "unique": true } }, "R4": { "role": "http://www.sightsciences.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited", "longName": "100060 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited)", "shortName": "Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "4", "firstAnchor": { "contextRef": "C_852b779c-14c2-48bf-9a41-ee0125dbe8e2", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "body", "html"], "reportCount": 1, "baseRef": "sght-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_852b779c-14c2-48bf-9a41-ee0125dbe8e2", "name": "us-gaap:ResearchAndDevelopmentExpense", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "body", "html"], "reportCount": 1,

```
"baseRef": "sght-20240930.htm", "unique": true } }, "R5": { "role":
"http://www.sightsciences.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityUnaudited", "longName":
"100070 - Statement - Condensed Consolidated Statements of Redeemable Convertible Preferred Stock and Stockholders' Equity (Unaudited)", "shortName": "Condensed Consolidated
Statements of Redeemable Convertible Preferred Stock and Stockholders' Equity (Unaudited)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements",
"order": "5", "firstAnchor": { "contextRef": "C_1d48a533-e587-4b48-8bd4-72a3c59f4552", "name": "us-gaap:StockholdersEquity", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals":
"-3", "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "sght-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef":
"C_1d48a533-e587-4b48-8bd4-72a3c59f4552", "name": "us-gaap:StockholdersEquity", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr",
"table", "body", "html" ], "reportCount": 1, "baseRef": "sght-20240930.htm", "first": true, "unique": true } }, "R6": { "role":
"http://www.sightsciences.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited", "longName": "100090 - Statement - Condensed Consolidated
Statements of Cash Flows (Unaudited)", "shortName": "Condensed Consolidated Statements of Cash Flows (Unaudited)", "isDefault": "false", "groupType": "statement", "subGroupType": "",
"menuCat": "Statements", "order": "6", "firstAnchor": { "contextRef": "C_65414eb4-cf20-46fb-8a2e-a0aa6d34f146", "name": "us-gaap:ProfitLoss", "unitRef": "U_USD", "xsiNil": "false", "lang":
null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "sght-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": {
"contextRef": "C_65414eb4-cf20-46fb-8a2e-a0aa6d34f146", "name": "us-gaap:ProfitLoss", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr",
"table", "body", "html" ], "reportCount": 1, "baseRef": "sght-20240930.htm", "first": true, "unique": true } }, "R7": { "role": "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "longName": "995410 -
Disclosure - Pay vs Performance Disclosure", "shortName": "Pay vs Performance Disclosure", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order":
"7", "firstAnchor": { "contextRef": "C_852b779c-14c2-48bf-9a41-ee0125dbe8e2", "name": "us-gaap:NetIncomeLoss", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3",
"ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "sght-20240930.htm", "first": true }, "uniqueAnchor": null }, "R8": { "role":
"http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "longName": "995445 - Disclosure - Insider Trading Arrangements", "shortName": "Insider Trading Arrangements", "isDefault":
"false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "8", "firstAnchor": { "contextRef": "C_852b779c-14c2-48bf-9a41-ee0125dbe8e2", "name":
"ecd:MtrlTermsOfTrdArrTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "sght-20240930.htm",
"first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_852b779c-14c2-48bf-9a41-ee0125dbe8e2", "name": "ecd:MtrlTermsOfTrdArrTextBlock", "unitRef": null, "xsiNil": "false", "lang":
"en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "sght-20240930.htm", "first": true, "unique": true } }, "R9": { "role":
"http://www.sightsciences.com/20240930/taxonomy/role/Role_DisclosureCompanyAndNatureOfBusiness", "longName": "995455 - Disclosure - Company and Nature of Business", "shortName":
"Company and Nature of Business", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "9", "firstAnchor": { "contextRef": "C_65414eb4-cf20-46fb-
8a2e-a0aa6d34f146", "name": "us-gaap:NatureOfOperations", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef":
"sght-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_65414eb4-cf20-46fb-8a2e-a0aa6d34f146", "name": "us-gaap:NatureOfOperations", "unitRef": null,
"xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "sght-20240930.htm", "first": true, "unique": true } }, "R10": { "role":
"http://www.sightsciences.com/20240930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies", "longName": "995465 - Disclosure - Summary of Significant Accounting
Policies", "shortName": "Summary of Significant Accounting Policies", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "10", "firstAnchor": {
"contextRef": "C_65414eb4-cf20-46fb-8a2e-a0aa6d34f146", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null,
"ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "sght-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_65414eb4-cf20-46fb-8a2e-
a0aa6d34f146", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ],
"reportCount": 1, "baseRef": "sght-20240930.htm", "first": true, "unique": true } }, "R11": { "role": "http://www.sightsciences.com/20240930/taxonomy/role/Role_DisclosureFairValueMeasurements",
"longName": "995475 - Disclosure - Fair Value Measurements", "shortName": "Fair Value Measurements", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat":
"Notes", "order": "11", "firstAnchor": { "contextRef": "C_65414eb4-cf20-46fb-8a2e-a0aa6d34f146", "name": "us-gaap:FairValueMeasurementInputsDisclosureTextBlock", "unitRef": null, "xsiNil":
"false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "sght-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef":
"C_65414eb4-cf20-46fb-8a2e-a0aa6d34f146", "name": "us-gaap:FairValueMeasurementInputsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null,
"ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "sght-20240930.htm", "first": true, "unique": true } }, "R12": { "role":
"http://www.sightsciences.com/20240930/taxonomy/role/Role_DisclosureBalanceSheetComponents", "longName": "995485 - Disclosure - Balance Sheet Components", "shortName": "Balance
Sheet Components", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "12", "firstAnchor": { "contextRef": "C_65414eb4-cf20-46fb-8a2e-
a0aa6d34f146", "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ],
"reportCount": 1, "baseRef": "sght-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_65414eb4-cf20-46fb-8a2e-a0aa6d34f146", "name": "us-
gaap:SupplementalBalanceSheetDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "sght-
20240930.htm", "first": true, "unique": true } }, "R13": { "role": "http://www.sightsciences.com/20240930/taxonomy/role/Role_DisclosureDebt", "longName": "995495 - Disclosure - Debt",
"shortName": "Debt", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "13", "firstAnchor": { "contextRef": "C_65414eb4-cf20-46fb-8a2e-
a0aa6d34f146", "name": "us-gaap:DebtDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef":
"sght-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_65414eb4-cf20-46fb-8a2e-a0aa6d34f146", "name": "us-gaap:DebtDisclosureTextBlock", "unitRef": null,
"xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "sght-20240930.htm", "first": true, "unique": true } }, "R14": { "role":
"http://www.sightsciences.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingencies", "longName": "995505 - Disclosure - Commitments and Contingencies", "shortName":
"Commitments and Contingencies", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "14", "firstAnchor": { "contextRef": "C_65414eb4-cf20-46fb-
8a2e-a0aa6d34f146", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body",
"html" ], "reportCount": 1, "baseRef": "sght-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_65414eb4-cf20-46fb-8a2e-a0aa6d34f146", "name": "us-
gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef":
"sght-20240930.htm", "first": true, "unique": true } }, "R15": { "role": "http://www.sightsciences.com/20240930/taxonomy/role/DisclosureStockholdersEquity1", "longName": "995515 -
Disclosure - Stockholders' Equity", "shortName": "Stockholders' Equity", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "15", "firstAnchor": {
"contextRef": "C_65414eb4-cf20-46fb-8a2e-a0aa6d34f146", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null,
"ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "sght-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_65414eb4-cf20-46fb-8a2e-
a0aa6d34f146", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ],
"reportCount": 1, "baseRef": "sght-20240930.htm", "first": true, "unique": true } }, "R16": { "role": "http://www.sightsciences.com/20240930/taxonomy/role/DisclosureEquityIncentivePlans1",
"longName": "995525 - Disclosure - Equity Incentive Plans", "shortName": "Equity Incentive Plans", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes",
"order": "16", "firstAnchor": { "contextRef": "C_65414eb4-cf20-46fb-8a2e-a0aa6d34f146", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "unitRef":
null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "sght-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": {
"contextRef": "C_65414eb4-cf20-46fb-8a2e-a0aa6d34f146", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "unitRef": null, "xsiNil": "false", "lang":
"en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "sght-20240930.htm", "first": true, "unique": true } }, "R17": { "role":
"http://www.sightsciences.com/20240930/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToCommonStockholders", "longName": "995535 - Disclosure - Net Loss per Share
Attributable to Common Stockholders", "shortName": "Net Loss per Share Attributable to Common Stockholders", "isDefault": "false", "groupType": "disclosure", "subGroupType": "",
"menuCat": "Notes", "order": "17", "firstAnchor": { "contextRef": "C_65414eb4-cf20-46fb-8a2e-a0aa6d34f146", "name": "us-gaap:EarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false",
"lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "sght-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef":
"C_65414eb4-cf20-46fb-8a2e-a0aa6d34f146", "name": "us-gaap:EarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body",
"html" ], "reportCount": 1, "baseRef": "sght-20240930.htm", "first": true, "unique": true } }, "R18": { "role":
"http://www.sightsciences.com/20240930/taxonomy/role/Role_DisclosureSegmentInformation", "longName": "995555 - Disclosure - Segment Information", "shortName": "Segment Information",
"isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "18", "firstAnchor": { "contextRef": "C_65414eb4-cf20-46fb-8a2e-a0aa6d34f146", "name": "us-
gaap:SegmentReportingDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "sght-
20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_65414eb4-cf20-46fb-8a2e-a0aa6d34f146", "name": "us-gaap:SegmentReportingDisclosureTextBlock",
"unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "sght-20240930.htm", "first": true, "unique": true } }, "R19":
{ "role": "http://www.sightsciences.com/20240930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies", "longName": "995575 - Disclosure - Summary of Significant
Accounting Policies (Policies)", "shortName": "Summary of Significant Accounting Policies (Policies)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "policies", "menuCat":
"Policies", "order": "19", "firstAnchor": { "contextRef": "C_65414eb4-cf20-46fb-8a2e-a0aa6d34f146", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "unitRef": null, "xsiNil": "false",
"lang": "en-US", "decimals": null, "ancestors": [ "div", "us-gaap:SignificantAccountingPoliciesTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "sght-20240930.htm", "first": true,
"unique": true }, "uniqueAnchor": { "contextRef": "C_65414eb4-cf20-46fb-8a2e-a0aa6d34f146", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "unitRef": null, "xsiNil": "false",
"lang": "en-US", "decimals": null, "ancestors": [ "div", "us-gaap:SignificantAccountingPoliciesTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "sght-20240930.htm", "first": true,
"unique": true } }, "R20": { "role": "http://www.sightsciences.com/20240930/taxonomy/role/Role_DisclosureFairValueMeasurementsTables", "longName": "995585 - Disclosure - Fair Value
Measurements (Tables)", "shortName": "Fair Value Measurements (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "20",
"firstAnchor": { "contextRef": "C_65414eb4-cf20-46fb-8a2e-a0aa6d34f146", "name": "us-gaap:FairValueByBalanceSheetGroupingTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US",
"decimals": null, "ancestors": [ "span", "p", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "sght-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": {
"contextRef": "C_65414eb4-cf20-46fb-8a2e-a0aa6d34f146", "name": "us-gaap:FairValueByBalanceSheetGroupingTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null,
"ancestors": [ "span", "p", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "sght-20240930.htm", "first": true, "unique": true } }, "R21": { "role":
"http://www.sightsciences.com/20240930/taxonomy/role/Role_DisclosureBalanceSheetComponentsTables", "longName": "995595 - Disclosure - Balance Sheet Components (Tables)",
"shortName": "Balance Sheet Components (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "21", "firstAnchor": { "contextRef":
"C_65414eb4-cf20-46fb-8a2e-a0aa6d34f146", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div",
"us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "sght-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": {
"contextRef": "C_65414eb4-cf20-46fb-8a2e-a0aa6d34f146", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null,
"ancestors": [ "div", "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "sght-20240930.htm", "first": true, "unique": true } }, "R22":
{ "role": "http://www.sightsciences.com/20240930/taxonomy/role/Role_DisclosureDebtTables", "longName": "995605 - Disclosure - Debt (Tables)", "shortName": "Debt (Tables)", "isDefault":
"false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "22", "firstAnchor": { "contextRef": "C_65414eb4-cf20-46fb-8a2e-a0aa6d34f146", "name": "us-
gaap:ScheduleOfDebtTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "ix:continuation", "div", "body", "html" ], "reportCount": 1,
"baseRef": "sght-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_65414eb4-cf20-46fb-8a2e-a0aa6d34f146", "name": "us-gaap:ScheduleOfDebtTableTextBlock",
"unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "sght-20240930.htm", "first": true,
"unique": true } }, "R23": { "role": "http://www.sightsciences.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesTables", "longName": "995615 - Disclosure -
Commitments and Contingencies (Tables)", "shortName": "Commitments and Contingencies (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat":
"Tables", "order": "23", "firstAnchor": { "contextRef": "C_65414eb4-cf20-46fb-8a2e-a0aa6d34f146", "name": "us-gaap:LeaseCostTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US",
"decimals": null, "ancestors": [ "div", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "sght-20240930.htm", "first": true,
"unique": true }, "uniqueAnchor": { "contextRef": "C_65414eb4-cf20-46fb-8a2e-a0aa6d34f146", "name": "us-gaap:LeaseCostTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US",
"decimals": null, "ancestors": [ "div", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "sght-20240930.htm", "first": true,
"unique": true } }, "R24": { "role": "http://www.sightsciences.com/20240930/taxonomy/role/DisclosureStockholdersEquityTables", "longName": "995625 - Disclosure - Stockholders' Equity
(Tables)", "shortName": "Stockholders' Equity (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "24", "firstAnchor": {
"contextRef": "C_65414eb4-cf20-46fb-8a2e-a0aa6d34f146", "name": "us-gaap:ScheduleOfStockByClassTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [
"div", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "sght-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": {
"contextRef": "C_65414eb4-cf20-46fb-8a2e-a0aa6d34f146", "name": "us-gaap:ScheduleOfStockByClassTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [
"div", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "sght-20240930.htm", "first": true, "unique": true } }, "R25": { "role":
"http://www.sightsciences.com/20240930/taxonomy/role/DisclosureEquityIncentivePlansTables", "longName": "995635 - Disclosure - Equity Incentive Plans (Tables)", "shortName": "Equity
Incentive Plans (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "25", "firstAnchor": { "contextRef": "C_65414eb4-cf20-46fb-
8a2e-a0aa6d34f146", "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors":
[ "div", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "sght-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_65414eb4-cf20-46fb-8a2e-
a0aa6d34f146", "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [
"div", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "sght-20240930.htm", "first": true, "unique": true } }, "R26": { "role":
"http://www.sightsciences.com/20240930/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToCommonStockholdersTables", "longName": "995645 - Disclosure - Net Loss per Share
Attributable to Common Stockholders (Tables)", "shortName": "Net Loss per Share Attributable to Common Stockholders (Tables)", "isDefault": "false", "groupType": "disclosure",
"subGroupType": "tables", "menuCat": "Tables", "order": "26", "firstAnchor": { "contextRef": "C_65414eb4-cf20-46fb-8a2e-a0aa6d34f146", "name": "us-
gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "ix:continuation", "div", "body", "html"
```

], "reportCount": 1, "baseRef": "sght-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_65414eb4-cf20-46fb-8a2e-a0aa6d34f146", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "sght-20240930.htm", "first": true, "unique": true } }, "R27": { "role": "http://www.sightsciences.com/20240930/taxonomy/role/Role_DisclosureSegmentInformationTables", "longName": "995655 - Disclosure - Segment Information (Tables)", "shortName": "Segment Information (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "27", "firstAnchor": { "contextRef": "C_65414eb4-cf20-46fb-8a2e-a0aa6d34f146", "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "sght-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_65414eb4-cf20-46fb-8a2e-a0aa6d34f146", "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "sght-20240930.htm", "first": true, "unique": true } }, "R28": { "role": "http://www.sightsciences.com/20240930/taxonomy/role/Role_DisclosureCompanyAndNatureOfBusinessAdditionalInformationDetails", "longName": "995665 - Disclosure - Company and Nature of Business - Additional Information (Details)", "shortName": "Company and Nature of Business - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "28", "firstAnchor": { "contextRef": "C_27bdb57f-fb7b-4248-88fc-b11e5858c198", "name": "us-gaap:RetainedEarningsAccumulatedDeficit", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "body", "html"], "reportCount": 1, "baseRef": "sght-20240930.htm", "first": true }, "uniqueAnchor": null }, "R29": { "role": "http://www.sightsciences.com/20240930/taxonomy/role/Role_DisclosureFairValueMeasurementAdditionalInformationDetails", "longName": "995695 - Disclosure - Fair value Measurement - Additional Information (Details)", "shortName": "Fair value Measurement - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "29", "firstAnchor": { "contextRef": "C_7fcfb1f5-920d-46d6-9712-67c95ff24209", "name": "us-gaap:InterestIncomeSecuritiesUSTreasury", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": ["span", "p", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "sght-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_7fcfb1f5-920d-46d6-9712-67c95ff24209", "name": "us-gaap:InterestIncomeSecuritiesUSTreasury", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": ["span", "p", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "sght-20240930.htm", "first": true, "unique": true } }, "R30": { "role": "http://www.sightsciences.com/20240930/taxonomy/role/DisclosureFairValueMeasurementHeldtomaturityDebtSecuritiesAtAmortizedCostDetails", "longName": "995705 - Disclosure - Fair Value Measurement - Held-to-maturity debt securities at amortized cost (Details)", "shortName": "Fair Value Measurement - Held-to-maturity debt securities at amortized cost (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "30", "firstAnchor": { "contextRef": "C_81935e86-ac2d-4d21-b86c-dc64f198c418", "name": "us-gaap:DebtSecuritiesHeldToMaturityAmortizedCostAfterAllowanceForCreditLoss", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "sght-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_81935e86-ac2d-4d21-b86c-dc64f198c418", "name": "us-gaap:DebtSecuritiesHeldToMaturityAmortizedCostAfterAllowanceForCreditLoss", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "sght-20240930.htm", "first": true, "unique": true } }, "R31": { "role": "http://www.sightsciences.com/20240930/taxonomy/role/Role_DisclosureBalanceSheetComponentsSummaryOfPropertyAndEquipmentNetDetails", "longName": "995715 - Disclosure - Balance Sheet Components - Summary of Property and Equipment, Net (Details)", "shortName": "Balance Sheet Components - Summary of Property and Equipment, Net (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "31", "firstAnchor": { "contextRef": "C_27bdb57f-fb7b-4248-88fc-b11e5858c198", "name": "us-gaap:PropertyPlantAndEquipmentGross", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "us-gaap:PropertyPlantAndEquipmentTextBlock", "div", "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "sght-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_27bdb57f-fb7b-4248-88fc-b11e5858c198", "name": "us-gaap:PropertyPlantAndEquipmentGross", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "us-gaap:PropertyPlantAndEquipmentTextBlock", "div", "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "sght-20240930.htm", "first": true, "unique": true } }, "R32": { "role": "http://www.sightsciences.com/20240930/taxonomy/role/Role_DisclosureBalanceSheetComponentsAdditionalInformationDetails", "longName": "995725 - Disclosure - Balance Sheet Components - Additional Information (Details)", "shortName": "Balance Sheet Components - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "32", "firstAnchor": { "contextRef": "C_852b779c-14c2-48bf-9a41-ee0125dbe8e2", "name": "us-gaap:Depreciation", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": ["span", "p", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "sght-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_852b779c-14c2-48bf-9a41-ee0125dbe8e2", "name": "us-gaap:Depreciation", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": ["span", "p", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "sght-20240930.htm", "first": true, "unique": true } }, "R33": { "role": "http://www.sightsciences.com/20240930/taxonomy/role/Role_DisclosureBalanceSheetComponentsSummaryOfAccruedAndOtherCurrentLiabilitiesDetails", "longName": "995735 - Disclosure - Balance Sheet Components - Summary of Accrued and Other Current Liabilities (Details)", "shortName": "Balance Sheet Components - Summary of Accrued and Other Current Liabilities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "33", "firstAnchor": { "contextRef": "C_27bdb57f-fb7b-4248-88fc-b11e5858c198", "name": "us-gaap:AccruedLiabilitiesCurrent", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "sght:AccruedAndOtherCurrentLiabilitiesTableTextBlock", "div", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "sght-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_27bdb57f-fb7b-4248-88fc-b11e5858c198", "name": "us-gaap:AccruedLiabilitiesCurrent", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "sght:AccruedAndOtherCurrentLiabilitiesTableTextBlock", "div", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "sght-20240930.htm", "first": true, "unique": true } }, "R34": { "role": "http://www.sightsciences.com/20240930/taxonomy/role/Role_DisclosureBalanceSheetComponentsSummaryOfOtherNoncurrentLiabilitiesDetails", "longName": "995745 - Disclosure - Balance Sheet Components - Summary of Other Noncurrent Liabilities (Details)", "shortName": "Balance Sheet Components - Summary of Other Noncurrent Liabilities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "34", "firstAnchor": { "contextRef": "C_27bdb57f-fb7b-4248-88fc-b11e5858c198", "name": "sght:InterestPayableNonCurrent", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "us-gaap:OtherNoncurrentLiabilitiesTableTextBlock", "div", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "sght-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_27bdb57f-fb7b-4248-88fc-b11e5858c198", "name": "sght:InterestPayableNonCurrent", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "us-gaap:OtherNoncurrentLiabilitiesTableTextBlock", "div", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "sght-20240930.htm", "first": true, "unique": true } }, "R35": { "role": "http://www.sightsciences.com/20240930/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails", "longName": "995755 - Disclosure - Debt - Additional Information (Details)", "shortName": "Debt - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "35", "firstAnchor": { "contextRef": "C_852b779c-14c2-48bf-9a41-ee0125dbe8e2", "name": "us-gaap:GainsLossesOnExtinguishmentOfDebt", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "body", "html"], "reportCount": 1, "baseRef": "sght-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_590163af-3567-443d-b705-123ca6480cea", "name": "us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": ["span", "p", "us-gaap:DebtDisclosureTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "sght-20240930.htm", "unique": true } }, "R36": { "role": "http://www.sightsciences.com/20240930/taxonomy/role/Role_DisclosureDebtScheduleOfLongTermAndShortTermDebtDetails", "longName": "995765 - Disclosure - Debt - Schedule of Long-term and Short-term Debt (Details)", "shortName": "Debt - Schedule of Long-term and Short-term Debt (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "36", "firstAnchor": { "contextRef": "C_27bdb57f-fb7b-4248-88fc-b11e5858c198", "name": "us-gaap:DebtInstrumentCarryingAmount", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "us-gaap:ScheduleOfDebtTableTextBlock", "div", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "sght-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_27bdb57f-fb7b-4248-88fc-b11e5858c198", "name": "us-gaap:DebtInstrumentCarryingAmount", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "us-gaap:ScheduleOfDebtTableTextBlock", "div", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "sght-20240930.htm", "first": true, "unique": true } }, "R37": { "role": "http://www.sightsciences.com/20240930/taxonomy/role/Role_DisclosureDebtScheduleRelatingToCompanySDebtDetails", "longName": "995775 - Disclosure - Debt - Schedule Relating to the Company's Debt (Details)", "shortName": "Debt - Schedule Relating to the Company's Debt (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "37", "firstAnchor": { "contextRef": "C_27bdb57f-fb7b-4248-88fc-b11e5858c198", "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "us-gaap:ScheduleOfExtinguishmentOfDebtTextBlock", "div", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "sght-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_27bdb57f-fb7b-4248-88fc-b11e5858c198", "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "us-gaap:ScheduleOfExtinguishmentOfDebtTextBlock", "div", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "sght-20240930.htm", "first": true, "unique": true } }, "R38": { "role": "http://www.sightsciences.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails", "longName": "995785 - Disclosure - Commitments and Contingencies - Additional Information (Details)", "shortName": "Commitments and Contingencies - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "38", "firstAnchor": { "contextRef": "C_27bdb57f-fb7b-4248-88fc-b11e5858c198", "name": "us-gaap:OperatingLeaseRightOfUseAsset", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "body", "html"], "reportCount": 1, "baseRef": "sght-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_62ce276d-368e-4217-bd6f-ba13010c02f9", "name": "us-gaap:LesseeOperatingLeaseOptionToExtend", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "p", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "sght-20240930.htm", "unique": true } }, "R39": { "role": "http://www.sightsciences.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfOperatingLeaseExpenseRecognizedAndSupplementalCashFlowDetails", "longName": "995795 - Disclosure - Commitments and Contingencies - Schedule of Operating Lease Expense Recognized and Supplemental Cash Flow (Details)", "shortName": "Commitments and Contingencies - Schedule of Operating Lease Expense Recognized and Supplemental Cash Flow (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "39", "firstAnchor": { "contextRef": "C_852b779c-14c2-48bf-9a41-ee0125dbe8e2", "name": "us-gaap:OperatingLeaseExpense", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "us-gaap:LeaseCostTableTextBlock", "div", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "sght-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_852b779c-14c2-48bf-9a41-ee0125dbe8e2", "name": "us-gaap:OperatingLeasePayments", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "us-gaap:LeaseCostTableTextBlock", "div", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "sght-20240930.htm", "unique": true } }, "R40": { "role": "http://www.sightsciences.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfAggregateFutureMinimumLeasePaymentsDetails", "longName": "995805 - Disclosure - Commitments and Contingencies - Schedule of Aggregate Future Minimum Lease Payments (Details)", "shortName": "Commitments and Contingencies - Schedule of Aggregate Future Minimum Lease Payments (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "40", "firstAnchor": { "contextRef": "C_27bdb57f-fb7b-4248-88fc-b11e5858c198", "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "sght:ScheduleOfFutureMinimumRentalPaymentsNoncancelableForOperatingLeasesTableTextBlock", "div", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "sght-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_27bdb57f-fb7b-4248-88fc-b11e5858c198", "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "sght:ScheduleOfFutureMinimumRentalPaymentsNoncancelableForOperatingLeasesTableTextBlock", "div", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "sght-20240930.htm", "first": true, "unique": true } }, "R41": { "role": "http://www.sightsciences.com/20240930/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails", "longName": "995815 - Disclosure - Stockholder's Equity - Additional Information (Details)", "shortName": "Stockholder's Equity - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "41", "firstAnchor": { "contextRef": "C_27bdb57f-fb7b-4248-88fc-b11e5858c198", "name": "us-gaap:CommonStockSharesAuthorized", "unitRef": "U_shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["span", "p", "td", "tr", "table", "body", "html"], "reportCount": 1, "baseRef": "sght-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_65414eb4-cf20-46fb-8a2e-a0aa6d34f146", "name": "us-gaap:DividendsCommonStock", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "sght-20240930.htm", "unique": true } }, "R42": { "role": "http://www.sightsciences.com/20240930/taxonomy/role/DisclosureStockholdersEquityScheduleOfReservedCommonStockForFutureIssuancesDetails", "longName": "995825 - Disclosure - Stockholder's Equity - Schedule of Reserved Common Stock for Future Issuances (Details)", "shortName": "Stockholder's Equity - Schedule of Reserved Common Stock for Future Issuances (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "42", "firstAnchor": { "contextRef": "C_27bdb57f-fb7b-4248-88fc-b11e5858c198", "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance", "unitRef": "U_shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["span", "p", "td", "tr", "table", "us-gaap:ScheduleOfStockByClassTextBlock", "div", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "sght-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_daf0bc7e-ac3d-4362-b40a-9b24d8b2ee0a", "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance", "unitRef": "U_shares", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["span", "p", "td", "tr", "table", "us-gaap:ScheduleOfStockByClassTextBlock", "div", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "sght-20240930.htm", "unique": true } }, "R43": { "role": "http://www.sightsciences.com/20240930/taxonomy/role/DisclosureEquityIncentivePlansAdditionalInformationDetail", "longName": "995835 - Disclosure - Equity Incentive Plans - Additional Information (Detail)", "shortName": "Equity Incentive Plans - Additional Information (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "43", "firstAnchor": { "contextRef": "C_65414eb4-cf20-46fb-8a2e-a0aa6d34f146", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "unitRef": "U_USDollarShare", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": ["span", "p", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "sght-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_65414eb4-cf20-46fb-8a2e-a0aa6d34f146", "name": "us-

gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "unitRef": "U_USDollarShare", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": ["span", "p", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "sght-20240930.htm", "first": true, "unique": true } }, "R44": { "role": "http://www.sightsciences.com/20240930/taxonomy/role/DisclosureEquityIncentivePlansSummaryOfCompanyStockOptionActivityDetail", "longName": "995845 - Disclosure - Equity Incentive Plans - Summary of Company Stock Option Activity (Detail)", "shortName": "Equity Incentive Plans - Summary of Company Stock Option Activity (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "44", "firstAnchor": { "contextRef": "C_a14eeac2-b121-4629-9dd3-594df88b2446", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "unitRef": "U_shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["span", "p", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "div", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "sght-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_65414eb4-cf20-46fb-8a2e-a0aa6d34f146", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod", "unitRef": "U_shares", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["span", "p", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "div", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "sght-20240930.htm", "unique": true } }, "R45": { "role": "http://www.sightsciences.com/20240930/taxonomy/role/DisclosureEquityIncentivePlansSummaryOfStockBasedCompensationFairValueAssumptionsDetails", "longName": "995855 - Disclosure - Equity Incentive Plans - Summary of Stock Based Compensation Fair Value Assumptions (Details)", "shortName": "Equity Incentive Plans - Summary of Stock Based Compensation Fair Value Assumptions (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "45", "firstAnchor": { "contextRef": "C_65414eb4-cf20-46fb-8a2e-a0aa6d34f146", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTerm1", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "p", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "sght-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_65414eb4-cf20-46fb-8a2e-a0aa6d34f146", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTerm1", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "p", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "sght-20240930.htm", "first": true, "unique": true } }, "R46": { "role": "http://www.sightsciences.com/20240930/taxonomy/role/DisclosureEquityIncentivePlansSummaryOfSharebasedCompensationExpenseByFunctionDetails", "longName": "995865 - Disclosure - Equity Incentive Plans - Summary of Share-Based Compensation Expense By Function (Details)", "shortName": "Equity Incentive Plans - Summary of Share-Based Compensation Expense By Function (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "46", "firstAnchor": { "contextRef": "C_852b779c-14c2-48bf-9a41-ee0125dbe8e2", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "div", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "sght-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_852b779c-14c2-48bf-9a41-ee0125dbe8e2", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "div", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "sght-20240930.htm", "first": true, "unique": true } }, "R47": { "role": "http://www.sightsciences.com/20240930/taxonomy/role/DisclosureEquityIncentivePlansSummarizesRestrictedShareAwardActivityUnderThe2021PlanDetails", "longName": "995875 - Disclosure - Equity Incentive Plans - Summarizes restricted share award activity under the 2021 Plan (Details)", "shortName": "Equity Incentive Plans - Summarizes restricted share award activity under the 2021 Plan (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "47", "firstAnchor": { "contextRef": "C_f61f45d1-9677-4a6b-b5fa-9c095776e881", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "unitRef": "U_shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["span", "p", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock", "div", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "sght-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_f61f45d1-9677-4a6b-b5fa-9c095776e881", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "unitRef": "U_shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["span", "p", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock", "div", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "sght-20240930.htm", "first": true, "unique": true } }, "R48": { "role": "http://www.sightsciences.com/20240930/taxonomy/role/DisclosureNetLossPerShareAttributableToCommonStockholdersScheduleOfComputationOfBasicAndDilutedNetLossPerShareAttributableT "longName": "995885 - Disclosure - Net Loss Per Share Attributable to Common Stockholders - Schedule of Computation of Basic and Diluted Net Loss per Share Attributable to Common Stockholders (Details)", "shortName": "Net Loss Per Share Attributable to Common Stockholders - Schedule of Computation of Basic and Diluted Net Loss per Share Attributable to Common Stockholders (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "48", "firstAnchor": { "contextRef": "C_852b779c-14c2-48bf-9a41-ee0125dbe8e2", "name": "us-gaap:NetIncomeLoss", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "body", "html"], "reportCount": 1, "baseRef": "sght-20240930.htm", "first": true }, "uniqueAnchor": null }, "R49": { "role": "http://www.sightsciences.com/20240930/taxonomy/role/DisclosureNetLossPerShareAttributableToCommonStockholdersScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsP "longName": "995895 - Disclosure - Net Loss Per Share Attributable to Common Stockholders - Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share (Details)", "shortName": "Net Loss Per Share Attributable to Common Stockholders - Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "49", "firstAnchor": { "contextRef": "C_65414eb4-cf20-46fb-8a2e-a0aa6d34f146", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "unitRef": "U_shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["span", "p", "td", "tr", "table", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "div", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "sght-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_65414eb4-cf20-46fb-8a2e-a0aa6d34f146", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "unitRef": "U_shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["span", "p", "td", "tr", "table", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "div", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "sght-20240930.htm", "first": true, "unique": true } }, "R50": { "role": "http://www.sightsciences.com/20240930/taxonomy/role/DisclosureSegmentInformationAdditionalInformationDetails", "longName": "995915 - Disclosure - Segment Information - Additional Information (Details)", "shortName": "Segment Information - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "50", "firstAnchor": { "contextRef": "C_65414eb4-cf20-46fb-8a2e-a0aa6d34f146", "name": "us-gaap:NumberOfReportableSegments", "unitRef": "U_Segment", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["span", "p", "us-gaap:SegmentReportingDisclosureTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "sght-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_65414eb4-cf20-46fb-8a2e-a0aa6d34f146", "name": "us-gaap:NumberOfReportableSegments", "unitRef": "U_Segment", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["span", "p", "us-gaap:SegmentReportingDisclosureTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "sght-20240930.htm", "first": true, "unique": true } }, "R51": { "role": "http://www.sightsciences.com/20240930/taxonomy/role/Role_DisclosureSegmentInformationSummaryOfOperatingResultInformationForEachReportableSegmentDetails", "longName": "995925 - Disclosure - Segment Information - Summary of Operating Result Information for Each Reportable Segment (Details)", "shortName": "Segment Information - Summary of Operating Result Information for Each Reportable Segment (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "51", "firstAnchor": { "contextRef": "C_852b779c-14c2-48bf-9a41-ee0125dbe8e2", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "body", "html"], "reportCount": 1, "baseRef": "sght-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_50468d19-1b45-4ab4-892d-7775c3fa9758", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "div", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "sght-20240930.htm", "unique": true } } }, "tag": { "sght_AccountingForPayrollProtectionProgramPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.sightsciences.com/20240930", "localname": "AccountingForPayrollProtectionProgramPolicyTextBlock", "presentation": ["http://www.sightsciences.com/20240930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"], "lang": { "en-us": { "role": { "terseLabel": "Accounting for Payroll Protection Program", "label": "Accounting For Payroll Protection Program [Policy Text Block]", "documentation": "Accounting for payroll protection program." } } }, "auth_ref": [] }, "us-gaap_AccountingPoliciesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountingPoliciesAbstract", "lang": { "en-us": { "role": { "label": "Accounting Policies [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsPayableAndOtherAccruedLiabilitiesCurrent", "crdr": "credit", "presentation": ["http://www.sightsciences.com/20240930/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited"], "lang": { "en-us": { "role": { "label": "Accounts Payable and Other Accrued Liabilities, Current", "terseLabel": "Accrued and other current liabilities", "totalLabel": "Total accrued and other current liabilities", "documentation": "Amount of liabilities incurred to vendors for goods and services received, and accrued liabilities classified as other, payable within one year or the normal operating cycle, if longer." } } }, "auth_ref": [] }, "us-gaap_AccountsPayableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsPayableCurrent", "crdr": "credit", "presentation": ["http://www.sightsciences.com/20240930/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited"], "lang": { "en-us": { "role": { "totalLabel": "Accounts Payable, Current, Total", "terseLabel": "Accounts payable", "label": "Accounts Payable, Current", "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": ["r53", "r751"] }, "us-gaap_AccountsReceivableNetCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsReceivableNetCurrent", "crdr": "debit", "presentation": ["http://www.sightsciences.com/20240930/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited"], "lang": { "en-us": { "role": { "terseLabel": "Accounts receivable, net of allowance for credit losses of $824 and $1,186 at September 30, 2024 and December 31, 2023, respectively", "label": "Accounts Receivable, after Allowance for Credit Loss, Current", "totalLabel": "Accounts Receivable, after Allowance for Credit Loss, Current, Total", "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current." } } }, "auth_ref": ["r894"] }, "sght_AccruedAccretionOnMaturityPayments": { "xbrltype": "monetaryItemType", "nsuri": "http://www.sightsciences.com/20240930", "localname": "AccruedAccretionOnMaturityPayments", "crdr": "debit", "presentation": ["http://www.sightsciences.com/20240930/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails"], "lang": { "en-us": { "role": { "label": "Accrued Accretion On Maturity Payments", "documentation": "Accrued accretion on maturity payments.", "terseLabel": "Accrued amount related accretion on maturity payments" } } }, "auth_ref": [] }, "sght_AccruedAndOtherCurrentLiabilitiesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.sightsciences.com/20240930", "localname": "AccruedAndOtherCurrentLiabilitiesTableTextBlock", "presentation": ["http://www.sightsciences.com/20240930/taxonomy/role/Role_DisclosureBalanceSheetComponentsTables"], "lang": { "en-us": { "role": { "terseLabel": "Summary of Accrued and Other Current Liabilities", "label": "Accrued And Other Current Liabilities [Table Text Block]", "documentation": "Accrued and other current liabilities." } } }, "auth_ref": [] }, "us-gaap_AccruedLiabilitiesAndOtherLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccruedLiabilitiesAndOtherLiabilities", "crdr": "credit", "presentation": ["http://www.sightsciences.com/20240930/taxonomy/role/Role_DisclosureBalanceSheetComponentsSummaryOfAccruedAndOtherCurrentLiabilitiesDetails"], "lang": { "en-us": { "role": { "totalLabel": "Total accrued and other current liabilities", "label": "Accrued Liabilities and Other Liabilities", "documentation": "Amount of expenses incurred but not yet paid nor invoiced, and liabilities classified as other." } } }, "auth_ref": [] }, "us-gaap_AccruedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccruedLiabilitiesCurrent", "crdr": "credit", "presentation": ["http://www.sightsciences.com/20240930/taxonomy/role/Role_DisclosureBalanceSheetComponentsSummaryOfAccruedAndOtherCurrentLiabilitiesDetails"], "lang": { "en-us": { "role": { "label": "Accrued Liabilities, Current", "totalLabel": "Accrued Liabilities, Current, Total", "terseLabel": "Accrued expenses", "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": ["r56"] }, "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "crdr": "credit", "presentation": ["http://www.sightsciences.com/20240930/taxonomy/role/Role_DisclosureBalanceSheetComponentsSummaryOfPropertyAndEquipmentNetDetails"], "lang": { "en-us": { "role": { "negatedLabel": "Less: Accumulated depreciation", "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment", "totalLabel": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Total", "periodStartLabel": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Beginning Balance", "periodEndLabel": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Ending Balance", "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services." } } }, "auth_ref": ["r31", "r132", "r567"] }, "ecd_Additional402vDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "Additional402vDisclosureTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Additional 402(v) Disclosure [Text Block]", "terseLabel": "Additional 402(v) Disclosure" } } }, "auth_ref": ["r811"] }, "us-gaap_AdditionalPaidInCapitalCommonStock": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdditionalPaidInCapitalCommonStock", "crdr": "credit", "presentation": ["http://www.sightsciences.com/20240930/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited"], "lang": { "en-us": { "role": { "terseLabel": "Additional paid-in-capital", "label": "Additional Paid-in Capital, Common Stock", "periodStartLabel": "Additional Paid in Capital, Common Stock, Beginning Balance", "periodEndLabel": "Additional Paid in Capital, Common Stock, Ending Balance", "documentation": "Value received from shareholders in common stock related transactions that are in excess of par value or stated value and amounts received from other stock related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital." } } }, "auth_ref": ["r67"] }, "us-gaap_AdditionalPaidInCapitalMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdditionalPaidInCapitalMember", "presentation": ["http://www.sightsciences.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityUnaudited"], "lang": { "en-us": { "role": { "label": "Additional Paid-in Capital [Member]", "terseLabel": "Additional Paid-In Capital", "documentation": "Excess of issue price over par or stated value of the entity's

capital stock and amounts received from other transactions involving the entity's stock or stockholders." } } }, "auth_ref": ["r604", "r882", "r883", "r884", "r885", "r951", "r1012"] }, "ecd_AdjToCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToCompAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Adjustment to Compensation Amount", "terseLabel": "Adjustment to Compensation, Amount" } } }, "auth_ref": ["r824"] }, "ecd_AdjToCompAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToCompAxis", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Adjustment to Compensation [Axis]", "terseLabel": "Adjustment to Compensation:" } } }, "auth_ref": ["r824"] }, "ecd_AdjToNonPeoNeoCompFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToNonPeoNeoCompFnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Adjustment to Non-PEO NEO Compensation Footnote [Text Block]", "terseLabel": "Adjustment to Non-PEO NEO Compensation Footnote" } } }, "auth_ref": ["r824"] }, "ecd_AdjToPeoCompFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToPeoCompFnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Adjustment To PEO Compensation, Footnote [Text Block]", "terseLabel": "Adjustment To PEO Compensation, Footnote" } } }, "auth_ref": ["r824"] }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": ["http://www.sightsciences.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"], "lang": { "en-us": { "role": { "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:", "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]" } } }, "auth_ref": [] }, "ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtChngPnsnValInSummryCompstnTblForAplblYrMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member]", "terseLabel": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table" } } }, "auth_ref": ["r857"] }, "ecd_AggtErrCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtErrCompAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Aggregate Erroneous Compensation Amount", "terseLabel": "Aggregate Erroneous Compensation Amount" } } }, "auth_ref": ["r783", "r793", "r803", "r835"] }, "ecd_AggtErrCompNotYetDeterminedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtErrCompNotYetDeterminedTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Aggregate Erroneous Compensation Not Yet Determined [Text Block]", "terseLabel": "Aggregate Erroneous Compensation Not Yet Determined" } } }, "auth_ref": ["r786", "r796", "r806", "r838"] }, "ecd_AggtPnsnAdjsSvcCstMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtPnsnAdjsSvcCstMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Aggregate Pension Adjustments Service Cost [Member]", "terseLabel": "Aggregate Pension Adjustments Service Cost" } } }, "auth_ref": ["r858"] }, "ecd_AllAdjToCompMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllAdjToCompMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "All Adjustments to Compensation [Member]", "terseLabel": "All Adjustments to Compensation" } } }, "auth_ref": ["r824"] }, "ecd_AllExecutiveCategoriesMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllExecutiveCategoriesMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "All Executive Categories [Member]", "terseLabel": "All Executive Categories" } } }, "auth_ref": ["r831"] }, "ecd_AllIndividualsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllIndividualsMember", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "All Individuals [Member]", "terseLabel": "All Individuals" } } }, "auth_ref": ["r787", "r797", "r807", "r831", "r839", "r843", "r851"] }, "ecd_AllTradingArrangementsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllTradingArrangementsMember", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "All Trading Arrangements [Member]", "terseLabel": "All Trading Arrangements" } } }, "auth_ref": ["r849"] }, "us-gaap_AllocatedShareBasedCompensationExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AllocatedShareBasedCompensationExpense", "crdr": "debit", "presentation": ["http://www.sightsciences.com/20240930/taxonomy/role/DisclosureEquityIncentivePlansSummaryOfSharebasedCompensationExpenseByFunctionDetails"], "lang": { "en-us": { "role": { "terseLabel": "Total stock-based compensation expense", "label": "Share-Based Payment Arrangement, Expense", "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized." } } }, "auth_ref": ["r410", "r416"] }, "us-gaap_AllowanceForDoubtfulAccountsReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AllowanceForDoubtfulAccountsReceivable", "crdr": "credit", "presentation": ["http://www.sightsciences.com/20240930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Deferred costs, current", "label": "Accounts Receivable, Allowance for Credit Loss", "periodEndLabel": "Accounts Receivable, Allowance for Credit Loss, Ending Balance", "periodStartLabel": "Accounts Receivable, Allowance for Credit Loss, Beginning Balance", "documentation": "Amount of allowance for credit loss on accounts receivable." } } }, "auth_ref": ["r141", "r229", "r264", "r267", "r269", "r980"] }, "us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AllowanceForDoubtfulAccountsReceivableCurrent", "crdr": "credit", "presentation": ["http://www.sightsciences.com/20240930/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnauditedParenthetical"], "lang": { "en-us": { "role": { "terseLabel": "Accounts receivable, net of allowance for credit losses", "label": "Accounts Receivable, Allowance for Credit Loss, Current", "documentation": "Amount of allowance for credit loss on accounts receivable, classified as current." } } }, "auth_ref": ["r141", "r229", "r264"] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AmendmentFlag", "presentation": ["http://www.sightsciences.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "terseLabel": "Amendment Flag", "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "us-gaap_AmortizationOfFinancingCostsAndDiscounts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AmortizationOfFinancingCostsAndDiscounts", "crdr": "debit", "presentation": ["http://www.sightsciences.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"], "lang": { "en-us": { "role": { "terseLabel": "Accretion of debt discount and debt issuance costs", "label": "Amortization of Debt Issuance Costs and Discounts", "totalLabel": "Amortization of Debt Issuance Costs and Discounts, Total", "documentation": "Amount of amortization expense attributable to debt discount (premium) and debt issuance costs." } } }, "auth_ref": ["r342", "r725", "r726", "r877", "r963"] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "presentation": ["http://www.sightsciences.com/20240930/taxonomy/role/DisclosureNetLossPerShareAttributableToCommonStockholdersScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPe], "lang": { "en-us": { "role": { "terseLabel": "Redeemable convertible preferred stock", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount", "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented." } } }, "auth_ref": ["r185"] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis", "presentation": ["http://www.sightsciences.com/20240930/taxonomy/role/DisclosureNetLossPerShareAttributableToCommonStockholdersScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPe], "lang": { "en-us": { "role": { "terseLabel": "Antidilutive Securities", "label": "Antidilutive Securities [Axis]", "documentation": "Information by type of antidilutive security." } } }, "auth_ref": ["r23"] }, "us-gaap_AntidilutiveSecuritiesNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesNameDomain", "presentation": ["http://www.sightsciences.com/20240930/taxonomy/role/DisclosureNetLossPerShareAttributableToCommonStockholdersScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPe], "lang": { "en-us": { "role": { "terseLabel": "Antidilutive Securities, Name", "label": "Antidilutive Securities, Name [Domain]", "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented." } } }, "auth_ref": ["r23"] }, "us-gaap_AreaOfLand": { "xbrltype": "areaItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AreaOfLand", "presentation": ["http://www.sightsciences.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Operating lease office space", "label": "Area of Land", "documentation": "Area of land held." } } }, "auth_ref": [] }, "us-gaap_Assets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Assets", "crdr": "debit", "presentation": ["http://www.sightsciences.com/20240930/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited"], "lang": { "en-us": { "role": { "totalLabel": "Total assets", "label": "Assets", "documentation": "Amount of asset recognized for present right to economic benefit." } } }, "auth_ref": ["r102", "r113", "r134", "r160", "r189", "r197", "r216", "r220", "r261", "r311", "r312", "r313", "r314", "r315", "r316", "r317", "r318", "r319", "r432", "r436", "r464", "r560", "r641", "r713", "r714", "r751", "r774", "r918", "r919", "r969"] }, "us-gaap_AssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsAbstract", "presentation": ["http://www.sightsciences.com/20240930/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited"], "lang": { "en-us": { "role": { "terseLabel": "Assets", "label": "Assets [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsCurrent", "crdr": "debit", "presentation": ["http://www.sightsciences.com/20240930/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited"], "lang": { "en-us": { "role": { "totalLabel": "Total current assets", "label": "Assets, Current", "documentation": "Amount of asset recognized for present right to economic benefit, classified as current." } } }, "auth_ref": ["r128", "r143", "r160", "r261", "r311", "r312", "r313", "r314", "r315", "r316", "r317", "r318", "r319", "r432", "r436", "r464", "r751", "r918", "r919", "r969"] }, "us-gaap_AssetsCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsCurrentAbstract", "presentation": ["http://www.sightsciences.com/20240930/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited"], "lang": { "en-us": { "role": { "terseLabel": "Current assets:", "label": "Assets, Current [Abstract]" } } }, "auth_ref": [] }, "ecd_AwardExrcPrice": { "xbrltype": "perShareItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardExrcPrice", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Award Exercise Price", "terseLabel": "Exercise Price" } } }, "auth_ref": ["r846"] }, "ecd_AwardGrantDateFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardGrantDateFairValue", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Award Grant Date Fair Value", "terseLabel": "Fair Value as of Grant Date" } } }, "auth_ref": ["r847"] }, "ecd_AwardTmgDiscLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgDiscLineItems", "lang": { "en-us": { "role": { "label": "Award Timing Disclosures [Line Items]", "terseLabel": "Award Timing Disclosures" } } }, "auth_ref": ["r842"] }, "ecd_AwardTmgHowMnpiCnsdrdTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgHowMnpiCnsdrdTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Award Timing, How MNPI Considered [Text Block]", "terseLabel": "Award Timing, How MNPI Considered" } } }, "auth_ref": ["r842"] }, "ecd_AwardTmgMethodTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgMethodTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Award Timing Method [Text Block]", "terseLabel": "Award Timing Method" } } }, "auth_ref": ["r842"] }, "ecd_AwardTmgMnpiCnsdrdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgMnpiCnsdrdFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Award Timing MNPI Considered [Flag]", "terseLabel": "Award Timing MNPI Considered" } } }, "auth_ref": ["r842"] }, "ecd_AwardTmgMnpiDiscTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgMnpiDiscTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Award Timing MNPI Disclosure [Text Block]", "terseLabel": "Award Timing MNPI Disclosure" } } }, "auth_ref": ["r842"] }, "ecd_AwardTmgPredtrmndFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgPredtrmndFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Award Timing Predetermined [Flag]", "terseLabel": "Award Timing Predetermined" } } }, "auth_ref": ["r842"] }, "us-gaap_AwardTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AwardTypeAxis", "presentation": ["http://www.sightsciences.com/20240930/taxonomy/role/DisclosureEquityIncentivePlansAdditionalInformationDetail", "http://www.sightsciences.com/20240930/taxonomy/role/DisclosureEquityIncentivePlansSummarizesRestrictedShareAwardActivityUnderThe2021PlanDetails", "http://www.sightsciences.com/20240930/taxonomy/role/DisclosureNetLossPerShareAttributableToCommonStockholdersScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPe "http://www.sightsciences.com/20240930/taxonomy/role/DisclosureStockholdersEquityScheduleOfReservedCommonStockForFutureIssuancesDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Award Type [Axis]", "terseLabel": "Award Type", "documentation": "Information by type of award under share-based payment arrangement." } } }, "auth_ref": ["r384", "r385", "r386", "r387", "r388", "r389", "r390", "r391", "r392", "r393", "r394", "r395", "r396", "r397", "r398", "r399", "r400", "r401", "r402", "r403", "r404", "r405", "r406", "r407", "r408", "r409"] }, "ecd_AwardUndrlygSecuritiesAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardUndrlygSecuritiesAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Award Underlying Securities Amount", "terseLabel": "Underlying Securities" } } }, "auth_ref": ["r845"] }, "ecd_AwardsCloseToMnpiDiscIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardsCloseToMnpiDiscIndName", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Awards Close in Time to MNPI Disclosures, Individual Name", "terseLabel": "Name" } } }, "auth_ref": ["r844"] }, "ecd_AwardsCloseToMnpiDiscTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardsCloseToMnpiDiscTable", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Awards Close in Time to MNPI Disclosures [Table]", "terseLabel": "Awards Close in Time to MNPI Disclosures" } } }, "auth_ref": ["r843"] }, "ecd_AwardsCloseToMnpiDiscTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardsCloseToMnpiDiscTableTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Awards Close in Time to MNPI Disclosures [Table Text Block]", "terseLabel": "Awards Close in Time to MNPI Disclosures, Table" } } }, "auth_ref": ["r843"] }, "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BasisOfAccountingPolicyPolicyTextBlock", "presentation": ["http://www.sightsciences.com/20240930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"], "lang": { "en-us": { "role": { "terseLabel": "Basis of Presentation", "label": "Basis of Accounting, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)." } } }, "auth_ref": [] }, "stpr_CA": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/stpr/2024", "localname": "CA", "presentation": ["http://www.sightsciences.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"], "lang": { "en-us": { "role": { "label": "CALIFORNIA", "terseLabel": "California [Member]" } } }, "auth_ref": [] }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024",

"localname": "CashAndCashEquivalentsAtCarryingValue", "crdr": "debit", "presentation": [
"http://www.sightsciences.com/20240930/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited"], "lang": { "en-us": { "role": { "terseLabel": "Cash and cash equivalents", "periodStartLabel": "Cash and cash equivalents at beginning of period", "periodEndLabel": "Cash and cash equivalents at end of period", "label": "Cash and Cash Equivalents, at Carrying Value", "totalLabel": "Cash and Cash Equivalents, at Carrying Value, Total", "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation." } } }, "auth_ref": ["r18", "r130", "r703"] }, "us-gaap_CashAndCashEquivalentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "CashAndCashEquivalentsAxis", "presentation": [
"http://www.sightsciences.com/20240930/taxonomy/role/DisclosureFairValueMeasurementHeldtomaturityDebtSecuritiesAtAmortizedCostDetails"], "lang": { "en-us": { "role": { "label": "Cash and Cash Equivalents [Axis]", "documentation": "Information by type of cash and cash equivalent balance." } } }, "auth_ref": ["r130"] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "crdr": "debit", "presentation": [
"http://www.sightsciences.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"], "lang": { "en-us": { "role": { "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents", "totalLabel": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Total", "periodStartLabel": "Cash and cash equivalents at beginning of period", "periodEndLabel": "Cash and cash equivalents at end of period", "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": ["r18", "r84", "r156"] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "xbrltype": "monetaryItemType",
"nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "crdr": "debit",
"presentation": ["http://www.sightsciences.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"], "lang": { "en-us": { "role": { "totalLabel": "Net change in cash and cash equivalents", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
"documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage, including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": ["r0", "r84"] }, "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": { "xbrltype":
"stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract", "presentation": [
"http://www.sightsciences.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"], "lang": { "en-us": { "role": { "terseLabel": "Supplemental noncash disclosure of investing and financing activities", "label": "Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]" } } }, "auth_ref": [] },
"ecd_ChangedPeerGroupFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ChangedPeerGroupFnTextBlock", "presentation": [
"http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Changed Peer Group, Footnote [Text Block]", "terseLabel": "Changed Peer Group, Footnote" } } }, "auth_ref": ["r822"] }, "ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname":
"ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member]", "terseLabel": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year" } } }, "auth_ref": ["r819"] }, "ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname":
"ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member]", "terseLabel": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested" } } }, "auth_ref": ["r817"] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024",
"localname": "CityAreaCode", "presentation": ["http://www.sightsciences.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": {
"terseLabel": "City Area Code", "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "us-gaap_ClassOfStockDomain": { "xbrltype": "domainItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "ClassOfStockDomain", "presentation": [
"http://www.sightsciences.com/20240930/taxonomy/role/DisclosureNetLossPerShareAttributableToCommonStockholdersScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPe
"http://www.sightsciences.com/20240930/taxonomy/role/DisclosureStockholdersEquityScheduleOfReservedCommonStockForFutureIssuancesDetails",
"http://www.sightsciences.com/20240930/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails",
"http://www.sightsciences.com/20240930/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFairValueMeasurementLiabilitiesMeasuredOnRecurringBasisDetails",
"http://www.sightsciences.com/20240930/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnauditedParenthetical",
"http://www.sightsciences.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited",
"http://www.sightsciences.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityUnaudited"], "lang": {
"en-us": { "role": { "terseLabel": "Class of Stock", "label": "Class of Stock [Domain]", "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock." } } }, "auth_ref": ["r124", "r138", "r139", "r140", "r160", "r179", "r180", "r182", "r184", "r191", "r192", "r261", "r311", "r313", "r314", "r315", "r318", "r319", "r352", "r353", "r355", "r358", "r365", "r464", "r598", "r599", "r600", "r601", "r604", "r605", "r606", "r607", "r608", "r609", "r610", "r611", "r612", "r613", "r614", "r615", "r629", "r650", "r668", "r682", "r683", "r684", "r685", "r686", "r862", "r878", "r886"] }, "us-gaap_ClassOfWarrantOrRightAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfWarrantOrRightAxis", "presentation": [
"http://www.sightsciences.com/20240930/taxonomy/role/Role_DisclosureCompanyAndNatureOfBusinessAdditionalInformationDetails",
"http://www.sightsciences.com/20240930/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Class of Warrant or Right", "label":
"Class of Warrant or Right [Axis]", "documentation": "Information by type of warrant or right issued." } } }, "auth_ref": ["r43"] }, "us-gaap_ClassOfWarrantOrRightDomain": { "xbrltype":
"domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfWarrantOrRightDomain", "presentation": [
"http://www.sightsciences.com/20240930/taxonomy/role/Role_DisclosureCompanyAndNatureOfBusinessAdditionalInformationDetails",
"http://www.sightsciences.com/20240930/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Class of Warrant or Right", "label":
"Class of Warrant or Right [Domain]", "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months." } } }, "auth_ref": [] }, "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1", "presentation": [
"http://www.sightsciences.com/20240930/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails",
"http://www.sightsciences.com/20240930/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails"], "lang": { "en-us": { "role": { "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights", "terseLabel": "Class of warrant exercise price", "documentation": "Exercise price per share or per unit of warrants or rights outstanding." } } }, "auth_ref": ["r366"] }, "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights", "presentation": [
"http://www.sightsciences.com/20240930/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails",
"http://www.sightsciences.com/20240930/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails"], "lang": { "en-us": { "role": { "label": "Class of Warrant or Right, Number of Securities Called by Warrants or Rights", "verboseLabel": "Warrants issued to purchase shares of convertible preferred stock", "terseLabel": "Warrants to purchase common stock",
"documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares." }
} }, "auth_ref": ["r366"] }, "us-gaap_ClassOfWarrantOrRightOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ClassOfWarrantOrRightOutstanding", "presentation": ["http://www.sightsciences.com/20240930/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails"], "lang": { "en-us":
{ "role": { "label": "Class of Warrant or Right, Outstanding", "terseLabel": "Warrant outstanding", "documentation": "Number of warrants or rights outstanding." } } }, "auth_ref": [] }, "us-gaap_ClassOfWarrantOrRightUnissued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfWarrantOrRightUnissued", "presentation": [
"http://www.sightsciences.com/20240930/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails"], "lang": { "en-us": { "role": { "label": "Class of Warrant or Right, Unissued", "documentation": "The number of warrants or rights which entitle the entity to receive future services in exchange for the unvested, forfeitable warrants or rights." } } }, "auth_ref":
[] }, "sght_ClassOfWarrantOrRightWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://www.sightsciences.com/20240930", "localname":
"ClassOfWarrantOrRightWeightedAverageExercisePrice", "presentation": ["http://www.sightsciences.com/20240930/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails"
], "lang": { "en-us": { "role": { "terseLabel": "Weighted average exercise price", "label": "Class Of Warrant Or Right Weighted Average Exercise Price", "documentation": "Class of warrant or right weighted average exercise price." } } }, "auth_ref": [] }, "ecd_CoSelectedMeasureAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname":
"CoSelectedMeasureAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Company Selected Measure Amount", "terseLabel": "Company Selected Measure Amount" } } }, "auth_ref": ["r823"] }, "ecd_CoSelectedMeasureName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname":
"CoSelectedMeasureName", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Company Selected Measure Name", "terseLabel": "Company Selected Measure Name" } } }, "auth_ref": ["r823"] }, "us-gaap_CommitmentsAndContingencies": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"CommitmentsAndContingencies", "crdr": "credit", "presentation": ["http://www.sightsciences.com/20240930/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited"],
"lang": { "en-us": { "role": { "terseLabel": "Commitments and contingencies (Note 6)", "label": "Commitments and Contingencies", "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur." } } }, "auth_ref": ["r62", "r105", "r561", "r628"] }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"CommitmentsAndContingenciesDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Commitments and Contingencies Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"CommitmentsAndContingenciesDisclosureTextBlock", "presentation": ["http://www.sightsciences.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingencies"], "lang": {
"en-us": { "role": { "terseLabel": "Commitments and Contingencies", "label": "Commitments and Contingencies Disclosure [Text Block]", "documentation": "The entire disclosure for commitments and contingencies." } } }, "auth_ref": ["r91", "r301", "r302", "r689", "r905", "r911"] }, "sght_CommonStockAvailableForFutureGrantMember": { "xbrltype": "domainItemType",
"nsuri": "http://www.sightsciences.com/20240930", "localname": "CommonStockAvailableForFutureGrantMember", "presentation": [
"http://www.sightsciences.com/20240930/taxonomy/role/DisclosureStockholdersEquityScheduleOfReservedCommonStockForFutureIssuancesDetails"], "lang": { "en-us": { "role": {
"documentation": "Common stock available for future grant.", "label": "Common Stock Available For Future Grant [Member]", "terseLabel": "Common stock available for future grants" } } },
"auth_ref": [] }, "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"CommonStockCapitalSharesReservedForFutureIssuance", "presentation": [
"http://www.sightsciences.com/20240930/taxonomy/role/DisclosureEquityIncentivePlansAdditionalInformationDetail",
"http://www.sightsciences.com/20240930/taxonomy/role/DisclosureStockholdersEquityScheduleOfReservedCommonStockForFutureIssuancesDetails"], "lang": { "en-us": { "role": {
"terseLabel": "Common stock reserved for future issuance", "label": "Common Stock, Capital Shares Reserved for Future Issuance", "verboseLabel": "Common stock reserved for future issuance", "documentation": "Aggregate number of common shares reserved for future issuance." } } }, "auth_ref": ["r66"] }, "us-gaap_CommonStockMember": { "xbrltype":
"domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockMember", "presentation": [
"http://www.sightsciences.com/20240930/taxonomy/role/Role_DisclosureCompanyAndNatureOfBusinessAdditionalInformationDetails",
"http://www.sightsciences.com/20240930/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails",
"http://www.sightsciences.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityUnaudited"], "lang": {
"en-us": { "role": { "terseLabel": "Common Stock", "label": "Common Stock [Member]", "documentation": "Stock that is subordinate to all other stock of the issuer." } } }, "auth_ref": ["r764", "r765", "r766", "r768", "r769", "r770", "r771", "r882", "r883", "r885", "r951", "r1011", "r1012"] }, "sght_CommonStockOptionsIssuedAndOutstandingMember": { "xbrltype": "domainItemType",
"nsuri": "http://www.sightsciences.com/20240930", "localname": "CommonStockOptionsIssuedAndOutstandingMember", "presentation": [
"http://www.sightsciences.com/20240930/taxonomy/role/DisclosureStockholdersEquityScheduleOfReservedCommonStockForFutureIssuancesDetails"], "lang": { "en-us": { "role": {
"documentation": "Common stock options issued and outstanding.", "label": "Common Stock Options Issued And Outstanding [Member]", "terseLabel": "Common stock options issued and outstanding" } } }, "auth_ref": [] }, "us-gaap_CommonStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"CommonStockParOrStatedValuePerShare", "presentation": ["http://www.sightsciences.com/20240930/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails",
"http://www.sightsciences.com/20240930/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnauditedParenthetical"], "lang": { "en-us": { "role": { "terseLabel": "Common stock,

par value", "label": "Common Stock, Par or Stated Value Per Share", "documentation": "Face amount or stated value per share of common stock." } } }, "auth_ref": ["r66"] }, "us-gaap_CommonStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesAuthorized", "presentation": ["http://www.sightsciences.com/20240930/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails", "http://www.sightsciences.com/20240930/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnauditedParenthetical"], "lang": { "en-us": { "role": { "terseLabel": "Common stock, shares authorized", "label": "Common Stock, Shares Authorized", "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": ["r66", "r629"] }, "us-gaap_CommonStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesIssued", "presentation": ["http://www.sightsciences.com/20240930/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails", "http://www.sightsciences.com/20240930/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnauditedParenthetical"], "lang": { "en-us": { "role": { "terseLabel": "Common stock, shares issued", "label": "Common Stock, Shares, Issued", "totalLabel": "Common Stock, Shares, Issued, Total", "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury." } } }, "auth_ref": ["r66"] }, "us-gaap_CommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesOutstanding", "presentation": ["http://www.sightsciences.com/20240930/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnauditedParenthetical"], "lang": { "en-us": { "role": { "terseLabel": "Common stock, shares outstanding", "label": "Common Stock, Shares, Outstanding", "periodStartLabel": "Common Stock, Shares, Outstanding, Beginning Balance", "periodEndLabel": "Common Stock, Shares, Outstanding, Ending Balance", "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation." } } }, "auth_ref": ["r10", "r66", "r629", "r647", "r1012", "r1013"] }, "us-gaap_CommonStockSharesSubscribedButUnissued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesSubscribedButUnissued", "presentation": ["http://www.sightsciences.com/20240930/taxonomy/role/Role_DisclosureFairValueMeasurementAdditionalInformationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Common Stock, Shares Subscribed but Unissued", "label": "Common Stock, Shares Subscribed but Unissued", "documentation": "Amount of common stock allocated to investors to buy shares of a new issue of common stock before they are offered to the public. When stock is sold on a subscription basis, the issuer does not initially receive the total proceeds. In general, the issuer does not issue the shares to the investor until it receives the entire proceeds." } } }, "auth_ref": ["r66"] }, "us-gaap_CommonStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockValue", "crdr": "credit", "presentation": ["http://www.sightsciences.com/20240930/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited"], "lang": { "en-us": { "role": { "terseLabel": "Common stock, par value $0.001 per share; 200,000,000 shares authorized; 50,398,148 and 49,131,363 shares issued and outstanding as of September 30, 2024 and December 31, 2023, respectively", "label": "Common Stock, Value, Issued", "totalLabel": "Common Stock, Value, Issued, Total", "periodStartLabel": "Common Stock, Value, Issued, Beginning Balance", "periodEndLabel": "Common Stock, Value, Issued, Ending Balance", "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": ["r66", "r563", "r751"] }, "sght_CommonStockVoteForEachShare": { "xbrltype": "integerItemType", "nsuri": "http://www.sightsciences.com/20240930", "localname": "CommonStockVoteForEachShare", "presentation": ["http://www.sightsciences.com/20240930/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Number of votes entitled per share of common stock", "label": "Common Stock Vote for Each Share", "documentation": "Common stock, vote for each share." } } }, "auth_ref": [] }, "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Company Selected Measure [Text Block]", "terseLabel": "Compensation Actually Paid vs. Company Selected Measure" } } }, "auth_ref": ["r828"] }, "ecd_CompActuallyPaidVsNetIncomeTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsNetIncomeTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Net Income [Text Block]", "terseLabel": "Compensation Actually Paid vs. Net Income" } } }, "auth_ref": ["r827"] }, "ecd_CompActuallyPaidVsOtherMeasureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsOtherMeasureTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Other Measure [Text Block]", "terseLabel": "Compensation Actually Paid vs. Other Measure" } } }, "auth_ref": ["r829"] }, "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Total Shareholder Return [Text Block]", "terseLabel": "Compensation Actually Paid vs. Total Shareholder Return" } } }, "auth_ref": ["r826"] }, "us-gaap_ComputerEquipmentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ComputerEquipmentMember", "presentation": ["http://www.sightsciences.com/20240930/taxonomy/role/Role_DisclosureBalanceSheetComponentsSummaryOfPropertyAndEquipmentNetDetails"], "lang": { "en-us": { "role": { "terseLabel": "Computer Equipment and Software", "label": "Computer Equipment [Member]", "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems." } } }, "auth_ref": [] }, "us-gaap_ConstructionInProgressMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConstructionInProgressMember", "presentation": ["http://www.sightsciences.com/20240930/taxonomy/role/Role_DisclosureBalanceSheetComponentsSummaryOfPropertyAndEquipmentNetDetails"], "lang": { "en-us": { "role": { "terseLabel": "Construction In Process", "label": "Construction in Progress [Member]", "documentation": "Structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service." } } }, "auth_ref": [] }, "sght_ConversionAndReclassificationOfPreferredStockWarrantsToCommonStockWarrantsUponInitialPublicOffering": { "xbrltype": "monetaryItemType", "nsuri": "http://www.sightsciences.com/20240930", "localname": "ConversionAndReclassificationOfPreferredStockWarrantsToCommonStockWarrantsUponInitialPublicOffering", "crdr": "credit", "presentation": ["http://www.sightsciences.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityUnaudited"], "lang": { "en-us": { "role": { "terseLabel": "Conversion of redeemable convertible preferred stock warrants to common stock warrants upon initial public offering", "label": "Conversion and Reclassification of Preferred Stock Warrants to Common Stock Warrants Upon Initial Public Offering", "documentation": "Conversion and reclassification of preferred stock warrants to common stock warrants upon initial public offering." } } }, "auth_ref": [] }, "sght_ConversionAndReclassificationOfPreferredStockWarrantsToCommonStockWarrantsUponInitialPublicOfferingShares": { "xbrltype": "sharesItemType", "nsuri": "http://www.sightsciences.com/20240930", "localname": "ConversionAndReclassificationOfPreferredStockWarrantsToCommonStockWarrantsUponInitialPublicOfferingShares", "presentation": ["http://www.sightsciences.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityUnaudited"], "lang": { "en-us": { "role": { "terseLabel": "Conversion and reclassification of preferred stock warrants to common stock warrants upon initial public offering, shares", "label": "Conversion and Reclassification of Preferred Stock Warrants to Common Stock Warrants Upon Initial Public Offering, Shares", "documentation": "Conversion and Reclassification of Preferred Stock Warrants to Common Stock Warrants Upon Initial Public Offering, Shares" } } }, "auth_ref": [] }, "us-gaap_ConversionOfStockSharesIssued1": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConversionOfStockSharesIssued1", "presentation": ["http://www.sightsciences.com/20240930/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails"], "lang": { "en-us": { "role": { "label": "Conversion of Stock, Shares Issued", "terseLabel": "Share of common stock issued upon warrant exercised", "documentation": "The number of new shares issued in the conversion of stock in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period." } } }, "auth_ref": ["r20", "r21", "r22"] }, "us-gaap_CostOfGoodsAndServicesSold": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CostOfGoodsAndServicesSold", "crdr": "debit", "presentation": ["http://www.sightsciences.com/20240930/taxonomy/role/Role_DisclosureSegmentInformationSummaryOfOperatingResultInformationForEachReportableSegmentDetails", "http://www.sightsciences.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited"], "lang": { "en-us": { "role": { "negatedLabel": "Total", "terseLabel": "Cost of goods sold", "label": "Cost of Goods and Services Sold", "totalLabel": "Cost of Goods and Services Sold, Total", "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities." } } }, "auth_ref": ["r74", "r75", "r524"] }, "us-gaap_CostOfGoodsAndServicesSoldAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CostOfGoodsAndServicesSoldAbstract", "presentation": ["http://www.sightsciences.com/20240930/taxonomy/role/Role_DisclosureSegmentInformationSummaryOfOperatingResultInformationForEachReportableSegmentDetails"], "lang": { "en-us": { "role": { "terseLabel": "Cost of goods sold", "label": "Cost of Goods and Services Sold [Abstract]" } } }, "auth_ref": [] }, "us-gaap_CostOfSalesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CostOfSalesMember", "presentation": ["http://www.sightsciences.com/20240930/taxonomy/role/DisclosureEquityIncentivePlansSummaryOfSharebasedCompensationExpenseByFunctionDetails"], "lang": { "en-us": { "role": { "terseLabel": "Cost of Goods Sold", "label": "Cost of Sales [Member]", "documentation": "Primary financial statement caption encompassing cost of sales." } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "us-gaap_CreditFacilityAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CreditFacilityAxis", "presentation": ["http://www.sightsciences.com/20240930/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails", "http://www.sightsciences.com/20240930/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails"], "lang": { "en-us": { "role": { "label": "Credit Facility [Axis]", "terseLabel": "Credit Facility", "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing." } } }, "auth_ref": ["r310", "r916"] }, "us-gaap_CreditFacilityDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CreditFacilityDomain", "presentation": ["http://www.sightsciences.com/20240930/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails", "http://www.sightsciences.com/20240930/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Credit Facility", "label": "Credit Facility [Domain]", "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing." } } }, "auth_ref": ["r310", "r916", "r917"] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CurrentFiscalYearEndDate", "presentation": ["http://www.sightsciences.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "terseLabel": "Current Fiscal Year End Date", "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "us-gaap_DebtDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Debt Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_DebtDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtDisclosureTextBlock", "presentation": ["http://www.sightsciences.com/20240930/taxonomy/role/Role_DisclosureDebt"], "lang": { "en-us": { "role": { "terseLabel": "Debt", "label": "Debt Disclosure [Text Block]", "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants." } } }, "auth_ref": ["r92", "r158", "r290", "r291", "r292", "r293", "r294", "r309", "r310", "r320", "r326", "r327", "r328", "r329", "r330", "r331", "r336", "r343", "r344", "r346", "r473"] }, "us-gaap_DebtInstrumentAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentAxis", "presentation": ["http://www.sightsciences.com/20240930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails", "http://www.sightsciences.com/20240930/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails", "http://www.sightsciences.com/20240930/taxonomy/role/Role_DisclosureDebtScheduleOfLongTermAndShortTermDebtDetails"], "lang": { "en-us": { "role": { "terseLabel": "Debt Instrument", "label": "Debt Instrument [Axis]", "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities." } } }, "auth_ref": ["r14", "r55", "r56", "r103", "r104", "r161", "r321", "r322", "r323", "r324", "r325", "r327", "r332", "r333", "r334", "r335", "r337", "r338", "r339", "r340", "r341", "r342", "r722", "r723", "r724", "r725", "r726", "r748", "r879", "r906", "r907", "r908", "r962", "r964"] }, "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentBasisSpreadOnVariableRate1", "presentation": ["http://www.sightsciences.com/20240930/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails"], "lang": { "en-us": { "role": { "label": "Debt Instrument, Basis Spread on Variable Rate", "terseLabel": "Debt instrument, variable rate", "documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument." } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentCarryingAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentCarryingAmount", "crdr": "credit", "presentation": ["http://www.sightsciences.com/20240930/taxonomy/role/Role_DisclosureDebtScheduleOfLongTermAndShortTermDebtDetails"], "lang": { "en-us": { "role": { "label": "Long-Term Debt, Gross", "terseLabel": "Total principal payments due", "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt." } } }, "auth_ref": ["r14", "r104", "r347"] }, "us-gaap_DebtInstrumentCovenantDescription": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentCovenantDescription", "presentation": ["http://www.sightsciences.com/20240930/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Debt Instrument, Covenant Description", "label": "Debt Instrument, Covenant Description", "documentation": "Description of minimum financial levels (for example, tangible net worth and working capital) and achievement of certain financial ratios (for example, working capital ratio and debt service coverage ratio), and adherence to certain clauses which generally require or restrict certain actions (for example, entering into a debt arrangement with equal or greater seniority, and selling or discontinuing a certain business segment or material subsidiary) to be in compliance with the covenant clauses of the debt agreement. May also include a discussion of the adverse consequences that would result if the entity violates or fails to satisfy the covenants." } } }, "auth_ref": ["r14", "r52"] }, "sght_DebtInstrumentCovenantMaximumRevenue": { "xbrltype": "monetaryItemType", "nsuri": "http://www.sightsciences.com/20240930", "localname": "DebtInstrumentCovenantMaximumRevenue", "crdr": "credit", "presentation": ["http://www.sightsciences.com/20240930/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails"], "lang": { "en-us": { "role": { "label": "Debt Instrument Covenant Maximum Revenue", "documentation": "Debt instrument covenant maximum revenue.", "terseLabel": "Debt instrument covenant

maximum revenue" } } }, "auth_ref": [] }, "sght_DebtInstrumentCovenantMinimumRevenue": { "xbrltype": "monetaryItemType", "nsuri": "http://www.sightsciences.com/20240930", "localname": "DebtInstrumentCovenantMinimumRevenue", "crdr": "credit", "presentation": ["http://www.sightsciences.com/20240930/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails"], "lang": { "en-us": { "role": { "label": "Debt Instrument Covenant Minimum Revenue", "documentation": "Debt instrument covenant minimum revenue.", "terseLabel": "Debt instrument covenant minimum revenue" } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentFairValue", "crdr": "credit", "presentation": ["http://www.sightsciences.com/20240930/taxonomy/role/Role_DisclosureFairValueMeasurementAdditionalInformationDetails"], "lang": { "en-us": { "role": { "label": "Debt Instrument, Fair Value Disclosure", "totalLabel": "Debt Instrument, Fair Value Disclosure, Total", "terseLabel": "Fair value of outstanding debt", "documentation": "Fair value portion of debt instrument payable, including, but not limited to, notes payable and loans payable." } } }, "auth_ref": ["r334", "r463", "r723", "r724", "r954", "r955", "r956", "r957", "r958"] }, "sght_DebtInstrumentFairValueAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://www.sightsciences.com/20240930", "localname": "DebtInstrumentFairValueAmount", "crdr": "credit", "presentation": [
"http://www.sightsciences.com/20240930/taxonomy/role/Role_DisclosureFairValueMeasurementAdditionalInformationDetails"], "lang": { "en-us": { "role": { "documentation": "Debt Instrument Fair Value, Amount", "label": "Debt Instrument Fair Value Amount", "terseLabel": "Debt Instrument, Fair Value Amount" } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentFrequencyOfPeriodicPayment": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentFrequencyOfPeriodicPayment", "presentation": ["http://www.sightsciences.com/20240930/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails"], "lang": { "en-us": { "role": { "label": "Debt Instrument, Frequency of Periodic Payment", "terseLabel": "Debt instrument, frequency of periodic payment", "documentation": "Description of the frequency of periodic payments (monthly, quarterly, annual)." } } }, "auth_ref": ["r14", "r51"] }, "sght_DebtInstrumentInterestPaymentExtendedTerm": { "xbrltype": "durationItemType", "nsuri": "http://www.sightsciences.com/20240930", "localname": "DebtInstrumentInterestPaymentExtendedTerm", "presentation": ["http://www.sightsciences.com/20240930/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails"], "lang": { "en-us": { "role": { "documentation": "Debt instrument interest payment extended term.", "label": "Debt Instrument Interest Payment Extended Term", "terseLabel": "Debt instrument interest payment extended term" } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentInterestRateDuringPeriod": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentInterestRateDuringPeriod", "presentation": ["http://www.sightsciences.com/20240930/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Interest Rate During Period", "label": "Debt Instrument, Interest Rate During Period", "documentation": "The average effective interest rate during the reporting period." } } }, "auth_ref": ["r58", "r339", "r962"] }, "us-gaap_DebtInstrumentInterestRateEffectivePercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentInterestRateEffectivePercentage", "presentation": ["http://www.sightsciences.com/20240930/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails"], "lang": { "en-us": { "role": { "label": "Debt Instrument, Interest Rate, Effective Percentage", "terseLabel": "Debt instrument, effective interest rate", "documentation": "Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium." } } }, "auth_ref": ["r58", "r349", "r473", "r474", "r748"] }, "us-gaap_DebtInstrumentInterestRateStatedPercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentInterestRateStatedPercentage", "presentation": ["http://www.sightsciences.com/20240930/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Debt Instrument, Initial interest rate", "label": "Debt Instrument, Interest Rate, Stated Percentage", "documentation": "Contractual interest rate for funds borrowed, under the debt agreement." } } }, "auth_ref": ["r58", "r322"] }, "us-gaap_DebtInstrumentLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentLineItems", "presentation": [
"http://www.sightsciences.com/20240930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
"http://www.sightsciences.com/20240930/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails",
"http://www.sightsciences.com/20240930/taxonomy/role/Role_DisclosureDebtScheduleOfLongTermAndShortTermDebtDetails"], "lang": { "en-us": { "role": { "terseLabel": "Debt Instrument [Line Items]", "label": "Debt Instrument [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r161", "r321", "r322", "r323", "r324", "r325", "r327", "r332", "r333", "r334", "r335", "r337", "r338", "r339", "r340", "r341", "r342", "r345", "r722", "r723", "r724", "r725", "r726", "r748", "r879", "r962", "r964"] }, "us-gaap_DebtInstrumentMaturityDate": { "xbrltype": "dateItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentMaturityDate", "presentation": [
"http://www.sightsciences.com/20240930/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Maturity date", "label": "Debt Instrument, Maturity Date", "documentation": "Date when the debt instrument is scheduled to be fully repaid, in YYYY-MM-DD format." } } }, "auth_ref": ["r136", "r722", "r956", "r957"] }, "us-gaap_DebtInstrumentNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentNameDomain", "presentation": [
"http://www.sightsciences.com/20240930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
"http://www.sightsciences.com/20240930/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails",
"http://www.sightsciences.com/20240930/taxonomy/role/Role_DisclosureDebtScheduleOfLongTermAndShortTermDebtDetails"], "lang": { "en-us": { "role": { "terseLabel": "Debt Instrument, Name", "label": "Debt Instrument, Name [Domain]", "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities." } } }, "auth_ref": ["r14", "r161", "r321", "r322", "r323", "r324", "r325", "r327", "r332", "r333", "r334", "r335", "r337", "r338", "r339", "r340", "r341", "r342", "r722", "r723", "r724", "r725", "r726", "r748", "r879", "r906", "r907", "r908", "r962", "r964"] }, "sght_DebtInstrumentPercentageOfPrepaymentPremiumYearOne": { "xbrltype": "percentItemType", "nsuri": "http://www.sightsciences.com/20240930", "localname": "DebtInstrumentPercentageOfPrepaymentPremiumYearOne", "presentation": [
"http://www.sightsciences.com/20240930/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails"], "lang": { "en-us": { "role": { "label": "Debt Instrument Percentage of Prepayment Premium Year One", "terseLabel": "Percentage of prepayment premium year one", "documentation": "Debt instrument percentage of prepayment premium year one." } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentTable", "presentation": [
"http://www.sightsciences.com/20240930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
"http://www.sightsciences.com/20240930/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails",
"http://www.sightsciences.com/20240930/taxonomy/role/Role_DisclosureDebtScheduleOfLongTermAndShortTermDebtDetails"], "lang": { "en-us": { "role": { "terseLabel": "Debt Instrument [Table]", "label": "Schedule of Long-Term Debt Instruments [Table]", "documentation": "Disclosure of information about long-term debt instrument or arrangement." } } }, "auth_ref": ["r14", "r39", "r42", "r50", "r94", "r95", "r161", "r321", "r322", "r323", "r324", "r325", "r327", "r332", "r333", "r334", "r335", "r337", "r338", "r339", "r340", "r341", "r342", "r345", "r722", "r723", "r724", "r725", "r726", "r748", "r879", "r962", "r964"] }, "us-gaap_DebtInstrumentUnamortizedDiscount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentUnamortizedDiscount", "crdr": "debit", "presentation": [
"http://www.sightsciences.com/20240930/taxonomy/role/Role_DisclosureDebtScheduleOfLongTermAndShortTermDebtDetails"], "lang": { "en-us": { "role": { "negatedLabel": "Less: unamortized discount and debt issuance costs", "label": "Debt Instrument, Unamortized Discount", "totalLabel": "Debt Instrument, Unamortized Discount, Total", "documentation": "Amount, after accumulated amortization, of debt discount." } } }, "auth_ref": ["r921", "r961", "r962", "r964"] }, "us-gaap_DebtLongtermAndShorttermCombinedAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtLongtermAndShorttermCombinedAmount", "crdr": "credit", "presentation": [
"http://www.sightsciences.com/20240930/taxonomy/role/Role_DisclosureDebtScheduleOfLongTermAndShortTermDebtDetails"], "lang": { "en-us": { "role": { "totalLabel": "Total amounts outstanding", "label": "Debt, Long-Term and Short-Term, Combined Amount", "documentation": "Represents the aggregate of total long-term debt, including current maturities and short-term debt." } } }, "auth_ref": [] }, "us-gaap_DebtSecuritiesAvailableForSaleAndHeldToMaturityCumulativeUnrecognizedGain": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtSecuritiesAvailableForSaleAndHeldToMaturityCumulativeUnrecognizedGain", "crdr": "credit", "presentation": [
"http://www.sightsciences.com/20240930/taxonomy/role/DisclosureFairValueMeasurementHeldtomaturityDebtSecuritiesAtAmortizedCostDetails"], "lang": { "en-us": { "role": { "label": "Debt Securities, Available-for-Sale and Held-to-Maturity, Cumulative Unrecognized Gain", "totalLabel": "Unrealized Gains", "terseLabel": "Unrealized Gains", "documentation": "Amount of cumulative unrecognized gain on investment in debt security measured at amortized cost (held-to-maturity) and investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": ["r895", "r897"] }, "us-gaap_DebtSecuritiesAvailableForSaleAndHeldToMaturityCumulativeUnrecognizedLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtSecuritiesAvailableForSaleAndHeldToMaturityCumulativeUnrecognizedLoss", "crdr": "debit", "presentation": ["http://www.sightsciences.com/20240930/taxonomy/role/DisclosureFairValueMeasurementHeldtomaturityDebtSecuritiesAtAmortizedCostDetails"], "lang": { "en-us": { "role": { "negatedLabel": "Unrealized Losses", "label": "Debt Securities, Available-for-Sale and Held-to-Maturity, Cumulative Unrecognized Loss", "totalLabel": "Unrealized Losses", "terseLabel": "Unrealized Losses", "documentation": "Amount of cumulative unrecognized loss on investment in debt security measured at amortized cost (held-to-maturity) and investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": ["r896", "r898"] }, "us-gaap_DebtSecuritiesHeldToMaturityAmortizedCostAfterAllowanceForCreditLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtSecuritiesHeldToMaturityAmortizedCostAfterAllowanceForCreditLoss", "crdr": "debit", "presentation": [
"http://www.sightsciences.com/20240930/taxonomy/role/DisclosureFairValueMeasurementHeldtomaturityDebtSecuritiesAtAmortizedCostDetails"], "lang": { "en-us": { "role": { "label": "Debt Securities, Held-to-Maturity, Amortized Cost, after Allowance for Credit Loss", "totalLabel": "Amortized Cost", "terseLabel": "Amortized Cost", "documentation": "Amount, after allowance for credit loss, of investment in debt security measured at amortized cost (held-to-maturity)." } } }, "auth_ref": ["r230", "r246", "r248", "r555"] }, "us-gaap_DeferredCostsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredCostsCurrent", "crdr": "debit", "presentation": [
"http://www.sightsciences.com/20240930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Deferred costs, current", "totalLabel": "Deferred Costs, Total", "label": "Deferred Costs, Current", "documentation": "Sum of the carrying amounts as of the balance sheet date of deferred costs capitalized at the end of the reporting period that are expected to be charged against earnings within one year or the normal operating cycle, if longer." } } }, "auth_ref": ["r873"] }, "us-gaap_DeferredOfferingCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredOfferingCosts", "crdr": "debit", "presentation": [
"http://www.sightsciences.com/20240930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"], "lang": { "en-us": { "role": { "verboseLabel": "Deferred initial public offering cost recorded to additional paid in capital", "totalLabel": "Total deferred costs", "label": "Deferred Offering Costs", "terseLabel": "Deferred offering costs", "documentation": "Specific incremental costs directly attributable to a proposed or actual offering of securities which are deferred at the end of the reporting period." } } }, "auth_ref": ["r904"] }, "sght_DeferredOfferingCostsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.sightsciences.com/20240930", "localname": "DeferredOfferingCostsPolicyTextBlock", "presentation": ["http://www.sightsciences.com/20240930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"], "lang": { "en-us": { "role": { "terseLabel": "Deferred Offering Costs", "label": "Deferred Offering Costs [Policy Text Block]", "documentation": "Deferred offering costs." } } }, "auth_ref": [] }, "us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount", "crdr": "debit", "presentation": [
"http://www.sightsciences.com/20240930/taxonomy/role/Role_DisclosureDefinedContributionPlanAdditionalInformationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Defined contribution plan, maximum annual contributions per employee amount", "label": "Defined Contribution Plan, Maximum Annual Contributions Per Employee, Amount", "documentation": "Maximum amount the employee may contribute to a defined contribution plan." } } }, "auth_ref": [] }, "us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent", "presentation": [
"http://www.sightsciences.com/20240930/taxonomy/role/Role_DisclosureDefinedContributionPlanAdditionalInformationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Defined contribution plan, maximum annual contributions per employee", "label": "Defined Contribution Plan, Maximum Annual Contributions Per Employee, Percent", "documentation": "Maximum percentage of employee gross pay the employee may contribute to a defined contribution plan." } } }, "auth_ref": [] }, "us-gaap_DefinedContributionPlanTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedContributionPlanTextBlock", "presentation": [
"http://www.sightsciences.com/20240930/taxonomy/role/Role_DisclosureDefinedContributionPlan"], "lang": { "en-us": { "role": { "terseLabel": "Defined Contribution Plan", "label": "Defined Contribution Plan [Text Block]", "documentation": "The entire disclosure for defined contribution plan." } } }, "auth_ref": ["r377", "r378"] }, "sght_Denominator": { "xbrltype": "stringItemType", "nsuri": "http://www.sightsciences.com/20240930", "localname": "Denominator", "presentation": [
"http://www.sightsciences.com/20240930/taxonomy/role/DisclosureNetLossPerShareAttributableToCommonStockholdersScheduleOfComputationOfBasicAndDilutedNetLossPerShareAttributable"], "lang": { "en-us": { "role": { "label": "Denominator:", "documentation": "Denominator:" } } }, "auth_ref": [] }, "us-gaap_Depreciation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Depreciation", "crdr": "debit", "presentation": [
"http://www.sightsciences.com/20240930/taxonomy/role/Role_DisclosureBalanceSheetComponentsAdditionalInformationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Depreciation and amortization", "label": "Depreciation", "totalLabel": "Depreciation, Total", "verboseLabel": "Depreciation expense", "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation." } } }, "auth_ref": ["r4", "r30"] }, "us-gaap_DepreciationDepletionAndAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DepreciationDepletionAndAmortization", "crdr": "debit", "presentation": ["http://www.sightsciences.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"], "lang": { "en-us": { "role": { "terseLabel": "Depreciation and amortization", "label": "Depreciation, Depletion and Amortization", "totalLabel": "Depreciation, Depletion and Amortization, Total", "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets." } } }, "auth_ref": ["r4", "r189", "r202", "r220", "r713", "r714"] }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "presentation": [
"http://www.sightsciences.com/20240930/taxonomy/role/DisclosureEquityIncentivePlans1"], "lang": { "en-us": { "role": { "terseLabel": "Equity Incentive Plans", "label": "Share-Based Payment Arrangement [Text Block]", "documentation": "The entire disclosure for share-based payment arrangement." } } }, "auth_ref": ["r380", "r383", "r411", "r412", "r414", "r733"] }, "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract", "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement [Abstract]" } } }, "auth_ref": [] }, "us-gaap_DividendsCommonStock": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DividendsCommonStock", "crdr": "debit", "presentation": [
"http://www.sightsciences.com/20240930/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Dividends declared", "label": "Dividends, Common Stock", "totalLabel": "Dividends, Common Stock, Total", "documentation": "Amount of paid and unpaid common stock dividends declared with the form of settlement in

cash, stock and payment-in-kind (PIK)." } } }, "auth_ref": ["r2", "r96"] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFiscalPeriodFocus", "presentation": ["http://www.sightsciences.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "terseLabel": "Document Fiscal Period Focus", "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFiscalYearFocus", "presentation": [
"http://www.sightsciences.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "terseLabel": "Document Fiscal Year Focus", "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentPeriodEndDate", "presentation": [
"http://www.sightsciences.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "terseLabel": "Document Period End Date", "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] },
"dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentQuarterlyReport", "presentation": [
"http://www.sightsciences.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "terseLabel": "Document Quarterly Report", "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": ["r778"] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentTransitionReport", "presentation": [
"http://www.sightsciences.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "terseLabel": "Document Transition Report", "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": ["r810"] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentType", "presentation": [
"http://www.sightsciences.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "terseLabel": "Document Type", "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "sght_DryEyeMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sightsciences.com/20240930", "localname": "DryEyeMember", "presentation": ["http://www.sightsciences.com/20240930/taxonomy/role/Role_DisclosureSegmentInformationSummaryOfOperatingResultInformationForEachReportableSegmentDetails"], "lang": { "en-us": { "role": { "label": "Dry Eye [Member]", "documentation": "Dry eye.", "terseLabel": "Dry Eye" } } }, "auth_ref": [] },
"ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRfldtdInTtlCompForCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRfldtdInTtlCompForCvrdYrMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member]", "terseLabel": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year" } } }, "auth_ref": ["r821"] }, "us-gaap_EarningsPerShareAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareAbstract", "lang": { "en-us": { "role": { "label": "Earnings Per Share [Abstract]" } } }, "auth_ref": [] }, "us-gaap_EarningsPerShareBasic": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareBasic", "presentation": [
"http://www.sightsciences.com/20240930/taxonomy/role/DisclosureNetLossPerShareAttributableToCommonStockholdersScheduleOfComputationOfBasicAndDilutedNetLossPerShareAttributable",
"http://www.sightsciences.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited"], "lang": { "en-us": { "role": { "terseLabel": "Net loss per share attributable to common stockholders-basic", "label": "Earnings Per Share, Basic", "totalLabel": "Earnings Per Share, Basic, Total", "verboseLabel": "Net loss per share attributable to common stockholders-basic", "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period." } } }, "auth_ref": ["r149", "r167", "r168", "r169", "r170", "r171", "r172", "r177", "r179", "r182", "r183", "r184", "r188", "r427", "r430", "r447", "r448", "r556", "r574", "r706"] }, "us-gaap_EarningsPerShareDiluted": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareDiluted", "presentation": [
"http://www.sightsciences.com/20240930/taxonomy/role/DisclosureNetLossPerShareAttributableToCommonStockholdersScheduleOfComputationOfBasicAndDilutedNetLossPerShareAttributable",
"http://www.sightsciences.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited"], "lang": { "en-us": { "role": { "terseLabel": "Net loss per share attributable to common stockholders-diluted", "label": "Earnings Per Share, Diluted", "totalLabel": "Earnings Per Share, Diluted, Total", "verboseLabel": "Net loss per share attributable to common stockholders-diluted", "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period." } } }, "auth_ref": ["r149", "r167", "r168", "r169", "r170", "r171", "r172", "r179", "r182", "r183", "r184", "r188", "r427", "r430", "r447", "r448", "r556", "r574", "r706"] }, "us-gaap_EarningsPerShareReconciliationAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareReconciliationAbstract", "presentation": [
"http://www.sightsciences.com/20240930/taxonomy/role/DisclosureNetLossPerShareAttributableToCommonStockholdersScheduleOfComputationOfBasicAndDilutedNetLossPerShareAttributable"], "lang": { "en-us": { "role": { "terseLabel": "Numerator:", "label": "Earnings Per Share Reconciliation [Abstract]" } } }, "auth_ref": [] }, "us-gaap_EarningsPerShareTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareTextBlock", "presentation": [
"http://www.sightsciences.com/20240930/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToCommonStockholders"], "lang": { "en-us": { "role": { "terseLabel": "Net Loss per Share Attributable to Common Stockholders", "label": "Earnings Per Share [Text Block]", "documentation": "The entire disclosure for earnings per share." } } }, "auth_ref": ["r176", "r185", "r186", "r187"] }, "us-gaap_EmployeeBenefitsAndShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeBenefitsAndShareBasedCompensation", "crdr": "debit", "presentation": [
"http://www.sightsciences.com/20240930/taxonomy/role/DisclosureEquityIncentivePlansAdditionalInformationDetail"], "lang": { "en-us": { "role": { "terseLabel": "Stock based compensation", "label": "Employee Benefits and Share-Based Compensation", "documentation": "Amount of expense for employee benefit and equity-based compensation." } } }, "auth_ref": [] }, "us-gaap_EmployeeRelatedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeRelatedLiabilitiesCurrent", "crdr": "credit", "presentation": ["http://www.sightsciences.com/20240930/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited"], "lang": { "en-us": { "role": { "terseLabel": "Accrued compensation", "label": "Employee-related Liabilities, Current", "totalLabel": "Employee-related Liabilities, Current, Total", "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": ["r56"] }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized", "crdr": "debit", "presentation": [
"http://www.sightsciences.com/20240930/taxonomy/role/DisclosureEquityIncentivePlansAdditionalInformationDetail"], "lang": { "en-us": { "role": { "terseLabel": "Unrecognized stock-based compensation of unvested options", "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount", "totalLabel": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total", "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement." } } }, "auth_ref": ["r413"] }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1", "presentation": [
"http://www.sightsciences.com/20240930/taxonomy/role/DisclosureEquityIncentivePlansAdditionalInformationDetail"], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition", "terseLabel": "Weighted-average period expected to recognize", "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": ["r413"] }, "us-gaap_EmployeeStockOptionMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeStockOptionMember", "presentation": [
"http://www.sightsciences.com/20240930/taxonomy/role/DisclosureNetLossPerShareAttributableToCommonStockholdersScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsP
"http://www.sightsciences.com/20240930/taxonomy/role/DisclosureStockholdersEquityScheduleOfReservedCommonStockForFutureIssuancesDetails",
"http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Employee Stock Option [Member]", "terseLabel": "Employee Stock Option", "verboseLabel": "Stock option awards", "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine1", "presentation": ["http://www.sightsciences.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Address Line One", "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine2", "presentation": [
"http://www.sightsciences.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Address Line Two", "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressCityOrTown", "presentation": [
"http://www.sightsciences.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, City or Town", "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressPostalZipCode", "presentation": [
"http://www.sightsciences.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Postal Zip Code", "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressStateOrProvince", "presentation": [
"http://www.sightsciences.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, State or Province", "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCentralIndexKey", "presentation": [
"http://www.sightsciences.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "terseLabel": "Entity Central Index Key", "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": ["r776"] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCommonStockSharesOutstanding", "presentation": ["http://www.sightsciences.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "terseLabel": "Entity Common Stock, Shares Outstanding", "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] },
"dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCurrentReportingStatus", "presentation": [
"http://www.sightsciences.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "terseLabel": "Entity Current Reporting Status", "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityEmergingGrowthCompany", "presentation": [
"http://www.sightsciences.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "terseLabel": "Entity Emerging Growth Company", "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": ["r776"] },
"dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityExTransitionPeriod", "presentation": [
"http://www.sightsciences.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "terseLabel": "Entity Ex Transition Period", "label": "Entity Ex Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth_ref": ["r861"] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFileNumber", "presentation": ["http://www.sightsciences.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Securities Act File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFilerCategory", "presentation": ["http://www.sightsciences.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "terseLabel": "Entity Filer Category", "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": ["r776"] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityIncorporationStateCountryCode", "presentation": ["http://www.sightsciences.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "terseLabel": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname":

```
"EntityInteractiveDataCurrent", "presentation": [ "http://www.sightsciences.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Interactive Data Current", "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r860" ] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityRegistrantName", "presentation": [ "http://www.sightsciences.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Registrant Name", "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r776" ] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityShellCompany", "presentation": [
"http://www.sightsciences.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Shell Company", "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r776" ] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntitySmallBusiness", "presentation": [
"http://www.sightsciences.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Small Business", "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r776" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityTaxIdentificationNumber", "presentation": [
"http://www.sightsciences.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Tax Identification Number", "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r776" ] }, "ecd_EqtyAwrdsAdjFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsAdjFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Equity Awards Adjustments, Footnote [Text Block]", "terseLabel": "Equity Awards Adjustments, Footnote" } } }, "auth_ref": [ "r815" ] }, "ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member]", "terseLabel": "Equity Awards Adjustments, Excluding Value Reported in Compensation Table" } } }, "auth_ref": [ "r856" ] }, "ecd_EqtyAwrdsAdjsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsAdjsMember", "presentation": [
"http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Equity Awards Adjustments [Member]", "terseLabel": "Equity Awards Adjustments" } } }, "auth_ref": [ "r856" ] }, "ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname":
"EqtyAwrdsInSummryCompstnTblForAplblYrMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member]", "terseLabel": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table" } } }, "auth_ref": [ "r856" ] }, "us-gaap_EquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquityAbstract", "lang": { "en-us": { "role": { "label": "Equity [Abstract]" } } }, "auth_ref": [] }, "us-gaap_EquityComponentDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"EquityComponentDomain", "presentation": [ "http://www.sightsciences.com/20240930/taxonomy/role/DisclosureEquityIncentivePlansAdditionalInformationDetail",
"http://www.sightsciences.com/20240930/taxonomy/role/Role_DisclosureCompanyAndNatureOfBusinessAdditionalInformationDetails",
"http://www.sightsciences.com/20240930/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails",
"http://www.sightsciences.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Equity Component", "label": "Equity Component [Domain]", "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc." } } }, "auth_ref": [ "r10", "r125", "r146", "r147", "r148", "r162", "r163", "r164", "r166", "r171", "r173", "r175", "r190", "r262", "r263", "r287", "r367", "r421", "r422", "r424", "r425", "r426", "r428", "r429", "r430", "r438", "r439", "r440", "r441", "r442", "r443", "r446", "r465", "r466", "r467", "r468", "r469", "r470", "r475", "r476", "r488", "r572", "r591", "r592", "r593", "r604", "r668" ] }, "ecd_EquityValuationAssumptionDifferenceFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri":
"http://xbrl.sec.gov/ecd/2024", "localname": "EquityValuationAssumptionDifferenceFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Equity Valuation Assumption Difference, Footnote [Text Block]", "terseLabel": "Equity Valuation Assumption Difference, Footnote" } } }, "auth_ref": [ "r825" ] }, "ecd_ErrCompAnalysisTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ErrCompAnalysisTextBlock", "presentation": [
"http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Erroneous Compensation Analysis [Text Block]", "terseLabel": "Erroneous Compensation Analysis" } } }, "auth_ref": [ "r783", "r793", "r803", "r835" ] }, "ecd_ErrCompRecoveryTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ErrCompRecoveryTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Erroneously Awarded Compensation Recovery [Table]", "terseLabel": "Erroneously Awarded Compensation Recovery" } } }, "auth_ref": [ "r780", "r790", "r800", "r832" ] }, "ecd_ExecutiveCategoryAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ExecutiveCategoryAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Executive Category [Axis]", "terseLabel": "Executive Category:" } } }, "auth_ref": [ "r831" ] }, "sght_ExerciseOfCommonStockWarrants": { "xbrltype": "monetaryItemType", "nsuri": "http://www.sightsciences.com/20240930", "localname":
"ExerciseOfCommonStockWarrants", "crdr": "credit", "presentation": [
"http://www.sightsciences.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Exercise of common stock warrants", "label": "Exercise of Common Stock Warrants", "documentation": "Exercise of common stock warrants." } } }, "auth_ref": [] }, "sght_ExerciseOfCommonStockWarrantsShares": { "xbrltype": "sharesItemType", "nsuri": "http://www.sightsciences.com/20240930", "localname":
"ExerciseOfCommonStockWarrantsShares", "presentation": [
"http://www.sightsciences.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Exercise of common stock warrants, shares", "label": "Exercise of Common Stock Warrants, Shares", "documentation": "Exercise of common stock warrants shares." } } }, "auth_ref": [] }, "sght_ExerciseOfOptionsUnderStockPlanMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sightsciences.com/20240930", "localname":
"ExerciseOfOptionsUnderStockPlanMember", "presentation": [
"http://www.sightsciences.com/20240930/taxonomy/role/DisclosureStockholdersEquityScheduleOfReservedCommonStockForFutureIssuancesDetails" ], "lang": { "en-us": { "role": { "documentation": "Exercise of options under stock plan.", "label": "Exercise of Options Under Stock Plan [Member]", "terseLabel": "Exercise of Options under Stock Plan" } } }, "auth_ref": [] }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems", "presentation": [
"http://www.sightsciences.com/20240930/taxonomy/role/DisclosureFairValueMeasurementHeldtomaturityDebtSecuritiesAtAmortizedCostDetails",
"http://www.sightsciences.com/20240930/taxonomy/role/Role_DisclosureFairValueMeasurementAdditionalInformationDetails",
"http://www.sightsciences.com/20240930/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFairValueMeasurementLiabilitiesMeasuredOnRecurringBasisDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]", "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r450", "r451", "r459", "r738" ] }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable", "presentation": [
"http://www.sightsciences.com/20240930/taxonomy/role/DisclosureFairValueMeasurementHeldtomaturityDebtSecuritiesAtAmortizedCostDetails",
"http://www.sightsciences.com/20240930/taxonomy/role/Role_DisclosureFairValueMeasurementAdditionalInformationDetails",
"http://www.sightsciences.com/20240930/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFairValueMeasurementLiabilitiesMeasuredOnRecurringBasisDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table]", "label": "Fair Value, Recurring and Nonrecurring [Table]", "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis." } } }, "auth_ref": [ "r450", "r451", "r459", "r738" ] }, "us-gaap_FairValueByBalanceSheetGroupingTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueByBalanceSheetGroupingTextBlock", "presentation": [ "http://www.sightsciences.com/20240930/taxonomy/role/Role_DisclosureFairValueMeasurementsTables" ], "lang": { "en-us": { "role": { "label": "Fair Value, by Balance Sheet Grouping [Table Text Block]", "terseLabel": "Summary of Held-to-maturity debt securities at amortized cost in the financial statements.", "documentation": "Tabular disclosure of the fair value of financial instruments, including financial assets and financial liabilities, and the measurements of those instruments, assets, and liabilities." } } }, "auth_ref": [ "r48" ] }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueByFairValueHierarchyLevelAxis", "presentation": [ "http://www.sightsciences.com/20240930/taxonomy/role/Role_DisclosureFairValueMeasurementAdditionalInformationDetails",
"http://www.sightsciences.com/20240930/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFairValueMeasurementLiabilitiesMeasuredOnRecurringBasisDetails",
"http://www.sightsciences.com/20240930/taxonomy/role/Role_DisclosureFairValueMeasurementsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value Hierarchy and NAV", "label": "Fair Value Hierarchy and NAV [Axis]", "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient." } } }, "auth_ref": [ "r334", "r371", "r372", "r373", "r374", "r375", "r376", "r449", "r451", "r452", "r453", "r454", "r458", "r459", "r461", "r495", "r496", "r497", "r723", "r724", "r729", "r730", "r731", "r738", "r741" ] }, "us-gaap_FairValueByMeasurementFrequencyAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"FairValueByMeasurementFrequencyAxis", "presentation": [ "http://www.sightsciences.com/20240930/taxonomy/role/Role_DisclosureFairValueMeasurementAdditionalInformationDetails",
"http://www.sightsciences.com/20240930/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFairValueMeasurementLiabilitiesMeasuredOnRecurringBasisDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Measurement Frequency", "label": "Measurement Frequency [Axis]", "documentation": "Information by measurement frequency." } } }, "auth_ref": [ "r450", "r451", "r452", "r454", "r738", "r956", "r959" ] }, "us-gaap_FairValueDisclosuresAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"FairValueDisclosuresAbstract", "lang": { "en-us": { "role": { "label": "Fair Value Disclosures [Abstract]" } } }, "auth_ref": [] }, "us-gaap_FairValueInputsLevel1Member": { "xbrltype":
"domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueInputsLevel1Member", "presentation": [
"http://www.sightsciences.com/20240930/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFairValueMeasurementLiabilitiesMeasuredOnRecurringBasisDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value, Inputs, Level 1", "label": "Fair Value, Inputs, Level 1 [Member]", "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date." } } }, "auth_ref": [ "r334", "r371", "r376", "r451", "r459", "r495", "r729", "r730", "r731", "r738" ] }, "us-gaap_FairValueInputsLevel2Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueInputsLevel2Member", "presentation": [
"http://www.sightsciences.com/20240930/taxonomy/role/Role_DisclosureFairValueMeasurementAdditionalInformationDetails",
"http://www.sightsciences.com/20240930/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFairValueMeasurementLiabilitiesMeasuredOnRecurringBasisDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value, Inputs, Level 2", "label": "Fair Value, Inputs, Level 2 [Member]", "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets." } } }, "auth_ref": [ "r334", "r371", "r376", "r451", "r452", "r459", "r496", "r723", "r724", "r729", "r730", "r731", "r738" ] }, "us-gaap_FairValueInputsLevel3Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueInputsLevel3Member", "presentation": [
"http://www.sightsciences.com/20240930/taxonomy/role/Role_DisclosureFairValueMeasurementAdditionalInformationDetails",
"http://www.sightsciences.com/20240930/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFairValueMeasurementLiabilitiesMeasuredOnRecurringBasisDetails",
"http://www.sightsciences.com/20240930/taxonomy/role/Role_DisclosureFairValueMeasurementsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value, Inputs, Level 3", "label": "Fair Value, Inputs, Level 3 [Member]", "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing." } } }, "auth_ref": [ "r334", "r371", "r372", "r373", "r374", "r375", "r376", "r451", "r452", "r453", "r454", "r459", "r497", "r723", "r724", "r729", "r730", "r731", "r738", "r741" ] }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock", "presentation": [ "http://www.sightsciences.com/20240930/taxonomy/role/Role_DisclosureFairValueMeasurementsTables" ], "lang": { "en-us": { "role": { "label": "Fair Value, Liabilities Measured on Recurring Basis [Table Text Block]", "terseLabel": "Summary of Fair Value Measurement of Liabilities of Measured on Recurring Basis", "documentation": "Tabular disclosure of liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3). Where the quoted price in an active market for the identical liability is not available, the Level 1 input is the quoted price of an identical liability when traded as an asset." } } }, "auth_ref": [ "r953", "r954" ] }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock": { "xbrltype":
"textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "presentation": [
"http://www.sightsciences.com/20240930/taxonomy/role/Role_DisclosureFairValueMeasurementsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Summary of Changes in Level 3 Fair Value Instruments", "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]", "documentation": "Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability." } } }, "auth_ref": [ "r455", "r457", "r460" ] }, "us-gaap_FairValueMeasurementFrequencyDomain": { "xbrltype": "domainItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "FairValueMeasurementFrequencyDomain", "presentation": [
"http://www.sightsciences.com/20240930/taxonomy/role/Role_DisclosureFairValueMeasurementAdditionalInformationDetails",
```

```
"http://www.sightsciences.com/20240930/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFairValueMeasurementLiabilitiesMeasuredOnRecurringBasisDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Measurement Frequency", "label": "Measurement Frequency [Domain]", "documentation": "Measurement frequency." } } }, "auth_ref": [ "r450", "r451", "r452", "r454", "r738", "r956", "r959" ] }, "us-gaap_FairValueMeasurementInputsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueMeasurementInputsDisclosureTextBlock", "presentation": [ "http://www.sightsciences.com/20240930/taxonomy/role/Role_DisclosureFairValueMeasurements" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value Measurements", "label": "Fair Value Measurement and Measurement Inputs, Recurring and Nonrecurring [Text Block]", "documentation": "The entire disclosure of the fair value measurement of assets and liabilities, which includes financial instruments measured at fair value that are classified in shareholders' equity, which may be measured on a recurring or nonrecurring basis." } } }, "auth_ref": [ "r101" ] }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueMeasurementsFairValueHierarchyDomain", "presentation": [
"http://www.sightsciences.com/20240930/taxonomy/role/Role_DisclosureFairValueMeasurementAdditionalInformationDetails",
"http://www.sightsciences.com/20240930/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFairValueMeasurementLiabilitiesMeasuredOnRecurringBasisDetails",
"http://www.sightsciences.com/20240930/taxonomy/role/Role_DisclosureFairValueMeasurementsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value Hierarchy and NAV", "label": "Fair Value Hierarchy and NAV [Domain]", "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value." } } }, "auth_ref": [ "r334", "r371", "r372", "r373", "r374", "r375", "r376", "r449", "r451", "r452", "r453", "r454", "r458", "r459", "r461", "r495", "r496", "r497", "r723", "r724", "r729", "r730", "r731", "r738", "r741" ] }, "us-gaap_FairValueMeasurementsRecurringMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueMeasurementsRecurringMember", "presentation": [ "http://www.sightsciences.com/20240930/taxonomy/role/Role_DisclosureFairValueMeasurementAdditionalInformationDetails",
"http://www.sightsciences.com/20240930/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFairValueMeasurementLiabilitiesMeasuredOnRecurringBasisDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value, Recurring", "label": "Fair Value, Recurring [Member]", "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value." } } }, "auth_ref": [ "r738", "r953", "r954", "r955", "r956", "r957", "r959" ] }, "us-gaap_FairValueOfFinancialInstrumentsPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueOfFinancialInstrumentsPolicy", "presentation": [ "http://www.sightsciences.com/20240930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value of Financial Instruments", "label": "Fair Value of Financial Instruments, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments." } } }, "auth_ref": [ "r8" ] }, "sght_FairValueOfTheUnissuedCommonStockWarrants": { "xbrltype": "monetaryItemType", "nsuri": "http://www.sightsciences.com/20240930", "localname": "FairValueOfTheUnissuedCommonStockWarrants", "crdr": "debit", "presentation": [
"http://www.sightsciences.com/20240930/taxonomy/role/Role_DisclosureFairValueMeasurementAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Fair Value Of The Unissued Common Stock Warrants", "documentation": "Fair Value Of The Unissued Common Stock Warrants", "terseLabel": "Fair value of the unissued common stock warrants" } } }, "auth_ref": [] }, "sght_FairValueOfWarrants": { "xbrltype": "monetaryItemType", "nsuri": "http://www.sightsciences.com/20240930", "localname": "FairValueOfWarrants", "crdr": "credit", "presentation": [
"http://www.sightsciences.com/20240930/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails",
"http://www.sightsciences.com/20240930/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Fair Value Of Warrants", "documentation": "Fair value of warrants.", "terseLabel": "Fair value of warrants" } } }, "auth_ref": [] }, "sght_FinalFeeDueAtMaturity": { "xbrltype": "monetaryItemType", "nsuri": "http://www.sightsciences.com/20240930", "localname": "FinalFeeDueAtMaturity", "crdr": "credit", "presentation": [
"http://www.sightsciences.com/20240930/taxonomy/role/Role_DisclosureDebtScheduleRelatingToCompanySDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Final fee due at maturity", "label": "Final Fee Due at Maturity", "documentation": "Final Fee Due at Maturity" } } }, "auth_ref": [] }, "us-gaap_FinancialInstrumentAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinancialInstrumentAxis", "presentation": [
"http://www.sightsciences.com/20240930/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Financial Instrument [Axis]", "documentation": "Information by type of financial instrument." } } }, "auth_ref": [ "r231", "r232", "r233", "r234", "r235", "r236", "r237", "r238", "r239", "r240", "r241", "r242", "r243", "r244", "r245", "r246", "r247", "r248", "r249", "r250", "r251", "r252", "r253", "r254", "r255", "r256", "r257", "r258", "r259", "r260", "r265", "r266", "r270", "r271", "r272", "r273", "r274", "r275", "r345", "r363", "r444", "r462", "r492", "r493", "r494", "r495", "r496", "r497", "r498", "r499", "r500", "r501", "r502", "r503", "r504", "r505", "r506", "r508", "r509", "r510", "r511", "r512", "r513", "r514", "r515", "r516", "r517", "r518", "r519", "r520", "r521", "r522", "r573", "r719", "r738", "r739", "r741", "r742", "r743", "r744", "r745", "r746", "r747", "r752", "r863", "r864", "r865", "r866", "r867", "r868", "r869", "r899", "r900", "r901", "r902", "r952", "r955", "r956", "r957", "r958", "r959" ] }, "us-gaap_FinancialLiabilitiesFairValueDisclosure": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinancialLiabilitiesFairValueDisclosure", "crdr": "credit", "presentation": [
"http://www.sightsciences.com/20240930/taxonomy/role/Role_DisclosureFairValueMeasurementAdditionalInformationDetails",
"http://www.sightsciences.com/20240930/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFairValueMeasurementLiabilitiesMeasuredOnRecurringBasisDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Total liabilities measured at fair value", "label": "Financial Liabilities Fair Value Disclosure", "totalLabel": "Financial Liabilities Fair Value Disclosure, Total", "documentation": "Fair value of financial obligations, including, but not limited to, debt instruments, derivative liabilities, federal funds purchased and sold under agreements to repurchase, securities loaned or sold under agreements to repurchase, financial instruments sold not yet purchased, guarantees, line of credit, loans and notes payable, servicing liability, and trading liabilities." } } }, "auth_ref": [ "r953", "r954", "r958" ] }, "us-gaap_FinancialLiabilitiesFairValueDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinancialLiabilitiesFairValueDisclosureAbstract", "presentation": [
"http://www.sightsciences.com/20240930/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFairValueMeasurementLiabilitiesMeasuredOnRecurringBasisDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Liabilities:", "label": "Financial Liabilities Fair Value Disclosure [Abstract]" } } }, "auth_ref": [] },
"ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount", "terseLabel": "Forgone Recovery due to Disqualification of Tax Benefits, Amount" } } }, "auth_ref": [ "r787", "r797", "r807", "r839" ] },
"ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Forgone Recovery due to Expense of Enforcement, Amount", "terseLabel": "Forgone Recovery due to Expense of Enforcement, Amount" } } }, "auth_ref": [ "r787", "r797", "r807", "r839" ] },
"ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Forgone Recovery due to Violation of Home Country Law, Amount", "terseLabel": "Forgone Recovery due to Violation of Home Country Law, Amount" } } }, "auth_ref": [ "r787", "r797", "r807", "r839" ] },
"ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Forgone Recovery, Explanation of Impracticability [Text Block]", "terseLabel": "Forgone Recovery, Explanation of Impracticability" } } }, "auth_ref": [ "r787", "r797", "r807", "r839" ] },
"ecd_ForgoneRecoveryIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryIndName", "presentation": [
"http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Forgone Recovery, Individual Name", "terseLabel": "Name" } } }, "auth_ref": [ "r787", "r797", "r807", "r839" ] }, "ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member]", "terseLabel": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year" } } }, "auth_ref": [ "r820" ] }, "us-gaap_FurnitureAndFixturesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FurnitureAndFixturesMember", "presentation": [
"http://www.sightsciences.com/20240930/taxonomy/role/Role_DisclosureBalanceSheetComponentsSummaryOfPropertyAndEquipmentNetDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Furniture and Fixtures", "label": "Furniture and Fixtures [Member]", "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases." } } }, "auth_ref": [] }, "us-gaap_GainContingencyUnrecordedAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GainContingencyUnrecordedAmount", "crdr": "credit", "presentation": [
"http://www.sightsciences.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Gain Contingency, Unrecorded Amount", "label": "Gain Contingency, Unrecorded Amount", "documentation": "The amount or range of possible amounts of gain that could be realized upon the resolution of a contingency." } } }, "auth_ref": [ "r915" ] }, "us-gaap_GainLossOnSaleOfPropertyPlantEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GainLossOnSaleOfPropertyPlantEquipment", "crdr": "credit", "presentation": [
"http://www.sightsciences.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "negatedLabel": "Loss on disposal of property and equipment", "label": "Gain (Loss) on Disposition of Property Plant Equipment", "totalLabel": "Gain (Loss) on Disposition of Property Plant Equipment, Total", "documentation": "Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property." } } }, "auth_ref": [ "r4" ] }, "us-gaap_GainLossRelatedToLitigationSettlement": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GainLossRelatedToLitigationSettlement", "crdr": "credit", "presentation": [ "http://www.sightsciences.com/20240930/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails",
"http://www.sightsciences.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Lost profits damages", "label": "Gain (Loss) from Litigation Settlement", "documentation": "Amount of gain (loss) recognized in settlement of litigation and insurance claims. Excludes claims within an insurance entity's normal claims settlement process." } } }, "auth_ref": [ "r713", "r912" ] }, "us-gaap_GainsLossesOnExtinguishmentOfDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GainsLossesOnExtinguishmentOfDebt", "crdr": "credit", "presentation": [
"http://www.sightsciences.com/20240930/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails",
"http://www.sightsciences.com/20240930/taxonomy/role/Role_DisclosureSegmentInformationSummaryOfOperatingResultInformationForEachReportableSegmentDetails",
"http://www.sightsciences.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Loss on debt extinguishment", "negatedLabel": "Noncash loss on extinguishment of debt", "label": "Gain (Loss) on Extinguishment of Debt", "totalLabel": "Gain (Loss) on Extinguishment of Debt, Total", "documentation": "Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity." } } }, "auth_ref": [ "r4", "r33", "r34" ] }, "us-gaap_GrossProfit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GrossProfit", "crdr": "credit", "presentation": [
"http://www.sightsciences.com/20240930/taxonomy/role/Role_DisclosureSegmentInformationSummaryOfOperatingResultInformationForEachReportableSegmentDetails",
"http://www.sightsciences.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Gross profit", "terseLabel": "Surgical Glaucoma", "label": "Gross Profit", "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity." } } }, "auth_ref": [ "r72", "r76", "r112", "r160", "r261", "r311", "r312", "r313", "r314", "r315", "r316", "r317", "r318", "r319", "r464", "r708", "r713", "r888", "r890", "r891", "r892", "r893", "r918" ] }, "us-gaap_GrossProfitAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GrossProfitAbstract", "presentation": [
"http://www.sightsciences.com/20240930/taxonomy/role/Role_DisclosureSegmentInformationSummaryOfOperatingResultInformationForEachReportableSegmentDetails" ], "lang": { "en-us": { "role": { "label": "Gross Profit [Abstract]", "terseLabel": "Gross profit" } } }, "auth_ref": [] }, "us-gaap_HeldToMaturitySecuritiesFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "HeldToMaturitySecuritiesFairValue", "crdr": "debit", "presentation": [
"http://www.sightsciences.com/20240930/taxonomy/role/DisclosureFairValueMeasurementHeldtomaturityDebtSecuritiesAtAmortizedCostDetails" ], "lang": { "en-us": { "role": { "label": "Debt Securities, Held-to-Maturity, Fair Value", "totalLabel": "Aggregate Fair Value", "terseLabel": "Aggregate Fair Value", "documentation": "Fair value of investment in debt security measured at amortized cost (held-to-maturity)." } } }, "auth_ref": [ "r114", "r253", "r451", "r458", "r555", "r559" ] }, "sght_HerculesCreditAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sightsciences.com/20240930", "localname": "HerculesCreditAgreementMember", "presentation": [
"http://www.sightsciences.com/20240930/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails",
"http://www.sightsciences.com/20240930/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails",
"http://www.sightsciences.com/20240930/taxonomy/role/Role_DisclosureDebtScheduleOfLongTermAndShortTermDebtDetails" ], "lang": { "en-us": { "role": { "label": "Hercules Credit Agreement [Member]", "documentation": "Hercules Credit Agreement [Member]" } } }, "auth_ref": [] }, "us-gaap_IPOMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IPOMember", "presentation": [ "http://www.sightsciences.com/20240930/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails",
"http://www.sightsciences.com/20240930/taxonomy/role/Role_DisclosureCompanyAndNatureOfBusinessAdditionalInformationDetails",
"http://www.sightsciences.com/20240930/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails",
"http://www.sightsciences.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityUnauditedParenthetical" ], "lang": { "en-us": { "role": { "label": "IPO [Member]", "terseLabel": "IPO [Member]", "documentation": "First sale of stock by a private company to the public." } } }, "auth_ref": [] },
"sght_ISOMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sightsciences.com/20240930", "localname": "ISOMember", "presentation": [
"http://www.sightsciences.com/20240930/taxonomy/role/DisclosureEquityIncentivePlansAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "I S O [Member]", "documentation": "ISO", "terseLabel": "ISO" } } }, "auth_ref": [] }, "sght_IncentiveStockOptionMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sightsciences.com/20240930", "localname": "IncentiveStockOptionMember", "presentation": [ "http://www.sightsciences.com/20240930/taxonomy/role/DisclosureEquityIncentivePlansAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Incentive Stock Option [Member]", "documentation": "Incentive stock option.", "terseLabel": "Incentive Stock Option" } } }, "auth_ref": [] }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "crdr": "credit", "presentation": [
```

"http://www.sightsciences.com/20240930/taxonomy/role/Role_DisclosureSegmentInformationSummaryOfOperatingResultInformationForEachReportableSegmentDetails",
"http://www.sightsciences.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited"], "lang": { "en-us": { "role": { "totalLabel": "Loss before income taxes", "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest", "terseLabel": "Loss before income tax", "verboseLabel": "Loss before income taxes", "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest." } } }, "auth_ref": ["r73", "r107", "r112", "r557", "r569", "r708", "r713", "r888", "r890", "r891", "r892", "r893"] }, "us-gaap_IncomeStatementAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementAbstract", "lang": { "en-us": { "role": { "label": "Income Statement [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IncomeStatementLocationAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementLocationAxis", "presentation": [
"http://www.sightsciences.com/20240930/taxonomy/role/DisclosureEquityIncentivePlansSummaryOfSharebasedCompensationExpenseByFunctionDetails"], "lang": { "en-us": { "role": { "terseLabel": "Income Statement Location", "label": "Statement of Income Location, Balance [Axis]", "documentation": "Information by location in statement of income where disaggregated amount has been reported." } } } }, "auth_ref": ["r288", "r295", "r296", "r456", "r457", "r460", "r588", "r590", "r653", "r701", "r740", "r982"] }, "us-gaap_IncomeStatementLocationDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementLocationDomain", "presentation": [
"http://www.sightsciences.com/20240930/taxonomy/role/DisclosureEquityIncentivePlansSummaryOfSharebasedCompensationExpenseByFunctionDetails"], "lang": { "en-us": { "role": { "terseLabel": "Income Statement Location", "label": "Statement of Income Location, Balance [Domain]", "documentation": "Location in statement of income where disaggregated amount has been reported." } } }, "auth_ref": ["r295", "r296", "r456", "r457", "r460", "r588", "r590", "r653", "r701", "r740", "r982"] }, "us-gaap_IncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxExpenseBenefit", "crdr": "debit", "presentation": [
"http://www.sightsciences.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited"], "lang": { "en-us": { "role": { "terseLabel": "Provision for income taxes", "label": "Income Tax Expense (Benefit)", "totalLabel": "Income Tax Expense (Benefit), Total", "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations." } } }, "auth_ref": ["r116", "r122", "r174", "r175", "r189", "r205", "r220", "r419", "r420", "r423", "r575", "r735"] }, "us-gaap_IncreaseDecreaseInAccountsPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInAccountsPayable", "crdr": "debit", "presentation": [
"http://www.sightsciences.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"], "lang": { "en-us": { "role": { "terseLabel": "Accounts payable", "label": "Increase (Decrease) in Accounts Payable", "totalLabel": "Increase (Decrease) in Accounts Payable, Total", "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business." } } }, "auth_ref": ["r3"] }, "us-gaap_IncreaseDecreaseInAccountsReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInAccountsReceivable", "crdr": "credit", "presentation": [
"http://www.sightsciences.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"], "lang": { "en-us": { "role": { "negatedLabel": "Accounts receivable", "label": "Increase (Decrease) in Accounts Receivable", "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services." } } }, "auth_ref": ["r3"] }, "us-gaap_IncreaseDecreaseInAccruedLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInAccruedLiabilities", "crdr": "debit", "presentation": [
"http://www.sightsciences.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"], "lang": { "en-us": { "role": { "terseLabel": "Accrued and other current liabilities", "label": "Increase (Decrease) in Accrued Liabilities", "totalLabel": "Increase (Decrease) in Accrued Liabilities, Total", "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid." } } }, "auth_ref": ["r3"] }, "us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInEmployeeRelatedLiabilities", "crdr": "debit", "presentation": [
"http://www.sightsciences.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"], "lang": { "en-us": { "role": { "terseLabel": "Accrued compensation", "label": "Increase (Decrease) in Employee Related Liabilities", "totalLabel": "Increase (Decrease) in Employee Related Liabilities, Total", "documentation": "The increase (decrease) during the reporting period in the aggregate amount of obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits." } } }, "auth_ref": ["r3"] }, "us-gaap_IncreaseDecreaseInInventories": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInInventories", "crdr": "credit", "presentation": [
"http://www.sightsciences.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"], "lang": { "en-us": { "role": { "negatedLabel": "Inventory", "label": "Increase (Decrease) in Inventories", "totalLabel": "Increase (Decrease) in Inventories, Total", "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities." } } }, "auth_ref": ["r3"] }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "presentation": ["http://www.sightsciences.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"], "lang": { "en-us": { "role": { "terseLabel": "Changes in operating assets and liabilities:", "label": "Increase (Decrease) in Operating Capital [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInOtherNoncurrentAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInOtherNoncurrentAssets", "crdr": "credit", "presentation": [
"http://www.sightsciences.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Other Noncurrent Assets", "negatedLabel": "Other noncurrent assets", "documentation": "Amount of increase (decrease) in noncurrent assets classified as other." } } }, "auth_ref": ["r876"] }, "us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInOtherNoncurrentLiabilities", "crdr": "debit", "presentation": [
"http://www.sightsciences.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"], "lang": { "en-us": { "role": { "terseLabel": "Other noncurrent liabilities", "label": "Increase (Decrease) in Other Noncurrent Liabilities", "documentation": "Amount of increase (decrease) in noncurrent operating liabilities classified as other." } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "crdr": "credit", "presentation": [
"http://www.sightsciences.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"], "lang": { "en-us": { "role": { "negatedLabel": "Prepaid expenses and other current assets", "label": "Increase (Decrease) in Prepaid Expense and Other Assets", "totalLabel": "Increase (Decrease) in Prepaid Expense and Other Assets, Total", "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other." } } }, "auth_ref": ["r3"] }, "ecd_IndividualAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "IndividualAxis", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Individual [Axis]", "terseLabel": "Individual:" } } }, "auth_ref": ["r787", "r797", "r807", "r831", "r839", "r843", "r851"] }, "ecd_InsiderTradingArrLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTradingArrLineItems", "lang": { "en-us": { "role": { "label": "Insider Trading Arrangements [Line Items]", "terseLabel": "Insider Trading Arrangements:" } } }, "auth_ref": ["r849"] }, "ecd_InsiderTradingPoliciesProcLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTradingPoliciesProcLineItems", "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures [Line Items]", "terseLabel": "Insider Trading Policies and Procedures:" } } }, "auth_ref": ["r779", "r855"] }, "ecd_InsiderTrdPoliciesProcAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTrdPoliciesProcAdoptedFlag", "presentation": [
"http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"], "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures Adopted [Flag]", "terseLabel": "Insider Trading Policies and Procedures Adopted" } } }, "auth_ref": ["r779", "r855"] }, "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"], "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures Not Adopted [Text Block]", "terseLabel": "Insider Trading Policies and Procedures Not Adopted" } } }, "auth_ref": ["r779", "r855"] }, "us-gaap_InterestExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InterestExpense", "crdr": "debit", "presentation": [
"http://www.sightsciences.com/20240930/taxonomy/role/Role_DisclosureSegmentInformationSummaryOfOperatingResultInformationForEachReportableSegmentDetails",
"http://www.sightsciences.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited"], "lang": { "en-us": { "role": { "label": "Interest Expense, Operating and Nonoperating", "totalLabel": "Interest Expense, Total", "negatedLabel": "Interest expense", "documentation": "Amount of interest expense classified as operating and nonoperating. Includes, but is not limited to, cost of borrowing accounted for as interest expense." } } }, "auth_ref": ["r189", "r197", "r201", "r207", "r220", "r472", "r713", "r714"] }, "us-gaap_InterestExpenseDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InterestExpenseDebt", "crdr": "debit", "presentation": [
"http://www.sightsciences.com/20240930/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails"], "lang": { "en-us": { "role": { "label": "Interest Expense, Debt", "totalLabel": "Interest Expense, Debt, Total", "terseLabel": "Interest expense, debt", "documentation": "Amount of the cost of borrowed funds accounted for as interest expense for debt." } } }, "auth_ref": ["r81", "r340", "r350", "r725", "r726"] }, "us-gaap_InterestIncomeSecuritiesUSTreasury": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InterestIncomeSecuritiesUSTreasury", "crdr": "credit", "presentation": [
"http://www.sightsciences.com/20240930/taxonomy/role/Role_DisclosureFairValueMeasurementAdditionalInformationDetails"], "lang": { "en-us": { "role": { "label": "Interest Income, Securities, US Treasury", "terseLabel": "Treasury bills", "documentation": "Interest income on US treasury securities. US treasury securities are negotiable debt obligations of the US government, secured by its full faith and credit and issued at various schedules and maturities. The income from treasury securities is exempt from state and local, but not federal, taxes. There are three types of securities issued by the US treasury (bonds, bills, and notes), which are distinguished by the amount of time from the initial sale of the bond to maturity." } } }, "auth_ref": ["r108"] }, "sght_InterestOnPeriodIncrements": { "xbrltype": "monetaryItemType", "nsuri": "http://www.sightsciences.com/20240930", "localname": "InterestOnPeriodIncrements", "crdr": "credit", "presentation": ["http://www.sightsciences.com/20240930/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Interest in increments period", "label": "Interest On period Increments", "documentation": "Interest On period Increments" } } }, "auth_ref": [] }, "us-gaap_InterestPaidNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InterestPaidNet", "crdr": "credit", "presentation": [
"http://www.sightsciences.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"], "lang": { "en-us": { "role": { "terseLabel": "Cash paid for interest", "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities", "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount." } } }, "auth_ref": ["r151", "r154", "r155"] }, "us-gaap_InterestPayableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InterestPayableCurrent", "crdr": "credit", "presentation": [
"http://www.sightsciences.com/20240930/taxonomy/role/Role_DisclosureBalanceSheetComponentsSummaryOfAccruedAndOtherCurrentLiabilitiesDetails"], "lang": { "en-us": { "role": { "label": "Interest Payable, Current", "terseLabel": "Short-term interest payable", "documentation": "Carrying value as of the balance sheet date of [accrued] interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": ["r56"] }, "sght_InterestPayableNonCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.sightsciences.com/20240930", "localname": "InterestPayableNonCurrent", "crdr": "credit", "presentation": ["http://www.sightsciences.com/20240930/taxonomy/role/Role_DisclosureBalanceSheetComponentsSummaryOfOtherNoncurrentLiabilitiesDetails"], "lang": { "en-us": { "role": { "label": "Interest Payable Non Current", "documentation": "Interest payable non current.", "terseLabel": "Long-term interest payable" } } }, "auth_ref": [] }, "us-gaap_InventoryNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryNet", "crdr": "debit", "presentation": [
"http://www.sightsciences.com/20240930/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited"], "lang": { "en-us": { "role": { "totalLabel": "Inventory, Net, Total", "terseLabel": "Inventory, net", "label": "Inventory, Net", "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer." } } }, "auth_ref": ["r142", "r704", "r751"] }, "us-gaap_InventoryWriteDown": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryWriteDown", "crdr": "debit", "presentation": ["http://www.sightsciences.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"], "lang": { "en-us": { "role": { "terseLabel": "Provision (benefit) for excess and obsolete inventories", "label": "Inventory Write-down", "documentation": "Amount of loss from reductions in inventory due to subsequent measurement adjustments, including, but not limited to, physical deterioration, obsolescence, or changes in price levels." } } }, "auth_ref": ["r276"] }, "us-gaap_InvestmentIncomeNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InvestmentIncomeNet", "crdr": "credit", "presentation": [
"http://www.sightsciences.com/20240930/taxonomy/role/Role_DisclosureSegmentInformationSummaryOfOperatingResultInformationForEachReportableSegmentDetails",
"http://www.sightsciences.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited"], "lang": { "en-us": { "role": { "verboseLabel": "Investment income", "totalLabel": "Investment Income, Net, Total", "label": "Investment Income, Net", "terseLabel": "Investment income", "documentation": "Amount after accretion (amortization) of discount (premium), and investment expense, of interest income and dividend income on nonoperating securities." } } }, "auth_ref": ["r79", "r80", "r81"] }, "sght_IssuanceOfCommonStockUponExerciseOfStockOptions": { "xbrltype": "monetaryItemType", "nsuri": "http://www.sightsciences.com/20240930", "localname": "IssuanceOfCommonStockUponExerciseOfStockOptions", "crdr": "credit", "presentation": [
"http://www.sightsciences.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityUnaudited"], "lang": { "en-us": { "role": { "terseLabel": "Issuance of common stock upon exercise of stock options", "label": "Issuance of common stock upon exercise of stock options", "documentation": "Issuance of common stock upon exercise of stock options" } } }, "auth_ref": [] }, "sght_IssuanceOfCommonStockUponExerciseOfStockOptionsShares": { "xbrltype": "sharesItemType", "nsuri": "http://www.sightsciences.com/20240930", "localname": "IssuanceOfCommonStockUponExerciseOfStockOptionsShares", "presentation": [
"http://www.sightsciences.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityUnaudited"], "lang": { "en-us": { "role": { "terseLabel": "Issuance of common stock upon exercise of stock options", "label": "Issuance of common stock upon exercise of stock options, Shares", "documentation": "Issuance of common stock upon exercise of stock options, Shares" } } }, "auth_ref": [] }, "sght_IssuanceOfCommonStockUponVestingOfRestrictedStockUnits": { "xbrltype": "monetaryItemType", "nsuri": "http://www.sightsciences.com/20240930", "localname": "IssuanceOfCommonStockUponVestingOfRestrictedStockUnits", "crdr": "credit", "presentation": [
"http://www.sightsciences.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityUnaudited"], "lang": {

"en-us": { "role": { "terseLabel": "Issuance of common stock upon vesting of restricted stock units", "label": "Issuance of common stock upon vesting of restricted stock units", "documentation": "Issuance of common stock upon vesting of restricted stock units" } } }, "auth_ref": [] }, "sght_IssuanceOfCommonStockUponVestingOfRestrictedStockUnitsShares": { "xbrltype": "sharesItemType", "nsuri": "http://www.sightsciences.com/20240930", "localname": "IssuanceOfCommonStockUponVestingOfRestrictedStockUnitsShares", "presentation": ["http://www.sightsciences.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityUnaudited"], "lang": { "en-us": { "role": { "label": "Issuance of common stock upon vesting of restricted stock units, shares", "documentation": "Issuance of common stock upon vesting of restricted stock units, shares", "terseLabel": "Issuance of common stock upon vesting of restricted stock units, shares" } } }, "auth_ref": [] }, "sght_IssuanceOfOptionsAndRestrictedStockUnitsUnderStockPlanMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sightsciences.com/20240930", "localname": "IssuanceOfOptionsAndRestrictedStockUnitsUnderStockPlanMember", "presentation": ["http://www.sightsciences.com/20240930/taxonomy/role/DisclosureStockholdersEquityScheduleOfReservedCommonStockForFutureIssuancesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Issuance of options and restricted stock units under stock plan", "label": "Issuance of options and restricted stock units under stock plan [Member]", "documentation": "Issuance of options and restricted stock units under stock plan [Member]" } } }, "auth_ref": [] }, "sght_IssuanceOfOptionsUnderStockPlanMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sightsciences.com/20240930", "localname": "IssuanceOfOptionsUnderStockPlanMember", "presentation": ["http://www.sightsciences.com/20240930/taxonomy/role/DisclosureStockholdersEquityScheduleOfReservedCommonStockForFutureIssuancesDetails"], "lang": { "en-us": { "role": { "documentation": "Issuance of options under stock plan.", "label": "Issuance of Options Under Stock Plan [Member]", "terseLabel": "Issuance of Options under Plan" } } }, "auth_ref": [] }, "sght_IssuanceOfWarrant": { "xbrltype": "monetaryItemType", "nsuri": "http://www.sightsciences.com/20240930", "localname": "IssuanceOfWarrant", "crdr": "credit", "presentation": ["http://www.sightsciences.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityUnaudited"], "lang": { "en-us": { "role": { "terseLabel": "Warrant issuance", "label": "Issuance of Warrant", "documentation": "Issuance of Warrant" } } }, "auth_ref": [] }, "sght_JeremyBHaydenMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sightsciences.com/20240930", "localname": "JeremyBHaydenMember", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "terseLabel": "Jeremy B. Hayden [Member]", "label": "Jeremy B. Hayden [Member]", "documentation": "Jeremy B. Hayden [Member]" } } }, "auth_ref": [] }, "sght_LeaseCommencementDate": { "xbrltype": "dateItemType", "nsuri": "http://www.sightsciences.com/20240930", "localname": "LeaseCommencementDate", "presentation": ["http://www.sightsciences.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"], "lang": { "en-us": { "role": { "label": "Lease Commencement Date", "documentation": "Lease Commencement Date", "terseLabel": "Lease commencement date" } } }, "auth_ref": [] }, "us-gaap_LeaseCostTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LeaseCostTableTextBlock", "presentation": ["http://www.sightsciences.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesTables"], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Operating Lease Expense Recognized and Supplemental Cash Flow", "label": "Lease, Cost [Table Text Block]", "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income." } } }, "auth_ref": ["r968"] }, "us-gaap_LeaseExpirationDate1": { "xbrltype": "dateItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LeaseExpirationDate1", "presentation": ["http://www.sightsciences.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Lease expiration date", "label": "Lease Expiration Date", "documentation": "Date which lease or group of leases is set to expire, in YYYY-MM-DD format." } } }, "auth_ref": [] }, "us-gaap_LeaseholdImprovementsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LeaseholdImprovementsMember", "presentation": ["http://www.sightsciences.com/20240930/taxonomy/role/Role_DisclosureBalanceSheetComponentsSummaryOfPropertyAndEquipmentNetDetails"], "lang": { "en-us": { "role": { "terseLabel": "Leasehold Improvements", "label": "Leasehold Improvements [Member]", "documentation": "Additions or improvements to assets held under a lease arrangement." } } }, "auth_ref": ["r90", "r486"] }, "sght_LendersMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sightsciences.com/20240930", "localname": "LendersMember", "presentation": ["http://www.sightsciences.com/20240930/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails"], "lang": { "en-us": { "role": { "label": "Lenders [Member]", "documentation": "Lenders [Member]" } } }, "auth_ref": [] }, "us-gaap_LesseeOperatingLeaseDiscountRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseDiscountRate", "presentation": ["http://www.sightsciences.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Operating lease, discount rate", "label": "Lessee, Operating Lease, Discount Rate", "documentation": "Discount rate used by lessee to determine present value of operating lease payments." } } }, "auth_ref": ["r749"] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsDue", "crdr": "credit", "presentation": ["http://www.sightsciences.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfAggregateFutureMinimumLeasePaymentsDetails"], "lang": { "en-us": { "role": { "totalLabel": "Total future minimum lease payments", "label": "Lessee, Operating Lease, Liability, to be Paid", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease." } } }, "auth_ref": ["r485"] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "crdr": "credit", "presentation": ["http://www.sightsciences.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfAggregateFutureMinimumLeasePaymentsDetails"], "lang": { "en-us": { "role": { "terseLabel": "2024 (remainder)", "label": "Lessee, Operating Lease, Liability, to be Paid, Year One", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": ["r485"] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour", "crdr": "credit", "presentation": ["http://www.sightsciences.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfAggregateFutureMinimumLeasePaymentsDetails"], "lang": { "en-us": { "role": { "terseLabel": "2027", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": ["r485"] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree", "crdr": "credit", "presentation": ["http://www.sightsciences.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfAggregateFutureMinimumLeasePaymentsDetails"], "lang": { "en-us": { "role": { "terseLabel": "2026", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": ["r485"] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo", "crdr": "credit", "presentation": ["http://www.sightsciences.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfAggregateFutureMinimumLeasePaymentsDetails"], "lang": { "en-us": { "role": { "terseLabel": "2025", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": ["r485"] }, "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount", "crdr": "credit", "presentation": ["http://www.sightsciences.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfAggregateFutureMinimumLeasePaymentsDetails"], "lang": { "en-us": { "role": { "negatedLabel": "Less: imputed interest", "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount", "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease." } } }, "auth_ref": ["r485"] }, "us-gaap_LesseeOperatingLeaseOptionToExtend": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseOptionToExtend", "presentation": ["http://www.sightsciences.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Extending the lease term", "label": "Lessee, Operating Lease, Option to Extend", "documentation": "Description of terms and conditions of option to extend lessee's operating lease. Includes, but is not limited to, information about option recognized as part of right-of-use asset and lease liability." } } }, "auth_ref": ["r481"] }, "us-gaap_LesseeOperatingLeaseRemainingLeaseTerm": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseRemainingLeaseTerm", "presentation": ["http://www.sightsciences.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Remaining lease term", "label": "Lessee, Operating Lease, Remaining Lease Term", "documentation": "Remaining lease term of operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": ["r487", "r966"] }, "us-gaap_LesseeOperatingLeaseTermOfContract": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseTermOfContract", "presentation": ["http://www.sightsciences.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Operating lease term", "label": "Lessee, Operating Lease, Term of Contract", "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": ["r967"] }, "us-gaap_Liabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Liabilities", "crdr": "credit", "presentation": ["http://www.sightsciences.com/20240930/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited"], "lang": { "en-us": { "role": { "totalLabel": "Total liabilities", "label": "Liabilities", "documentation": "Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others." } } }, "auth_ref": ["r14", "r55", "r56", "r57", "r60", "r61", "r62", "r63", "r160", "r261", "r311", "r312", "r313", "r314", "r315", "r316", "r317", "r318", "r319", "r433", "r436", "r437", "r464", "r627", "r707", "r774", "r918", "r969", "r970"] }, "us-gaap_LiabilitiesAndStockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesAndStockholdersEquity", "crdr": "credit", "presentation": ["http://www.sightsciences.com/20240930/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited"], "lang": { "en-us": { "role": { "label": "Liabilities and Equity", "totalLabel": "Total liabilities and stockholders' equity", "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any." } } }, "auth_ref": ["r71", "r106", "r566", "r751", "r880", "r903", "r960"] }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesAndStockholdersEquityAbstract", "presentation": ["http://www.sightsciences.com/20240930/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited"], "lang": { "en-us": { "role": { "terseLabel": "Liabilities and stockholders' equity", "label": "Liabilities and Equity [Abstract]" } } }, "auth_ref": [] }, "us-gaap_LiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesCurrent", "crdr": "credit", "presentation": ["http://www.sightsciences.com/20240930/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited"], "lang": { "en-us": { "role": { "totalLabel": "Total current liabilities", "label": "Liabilities, Current", "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer." } } }, "auth_ref": ["r57", "r129", "r160", "r261", "r311", "r312", "r313", "r314", "r315", "r316", "r317", "r318", "r319", "r433", "r436", "r437", "r464", "r751", "r918", "r969", "r970"] }, "us-gaap_LiabilitiesCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesCurrentAbstract", "presentation": ["http://www.sightsciences.com/20240930/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited"], "lang": { "en-us": { "role": { "terseLabel": "Current liabilities:", "label": "Liabilities, Current [Abstract]" } } }, "auth_ref": [] }, "us-gaap_LineOfCreditFacilityAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LineOfCreditFacilityAxis", "presentation": ["http://www.sightsciences.com/20240930/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails"], "lang": { "en-us": { "role": { "label": "Lender Name [Axis]", "documentation": "Information by name of lender, which may be a single entity (for example, but not limited to, a bank, pension fund, venture capital firm) or a group of entities that participate in the line of credit." } } }, "auth_ref": ["r54", "r59", "r879", "r916", "r917"] }, "sght_LineOfCreditFacilityCollateralFeesPercentage": { "xbrltype": "percentItemType", "nsuri": "http://www.sightsciences.com/20240930", "localname": "LineOfCreditFacilityCollateralFeesPercentage", "presentation": ["http://www.sightsciences.com/20240930/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails"], "lang": { "en-us": { "role": { "label": "Line Of Credit Facility Collateral Fees Percentage", "documentation": "Line of credit facility collateral fees.", "terseLabel": "Line of credit facility collateral fees" } } }, "auth_ref": [] }, "us-gaap_LineOfCreditFacilityCommitmentFeeAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LineOfCreditFacilityCommitmentFeeAmount", "crdr": "debit", "presentation": ["http://www.sightsciences.com/20240930/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails"], "lang": { "en-us": { "role": { "label": "Line of Credit Facility, Commitment Fee Amount", "terseLabel": "Line of credit facility commitment fee amount", "documentation": "Amount of the fee for available but unused credit capacity under the credit facility." } } }, "auth_ref": ["r54", "r59", "r310"] }, "us-gaap_LineOfCreditFacilityCommitmentFeeDescription": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LineOfCreditFacilityCommitmentFeeDescription", "presentation": ["http://www.sightsciences.com/20240930/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails"], "lang": { "en-us": { "role": { "label": "Line of Credit Facility, Commitment Fee Description", "terseLabel": "Line of credit facility, commitment fee description", "documentation": "Description of the fees for amounts available, but unused under the credit facility." } } }, "auth_ref": ["r54", "r59"] }, "us-gaap_LineOfCreditFacilityCommitmentFeePercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LineOfCreditFacilityCommitmentFeePercentage", "presentation": ["http://www.sightsciences.com/20240930/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails"], "lang": { "en-us": { "role": { "label": "Line of Credit Facility, Commitment Fee Percentage", "terseLabel": "Percentage of final payment fee", "documentation": "The fee, expressed as a percentage of the line of credit facility, for the line of credit facility regardless of whether the facility has been used." } } }, "auth_ref": [] }, "us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LineOfCreditFacilityCurrentBorrowingCapacity", "crdr": "credit", "presentation": ["http://www.sightsciences.com/20240930/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails"], "lang": { "en-us": { "role": { "label": "Line of Credit Facility, Current Borrowing Capacity", "terseLabel": "Line of credit facility, current borrowing capacity", "documentation": "Amount of current borrowing capacity under the credit facility considering any current restrictions on the amount that could be borrowed (for example, borrowings may be limited by the amount of current assets), but without considering any amounts currently outstanding under the facility." } } }, "auth_ref": ["r54", "r59"] }, "us-gaap_LineOfCreditFacilityInitiationDate1": { "xbrltype": "dateItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LineOfCreditFacilityInitiationDate1", "presentation": ["http://www.sightsciences.com/20240930/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Loan agreement initiation Date", "label": "Line of Credit Facility, Initiation Date", "documentation": "Date the credit facility first became available, in YYYY-MM-DD format." } } }, "auth_ref": ["r54", "r59"] }, "us-gaap_LineOfCreditFacilityLenderDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":

"LineOfCreditFacilityLenderDomain", "presentation": ["http://www.sightsciences.com/20240930/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails"], "lang": { "en-us": { "role": { "label": "Line of Credit Facility, Lender [Domain]", "documentation": "Identification of the lender, which may be a single entity (for example, a bank, pension fund, venture capital firm) or a group of entities that participate in the line of credit, including a letter of credit facility." } } }, "auth_ref": ["r54", "r59", "r879", "r916"] }, "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LineOfCreditFacilityMaximumBorrowingCapacity", "crdr": "credit", "presentation": [
"http://www.sightsciences.com/20240930/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails",
"http://www.sightsciences.com/20240930/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails"], "lang": { "en-us": { "role": { "label": "Line of Credit Facility, Maximum Borrowing Capacity", "terseLabel": "Maximum borrowing capacity", "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility." } } }, "auth_ref": ["r54", "r59"] }, "us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LineOfCreditFacilityRemainingBorrowingCapacity", "crdr": "credit", "presentation": [
"http://www.sightsciences.com/20240930/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails"], "lang": { "en-us": { "role": { "label": "Line of Credit Facility, Remaining Borrowing Capacity", "terseLabel": "Line of credit facility, remaining borrowing capacity", "documentation": "Amount of borrowing capacity currently available under the credit facility (current borrowing capacity less the amount of borrowings outstanding)." } } }, "auth_ref": ["r54", "r59", "r310"] }, "us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage", "presentation": [
"http://www.sightsciences.com/20240930/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails"], "lang": { "en-us": { "role": { "label": "Line of Credit Facility, Unused Capacity, Commitment Fee Percentage", "terseLabel": "Line of credit facility, unused capacity, commitment fee percentage", "documentation": "The fee, expressed as a percentage of the line of credit facility, for available but unused credit capacity under the credit facility." } } }, "auth_ref": [] }, "us-gaap_LineOfCreditMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LineOfCreditMember", "presentation": ["http://www.sightsciences.com/20240930/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails"], "lang": { "en-us": { "role": { "label": "Line of Credit [Member]", "documentation": "A contractual arrangement with a lender under which borrowings can be made up to a specific amount at any point in time, and under which borrowings outstanding may be either short-term or long-term, depending upon the particulars." } } }, "auth_ref": [] },
"sght_Lineofcreditachievementofcertainperformancemilestones": { "xbrltype": "monetaryItemType", "nsuri": "http://www.sightsciences.com/20240930", "localname": "Lineofcreditachievementofcertainperformancemilestones", "crdr": "credit", "presentation": [
"http://www.sightsciences.com/20240930/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Line of credit achievement of certain performance milestones", "label": "LineOfCreditAchievementOfCertainPerformanceMilestones", "documentation": "Line Of Credit Achievement Of Certain Performance Milestones" } } },
"auth_ref": [] }, "us-gaap_LitigationStatusAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LitigationStatusAxis", "presentation": [
"http://www.sightsciences.com/20240930/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails",
"http://www.sightsciences.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"], "lang": { "en-us": { "role": { "label": "Litigation Status [Axis]", "documentation": "Information by status of pending, threatened, or settled litigation." } } }, "auth_ref": ["r906", "r907", "r908", "r912"] }, "us-gaap_LitigationStatusDomain": {
"xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LitigationStatusDomain", "presentation": [
"http://www.sightsciences.com/20240930/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails",
"http://www.sightsciences.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"], "lang": { "en-us": { "role": { "label": "Litigation Status [Domain]", "documentation": "Status of pending, threatened, or settled litigation." } } }, "auth_ref": ["r906", "r907", "r908", "r912"] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "LocalPhoneNumber", "presentation": [
"http://www.sightsciences.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "terseLabel": "Local Phone Number", "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "us-gaap_LongTermDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermDebt", "crdr": "credit", "presentation": ["http://www.sightsciences.com/20240930/taxonomy/role/Role_DisclosureDebtScheduleRelatingToCompanySDebtDetails"], "lang": { "en-us": { "role": { "terseLabel": "Long-term Debt", "label": "Long-Term Debt", "verboseLabel": "Term Loan", "negatedLabel": "Total repayments", "negatedTotalLabel": "Total repayments", "totalLabel": "Total repayments", "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation." } } }, "auth_ref": ["r14", "r104", "r333", "r348", "r723", "r724", "r748", "r979"] }, "us-gaap_LongTermDebtCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermDebtCurrent", "crdr": "credit", "presentation": [
"http://www.sightsciences.com/20240930/taxonomy/role/Role_DisclosureDebtScheduleOfLongTermAndShortTermDebtDetails",
"http://www.sightsciences.com/20240930/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited"], "lang": { "en-us": { "role": { "negatedLabel": "Less: current portion", "terseLabel": "Current portion - long-term debt, net", "verboseLabel": "Less: current portion", "label": "Long-Term Debt, Current Maturities", "totalLabel": "Long-term Debt, Current Maturities, Total", "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as current. Excludes lease obligation." } } },
"auth_ref": ["r135"] }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths", "crdr": "credit", "presentation": [
"http://www.sightsciences.com/20240930/taxonomy/role/Role_DisclosureDebtScheduleRelatingToCompanySDebtDetails"], "lang": { "en-us": { "role": { "terseLabel": "2025", "negatedLabel": "2023", "label": "Long-Term Debt, Maturity, Year One", "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": ["r7", "r161", "r338"] }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree", "crdr": "credit", "presentation": [
"http://www.sightsciences.com/20240930/taxonomy/role/Role_DisclosureDebtScheduleRelatingToCompanySDebtDetails"], "lang": { "en-us": { "role": { "terseLabel": "2027", "negatedLabel": "2025", "label": "Long-Term Debt, Maturity, Year Three", "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": ["r7", "r161", "r338"] }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo", "crdr": "credit", "presentation": [
"http://www.sightsciences.com/20240930/taxonomy/role/Role_DisclosureDebtScheduleRelatingToCompanySDebtDetails"], "lang": { "en-us": { "role": { "terseLabel": "2026", "negatedLabel": "2024", "label": "Long-Term Debt, Maturity, Year Two", "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": ["r7", "r161", "r338"] }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear": {
"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear", "crdr": "credit", "presentation": ["http://www.sightsciences.com/20240930/taxonomy/role/Role_DisclosureDebtScheduleRelatingToCompanySDebtDetails"], "lang": { "en-us": { "role": { "terseLabel": "2024 (remainder)", "negatedLabel": "2022 (remainder)", "label": "Long-Term Debt, Maturity, Remainder of Fiscal Year", "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in remainder of current fiscal year." } } }, "auth_ref": ["r881"] },
"sght_LongTermDebtMaturityAfterYearThree": { "xbrltype": "monetaryItemType", "nsuri": "http://www.sightsciences.com/20240930", "localname": "LongTermDebtMaturityAfterYearThree", "crdr": "credit", "presentation": ["http://www.sightsciences.com/20240930/taxonomy/role/Role_DisclosureDebtScheduleRelatingToCompanySDebtDetails"], "lang": { "en-us": { "role": {
"terseLabel": "Thereafter", "negatedLabel": "Thereafter", "label": "Long-Term Debt, Maturity, after Year Three", "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing after third fiscal year following current fiscal year." } } }, "auth_ref": [] }, "us-gaap_LongTermDebtNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermDebtNoncurrent", "crdr": "credit", "presentation": [
"http://www.sightsciences.com/20240930/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails",
"http://www.sightsciences.com/20240930/taxonomy/role/Role_DisclosureDebtScheduleOfLongTermAndShortTermDebtDetails",
"http://www.sightsciences.com/20240930/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited"], "lang": { "en-us": { "role": { "label": "Long-Term Debt, Excluding Current Maturities", "verboseLabel": "Total accrued and other current liabilities", "terseLabel": "Long-term debt, net", "totalLabel": "Long-term debt, net", "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation." } } }, "auth_ref": ["r137"] }, "us-gaap_LongTermDebtPercentageBearingFixedInterestRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermDebtPercentageBearingFixedInterestRate", "presentation": ["http://www.sightsciences.com/20240930/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Percentage of long term debt fee payable", "label": "Long-Term Debt, Percentage Bearing Fixed Interest, Percentage Rate", "documentation": "The interest rate applicable to the portion of the carrying amount of long-term borrowings outstanding as of the balance sheet date, including current maturities, which accrues interest at a set, unchanging rate." } } }, "auth_ref": ["r58"] }, "us-gaap_LongtermDebtTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongtermDebtTypeAxis", "presentation": ["http://www.sightsciences.com/20240930/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails"], "lang": { "en-us": { "role": { "label": "Long-Term Debt, Type [Axis]", "documentation": "Information by type of long-term debt." } } }, "auth_ref": ["r14", "r906", "r907", "r908"] }, "us-gaap_LongtermDebtTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongtermDebtTypeDomain", "presentation": [
"http://www.sightsciences.com/20240930/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails"], "lang": { "en-us": { "role": { "label": "Long-Term Debt, Type [Domain]", "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer." } } }, "auth_ref": ["r14", "r32", "r906", "r907", "r908"] }, "us-gaap_LossContingenciesByNatureOfContingencyAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LossContingenciesByNatureOfContingencyAxis", "presentation": ["http://www.sightsciences.com/20240930/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails",
"http://www.sightsciences.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"], "lang": { "en-us": { "role": { "label": "Loss Contingency Nature [Axis]", "documentation": "Information by type of existing condition, situation, or set of circumstances involving uncertainty as to possible loss to an enterprise that will ultimately be resolved when one or more future events occur or fail to occur." } } }, "auth_ref": ["r303", "r304", "r305", "r308", "r417", "r596", "r721", "r913", "r914"] }, "us-gaap_LossContingencyNatureDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LossContingencyNatureDomain", "presentation": [
"http://www.sightsciences.com/20240930/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails",
"http://www.sightsciences.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"], "lang": { "en-us": { "role": { "label": "Loss Contingency Nature [Domain]", "documentation": "An existing condition, situation, or set of circumstances involving uncertainty as to possible loss to an enterprise that will ultimately be resolved when one or more future events occur or fail to occur. Resolution of the uncertainty may confirm the incurrence of a loss or impairment of an asset or the incurrence of a liability." } } }, "auth_ref": [
"r303", "r304", "r305", "r308", "r417", "r596", "r721", "r913", "r914"] }, "sght_LostProfitsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sightsciences.com/20240930", "localname": "LostProfitsMember", "presentation": ["http://www.sightsciences.com/20240930/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails",
"http://www.sightsciences.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"], "lang": { "en-us": { "role": { "label": "Lost Profits [Member]", "documentation": "Lost Profits [Member]" } } }, "auth_ref": [] }, "srt_MaximumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "MaximumMember", "presentation": ["http://www.sightsciences.com/20240930/taxonomy/role/DisclosureEquityIncentivePlansAdditionalInformationDetail",
"http://www.sightsciences.com/20240930/taxonomy/role/DisclosureEquityIncentivePlansSummaryOfStockBasedCompensationFairValueAssumptionsDetails",
"http://www.sightsciences.com/20240930/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails",
"http://www.sightsciences.com/20240930/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails"], "lang": { "en-us": { "role": { "label": "Maximum [Member]", "terseLabel": "Maximum", "verboseLabel": "Maximum [Member]" } } }, "auth_ref": ["r304", "r305", "r306", "r307", "r379", "r417", "r454", "r523", "r587", "r589", "r596", "r619", "r620", "r673", "r675", "r677", "r678", "r680", "r699", "r700", "r718", "r727", "r732", "r741", "r742", "r746", "r747", "r761", "r920", "r971", "r972", "r973", "r974", "r975", "r976"] }, "ecd_MeasureAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MeasureAxis", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Measure [Axis]", "terseLabel": "Measure:" } } }, "auth_ref": ["r823"] }, "ecd_MeasureName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MeasureName", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Measure Name", "terseLabel": "Name" } } }, "auth_ref": ["r823"] },
"sght_MidCapFinancialServicesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sightsciences.com/20240930", "localname": "MidCapFinancialServicesMember", "presentation": [
"http://www.sightsciences.com/20240930/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails"], "lang": { "en-us": { "role": { "label": "Mid Cap Financial Services [Member]", "documentation": "Mid Cap Financial Services.", "terseLabel": "Mid Cap Financial Services" } } }, "auth_ref": [] }, "sght_MidcapCreditFacilityAgreementsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sightsciences.com/20240930", "localname": "MidcapCreditFacilityAgreementsMember", "presentation": [
"http://www.sightsciences.com/20240930/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails"], "lang": { "en-us": { "role": { "label": "MidCap Credit Facility Agreements [Member]", "documentation": "MidCap Credit Facility Agreements" } } }, "auth_ref": [] }, "sght_MidcapTermLoanMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sightsciences.com/20240930", "localname": "MidcapTermLoanMember", "presentation": [
"http://www.sightsciences.com/20240930/taxonomy/role/Role_DisclosureDebtScheduleOfLongTermAndShortTermDebtDetails"], "lang": { "en-us": { "role": { "label": "MidCap Term Loan [Member]", "documentation": "MidCap Term Loan [Member]" } } }, "auth_ref": [] }, "srt_MinimumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "MinimumMember", "presentation": ["http://www.sightsciences.com/20240930/taxonomy/role/DisclosureEquityIncentivePlansAdditionalInformationDetail",
"http://www.sightsciences.com/20240930/taxonomy/role/DisclosureEquityIncentivePlansSummaryOfStockBasedCompensationFairValueAssumptionsDetails",
"http://www.sightsciences.com/20240930/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails"], "lang": { "en-us": { "role": { "label": "Minimum [Member]", "terseLabel":

"Minimum" } } }, "auth_ref": ["r304", "r305", "r306", "r307", "r379", "r417", "r454", "r523", "r587", "r589", "r596", "r619", "r620", "r673", "r675", "r677", "r678", "r680", "r699", "r700", "r718", "r727", "r732", "r741", "r742", "r746", "r761", "r920", "r971", "r972", "r973", "r974", "r975", "r976"] }, "ecd_MnpiDiscTimedForCompValFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MnpiDiscTimedForCompValFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "MNPI Disclosure Timed for Compensation Value [Flag]", "terseLabel": "MNPI Disclosure Timed for Compensation Value" } } }, "auth_ref": ["r842"] }, "ecd_MtrlTermsOfTrdArrTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MtrlTermsOfTrdArrTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Material Terms of Trading Arrangement [Text Block]", "terseLabel": "Material Terms of Trading Arrangement" } } }, "auth_ref": ["r850"] }, "ecd_NamedExecutiveOfficersFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NamedExecutiveOfficersFnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Named Executive Officers, Footnote [Text Block]", "terseLabel": "Named Executive Officers, Footnote" } } }, "auth_ref": ["r824"] }, "us-gaap_NatureOfOperations": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NatureOfOperations", "presentation": ["http://www.sightsciences.com/20240930/taxonomy/role/Role_DisclosureCompanyAndNatureOfBusiness"], "lang": { "en-us": { "role": { "terseLabel": "Company and Nature of Business", "label": "Nature of Operations [Text Block]", "documentation": "The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward." } } }, "auth_ref": ["r117", "r123"] }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInFinancingActivities", "crdr": "debit", "presentation": [
"http://www.sightsciences.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Financing Activities", "totalLabel": "Net cash (used in) provided by financing activities", "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit." } } }, "auth_ref": ["r153"] }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "presentation": [
"http://www.sightsciences.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"], "lang": { "en-us": { "role": { "terseLabel": "Cash flows from financing activities", "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInInvestingActivities", "crdr": "debit", "presentation": [
"http://www.sightsciences.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"], "lang": { "en-us": { "role": { "totalLabel": "Net cash used in investing activities", "label": "Net Cash Provided by (Used in) Investing Activities", "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets." } } }, "auth_ref": ["r153"] }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "presentation": [
"http://www.sightsciences.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"], "lang": { "en-us": { "role": { "terseLabel": "Cash flows from investing activities", "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInOperatingActivities", "presentation": [
"http://www.sightsciences.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"], "lang": { "en-us": { "role": { "totalLabel": "Net cash used in operating activities", "label": "Net Cash Provided by (Used in) Operating Activities", "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities." } } }, "auth_ref": ["r84", "r85", "r86"] }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": [
"http://www.sightsciences.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"], "lang": { "en-us": { "role": { "terseLabel": "Cash flows from operating activities", "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NetIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetIncomeLoss", "crdr": "credit", "presentation": [
"http://www.sightsciences.com/20240930/taxonomy/role/DisclosureNetLossPerShareAttributableToCommonStockholdersScheduleOfComputationOfBasicAndDilutedNetLossPerShareAttributable",
"http://www.sightsciences.com/20240930/taxonomy/role/Role_DisclosureCompanyAndNatureOfBusinessAdditionalInformationDetails",
"http://www.sightsciences.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited",
"http://www.sightsciences.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityUnaudited",
"http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Net Income (Loss)", "terseLabel": "Net Income (Loss)", "negatedLabel": "Net loss", "totalLabel": "Net loss and comprehensive loss", "verboseLabel": "Net loss attributable to common stockholders", "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent." } } }, "auth_ref": ["r77", "r86", "r109", "r127", "r144", "r145", "r148", "r160", "r165", "r167", "r168", "r169", "r170", "r171", "r174", "r175", "r181", "r261", "r311", "r312", "r313", "r314", "r315", "r316", "r317", "r318", "r319", "r427", "r430", "r448", "r464", "r571", "r649", "r666", "r667", "r772", "r918"] }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "presentation": [
"http://www.sightsciences.com/20240930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"], "lang": { "en-us": { "role": { "terseLabel": "New Accounting Pronouncements", "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact." } } }, "auth_ref": [] }, "ecd_NonGaapMeasureDescriptionTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonGaapMeasureDescriptionTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Non-GAAP Measure Description [Text Block]", "terseLabel": "Non-GAAP Measure Description" } } }, "auth_ref": ["r823"] }, "ecd_NonNeosMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonNeosMember", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Non-NEOs [Member]", "terseLabel": "Non-NEOs" } } }, "auth_ref": ["r787", "r797", "r807", "r831", "r839"] }, "ecd_NonPeoNeoAvgCompActuallyPaidAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonPeoNeoAvgCompActuallyPaidAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Non-PEO NEO Average Compensation Actually Paid Amount", "terseLabel": "Non-PEO NEO Average Compensation Actually Paid Amount" } } }, "auth_ref": ["r814"] }, "ecd_NonPeoNeoAvgTotalCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonPeoNeoAvgTotalCompAmt", "presentation": [
"http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Non-PEO NEO Average Total Compensation Amount", "terseLabel": "Non-PEO NEO Average Total Compensation Amount" } } }, "auth_ref": ["r813"] }, "ecd_NonPeoNeoMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonPeoNeoMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Non-PEO NEO [Member]", "terseLabel": "Non-PEO NEO" } } }, "auth_ref": ["r831"] }, "sght_NonRule10B51ArrModifiedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://www.sightsciences.com/20240930", "localname": "NonRule10B51ArrModifiedFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Non-Rule 10b5-1 Arrangement Modified [Flag]", "terseLabel": "Non-Rule 10b5-1 Arrangement Modified", "documentation": "Non-Rule 10b5-1 Arr Modified [Flag]" } } }, "auth_ref": [] }, "ecd_NonRule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonRule10b51ArrAdoptedFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Non-Rule 10b5-1 Arrangement Adopted [Flag]", "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted" } } }, "auth_ref": ["r850"] }, "ecd_NonRule10b51ArrTrmntdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonRule10b51ArrTrmntdFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Non-Rule 10b5-1 Arrangement Terminated [Flag]", "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated" } } }, "auth_ref": ["r850"] }, "sght_NoncashLossOnExtinguishmentOfDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://www.sightsciences.com/20240930", "localname": "NoncashLossOnExtinguishmentOfDebt", "crdr": "debit", "presentation": ["http://www.sightsciences.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"], "lang": { "en-us": { "role": { "terseLabel": "Noncash loss on debt extinguishment", "label": "Noncash Loss On Extinguishment Of Debt", "documentation": "Noncash Loss On Extinguishment Of Debt" } } }, "auth_ref": [] }, "sght_NoncashOperatingLeaseCost": { "xbrltype": "monetaryItemType", "nsuri": "http://www.sightsciences.com/20240930", "localname": "NoncashOperatingLeaseCost", "crdr": "debit", "presentation": ["http://www.sightsciences.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"], "lang": { "en-us": { "role": { "terseLabel": "Noncash operating lease expense", "label": "Noncash Operating Lease Cost", "documentation": "Noncash Operating Lease Cost" } } }, "auth_ref": [] }, "us-gaap_NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1", "crdr": "debit", "presentation": [
"http://www.sightsciences.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"], "lang": { "en-us": { "role": { "terseLabel": "Acquisition of property and equipment included in accounts payable and accrued liabilities", "label": "Noncash or Part Noncash Acquisition, Fixed Assets Acquired", "documentation": "The amount of fixed assets that an Entity acquires in a noncash (or part noncash) acquisition. Noncash is defined as information about all investing and financing activities of an enterprise during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period." } } }, "auth_ref": ["r20", "r21", "r22"] }, "us-gaap_NumberOfReportableSegments": { "xbrltype": "integerItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NumberOfReportableSegments", "presentation": ["http://www.sightsciences.com/20240930/taxonomy/role/DisclosureSegmentInformationAdditionalInformationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Number of Reportable Segments", "label": "Number of Reportable Segments", "documentation": "Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements." } } }, "auth_ref": ["r709", "r717", "r889"] }, "us-gaap_OperatingExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingExpenses", "crdr": "debit", "presentation": [
"http://www.sightsciences.com/20240930/taxonomy/role/Role_DisclosureSegmentInformationSummaryOfOperatingResultInformationForEachReportableSegmentDetails",
"http://www.sightsciences.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited"], "lang": { "en-us": { "role": { "terseLabel": "Operating expense", "negatedLabel": "Operating expense", "totalLabel": "Total operating expenses", "label": "Operating Expenses", "verboseLabel": "Operating expenses", "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense." } } }, "auth_ref": [] }, "us-gaap_OperatingExpensesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingExpensesAbstract", "presentation": [
"http://www.sightsciences.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited"], "lang": { "en-us": { "role": { "terseLabel": "Operating expenses:", "label": "Operating Expenses [Abstract]" } } }, "auth_ref": [] }, "us-gaap_OperatingIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingIncomeLoss", "crdr": "credit", "presentation": [
"http://www.sightsciences.com/20240930/taxonomy/role/Role_DisclosureSegmentInformationSummaryOfOperatingResultInformationForEachReportableSegmentDetails",
"http://www.sightsciences.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited"], "lang": { "en-us": { "role": { "totalLabel": "Loss from operations", "label": "Operating Income (Loss)", "terseLabel": "Loss from operations", "documentation": "The net result for the period of deducting operating expenses from operating revenues." } } }, "auth_ref": ["r112", "r708", "r888", "r890", "r891", "r892", "r893"] }, "us-gaap_OperatingLeaseExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseExpense", "crdr": "debit", "presentation": [
"http://www.sightsciences.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
"http://www.sightsciences.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfOperatingLeaseExpenseRecognizedAndSupplementalCashFlowDetails"], "lang": { "en-us": { "role": { "label": "Operating Lease, Expense", "verboseLabel": "Operating leases, rent expense", "terseLabel": "Operating lease expense", "documentation": "Amount of operating lease expense. Excludes sublease income." } } }, "auth_ref": ["r965"] }, "us-gaap_OperatingLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiability", "crdr": "credit", "presentation": [
"http://www.sightsciences.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfAggregateFutureMinimumLeasePaymentsDetails"], "lang": { "en-us": { "role": { "totalLabel": "Present value of future minimum lease payments", "terseLabel": "Present value of future minimum lease payments", "label": "Operating Lease, Liability", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease." } } }, "auth_ref": ["r478"] }, "us-gaap_OperatingLeaseLiabilityCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiabilityCurrent", "crdr": "credit", "presentation": [
"http://www.sightsciences.com/20240930/taxonomy/role/Role_DisclosureBalanceSheetComponentsSummaryOfAccruedAndOtherCurrentLiabilitiesDetails",
"http://www.sightsciences.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfAggregateFutureMinimumLeasePaymentsDetails"], "lang": { "en-us": { "role": { "negatedLabel": "Less: current portion of operating lease liability", "terseLabel": "Current portion of lease liabilities", "label": "Operating Lease, Liability, Current", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current." } } }, "auth_ref": ["r478"] }, "us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList": { "xbrltype": "enumerationSetItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList", "presentation": [
"http://www.sightsciences.com/20240930/taxonomy/role/Role_DisclosureBalanceSheetComponentsSummaryOfAccruedAndOtherCurrentLiabilitiesDetails"], "lang": { "en-us": { "role": { "label": "Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]", "documentation": "Indicates line item in statement of financial position that includes current operating lease liability." } } }, "auth_ref": ["r479"] }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiabilityNoncurrent", "crdr": "credit", "presentation": [

```
"http://www.sightsciences.com/20240930/taxonomy/role/Role_DisclosureBalanceSheetComponentsSummaryOfOtherNoncurrentLiabilitiesDetails",
"http://www.sightsciences.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfAggregateFutureMinimumLeasePaymentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Noncurrent portion of lease liabilities", "label": "Operating Lease, Liability, Noncurrent", "verboseLabel": "Noncurrent portion of lease liabilities", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent." } } }, "auth_ref": [ "r478" ] }, "us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList": { "xbrltype": "enumerationSetItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList", "presentation": [
"http://www.sightsciences.com/20240930/taxonomy/role/Role_DisclosureBalanceSheetComponentsSummaryOfOtherNoncurrentLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]", "documentation": "Indicates line item in statement of financial position that includes noncurrent operating lease liability." } } }, "auth_ref": [ "r479" ] }, "us-gaap_OperatingLeasePayments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeasePayments", "crdr": "credit", "presentation": [
"http://www.sightsciences.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfOperatingLeaseExpenseRecognizedAndSupplementalCashFlowDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cash paid for operating leases", "label": "Operating Lease, Payments", "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use." } } }, "auth_ref": [ "r480", "r482" ] }, "us-gaap_OperatingLeaseRightOfUseAsset": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseRightOfUseAsset", "crdr": "debit", "presentation": [
"http://www.sightsciences.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
"http://www.sightsciences.com/20240930/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Operating lease right-of-use assets", "label": "Operating Lease, Right-of-Use Asset", "documentation": "Amount of lessee's right to use underlying asset under operating lease." } } }, "auth_ref": [ "r477" ] }, "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseWeightedAverageDiscountRatePercent", "presentation": [
"http://www.sightsciences.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Lease, borrowing rate", "label": "Operating Lease, Weighted Average Discount Rate, Percent", "documentation": "Weighted average discount rate for operating lease calculated at point in time." } } }, "auth_ref": [ "r484", "r750" ] }, "sght_OptionsGrantedMeritAwardsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sightsciences.com/20240930", "localname": "OptionsGrantedMeritAwardsMember", "presentation": [ "http://www.sightsciences.com/20240930/taxonomy/role/DisclosureEquityIncentivePlansAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Options Granted Merit Awards [Member]", "terseLabel": "Options Granted Merit Awards", "documentation": "Options granted merit awards." } } }, "auth_ref": [] }, "sght_OptionsGrantedToNewHiresMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sightsciences.com/20240930", "localname": "OptionsGrantedToNewHiresMember", "presentation": [ "http://www.sightsciences.com/20240930/taxonomy/role/DisclosureEquityIncentivePlansAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Options Granted To New Hires [Member]", "documentation": "Options granted to new hires.", "terseLabel": "Options Granted to New Hires" } } }, "auth_ref": [] }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "lang": { "en-us": { "role": { "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]" } } }, "auth_ref": [] }, "sght_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://www.sightsciences.com/20240930", "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems", "presentation": [
"http://www.sightsciences.com/20240930/taxonomy/role/Role_DisclosureCompanyAndNatureOfBusinessAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]", "label": "Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]", "documentation": "Organization consolidation and presentation of financial statements disclosure." } } }, "auth_ref": [] }, "sght_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTable": { "xbrltype": "stringItemType", "nsuri": "http://www.sightsciences.com/20240930", "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTable", "presentation": [
"http://www.sightsciences.com/20240930/taxonomy/role/Role_DisclosureCompanyAndNatureOfBusinessAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Organization Consolidation And Presentation Of Financial Statements Disclosure [Table]", "label": "Organization Consolidation And Presentation Of Financial Statements Disclosure [Table]", "documentation": "Organization consolidation and presentation of financial statements disclosure." } } }, "auth_ref": [] }, "us-gaap_OtherAccruedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherAccruedLiabilitiesCurrent", "crdr": "credit", "presentation": [
"http://www.sightsciences.com/20240930/taxonomy/role/Role_DisclosureBalanceSheetComponentsSummaryOfAccruedAndOtherCurrentLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other accrued liabilities", "label": "Other Accrued Liabilities, Current", "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r56" ] }, "us-gaap_OtherAssetsNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherAssetsNoncurrent", "crdr": "debit", "presentation": [ "http://www.sightsciences.com/20240930/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Other noncurrent assets", "totalLabel": "Other Assets, Noncurrent, Total", "label": "Other Assets, Noncurrent", "documentation": "Amount of noncurrent assets classified as other." } } }, "auth_ref": [ "r133" ] }, "us-gaap_OtherLiabilitiesNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherLiabilitiesNoncurrent", "crdr": "credit", "presentation": [
"http://www.sightsciences.com/20240930/taxonomy/role/Role_DisclosureBalanceSheetComponentsSummaryOfOtherNoncurrentLiabilitiesDetails",
"http://www.sightsciences.com/20240930/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Total other noncurrent liabilities", "terseLabel": "Other noncurrent liabilities", "label": "Other Liabilities, Noncurrent", "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r61" ] }, "sght_OtherNonCurrentLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://www.sightsciences.com/20240930", "localname": "OtherNonCurrentLiabilities", "crdr": "credit", "presentation": [
"http://www.sightsciences.com/20240930/taxonomy/role/Role_DisclosureBalanceSheetComponentsSummaryOfOtherNoncurrentLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other noncurrent liabilities", "label": "Other Non-Current Liabilities", "documentation": "Other non-current liabilities." } } }, "auth_ref": [] }, "us-gaap_OtherNoncurrentLiabilitiesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherNoncurrentLiabilitiesTableTextBlock", "presentation": [ "http://www.sightsciences.com/20240930/taxonomy/role/Role_DisclosureBalanceSheetComponentsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Summary of Other Noncurrent Liabilities", "label": "Other Noncurrent Liabilities [Table Text Block]", "documentation": "Tabular disclosure of other noncurrent liabilities." } } }, "auth_ref": [] }, "us-gaap_OtherNonoperatingIncomeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherNonoperatingIncomeExpense", "crdr": "credit", "presentation": [ "http://www.sightsciences.com/20240930/taxonomy/role/Role_DisclosureSegmentInformationSummaryOfOperatingResultInformationForEachReportableSegmentDetails",
"http://www.sightsciences.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Other income (expense), net", "verboseLabel": "Other income (expense), net", "label": "Other Nonoperating Income (Expense)", "totalLabel": "Other Nonoperating Income (Expense), Total", "documentation": "Amount of income (expense) related to nonoperating activities, classified as other." } } }, "auth_ref": [ "r82" ] }, "ecd_OtherPerfMeasureAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OtherPerfMeasureAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Other Performance Measure, Amount", "terseLabel": "Other Performance Measure, Amount" } } }, "auth_ref": [ "r823" ] }, "ecd_OutstandingAggtErrCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OutstandingAggtErrCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Outstanding Aggregate Erroneous Compensation Amount", "terseLabel": "Outstanding Aggregate Erroneous Compensation Amount" } } }, "auth_ref": [ "r785", "r795", "r805", "r837" ] }, "ecd_OutstandingRecoveryCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OutstandingRecoveryCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Outstanding Recovery Compensation Amount", "terseLabel": "Compensation Amount" } } }, "auth_ref": [ "r788", "r798", "r808", "r840" ] }, "ecd_OutstandingRecoveryIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OutstandingRecoveryIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Outstanding Recovery, Individual Name", "terseLabel": "Name" } } }, "auth_ref": [ "r788", "r798", "r808", "r840" ] }, "us-gaap_OverAllotmentOptionMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OverAllotmentOptionMember", "presentation": [
"http://www.sightsciences.com/20240930/taxonomy/role/Role_DisclosureCompanyAndNatureOfBusinessAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Over-Allotment Option [Member]", "terseLabel": "Underwriters' Option", "documentation": "Right given to the underwriter to sell additional shares over the initial allotment." } } }, "auth_ref": [] }, "ecd_PayVsPerformanceDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PayVsPerformanceDisclosureLineItems", "lang": { "en-us": { "role": { "label": "Pay vs Performance Disclosure [Line Items]", "terseLabel": "Pay vs Performance Disclosure" } } }, "auth_ref": [ "r812" ] }, "sght_PaycheckProtectionProgramLoanMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sightsciences.com/20240930", "localname": "PaycheckProtectionProgramLoanMember", "presentation": [
"http://www.sightsciences.com/20240930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "PPP Loan", "label": "Paycheck Protection Program Loan [Member]", "documentation": "Paycheck Protection Program loan." } } }, "auth_ref": [] }, "us-gaap_PaymentsForProceedsFromDepositOnLoan": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsForProceedsFromDepositOnLoan", "crdr": "credit", "presentation": [ "http://www.sightsciences.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "negatedLabel": "Net proceeds from Hercules Loan Agreement", "label": "Payments for (Proceeds from) Deposit on Loan", "documentation": "The net cash inflow or outflow from resulting from payment, receipt or drawdown of cash deposit to guarantee a loan during the period." } } }, "auth_ref": [ "r5", "r19" ] }, "us-gaap_PaymentsOfDebtIssuanceCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsOfDebtIssuanceCosts", "crdr": "credit", "presentation": [
"http://www.sightsciences.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "negatedLabel": "Debt issuance costs", "label": "Payments of Debt Issuance Costs", "documentation": "The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt." } } }, "auth_ref": [ "r17" ] }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "crdr": "credit", "presentation": [
"http://www.sightsciences.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "negatedLabel": "Purchases of property and equipment", "label": "Payments to Acquire Property, Plant, and Equipment", "totalLabel": "Payments to Acquire Property, Plant, and Equipment, Total", "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets." } } }, "auth_ref": [ "r83" ] }, "ecd_PeerGroupIssuersFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeerGroupIssuersFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Peer Group Issuers, Footnote [Text Block]", "terseLabel": "Peer Group Issuers, Footnote" } } }, "auth_ref": [ "r822" ] }, "ecd_PeerGroupTotalShareholderRtnAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeerGroupTotalShareholderRtnAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Peer Group Total Shareholder Return Amount", "terseLabel": "Peer Group Total Shareholder Return Amount" } } }, "auth_ref": [ "r822" ] }, "ecd_PeoActuallyPaidCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoActuallyPaidCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "PEO Actually Paid Compensation Amount", "terseLabel": "PEO Actually Paid Compensation Amount" } } }, "auth_ref": [ "r814" ] }, "ecd_PeoMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "PEO [Member]", "terseLabel": "PEO" } } }, "auth_ref": [ "r831" ] }, "ecd_PeoName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoName", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "PEO Name", "terseLabel": "PEO Name" } } }, "auth_ref": [ "r824" ] }, "ecd_PeoTotalCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoTotalCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "PEO Total Compensation Amount", "terseLabel": "PEO Total Compensation Amount" } } }, "auth_ref": [ "r813" ] }, "sght_PercentageOfVotingPowerRequiredToOwn": { "xbrltype": "percentItemType", "nsuri": "http://www.sightsciences.com/20240930", "localname": "PercentageOfVotingPowerRequiredToOwn", "presentation": [
"http://www.sightsciences.com/20240930/taxonomy/role/DisclosureEquityIncentivePlansAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "documentation": "Percentage of voting power required to own", "label": "Percentage of Voting Power Required to Own", "terseLabel": "Percentage of voting power required to own" } } }, "auth_ref": [] }, "us-gaap_PlanNameAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PlanNameAxis", "presentation": [
"http://www.sightsciences.com/20240930/taxonomy/role/DisclosureEquityIncentivePlansAdditionalInformationDetail",
"http://www.sightsciences.com/20240930/taxonomy/role/DisclosureEquityIncentivePlansSummaryOfCompanyStockOptionActivityDetail",
"http://www.sightsciences.com/20240930/taxonomy/role/DisclosureEquityIncentivePlansSummaryOfStockBasedCompensationFairValueAssumptionsDetails",
"http://www.sightsciences.com/20240930/taxonomy/role/DisclosureEquityIncentivePlansTables",
"http://www.sightsciences.com/20240930/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Plan Name", "label": "Plan Name [Axis]", "documentation": "Information by plan name for share-based payment arrangement." } } }, "auth_ref": [ "r924", "r925", "r926", "r927", "r928", "r929", "r930", "r931", "r932", "r933", "r934", "r935", "r936", "r937", "r938", "r939", "r940", "r941", "r942", "r943", "r944", "r945", "r946", "r947", "r948", "r949" ] }, "us-gaap_PlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PlanNameDomain", "presentation": [
"http://www.sightsciences.com/20240930/taxonomy/role/DisclosureEquityIncentivePlansAdditionalInformationDetail",
"http://www.sightsciences.com/20240930/taxonomy/role/DisclosureEquityIncentivePlansSummaryOfCompanyStockOptionActivityDetail",
"http://www.sightsciences.com/20240930/taxonomy/role/DisclosureEquityIncentivePlansSummaryOfStockBasedCompensationFairValueAssumptionsDetails",
"http://www.sightsciences.com/20240930/taxonomy/role/DisclosureEquityIncentivePlansTables",
"http://www.sightsciences.com/20240930/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Plan Name", "label": "Plan Name
```

[Domain]", "documentation": "Plan name for share-based payment arrangement." } } }, "auth_ref": ["r924", "r925", "r926", "r927", "r928", "r929", "r930", "r931", "r932", "r933", "r934", "r935", "r936", "r937", "r938", "r939", "r940", "r941", "r942", "r943", "r944", "r945", "r946", "r947", "r948", "r949"] }, "ecd_PnsnAdjsPrrSvcCstMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PnsnAdjsPrrSvcCstMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Pension Adjustments Prior Service Cost [Member]", "terseLabel": "Pension Adjustments Prior Service Cost" } } }, "auth_ref": ["r815"] }, "ecd_PnsnAdjsSvcCstMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PnsnAdjsSvcCstMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Pension Adjustments Service Cost [Member]", "terseLabel": "Pension Adjustments Service Cost" } } }, "auth_ref": ["r859"] }, "ecd_PnsnBnftsAdjFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PnsnBnftsAdjFnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Pension Benefits Adjustments, Footnote [Text Block]", "terseLabel": "Pension Benefits Adjustments, Footnote" } } }, "auth_ref": ["r814"] }, "us-gaap_PostemploymentBenefitsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PostemploymentBenefitsAbstract", "lang": { "en-us": { "role": { "label": "Postemployment Benefits [Abstract]" } } }, "auth_ref": [] }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockParOrStatedValuePerShare", "presentation": [
"http://www.sightsciences.com/20240930/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails",
"http://www.sightsciences.com/20240930/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnauditedParenthetical"], "lang": { "en-us": { "role": { "terseLabel": "Preferred stock par value", "label": "Preferred Stock, Par or Stated Value Per Share", "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer." } } }, "auth_ref": ["r65", "r352"] }, "us-gaap_PreferredStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockSharesAuthorized", "presentation": ["http://www.sightsciences.com/20240930/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails",
"http://www.sightsciences.com/20240930/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnauditedParenthetical"], "lang": { "en-us": { "role": { "terseLabel": "Preferred stock, shares authorized", "label": "Preferred Stock, Shares Authorized", "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": ["r65", "r629"] }, "us-gaap_PreferredStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockSharesIssued", "presentation": [
"http://www.sightsciences.com/20240930/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnauditedParenthetical"], "lang": { "en-us": { "role": { "terseLabel": "Preferred Stock, Shares Issued", "label": "Preferred Stock, Shares Issued", "totalLabel": "Preferred Stock, Shares Issued, Total", "documentation": "Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt." } } }, "auth_ref": ["r65", "r352"] }, "us-gaap_PreferredStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockSharesOutstanding", "presentation": ["http://www.sightsciences.com/20240930/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnauditedParenthetical"], "lang": { "en-us": { "role": { "terseLabel": "Preferred Stock, Shares Outstanding", "label": "Preferred Stock, Shares Outstanding", "periodEndLabel": "Preferred Stock, Shares Outstanding, Ending Balance", "periodStartLabel": "Preferred Stock, Shares Outstanding, Beginning Balance", "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased." } } }, "auth_ref": ["r65", "r629", "r647", "r1012", "r1013"] }, "us-gaap_PreferredStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockValue", "crdr": "credit", "presentation": ["http://www.sightsciences.com/20240930/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited"], "lang": { "en-us": { "role": { "terseLabel": "Preferred stock, par value $0.001 per share; 10,000,000 shares authorized; no shares issued and outstanding as of September 30, 2024 and December 31, 2023", "label": "Preferred Stock, Value, Issued", "periodEndLabel": "Preferred Stock, Value, Issued, Ending Balance", "periodStartLabel": "Preferred Stock, Value, Issued, Beginning Balance", "totalLabel": "Preferred Stock, Value, Issued, Total", "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": ["r65", "r562", "r751"] }, "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PrepaidExpenseAndOtherAssetsCurrent", "crdr": "debit", "presentation": ["http://www.sightsciences.com/20240930/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited"], "lang": { "en-us": { "role": { "terseLabel": "Prepaid expenses and other current assets", "label": "Prepaid Expense and Other Assets, Current", "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer." } } }, "auth_ref": ["r874"] }, "sght_ProceedsFromEmployeeStockPurchasePlanPurchases": { "xbrltype": "monetaryItemType", "nsuri": "http://www.sightsciences.com/20240930", "localname": "ProceedsFromEmployeeStockPurchasePlanPurchases", "crdr": "debit", "presentation": [
"http://www.sightsciences.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"], "lang": { "en-us": { "role": { "documentation": "Proceeds from employee stock purchase plan purchases", "label": "Proceeds from employee stock purchase plan purchases", "terseLabel": "Proceeds from employee stock purchase plan purchases" } } }, "auth_ref": [] }, "us-gaap_ProceedsFromIssuanceOfCommonStock": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromIssuanceOfCommonStock", "crdr": "debit", "presentation": ["http://www.sightsciences.com/20240930/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails"], "lang": { "en-us": { "role": { "label": "Proceeds from Issuance of Common Stock", "terseLabel": "Proceeds from issuance of common stock", "documentation": "The cash inflow from the additional capital contribution to the entity." } } }, "auth_ref": ["r1"] }, "us-gaap_ProceedsFromShortTermDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromShortTermDebt", "crdr": "debit", "presentation": [
"http://www.sightsciences.com/20240930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"], "lang": { "en-us": { "role": { "label": "Proceeds from Short-Term Debt", "totalLabel": "Proceeds from Short-term Debt, Total", "terseLabel": "Loan received", "documentation": "The cash inflow from a borrowing having initial term of repayment within one year or the normal operating cycle, if longer." } } }, "auth_ref": ["r16"] }, "us-gaap_ProceedsFromStockOptionsExercised": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromStockOptionsExercised", "crdr": "debit", "presentation": [
"http://www.sightsciences.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from exercise of common stock options", "label": "Proceeds from Stock Options Exercised", "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement." } } }, "auth_ref": ["r1", "r13"] }, "us-gaap_ProceedsFromStockPlans": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromStockPlans", "crdr": "debit", "presentation": ["http://www.sightsciences.com/20240930/taxonomy/role/DisclosureEquityIncentivePlansAdditionalInformationDetail"], "lang": { "en-us": { "role": { "label": "Proceeds from Stock Plans", "terseLabel": "Collected withholdings under plan", "documentation": "The cash inflow associated with the amount received from the stock plan during the period." } } }, "auth_ref": ["r1"] }, "us-gaap_ProfitLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProfitLoss", "crdr": "credit", "presentation": ["http://www.sightsciences.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"], "lang": { "en-us": { "role": { "negatedLabel": "Net loss", "terseLabel": "Net loss", "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest", "totalLabel": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest, Total", "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest." } } }, "auth_ref": ["r127", "r144", "r145", "r152", "r160", "r165", "r171", "r174", "r175", "r261", "r311", "r312", "r313", "r314", "r315", "r316", "r317", "r318", "r319", "r427", "r430", "r431", "r434", "r435", "r448", "r464", "r557", "r570", "r603", "r649", "r666", "r667", "r736", "r737", "r773", "r875", "r918"] }, "us-gaap_PropertyPlantAndEquipmentByTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentByTypeAxis", "presentation": [
"http://www.sightsciences.com/20240930/taxonomy/role/Role_DisclosureBalanceSheetComponentsSummaryOfPropertyAndEquipmentNetDetails"], "lang": { "en-us": { "role": { "terseLabel": "Long-Lived Tangible Asset", "label": "Long-Lived Tangible Asset [Axis]", "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale." } } }, "auth_ref": ["r6", "r486"] }, "us-gaap_PropertyPlantAndEquipmentGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentGross", "crdr": "debit", "presentation": [
"http://www.sightsciences.com/20240930/taxonomy/role/Role_DisclosureBalanceSheetComponentsSummaryOfPropertyAndEquipmentNetDetails"], "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment, Gross", "totalLabel": "Property, Plant and Equipment, Gross, Total", "periodStartLabel": "Property, Plant and Equipment, Gross, Beginning Balance", "periodEndLabel": "Property, Plant and Equipment, Gross, Ending Balance", "terseLabel": "Property and equipment, gross", "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures." } } }, "auth_ref": ["r90", "r131", "r568"] }, "us-gaap_PropertyPlantAndEquipmentLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentLineItems", "presentation": [
"http://www.sightsciences.com/20240930/taxonomy/role/Role_DisclosureBalanceSheetComponentsSummaryOfPropertyAndEquipmentNetDetails"], "lang": { "en-us": { "role": { "terseLabel": "Property Plant And Equipment [Line Items]", "label": "Property, Plant and Equipment [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r486"] }, "us-gaap_PropertyPlantAndEquipmentNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentNet", "crdr": "debit", "presentation": ["http://www.sightsciences.com/20240930/taxonomy/role/Role_DisclosureBalanceSheetComponentsSummaryOfPropertyAndEquipmentNetDetails",
"http://www.sightsciences.com/20240930/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited"], "lang": { "en-us": { "role": { "totalLabel": "Property and equipment, net", "terseLabel": "Property and equipment, net", "label": "Property, Plant and Equipment, Net", "periodStartLabel": "Property, Plant and Equipment, Net, Beginning Balance", "periodEndLabel": "Property, Plant and Equipment, Net, Ending Balance", "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures." } } }, "auth_ref": ["r6", "r486", "r558", "r568", "r751"] }, "us-gaap_PropertyPlantAndEquipmentTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentTextBlock", "presentation": ["http://www.sightsciences.com/20240930/taxonomy/role/Role_DisclosureBalanceSheetComponentsTables"], "lang": { "en-us": { "role": { "terseLabel": "Summary of Property and Equipment, Net", "label": "Property, Plant and Equipment [Table Text Block]", "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation." } } }, "auth_ref": ["r6"] }, "us-gaap_PropertyPlantAndEquipmentTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentTypeDomain", "presentation": [
"http://www.sightsciences.com/20240930/taxonomy/role/Role_DisclosureBalanceSheetComponentsSummaryOfPropertyAndEquipmentNetDetails"], "lang": { "en-us": { "role": { "terseLabel": "Long-Lived Tangible Asset", "label": "Long-Lived Tangible Asset [Domain]", "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software." } } }, "auth_ref": ["r90", "r486"] }, "us-gaap_ProvisionForDoubtfulAccounts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProvisionForDoubtfulAccounts", "crdr": "debit", "presentation": [
"http://www.sightsciences.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"], "lang": { "en-us": { "role": { "terseLabel": "Allowance for credit losses", "label": "Accounts Receivable, Credit Loss Expense (Reversal)", "documentation": "Amount of expense (reversal of expense) for expected credit loss on accounts receivable." } } }, "auth_ref": ["r150", "r268"] }, "ecd_PvpTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PvpTable", "presentation": [
"http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Pay vs Performance Disclosure [Table]", "terseLabel": "Pay vs Performance Disclosure" } } }, "auth_ref": ["r812"] }, "ecd_PvpTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PvpTableTextBlock", "presentation": [
"http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Pay vs Performance [Table Text Block]", "terseLabel": "Pay vs Performance Disclosure, Table" } } }, "auth_ref": ["r812"] }, "srt_RangeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "RangeAxis", "presentation": [
"http://www.sightsciences.com/20240930/taxonomy/role/DisclosureEquityIncentivePlansAdditionalInformationDetail",
"http://www.sightsciences.com/20240930/taxonomy/role/DisclosureEquityIncentivePlansSummaryOfStockBasedCompensationFairValueAssumptionsDetails",
"http://www.sightsciences.com/20240930/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails",
"http://www.sightsciences.com/20240930/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Statistical Measurement", "label": "Statistical Measurement [Axis]" } } }, "auth_ref": ["r304", "r305", "r306", "r307", "r370", "r379", "r406", "r407", "r408", "r417", "r454", "r498", "r507", "r523", "r587", "r589", "r596", "r619", "r620", "r673", "r675", "r677", "r678", "r680", "r699", "r700", "r718", "r727", "r732", "r741", "r742", "r746", "r747", "r761", "r766", "r909", "r920", "r956", "r972", "r973", "r974", "r975", "r976"] }, "srt_RangeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "RangeMember", "presentation": [
"http://www.sightsciences.com/20240930/taxonomy/role/DisclosureEquityIncentivePlansAdditionalInformationDetail",
"http://www.sightsciences.com/20240930/taxonomy/role/DisclosureEquityIncentivePlansSummaryOfStockBasedCompensationFairValueAssumptionsDetails",
"http://www.sightsciences.com/20240930/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails",
"http://www.sightsciences.com/20240930/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Statistical Measurement", "label": "Statistical Measurement [Domain]" } } }, "auth_ref": ["r304", "r305", "r306", "r307", "r370", "r379", "r406", "r407", "r408", "r417", "r454", "r498", "r507", "r523", "r587", "r589", "r596", "r619", "r620", "r673", "r675", "r677", "r678", "r680", "r699", "r700", "r718", "r727", "r732", "r741", "r742", "r746", "r747", "r761", "r766", "r909", "r920", "r956", "r972", "r973", "r974", "r975", "r976"] }, "ecd_RecoveryOfErrCompDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RecoveryOfErrCompDisclosureLineItems", "lang": { "en-us": { "role": { "label": "Recovery of Erroneously Awarded Compensation Disclosure [Line Items]", "terseLabel": "Recovery of Erroneously Awarded Compensation Disclosure" } } }, "auth_ref": ["r780", "r790", "r800", "r832"] }, "sght_RedeemableConvertiblePreferredStockIssuanceCostValue": { "xbrltype": "monetaryItemType", "nsuri": "http://www.sightsciences.com/20240930", "localname": "RedeemableConvertiblePreferredStockIssuanceCostValue", "crdr": "debit", "presentation": [
"http://www.sightsciences.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityUnaudited"], "lang": { "en-us": { "role": { "terseLabel": "Series F redeemable convertible preferred stock issuance cost", "label": "Redeemable Convertible Preferred Stock Issuance Cost Value", "documentation": "redeemable convertible preferred stock issuance cost value." } } }, "auth_ref": [] }, "us-gaap_RedeemableConvertiblePreferredStockMember": { "xbrltype": "domainItemType", "nsuri":

```
"http://fasb.org/us-gaap/2024", "localname": "RedeemableConvertiblePreferredStockMember", "presentation": [
"http://www.sightsciences.com/20240930/taxonomy/role/DisclosureNetLossPerShareAttributableToCommonStockholdersScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPe
"http://www.sightsciences.com/20240930/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails",
"http://www.sightsciences.com/20240930/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFairValueMeasurementLiabilitiesMeasuredOnRecurringBasisDetails",
"http://www.sightsciences.com/20240930/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnauditedParenthetical",
"http://www.sightsciences.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityUnaudited" ], "lang": {
"en-us": { "role": { "terseLabel": "Redeemable Convertible Preferred Stock", "label": "Redeemable Convertible Preferred Stock [Member]", "documentation": "Description of type or class of
redeemable convertible preferred stock. Convertible redeemable preferred stock possess conversion and redemption features. The stock has redemption features that are outside the control of
the issuer." } } }, "auth_ref": [] }, "sght_RedeemableConvertiblePreferredStockOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://www.sightsciences.com/20240930", "localname":
"RedeemableConvertiblePreferredStockOutstanding", "presentation": [ "http://www.sightsciences.com/20240930/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails" ],
"lang": { "en-us": { "role": { "label": "Redeemable convertible preferred stock outstanding", "documentation": "redeemable convertible preferred stock outstanding." } } }, "auth_ref": [] },
"sght_RedeemableConvertiblePreferredStockWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sightsciences.com/20240930", "localname":
"RedeemableConvertiblePreferredStockWarrantsMember", "presentation": [
"http://www.sightsciences.com/20240930/taxonomy/role/DisclosureNetLossPerShareAttributableToCommonStockholdersScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPe
"http://www.sightsciences.com/20240930/taxonomy/role/Role_DisclosureCompanyAndNatureOfBusinessAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Redeemable
Convertible Preferred Stock Warrants", "label": "Redeemable Convertible Preferred Stock Warrants [Member]", "documentation": "Redeemable convertible preferred stock warrants liabilities."
} } }, "auth_ref": [] }, "sght_RedeemablePreferredStockWarrantsLiabilitiesNonCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.sightsciences.com/20240930", "localname":
"RedeemablePreferredStockWarrantsLiabilitiesNonCurrent", "crdr": "credit", "presentation": [
"http://www.sightsciences.com/20240930/taxonomy/role/Role_DisclosureBalanceSheetComponentsSummaryOfOtherNoncurrentLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel":
"Redeemable preferred stock warrants liabilities", "label": "Redeemable Preferred Stock Warrants Liabilities Non Current", "documentation": "Redeemable preferred stock warrants liabilities
non current." } } }, "auth_ref": [] }, "sght_ReductionInWorkforce": { "xbrltype": "percentItemType", "nsuri": "http://www.sightsciences.com/20240930", "localname": "ReductionInWorkforce",
"presentation": [ "http://www.sightsciences.com/20240930/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Reduction
in workforce", "label": "Reduction in workforce" } } }, "auth_ref": [] }, "us-gaap_RepaymentsOfLongtermLoansFromVendors": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-
gaap/2024", "localname": "RepaymentsOfLongtermLoansFromVendors", "crdr": "credit", "presentation": [
"http://www.sightsciences.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "label": "Repayments of Long-Term
Loans from Vendors", "negatedLabel": "Repayment of MidCap Loan Agreement", "documentation": "Cash outflows under financing arrangements with vendors (seller financed debt), which had
a maturity date at inception of more than one year (or more than one operating cycle, if longer), such debt may have arisen from purchases of property, plant and equipment or other productive
assets." } } }, "auth_ref": [ "r87" ] }, "sght_ReplacementCostOfDevice": { "xbrltype": "monetaryItemType", "nsuri": "http://www.sightsciences.com/20240930", "localname":
"ReplacementCostOfDevice", "crdr": "debit", "presentation": [
"http://www.sightsciences.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Replacement cost
of device", "documentation": "Replacement cost of Device" } } }, "auth_ref": [] }, "us-gaap_ResearchAndDevelopmentExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-
gaap/2024", "localname": "ResearchAndDevelopmentExpense", "crdr": "debit", "presentation": [
"http://www.sightsciences.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited" ], "lang": { "en-us": { "role": {
"label": "Research and Development Expense", "totalLabel": "Research and Development Expense, Total", "terseLabel": "Research and development", "documentation": "Amount of expense for
research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets
acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture
formation or both, used in research and development activity." } } }, "auth_ref": [ "r418", "r701", "r713", "r977" ] }, "us-gaap_ResearchAndDevelopmentExpenseMember": { "xbrltype":
"domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ResearchAndDevelopmentExpenseMember", "presentation": [
"http://www.sightsciences.com/20240930/taxonomy/role/DisclosureEquityIncentivePlansSummaryOfSharebasedCompensationExpenseByFunctionDetails" ], "lang": { "en-us": { "role": {
"verboseLabel": "Research and Development", "terseLabel": "Research and Development Expenses", "label": "Research and Development Expense [Member]", "documentation": "Primary
financial statement caption in which the reported facts about research and development expense have been included." } } }, "auth_ref": [] }, "ecd_RestatementDateAxis": { "xbrltype":
"stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RestatementDateAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": {
"label": "Restatement Determination Date [Axis]", "terseLabel": "Restatement Determination Date:" } } }, "auth_ref": [ "r781", "r791", "r801", "r833" ] }, "ecd_RestatementDeterminationDate":
{ "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RestatementDeterminationDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang":
{ "en-us": { "role": { "label": "Restatement Determination Date", "terseLabel": "Restatement Determination Date" } } }, "auth_ref": [ "r782", "r792", "r802", "r834" ] },
"ecd_RestatementDoesNotRequireRecoveryTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname":
"RestatementDoesNotRequireRecoveryTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Restatement Does Not Require
Recovery [Text Block]", "terseLabel": "Restatement does not require Recovery" } } }, "auth_ref": [ "r789", "r799", "r809", "r841" ] }, "us-
gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember", "presentation": [
"http://www.sightsciences.com/20240930/taxonomy/role/DisclosureFairValueMeasurementHeldtomaturityDebtSecuritiesAtAmortizedCostDetails" ], "lang": { "en-us": { "role": { "label": "Cash
and Cash Equivalents [Domain]", "documentation": "Type of cash and cash equivalent. Cash is currency on hand as well as demand deposits with banks or financial institutions. Includes other
kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so
near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r130" ] }, "us-gaap_RestrictedStockMember": { "xbrltype":
"domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestrictedStockMember", "presentation": [
"http://www.sightsciences.com/20240930/taxonomy/role/DisclosureEquityIncentivePlansSummarizesRestrictedShareAwardActivityUnderThe2021PlanDetails" ], "lang": { "en-us": { "role": {
"label": "Restricted Stock [Member]", "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified
performance conditions are met." } } }, "auth_ref": [ "r23" ] }, "sght_RestrictedStockUnitsOutstandingMember": { "xbrltype": "domainItemType", "nsuri":
"http://www.sightsciences.com/20240930", "localname": "RestrictedStockUnitsOutstandingMember", "presentation": [
"http://www.sightsciences.com/20240930/taxonomy/role/DisclosureStockholdersEquityScheduleOfReservedCommonStockForFutureIssuancesDetails" ], "lang": { "en-us": { "role": {
"documentation": "Restricted stock units outstanding.", "label": "Restricted Stock Units Outstanding [Member]", "terseLabel": "Restricted stock units outstanding" } } }, "auth_ref": [] }, "us-
gaap_RestrictedStockUnitsRSUMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestrictedStockUnitsRSUMember", "presentation": [
"http://www.sightsciences.com/20240930/taxonomy/role/DisclosureEquityIncentivePlansAdditionalInformationDetail",
"http://www.sightsciences.com/20240930/taxonomy/role/DisclosureNetLossPerShareAttributableToCommonStockholdersScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPe
], "lang": { "en-us": { "role": { "verboseLabel": "Restricted Stock Units", "label": "Restricted Stock Units (RSUs) [Member]", "terseLabel": "Restricted Stock Units RSU", "documentation": "Share
instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met." } } }, "auth_ref": [] }, "us-
gaap_RestrictedStockValueSharesIssuedNetOfTaxWithholdings": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"RestrictedStockValueSharesIssuedNetOfTaxWithholdings", "crdr": "credit", "presentation": [
"http://www.sightsciences.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityUnaudited" ], "lang": {
"en-us": { "role": { "label": "Restricted Stock, Value, Shares Issued Net of Tax Withholdings", "terseLabel": "Withholding taxes on net share settlement of restricted stock units",
"documentation": "Value, after value of shares used to satisfy grantee's tax withholding obligation for award under share-based payment arrangement, of restricted shares issued. Excludes cash
used to satisfy grantee's tax withholding obligation." } } }, "auth_ref": [] }, "us-gaap_RestructuringCharges": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "RestructuringCharges", "crdr": "debit", "presentation": [ "http://www.sightsciences.com/20240930/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails" ],
"lang": { "en-us": { "role": { "totalLabel": "Restructuring Charges, Total", "label": "Restructuring Charges", "documentation": "Amount of expenses associated with exit or disposal activities
pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation." } } }, "auth_ref": [ "r4", "r298", "r299", "r910" ] }, "us-
gaap_RetainedEarningsAccumulatedDeficit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RetainedEarningsAccumulatedDeficit", "crdr": "credit",
"presentation": [ "http://www.sightsciences.com/20240930/taxonomy/role/Role_DisclosureCompanyAndNatureOfBusinessAdditionalInformationDetails",
"http://www.sightsciences.com/20240930/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Retained Earnings
(Accumulated Deficit), Total", "periodStartLabel": "Retained Earnings (Accumulated Deficit), Beginning Balance", "periodEndLabel": "Retained Earnings (Accumulated Deficit), Ending Balance",
"terseLabel": "Accumulated deficit", "label": "Retained Earnings (Accumulated Deficit)", "negatedTerseLabel": "Accumulated deficit", "documentation": "Amount of accumulated undistributed
earnings (deficit)." } } }, "auth_ref": [ "r68", "r96", "r565", "r594", "r595", "r602", "r630", "r751" ] }, "us-gaap_RetainedEarningsMember": { "xbrltype": "domainItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "RetainedEarningsMember", "presentation": [
"http://www.sightsciences.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityUnaudited" ], "lang": {
"en-us": { "role": { "label": "Retained Earnings [Member]", "terseLabel": "Accumulated Deficit", "documentation": "Accumulated undistributed earnings (deficit)." } } }, "auth_ref": [ "r125",
"r162", "r163", "r164", "r166", "r171", "r173", "r175", "r262", "r263", "r287", "r421", "r422", "r424", "r425", "r426", "r428", "r429", "r430", "r438", "r440", "r441", "r443", "r446", "r475", "r476",
"r591", "r593", "r604", "r1012" ] }, "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "RevenueFromContractWithCustomerExcludingAssessedTax", "crdr": "credit", "presentation": [
"http://www.sightsciences.com/20240930/taxonomy/role/Role_DisclosureSegmentInformationSummaryOfOperatingResultInformationForEachReportableSegmentDetails",
"http://www.sightsciences.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited" ], "lang": { "en-us": { "role": {
"terseLabel": "Revenue", "label": "Revenue from Contract with Customer, Excluding Assessed Tax", "totalLabel": "Revenue from Contract with Customer, Excluding Assessed Tax, Total",
"documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected
from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue producing transaction, including, but not limited to, sales, use, value
added and excise." } } }, "auth_ref": [ "r110", "r111", "r189", "r198", "r199", "r214", "r220", "r223", "r225", "r227", "r368", "r369", "r524" ] }, "us-gaap_RevenuesAbstract": { "xbrltype":
"stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevenuesAbstract", "presentation": [
"http://www.sightsciences.com/20240930/taxonomy/role/Role_DisclosureSegmentInformationSummaryOfOperatingResultInformationForEachReportableSegmentDetails" ], "lang": { "en-us": {
"role": { "terseLabel": "Revenue", "label": "Revenues [Abstract]" } } }, "auth_ref": [] }, "sght_RevolverAgreementMember": { "xbrltype": "domainItemType", "nsuri":
"http://www.sightsciences.com/20240930", "localname": "RevolverAgreementMember", "presentation": [
"http://www.sightsciences.com/20240930/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Revolver Agreement [Member]",
"documentation": "Revolver Agreement [Member]" } } }, "auth_ref": [] }, "sght_RevolvingCreditFacilityTwoThousandNineteenMember": { "xbrltype": "domainItemType", "nsuri":
"http://www.sightsciences.com/20240930", "localname": "RevolvingCreditFacilityTwoThousandNineteenMember", "presentation": [
"http://www.sightsciences.com/20240930/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Revolving Credit Facility Two Thousand
Nineteen [Member]", "documentation": "Revolving credit facility 2019.", "terseLabel": "Revolver 2019" } } }, "auth_ref": [] }, "sght_RevolvingCreditFacilityTwoThousandTwentyMember": {
"xbrltype": "domainItemType", "nsuri": "http://www.sightsciences.com/20240930", "localname": "RevolvingCreditFacilityTwoThousandTwentyMember", "presentation": [
"http://www.sightsciences.com/20240930/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Revolving Credit Facility Two Thousand
Twenty [Member]", "documentation": "Revolving credit facility 2020.", "terseLabel": "Revolving 2020" } } }, "auth_ref": [] }, "us-
gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability", "crdr": "debit", "presentation": [
"http://www.sightsciences.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfOperatingLeaseExpenseRecognizedAndSupplementalCashFlowDetails" ],
"lang": { "en-us": { "role": { "terseLabel": "New operating lease assets obtained in exchange for operating lease liabilities", "label": "Right-of-Use Asset Obtained in Exchange for Operating
Lease Liability", "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability." } } }, "auth_ref": [ "r483", "r750" ] },
"sght_RoyaltyDamagesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sightsciences.com/20240930", "localname": "RoyaltyDamagesMember", "presentation": [
"http://www.sightsciences.com/20240930/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails",
"http://www.sightsciences.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Royalty Damages
[Member]", "documentation": "Royalty Damages [Member]" } } }, "auth_ref": [] }, "sght_Rule10B51ArrModifiedFlag": { "xbrltype": "booleanItemType", "nsuri":
"http://www.sightsciences.com/20240930", "localname": "Rule10B51ArrModifiedFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": {
"label": "Rule 10b5-1 Arrangement Modified [Flag]", "terseLabel": "Rule 10b5-1 Arrangement Modified", "documentation": "Rule 10b5-1 Arr Modified [Flag]" } } }, "auth_ref": [] },
"ecd_Rule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "Rule10b51ArrAdoptedFlag", "presentation": [
"http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Rule 10b5-1 Arrangement Adopted [Flag]", "terseLabel": "Rule 10b5-1 Arrangement Adopted"
} } }, "auth_ref": [ "r850" ] }, "ecd_Rule10b51ArrTrmntdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "Rule10b51ArrTrmntdFlag", "presentation":
[ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Rule 10b5-1 Arrangement Terminated [Flag]", "terseLabel": "Rule 10b5-1 Arrangement
```

Terminated" } } }, "auth_ref": ["r850"] }, "us-gaap_SaleOfStockDescriptionOfTransaction": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SaleOfStockDescriptionOfTransaction", "presentation": ["http://www.sightsciences.com/20240930/taxonomy/role/DisclosureEquityIncentivePlansAdditionalInformationDetail"], "lang": { "en-us": { "role": { "terseLabel": "Description of Transaction of Future issuance", "label": "Sale of Stock, Description of Transaction", "documentation": "Description of stock transaction which may include details of the offering (IPO, private placement), a description of the stock sold, percentage of subsidiary's or equity investee's stock sold, a description of the investors and whether the stock was issued in a business combination." } } }, "auth_ref": ["r9", "r47", "r100"] }, "us-gaap_SaleOfStockNameOfTransactionDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SaleOfStockNameOfTransactionDomain", "presentation": [
"http://www.sightsciences.com/20240930/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails",
"http://www.sightsciences.com/20240930/taxonomy/role/Role_DisclosureCompanyAndNatureOfBusinessAdditionalInformationDetails",
"http://www.sightsciences.com/20240930/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails",
"http://www.sightsciences.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityUnauditedParenthetical"], "lang": { "en-us": { "role": { "terseLabel": "Sale of Stock", "label": "Sale of Stock [Domain]", "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "presentation": [
"http://www.sightsciences.com/20240930/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToCommonStockholdersTables"], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share", "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]", "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities." } } }, "auth_ref": ["r23"] }, "us-gaap_ScheduleOfDebtTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfDebtTableTextBlock", "presentation": ["http://www.sightsciences.com/20240930/taxonomy/role/Role_DisclosureDebtTables"], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Long-term and Short-term Debt", "label": "Schedule of Debt [Table Text Block]", "documentation": "Tabular disclosure of information pertaining to short-term and long-debt instruments or arrangements, including but not limited to identification of terms, features, collateral requirements and other information necessary to a fair presentation." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "presentation": [
"http://www.sightsciences.com/20240930/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToCommonStockholdersTables"], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Computation of Basic and Diluted Net Loss per Share Attributable to Common Stockholders", "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]", "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations." } } }, "auth_ref": ["r887"] }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "presentation": ["http://www.sightsciences.com/20240930/taxonomy/role/DisclosureEquityIncentivePlansTables"], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]", "terseLabel": "Summary of Stock-Based Compensation Expense by Function", "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement." } } }, "auth_ref": ["r46"] }, "us-gaap_ScheduleOfExtinguishmentOfDebtTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfExtinguishmentOfDebtTextBlock", "presentation": [
"http://www.sightsciences.com/20240930/taxonomy/role/Role_DisclosureDebtTables"], "lang": { "en-us": { "role": { "terseLabel": "Repayment Schedule Relating to the Company's Debt", "label": "Schedule of Extinguishment of Debt [Table Text Block]", "documentation": "Tabular disclosure of debt extinguished which may include, amount of gain (loss), the income tax effect and the per share amount of the aggregate gain (loss), net of the related income tax." } } }, "auth_ref": ["r35"] }, "us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock", "presentation": [
"http://www.sightsciences.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesTables"], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Aggregate Future Minimum Lease Payments", "label": "Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block]", "documentation": "Tabular disclosure of future minimum payments required in the aggregate and for each of the five succeeding fiscal years for operating leases having initial or remaining noncancelable lease terms in excess of one year and the total minimum rentals to be received in the future under noncancelable subleases as of the balance sheet date." } } }, "auth_ref": ["r115"] },
"sght_ScheduleOfFutureMinimumRentalPaymentsNoncancelableForOperatingLeasesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.sightsciences.com/20240930", "localname": "ScheduleOfFutureMinimumRentalPaymentsNoncancelableForOperatingLeasesTableTextBlock", "presentation": [
"http://www.sightsciences.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesTables"], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Aggregate Future Minimum Lease Payments", "label": "Schedule Of Future Minimum Rental Payments Noncancelable For Operating Leases [Table Text Block]", "documentation": "Schedule Of Future Minimum Rental Payments Noncancelable For Operating Leases [Table Text Block]" } } }, "auth_ref": [] }, "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfPropertyPlantAndEquipmentTable", "presentation": [
"http://www.sightsciences.com/20240930/taxonomy/role/Role_DisclosureBalanceSheetComponentsSummaryOfPropertyAndEquipmentNetDetails"], "lang": { "en-us": { "role": { "terseLabel": "Schedule Of Property Plant And Equipment [Table]", "label": "Property, Plant and Equipment [Table]", "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated depreciation." } } }, "auth_ref": ["r6", "r486"] }, "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfSegmentReportingInformationBySegmentTable", "presentation": [
"http://www.sightsciences.com/20240930/taxonomy/role/Role_DisclosureSegmentInformationSummaryOfOperatingResultInformationForEachReportableSegmentDetails"], "lang": { "en-us": { "role": { "label": "Schedule of Segment Reporting Information, by Segment [Table]", "documentation": "Disclosure of information about profit (loss) and total assets by reportable segment." } } }, "auth_ref": ["r27", "r28", "r29"] }, "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfSegmentReportingInformationBySegmentTextBlock", "presentation": [
"http://www.sightsciences.com/20240930/taxonomy/role/Role_DisclosureSegmentInformationTables"], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Segment Reporting Information", "label": "Schedule of Segment Reporting Information, by Segment [Table Text Block]", "documentation": "Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss." } } }, "auth_ref": ["r27", "r28", "r29"] }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "presentation": [
"http://www.sightsciences.com/20240930/taxonomy/role/DisclosureEquityIncentivePlansAdditionalInformationDetail",
"http://www.sightsciences.com/20240930/taxonomy/role/DisclosureEquityIncentivePlansSummarizesRestrictedShareAwardActivityUnderThe2021PlanDetails",
"http://www.sightsciences.com/20240930/taxonomy/role/DisclosureEquityIncentivePlansSummaryOfCompanyStockOptionActivityDetail",
"http://www.sightsciences.com/20240930/taxonomy/role/DisclosureEquityIncentivePlansSummaryOfSharebasedCompensationExpenseByFunctionDetails",
"http://www.sightsciences.com/20240930/taxonomy/role/DisclosureEquityIncentivePlansSummaryOfStockBasedCompensationFairValueAssumptionsDetails",
"http://www.sightsciences.com/20240930/taxonomy/role/DisclosureEquityIncentivePlansTables",
"http://www.sightsciences.com/20240930/taxonomy/role/DisclosureStockholdersEquityScheduleOfReservedCommonStockForFutureIssuancesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]", "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]", "documentation": "Disclosure of information about share-based payment arrangement." } } }, "auth_ref": ["r381", "r382", "r384", "r385", "r386", "r387", "r388", "r389", "r390", "r391", "r392", "r393", "r394", "r395", "r396", "r397", "r398", "r399", "r400", "r401", "r402", "r403", "r404", "r405", "r406", "r407", "r408", "r409"] }, "us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock", "presentation": [
"http://www.sightsciences.com/20240930/taxonomy/role/DisclosureEquityIncentivePlansTables"], "lang": { "en-us": { "role": { "terseLabel": "Share-based Payment Arrangement, Restricted Stock Unit, Activity", "label": "Share-Based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block]", "documentation": "Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year." } } }, "auth_ref": ["r97"] }, "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "presentation": [
"http://www.sightsciences.com/20240930/taxonomy/role/DisclosureEquityIncentivePlansTables"], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]", "terseLabel": "Summary of Stock Option Activity", "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value." } } }, "auth_ref": ["r11", "r12", "r97"] }, "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "presentation": [
"http://www.sightsciences.com/20240930/taxonomy/role/DisclosureEquityIncentivePlansTables"], "lang": { "en-us": { "role": { "terseLabel": "Summary of Weighted Average Valuation Assumptions Used to Estimate Fair Value of Employee Stock Options", "label": "Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]", "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions." } } }, "auth_ref": ["r99"] }, "us-gaap_ScheduleOfStockByClassTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfStockByClassTextBlock", "presentation": [
"http://www.sightsciences.com/20240930/taxonomy/role/DisclosureStockholdersEquityTables"], "lang": { "en-us": { "role": { "label": "Schedule of Stock by Class [Table Text Block]", "terseLabel": "Reserved Common Stock for Future Issuances", "documentation": "Tabular disclosure of an entity's stock, including par or stated value per share, number and dollar amount of share subscriptions, shares authorized, shares issued, shares outstanding, number and dollar amount of shares held in an employee trust, dividend per share, total dividends, share conversion features, par value plus additional paid in capital, the value of treasury stock and other information necessary to a fair presentation, and EPS information. Stock by class includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. Includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity. If more than one issue is outstanding, state the title of each issue and the corresponding dollar amount; dollar amount of any shares subscribed but unissued and the deduction of subscriptions receivable there from; number of shares authorized, issued, and outstanding." } } }, "auth_ref": ["r15", "r36", "r37", "r38", "r39", "r40", "r41", "r42", "r65", "r66", "r94", "r95", "r96"] }, "us-gaap_ScheduleOfSubsidiaryOrEquityMethodInvesteeTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfSubsidiaryOrEquityMethodInvesteeTable", "presentation": [
"http://www.sightsciences.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityUnauditedParenthetical"], "lang": { "en-us": { "role": { "label": "Subsidiary or Equity Method Investee, Sale of Stock [Table]", "documentation": "Disclosure of information about sale of stock made by subsidiary or equity method investee to investor outside consolidated group. Includes, but is not limited to, stock issued in business combination in exchange for share of acquired entity." } } }, "auth_ref": [] }, "us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember", "presentation": [
"http://www.sightsciences.com/20240930/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails"], "lang": { "en-us": { "role": { "terseLabel": "SOFR [Member]", "label": "Secured Overnight Financing Rate (SOFR) Overnight Index Swap Rate [Member]", "documentation": "Fixed rate on U.S. dollar, constant-notional interest rate swap that has its variable-rate leg referenced to Secured Overnight Financing Rate (SOFR) with no additional spread over SOFR on variable-rate leg." } } }, "auth_ref": ["r950"] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "Security12bTitle", "presentation": [
"http://www.sightsciences.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "terseLabel": "Title of 12(b) Security", "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": ["r775"] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "SecurityExchangeName", "presentation": ["http://www.sightsciences.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "terseLabel": "Security Exchange Name", "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": ["r777"] }, "us-gaap_SegmentDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SegmentDomain", "presentation": [
"http://www.sightsciences.com/20240930/taxonomy/role/Role_DisclosureSegmentInformationSummaryOfOperatingResultInformationForEachReportableSegmentDetails"], "lang": { "en-us": { "role": { "terseLabel": "Segments", "label": "Segments [Domain]", "documentation": "Components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity." } } }, "auth_ref": ["r110", "r111", "r112", "r113", "r189", "r194", "r197", "r198", "r199", "r200", "r201", "r202", "r203", "r204", "r205", "r206", "r208", "r209", "r211", "r212", "r213", "r214", "r215", "r216", "r217", "r218", "r220", "r221", "r222", "r227", "r277", "r278", "r279", "r280", "r281", "r282", "r283", "r284", "r285", "r286", "r297", "r300", "r576", "r577", "r578", "r579", "r580", "r581", "r582", "r583", "r584", "r585", "r586", "r710", "r713", "r714", "r720", "r763", "r981", "r983", "r984", "r985", "r986", "r987", "r988", "r989", "r990", "r991", "r992", "r993", "r994", "r995", "r996", "r997", "r998", "r999", "r1000", "r1001", "r1002", "r1003", "r1004", "r1005", "r1006", "r1007", "r1008", "r1009", "r1010"] }, "srt_SegmentGeographicalDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "SegmentGeographicalDomain", "presentation": [

```
"http://www.sightsciences.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Geographical [Domain]" } } }, "auth_ref": [ "r225", "r226", "r525", "r526", "r527", "r528", "r529", "r530", "r531", "r532", "r533", "r534", "r535", "r536", "r537", "r538", "r539", "r540", "r541", "r542", "r543", "r544", "r545", "r546", "r547", "r548", "r549", "r550", "r551", "r552", "r553", "r554", "r616", "r617", "r618", "r674", "r676", "r679", "r681", "r688", "r690", "r691", "r692", "r693", "r694", "r695", "r696", "r697", "r698", "r702", "r728", "r753", "r754", "r755", "r756", "r757", "r758", "r759", "r760", "r762", "r766", "r923", "r981", "r983", "r984", "r986", "r987", "r988", "r989", "r990", "r991", "r992", "r993", "r994", "r995", "r996", "r997", "r998", "r999", "r1000", "r1001", "r1002", "r1003", "r1004", "r1005", "r1006", "r1007", "r1008", "r1009", "r1010" ] }, "us-gaap_SegmentReportingAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SegmentReportingAbstract", "lang": { "en-us": { "role": { "label": "Segment Reporting [Abstract]" } } }, "auth_ref": [] }, "us-gaap_SegmentReportingDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SegmentReportingDisclosureTextBlock", "presentation": [ "http://www.sightsciences.com/20240930/taxonomy/role/Role_DisclosureSegmentInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Segment Information", "label": "Segment Reporting Disclosure [Text Block]", "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments." } } }, "auth_ref": [ "r113", "r189", "r193", "r194", "r195", "r196", "r197", "r210", "r212", "r213", "r218", "r219", "r220", "r221", "r222", "r223", "r224", "r227", "r709", "r711", "r712", "r713", "r715", "r716", "r717" ] }, "us-gaap_SegmentReportingInformationLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SegmentReportingInformationLineItems", "presentation": [
"http://www.sightsciences.com/20240930/taxonomy/role/Role_DisclosureSegmentInformationSummaryOfOperatingResultInformationForEachReportableSegmentDetails" ], "lang": { "en-us": { "role": { "label": "Segment Reporting Information [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_SellingGeneralAndAdministrativeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SellingGeneralAndAdministrativeExpense", "crdr": "debit", "presentation": [
"http://www.sightsciences.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Selling, general and administrative", "label": "Selling, General and Administrative Expense", "totalLabel": "Selling, General and Administrative Expense, Total", "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc." } } }, "auth_ref": [ "r78" ] }, "us-gaap_SellingGeneralAndAdministrativeExpensesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SellingGeneralAndAdministrativeExpensesMember", "presentation": [
"http://www.sightsciences.com/20240930/taxonomy/role/DisclosureEquityIncentivePlansSummaryOfSharebasedCompensationExpenseByFunctionDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Selling, General and Administrative", "terseLabel": "Selling, General and Administrative Expenses", "label": "Selling, General and Administrative Expenses [Member]", "documentation": "Primary financial statement caption encompassing selling, general and administrative expense." } } }, "auth_ref": [] }, "sght_SeniorSecuredTwentyTwentyTermLoanMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sightsciences.com/20240930", "localname": "SeniorSecuredTwentyTwentyTermLoanMember", "presentation": [
"http://www.sightsciences.com/20240930/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Senior Secured Twenty Twenty Term Loan [Member]", "documentation": "Senior secured 2020 term loan.", "terseLabel": "Senior Secured 2020 Term Loan" } } }, "auth_ref": [] },
"sght_SeniorSecuredTwoThousandNineteenTermLoanMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sightsciences.com/20240930", "localname": "SeniorSecuredTwoThousandNineteenTermLoanMember", "presentation": [ "http://www.sightsciences.com/20240930/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Senior Secured Two Thousand Nineteen Term Loan [Member]", "documentation": "Senior secured 2019 term loan.", "terseLabel": "Senior Secured 2019 Term Loan" } } }, "auth_ref": [] }, "sght_SeriesARedeemableConvertiblePreferredStockMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sightsciences.com/20240930", "localname": "SeriesARedeemableConvertiblePreferredStockMember", "presentation": [
"http://www.sightsciences.com/20240930/taxonomy/role/DisclosureNetLossPerShareAttributableToCommonStockholdersScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPe
"http://www.sightsciences.com/20240930/taxonomy/role/DisclosureStockholdersEquityScheduleOfReservedCommonStockForFutureIssuancesDetails" ], "lang": { "en-us": { "role": { "documentation": "Series A redeemable convertible preferred stock.", "label": "Series A Redeemable Convertible Preferred Stock [Member]", "terseLabel": "Series A", "verboseLabel": "Series A Redeemable Convertible Preferred Stock" } } }, "auth_ref": [] }, "sght_SeriesBRedeemableConvertiblePreferredStockMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sightsciences.com/20240930", "localname": "SeriesBRedeemableConvertiblePreferredStockMember", "presentation": [
"http://www.sightsciences.com/20240930/taxonomy/role/DisclosureNetLossPerShareAttributableToCommonStockholdersScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPe
"http://www.sightsciences.com/20240930/taxonomy/role/DisclosureStockholdersEquityScheduleOfReservedCommonStockForFutureIssuancesDetails" ], "lang": { "en-us": { "role": { "label": "Series B", "documentation": "Series B redeemable convertible preferred stock.", "verboseLabel": "Series B Redeemable Convertible Preferred Stock" } } }, "auth_ref": [] },
"sght_SeriesCRedeemableConvertiblePreferredStockAndWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sightsciences.com/20240930", "localname": "SeriesCRedeemableConvertiblePreferredStockAndWarrantsMember", "presentation": [
"http://www.sightsciences.com/20240930/taxonomy/role/DisclosureStockholdersEquityScheduleOfReservedCommonStockForFutureIssuancesDetails" ], "lang": { "en-us": { "role": { "documentation": "Series C redeemable convertible preferred stock and warrants.", "label": "Series C Redeemable Convertible Preferred Stock and Warrants [Member]", "terseLabel": "Series C Redeemable Convertible Preferred Stock and Warrants", "verboseLabel": "Series C Redeemable Convertible Preferred Stock and Warrants" } } }, "auth_ref": [] },
"sght_SeriesCRedeemableConvertiblePreferredStockMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sightsciences.com/20240930", "localname": "SeriesCRedeemableConvertiblePreferredStockMember", "presentation": [
"http://www.sightsciences.com/20240930/taxonomy/role/DisclosureNetLossPerShareAttributableToCommonStockholdersScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPe
"http://www.sightsciences.com/20240930/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Series C Redeemable Convertible Preferred Stock [Member]", "terseLabel": "Series C", "verboseLabel": "Series C Redeemable Convertible Preferred Stock", "documentation": "Series C redeemable convertible preferred stock." } } },
"auth_ref": [] }, "sght_SeriesDRedeemableConvertiblePreferredStockMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sightsciences.com/20240930", "localname": "SeriesDRedeemableConvertiblePreferredStockMember", "presentation": [
"http://www.sightsciences.com/20240930/taxonomy/role/DisclosureNetLossPerShareAttributableToCommonStockholdersScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPe
"http://www.sightsciences.com/20240930/taxonomy/role/DisclosureStockholdersEquityScheduleOfReservedCommonStockForFutureIssuancesDetails" ], "lang": { "en-us": { "role": { "documentation": "Series D redeemable convertible preferred stock.", "label": "Series D Redeemable Convertible Preferred Stock [Member]", "terseLabel": "Series D", "verboseLabel": "Series D Redeemable Convertible Preferred Stock" } } }, "auth_ref": [] }, "us-gaap_SeriesEPreferredStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SeriesEPreferredStockMember", "presentation": [ "http://www.sightsciences.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Series E", "label": "Series E Preferred Stock [Member]", "documentation": "Series E preferred stock." } } }, "auth_ref": [ "r871", "r872", "r922" ] },
"sght_SeriesERedeemableConvertiblePreferredStockMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sightsciences.com/20240930", "localname": "SeriesERedeemableConvertiblePreferredStockMember", "presentation": [
"http://www.sightsciences.com/20240930/taxonomy/role/DisclosureNetLossPerShareAttributableToCommonStockholdersScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPe
"http://www.sightsciences.com/20240930/taxonomy/role/DisclosureStockholdersEquityScheduleOfReservedCommonStockForFutureIssuancesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Series E", "documentation": "Series E redeemable convertible preferred stock.", "label": "Series E Redeemable Convertible Preferred Stock [Member]", "verboseLabel": "Series E Redeemable Convertible Preferred Stock" } } }, "auth_ref": [] }, "us-gaap_SeriesFPreferredStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SeriesFPreferredStockMember", "presentation": [ "http://www.sightsciences.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Series F", "label": "Series F Preferred Stock [Member]", "documentation": "Series F preferred stock." } } }, "auth_ref": [ "r871", "r872", "r922" ] },
"sght_SeriesFRedeemableConvertiblePreferredStockAndWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sightsciences.com/20240930", "localname": "SeriesFRedeemableConvertiblePreferredStockAndWarrantsMember", "presentation": [
"http://www.sightsciences.com/20240930/taxonomy/role/DisclosureStockholdersEquityScheduleOfReservedCommonStockForFutureIssuancesDetails" ], "lang": { "en-us": { "role": { "documentation": "Series F redeemable convertible preferred stock and warrants.", "label": "Series F Redeemable Convertible Preferred Stock and Warrants [Member]", "terseLabel": "Series F Redeemable Convertible Preferred Stock and Warrants", "verboseLabel": "Series F Redeemable Convertible Preferred Stock and Warrants" } } }, "auth_ref": [] },
"sght_SeriesFRedeemableConvertiblePreferredStockMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sightsciences.com/20240930", "localname": "SeriesFRedeemableConvertiblePreferredStockMember", "presentation": [ "http://www.sightsciences.com/20240930/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Series F Redeemable Convertible Preferred Stock [Member]", "terseLabel": "Series F", "verboseLabel": "Series F Redeemable Convertible Preferred Stock", "documentation": "Series F redeemable convertible preferred stock." } } } }, "auth_ref": [] }, "us-gaap_SettledLitigationMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SettledLitigationMember", "presentation": [ "http://www.sightsciences.com/20240930/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails",
"http://www.sightsciences.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Settled Litigation", "label": "Settled Litigation [Member]", "documentation": "Agreement reached between parties in a litigation that occurs without judicial intervention, supervision or approval." } } }, "auth_ref": [ "r912" ] }, "us-gaap_ShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensation", "crdr": "debit", "presentation": [ "http://www.sightsciences.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Stock-based compensation expense", "label": "Share-Based Payment Arrangement, Noncash Expense", "totalLabel": "Share-based Payment Arrangement, Noncash Expense, Total", "documentation": "Amount of noncash expense for share-based payment arrangement." } } }, "auth_ref": [ "r3" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract", "presentation": [
"http://www.sightsciences.com/20240930/taxonomy/role/DisclosureEquityIncentivePlansSummaryOfCompanyStockOptionActivityDetail" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Additional General Disclosures [Abstract]" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1", "presentation": [
"http://www.sightsciences.com/20240930/taxonomy/role/DisclosureEquityIncentivePlansAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Stock Option Granted For period", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period", "verboseLabel": "Vesting period", "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition." } } }, "auth_ref": [ "r733" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod", "presentation": [ "http://www.sightsciences.com/20240930/taxonomy/role/DisclosureEquityIncentivePlansSummarizesRestrictedShareAwardActivityUnderThe2021PlanDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Number of Shares, Forfeited/cancelled", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period", "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period." } } }, "auth_ref": [ "r400" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue", "presentation": [
"http://www.sightsciences.com/20240930/taxonomy/role/DisclosureEquityIncentivePlansSummarizesRestrictedShareAwardActivityUnderThe2021PlanDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted- Average Grant Date Fair Value Per Share, Forfeited/cancelled", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value", "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event." } } }, "auth_ref": [ "r400" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "presentation": [
"http://www.sightsciences.com/20240930/taxonomy/role/DisclosureEquityIncentivePlansSummarizesRestrictedShareAwardActivityUnderThe2021PlanDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of Shares, Grants", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period", "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)." } } }, "auth_ref": [ "r398" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "presentation": [
"http://www.sightsciences.com/20240930/taxonomy/role/DisclosureEquityIncentivePlansSummarizesRestrictedShareAwardActivityUnderThe2021PlanDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted- Average Grant Date Fair Value Per Share, Grants", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than
```

Options, Grants in Period, Weighted Average Grant Date Fair Value", "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)." } } }, "auth_ref": ["r398"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "presentation": ["http://www.sightsciences.com/20240930/taxonomy/role/DisclosureEquityIncentivePlansSummarizesRestrictedShareAwardActivityUnderThe2021PlanDetails"], "lang": { "en-us": { "role": { "periodStartLabel": "Number of Shares, Outstanding, December 31, 2023", "periodEndLabel": "Number of Shares, Outstanding, September 30, 2024", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number", "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date." } } }, "auth_ref": ["r395", "r396"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue", "presentation": ["http://www.sightsciences.com/20240930/taxonomy/role/DisclosureEquityIncentivePlansSummarizesRestrictedShareAwardActivityUnderThe2021PlanDetails"], "lang": { "en-us": { "role": { "periodEndLabel": "Weighted- Average Grant Date Fair Value Per Share, Outstanding, September 30, 2024", "periodStartLabel": "Weighted- Average Grant Date Fair Value Per Share, Outstanding, December 31, 2023", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value", "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options." } } }, "auth_ref": ["r395", "r396"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod", "presentation": ["http://www.sightsciences.com/20240930/taxonomy/role/DisclosureEquityIncentivePlansSummarizesRestrictedShareAwardActivityUnderThe2021PlanDetails"], "lang": { "en-us": { "role": { "negatedLabel": "Number of Shares, Vested", "terseLabel": "Number of Shares, Vested", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period", "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period." } } }, "auth_ref": ["r399"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue", "presentation": ["http://www.sightsciences.com/20240930/taxonomy/role/DisclosureEquityIncentivePlansSummarizesRestrictedShareAwardActivityUnderThe2021PlanDetails"], "lang": { "en-us": { "role": { "terseLabel": "Weighted- Average Grant Date Fair Value Per Share, Vested", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value", "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement." } } }, "auth_ref": ["r399"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate", "presentation": ["http://www.sightsciences.com/20240930/taxonomy/role/DisclosureEquityIncentivePlansAdditionalInformationDetail", "http://www.sightsciences.com/20240930/taxonomy/role/DisclosureEquityIncentivePlansSummaryOfStockBasedCompensationFairValueAssumptionsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Dividend yield", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate", "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term." } } }, "auth_ref": ["r407"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate", "presentation": ["http://www.sightsciences.com/20240930/taxonomy/role/DisclosureEquityIncentivePlansSummaryOfStockBasedCompensationFairValueAssumptionsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Expected volatility", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate", "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period." } } }, "auth_ref": ["r406"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "presentation": ["http://www.sightsciences.com/20240930/taxonomy/role/DisclosureEquityIncentivePlansSummaryOfStockBasedCompensationFairValueAssumptionsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Risk-free interest rate", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate", "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares." } } }, "auth_ref": ["r408"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "presentation": ["http://www.sightsciences.com/20240930/taxonomy/role/DisclosureEquityIncentivePlansAdditionalInformationDetail", "http://www.sightsciences.com/20240930/taxonomy/role/DisclosureEquityIncentivePlansSummarizesRestrictedShareAwardActivityUnderThe2021PlanDetails", "http://www.sightsciences.com/20240930/taxonomy/role/DisclosureEquityIncentivePlansSummaryOfCompanyStockOptionActivityDetail", "http://www.sightsciences.com/20240930/taxonomy/role/DisclosureEquityIncentivePlansSummaryOfSharebasedCompensationExpenseByFunctionDetails", "http://www.sightsciences.com/20240930/taxonomy/role/DisclosureEquityIncentivePlansSummaryOfStockBasedCompensationFairValueAssumptionsDetails", "http://www.sightsciences.com/20240930/taxonomy/role/DisclosureEquityIncentivePlansTables", "http://www.sightsciences.com/20240930/taxonomy/role/DisclosureStockholdersEquityScheduleOfReservedCommonStockForFutureIssuancesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Share Based Compensation Arrangement By Share Based Payment Award [Line Items]", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r381", "r382", "r384", "r385", "r386", "r387", "r388", "r389", "r390", "r391", "r392", "r393", "r394", "r395", "r396", "r397", "r398", "r399", "r400", "r401", "r402", "r403", "r404", "r405", "r406", "r407", "r408", "r409"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized", "presentation": ["http://www.sightsciences.com/20240930/taxonomy/role/DisclosureEquityIncentivePlansSummaryOfCompanyStockOptionActivityDetail"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized", "terseLabel": "Shares Available for Grant, Additional shares reserved", "documentation": "Number of additional shares authorized for issuance under share-based payment arrangement." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant", "presentation": ["http://www.sightsciences.com/20240930/taxonomy/role/DisclosureEquityIncentivePlansAdditionalInformationDetail", "http://www.sightsciences.com/20240930/taxonomy/role/DisclosureEquityIncentivePlansSummaryOfCompanyStockOptionActivityDetail"], "lang": { "en-us": { "role": { "periodStartLabel": "Shares Available for Grant", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant", "terseLabel": "Common stock available for issuance", "periodEndLabel": "Shares Available for Grant", "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable." } } }, "auth_ref": ["r44"] }, "sght_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantForfeitedInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://www.sightsciences.com/20240930", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantForfeitedInPeriod", "presentation": ["http://www.sightsciences.com/20240930/taxonomy/role/DisclosureEquityIncentivePlansSummaryOfCompanyStockOptionActivityDetail"], "lang": { "en-us": { "role": { "terseLabel": "Shares Available for Grant, Forfeited/cancelled", "documentation": "Share-based compensation arrangement by share-based payment award, number of shares available for grant, forfeited in period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant, Forfeited in Period" } } }, "auth_ref": [] }, "sght_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantGrantedInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://www.sightsciences.com/20240930", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantGrantedInPeriod", "presentation": ["http://www.sightsciences.com/20240930/taxonomy/role/DisclosureEquityIncentivePlansSummaryOfCompanyStockOptionActivityDetail"], "lang": { "en-us": { "role": { "negatedLabel": "Shares Available for Grant, Granted", "documentation": "Share-based compensation arrangement by share-based payment award, number of shares available for grant, granted in period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant, Granted in Period" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract", "presentation": ["http://www.sightsciences.com/20240930/taxonomy/role/DisclosureEquityIncentivePlansSummaryOfCompanyStockOptionActivityDetail"], "lang": { "en-us": { "role": { "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract]" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice", "presentation": ["http://www.sightsciences.com/20240930/taxonomy/role/DisclosureEquityIncentivePlansSummaryOfCompanyStockOptionActivityDetail"], "lang": { "en-us": { "role": { "terseLabel": "Vested and expected to vest as of September 30, 2024", "periodEndLabel": "Weighted-Average Exercise Price, Expected to vest as of March 31, 2022", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price", "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan." } } }, "auth_ref": ["r389"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue", "crdr": "debit", "presentation": ["http://www.sightsciences.com/20240930/taxonomy/role/DisclosureEquityIncentivePlansAdditionalInformationDetail"], "lang": { "en-us": { "role": { "terseLabel": "Aggregate intrinsic value of options exercised", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value", "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares." } } }, "auth_ref": ["r402"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod", "presentation": ["http://www.sightsciences.com/20240930/taxonomy/role/DisclosureEquityIncentivePlansSummaryOfCompanyStockOptionActivityDetail"], "lang": { "en-us": { "role": { "negatedLabel": "Number of Shares, Forfeited/cancelled", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period", "terseLabel": "Shares Available for Grant, Options forfeited/cancelled", "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan." } } }, "auth_ref": ["r393"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "presentation": ["http://www.sightsciences.com/20240930/taxonomy/role/DisclosureEquityIncentivePlansAdditionalInformationDetail", "http://www.sightsciences.com/20240930/taxonomy/role/DisclosureEquityIncentivePlansSummaryOfCompanyStockOptionActivityDetail"], "lang": { "en-us": { "role": { "verboseLabel": "Number of Shares, Grants", "terseLabel": "Issuance of options under plan", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross", "negatedLabel": "Shares Available for Grant, Option granted", "documentation": "Gross number of share options (or share units) granted during the period." } } }, "auth_ref": ["r391"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "presentation": ["http://www.sightsciences.com/20240930/taxonomy/role/DisclosureEquityIncentivePlansAdditionalInformationDetail"], "lang": { "en-us": { "role": { "terseLabel": "Weighted-average grant-date fair values of options granted", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value", "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology." } } }, "auth_ref": ["r401"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue", "crdr": "debit", "presentation": ["http://www.sightsciences.com/20240930/taxonomy/role/DisclosureEquityIncentivePlansSummaryOfCompanyStockOptionActivityDetail"], "lang": { "en-us": { "role": { "terseLabel": "Average

Intrinsic Value", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value", "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding." } } }, "auth_ref": ["r44"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "presentation": ["http://www.sightsciences.com/20240930/taxonomy/role/DisclosureEquityIncentivePlansSummaryOfCompanyStockOptionActivityDetail"], "lang": { "en-us": { "role": { "periodEndLabel": "Number of Shares", "periodStartLabel": "Number of Shares", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number", "documentation": "Number of options outstanding, including both vested and non-vested options." } } } }, "auth_ref": ["r387", "r388"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward", "presentation": ["http://www.sightsciences.com/20240930/taxonomy/role/DisclosureEquityIncentivePlansSummaryOfCompanyStockOptionActivityDetail"], "lang": { "en-us": { "role": { "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "presentation": ["http://www.sightsciences.com/20240930/taxonomy/role/DisclosureEquityIncentivePlansSummaryOfCompanyStockOptionActivityDetail"], "lang": { "en-us": { "role": { "terseLabel": "Balances as of June 30, 2021", "periodStartLabel": "Weighted-Average Exercise Price", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price", "periodEndLabel": "Weighted-Average Exercise Price", "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan." } } } }, "auth_ref": ["r387", "r388"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward", "presentation": ["http://www.sightsciences.com/20240930/taxonomy/role/DisclosureEquityIncentivePlansSummaryOfCompanyStockOptionActivityDetail"], "lang": { "en-us": { "role": { "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Weighted Average Exercise Price", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]" } } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue", "crdr": "debit", "presentation": ["http://www.sightsciences.com/20240930/taxonomy/role/DisclosureEquityIncentivePlansSummaryOfCompanyStockOptionActivityDetail"], "lang": { "en-us": { "role": { "periodEndLabel": "Average Intrinsic Value, Vested and expected as of September 30, 2024", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value", "terseLabel": "Weighted average contractual term, vested and expected", "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur." } } }, "auth_ref": ["r404"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber", "presentation": ["http://www.sightsciences.com/20240930/taxonomy/role/DisclosureEquityIncentivePlansSummaryOfCompanyStockOptionActivityDetail"], "lang": { "en-us": { "role": { "periodEndLabel": "Number of Shares, Vested and expected to vest as of September 30, 2024", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number", "documentation": "Number of fully vested and expected to vest exercisable options that may be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur." } } } }, "auth_ref": ["r404"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber", "presentation": ["http://www.sightsciences.com/20240930/taxonomy/role/DisclosureEquityIncentivePlansSummaryOfCompanyStockOptionActivityDetail"], "lang": { "en-us": { "role": { "periodEndLabel": "Number of Shares Vested and exercisable as of September 30, 2024", "terseLabel": "Vested and exercisable as of June 30, 2021", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number", "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur." } } } }, "auth_ref": ["r403"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice", "presentation": ["http://www.sightsciences.com/20240930/taxonomy/role/DisclosureEquityIncentivePlansSummaryOfCompanyStockOptionActivityDetail"], "lang": { "en-us": { "role": { "terseLabel": "Vested and exercisable as of September 30, 2024", "periodEndLabel": "Weighted-Average Exercise Price, Vested and exercisable as of March 31, 2022", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price", "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur." } } } }, "auth_ref": ["r403"] }, "sght_ShareBasedCompensationArrangementByShareBasedPaymentExercisePricePercentageGranted": { "xbrltype": "percentItemType", "nsuri": "http://www.sightsciences.com/20240930", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentExercisePricePercentageGranted", "presentation": ["http://www.sightsciences.com/20240930/taxonomy/role/DisclosureEquityIncentivePlansAdditionalInformationDetail"], "lang": { "en-us": { "role": { "terseLabel": "Exercise price percentage of an ISO granted", "label": "Share Based Compensation Arrangement by Share Based Payment Exercise Price Percentage Granted", "documentation": "Share based compensation arrangement by share based payment exercise price percentage granted." } } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "presentation": ["http://www.sightsciences.com/20240930/taxonomy/role/DisclosureEquityIncentivePlansAdditionalInformationDetail", "http://www.sightsciences.com/20240930/taxonomy/role/DisclosureEquityIncentivePlansSummarizesRestrictedShareAwardActivityUnderThe2021PlanDetails", "http://www.sightsciences.com/20240930/taxonomy/role/DisclosureNetLossPerShareAttributableToCommonStockholdersScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPe", "http://www.sightsciences.com/20240930/taxonomy/role/DisclosureStockholdersEquityScheduleOfReservedCommonStockForFutureIssuancesDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "All Award Types", "terseLabel": "All Award Types", "documentation": "Award under share-based payment arrangement." } } } }, "auth_ref": ["r384", "r385", "r386", "r387", "r388", "r389", "r390", "r391", "r392", "r393", "r394", "r395", "r396", "r397", "r398", "r399", "r400", "r401", "r402", "r403", "r404", "r405", "r406", "r407", "r408", "r409"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice", "presentation": ["http://www.sightsciences.com/20240930/taxonomy/role/DisclosureEquityIncentivePlansSummaryOfCompanyStockOptionActivityDetail"], "lang": { "en-us": { "role": { "terseLabel": "Weighted-Average Exercise Price, Exercised/released", "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price", "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares." } } } }, "auth_ref": ["r392"] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice", "presentation": ["http://www.sightsciences.com/20240930/taxonomy/role/DisclosureEquityIncentivePlansSummaryOfCompanyStockOptionActivityDetail"], "lang": { "en-us": { "role": { "terseLabel": "Weighted-Average Exercise Price, Forfeited/cancelled", "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price", "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated." } } }, "auth_ref": ["r393"] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "presentation": ["http://www.sightsciences.com/20240930/taxonomy/role/DisclosureEquityIncentivePlansAdditionalInformationDetail", "http://www.sightsciences.com/20240930/taxonomy/role/DisclosureEquityIncentivePlansSummaryOfCompanyStockOptionActivityDetail"], "lang": { "en-us": { "role": { "terseLabel": "Weighted-Average Exercise Price, Granted", "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price", "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options." } } }, "auth_ref": ["r391"] }, "us-gaap_ShareBasedCompensationAwardTrancheOneMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationAwardTrancheOneMember", "presentation": ["http://www.sightsciences.com/20240930/taxonomy/role/DisclosureEquityIncentivePlansAdditionalInformationDetail"], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Tranche One [Member]", "terseLabel": "At the End of One Year", "documentation": "First portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period." } } } }, "auth_ref": [] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage", "presentation": ["http://www.sightsciences.com/20240930/taxonomy/role/DisclosureEquityIncentivePlansAdditionalInformationDetail"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Percentage", "terseLabel": "Vesting percentage", "documentation": "Percentage of vesting of award under share-based payment arrangement." } } } }, "auth_ref": ["r924"] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod", "presentation": ["http://www.sightsciences.com/20240930/taxonomy/role/DisclosureEquityIncentivePlansAdditionalInformationDetail"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period", "terseLabel": "Stock option grant period", "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } } }, "auth_ref": ["r734"] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "presentation": ["http://www.sightsciences.com/20240930/taxonomy/role/DisclosureEquityIncentivePlansSummaryOfStockBasedCompensationFairValueAssumptionsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Expected term (in years)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term", "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } } }, "auth_ref": ["r405"] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1", "crdr": "debit", "presentation": ["http://www.sightsciences.com/20240930/taxonomy/role/DisclosureEquityIncentivePlansSummaryOfCompanyStockOptionActivityDetail"], "lang": { "en-us": { "role": { "periodEndLabel": "Average Intrinsic Value, Vested and exercisable as of September 30, 2024", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value", "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable." } } } }, "auth_ref": ["r44"] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1", "presentation": ["http://www.sightsciences.com/20240930/taxonomy/role/DisclosureEquityIncentivePlansSummaryOfCompanyStockOptionActivityDetail"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term", "terseLabel": "Weighted average contractual term, vested and exercisable", "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } } }, "auth_ref": ["r44"] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "presentation": ["http://www.sightsciences.com/20240930/taxonomy/role/DisclosureEquityIncentivePlansSummaryOfCompanyStockOptionActivityDetail"], "lang": { "en-us": { "role": { "terseLabel": "Weighted Average Remaining Contractual Term", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term", "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } } }, "auth_ref": ["r98"] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":

"SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1", "presentation": [
"http://www.sightsciences.com/20240930/taxonomy/role/DisclosureEquityIncentivePlansSummaryOfCompanyStockOptionActivityDetail"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term", "terseLabel": "Weighted average contractual term, vested and expected", "documentation": "Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur." } } }, "auth_ref": ["r403"] },
"us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent", "presentation": [
"http://www.sightsciences.com/20240930/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Additional warrants to purchase common stock", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Purchase Price of Common Stock, Percent", "documentation": "Purchase price of common stock expressed as a percentage of its fair value." } } }, "auth_ref": [] }, "sght_SharesAvailableForFuturePurchaseUnderESPPMember": { "xbrltype": "domainItemType", "nsuri":
"http://www.sightsciences.com/20240930", "localname": "SharesAvailableForFuturePurchaseUnderESPPMember", "presentation": [
"http://www.sightsciences.com/20240930/taxonomy/role/DisclosureStockholdersEquityScheduleOfReservedCommonStockForFutureIssuancesDetails"], "lang": { "en-us": { "role": {
"documentation": "Shares available for future purchase under ESPP.", "label": "Shares Available For Future Purchase Under E S P P [Member]", "terseLabel": "Shares available for future purchase under employee stock purchase plan" } } }, "auth_ref": [] }, "us-gaap_SharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"SharesOutstanding", "presentation": [
"http://www.sightsciences.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityUnaudited"], "lang": {
"en-us": { "role": { "label": "Shares, Outstanding", "periodStartLabel": "Beginning Balance, shares", "periodEndLabel": "Ending Balance, shares", "documentation": "Number of shares issued which are neither cancelled nor held in the treasury." } } }, "auth_ref": [] }, "us-gaap_SignificantAccountingPoliciesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SignificantAccountingPoliciesTextBlock", "presentation": [
"http://www.sightsciences.com/20240930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies"], "lang": { "en-us": { "role": { "terseLabel": "Summary of Significant Accounting Policies", "label": "Significant Accounting Policies [Text Block]", "documentation": "The entire disclosure for all significant accounting policies of the reporting entity." } } },
"auth_ref": ["r88", "r157"] }, "us-gaap_StatementBusinessSegmentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"StatementBusinessSegmentsAxis", "presentation": [
"http://www.sightsciences.com/20240930/taxonomy/role/Role_DisclosureSegmentInformationSummaryOfOperatingResultInformationForEachReportableSegmentDetails"], "lang": { "en-us": {
"role": { "terseLabel": "Segments", "label": "Segments [Axis]", "documentation": "Information by business segments." } } }, "auth_ref": ["r110", "r111", "r112", "r113", "r126", "r189", "r194",
"r197", "r198", "r199", "r200", "r201", "r202", "r203", "r204", "r205", "r206", "r208", "r209", "r211", "r212", "r213", "r214", "r215", "r216", "r217", "r218", "r220", "r221", "r222", "r227", "r277",
"r278", "r279", "r280", "r281", "r282", "r283", "r284", "r285", "r286", "r289", "r297", "r300", "r576", "r577", "r578", "r579", "r580", "r581", "r582", "r583", "r584", "r585", "r586", "r710", "r713",
"r714", "r720", "r763", "r981", "r983", "r984", "r985", "r986", "r987", "r988", "r989", "r990", "r991", "r992", "r993", "r994", "r995", "r996", "r997", "r998", "r999", "r1000", "r1001", "r1002",
"r1003", "r1004", "r1005", "r1006", "r1007", "r1008", "r1009", "r1010"] }, "us-gaap_StatementClassOfStockAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "StatementClassOfStockAxis", "presentation": [
"http://www.sightsciences.com/20240930/taxonomy/role/DisclosureNetLossPerShareAttributableToCommonStockholdersScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPe
"http://www.sightsciences.com/20240930/taxonomy/role/DisclosureStockholdersEquityScheduleOfReservedCommonStockForFutureIssuancesDetails",
"http://www.sightsciences.com/20240930/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails",
"http://www.sightsciences.com/20240930/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFairValueMeasurementLiabilitiesMeasuredOnRecurringBasisDetails",
"http://www.sightsciences.com/20240930/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnauditedParenthetical",
"http://www.sightsciences.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited",
"http://www.sightsciences.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityUnaudited"], "lang": {
"en-us": { "role": { "terseLabel": "Class of Stock", "label": "Class of Stock [Axis]", "documentation": "Information by the different classes of stock of the entity." } } }, "auth_ref": ["r124", "r138",
"r139", "r140", "r160", "r179", "r180", "r182", "r184", "r191", "r192", "r261", "r311", "r313", "r314", "r315", "r318", "r319", "r352", "r353", "r355", "r358", "r365", "r464", "r598", "r599", "r600",
"r601", "r604", "r605", "r606", "r607", "r608", "r609", "r610", "r611", "r612", "r613", "r614", "r615", "r629", "r650", "r668", "r682", "r683", "r684", "r685", "r686", "r862", "r878", "r886"] }, "us-gaap_StatementEquityComponentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementEquityComponentsAxis", "presentation": [
"http://www.sightsciences.com/20240930/taxonomy/role/DisclosureEquityIncentivePlansAdditionalInformationDetail",
"http://www.sightsciences.com/20240930/taxonomy/role/Role_DisclosureCompanyAndNatureOfBusinessAdditionalInformationDetails",
"http://www.sightsciences.com/20240930/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails",
"http://www.sightsciences.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityUnaudited"], "lang": {
"en-us": { "role": { "terseLabel": "Equity Components", "label": "Equity Components [Axis]", "documentation": "Information by component of equity." } } }, "auth_ref": ["r10", "r66", "r69", "r70",
"r125", "r146", "r147", "r148", "r162", "r163", "r164", "r166", "r171", "r173", "r175", "r190", "r262", "r263", "r287", "r367", "r421", "r422", "r424", "r425", "r426", "r428", "r429", "r430", "r438",
"r439", "r440", "r441", "r442", "r443", "r446", "r465", "r466", "r467", "r468", "r469", "r470", "r475", "r476", "r488", "r572", "r591", "r592", "r593", "r604", "r668"] },
"srt_StatementGeographicalAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "StatementGeographicalAxis", "presentation": [
"http://www.sightsciences.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"], "lang": { "en-us": { "role": { "label": "Geographical [Axis]" } } }, "auth_ref": ["r225", "r226", "r525", "r526", "r527", "r528", "r529", "r530", "r531", "r532", "r533", "r534", "r535", "r536", "r537", "r538", "r539", "r540", "r541", "r542", "r543",
"r544", "r545", "r546", "r547", "r548", "r549", "r550", "r551", "r552", "r553", "r554", "r616", "r617", "r618", "r674", "r676", "r679", "r681", "r688", "r690", "r691", "r692", "r693", "r694", "r695",
"r696", "r697", "r698", "r702", "r728", "r753", "r754", "r755", "r756", "r757", "r758", "r759", "r760", "r762", "r766", "r923", "r981", "r983", "r984", "r986", "r987", "r988", "r989", "r990", "r991",
"r992", "r993", "r994", "r995", "r996", "r997", "r998", "r999", "r1000", "r1001", "r1002", "r1003", "r1004", "r1005", "r1006", "r1007", "r1008", "r1009", "r1010"] }, "us-
gaap_StatementLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementLineItems", "presentation": [
"http://www.sightsciences.com/20240930/taxonomy/role/DisclosureNetLossPerShareAttributableToCommonStockholdersScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPe
"http://www.sightsciences.com/20240930/taxonomy/role/Role_DisclosureFairValueMeasurementsTables",
"http://www.sightsciences.com/20240930/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited",
"http://www.sightsciences.com/20240930/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnauditedParenthetical",
"http://www.sightsciences.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited",
"http://www.sightsciences.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityUnaudited"], "lang": {
"en-us": { "role": { "terseLabel": "Statement [Line Items]", "label": "Statement [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r162", "r163", "r164", "r190", "r476", "r524", "r597",
"r615", "r621", "r622", "r623", "r624", "r625", "r626", "r629", "r632", "r633", "r634", "r635", "r636", "r637", "r638", "r639", "r640", "r642", "r643", "r644", "r645", "r646", "r648", "r651", "r652",
"r654", "r655", "r656", "r657", "r658", "r659", "r660", "r661", "r662", "r663", "r664", "r665", "r668", "r767"] }, "us-gaap_StatementOfCashFlowsAbstract": { "xbrltype": "stringItemType",
"nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfCashFlowsAbstract", "lang": { "en-us": { "role": { "label": "Statement of Cash Flows [Abstract]" } } }, "auth_ref": [] }, "us-
gaap_StatementOfFinancialPositionAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfFinancialPositionAbstract", "lang": { "en-us": {
"role": { "label": "Statement of Financial Position [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "StatementOfStockholdersEquityAbstract", "lang": { "en-us": { "role": { "label": "Statement of Stockholders' Equity [Abstract]" } } }, "auth_ref": [] },
"us-gaap_StatementTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementTable", "presentation": [
"http://www.sightsciences.com/20240930/taxonomy/role/DisclosureNetLossPerShareAttributableToCommonStockholdersScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPe
"http://www.sightsciences.com/20240930/taxonomy/role/Role_DisclosureFairValueMeasurementsTables",
"http://www.sightsciences.com/20240930/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnauditedParenthetical",
"http://www.sightsciences.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited",
"http://www.sightsciences.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityUnaudited"], "lang": {
"en-us": { "role": { "terseLabel": "Statement [Table]", "label": "Statement [Table]", "documentation": "Disclosure of information about statement of comprehensive income, income, other comprehensive income, financial position, cash flows, and shareholders' equity." } } }, "auth_ref": ["r162", "r163", "r164", "r190", "r228", "r476", "r524", "r597", "r615", "r621", "r622", "r623",
"r624", "r625", "r626", "r629", "r632", "r633", "r634", "r635", "r636", "r637", "r638", "r639", "r640", "r642", "r643", "r644", "r645", "r646", "r648", "r651", "r652", "r654", "r655", "r656", "r657",
"r658", "r659", "r660", "r661", "r662", "r663", "r664", "r665", "r668", "r767"] }, "ecd_StkPrcOrTsrEstimationMethodTextBlock": { "xbrltype": "textBlockItemType", "nsuri":
"http://xbrl.sec.gov/ecd/2024", "localname": "StkPrcOrTsrEstimationMethodTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label":
"Stock Price or TSR Estimation Method [Text Block]", "terseLabel": "Stock Price or TSR Estimation Method" } } }, "auth_ref": ["r784", "r794", "r804", "r836"] }, "us-
gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants", "crdr": "credit", "presentation": [
"http://www.sightsciences.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"], "lang": { "en-us": { "role": { "terseLabel": "Conversion of preferred stock warrants to common stock warrants upon the closing of the IPO", "label": "Stock and Warrants Issued During Period, Value, Preferred Stock and Warrants", "verboseLabel":
"Common stock warrants issued upon execution of Hercules Loan Agreement", "documentation": "Value of preferred stock and warrants for common stock issued." } } }, "auth_ref": [] }, "us-
gaap_StockAppreciationRightsSARSMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockAppreciationRightsSARSMember", "presentation": [
"http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Stock Appreciation Rights (SARs) [Member]", "terseLabel": "Stock Appreciation Rights (SARs)",
"documentation": "Right to receive cash or shares equal to appreciation of predetermined number of grantor's shares during predetermined time period." } } }, "auth_ref": [] }, "us-
gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities", "presentation": [
"http://www.sightsciences.com/20240930/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails",
"http://www.sightsciences.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityUnaudited"], "lang": {
"en-us": { "role": { "terseLabel": "Conversion of redeemable convertible preferred stock to common stock upon initial public offering, Shares", "verboseLabel": "Conversion of redeemable convertible preferred stock", "label": "Stock Issued During Period, Shares, Conversion of Convertible Securities", "documentation": "Number of shares issued during the period as a result of the conversion of convertible securities." } } }, "auth_ref": ["r10", "r39", "r66", "r69", "r96", "r337"] }, "us-gaap_StockIssuedDuringPeriodSharesNewIssues": { "xbrltype": "sharesItemType",
"nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharesNewIssues", "presentation": [
"http://www.sightsciences.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityUnaudited"], "lang": {
"en-us": { "role": { "terseLabel": "ssuance of common stock in connection with initial public offering, net of underwriting discounts and commissions and other offering costs of $23.8 million, Shares", "label": "Stock Issued During Period, Shares, New Issues", "documentation": "Number of new stock issued during the period." } } }, "auth_ref": ["r10", "r65", "r66", "r96", "r598",
"r668", "r683"] }, "us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"StockIssuedDuringPeriodSharesPurchaseOfAssets", "presentation": ["http://www.sightsciences.com/20240930/taxonomy/role/DisclosureEquityIncentivePlansAdditionalInformationDetail",
"http://www.sightsciences.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityUnaudited"], "lang": {
"en-us": { "role": { "terseLabel": "ESPP purchase, Shares", "label": "Stock Issued During Period, Shares, Purchase of Assets", "documentation": "Number of shares of stock issued during the period as part of a transaction to acquire assets that do not qualify as a business combination." } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
"xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "presentation": [
"http://www.sightsciences.com/20240930/taxonomy/role/DisclosureEquityIncentivePlansSummaryOfCompanyStockOptionActivityDetail"], "lang": { "en-us": { "role": { "terseLabel": "Exercise of stock options, Shares", "negatedLabel": "Number of Shares, Exercised/released", "verboseLabel": "Exercise of options under stock plan", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period", "documentation": "Number of share options (or share units) exercised during the current period." } } }, "auth_ref": ["r10", "r65",
"r66", "r96", "r392"] }, "us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"StockIssuedDuringPeriodValueConversionOfConvertibleSecurities", "crdr": "credit", "presentation": [
"http://www.sightsciences.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityUnaudited"], "lang": {
"en-us": { "role": { "verboseLabel": "Conversion of redeemable convertible preferred stock to common stock upon initial public offering", "terseLabel": "Common Stock issued on conversion of convertible preferred stock", "label": "Stock Issued During Period, Value, Conversion of Convertible Securities", "documentation": "The gross value of stock issued during the period upon the conversion of convertible securities." } } }, "auth_ref": ["r10", "r66", "r69", "r70", "r96"] }, "us-gaap_StockIssuedDuringPeriodValueNewIssues": { "xbrltype": "monetaryItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodValueNewIssues", "crdr": "credit", "presentation": [
"http://www.sightsciences.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityUnaudited"], "lang": {
"en-us": { "role": { "terseLabel": "ssuance of common stock in connection with initial public offering, net of underwriting discounts and commissions and other offering costs of $23.8 million", "label": "Stock Issued During Period, Value, New Issues", "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering

or a secondary public offering." } } }, "auth_ref": ["r10", "r65", "r66", "r96", "r604", "r668", "r683", "r773"] }, "us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodValuePurchaseOfAssets", "crdr": "credit", "presentation": ["http://www.sightsciences.com/20240930/taxonomy/role/DisclosureEquityIncentivePlansAdditionalInformationDetail", "http://www.sightsciences.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityUnaudited"], "lang": { "en-us": { "role": { "terseLabel": "ESPP purchase", "label": "Stock Issued During Period, Value, Purchase of Assets", "documentation": "Value of shares of stock issued during the period as part of a transaction to acquire assets that do not qualify as a business combination." } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodValueShareBasedCompensation", "crdr": "credit", "presentation": ["http://www.sightsciences.com/20240930/taxonomy/role/DisclosureEquityIncentivePlansAdditionalInformationDetail", "http://www.sightsciences.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityUnaudited"], "lang": { "en-us": { "role": { "verboseLabel": "Share of common stock purchased", "terseLabel": "Stock based compensation expense", "label": "Shares Issued, Value, Share Based Payment Arrangement, after Forfeiture", "totalLabel": "Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture, Total", "documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement, Excludes employee stock ownership plan (ESOP)." } } }, "auth_ref": ["r45", "r65", "r66", "r96"] }, "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodValueStockOptionsExercised", "crdr": "credit", "presentation": ["http://www.sightsciences.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityUnaudited"], "lang": { "en-us": { "role": { "terseLabel": "Exercise of stock options, Amount", "label": "Stock Issued During Period, Value, Stock Options Exercised", "verboseLabel": "Common stock warrants, net exercised", "documentation": "Value of stock issued as a result of the exercise of stock options." } } }, "auth_ref": ["r10", "r66", "r69", "r70", "r96"] }, "us-gaap_StockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquity", "crdr": "credit", "presentation": ["http://www.sightsciences.com/20240930/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited", "http://www.sightsciences.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityUnaudited"], "lang": { "en-us": { "role": { "periodStartLabel": "Beginning Balance", "periodEndLabel": "Ending Balance", "label": "Equity, Attributable to Parent", "totalLabel": "Total stockholders' equity", "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest." } } }, "auth_ref": ["r66", "r69", "r70", "r89", "r631", "r647", "r669", "r670", "r751", "r774", "r880", "r903", "r960", "r1012"] }, "us-gaap_StockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquityAbstract", "presentation": ["http://www.sightsciences.com/20240930/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited"], "lang": { "en-us": { "role": { "label": "Equity, Attributable to Parent [Abstract]", "terseLabel": "Stockholders' equity:" } } }, "auth_ref": [] }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquityNoteDisclosureTextBlock", "presentation": ["http://www.sightsciences.com/20240930/taxonomy/role/DisclosureStockholdersEquity1"], "lang": { "en-us": { "role": { "terseLabel": "Stockholders' Equity", "label": "Equity [Text Block]", "documentation": "The entire disclosure for equity." } } }, "auth_ref": ["r93", "r159", "r351", "r353", "r354", "r355", "r356", "r357", "r358", "r359", "r360", "r361", "r362", "r364", "r367", "r445", "r671", "r672", "r687"] }, "us-gaap_SubsequentEventDescription": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventDescription", "presentation": ["http://www.sightsciences.com/20240930/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"], "lang": { "en-us": { "role": { "label": "Subsequent Event, Description", "terseLabel": "Subsequent event, Description", "documentation": "Describes the event or transaction that occurred between the balance sheet date and the date the financial statements are issued or available to be issued." } } }, "auth_ref": ["r49"] }, "us-gaap_SubsequentEventLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventLineItems", "presentation": ["http://www.sightsciences.com/20240930/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"], "lang": { "en-us": { "role": { "label": "Subsequent Event [Line Items]", "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event." } } }, "auth_ref": ["r471", "r490"] }, "us-gaap_SubsequentEventMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventMember", "presentation": ["http://www.sightsciences.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails", "http://www.sightsciences.com/20240930/taxonomy/role/Role_DisclosureCompanyAndNatureOfBusinessAdditionalInformationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Subsequent Event", "label": "Subsequent Event [Member]", "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": ["r471", "r490"] }, "us-gaap_SubsequentEventTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventTable", "presentation": ["http://www.sightsciences.com/20240930/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"], "lang": { "en-us": { "role": { "label": "Subsequent Event [Table]", "documentation": "Disclosure of information about significant event or transaction occurring between statement of financial position date and date when financial statements were issued." } } }, "auth_ref": ["r471", "r490"] }, "us-gaap_SubsequentEventTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventTypeAxis", "presentation": ["http://www.sightsciences.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails", "http://www.sightsciences.com/20240930/taxonomy/role/Role_DisclosureCompanyAndNatureOfBusinessAdditionalInformationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Subsequent Event Type", "label": "Subsequent Event Type [Axis]", "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": ["r471", "r490"] }, "us-gaap_SubsequentEventTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventTypeDomain", "presentation": ["http://www.sightsciences.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails", "http://www.sightsciences.com/20240930/taxonomy/role/Role_DisclosureCompanyAndNatureOfBusinessAdditionalInformationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Subsequent Event Type", "label": "Subsequent Event Type [Domain]", "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": ["r471", "r490"] }, "us-gaap_SubsequentEventsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventsAbstract", "lang": { "en-us": { "role": { "label": "Subsequent Events [Abstract]" } } }, "auth_ref": [] }, "us-gaap_SubsequentEventsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventsTextBlock", "presentation": ["http://www.sightsciences.com/20240930/taxonomy/role/DisclosureSubsequentEvents1"], "lang": { "en-us": { "role": { "terseLabel": "Subsequent Events", "label": "Subsequent Events [Text Block]", "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business." } } }, "auth_ref": ["r489", "r491"] }, "us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable", "presentation": ["http://www.sightsciences.com/20240930/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails"], "lang": { "en-us": { "role": { "label": "Subsidiary or Equity Method Investee, Sale of Stock, Type [Table]", "documentation": "Disclosure of information about sale of stock made by subsidiary or equity method investee to investor outside consolidated group by type of sale. Includes, but is not limited to, stock issued in business combination in exchange for share of acquired entity." } } }, "auth_ref": [] }, "us-gaap_SubsidiarySaleOfStockAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsidiarySaleOfStockAxis", "presentation": ["http://www.sightsciences.com/20240930/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails", "http://www.sightsciences.com/20240930/taxonomy/role/Role_DisclosureCompanyAndNatureOfBusinessAdditionalInformationDetails", "http://www.sightsciences.com/20240930/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails", "http://www.sightsciences.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityUnauditedParenthetical"], "lang": { "en-us": { "role": { "terseLabel": "Sale of Stock", "label": "Sale of Stock [Axis]", "documentation": "Information by type of sale of the entity's stock." } } }, "auth_ref": [] }, "us-gaap_SubsidiarySaleOfStockLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsidiarySaleOfStockLineItems", "presentation": ["http://www.sightsciences.com/20240930/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails", "http://www.sightsciences.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityUnauditedParenthetical"], "lang": { "en-us": { "role": { "label": "Subsidiary, Sale of Stock [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_SupplementalBalanceSheetDisclosuresTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SupplementalBalanceSheetDisclosuresTextBlock", "presentation": ["http://www.sightsciences.com/20240930/taxonomy/role/Role_DisclosureBalanceSheetComponents"], "lang": { "en-us": { "role": { "terseLabel": "Balance Sheet Components", "label": "Supplemental Balance Sheet Disclosures [Text Block]", "documentation": "The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity." } } }, "auth_ref": ["r870"] }, "us-gaap_SupplementalCashFlowInformationAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SupplementalCashFlowInformationAbstract", "presentation": ["http://www.sightsciences.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"], "lang": { "en-us": { "role": { "terseLabel": "Supplemental disclosure of cash flow information", "label": "Supplemental Cash Flow Information [Abstract]" } } }, "auth_ref": [] }, "us-gaap_SupplyCommitmentArrangementMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SupplyCommitmentArrangementMember", "presentation": ["http://www.sightsciences.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"], "lang": { "en-us": { "role": { "label": "Supply Commitment Arrangement [Domain]", "documentation": "This item is intended to be populated, by the entity, with Members identifying each supply commitment about which information required or determined to be disclosed is being provided. If only one such commitment exists, this item may be used to capture such information; if multiple commitments exist, this item is the dimensional default, which will aggregate such information, as appropriate." } } }, "auth_ref": ["r62", "r105"] }, "us-gaap_SupplyCommitmentAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SupplyCommitmentAxis", "presentation": ["http://www.sightsciences.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"], "lang": { "en-us": { "role": { "label": "Supply Commitment [Axis]", "documentation": "Information by arrangements in which the entity has committed resources to supply goods or services to a customer." } } }, "auth_ref": ["r62", "r105"] }, "us-gaap_SupplyCommitmentLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SupplyCommitmentLineItems", "presentation": ["http://www.sightsciences.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"], "lang": { "en-us": { "role": { "label": "Supply Commitment [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_SupplyCommitmentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SupplyCommitmentMember", "presentation": ["http://www.sightsciences.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"], "lang": { "en-us": { "role": { "label": "Supply Commitment [Member]", "terseLabel": "Supply agreement [Member]", "documentation": "Supply arrangement in which the entity has agreed to commit resources to supply goods or services to a customer. Excludes long-term commitments." } } }, "auth_ref": ["r62", "r105"] }, "us-gaap_SupplyCommitmentTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SupplyCommitmentTable", "presentation": ["http://www.sightsciences.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"], "lang": { "en-us": { "role": { "label": "Supply Commitment [Table]", "documentation": "Disclosure of information about supply arrangement in which resource is committed to supply product or service or both, to customer. Includes, but is not limited to, identification of committed product and service, purchasing party, price, effect on price for failing to deliver required quantity, cancellation right, and termination provision." } } }, "auth_ref": ["r62", "r105"] }, "sght_SurgicalGlaucomaMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sightsciences.com/20240930", "localname": "SurgicalGlaucomaMember", "presentation": ["http://www.sightsciences.com/20240930/taxonomy/role/Role_DisclosureSegmentInformationSummaryOfOperatingResultInformationForEachReportableSegmentDetails"], "lang": { "en-us": { "role": { "label": "Surgical Glaucoma [Member]", "documentation": "Surgical Glaucoma.", "terseLabel": "Surgical Glaucoma" } } }, "auth_ref": [] }, "ecd_TabularListTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TabularListTableTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Tabular List [Table Text Block]", "terseLabel": "Tabular List, Table" } } }, "auth_ref": ["r830"] }, "sght_TaxesPaidOnTheNetShareSettlementOfRestrictedStockUnits": { "xbrltype": "monetaryItemType", "nsuri": "http://www.sightsciences.com/20240930", "localname": "TaxesPaidOnTheNetShareSettlementOfRestrictedStockUnits", "crdr": "debit", "presentation": ["http://www.sightsciences.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"], "lang": { "en-us": { "role": { "terseLabel": "Withholding taxes on net share settlement of restricted stock units", "documentation": "Taxes paid on the net share settlement of restricted stock units", "label": "Taxes paid on the net share settlement of restricted stock units", "verboseLabel": "Taxes paid on net share settlement of restricted stock units" } } }, "auth_ref": [] }, "us-gaap_TemporaryEquityCarryingAmountAttributableToParent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TemporaryEquityCarryingAmountAttributableToParent", "crdr": "credit", "presentation": ["http://www.sightsciences.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityUnaudited"], "lang": { "en-us": { "role": { "verboseLabel": "Preferred stock par value of $0.001 per share; 10,000,000 shares authorized; no shares issued and outstanding as of March 31, 2022 and December 31, 2021, respectively", "terseLabel": "Convertible preferred stock par value of $0.001 per share; 10,000,000 shares authorized; no shares issued and outstanding as of March 31, 2022 and December 31, 2021, respectively", "totalLabel": "Carrying Value", "periodStartLabel": "Beginning Balance", "periodEndLabel": "Ending Balance", "label": "Temporary Equity, Carrying Amount, Attributable to Parent", "documentation": "Carrying amount, attributable to parent, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer." } } }, "auth_ref": ["r311", "r313", "r314", "r315", "r318", "r319", "r415", "r564"] }, "sght_TemporaryEquityIssuanceCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://www.sightsciences.com/20240930", "localname": "TemporaryEquityIssuanceCosts", "crdr": "debit", "presentation": ["http://www.sightsciences.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityUnauditedParenthetical"], "lang": { "en-us": { "role": { "terseLabel": "Issuance costs", "documentation": "Temporary equity, issuance costs.", "label": "Temporary Equity, Issuance Costs" } } }, "auth_ref": [] }, "us-

gaap_TemporaryEquityParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TemporaryEquityParOrStatedValuePerShare", "presentation": ["http://www.sightsciences.com/20240930/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnauditedParenthetical"], "lang": { "en-us": { "role": { "terseLabel": "Redeemable convertible preferred stock, par value", "label": "Temporary Equity, Par or Stated Value Per Share", "documentation": "Per share amount of par value or stated value of stock classified as temporary equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable." } } }, "auth_ref": ["r15", "r36"] }, "us-gaap_TemporaryEquitySharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TemporaryEquitySharesAuthorized", "presentation": [
"http://www.sightsciences.com/20240930/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnauditedParenthetical"], "lang": { "en-us": { "role": { "verboseLabel": "Redeemable convertible preferred stock, shares authorized", "label": "Temporary Equity, Shares Authorized", "terseLabel": "Shares Authorized", "documentation": "The maximum number of securities classified as temporary equity that are permitted to be issued by an entity's charter and bylaws. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer." } } }, "auth_ref": ["r64"] }, "us-gaap_TemporaryEquitySharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TemporaryEquitySharesIssued", "presentation": ["http://www.sightsciences.com/20240930/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnauditedParenthetical"], "lang": { "en-us": { "role": { "terseLabel": "Redeemable convertible preferred stock, shares issued", "label": "Temporary Equity, Shares Issued", "verboseLabel": "Shares Issued", "documentation": "The number of securities classified as temporary equity that have been sold (or granted) to the entity's shareholders. Securities issued include securities outstanding and securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer." } } }, "auth_ref": ["r64"] }, "us-gaap_TemporaryEquitySharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TemporaryEquitySharesOutstanding", "presentation": [
"http://www.sightsciences.com/20240930/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnauditedParenthetical",
"http://www.sightsciences.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityUnaudited"], "lang": { "en-us": { "role": { "terseLabel": "Redeemable convertible preferred stock, shares outstanding", "label": "Temporary Equity, Shares Outstanding", "verboseLabel": "Shares Outstanding", "periodStartLabel": "Beginning Balance, shares", "periodEndLabel": "Ending Balance, shares", "documentation": "The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer." } } }, "auth_ref": ["r64"] }, "sght_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues": { "xbrltype": "sharesItemType", "nsuri": "http://www.sightsciences.com/20240930", "localname": "TemporaryEquityStockIssuedDuringPeriodSharesNewIssues", "presentation": [
"http://www.sightsciences.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityUnaudited"], "lang": { "en-us": { "role": { "documentation": "Temporary equity, stock issued during period shares, new issues.", "label": "Temporary Equity Stock Issued During Period Shares New Issues", "terseLabel": "Issuance of Series E convertible preferred stock, shares" } } }, "auth_ref": [] }, "us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TemporaryEquityStockIssuedDuringPeriodValueNewIssues", "crdr": "credit", "presentation": [
"http://www.sightsciences.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityUnaudited"], "lang": { "en-us": { "role": { "terseLabel": "Stock issuance costs", "label": "Temporary Equity, Stock Issued During Period, Value, New Issues", "verboseLabel": "Issuance of Series E convertible preferred stock", "documentation": "Value of new stock classified as temporary equity issued during the period." } } }, "auth_ref": [] }, "sght_TermLoanMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sightsciences.com/20240930", "localname": "TermLoanMember", "presentation": [
"http://www.sightsciences.com/20240930/taxonomy/role/Role_DisclosureDebtScheduleOfLongTermAndShortTermDebtDetails"], "lang": { "en-us": { "role": { "documentation": "Term loan.", "label": "Term Loan [Member]", "terseLabel": "Term Loan" } } }, "auth_ref": [] }, "us-gaap_ToolsDiesAndMoldsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ToolsDiesAndMoldsMember", "presentation": [
"http://www.sightsciences.com/20240930/taxonomy/role/Role_DisclosureBalanceSheetComponentsSummaryOfPropertyAndEquipmentNetDetails"], "lang": { "en-us": { "role": { "terseLabel": "Tools and Equipment", "label": "Tools, Dies and Molds [Member]", "documentation": "Equipment commonly used to cut, shape, and form metal and other materials into goods for sale." } } }, "auth_ref": [] }, "sght_TotalBaseRentUnderLeaseAgreement": { "xbrltype": "monetaryItemType", "nsuri": "http://www.sightsciences.com/20240930", "localname": "TotalBaseRentUnderLeaseAgreement", "crdr": "debit", "presentation": [
"http://www.sightsciences.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Total base rent under lease agreement", "label": "Total base rent under lease agreement", "documentation": "Total base rent under lease agreement." } } }, "auth_ref": [] }, "sght_TotalPrincipalPayments": { "xbrltype": "monetaryItemType", "nsuri": "http://www.sightsciences.com/20240930", "localname": "TotalPrincipalPayments", "crdr": "credit", "presentation": [
"http://www.sightsciences.com/20240930/taxonomy/role/Role_DisclosureDebtScheduleRelatingToCompanysDebtDetails"], "lang": { "en-us": { "role": { "totalLabel": "Total principal payments", "label": "Total Principal Payments", "documentation": "Total Principal Payments" } } }, "auth_ref": [] }, "ecd_TotalShareholderRtnAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TotalShareholderRtnAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Total Shareholder Return Amount", "terseLabel": "Total Shareholder Return Amount" } } }, "auth_ref": ["r822"] }, "ecd_TotalShareholderRtnVsPeerGroupTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TotalShareholderRtnVsPeerGroupTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Total Shareholder Return Vs Peer Group [Text Block]", "terseLabel": "Total Shareholder Return Vs Peer Group" } } }, "auth_ref": ["r829"] }, "ecd_TradingArrAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TradingArrAxis", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Trading Arrangement [Axis]", "terseLabel": "Trading Arrangement:" } } }, "auth_ref": ["r849"] }, "ecd_TradingArrByIndTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TradingArrByIndTable", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Trading Arrangements, by Individual [Table]", "terseLabel": "Trading Arrangements, by Individual" } } }, "auth_ref": ["r851"] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "TradingSymbol", "presentation": ["http://www.sightsciences.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "terseLabel": "Trading Symbol", "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "sght_TrancheOneAndTwoLoansMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sightsciences.com/20240930", "localname": "TrancheOneAndTwoLoansMember", "presentation": ["http://www.sightsciences.com/20240930/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails"], "lang": { "en-us": { "role": { "label": "Tranche One And Two Loans [Member]", "documentation": "Tranche one and two loans.", "terseLabel": "Tranche One and Two Loans" } } }, "auth_ref": [] }, "sght_TrancheOneLoansMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sightsciences.com/20240930", "localname": "TrancheOneLoansMember", "presentation": [
"http://www.sightsciences.com/20240930/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Tranche One Loans", "label": "Tranche One Loans [Member]", "documentation": "Tranche one loans." } } }, "auth_ref": [] }, "sght_TrancheThreeLoansMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sightsciences.com/20240930", "localname": "TrancheThreeLoansMember", "presentation": [
"http://www.sightsciences.com/20240930/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Tranche Three Loans", "label": "Tranche Three Loans [Member]", "documentation": "Tranche three loans." } } }, "auth_ref": [] }, "sght_TrancheTwoLoansMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sightsciences.com/20240930", "localname": "TrancheTwoLoansMember", "presentation": [
"http://www.sightsciences.com/20240930/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Tranche Two Loans", "label": "Tranche Two Loans [Member]", "documentation": "Tranche two loans." } } }, "auth_ref": [] }, "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain", "presentation": [
"http://www.sightsciences.com/20240930/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"], "lang": { "en-us": { "role": { "label": "Financial Instruments [Domain]", "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms." } } }, "auth_ref": ["r231", "r232", "r233", "r234", "r235", "r236", "r237", "r238", "r239", "r240", "r241", "r242", "r243", "r244", "r245", "r246", "r247", "r248", "r249", "r250", "r251", "r252", "r253", "r254", "r255", "r256", "r257", "r258", "r259", "r260", "r345", "r363", "r444", "r462", "r492", "r493", "r494", "r495", "r496", "r497", "r498", "r499", "r500", "r501", "r502", "r503", "r504", "r505", "r506", "r508", "r509", "r510", "r511", "r512", "r513", "r514", "r515", "r516", "r517", "r518", "r519", "r520", "r521", "r522", "r573", "r738", "r739", "r741", "r742", "r743", "r744", "r745", "r746", "r747", "r752", "r863", "r864", "r865", "r866", "r867", "r868", "r869", "r899", "r900", "r901", "r902", "r952", "r955", "r956", "r957", "r958", "r959"] }, "ecd_TrdArrAdoptionDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrAdoptionDate", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Trading Arrangement Adoption Date", "terseLabel": "Adoption Date" } } }, "auth_ref": ["r852"] }, "ecd_TrdArrDuration": { "xbrltype": "durationItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrDuration", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Trading Arrangement Duration", "terseLabel": "Arrangement Duration" } } }, "auth_ref": ["r853"] }, "ecd_TrdArrExpirationDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrExpirationDate", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Trading Arrangement Expiration Date", "terseLabel": "Expiration Date" } } }, "auth_ref": ["r853"] }, "ecd_TrdArrIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrIndName", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Trading Arrangement, Individual Name", "terseLabel": "Name" } } }, "auth_ref": ["r851"] }, "ecd_TrdArrIndTitle": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrIndTitle", "presentation": [
"http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Trading Arrangement, Individual Title", "terseLabel": "Title" } } }, "auth_ref": ["r851"] }, "ecd_TrdArrSecuritiesAggAvailAmt": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrSecuritiesAggAvailAmt", "presentation": [
"http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Trading Arrangement, Securities Aggregate Available Amount", "terseLabel": "Aggregate Available" } } }, "auth_ref": ["r854"] }, "ecd_TrdArrTerminationDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrTerminationDate", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Trading Arrangement Termination Date", "terseLabel": "Termination Date" } } }, "auth_ref": ["r852"] }, "sght_TwoThousandAndElevenPlanMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sightsciences.com/20240930", "localname": "TwoThousandAndElevenPlanMember", "presentation": ["http://www.sightsciences.com/20240930/taxonomy/role/DisclosureEquityIncentivePlansAdditionalInformationDetail"], "lang": { "en-us": { "role": { "label": "Two Thousand And Eleven Plan [Member]", "terseLabel": "2011 Plan", "documentation": "Two thousand and Eleven plan." } } }, "auth_ref": [] },
"sght_TwoThousandAndTwentyOnePlanMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sightsciences.com/20240930", "localname": "TwoThousandAndTwentyOnePlanMember", "presentation": ["http://www.sightsciences.com/20240930/taxonomy/role/DisclosureEquityIncentivePlansAdditionalInformationDetail"], "lang": { "en-us": { "role": { "terseLabel": "2021 Plan", "label": "Two Thousand And Twenty One Plan [Member]", "documentation": "Two thousand and twenty one plan." } } }, "auth_ref": [] },
"sght_TwoThousandElevenPlanAndTwoThousandTwentyOnePlanMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sightsciences.com/20240930", "localname": "TwoThousandElevenPlanAndTwoThousandTwentyOnePlanMember", "presentation": [
"http://www.sightsciences.com/20240930/taxonomy/role/DisclosureEquityIncentivePlansSummaryOfCompanyStockOptionActivityDetail"], "lang": { "en-us": { "role": { "terseLabel": "2011 Plan and 2021 Plan", "label": "Two Thousand Eleven Plan And Two Thousand Twenty One Plan [Member]", "documentation": "Two Thousand Eleven Plan And Two Thousand Twenty One Plan" } } }, "auth_ref": [] }, "sght_TwoThousandNineteenWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sightsciences.com/20240930", "localname": "TwoThousandNineteenWarrantsMember", "presentation": ["http://www.sightsciences.com/20240930/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails"], "lang": { "en-us": { "role": { "verboseLabel": "2019 Warrants [Member]", "terseLabel": "2019 Warrants", "label": "Two Thousand Nineteen Warrants [Member]", "documentation": "Two thousand nineteen warrants." } } }, "auth_ref": [] }, "sght_TwoThousandTwentyOneEmployeeStockPurchasePlanMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sightsciences.com/20240930", "localname": "TwoThousandTwentyOneEmployeeStockPurchasePlanMember", "presentation": [
"http://www.sightsciences.com/20240930/taxonomy/role/DisclosureEquityIncentivePlansAdditionalInformationDetail",
"http://www.sightsciences.com/20240930/taxonomy/role/DisclosureEquityIncentivePlansSummaryOfStockBasedCompensationFairValueAssumptionsDetails",
"http://www.sightsciences.com/20240930/taxonomy/role/DisclosureEquityIncentivePlansTables"], "lang": { "en-us": { "role": { "label": "Two Thousand Twenty One Employee Stock Purchase Plan [Member]", "documentation": "Two thousand twenty one employee stock purchase plan.", "terseLabel": "2021 Employee Stock Purchase Plan" } } }, "auth_ref": [] },
"sght_TwoThousandTwentyWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sightsciences.com/20240930", "localname": "TwoThousandTwentyWarrantsMember",

```
"presentation": [ "http://www.sightsciences.com/20240930/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "2020 Warrants [Member]", "label": "Two Thousand Twenty Warrants [Member]", "terseLabel": "2020 Warrants", "documentation": "Two thousand Twenty warrant." } } }, "auth_ref": [] }, "us-gaap_USTreasurySecuritiesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "USTreasurySecuritiesMember", "presentation": [ "http://www.sightsciences.com/20240930/taxonomy/role/DisclosureFairValueMeasurementHeldtomaturityDebtSecuritiesAtAmortizedCostDetails" ], "lang": { "en-us": { "role": { "label": "US Treasury Securities [Member]", "terseLabel": "US Treasury Securities [Member]", "documentation": "This category includes information about debt securities issued by the United States Department of the Treasury and backed by the United States government. Such securities primarily consist of treasury bills (short-term maturities - one year or less), treasury notes (intermediate term maturities - two to ten years), and treasury bonds (long-term maturities - ten to thirty years)." } } }, "auth_ref": [ "r705", "r729", "r731", "r738", "r978" ] }, "ecd_UndrlygSecurityMktPriceChngPct": { "xbrltype": "pureItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "UndrlygSecurityMktPriceChngPct", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Underlying Security Market Price Change, Percent", "terseLabel": "Underlying Security Market Price Change" } } }, "auth_ref": [ "r848" ] }, "us-gaap_UseOfEstimates": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "UseOfEstimates", "presentation": [ "http://www.sightsciences.com/20240930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Use of Estimates", "label": "Use of Estimates, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles." } } }, "auth_ref": [ "r24", "r25", "r26", "r118", "r119", "r120", "r121" ] }, "us-gaap_VariableRateAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "VariableRateAxis", "presentation": [
"http://www.sightsciences.com/20240930/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Variable Rate", "label": "Variable Rate [Axis]", "documentation": "Information by type of variable rate." } } }, "auth_ref": [] }, "us-gaap_VariableRateDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "VariableRateDomain", "presentation": [ "http://www.sightsciences.com/20240930/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Variable Rate", "label": "Variable Rate [Domain]", "documentation": "Interest rate that fluctuates over time as a result of an underlying benchmark interest rate or index." } } }, "auth_ref": [] }, "us-gaap_VestingAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "VestingAxis", "presentation": [
"http://www.sightsciences.com/20240930/taxonomy/role/DisclosureEquityIncentivePlansAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Vesting [Axis]", "documentation": "Information by vesting schedule of award under share-based payment arrangement." } } }, "auth_ref": [ "r924", "r925", "r926", "r927", "r928", "r929", "r930", "r931", "r932", "r933", "r934", "r935", "r936", "r937", "r938", "r939", "r940", "r941", "r942", "r943", "r944", "r945", "r946", "r947", "r948", "r949" ] }, "us-gaap_VestingDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "VestingDomain", "presentation": [
"http://www.sightsciences.com/20240930/taxonomy/role/DisclosureEquityIncentivePlansAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Vesting [Domain]", "documentation": "Vesting schedule of award under share-based payment arrangement." } } }, "auth_ref": [ "r924", "r925", "r926", "r927", "r928", "r929", "r930", "r931", "r932", "r933", "r934", "r935", "r936", "r937", "r938", "r939", "r940", "r941", "r942", "r943", "r944", "r945", "r946", "r947", "r948", "r949" ] }, "ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember", "presentation": [
"http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member]", "terseLabel": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year" } } }, "auth_ref": [ "r818" ] }, "us-gaap_WarrantMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WarrantMember", "presentation": [
"http://www.sightsciences.com/20240930/taxonomy/role/DisclosureNetLossPerShareAttributableToCommonStockholdersScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPe
"http://www.sightsciences.com/20240930/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Common stock warrants", "terseLabel": "Warrants", "label": "Warrant [Member]", "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount." } } }, "auth_ref": [ "r764", "r765", "r768", "r769", "r770", "r771" ] }, "us-gaap_WarrantsAndRightsOutstanding": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WarrantsAndRightsOutstanding", "crdr": "credit", "presentation": [
"http://www.sightsciences.com/20240930/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Warrants and Rights Outstanding", "terseLabel": "Unused warrants value", "documentation": "Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price." } } }, "auth_ref": [ "r955", "r956", "r957" ] }, "sght_WarrantsExpirationTerm": { "xbrltype": "durationItemType", "nsuri": "http://www.sightsciences.com/20240930", "localname": "WarrantsExpirationTerm", "presentation": [ "http://www.sightsciences.com/20240930/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Warrants expiration date", "label": "Warrants Expiration Term", "documentation": "Warrants Expiration Term." } } }, "auth_ref": [] }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "presentation": [
"http://www.sightsciences.com/20240930/taxonomy/role/DisclosureNetLossPerShareAttributableToCommonStockholdersScheduleOfComputationOfBasicAndDilutedNetLossPerShareAttributable
"http://www.sightsciences.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted-average shares used in computing net loss per share attributable to common stockholders-diluted", "label": "Weighted Average Number of Shares Outstanding, Diluted", "totalLabel": "Weighted Average Number of Shares Outstanding, Diluted, Total", "verboseLabel": "Weighted-average shares of common stock outstanding-diluted", "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period." } } }, "auth_ref": [ "r178", "r184" ] }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "presentation": [
"http://www.sightsciences.com/20240930/taxonomy/role/DisclosureNetLossPerShareAttributableToCommonStockholdersScheduleOfComputationOfBasicAndDilutedNetLossPerShareAttributable
"http://www.sightsciences.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted-average shares used in computing net loss per share attributable to common stockholders-basic", "label": "Weighted Average Number of Shares Outstanding, Basic", "totalLabel": "Weighted Average Number of Shares Outstanding, Basic, Total", "verboseLabel": "Weighted-average shares of common stock outstanding-basic", "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period." } } }, "auth_ref": [ "r177", "r184" ] },
"ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member]", "terseLabel": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested" } } }, "auth_ref": [ "r816" ] } } }, "std_ref": { "r0": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "SubTopic": "230", "Topic": "830", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1" }, "r1": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14" }, "r2": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "SubTopic": "405", "Topic": "942", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477787/942-405-45-2" }, "r3": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r4": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r5": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "9", "Subparagraph": "(c)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-9" }, "r6": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic": "360", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1" }, "r7": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic": "470", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-1" }, "r8": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic": "825", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-1" }, "r9": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "SubTopic": "10", "Topic": "810", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1B" }, "r10": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "SubTopic": "10", "Topic": "505", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2" }, "r11": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r12": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r13": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2A", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2A" }, "r14": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22))", "SubTopic": "10", "Topic": "210", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r15": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(27))", "SubTopic": "10", "Topic": "210", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r16": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "14", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14" }, "r17": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "15", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15" }, "r18": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-4" }, "r19": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-8" }, "r20": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-3" }, "r21": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-4" }, "r22": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-5" }, "r23": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r24": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-4" }, "r25": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-8" }, "r26": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-9" }, "r27": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "280", "SubTopic": "10", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r28": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "280", "SubTopic": "10", "Section": "50", "Paragraph": "25", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25" }, "r29": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "280", "SubTopic": "10", "Section": "50", "Paragraph": "30", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r30": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "360", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1" }, "r31": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "360", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1" }, "r32": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "470", "SubTopic": "10", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-5" }, "r33": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "470", "SubTopic": "50", "Section": "40", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481303/470-50-40-2" }, "r34": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "470", "SubTopic": "50", "Section": "40", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481303/470-50-40-4" }, "r35": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "470", "SubTopic": "50", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481244/470-50-50-1" }, "r36": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "480", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1" }, "r37": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481142/505-10-45-2" }, "r38": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-10" }, "r39": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3" }, "r40": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-4" }, "r41": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-5" }, "r42": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
```

"Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-8" }, "r43": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-1" }, "r44": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r45": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r46": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r47": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "50", "Paragraph": "1A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A" }, "r48": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "825", "SubTopic": "10", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-11" }, "r49": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "855", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2" }, "r50": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "470", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477734/942-470-50-3" }, "r51": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "470", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477734/942-470-50-3" }, "r52": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "470", "Section": "50", "Paragraph": "3", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477734/942-470-50-3" }, "r53": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r54": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r55": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r56": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r57": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(21))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r58": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r59": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r60": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r61": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r62": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r63": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(26))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r64": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(27)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r65": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r66": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(29))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r67": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r68": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r69": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r70": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(31))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r71": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(32))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r72": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r73": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(10))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r74": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r75": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(2)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r76": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r77": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r78": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r79": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(7)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r80": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(7)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r81": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r82": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r83": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13" }, "r84": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24" }, "r85": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25" }, "r86": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r87": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "15", "Subparagraph": "(e)", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15" }, "r88": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "235", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/235/tableOfContent" }, "r89": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 4.E)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480418/310-10-S99-2" }, "r90": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1" }, "r91": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "440", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/440/tableOfContent" }, "r92": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "470", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/470/tableOfContent" }, "r93": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/505/tableOfContent" }, "r94": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-6" }, "r95": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-7" }, "r96": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1" }, "r97": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r98": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Subparagraph": "(e)(1)", "Name": "Accounting Standards Codification", "Paragraph": "2", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r99": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Subparagraph": "(f)(2)", "Name": "Accounting Standards Codification", "Paragraph": "2", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r100": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-23" }, "r101": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "820", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/820/tableOfContent" }, "r102": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r103": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(13))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r104": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(16))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r105": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r106": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r107": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r108": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r109": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r110": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r111": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r112": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r113": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r114": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(aa)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r115": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "840", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481501/840-20-50-2" }, "r116": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Subparagraph": "(a)", "SubTopic": "20", "Topic": "740", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482659/740-20-45-2" }, "r117": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1" }, "r118": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1" }, "r119": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards

Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1" }, "r120": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-11" }, "r121": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-12" }, "r122": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h))", "SubTopic": "10", "Topic": "235", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r123": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/275/tableOfContent" }, "r124": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "a", "Publisher": "SEC" }, "r125": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6" }, "r126": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-1" }, "r127": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7" }, "r128": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, "r129": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-5" }, "r130": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r131": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(13))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r132": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(14))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r133": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r134": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r135": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r136": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r137": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r138": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(27)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r139": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r140": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(29))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r141": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r142": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r143": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r144": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A" }, "r145": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B" }, "r146": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4" }, "r147": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5" }, "r148": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6" }, "r149": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r150": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r151": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-17" }, "r152": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-2" }, "r153": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24" }, "r154": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25" }, "r155": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2" }, "r156": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8" }, "r157": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-1" }, "r158": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r159": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(e)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r160": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r161": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-04(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-3" }, "r162": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23" }, "r163": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24" }, "r164": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5" }, "r165": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1" }, "r166": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1" }, "r167": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11" }, "r168": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11" }, "r169": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3" }, "r170": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4" }, "r171": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6" }, "r172": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7" }, "r173": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7" }, "r174": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-8" }, "r175": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-9" }, "r176": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/260/tableOfContent" }, "r177": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-10" }, "r178": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-16" }, "r179": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-2" }, "r180": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-3" }, "r181": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B" }, "r182": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B" }, "r183": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-7" }, "r184": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r185": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r186": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2" }, "r187": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-3" }, "r188": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-15" }, "r189": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "270", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1" }, "r190": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-1" }, "r191": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-1" }, "r192": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-3" }, "r193": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/280/tableOfContent" }, "r194": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-15" }, "r195": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21" }, "r196": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21" }, "r197": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r198": { "role":

{"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r199": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r200": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r201": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r202": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r203": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r204": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r205": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r206": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r207": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-24" }, "r208": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "25", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25" }, "r209": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "25", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25" }, "r210": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "26", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26" }, "r211": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "26A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26A" }, "r212": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "26B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26B" }, "r213": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "26C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26C" }, "r214": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r215": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r216": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r217": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r218": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31" }, "r219": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r220": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(ee)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r221": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r222": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "34", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-34" }, "r223": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "40", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-40" }, "r224": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41" }, "r225": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41" }, "r226": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41" }, "r227": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "42", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-42" }, "r228": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13" }, "r229": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-4" }, "r230": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481830/320-10-45-1" }, "r231": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r232": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r233": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(aa)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r234": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(aaa)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r235": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r236": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r237": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r238": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3" }, "r239": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3" }, "r240": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3" }, "r241": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3" }, "r242": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3" }, "r243": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r244": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r245": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(aaa)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r246": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r247": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r248": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r249": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r250": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r251": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r252": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r253": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A" }, "r254": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A" }, "r255": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A" }, "r256": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B" }, "r257": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B" }, "r258": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B" }, "r259": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B" }, "r260": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B" }, "r261": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3" }, "r262": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4" }, "r263": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5" }, "r264": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479344/326-20-45-1" }, "r265": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-11" }, "r266": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-13" }, "r267": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-13" }, "r268": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-13" }, "r269": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-13" }, "r270": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-14" }, "r271": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-16" }, "r272": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-5" }, "r273": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-4" }, "r274": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-7" }, "r275": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-9" }, "r276": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "330", "SubTopic": "10", "Name": "Accounting Standards

Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483080/330-10-50-2" }, "r277": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r278": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r279": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r280": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r281": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r282": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r283": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r284": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r285": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r286": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-3" }, "r287": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1" }, "r288": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3" }, "r289": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3" }, "r290": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r291": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r292": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r293": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r294": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r295": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r296": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1" }, "r297": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1" }, "r298": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.P.3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-1" }, "r299": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.P.4.b.1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2" }, "r300": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.P.4.d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2" }, "r301": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4" }, "r302": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4" }, "r303": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-1" }, "r304": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4" }, "r305": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9" }, "r306": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1" }, "r307": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1" }, "r308": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "460", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482425/460-10-50-3" }, "r309": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6" }, "r310": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6" }, "r311": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r312": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r313": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r314": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r315": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r316": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r317": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r318": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r319": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r320": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r321": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r322": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r323": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r324": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r325": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r326": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r327": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r328": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r329": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1C", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C" }, "r330": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1C", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C" }, "r331": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1C", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C" }, "r332": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D" }, "r333": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D" }, "r334": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D" }, "r335": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E" }, "r336": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E" }, "r337": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E" }, "r338": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E" }, "r339": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F" }, "r340": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F" }, "r341": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F" }, "r342": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F" }, "r343": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I" }, "r344": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I" }, "r345": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I" }, "r346": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I" }, "r347": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-4" }, "r348": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-4" }, "r349": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-6" }, "r350": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-6" }, "r351": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r352": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13",

"Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r353": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r354": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r355": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r356": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r357": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14" }, "r358": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14" }, "r359": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14" }, "r360": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "16", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-16" }, "r361": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18" }, "r362": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18" }, "r363": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18" }, "r364": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18" }, "r365": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2" }, "r366": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3" }, "r367": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1" }, "r368": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-4" }, "r369": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5" }, "r370": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r371": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r372": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r373": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(A)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r374": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(B)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r375": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(C)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r376": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r377": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "70", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/715-70/tableOfContent" }, "r378": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "70", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480794/715-70-50-1" }, "r379": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5" }, "r380": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/718/tableOfContent" }, "r381": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "1D", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-1D" }, "r382": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-3" }, "r383": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r384": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r385": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r386": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r387": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r388": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r389": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r390": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r391": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r392": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r393": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r394": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r395": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r396": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r397": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r398": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r399": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r400": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r401": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r402": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r403": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r404": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r405": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r406": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r407": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r408": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r409": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(v)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r410": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r411": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r412": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r413": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r414": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(l)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r415": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.E.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1" }, "r416": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.F)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1" }, "r417": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "720", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483359/720-20-50-1" }, "r418": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "730", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482916/730-10-50-1" }, "r419": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-10" }, "r420": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12" }, "r421": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8" }, "r422": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8" }, "r423": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.7)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1" }, "r424": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r425": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r426": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r427": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r428": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r429": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1",

"Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1" }, "r430": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1" }, "r431": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-19" }, "r432": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25" }, "r433": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25" }, "r434": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A" }, "r435": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A" }, "r436": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3" }, "r437": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3" }, "r438": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r439": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r440": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r441": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r442": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r443": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(i)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r444": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-5" }, "r445": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-6" }, "r446": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r447": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r448": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r449": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "54B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B" }, "r450": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r451": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r452": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r453": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r454": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r455": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r456": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r457": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r458": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E" }, "r459": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3" }, "r460": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3" }, "r461": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r462": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6B" }, "r463": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-10" }, "r464": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28" }, "r465": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-17" }, "r466": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r467": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r468": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r469": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r470": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-1" }, "r471": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-2" }, "r472": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "835", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483013/835-20-50-1" }, "r473": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2" }, "r474": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482900/835-30-50-1" }, "r475": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8" }, "r476": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "12A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479165/842-20-35-12A" }, "r477": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1" }, "r478": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1" }, "r479": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-2" }, "r480": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-5" }, "r481": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3" }, "r482": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r483": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r484": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r485": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6" }, "r486": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A" }, "r487": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A" }, "r488": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(3)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2" }, "r489": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/855/tableOfContent" }, "r490": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2" }, "r491": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2" }, "r492": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r493": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r494": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r495": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r496": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r497": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r498": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r499": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r500": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r501": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r502": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r503": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r504": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r505": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481444/860-30-45-1" }, "r506": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7" }, "r507": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(d)",

"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7" }, "r508": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3" }, "r509": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3" }, "r510": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3" }, "r511": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(4)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3" }, "r512": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r513": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r514": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r515": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r516": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(5)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r517": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(6)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r518": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(7)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r519": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r520": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r521": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r522": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r523": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "910", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482546/910-10-50-6" }, "r524": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "924", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 11.L)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479941/924-10-S99-1" }, "r525": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478934/932-220-50-1" }, "r526": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18" }, "r527": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18" }, "r528": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18" }, "r529": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-19" }, "r530": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r531": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r532": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r533": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r534": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r535": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r536": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r537": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r538": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r539": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r540": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r541": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r542": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r543": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r544": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r545": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r546": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r547": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r548": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-6" }, "r549": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-7" }, "r550": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8" }, "r551": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8" }, "r552": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8" }, "r553": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "280", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478657/932-280-50-1" }, "r554": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478988/932-323-50-1" }, "r555": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r556": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(27))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r557": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-05(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1" }, "r558": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478451/942-360-50-1" }, "r559": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r560": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(12))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r561": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r562": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(21))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r563": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r564": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(23)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r565": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r566": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r567": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(8)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r568": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r569": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r570": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(16))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r571": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r572": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r573": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r574": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r575": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r576": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r577": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r578": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r579": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r580": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r581": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r582": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "

(SX 210.12-16(Column G))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r583": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column H))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r584": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column I))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r585": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column J))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r586": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column K))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r587": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r588": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r589": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r590": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(a)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-9" }, "r591": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r592": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r593": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r594": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r595": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r596": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.W.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479583/944-40-S99-1" }, "r597": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r598": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r599": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r600": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r601": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r602": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-11" }, "r603": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-3" }, "r604": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4" }, "r605": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-2" }, "r606": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "27", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-27" }, "r607": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r608": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r609": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r610": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r611": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r612": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r613": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r614": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r615": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-4" }, "r616": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1" }, "r617": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-2" }, "r618": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r619": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r620": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r621": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r622": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r623": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r624": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r625": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r626": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r627": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(14))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r628": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r629": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(16)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r630": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r631": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r632": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r633": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r634": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r635": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r636": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r637": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r638": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r639": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r640": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r641": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r642": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r643": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r644": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r645": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r646": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2" }, "r647": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2" }, "r648": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3" }, "r649": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-7" }, "r650": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478297/946-220-50-3" }, "r651": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r652": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r653": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(g)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r654": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r655": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r656": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(3))", "Publisher": "FASB", "URI":

"https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r657": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r658": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r659": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r660": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r661": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r662": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r663": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r664": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r665": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r666": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r667": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(1)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r668": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r669": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r670": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r671": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2" }, "r672": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2" }, "r673": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r674": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column C)(Footnote 5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r675": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2" }, "r676": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column C)(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2" }, "r677": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r678": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r679": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r680": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r681": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column F)(Footnote 7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r682": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-1" }, "r683": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2" }, "r684": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2" }, "r685": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2" }, "r686": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2" }, "r687": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-6" }, "r688": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "948", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-29(Column A)(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1" }, "r689": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "954", "SubTopic": "440", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478522/954-440-50-1" }, "r690": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r691": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r692": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r693": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r694": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r695": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r696": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column G))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r697": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column H))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r698": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column I))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r699": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "976", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477332/976-310-50-1" }, "r700": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "978", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479230/978-310-50-1" }, "r701": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "985", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2" }, "r702": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "13H", "Subparagraph": "(b)", "SubTopic": "40", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H" }, "r703": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, "r704": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, "r705": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(m)(1)(ii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r706": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "52", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-52" }, "r707": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r708": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31" }, "r709": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "47", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47" }, "r710": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "47", "Subparagraph": "(bb)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47" }, "r711": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "47", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47" }, "r712": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "47", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47" }, "r713": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "48", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-48" }, "r714": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "49", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-49" }, "r715": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "54", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54" }, "r716": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "54", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54" }, "r717": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "54", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54" }, "r718": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481933/310-10-55-12A" }, "r719": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479081/326-30-55-8" }, "r720": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482548/350-20-55-24" }, "r721": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "460", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "27", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482395/460-10-55-27" }, "r722": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r723": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69B" }, "r724": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69C" }, "r725": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69E" }, "r726": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69F", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69F" }, "r727": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r728": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r729": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r730": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r731": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20",

"Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480482/715-20-55-17" }, "r732": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480547/715-80-55-8" }, "r733": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r734": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r735": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "231", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-231" }, "r736": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "4J", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4J" }, "r737": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "4K", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4K" }, "r738": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "100", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100" }, "r739": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "101", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-101" }, "r740": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "102", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-102" }, "r741": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "103", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-103" }, "r742": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r743": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r744": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r745": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r746": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r747": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r748": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482949/835-30-55-8" }, "r749": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3" }, "r750": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "53", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479589/842-20-55-53" }, "r751": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481372/852-10-55-10" }, "r752": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481395/860-30-55-4" }, "r753": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-17" }, "r754": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-21" }, "r755": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-29" }, "r756": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-3" }, "r757": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-2" }, "r758": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-4" }, "r759": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-5" }, "r760": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-6" }, "r761": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "29F", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-29F" }, "r762": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "9C", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C" }, "r763": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "9C", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C" }, "r764": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1" }, "r765": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r766": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477439/946-210-55-1" }, "r767": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1" }, "r768": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r769": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2" }, "r770": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r771": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r772": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-10" }, "r773": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-11" }, "r774": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-12" }, "r775": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r776": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r777": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r778": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r779": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16", "Subsection": "J", "Paragraph": "a" }, "r780": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1" }, "r781": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i" }, "r782": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "A" }, "r783": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "B" }, "r784": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "C" }, "r785": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "D" }, "r786": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "E" }, "r787": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "ii" }, "r788": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "iii" }, "r789": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "2" }, "r790": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a" }, "r791": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1" }, "r792": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "i" }, "r793": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "ii" }, "r794": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iii" }, "r795": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iv" }, "r796": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "v" }, "r797": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "2" }, "r798": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "3" }, "r799": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "b" }, "r800": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a" }, "r801": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1" }, "r802": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "i" }, "r803": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "ii" }, "r804": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iii" }, "r805": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iv" }, "r806": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "v" }, "r807": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "2" }, "r808": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "3" }, "r809": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "b" }, "r810": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r811": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v" }, "r812": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "1" }, "r813": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "ii" }, "r814": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii" } , "r815": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "B", "Clause": "1", "Subclause": "ii" }, "r816": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "i" }, "r817": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "ii" }, "r818": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "iii" }, "r819": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "iv" }, "r820": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "v" }, "r821": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "vi" }, "r822": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iv" }, "r823": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "vi" }, "r824": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "3" }, "r825": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v",

"Paragraph": "4" }, "r826": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "y", "Paragraph": "5", "Subparagraph": "i" }, "r827": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "y", "Paragraph": "5", "Subparagraph": "ii" }, "r828": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "y", "Paragraph": "5", "Subparagraph": "iii" }, "r829": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "y", "Paragraph": "5", "Subparagraph": "iv" }, "r830": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "y", "Paragraph": "6" }, "r831": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "y", "Paragraph": "6", "Subparagraph": "i" }, "r832": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1" }, "r833": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i" }, "r834": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "A" }, "r835": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "B" }, "r836": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "C" }, "r837": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "D" }, "r838": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "E" }, "r839": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "ii" }, "r840": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "iii" }, "r841": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "2" }, "r842": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "1" }, "r843": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2" }, "r844": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "A" }, "r845": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "C" }, "r846": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "D" }, "r847": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "E" }, "r848": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "F" }, "r849": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a" }, "r850": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "1" }, "r851": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "A" }, "r852": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "B" }, "r853": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "C" }, "r854": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "D" }, "r855": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "b", "Paragraph": "1" }, "r856": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "402", "Number": "229", "Subsection": "y", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1" }, "r857": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "402", "Subsection": "y", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "A", "Number": "229" }, "r858": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "402", "Subsection": "y", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "B", "Clause": "1", "Number": "229" }, "r859": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "B", "Clause": "1", "Subclause": "i", "Number": "229" }, "r860": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r861": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "7A", "Section": "B", "Subsection": "2" }, "r862": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-3" }, "r863": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "a", "Publisher": "SEC" }, "r864": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "b", "Subparagraph": "(1)", "Publisher": "SEC" }, "r865": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "b", "Subparagraph": "(2)", "Publisher": "SEC" }, "r866": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "b", "Subparagraph": "(3)", "Publisher": "SEC" }, "r867": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "c", "Subparagraph": "(2)(ii)", "Publisher": "SEC" }, "r868": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "c", "Subparagraph": "(2)(ii)", "Publisher": "SEC" }, "r869": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "c", "Subparagraph": "(2)(iii)", "Publisher": "SEC" }, "r870": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/210/tableOfContent" }, "r871": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(27)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r872": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r873": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r874": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r875": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6" }, "r876": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r877": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r878": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r879": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(f))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r880": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r881": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-04(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-3" }, "r882": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23" }, "r883": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24" }, "r884": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5" }, "r885": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6" }, "r886": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "55", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-55" }, "r887": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r888": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "270", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1" }, "r889": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-18" }, "r890": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r891": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r892": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(ee)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r893": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r894": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-2" }, "r895": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r896": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r897": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A" }, "r898": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A" }, "r899": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-9" }, "r900": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "321", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3" }, "r901": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "321", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3" }, "r902": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "321", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3" }, "r903": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3" }, "r904": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "340", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.A)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480341/340-10-S99-1" }, "r905": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "405", "SubTopic": "30", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/405-30/tableOfContent" }, "r906": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r907": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r908": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r909": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "410", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481931/410-30-50-10" }, "r910": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482047/420-10-45-3" }, "r911": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/450/tableOfContent" }, "r912": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-1" }, "r913": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4" }, "r914": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20",

{"Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9" }, "r915": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483049/450-30-50-1" }, "r916": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6" }, "r917": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6" }, "r918": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r919": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r920": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r921": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D" }, "r922": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2" }, "r923": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5" }, "r924": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r925": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r926": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r927": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r928": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r929": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r930": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r931": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r932": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r933": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r934": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r935": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r936": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r937": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r938": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r939": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r940": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r941": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r942": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r943": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r944": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r945": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r946": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r947": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r948": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r949": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(v)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r950": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "6A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480682/815-20-25-6A" }, "r951": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r952": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "54B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B" }, "r953": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r954": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r955": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r956": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r957": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r958": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E" }, "r959": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r960": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28" }, "r961": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-1A" }, "r962": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2" }, "r963": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-3" }, "r964": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482900/835-30-50-1" }, "r965": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-4" }, "r966": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3" }, "r967": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3" }, "r968": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r969": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7" }, "r970": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7" }, "r971": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r972": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r973": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r974": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r975": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r976": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r977": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "912", "SubTopic": "730", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479532/912-730-25-1" }, "r978": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "942", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477268/942-320-50-2" }, "r979": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(16)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r980": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r981": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479432/944-30-50-2B" }, "r982": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3" }, "r983": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B" }, "r984": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B" }, "r985": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4C" }, "r986": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4D", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4D" }, "r987": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4G" }, "r988": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r989": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" },

"r990": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r991": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r992": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r993": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r994": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r995": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r996": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r997": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(5)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r998": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(6)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r999": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1000": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r1001": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r1002": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r1003": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r1004": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r1005": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r1006": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B" }, "r1007": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B" }, "r1008": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B" }, "r1009": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2" }, "r1010": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2" }, "r1011": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4" }, "r1012": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r1013": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" } } }

ZIP 66 0000950170-24-123403-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0000950170-24-123403-xbrl.zip M4$L#!!0 (Z#9UD[K'%E"-H! /ZS&P 1 ;3/Y%5$HC-8)!0 77/3!N52KE%Q"^6C(S\Z?]^/1P5GV/=E-7XYW\C MF_C?
BCCV52C'GW[^M^W!G;V!?_U_S33_\'H>+EJ[TWQ9OXI=CVD_)S2%DV M?E0UTSH6/^S__F.Q-QZ5XUC\IU_?ORY>5GYZ&,>3 A4'D\G1UO/G7[Y\V0RI M'#?5:#J'!OH-7QT^+Q".,Y31YN?
%R_M)!9;%%.."$%8?2!DB[MHC8%5?K_MPW@+XX6?54?'=?GI8%+\X'\LJ^@[$XCD;QN'A5CNW8EW94[,]IW8!A^LUB M>S0JWN>?.<7[!V,3ZDY,<8_YK?>=.]
MM/75U:.0GKR;/[9O4HSE\^[+,Z],+GU5=*!.%E\MSPQ@\6WV'-9Q E.+_=A MY? \ONOY;V>;D]>_7GC_S/SRM_.7RZ]7M4OR,#+\),\7GKX^K\1N@?%WZRW\6 M)O7SR?%1? XOHG'WYLFHFO*R.
<$,R// OWUOC^(AQ;=GWHS.:K/KFD3_>:G MZO/S_,WSS!+S5Z<-^F3MTSZI(,A)57W8\GU>4(&P7F@G^H":J;M\=?PO9D6RZ;BE*AOL6OWQL+$KIS4F98C< B]3& H M?
AZ_3N*X*=THMM@R4KN.#.*:>($0EP_J6U3(U*2(R)-%!90X2\H6 WP),!D[M%,M#QH:A9[\4 '30;0! BU^FI234?R%8/2WGYYW?^>GAW%B6TQ$\1_3\O// MSW:J.4QD@CX .STK?/?IYV<3F-
_S%FB>YU.?SYK]R57AN&@FQZ/X\[#6W\] MQUN%G4ZJ_U.>'E4U2,;DQ9$ &;ZW"GWT]46>*#](>RB!/*]^B@H-U$1@[SA!'&A!#)&
M*A2)BT1K13P#0H[M8>XEEEO,H!!"5@]O1O;3,*92)^]C@C7X* 4G/#],?*(8 M<9D" >*=`3Z^1D0=BN57V- R8X UGYI_ GI^9EA7CYJHX5U MPF/D*.&(.\^14=XC%QAU5G/-Y)E1[XZ!=L<[.,S:CO;&
(7[!CWA\]!' @@'(M!"-$J1N-_$8I"(P&114<@H%9&+.ER!G-@R'24^D71[HSK>N\N]"6[>A_HJUW-MQR$KT]L-%B%" 8MN-%*EA&?2:92\ D[P&!JSDJ .Q:1$HEU6!SIW#KHAOH. M6JK"*WC6W&ZH?
V-7C/)5:7UK4W3#3%@38C1%5')PR0!.4\%C!7(PID2.IXL MZ$PC:.U4AX?E) ^VV1Z'+*L@62#Y9;PP6*I<<$(EE)P">E&ND=8).(N0*+30 M'OI^5DS'9?>#/S[^L?\20*8IM\;E"
2^GD:0!$A:.\JS|%T[].=G$:..*=8M M20[R4S8IMI6@T,316MB;&7!^?.S!!KE-5Y^^R@SCUDT$5S6-W\VH1Y\XMM MMA^:,EJWGUJ3:6LVKW;9=CYJ8IB(6B(;:4 \P.2?RI_I5+613OL>*DZW\G[C[-
R??[!\^:.^"E3HOL8H+.O1Z/2EY/?XZ&# M+D)YF)49F."GY+/-0:8;_+.;-84=M93\6C;/?IF_\\?^!S";P00_WH]^6I<3 MH&W7XD_/+^WHE_D(3\;S_++)'!4B>;(4K<4U^:6UR;%!#)_,<_:_/\=\/
M$,.*VC!-G;$>4<=5EFV"+-_*.:[$2C5A+E5T^8&DX<)UL.HWGZ#&%P2.9)XHAZ6!).%#6<]E6$]Z='1Z/C4QP^*[SGOUVIX_*S M['@GB@CJE#(>$0X;@VN7D+%@ 8)Z(E0$%W5<.46^5W !M]0-!?
<?5=7_7\;L1\ GHH:R#CG(;?SW_MGLI95GX-2B@>5*,P=WA45Y\C:W2LE)_9$OE9.H,9#LAK!T:"\>O5<9[!45B M\#91*_I*!?T)\&;^32;/()(}$?AQ%^R$]^!'T@A\8=FT!)B/PX=@(GB;F /P)
M%S(;NPEI3#0BT?"(G2!:I;Z2)@O.&S#(.TID@W:KPY?]PT$U;>PX?/@"K1V_M'<=#.,'ZKXQCW)Y7 \QW8L@<@2OFWU]#HVG$Tl63KO06+?S8 ^/B[_5H>3@^7 M3_WS1M)-
L98M$6M##N$,ON$ MX#+:,NR-=^Q1.;&C!V,W)(9!8BWRS$2PY#CX\90!(X8N/(B.H][2Z$5"_# M%;DD)'-&(RZR(4@C11^;25WZ20PM"1^* MGC144@6^$1*1@6CYX,"$<1$)@OEQW
.>7SVY/W5-&4!;^ ;47R;VH4_2Y6] M=V\?#"68X!SC)C X*MKZY"F&E#14E*.]+TS=*7&8IE,.6 J/!3[YS<.Z M2_0.#;=&D"!1))8A6N/G 5!.#"14@N'.2%!8Y7^2$GI!G'/6P)L%B,HB&O*
MR!./>B[E?2/&#,)@RQ" V0CV3%)IU$??<(F!02.%!0Y:=%IFFX JY (\!0G$ M6*ZB]]IW2/L #'X_+DT"BF/O37(J0#"HT$_M$4BHDPI4AP3,>^4NAE=),] MF'L]/0W$+_UY5OTVW.PMU.U4S _@&?
@@04O-5+@%"/NG$1.@[^L"!?<8B $[ZT(=0KGE?7E'(;U#HUT!Q$B M2]H*.XX'9Y+(T],R!BID*9@4S@9.A7?1P_7FV)Q1JCHS3&1+B\\Z$;)>RLFW!K\&;3E_+&1+}TfY!EQ6B71C,
[VU*88MUK^KXCVD<^^,K1K+P:O,^IR#6Y?C3 M0_&%+3,T9$644MZ0-%XCS2F8A$X&'85E2O4WM:P'V]@'+!45$4P^<(*|%V 4 M]%E'AEG/"@RL Q9(%ZK
MWB;)W20BM3^M/Y7>CGX=V.FO#NWCE$_8H#_1S@ #_$@%=*!).0.&"6!(E# M;TW(IYRH=?:L]B6RBHC8&P<8'4'*?7(2[^0=4E%#!UQ0QIEX"!JU1YO62]P2!6=<"^\52MEGY59&Y!BX
M'.*HI(54TO/^;UJO&_S68Z4^=K\>0/WL36W#N**2$.B^5]MME\Y M :.$4#IHO 2GH"O7O3TH^FW[=7O!A%UYM4YY^-.2"DB2%M*R 6:_FS6TC M8"1:1BF"U?=PZ/&V%%GR5MV-
^WU=C3]:8GV8DU=.C9J.(VH[AK4 QGA=V?'* M]259DBGC)/7+1TK$(\\ANA#!3\ ,425))!1[27E?N:!G.0 K.2/@M,Y+"V8H M_#>>?#*!(,QP1*%*K/2P\#KUU&7IY G^)?H(S'ALI#<(\9U#ZK/Z( ]l(&R/'
M23K\L"V:>TTH6H?5XA68+=&@('#*&Q@<.0\2Y],4C' 2-=; JX_G64UF^G. M6V&34"A@ H!G$T'&*0.&98!!:49MZ.VAJ%XEO2Z3)DGI!)E#*64K ON<=@*X MYZG3T3FBJ5_Y#OFMK?
OOB5N]FM:C$FG=62BK$1O(/HCZ9UZ M>?)GV=:S,^ Y.99RB4(P67@C0XX)X!R3:!+82A-ZQRI/8S3@^U<+Q./,M=1 M /E':\E6"D 2:/:^]#.X>G?:6Y@:P@RFDXTVR
H,UI4BN<4231AHGA:PW@@HL.<.] M :YZ+4,]* _H+=9&^(@BRT52-<"VTQ*LYTS:8(C7JZ?MVC94O9=@1P/F.: \1>6A; *!']_8EP3 -=F.B5O'B$$T4+ =.=/(&(JD[Q1P6DO M:.^.Q?4T#+D> @:";1
XGRGV OQ$^.LI(T$0K3",!)OZNTFS#2V$,E\,\3F> M1O!WO_K1-,3PJJX.LUA.)RU9WZ9YOLF[6.\?V!I4TN4-G&6 ,[[@VZ/110DMH:28/K'1@_L3)Y@6%/("^\0=XDBK6DN
MA$^4#X)P'WOKV5UQ@/*.;47R;VH4_2Y6] M=V\?#"68X!SC)C X*MKZY"F&E#14E*.]+TS=*7&8IE,.6 J/!3[YS<.Z M2_0.#;=&D"!1))8A6N/G 5!.#"14@N'.2%!8Y7^2$GI!G'/6P)L%B,HB&O*
M2AC$[=('80WFNU>!8\]#ZI^O=^N8\@-5$2((P646(K#D.,D5UY/3B&+B2(R8 MTM@[?Y(L*^TL*$&"R==K./!1N4T261 !GY0*X3!IQK M_$:.J*5Y5RHQI $X$$TZ)A)R*97>A:+6546E!SDJX/WAG*
<"8L0"XDQ2Y#BV MR "=@G84[,W> ?X%@=H9V:8Y4Y]TI=Y"9&:[LRU'UHWBJZI^-/E35]'F9/?1Q^+T:A0>3 M'A' B(V"&Y1,SBL2S"-K0*QRH4/03.!;V_Z?'.F?8EJB#$7,>"2YY'SR@'3<
MY0,B($BPI&!2T'R96V /$ PHCIEO2LVI]" Z+ ,.N;=5*V>QDR-6<';+$>[U*+?>&<9$;ZN+!)ZDZ_%N(HG"\0M,H1#T*#E(*FHUQ$ M$H3D)CWTPY'W6()6=MXD>F0@G2(R%S#B
]+M,AN%]=.4.^ 8+V+'/?P_42 M[8VH!=!8!F0HT_D^%,-*4&>4;YT(\VD0G> M7]/ER59D64^()H)ZE4YQT!SM_:(@ZXY(@HRWVG.?]#>>]994>5F!;$TS[?%XO
MGP5S/H*^]@3E6NXHPT'.97MN>GM>^KHX6ZN5FXLAMKG,_S$.L=[=?_?NP80* M@N!!Y3+&8-%B+4@-!;N =+K 7OH[.*FKVFF<9L'+^=3O*:A0>4 MS1R#5,P8B23-Y.(L@1F<&)
(A.:,PYI* .A*Y!08"C(8%CB"JC=\V\V.AQ!W78>,$D=ES.GY M*8!]*I]MJU+.0V26@MTJG.CM[DAO%.G9F]26%7Q-S&#+1 *"A/8R5X:,22#. M6$@AO Q"/W0;YY"XLND"D]$!PLF"L&YD
3!R$G,$!414!#\.Z9[EXGTY$]? MKTE=^@.8FF]QLPK4)4L!62<=\M3K]'W@/4R)ZN6M..O9DDR2)"X"048]E8N" M.N1$LBB79Q)*R:C[>X=%#^[17N*F5PI.R10X"BYK0IRKTBO/X3^.XJ"CXOU-
M@[HN+G.91-U70&:.9)(J:R'Q_GJ+YPA>EP5CQ7 '%J+2!13H]"OT1$DFFIM&?8L=[2],>Y:DLT+C&VBD0*)K\V#(N MQTXXC\A8)0EXU\SPWH,#^NF-+0W@,)="\[@I[?)]* ,$2&H#QIR.%!RUZ%+/
MCE\LDR^]<49&AV0@#BQ9"RQI2$ $6Z-9E"2DWBK@M1Y/7$]4'6PBJ?+=/3'7 MU,.F"i3+Z2%L.:1*.2%%;\GUG8?N>C!H$H%&+E\S +8KXOF !$6 M"&:MQ]"D24R!!$?JGG
:R#F&.E@GI$G">M!UU>(#%8&@'RR2SV.G^5ESOC4W0 M@V@0H1(3D&[D L[U@.!`TB[O7(]+8\DI96Z(!MUK$@&&125$]# -C84B.>$D;6 M48=L$ PP.U:\ -41>QA66"=)=
(@FJFR_Y%K0Y*>#"F@8",GT6.IR;"%_)"T M&?!*@"+^Q4JM88>=!*ZM8 Q%D2NW.JY!]X<<*+7,"Y.X$"O? M,/P^_*;+\W,H3B01:<'R>GN5@IDJ",H:I0ZJ4=@[/*JKSP^K9BSEQE@)
MKF!R=';XU4F%$0Y<.4&(.:RW5.I]$M9Z7$,J7'!")2"I F5*LXK0R2-'"@- MH3TQ?5"F*^)GZW-@72/(LGNDI!N8M\MGNR)3C*=-O3W1V',3?ST&# 76)8 H M1 4-N9:8058Y
XZ;DODYIJ*W/EO\M:6:8DERT428*&W]=^% O>.!(PL(X8* M.,5 =0Q4Z:7/19/3-"(B.G[!YBWFP8:D#(RXQUF.?3W-'Y_MW66J.N8$ Z# M@Y.W1BWB*8BLR#&BT6&<.%4T]D[(UEEI=PW:B0F?C
+T<\GF6H]$ 0]DA.5-MK!8V@5?>VX3VU^4XQDU77M'W>QEV[.&K]OP?,>9O8\XHK>+%$L@K8(P#7%U1]&#,.16@\"9)UAIA]Z MH.3^]T+7X%)P:H7&PB#*+4=<6 =^>7
YM\]PQI4%WZ*O=.QQE=XE@C)7G#'% M!?CEN6I>U$ A0@S2#/R$H#5,]?\0V8*A=*:VLCW>/'V=A4*Z\CSHD)(P&<]3' M?-IQB)F7$2M)"5>XM^F/5U[^2'6AZ^KAU-[DAL5&:,24 M(ZPQ]
<3;)&3OHEM]"B&?/9NQ-&SS#+R 7#/'^O9R$+ U)9 F.,>U(BGHU%N] M7!G*^BW6?CJ*3??"R<6NRSJN?DT@[77,J1LKUVYD27(I,)C28XC M;6A 2BGA6;)&/8 :'OTI%+B>' "!/7.$>]1HR*66ZOG
M>@>N2U-Y@@A#J09O7H)!SZ. %\WF"YJ3H$!&O2TMU1Y6/?)UF!:"DYL4#&G M)\1<<IY$H*L*2 1]$*]2Z*WAI#Z=AZZ#PBJ I%,)60T\X@SHY'A"@16AN0I MPS+TMU!'E9"?
AR75=T6.X]A(1CW!I3E),;O#7V(95E&[;%)NHX@-"2"!!K MI$P,B*>YO_UCR9+,GNBB#9QCZ0P.2UE7=GQX=C;+]>5A.3FV7JI[Y!L.2+WH0(AF?(M:], M A0:%#*EO$>>&\ZZT?
T2.T7**=)WF05#]*/*.@OS1FR+]\A"P9@9'ZGQO M,R76?=:.^!QNJ$CQS'AU'/E&,N$P.:4O!!L'6RL!X(JLOG/E H$>**"F3*$;C M\ED+@!Z+(FY?F(NZIL"Z4((2G!#!5$^RMZIEOM,\5^-0E?8 M*L-
R45&>\I5WA.3<#8>.)5Y*G93DO1.,7BKT]:@I17VREG$@6L Y."N0BP1. MUYRY*+%7I/_Y-SU54VO 0"6$H_DB;1UC-]\Y^*O1.20H"89QB4-X>)'V>\S) M628PRGR''
MYYLC=+X@S8"Y.:W1B";I0<(==]RW50-[DR.^FA/U*F$AJ:7(T5RX0KM\BR^C M*!JO S8F?[6INMAVM5Z/&Z5!(TZ1!2T^X@[KY")22 >B$>0&9X3RS3 MU>2WJ[0XPPYPCO/0G@.
SX;\0R))8D%:.F1O0UO/+;_U#*][FXM;UW03:)T=2 MKG.'< 69()%4@/E2>2-2HISBWNZE]=[^64L883HN.\+^\?$(YGA"N,-NSK_,MVH_YPW.OYE_SBU@H6!U?>'W^>'+.*X.R_%ES=YT2F>.>'YV!
-^>^7O_EV8_+KUNP M=!#+#W'WW5'5M*H9>ABU:0XO7/45-?_0A-.KJJA&P1/7<#@C^8!))"0 $K< M(OAH\N+0@I4VIOIT7Z7[&$Y.M[Z /C2%& BE^()&& C^8NNFDRJ0W@WBQFR
MH_+3>&L4TR3WT1S9\;R;+P?E)"\)XXN/641W1E]H>O3C7]S>[@[Z^E&%RL)7* M"6K%>IP[^===_)A*_^.EYI@N6\&AA&1_M%/LXN97.;<:R>3)TDXJC21&JJ1O%
M%XMB<=+UVA=!/O0">^@WUN=GYZM156_],V[_]^+JN7I[(.=5H["X\+>=_1]O M]CILOBSV/VQ_V-U_JHNPOfOSQ_N]#WN[^\7VFY?%[G_O_+.]YM?=8N?M[_O
M]>_OO7WST%>&WG)E_FM[_[>[!]^>/MFHWBY4U LN+EJ+69SRJ*[O?%?3F!B M-LEO(\6U SRS8 !&+TXT:K>$FOF@FFI4AOF[=:L2>237KNXUT,+N&5KD=RU& M?^7]U=OWOQ?
SZ2^.YSO:AIF E3:NQJVI7/K6^GSUT?F8@A,681Y"GM?EW609 MD?82.QLX&'7N63%S0-[=._I&)LLZ\88KGULO+MOE+>[NW'@A*_G;"3F>6 MY9=!*E#N/,/Y;@DDN>';.^,O#R>X+S"5_
MBT:VN)I.H.6O.:SH6B<8.P(U9S_PV6T^:N)6$X\L>+81>H3&H?5ZWO3GLBE= M&\7:FK\]>PG>"B?$:QOG?UETHF:3Z+RHYU?\Q.CK?O/3\TE]?E S3ZZE^:64 M^
+S0ZZ.]L^M]K\H/[ADW'Y;@:4.5H: 9_@YUI.R?>\> M/"\%#IO8]%^]L2 MV^\ [+Y _3^%^]UW:]] *.[\7[_C^TW'XH/,PPMJ?3^ X5P05KQ]7Q#O0_BQ
M>/N]^/#;,K%@;I^8VML[' +7Q#!^V8K/11;^S3CT4 VIVP8A7E5U,3F(O3_F M,E-TD=8BQ_[#=2;6=.;U>86(%;7W())99PSF_@21-DG4V(1,P8M4D&998%!N_: MZ>QVX>0S4+ 5X DZA%X.\L]0L,?
H.:H;O7$_:+,?CR;=)@###&RLBA>6!)<\U M4MJ+?*>$1UIHCF!%B>22XWRYW9)(\:IL +K^!Y;X%3QI^K'(>>OA.H"^F3W\ M^,'B[?
O!L'N0AMT=&/!ZTXYK*.4#N$D\FWT5"GCDT74$T63#;= _9AWDQ.YF=MWJ.X.BX\G_RLF MU<*GCQ^?K]K8X$W.>B>%6"=@.1!A-L:T7V%O!(.0,@C0]YX MYX.5FOAP5_#<:=.U\F2ZN?
1CG3$FH"R$5D/8<4UAQR5O))UV1/GMA $3&$!G M.\L27.0R"!++I$&.O\A#)"P:OQQA>!_M34CQI\LF"I G'MY*]T]_9^ >U# ML;^SM_MF9W=_H]AfLL[Y
!>D7YN&M\6,'W;_6C\]LLV*A6G5"QL4^P?!9\S MZT)1CHMRTA0[!VU,XWPT>AU(@@<<64XNOK56QO?,[8S[NL@=-=GJ7BS/GSU# MX;;M.WFX G^_BWQ],Y,HXEXD\?E!G?-
U.N982RC[K(1=%;_T)#I/D2!.(\Z2 M1\8*BK3"+F!AH^)+TDNY!E(-GFU;^:A-W-^IIN-)?;Q3A7C1V6WR&_ENXMS. M4L*65\G/RSBR7VS.G[V5O_NPZ,VQ-E1]CA@3^1+.,#.]'5(Z84L#H9S8Y=#[
M@_VZ-\L([ZI=+9.*^$%^.@5 M,.EU\?=I73:A]*V?7J5%2BQYGILJ^S;W.MER$=K,.=>?[+C\W_;SCRL'D ?$ M%7N:[S?W-XO9@>;ZU\<__^4L2A1OJLU+E^P)*?%K6/AR9$_.*Z>Y S.X19K
M!;*>*X0CQS)1\#+]G7<>_V3?#J&.33/[)Y^T(BOD&8XY+G:LX9&+HU&O_?DZ M/:V]<9S=IKR%05[VS]9X]EP$GJL<(:>;D&E&2(TMP0+G^.,Z/_OSQJ7<'5T<]9J3.7@&ZS=*IR1/<S#
(U>5]VFE9]$0Y*G_^08REJO3>V1B'([CR.+= MD\!SV?C1N\S5?=KLIE(B0OBUF88W\S+R2&#IS?M)N9^.]J@:PM[VZTH7WX M8&=:.WX[#_%%JTV:+G)H,")T*?Y!KM(*'SX0\,:+
I*C;9+AAHW.I&YWMJ'(Q MAO%D2VPRQO[RC=6Y@QS>)ZC-G\C6G]0>-!@S>\'\ MV"N7J[GQX/L[4LUJ7+\QV5;NZ^ ^?1V],391K8N8/9S[[QX?P_0^WC=<, MG/YH.7V>S-B"8?S;6?
<%&%_0+#PYM="-_.Aj5JRF\OF4>XW#?^2H3_&*4(-G M24F#"7(TXIQG;I!S)"+B W6&4)DLNVNH869"O/J6I7V_4SRK3,(P %M*?-.M
NRWXG,NX5C\"UAXF.0C'$5;J6^I.RV7$!,\#OSH+Z=B'KEGSB%/3#X1D0S2 M#&NDO.Y7NF,K_)V3"V?:M% "RV/3_5]_^S"PX, G0445BXE:%)24B">6K\0F M JG$+2?84Q_OS()SL.R=::CVW.6%A-
:L_VZ;RWJE*7D0BS>V"?8?Q:^CRME1 ML1]'T4^*7*XF3FZQU7E_APGO"_Z;2V?O7'(N6:Q<,>%/XC^S^(P%_?Y8_C$M19AFBL7MZ_"A'UL]ZL(+=I*#DWQ [0';%4T M4["]>FH,]'P&9'WJ<'-
C)^:%_L6=!F8?8_7@VAQ\WVFCL#[2;HP/FA._=WS,+ MP^OMVL?"_C/(I9.V-Y780[2!SA-;@(MCC9K-HH>*;NRNWK%LF@Y?"^8BP-R#$ MT7EDG18H&6ZME!'E&\>6DI"P,ZUXF&%W
CNKE8F=W+J?HN(B@18^+O:S4 MK&]3'E[.B>W.YJY#E=.V%H/8[Z?P)EC^LY-BTU&7.KN//A0_9#VN7E!&-V<-AHQ(X@2RH!Y M>>>?R#//#*R>TRJ2.P<2 "P.N?"4!CH*[S@GTJ/M75E\G!_.M-
,$1B.[(0 M4SENBR>TV5@Y?X;B%U>-K_V:O)B_=NT+5X]O_F*V/F8O7S'6^9OEN$,]0AVB M.:^5-7'ET3[VY=:SEY89^']SF4-XQX*-CUW* M!KBYHG,[$U^.@2_F>]Y7A6N&!5H7IZQ?HWJ?DC-
1(*9Q1)P&C:Q4 840,.C& M*#O;TMY;RW!SV[B77OUX>1=9/"B3;)62M(+TDF'^P_R'^3^0^=\!=7@]W4[.NM7G?+#F@SH,W]HDWE_SRH1H_%&+V%&N&J3@*9-MX?.OY30-71;C&'85?;S/I=-
&SP:V[$O[2AOS8?UO6VKIZQ9B+](H?D6AK#NO*6?*3@_'+T+9'{WL\5;^]GSE*KPI-MRFYDL[V%[L'?I\VD3,?S#MN?(G# 7AQ5G:NR5<=\&N1S7,P,/1&+K^N(_]T;
M>7YZ#]L_^V\FU<')_LQLQ.5X!/H= 4+5LWSFLU_ 0G:/6\IV.S4V <=MV=$7 M>]S,TFH7B7PV))=)M$#V!?+E& Q HZ,%ZGR9:G@?VFS]5HVVCYJ>:X-KR^(I MA:,*>/,6Q;_Q)<7?
WHTL6Y9"8/ND32 M.S T;G/;38_D.49;CD]9V->])VN+@SK'1/X?5?476X>/HZKZ$P,SL;UCKZWH M< 6'"\D\N9REVGY"]+ .;KI: $V.=C>BKTPOS):9V5+RI)C&?6H>1Y(VF5]V@
MT.MN4.7^R:!.5MZN"FIQAB:K+=)SAU@JJGYPD9\MQMU\&O8^5/2KO3?;,W:V-MME\7>V]>O7W_^_:'O;=O!C5\#2"(00T_;]4TK$$_9'!0PSU3PUB&.FQ@^GNK?
^_60=^8CR#L%;1"L/=S[ZB0_<_"-EZ^4>QI56T$4_6DI MM/N&#V='(*7Q8W,0XU65 >\#+?[:C:/8S^-HBA_^&-MI@ [#CP-F#)@Q8$:.?
M../4O/A8I8_54>R$O_EHQ^%C3A+ .*[;=9H>IP9'SEIX>$+ MG!C3MFNXP\'M+!)>P?0TC'=#F.QA.#F@SH,W]HDWE_SRH1H_%&+V%&N&J3@*9-MX?.OY30-71;C&'85?;S/I=-
&SP:V[$O[2AOS8?UO6VKIZQ9B+](H?D6AK#NO*6?*3@_'+T+9'{WL\5;^]GSE*KPI-MRFYDL[V%[L'?I\VD3,?S#MN?(G# 7AQ5G:NR5<=\&N1S7,P,/1&+K^N(_]T;
M>7YZ#]L_^V\FU<')_LQLQ.5X!/H= 4+5LWSFLU_ 0G:/6\IV.S4V <=MV=$7 M>]S,TFH7B7PV))=)M$#V!?+E& Q HZ,%ZGR9:G@?VFS]5HVVCYJ>:X-KR^(I MA:,*>/,6Q;_Q)<7?
WHTL6Y9"8/ND32 M.S T;G/;38_D.49;CD]9V->])VN+@SK'1/X?5?476X>/HZKZ$P,SL;UCKZWH M< 6'"\D\N9REVGY"]+ .;KI: $V.=C>BKTPOS):9V5+RI)C&?6H>1Y(VF5]V@
MT.MN4.7^R:!.5MZN"FIQAB:K+=)SAU@JJGYPD9\MQMU\&O8^5/2KO3?;,W:V-MME\7>V]>O7W_^_:'O;=O!C5\#2"(00T_;]4TK$$_9'!0PSU3PUB&.FQ@^GNK?
^_60=^8CR#L%;1"L/=S[ZB0_<_"-EZ^4>QI56T$4_6DI MM/N&#V='(*7Q8W,0XU65 >\#+?[:C:/8S^-HBA_^&-MI@ [#CP-F#)@Q8$:.?
M../4O/A8I8_54>R$O_EHQ^%C3A+ .*[;=9H>IP9'SEIX>$+ MG!C3MFNXP\'M+!)>P?0TC'=#F.QA.#F@SH,W]HDWE_SRH1H_%&+V%&N&J3@*9-MX?.OY30-71;C&'85?;S/I=-
&SP;V[$O[2AOS8?UO6VKIZQ9B+](H?D6AK#NO*6?*3@_'+T+9'{WL\5;^]GSE*KPI-MRFYDL[V%[L'?I\VD3,?S#MN?(G# 7AQ5G:NR5<=\&N1S7,P,/1&+K^N(_]T;
M>7YZ#]L_^V\FU<')_LQLQ.5X!/H= 4+5LWSFLU_ 0G:/6\IV.S4V <=MV=$7 M>]S,TFH7B7PV))=)M$#V!?+E& Q HZ,%ZGR9:G@?VFS]5HVVCYJ>:X-KR^(I MA:,*>/,6Q;_Q)<7?
WHTL6Y9"8/ND32 M.S T;G/;38_D.49;CD]9V->])VN+@SK'1/X?5?476X>/HZKZ$P,SL;UCKZWH M< 6'"\D\N9REVGY"]+ .;KI: $V.=C>BKTPOS):9V5+RI)C&?6H>1Y(VF5]V@
MT.MN4.7^R:!.5MZN"FIQAB:K+=)SAU@JJGYPD9\MQMU\&O8^5/2KO3?;,W:V-MME\7>V]>O7W_^_:'O;=O!C5\#2"(00T_;]4TK$$_9'!0PSU3PUB&.FQ@^GNK?
^_60=^8CR#L%;1"L/=S[ZB0_<_"-EZ^4>QI56T$4_6DI MM/N&#V='(*7Q8W,0XU65 >\#+?[:C:/8S^-HBA_^&-MI@ [#CP-F#)@Q8$:.?
M../4O/A8I8_54>R$O_EHQ

!",.1E]DS]?N?QB,=V/N+(UI./9?FQRF7V[ON,Q-L/O^V^:\Y' M?(\BYH,B?MA*:%B#?@CAH(A[!HB?U &)UA4F'T?QDQUU/G!{>_R],,&O= M]]MU.FC=I6G=0?27+_K,CU+V[<>Z;/[\F*R?
5/6]R'V.=A>ONOX&D1]$OK\B M_TBWVZ?CKN1UK&/XV-A1;(\]O#8S]SX X(^%_HO]W'_>,9]E!N']'ZW+21F[MX/@?717OF94PX,6U>-'OE+_^'<>PJ7[MIG[/R>:\EH_3HVK\L8GCLJKAG[F<
MW@=DO)P H?CC*!P !4#+ RPT%]86,,F>0^6Y/S^.? F60^YZ,:MF@($!!OH+ ^(QPH!8TXY=>QO7WFFG@^@/HM]?T9>/ M4?3EQ_CUH'3E_1SLV9WU-0CZ-0S'AP,ZCVB+^MX+"L!3.
[DO.W[_I+:]K*\3 M:.) +Y1^%=U90[^T5=:[Y)K<>W/]UMIG2XC^O!X<3]WD?67!?ZW==P?$\F M\!+6:/ =[L]>]EVN'5WR@%X7;]Y^V"W>[_ZZ_?[EWIM?BU=OW_\7_(E>OWW! S37;&JSG
M,"!U8%M/Y46K&E%NMRENR(%M=V.:,.$LTMG&HVMLD8^\NZ],JL!X4XY)\O'L% M1B=N_ MVOX4&"1KHE!'=@JOVY/\VV$!G%D'W'IP_;A>UL?%[G$\^?VI/W?6WUZ*+.!!
M$AZ5)'2,&HN8J>^P/+)M0@-[!'90$Y*U=UQYECZ.*P*[X"+=,>&SCN-M&OR2%70)CK+O3,,ZYO /L-G1M 4X4.ZCRK>V.,;@U8.,6(68+ FSFSH &~2^U0X8RI^5@*V-W M;YDDV [P/.M9@SM+;%0+KG$
LF^>_PRB&LZ3&8O))M6X[!|&0S[$8 S!]F MAL{O>[_NSQV)XK222?8LLZ3,C?2-RVWX+ ^76OW=5WGFG?V9+1BP9#HO\436 M6O, /[!@0\\\(T#UV!],@U_0G6U4,W=G8[OICD\-
'>M"%DBSMO:,U_@>Y M@/ BVI9<=SZ?]/R'],2F/AX US HQO+FP?%6O Z8P;T,71AA!Q$SVR=_>9. M# ;V' CS.ZR. MZ?@UQ5RUESHP,,Y5 K8HZ95>;3.7K.OCJQ=?VTKK/M.]BZ M
O=^C^4OUZZS6%OI >|:(K2>U Q"%]7W61>OCIG;<@RSBWO]"?SHXTS]C]KJ MR+X"#FOLYWP:&]X"O&O-E(%#!PZ]4Z>B1^.RO;FLM8;R^5@*X1<5 M-L O:?#0F#[G-
ZI5E"=8-%UB'BR=W'BU\PA^X..\;[;(D@M. L*.V\!G Y]]A}:. M6[,MIGV]JR]G>885%]0YCW>Z9E;F\+:#I.?AM?Y&= MI9.7!Q8=6/3F#OC)=M*9/:^\Y3T: >9-<\),G?4SO]_3&8I&^?WOC*VL]5
M&3*+E8=M]"F#*W!KRV #4PY,>353GN0WS$+@7?#[ZV1V9^JGO '0>>1U_#0= MM0;EP%$#1]T8YF;(U8+W M8C_E3,')&1 \W?RIIA.?4Z[F .8N%;@8G>8#GNY:>6@O8_+LW9Q"E,=6BX'-
M!_Z_*?\?E/4*MGRTI_Q:..?!.M5X'$<#D@Z<[+T94B?;23GP/<\Y!=V=L6[P M0\:&NF;SY7.5C;B6IV8;,)/:MMKN]"!B5X$'?6Y>W5%_L^!J0:F^C9*=1DU MY\VGEKF@E2),,S@5, ,_4'S)^R>C43XU
4.%9LG4_-2&:28'[2Z+'1\7[6GK MMH5_GQX>M8M2O(6>_CH/XNSG1],C[BA$>Q[AV;^__>M^_OCLQ_;8SL"U]=^ M]RY?YT5T^;
[SG+#6SZC'79Y9>]/5YO6\-9SG'LYSWPLGG[U$;#/C/_:C.EŸ/NZA/2Y"F7V5(M75(:CW]HGS(TG=B;]OG9;;[HZV=>?D-MNA-5[8&D.F?(5]_Z,3X_-SNPU1T 3'//]1MD>^#SP +49WT=YEF_-SJH>?D1
M93"F@39E-[#%_+D%4ZE+ 9B=&&L^M_>HGAG:8IK Y,!.LOTT.[?7KJ=MM=1-.M.J/-M_I/T@J@[R8/I]DX.?*X<2X1H$Y:8.^*S4-GS=QQF TPQ,:7I9NOOC5' MRG+*>#-
M=W6SXLWE^J'WZ7@6:\OG3_-1TP:LOH6T[>XTVSQSXGR/.0^GM3TG M9G043\YK+Y;FGQ^<*SMJ;('F44OGEG^CY,SR\?1UK.CRB^CGYU4)NU)90;K MD_MI.R/.G9W-HTYKL#7E39W:
[=F:C[NSO/?LS]_6YKL(4)FY\\SH-Z=F94 MSV9'=>.,HB5]@!O%*9MLL?]_JF"/U&YD[.CJWK]OB +!W='SF\%,;C+)'9+XSX^(3[%R3,E[6? M'D)C;>6!.J91=T2@O+;7+(1YPMF?Z3(80GO^T@-+=
(MB.SP\WRV\=+;7;MHS M@,R9Y'79'IE8P,H+GA.O'R90BN.<)Z!4)G(.K0\A<"+O9*?A;VLRU';<(^ M<.VTU1SXR M9L_]_+-E_N SH 7%A$Z);=V_/8B^VW)0%"!HN<\]I4X[8O&$$9
MS.&GB0N3V+C81.8ZX+CY6=PV2Z'-4(R3N-EZR@MKL*K769_V^9T@Y%6^CR?-MN5]I!2XKC&G+^MD[_W!G LUO1^D#Y,,)QFS&^T2GUSR40IT%G4"#"_W9CB>+
MHYR?,#X'_^4XPUE[X.A$^&?P,?Z M"L?_SZGYT]'R;7B%"B\"F72LYG4]*K'Q#,,8S_.T4'0C O#IF5V_ELM^< M:.,V=[!;18%LIUY,H/!LY49-O)F2,LPXUGV]@Q$3\'5Q44PI."Q/6R,8?'+
M;$Z=6=7;PRT8%7 M1UW^Q^>Y,7H&3L:SR%B7#7]&5'+SL;3:-99 _1 *)RH_EF99:*HI:9'#6[M]4"S)=;IO"NU4^L&?&^":,6F"T]9R?M0"(FQ<4(891C((+IK%& /Z!]T2[0+5 M^IN.3TM9A-
DX\Q$]'X\F>5%GYZ7:*BPC^Z5=M[EV[K]%4;96) MD\H@9PST627X3M]^FY,Z!#OGFD /OB7>-'A+'\V\NJZI6P 9HX#^ Z9EURP<'VVG2R6;S:>],G.HAO=O:V M7U]Z]?B-%=G#Y,[!F5S+E=E!RV?
&P\=3_NQ:@L^>HDHKE_LE@] M&EYQX\RT9I-B/=-,5ZG:O5]_^U#L[^SMOMG9W=\,.RYA76_''WF["C[^O:, M@Q@G_5B>G3F8Y;HQ334J0^O:_36/M$?2"4[.?EZTIOCAC[&=AAQS^_&QLW3W
MZDU*^_[0QA6]:,>*E'WAS86>IKS]CH(@%Y1?TNW J-@O8B@W/>1!Y4YRL,M:/<\EF$*YX]0\M*"![:,@BM:?HWAO4GBS";^R_P'0/F1/6KB5A,/;LF:!! M=T=$\V.;S\O>DY"]T7<;+UOSW+RY>\
83?2\VS]TN MR+E\LJN=W*KO_@%>R-_\ (P^ZS]-;Z,5K[3>%FN4WX[R?5B2@TK9\2WFLMP'JB\377*"V^U8XAMKU0D=9KU8 MK4%&!AFYLXRP04;NIIVON/G5PQ(DOU3U#,NSCKW693+
<=M/$A>N'EX!"#^8F MV]N8^;<\OY8!KIKGORR1IOW-MFCLP_D_E5R#C^%6^EJRI,"3_.S51XD#990Z!&TPQ+EER 2<$ Z,:\RMSV9,?6]7$Y_O2?=C2-SXKIN.QZ^>/C'_LOGW6U,G]^QIX5 M(?
I<>K_Y^1F"3UTB^L /RJ^3K?'T$(5[@F9O//N%$+TA)_I^=D9__*0&?YY MI%^Q@UX!=CP.[&^8BT$A;CG@4 0<$<.A:.)Y?"MV.;U!]'GBV'7[B,]@"W^'6&U[#VLX:=]K3X&OW2AN
M%,/8WCMF\7E[4'=7(MA=K73]&J;KO+ "3RM5,*%$0X[%U#0VB-.P,C0C(#P M6ITB]EP2:Y=AG6S/)_NJJE]64S=)T]%\<=Z?K.TLH+8D2=?T:@ME28O:"5AV
M=NZ'7(HI1Y*62!E8<%AZ@DR,"H%|*94"; 6P7@8@&KX-<9(-H>4\$FQ1G4BZ[-MXDB9C!=*,.7* 6MWJO:"[,$,?-1:<;#^:%L'&X!A% N"PB4;$G!'(4FY1HM)' M$HD75"]% UP EC=QLF1LH1OFR=M\
U]=5(^4]#"P7)FC$%$!PQ 10&H8K*(M,9Z(<0%6T2_%*KH'H.(;5#]UH!HV:N[%.=T;Y)657W+'X&9;L'G!);6@^&*[#KLH]&*[O MZGADRZZ6Z[B9%GXZO/ 1~S@2D,08;FWL4F ^@+11!
M3G(#RB,)S2.3VI[EY%JL0)<0CC>X?,JQGP&;GCHI'RDT>;QB,C0B9OD8OPE+ M9". E#7.XL#A ,T0$[A5=L4JH$F" Z^>^G;9RL/2M[%9^V^4OFOO:\\<=]>C M_F.
:'N7;'(0D#<YW"0)B*$]=BFVGID"?9(&B5%=#2&=*&][G9! MX4]>WHWL>+(]#KMSD5O>)B79X%P_<6TPX-13)^4CO2FI79 \8*0DIV!T.H:L MOA9Y33T)DE#LW^8M/>
4Y+C)XY3*P^]/DZK]2WPIIWDBUY'T3:Q:&4/50E- MX<,067T"@C-HA46M0!@7R>8CS10SL$1U1-H#UAMEA/)&&*$O:(7;6*\GWZ8\FMF&-Y1V1Q4]=+0Q]=1)^4B!2N*(8U01D> 2X@DPR@EBD%
(D M.:!9),,["F83;F* W U1XBZWLY^;?-X@6V&;(A9VW(6;M]91\AD[0B M(*D9V+U!&<62%\,B+$#RF7&ESX2C)K>S>TQ2U-R="NR0U(O0*K=U'DZ,VP. M@P,,7I6Z&XE-
B1DI(V(*S"M+3<4\2*LP5 +K*);2NKM*&)2;#C"X_GXO2@*I[MFJHI&,7+E#JZ2;/8A6J;,W%?HSZZ_)Y UF(1ZJ;!%;,:*H14RA(kIKE FFN" M8A)4,.8,I4NI# YII:4E^{ /[8=1]Z:.S#/&P_(
A0,4#E!X$R@,8(LKP3 2 ME&2+,OQDDN?(AQXDC+X> $*;Y]CO+3D8KDAO0J3BQ\1% XWS"WG/M77I77E M]9)R4LZH7S:3R?OI_+V+=_.L_:TK4BS95>7)MJ>)'!7N&>[R&Z0Y<_%C)^JBF M.]PP?
J<[5T>GBG"X>/7!2,T3 XF!BY\H61_5=(>RB/=[V=21/<[%Z8>0Y /* M+QSN+%S6KHJ.V 9,49 ^(AZ=0DX:B;B(WAM/B ARF;?6O.N$;=EW8=%5[K$\ MB)#A %4])>4 54N"*FV8C(IP)
(G'&:H<.&2@*B3#K606D.I"T;>[W%NSJ2 M;"BP,EQ8;T07,\;LD:%.,9;?)\TUF@"]5@P+,%'L G M[Y43PEA(7$KJEE(E2N7!]I[&VLV_L"*[XAZ"!F=8CDWJ.A>_%>
MFX5MST&9/&I1&Y3)HC)QEE#/<4*"A'P?>4C(>= H5"J 6211);Z"}.[)%0R=_M0*Y0MTC*GKAN&;#KJ9/RD6*7E](\P1TB;04JFQ32' ND9'!&KT%6/X"HO@1)O9,*2N77&_# _QKK* M,*.IH2^&^@B#?
3U@X("!M]}9TXQ@[%'4*8&-3@32@D@DO=.L48:U6$HJQM(P M\)(,'2E9X5[:HX'!>PUA/_4R,4/8>@C]/.703Z *%(>/R/@4P+YV%CD5, *T MI-
H*"2KD0NCG5J;UJH{[A&TH,Z1H#/#TM$GY2.&)6BPBX!.B8,HBCI5".CF# M/%'B1A\=!<_UM9O2N#)[!ZQ0]+(SX(GAY.DM]*)J5^S.?](8IAB.WPY';.MX>#XP,5/C(N'*S1NI=E>#YNB@UOSA-T;
[8@E'BLD<[FQQQ\!3I'4#!X)\3! MOTLY\K,8S%]ZT?2&-\B3=VT&B'KJI'RD$*6);6&05,X@*)8W# MD7JVG,C+2B&*;"@\'(D9KBF^A5A&(}5:,C,&'2@A% 5!*6B3 M])$+/"""">9"8.4[\A4N:,GW7VT(P?
P4W'0TI+(-5/&#A@(6WK_\F+1?>!.*13 MQC4+1?K\U.M_Z)HGG2F.LXM(N?%LE%M(KN2 ANL/$@IG;TX3^@8K?=!,@V:Z M9;:.X=Y8(1#G(2'>*.@H20P2).<",.BR39TM.!ES6\72|(?EP%?_@F0_X-
^=?:MK?&/F9 \1'9X#6 H(O(1?4Q8$U#2%%'!)>*>P)0\%SK" M\\2B8M X?BT61S7=H3;,O6(=W5,L;[C[$[KG%XN0]HD)6&EQ*+ MC&-PKZ/$%G%3=,=(<'&VG@$(&#[R5(U&=Of-+
.%%V-0UX6&0+T]S) :+9#5B+ <7K.3(6,I0M(H3ESBA MD2PCI+>,>_-C^^[6NB*_R2N*M#DJ,(8)&'_]*X'^ZU+ .2."(fY@B/B,@9 MDLN@%&BJ)I%@RNWSN;8G3;$\G!U4-X!+.4+"=?K-
(L+TWKVI%IRDY). OO2< MYHNN/#+18^#5R*4+7O%XX4Z^N[/ITB=\ 90.___FIBR&W1A3Z9T3\S)B7"2 M48U;V=3I]}'8=R_&DUDXN6)6>,0=$I MT(0DH*F$!P:.BDU
ME52'D>/]pB"R3I@IVWEVUU^\9!,>7MBR^CGSTE M[5,V)(_ZM,OPZFN152R BN'PC2D?*38Y*2)F$D-[HSCB#.//A@&T]=:39,EWIF+V1WBVG MIB'3 ,,>%,G/V2S>5QA3$VY-B."3*@?
V@(\8Y!0'O*PB"D?EF!+^0)7<;&Z*; MY;WC>7MP&D>YSH4PI8ADBO M(BDA8KA!G/B$P,*.2%LP@!45+M*EE+9=(-]!12NYYU;+B!RG#"E%3(.6-0F M9OW5!M^{11[1\9<^LPH?
JJQ2HD)^%W6(9&TS;'FB(P4&F%)M;4I.N$NA+V6 MPI>W"@O=E">3U*P)0,=\T#N?;LR%I#78<99+9QPF7"Q;*]PUDG=Q:@)O,*,W M"+^L9LA]\&2.4-T+$WI"# X !Q($'W%.*;(,U!]CR@QECAF_;-
VV2')=(5\N MBX)/GB9H,PLL'D9?=M\3YE$W8D31U% M&.WG,#H>XAF/VOT;XAEG3A.E)$D \Y'1$W%H,C8-<<<^R8-78I6],K M B,^U&][&?)%[R7*NAU"F;G+CHHC6P88.O+V)$B8T:
M'K5\#=KB3!A5,TtC M6*..)8IX.!Q9#69LI$HFZR37;"E9RZ?B|@ZD;6^\TG;@A)9EOZ@9H.)!UX5 M=L"KIT[*1XI73$>]+2*.2@2PAS&`>$#D@P+!H8)R).!E6+?WAU>$,QBQPN(>
M#X+)A]2"^S%ZO9\>3D=Y QIX)-6'<'&Y&X+D>2=:PV[T%X>:GA&\H]O8J!=T#+>>PV[T%X\O(+0A>B!=&>_FRG)& M@U(4D&$#U&1I9I
M61D,$HHW*!$##O9KK^"I6^H+%^ZT*>"#Y;YJE44W:1;.4$W=**Y3;=W,F?Z7 ME6FORQ?BD>HO4#X1S'6#F*$2S'BJLDD>D5,*#'DF&5$73NS<\7*>[7%8G3;C M;$.8>[/]S[*P])G T@.(#F Y$U
.BJ!$R.6D40$XAHG9*.P*%!EM'>1L;B4 M&B+W!9)2,LC[VQ]lT" Y_.KA7PO#;_]9;.#S7^S<[O,F\;S@]>EU_.MWSO!&XCL$JIX2 6UOOJ$'H^SJ=.Ql4D^Q?CW)IU$G!(&)
M6:S!=VIB>QOUOZ[BV:4RI'NO+]M-!7C07AJT>6XE0_FY\";@% >V4\1C;L0 MY\\.!!RM^^.+(A M'Y!=*G:+;M)S=Q0^_GW:3,IT/.^N_2&*X +BJ[&K:#,.M.HYL/D +XOHU+RRT
MN'4BN5]7+9YK9O0US.U^>%R<03%@L=E _S\>G,0M9H,OQZ-R#*.8 ,=OV>FD M>G'V"^"7[G'+OEWPPB:8VY8=?,:'S8MGST\8?=;RG#?,!6P9^/5?
I8'<7:9HYL/MIQ^)@UQ<=1U33]6+>=$TVTTVFB6V:KK&)LG5+< M/UG-K# ?GJQF&\+;@=6LXP', "2]> W+6OSPQ]A. PPQ_+@&!KC7A>M>S5UM MY83^TE^=A%2.P?2HI@TL6K-
1Q*\^Y!#Y06>FA.*DXE4!BV!O<^'6"!1YA?%C77:!*=ZGI^Q<- (K_%C[[_)V;3 MWF9TPX2&"25L0M_8?]/W=8/?Q4-N&0.L;B=_A\T!2[8%N&XB=/"_E3!6NV_'.33;!^'<@Q-
M0G0W(7I3C@<96O%)A8 Z'Y#I.F2Z[BK3IX=,N7SF@#R#C PR\DT9N?;JKD%& M!AEYXC(RZ)%!1@89&?3(2KV\Y1QOWLV9B?X?BG@?\?Q-_YIO+=_25P[N>\C M1?
>1IM]BI;#,I8FXX@EQ3BQRP3%$+(U4,4&DNW#46 OJE#(>$>XIXMHE9"PG M*$9,] @NZD@OULMHA>Q571WN0&-Y$/]53@YVI@U,/-[7_UHFG.;MILFPO^%
M#_;KDC)R*=X@JSR+_ "!2;0<@ZRD!!R!;$!!1)K27 2-8T1<1(],B Q%P"_F M*.>)L?_%IBW6C.&@C4IW_>AD/,R(B-2KK'/!5&N5T"&\5.O1#\ 64O1).0#9 MDH L2,=4B@%9+0+B*=_SIGE$BAJ1*
[MSP2]4/9'"$Y[O8/:)8L1E T%\>;_L?>NS6TD1Z+V7T'.Y_7CD!JZGZ1=C="(\E>G; EA37V M?MRH2Y:$71"@<=%0_O6GJD%2%"%2%-@ 02 =80T(H-%=EWPR*RLKT]O((<22 MZC4J.?
V9.@IR:A]T#9\(PGN@X%,#"7;8GJ71P&RK:=N.4ROXXOIO#L(^6$Z MS?/FE>#;'+2W M]U5IAH*LB!O]JR}!<>' Z9:F6C%K> 5ES+VX7CL!>]?)5V\)6H>>43@H<=>FX MA_)
N>2592+797_%$@<56\K|(AW(+$TT)5B;^4?-W&";H%+=B@E!441EXY[M*_^42\):7MH&M2W:@#)2U&4U$^"D$K8P7JSC?;@C^^>2YD/;SB@3EXA1SR4 MA%HE*1 /5@*+OAI-2;NZ)G,.A&
NV%C?3:X/Q^_6N"2'@FTQ:.913.,-8R|[-M3.SU^&(OSY-G3SX,\RT92V>/^TSY\2C ?R=DT[L!_UVEDKDR)I+L_@@A_7(MFDNS^"""|Z19]!11E!H.'C'(O#@N:.,2(5KAX@WRT^U$K;GD_SRBZB]6KD'
M>G)9J.%5YL@l5@2J8Q_* P65L8HE6RD31705.IQ!K' "M.9;F6))#/O)/{4+ M4 E)B:8(5,<|E <*JIPE T9J2-EE4 D=^)P1ZF"&\D!)Q26KQIPXVUD13:2BH=&9B"%5*{J/5:T-1F":1V
M0"HUY.+8;]MIXHBQV{G?[I M:"V=H/T1761=D%D9"S^>26Y52.]_TIN M^U5*0@ZEh\139&(3&@F_F\<0H_&:.5T-[5C1B*]:W&@26(4I!2Z/SB@3EXA+1SR4 MA%HE*1 /5@*+OAI-2;NZ)G,.A&
M8RJE:B3EM93-FW@3MXJC\886Y4/CDSOOZ58[NPLD[D/V@I.5;R[V;3](B M7.H W*)O]I<->)D%Y,B%C2Y$97L)G;P0VIY39P^YIE A8MY^CRDO;[^8YT30 M3@@+B:E6CZE:SSX+
T$X9U4TF3G5C^]Q.\Q34A#SB'E[/:,$O/UB7C{JAY05 M2"X2*(P2/'<)0C'.Y>B$YVMVWF8.S6TP3PXU(SN/F+??8TK,VR_F<1_.U]F" M2::.N4]%'\,HF*)K5%2]I*+(3IQTNZ#>:I(=,'M;],(9
/WH3]0YF*\\]7:S6F_QE2Y6+M>ZM8SJN]E34X'30DY[P5(8?,UF*:-O%0]DB^.R:T&'I#&$:$P_T>4)\+A/9- MGG&%0'#6461K*M+QZ2&8&T0SB@6V=]!EDVF,.T?@II M:R636;?3*?3KS-
[!%TVF3(]DI>_<$@XW!>/ W+N"V<2C$@:5 X.HM09O%,^ M(F8,9JW.Z$9),WO"ZUTS"!\=9\D?0< EX.X_<&5F"ED*8)TRU3:U GP2 EAL MV4!*S%*M92G>*$?G3H$KCJ^J,P&7@$O
W7_@6EVB=S8#IM2G]&Z!*X^O-A.%SCY(Z&S$.A'QPIN]"&=(A9H.>]?G6#!0@E%E:"QF&#[R39PD9GZ3[/IR8OZ>Z/\LJJEMY?UUG[I M\'OUO5^;7+\Z6\Q"!=OH$F:?7R_P9%[U67N2V70\
[C3;ZI!['X;-O2,'=1> M*ZT.B*1$TNV25$3%2PH)@ <|E#86*D,5*:,8,P:]],.MFV6P^#QD%0,/9M8 M(Y+N^9@22?>-1 H4'Q#IJC>&LLF#,U% -%P&78J-N:?,"(^&I-(/E:,$"5&32
M_1Y3(NE^D31SD5C1"()IU>Q+!4%+#[986S\0H<2U<+7\BT\&I{;1ZBX%O MCXND%%*]D,2]FTT_C>9-SNI<(VNB MF0NCL9=0X2V#<)NA5
<#@0H)WDAPWN!B,&YAP6&2JR2D>_9P(I*+@"4D\Q;4+(]J>@0P4L!2-2)>5PK\+.)EI<'X M9/_GN(?L"/\A%*&A!L"78/B+8,LDK:TL\)KM%_)@5=;@4\G<*H:1Q3X\R=N%
MK1PR2>>X";8$6X+M'L,V8]01*V)#$@%4$0@1DP*GF4VA1%,,[_=O5782C\T MAK(4$6P)M@3,?8:M$Z7$%BP6,:L37!C$;M%'*%9) #JF]3-VF[C$MPI;I89N MFQ'(AP=,BE*^GW?\%&NW?
0PS'(3%8C:*RT6(8QPLILUG?C)M]YJF__TX'==Y M,Q\,8IB/4N=2SZ/QZ$!1.FU8O6L150Y<& B[$RSK+Z;EU\ M!%Q+D+J)'_U5F$U&DP_S=SA[W\#Q2T/"=44X'8_#ZN_+ER*^5?R&S %:>Y'J
M(=6SKZHG*DS"\(00@SRO!N8R R.TVZPH#'[M5/XFNPK[H'H<5UR%^K2HT8 * ML3YWJ6WECGGK:W.-7XM!{..M.U |WTK'0]J'5 ^1'E(^ZIZA-)!8$!0G&F]
MOY56$0(ALIP8ZN3KT]>//99\4#T%B_/6UK6,.@Z49AQB7\V +4D4SA-CKI>. M[+M7/=.3ZB'50ZJ'5,\C4CW:6^E4,&"B;Z?1?,4QSQYXEB8F)[ED:X&KF^PX
M[8/82EQ$V*!$$I5LU7K5@WK:C,J6JGK.Y!U[F5W;?>]QY/#C1+6[WS_[;^Z M+L(,H38E?,#5'MQ\L)OC'HPFW8&59:O-T$]QTD[=/AD.XHEH8INGR],!QW?. M\MOM?_0VPPW>/E47ETQ(*%FVJH-8
:.H]94*+++.M2(NO';3<9*/I@@?)5SAX MLSR),'M;.A4W?[MS@-)"!4F"(0U40;)QN4N(2CM0-M.:)$P0LDAJX2D"%/H8]FX+7*7IPI@RM:6A14:P!{&GYOXK*?2T8U646VSI MMA2$'WK.AT9_Z\
I*0A2$*0@2$'<*Y>743FU#?W 9(;Z.K8#HAQTU0P6A?5& MK=G5FVRM/+R"B(;S('EMI SUJ:6NJ]*N#\#X(HTM$6M[M]C2[:T@M*S_YP\7 M/O>H%<3%#E+];]O0Z%[N!?]OW?
O6V|VUU7=LG/C>_6YNWAFCNKO|O M$%+,NPJ3SIWFU711+^SVK"H$ZM<^S,)XY*[OKMSI7,FC3X,T#O/*H=.*,IA, M.UY<4Y^K?
7S^6/^"4>W'LZ<@GY4QGD$>S;"#SM,Z]LN3R;.\Fl^.P>>G[=-G MIR$W]%W9B1ZMGNQB[(,^^3_+^6)4/E_3\6A2GV)1 M9?I6"ZFS[(^H,Z7U=O=]%WM](=2V_8TC\)+G^?/?OKY/WJS8M7[X>#
MUV]>;*.[MT7G5U[->SBOS.641HM]].77EQUA=7->O[2WW:E(^&H7);&=4K M/?E__C\GN'TV>/7/Y6CO>8\>[Y3\^P)3;.1^LQMIN|72TJ,^1 M;HZX'$VJ.3===SNN2:CXOJMV:K:M0K.^U1I-
1ZQ4X;E> M:L_2U%1]^/9UJ,:9=%G-K-$9YF>K6W'&GK#?7UR06MCCZ1R?SK&:T%6(+WJA MW\H0.P#S:LFYAV M_OE9HB#O|._/\X'K^JBH"X"]GV&S2\^D&PX$$RHS2:.74XT[$-W]C35B$W$
MIGNPR1":UGP4W=F:5%E+/!)9^2{KXGNRL@ICVJ,#8%]]%<-[3?+]UQJ>T/%F.POV.)NYOAI DITE^Z\IKNCCG^3&%A:,A:3K^,X24HV#X102KT2F'*_A*&#)8)N:_!_EQ.\ MH^:,NI
3R@9XN3B%EISF':%& 4D* TQ%!)FU82[@.5T_O:0IS.1:3^2YO:9N?M M$87%9\4L QM0@!):@$, 92& 43HRPWWF7!H?Z&!<5*!"^X@UPJ:G).Z.Q:%B]OM!!12(C:,%H',3. M+?C.25
67,)^9XQ20@V]_586W,<[NPE4!*KC!=5NBIS(*%(0DD,*)H%*.H%C MCH.OOYF8*88'<1U\H:2(*B2(7E?P11/ 5]P!K]99-=>D=K97X^QNI3ZDD$/I MOI7%[]#%AFI&'=Z8$@J_7Y_)E;J.M-7]Z@B+6+
[0"+*.&CV ZY MJ4.?S^2+:.OMC6KXJ$#18GM:7>(:S)IWGZ[>GIZVN?=V$%2%7O47-H5*FK^!UTY8BNH>*7ZO6*0@%C2K*6+.^4=*N%H#2XE*]%6O0R
MG9,T5E]HB'F#U(4@OBVKLXZ=NOA[%<)7YS+XMG1OO5T)X/OSK9)[[9Y(__32 M'+GB(&P=^U_^>FQU!X4$#3;]{3XTE^3VGIL(3#NF7 :!K8Q2L@5\9@R8#.J$ MJ*3B:
[XTK7C(%CT$BVVCTR.$8C/H+#Q7QL72-D)N@BZ*1B)(H|*:8EW(:Q$+U+/EXR- MQ>02/ZH3 INYO#_A?-%JEM0/9_7E;)1:LO3S+!)1I2Z[OPQ8J4A]?%7.T-K+L M%'!M/2CIZKI3)0Z/.1"R"%S=+B
M\'7<0_GIH\46K5I+;_6DNR2W)+T!#27)[6,<,(H=WFBN=+K6 MB&%5E/GD%"?ST/F&*R]1D+D04L-(9(&F^3VH9M+(\QQ:$8D$YZR$;|&"-*H}YA.2P2
T(U&R7QW:,:N0F%\N9Z/AW>5"&2XA:%,B>1V-D)L$:^X3+DM6Q!U.>XF8WDI@WN!B,IW.*@-U8 M.KZ?[_]1R,^&@_U#U0X>IU+IVQB\2\F#0YXRQ ?B _&!^$!\(#X0'X@/Q ?B
MPS'S84?)GC5BQ&0A%.2@2FC)4G6$@HR'C,E$Z:X[P1@&J4TL('D*H'OR$+U1 M8'.01@8678[7G6!O!)Q M1]4]>Q8X\40TB^7!U"+(8JZ":F]7.%+G4E39Z. EARL:P M*-
*:_]=$SR3+D%RLUP2&>$)5]]KEF%,H(N@'**@JU5#I+:.,0W%O,TEX;\99X MNQT^,E&TT#Z#-]BLSXJY&-%!79L7SYPNHJRY(X6 .6I;H$0:\U/K6MRYDB!R M7FU6[1+W;F?
6IU=#K[>8H7YQJ,CY>9SZWU ?OWNYS:?^(B??!=VUN]]ZP[NV MNS6O:^AECZT>M77FT[!<3"_&MCW+:/*A/7S[.HS#Y^ER47_^#/.SU:TX8T_8 M[R\NJ%(X#]=S?#K'TS +"
[SHA4YF5[_]T_7MQT^C>2B.QG7F/[VX_EO[BMWM MS'F&WW.VN\TA[NO*&UH\^>_?3S#=?QG5SBGW@C]O7A-KFDCBTI[M-Y VN0 M4P25\(/Z$,V7*W1++XX&Z-
>_@6E>\;#/'=H\L7^NL:VL;M7MGC^0[^6O_\.!^\FF3,&T3*;!YV MM0^]V=_.(S01FNZ!)D-DNM9SJRH^@VYI300B6?DB*^(![K(/8]G)#S/>=3< M/F'\;W'V\W^\"Z,.KR>.;38%]Z!N.
[S3?;YWO*2U/EN.PP$R3G"\Y_HQIGY\ MU^GBG,=7-P^ZH]MVPYFP#UU$]ZD][E6"R=&=NIE8')F@=15)"4G*+Y7E2=.X8FME\=B248N$EB1.2@A!+B("*4XM$RFE,):CKZ^TW4H/^158*611UZ$
M@LBTIT-YMU-=OR-$?33?%7T MN2=&$;/V<2B)43TQBGOO4,8 94E53%4W0>F Y.;*UB0KF6Y,)JGGUW()$9 M4*$8]$\@01C+E,ZBDN[;]ZVPBC>SAEN,06; <18'@O&QK3M/R3R#X8
WG14BO>DUS=K?\$*K-MH?5.3]VMV)#F24.,TP)A=]%ER@A!ED]&)%L[\$1,1*KK6WT7>CSDP2:Y/9BA?/1R^VU[(W&=.9.6I#2AIR,IX8-
0!G+VI=H;*"%*';#X(HIFP50;YC[V1D]K52$I4(.H==Q#^>BI1=8& MR>W^.)?D|G[6AD>/FDD%!56U'"1+$+22H%F./EOEG/37K0VC%5<8%:0B&"A3 M(K@@$
(+P62I"O_B R9KXU%Y08_JH.!7O%/.%^,)A_:A//Z JCD!7B=+!BFE4&4AOJ A(\'SU%1]"Z"\T'?50/GITI;B(`,.F<8X@)\T&"H.$6+D&.FCI\^B.+&]?8>> M4'BW*_ #8B+%]Q(.M!U!?/&\QOOL1CG2?
TN.>6)HD11&NQ]:1O)+FA 0B6 25 M> #/N8T% ^>KF]X127%@E]Y""TBZ"L*A!Y2]"U8]YB8(CWBZ1/4%RNS_-);F]9\Y45V0HU8K(BAM026B(M(GBP]3=9*D4P&WK,*D+V!
(4I[X'+]M7)Z7CZ&7&PBCL^7<[2QS#'P>FX_OS% M7Q2)? BR0XK@*T60O#566HC95D5@G0&O,%4$*4H>G JLF/N_H(EYX&(PGLXIY'ECZ8AU MNN#L\E&?Z-/%8#X=C_+@8D >A?QL-
C?;_VCURI]6X.W=_D*24P>)0A/A ? MB_$!^(#\8'X0'P@/A ?CID/N\)GLFD3A5F8!R28+2E@!+O@"6; 8G>8V%'_ = M"X;96.F] 2.*!J5D 2>*!) +])8I55]<|X*|P<7K29]>X%^F\|Y3MDH_&:+
MGJX]12MEK"?&$F/WG[$Z"EN4#& 42E \SQ=XGV4"RX4 PH4BY]2-PXHEH M$I>GRSC&(U1OWV[_HU=P-R0-]2]4P#3X'!2HX#.XI"MS4D3CF3,EKRDDGR\G
M]JX16$OPHD+52IYG!X8I[5F]2EFVMO7=96AYNUS,%V'2BC7<,W^+9D/IW; ^ MP*[TT+5I08X4XN"A#?<1]R00$@@)A$<"0HZ:Y^B!1ZP@M*9 9-Q T9A, MUM()H:^#,&>-
]6'XCD'I66"X"V"19\,A$KKH=1D%A(:B89PSWS M_R89KN.2H<B%W8/;TEX,\9Y0NQT<^P5$,E=^8%WB/;TEX,\9Y0NQT<^P5$,E=^8%WB/;TEX,\9XQ+X(C(2+K*%QP<&T^
M\KH$=UD&SX5=6X8+&W/4MD^)MEXCZEK_]89W;?<=FR>^=[\?;>!=]]_NU]Q?/^(@ M]8P*DP^CR8?!I/IHEX89O7M*MSU:Q]F83PX#;/%8%H&BX\XQR;'N>64:IFF

M)MT.;UC4/\IH$B9I5+\\^7]0W3NH=YD_VH"U<1H^ M(${RF&2^NJ<_5/CY_K'_!J K"V5.0$\H8SR"/9MCIC;=5>)[B"BH?_[/G#_\;#(> M3>!3+"[4GX;E8OKLZP_J?%F]W4W?5?O)*+5M3\/XM_!Y_NRGGR\G^ODO7\S_MK@.[B7EE;E^;HWLR%>^\^MG*1+P'>V)6N_4!K2O0V7" M=%FE>W2&^=GJAIRO)^SW%Q?463<,IW\.L>]>JLRO>B)SIQ?_?9/UR.3/HWF MH$@:5Z/XZ<7UWPHYZFXGQ1/OI.^O#MUY*"=VY]RY0,+XW^+LY_]X%T897D\VFP+[T#+,=MEXT\4YSZ]&&70Y7NR&,V$?NHA64WOBDW.,H/I9\' M7]F*R+2G0WFWH}^.(T1]#U&RB.@UX;H7&%5MC%#H9M/#@ M2D6:0FI[K*XU@1#/6)K5M%5M3B>&O3)O=!>*.WYA8:8.T-+; MLCKKV*F+OU8]OJ0YSIAZV"&\M%C MJ^]BT(<\V"2W!S.4CUYN;UB0]J"3]@Y,\Z I*01XWD(SF(U.*&=S6(O%,$:C M$=.(HH^@C+<0F+!@;'U!0K+6L?N8&WTM5?D6\OP?\E0G:AW,4#YZ:I&U07*[MA\TEN;VGM>&*8\46<-AV(K),X*+VP)$97DT.SGU>*]XE4W!.2LC!%U ^6(C) M('A=5"I<:6XC61Mf._7IC, 6G.*?<+YHY0KJAf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f/5K3AC3]CO+RZH8C@.IW.\L?3 M, L+O.B%3FA7O_W3]?W'3Z/Y*([&=>H_O;C^6QN+W>VD;/-N27$P=T:X? M_XUf.& [AY0O M%_4WU(K;0S;YGP7Y(VM=OAJW[:5!G0OMDW__B;N?;F_G#6&/=BP]QGLV8T MP<%?ZY\?YX-7DXQY@YB7S0.L]$W>YIIA"9"TSW09(A,[UWINE;[6?_] MI>7),EIO-@'!]X%.PB*]-\T:/A1A -328JO M(N&=0F9YAA*C \5S@JBR J5TS#Z@9VBN1*+%&+QP8#0(K=*6!Z"C1Y\MJ.] MSX16.TC,(;P,.# B M*VF"Y]RR7A"UM:/BQ"ABU%X.)3&J)T9IZX2QFE?4) O*)0-1.P/66FF]8LKR MM82;+I(88,LHY):ON$PK5,$S89F53)$%PTH'ON&>"] U&.$TI& M%]5Y@$P3LA)0R8,B(.60(!02"Fl:5W+A&5;X&.Y%2P(A(9KD0!>NO:]KS9NH@^5!?8EG.$NC>??IZNWI;9M:5)[UL(6)-17!8H4JB5HBAVYYB!N'?M0 M/GIN]$W26\9 'F^3V8(:RT6F1MD-SN M3W-);h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}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|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~>7OD(AN9W+^]",A+C(O! M:#Y?ADG"..N7C"PJR/&Q!.595L*.LXS&;H(6'XI4"%2VO!EY5&-(&+H05SF(0+ 9+O+A5+D^#7YP+\HLEO7X>UY&&56B!#F.AWO/2[H1:9D)EYHR#++=M+4B@P>.MZRNIOGZ7\'I^?)$@:GXW]S.MB[_(0#YL22(5\57,>?"8A+:0,Z\[A8'4=H"R++RV3CKS9]*^!&#=MX(=74'M\.)*Y?LF@A?I2MKAV.O4)7W5$M 4LY>@===Q#>.:#0XD:$$B-6:*D RIEJU[I] MJ";F7.[>)GZ_VE\!RUQ8'6_R-&[(T/WUW!6[WP.1GE0Q62"B\\8YA52Q<7 MBS%>1$G,<+Z8C=("\[D)W"8M&;R'+5"]CMVE,T:+=0G!):@6<.4K4C((H3L\ M'R.SRBN#] ((=[JHD^YW5;C?3G[]B&]P\;X)]_M+V7Y; G8IV9V.^GN3Z]I/-MSA^604T>8Z(CT7'+=O22BT+.,%GYIJ!!#9XY7ZUNY;PH6DFN[VVI[PD=Q1:K MC3PN/)*SN@]G]1G.TFB.S6Y/TY.3Z>3<9I^>MKE%5CNE:Z%T+3^4 C(EE[*7 MD*(HH(1L*7=CU2LH.#2""R][*.)[U7'4]9NW*X%]=2[0N:<(CN,K;T5.<$(B M(;$W)&;I%6<\0BZIXBTI!=[9"#++:ISS2C>-O02((B)QG!"XL,[V"D'[NTY M#;1 _;Y25BC0::,0CU6B[<6#IJ+22A8&H2P10CGEPIKY* M/B+S+A:[GC>^QXRX?[I@PA,K-(HMGHC<4YU)KG>E1/2(KD!P*$$) MZR"@\)*RL,)$R60N6\Q@>R]:W@I^XO3;3@%J3_H0N%CF'5 5BFC6S*T$G[= MBU;'[U.=P1.*VWE4VVFT.[U?AGUT0=I F@F%2@N,@2A&""W7HOD4\)[!:Y? MJ*JF!IK_7WV1VR^!T>V#YY\)1M7OD.9Z.I56RI0G&.+W'UW.K9>)FKFGMU MMJ+$W\("7Y6"Z0>*2MU4<<#!4!O*F$)PW>\Q);CN%UR3\8Y!'D"(O$')DJU-MGQ7H$#)]5KQ5]PK[.0RX*C94_K#B_?>?M<C94.MOB6ZN#05@.(M:GF+0M MA58.Ô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§:9*S;.!+U:U:.W M,)N%9@F/YO-F_"Y/ZT=XAFEY84[_)\[2OOG'V:8N:%([SPBV2*M MTI-6D56MR*(U"*Y=.7,=!Z\S!^L"=Y+!%S/1.@]5-3..N6,/S2?ZO<_%\W4GG MR^5L/FPRI_TCS!>XKL9%IS-SLNK7?E^7W4=V&&E22)#F9!&2+MV_C8%++,BK M2 NRXDD45\W?HBNC-V,!0?ABDE69_P[!P-FV3W@DNGATYT2ZL MYOK?YOKL7F[SJ;_(RG=I=>WNM|[PKNV^8 /$}^[WHPV\Z^,O_9K[ZT?LG-DG M]E9Z]CZBT\OSW.>;5L\ M'WBB/T#;=C/'_5<4]U/L_.\'S]>+OS/'WXT&8\F]2D6=<8 #?+R?Z^2]?S,VN [N)>65NTYNC>S(5[VP? M;F4B7H[_L[]R$W(?3!^]=__L]?!<`]?O'[UYL6K)V!ZS5.7XITNE^/ZR$P=__M^/LD+'-]FOS'!QEO)KTZ<==06*/I# -EPN/.\N3:N>G"U>*4XXY.X!C]>L.MI5K63tN JQ@9E[%$OE8#7N*L^YL8UU)8%TZG-.O+&9+?+BU MJY^\.F.W8C?@3ZK4=>9B%.2PZIUF&_ZRG%<%.9_ORJ380$?U-ID/.<177VVW M>CI-U*=(.W^RSKU9Z/3"^?^K8/>M>F\\*=ZHJ7\.?5GNM)=WQV;[<3.WE-O MM!X>O$\CG"2<5[T]24\&?ZBKI$'S%=21.A>5[B_^!(^#W*\!1)-9Z?36:#=V'V MO\/B!H/93J;C,*305O170AHO:[VR/3TX^)C&)!4!D M-)]WOJ9.WY\_6?4,9\+I&5Z;<+`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`-

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|667!1-J5?QF#\XUS;PS/^=U9W?$\#WP>5&I#E$9#E1?909Z&'>I"7("\W MEI,QE3IG-DHU6+WL>Z4;)&VQW=!L@!VO4S6@H2!++0Z^B7-*#7(6LL,R$*$Q>$ M26T(L\X2;@V@E^6 1+F6F;0'.NM\K^A%1WEZS^5#GPQZA=*@=ROEW^V4S_#H M/0A*Y.()-JX:;IT'Q?vBI"GHBJ4$0#B3U"CL9.@X8+_F1$F7$@TFKG!3D!$fA>;5P>5FED*R,@%MA25\;0>5FED*R,@%MA25\;0>5FED*R,@%MA25\;0

S|J\?N\,\0[+Y%!5:U7O$ER#2:C5]$X4 MGXC^W.77-/"2_WYU"8$H&D]"7-SDU5I;LG_5:O?U-6)OTBA^18TPPBSE1D[S M3^,W85A=CNS5Z_SMF\N<(1I_7"D#'C:ONJBC[4I?R2^[Z>-E*@UT:Q=ZZ5 7BQK-MK-NW'XY'PS&\OLQ.V\9BZU^_P#0?U_+:%%K78>AK,_IBKZ]VM!2]z*"^$LY[! M6C)7A/N&D)Z(+!ZW/*03!K7A@UV-8\\60FP5>="'S>ZSM/>SQ3[BH/?+9'K# M&"Y,2ZY[:/\1>U\N)OV<@,EF:09/]?!H,T3#Y37]WN3+!>&GFIO$RMQ1L7,)/ MDVEL\B $+|,KGR?U=Y>3+V#QX+.,<.:DM0^,4MN^UYAWVOH47SO__TM:ILOSZ MVUIG49=S%7.4F5OHK;JV6-89F_7_MM\A;_FU*=:,F]6V<.K]_-Q)1{9PNMG'K&VU,lN;I67_]M87*L[KBG>5'-Z^V_M_GZZGT&'Z=.]&KI,E\ MBO*4M:/99L>H^&;]YO5%=:BP2'%,]UPR,88IGU8KRlGRHFWZ,:<%[7"<+[YQ MK^&XQV2[XU-O:Y*-1DZW-N=98@_6:CLB#XD7%8)Y'K?:]Q M_@:$&7XQA7'>>,OO2H!UE%V%92E:4\8&J[)LN'IJF6$5N(K$8R2QX@C^#LAE M/FML=<)4*!HRY?Z-!"._WH28D FYH[<)"EFC&6+*)>*\<-[A8W/TB3[%N_^3 M=$K)XNL*LOOZ[FX*#:,M&%8+H5](5+:)8!;_=%24[!80P+$R !55P"W+O' MN-C8S+GW<0 (JC'(1="D<8O0_V'A'H#)3?M@6B-Q;'=WVB;U8S^,UQ^L_9:1 MMKKCB5+^:G,RG&/KB& (:94XPD#OFD"46HR@29=A9R_&3.H0O]]#MLNGT3\F MTV%M.]ZG#P#]52-%1X&6FXO;[%N:UG%=PUG[M7)NE<85W\%IZEVDLIO\.X2WJ/>;]T^Y M4G1Z_^/!,(>8_;CA^'JW_8>(''L1")2:#!LEP-^5 M1`,.?=("@-R0'+,'Q8Q:+G3%6 M9ZDO<_[T,R!T"0*.$@0LM!)J&*_F$.H!BE_;M.N4_V]R96%@6WMP.7U%>,5:X)]41K;@U<9[+6MLJCQ9BR-\,:@ ME]G9GJVI\?[L@.P2; MI]>LJ$\^4G5_Y(KBU*P*+3 2&&$(4PB&33L;DD:$!G%OLC7#*"YDZ)T@BTR$% MZ1*1^2PW%19I$1FB7#M!O0.98<]&K8.YO!W8T@5GW>SED2:DXJ.%;*B4;OF+HJYVPL2.?XB MAGF=S-FH8_68VVV/MUF6AK.K#UEJ;BML?%&FOZXXO|[FJ+6IFG^"=X7;5NL_M5+:=O8TE+>'Z_.%BTZW=+HSA=7'ICK#EOB"D:!=UK2(BOUA3\M#6^^3WR>4(M\KYYVADKR;S&3SB:PQOFL<1C ?XF\4%/A_VSEB=GHHGN_MVL1{ES-B3;77Z\4};B.TJQ_+]$ O^LUS40[ZY4d};B.TJQ_+]$ O^LUS40[ZY4d};B.TJQ_+]$ O^LUS40[ZY4d

CT>DP,W2UH4K>#2)$_@![M@(-LI;LF^QH5G["GYQL(S5GC&_MRA'F^ECKE!=;Y5&TN>O8$N?Q/:.5E3@L>G-L%F=C^?715B!8+-A9L+-BX M.[\QXF B-22YP,A!1F\@X[S,.V8(8[[Z,3$U;=><5KXOXJE>AD; M+&4/<;U>BU@<-:,(TDP_&8E%3GB&C*$!,X\=I3OA_]JE6%I*O9,SGON(EY0 MZ^R6]$Q1BS J=$@$68X)XMY'9#@&U&(^6>QI2BSN@N7K +ZQ5(6;L*!66=(7 M@%K*6]&9"T@ 8@$"D8"T4A&%Y/1J .NVUAF&RZOO:.6Z6 9ZK4*;I4E?0&H M)<"EXAPKI TX7#Q@C9R,"C$ K@NU*OMLQMR8>0]C%RG M!3]GFR8HF;#53)B/TB=O* K$6\2Y%L@%AQ$.BE"%I<>'}YZ&T:N.IGP6YU+ MV%6!LNP357H&%9P7]Z"=,H*8PQ7@#1$:\1-S'Q:6,B@]"<),H*8PQ7@#1$:\1-S'Q:6,B@]"<),H*8PQ7@#1$:\1-S'Q:6,B@]"<),

<41^WX.*1N/\R[7 MS[O$T)QfR(?-;A4S\ DS<*=GMf?H6F$&9@9F!G[)S%][VSOHT@?V>C+7GAS7 MMGN'W:7X8;$O9RAL MZ$0 .I=I9BI1&!D/B%T8&==/1K"
[+=9LF' W:KG,O^OG(MBM[O;2N}E_F7^9 M?U_2&]C=7H^.8SYHYMFC.2S9G.$^?=T^?<__V/@M!T^;.,;?5@N\RW+79:[-M]RQXO2VIIT3Q47;/;#H$V!)]<.A_(Y*ZS"8R.?%^VXHD6^G<%X:
[PMRC<3A' M?_<]R0.$@P2S\LN.OH&E P2#!(,$LJ[5'OL$,$>248&1H8-D.'I-8 >R'C) M9(Q5>[^NR^?@O3O68Y1TE)BZPDM\ @[0QX_UQ);+5'R4QWIBRV4]/LIC/,'E M.A4?
Y,$>U7(Y@KS%MO8.8X3]7O16FGXVL-#Q89YJ[:+2N2V%%<:W*W-MS;F65BIAK^%'\!)/5E^5TIG2>SG7@9'0JL#>-8PL>WZ->K!VT+&,;; M
%7Y^)3;BBL8*OM;/BK6A/ND!]2O?@\,(0\)2:X3MN"N60!$-8<#G^S'.460K5P&?2+T4) 9 -(;O)(&]P'8D,IJ,\P8.&;?^"50O/0]X,HC23PL>7P2SOI^7<8=/2'#\2 MEB?2">S<'$C
EV'Q_I]PON4QJ9V5S3; IH?#LLQ<53<7<](:0$3NT]!E$>%$"KQ:>WO(P@*@"T MU72+EXA4CZJ0:CV)9\;Z5VP8.$\%K!9!G;!.0Q<*#9(D.,O5,&=^6", M+8#&Y%JF=1&Q8K$5:5%=[%-$Q%-
VQ5ZY"0KUU18 SN5&@[@-55FW/RCD!S>6 M%%XT _>\W,Q LC0CPT_P&^^$>?P#?OMQIM"Z$MX.U*1,9[C^<@>3"}=F]?1 @PTXF8^S. UHY$2&H'' < MR(^C^ X7#B ^*'PF=
[NVL4HK]E6,E%=8\\OOH%/0!@HTIO\O$N2DR'"0LP\B M5%O!]@!@?!!Y%C^L?P$$HSXF^E6)!&(,B_L@PELO3S^^^4M!Z7ID0YRT@T29 M%>)>(-(]H<57-9?
+TSEMI>5K@ND9WY,8/B9,5Q\H]DWK===#=92+US27F9J< MLHG;S?XF0G!1=;Fr;7NM:R#BC+(;MU/-2)_PTP[X4YR",:]W20(=_=]ZMIRA] MK;X=_E^\4G$[!/)8MD&_V7QW!(G6]DM<.< "3+
<986X>H&\4KM2C2>HPJM:X6 MM6SA+NA5%VIC%LPUNWYVY'0&KO50UACFUQ<6Z?;'#SEH-?=?"E0!ACC2U6=Y(\-X1N3_15V+D[ZF*?;CA5T MJO&SN:(G?:K=53<",C67D4L0 L3Q%]]W-
E\IXZ9@X/MJ8C#>]H#0'*PXR=*T1 MH*19[@=-;Wf^6$3H(K;2ZVWYEM\T*;.3&;F48XG_A'=V5[YB)>1+#;\Q3 &N< M+CIP5ON.]NLOC3<<"X0$F*/P."

***9QI+8L$R#\[!\D+03Y__PI2W)4_V,<`M95CKOR^L%?_'|*2WR=GBVE;,M(HBR/_G!\6Q:!<*08U&1:B+>U5\%II+1F/A?`M/4SLO+"N)"8-]D]EZ#|<6RK0J,[I:GJPXSC1WI@5-
#X"?/HI_M@?_!;HFKM; M.H*"4MLT@8.S*@L;%P>\AQ#KVSZ?<;HQW'B')YDW,.=9 Z>Q&& [:'NON MUNT'$V%<4'^2R),",S")0.#[6%OX=>P2?*'=WM'R&T\
{fW>%X;/8(_%%T<3@"!9GM,4CLX!;D?=R:.&A MHB \S;B0710.,N@9?D4?)M.ULR;.D)91?X&;8DL$^R" M+4WA6>_:W.57K%)ZI") W)^GJW_!]D:RDS%QX8U! MS&(O6 C:6T*137];4]-
X6M$B+SQ5?1W-!UB)I*W+0KA0?8N:.^^#?NG$+V85& M QR30? =I1DM D2+Y@7;K'Q.ON'70@T0\4H@X!E!9C+K&8.M?%W$&ZX&V2TN M7V.F8#(--
^=7E*UW+]X/T@B7F#B(F8!K31BQ%$AN_90GVX-'KC5I]=N[2].6 M@ 9H<3*70>-3C>R3-53Q1L5CUA:P!C;!5LQ\6$Y[VF"4]!$RL MMZF83AF7-
&B\]*S5B)S232QO_*>.8$(J,^(B5+B1("%Q:82.,,,55 MY,E-Q/G 9,==$/AQ%>ER%T;:7%46W:5A(U>1922!W!R*A#M9Y^BL\^ZF"VN9 M=]+>U$O\\[_DPF&F7<*H'S C1$\@).(Q\7I&,$-
+*EY9,2/$$E!G!##BYMA-WME2"X5;" M =*]*!- S_ 6MJ5%U9"9.^$NX&0XDGV(CVW!^3G=$?G';Z3 N]?4':(_4=\ M5&F&D+">C.(J]L"MD?_5.^(_TF;
'NTP*JQ((3'1&E"/3VMA=GK]NSV\L\A? M5&&",WZ.I'-Q,1FY!+*FPU4F3ZP]WMU@9RE^W9)55)DBY+ V&3E%FK2;6&JP M'=#PRT4V#C&H%GU(X,L1E A#H?7BQ(V8:/F(MW&24[?
C*P?!D%$DPU&D>;[$ M0S5?C>C62P\/8?R1+L4NYU_L$NOYY+R?DO@]P'1V<_J&*>,Q6F-^XQ$#\PKS MRG<:O[1Z3;,$LTX.0",6LJ>;1-L$>2FZ0\5_&]LLPZ '@%58 !"0_89"TN Q
MIEKL/1?O@8R#]D8L%255.)<*,'W\UZAC]1H!C2>5D@^&GB;;"%[M\(]T??[M)5YML;R2(+QKS).RTU/H1=D]\HD4\]948KNW1GX!^T^KNS5!G .WM*JX(65 MI/48[>+D2/T+
Q0L]OBJY.A!-\.DE2$KP_W@6F/LL>F2QQ^C:,M_F-JLR/_ M(8BPN-^ZY7=!2I24/$$#QW3QLO9X9[\C=?+D)5GY%\H/4JJ@/_0_D%_X"$LN MX?_.8YXC5K)8V/;_Y6E6\C\LY.#M!B%J.
<%>8CV"LI%/64/<'7I+T#;@W_?_M.419$9N\.L9)%OQ,5(9#:BHT(8)Q?<<)$;*%K L1#W&"][M%R$\?DOB(3R?& MMW8=?8X]WFE*306D#[&>'.$/\0NZBN=8%M(?
E(5T[@OHJXLA6U\LG%LN6819 M6A515XM)29<.IR:EO6WCO;X.WKW9D'4ILJWB"1A*B=@=2=VRDZW6"MZ$WG.IC.?=(6!EAM]4Y,<)O*:Q%1 '!23ZUQN6W^]*
{KO_08*Ds#Z&=79 MB;#BV,C%{):NERXO![RS\V.,9]N[0:R;RM\O,L*]JD?\G9HAW+T34&EG%P)(? M:$9<\Q\:(PNNV">[;9B3R-C[']N#%^W1QLO0_6Z'A(K=A)L =-OI/21]7-&#
M7O%ZLV?;-"&_!\2+BJ75NSA_S79Y6)FX^49E_A3-(3)- ?K^:^!;&)U0D$U5Q MNL0D5_V9&32CN(*;E]K$'85TY2KRPNQXE+.FFF<11$)?.OV.!!FZBS]X3R9C
MH.ZH,\'!2HFV<1V\'(BUA;[2SRC+"G,J?)7ED2L!HJN*(6QO2'S_GP/O-0A% MJL:2$IH/KC(C5L.OSV0#!\1AG0U_L.VGYLR)5>K$#\\#!%&8XR3Y.$IB3+4& MV";AQ)I=B3/.20J6.
{,LRO(Z/X' M86%YD!Z*9X7H8@*F)Y@$C>88GHR+HXH<#@5?ZEX+LM"4G6Z.(T8|-JT5_BX5 M],4XBL;'+#91U0PC@.2Q^0#^QO']Z93"Y,T/%.+!?)9$*$.HX8W3*97"2FXTB;BI--
M6O?/-;XEC"6]BL9)4X>A.HY4W;R.$X;].):FXFWBN%?'D?@9AQL5>#OKEFF:.M8G0=QY$!?_PYJ-=Q_$S%NEBQQ(ZC3@/#&AO6[A/0]V74A01[3B]3-_/H2!M
MQ]&G26T;#@*_C@Z:LB$7CF/#@-#0BZ]W'$53R0VR,?v.HU,/GU+)$;B*;K:7 M^Z0<1Y-A^XUQCC8AJJ:4M$09(HZW5IY.H92G,_<;-$^%4I5T'P#ULRE*4[3] MXSY^_Q/:^D6AL;?
{QYOTML*?R7WU9AV@PLYP3 M=YCF)+3_BQ)T/-W\XIU\%#%OHA%:.AR',MG%LN$'P'Y*I5[W^#_^:V61QZ\ M(*&1+E\PJ\-_+W@:,4"F2W'WV19W\Y_ZS>G&"XFG]OF
4/8#B?,WS(Y?,+G=_MX"__S@%#>CH$_,[__"7-KTVR/9P^HW<4"HH#2TZV#USSSO9W*JPNKK,&]8!Z M<7,K?2_.1F[YEE)Z^T]A&4?1#/M@-#2Y\@#\=81E3:SG85YQXZ5!*LUOE-9R
M O1O4?R:HH3FW]+CJZ3PD(H-%)V:D/4D5+N4"R0'M/R+#QH=4OFK:H_$TMR MSXTC]\U39L(5VYT4Y.X;,_$$B;.6,\[9.1HS"*5)3K',P(4,,,.H.1XU+%^
MW,A+4JZ9;&IK3=EP$$^(LN"=!AU:-]8PH^)7)$MJ3P_XYE0/*:/$5Q]>X@\: M=RY?&$*?\B$H4AX8DAW,+US??OE#3+ND]:I0=>\,TEWZ\R-^,<1YZD7^RP=& MRVD=
{6YP+]_>/689L)39#$(JO3(G2BE#F]B&A:W3HL FV!IB?:,*E\:^08M% M&4U&U*0,\M@7"'Q-\V/Q;Z/[X*/@$)6\OJQHG8I@%HOJ^\7 *#KS'&Q"!@0 MZP;S70SI-F@J,A$/]U'P;TPG-
/F*YJK)(T[W]PUNFD3 %M&.GT2%&2E6D)3 M8O^\.M!_C!#C.$KLD)R,: 0:L5+&4Y8LU(I8fY"C(Q"+:*]{+MARI2WUNE6 M55F8FX8E2FZ-7!Q'Y
M3PE*2?)5<1HE!H,7GJWTC0+@GMW6S#).IMZ5,3P25Q$!K66> MUL+PO/W^\)A0.1/$=Q1%B.X"+YU@#F,;(=6PQ]HA?PU1?_"'4J)R8H7 M_"D1_CFC(6U??&>YX]T'P3XKW1
9,4+^O9=$0;1/5]MM?LQIE8H[+.%N UX[M.HF)]IZ[^'@L#6U"EMH?!X6DA-MFC[6Z]<_/O.34>%X':.!)[O&8I?8-\A(Y$ M#L8RI#M*L@#_L5V*MZK#RW?
+JR]B[2#6>'M$&Z:9F(6M1TA'_/$V&[K5.:,<-M;;?'..?P.JI$G_TY>C54R"9J.7_$H"[*:$;;$5I<=H4#/-A%B_:M>;XBH"CN!!Q"9T(,)Y%F\N5;1-MQ!S%H931I?7F]!4XQT$?-
!D(;I,3*)!FK4)5L84%B4<9,DH&8R>,N9*ZM,1! M.63DR;_>$CDUSNK0"%. ZV$FHT1.@0G!47Q,IGYW3!>0T06'.S%?2\BQ1T!0 M)U;6((<5P4"@P +B6HQ0#>US?CSB=QY$_6
?!5AE($W%BW8 I!T=QN&6%-@S M$"ITL=V7=ON)TBS)90IV\49;,UNW-R1*N62-!+>M@WWN'_5LT8N5"PQFIV^#UY!^TI;7]_2N(,44D7_VF?>+3U(=_%)S/-M.I(fPFZ+JL8#.&X-
M,9QHD9\D I!C%Y0&[1%P,N 34I.MI=!VVRX<(B3[4E MQZ(\,A,>_GCG_)>23W93VF(^CZ"M#U+6+//[SR0=^9CE/EZ' >>? J+O ?#1G MA0!!GJG4$PT9&=(9<0*=@'\W9I'A-
N(VM*4;R 8@O?#+"[TOD+3IZ,2*0K%RS MS,C42# ;;%B_2I0KLVXX.6^[Z)2[BGSQIDGN6APE+1B&S#UZOV& GN\%8(A, M2_K6MX^PKV/C&CPDU$VP/"'"/L,O*EUX
Z566RYH#+69X M#++J^A5'B\O/MYZ4U\2Z3Dl8;_\6->KY_]QWZ)Z<6/U!S@XS&I2>(@=AV41 *.C4@U\13U>%[^'(7X+A O(R+,E-OS9)&5-
MEFIHRM6(W>9.U"6,Y(#3DD7^39]^B($WS6OCFEYH53=:,_M^C/NUKN7 Z]^TMA+5?2$=0SRDZ\O_F9QL2\N=HN6F,7%OKC8W3.,SLF?RM5. M0"-N<08N7]YYO("3^R)
<=WDI^B+@(\<49Y?1K.?B[-*-0QE|W_%49N/F)VMF M.(\"O\P CZ]&<Q-X_*9X-%0&=P(=0]?80_T+PL>'T9\]\G)B/U^"E899F9)-M1OK.DL(5B|=[\7K/Q^MJZZ4'O"WR'U)=]MT+NUU
NJ9M_@2+2<]5)V[V[MC_ M.1'?<&2UA!12ZTU^Q*""9BPG&:QI/T4S_9S1)ZJE_A+^52UGJ;5+BL*NE=% MAFXQ_PDR07B2]:VAJ+W#&IBAX)3A>8LK<7$E C"DBF0\R-B3T(=UR I-
5(D$ M*-"HDFN+.2C\M_-U+\&M(]@2-LZ<#%WS2PPSZ8F]7!9>O"(J6+Y(L%Z<)Q.@ MVAQ5S\G7(B'HNV;5[J1NW7@AX7;/\X2RNDW4N>KL4Q)C>10SRL@G3]-K=Z-
MK%NTI[VIA;2%46-O0V9]B8GV]A1N#\C/25<^]BY%IF?IZ3;,8%#W]2GAFPL& M)L$#YN;4;80L"U%C)CRP^AU19<%]SPG6/;MO2]O*9W1!{(_"]OZ(MMV[S1
M]EH!-5M9O^W.2BSA=]"5#;U'R5UK^P(P3X2#KS:K6>96O*68^WDO!7A^?)& MP[M6)10O79DBCWW<)Y@ 8W4!8K\A^ `^9/X](@DF6 /B,Q.,T0'?^\?C6Q*_
M%^@BA$,RS>"1H#1GO$/!9=8E JAD,XQ5G3N[PPW^H((RUM.FY@&H>>(5D5 M-%*D3+L* JP48]2E"/8$9ERS:"#=.MM"-*56V5PE83R9"Q=_G_Z;L>3=1P
M17K'+='CV+$^#6&NZ!-3$U>!<-S8KOEQI_K(7%$BIA"1:N.XFV D1H1ZDN/9 M%;/9B$CG"W]I8N&N[YONA/KO^-MK3>&VS,58H8TN.W.(,U%<;X$_M9[*X(_'KPM<2>?
5IC1"0QE\O/L6?WB:)^3-5 MK5('G1ZUQ$B59T%F&4/M(=*S%/7N\Y[_D#=S@H #Z31S41 M4\70M+D!9-^Q5Y,K+K-1U\F&R#;B7"ON>%@@R'3'9,ZP%YWA$1,7S0TF3\JZ
M1YA2ZE%16 B-Q$1[50*?UD"*2?VI=8% %%#1' **\WWQ?@3'\@3)TG\$43[M6^\-_Y+Q:B\J+6&_FR1[&K-3'34FTU&5.<<:*)W="\.\Q>ZQFD>@915B'IH&& MR'_YB%\.<9YZD?
!54T:&4$2:W1,9B"\K*:Y@#??OZ0@"MX&$X80[XR!]DB_ M0.OZ'241>93*V@?1GFSN.=XEYU\>L13QX_G#>R._"'GL96M"J'8Z%(S2&:=W MRVF2-;;+_U9O%?
_EMXT7[=GX[_XZZ;.^!!AZMR-M7^W+;M-VM"E)O*'MWV#>'ON:$[F"%//B!EYP:.K=((N&.MW?;6H*?^+ZQAF]^ M<1OT'H?O1.1L?8PA4_]OG/(:.01 =GTAH'8L*(!>"V#C4[Y>D/O?
&Z;9)] MRJQ*@0GLDX.3P)A]179*UE P&Q]AK[Z8S/D. JR%G^N>8:GB/=AR H$E)@!Y M;T1614"VZPL?25,T4;HH,">0\V5T!H*R6CT2SWOA^<9<!V<%8U5WIEGK"'X.
M3N7_JH!%N%.GU0(+VQY?"VS];D2A>M"@4"FL,;F(6ASR)0)J:P5STD,Q&259 M@SE%\PX+=YA@/^T!AK@[B3I(^X-U8T/S/7BW982B[<]!*B("\/_A,D>OR]O
M***%Q0!$6'8.0I5D<(6;WG'+3@+7@GQ+E"_8'&P@96Y Y(KC,X2#06?&<#2(" M"JE+<(&[2+"(YF?A:0'8.(A:OG\.=.$?A'@"D)"TJM8#D5^D@]9:$S2CN"HU
MOXZ>\$,;^X_1MJSVS*O8+0UY)**+BFI-8+2=73_(\TF ?I@>QJO2.(Y.!X %>!X0>CEW]UCO"JP'VR?O)$&AELZNF98J,>'^OUN04!&=2+XL.N*,--KUKZ+= M$OC[.L;7MT7YR4#
(A):;>7Y+D.>OHZ9!CJ==24\' F!U!M1I28QU/J;G+?]! MV\OQ4>$" (&\RTD)H>+2*@/8F@P0N/O=#FU)R:@+/#I&UAO5Vf)BGH2A%@I>' M-=*V_]4="?E>7H]KUPA#Y-
V=5L!KH*2HL"HL=-S_P/05I.@=!C;;H M_.:YMSP&.VXMHX]@?5%(+BUZ*YX5_*=CD!__!WD)UF&&7T.I54 I/B1$),BH M.(2&.8[*B0ZVW\CL;2'>
{-.JA.5%2]0USR@%5A\LPT\V"/^U5\U:?MXT M>RV.I.I[;<^#>R.&J49I"5" ?HORE)2_+4P4ES,"N?4,V 3{Z_]}MGKBA?C3 M*1<6]?F@CJ^%8&;#=M?9-
FM4;1'RTX]HX04=2EC:816@H^T#1Y?9!9/LAH]E)&?WR-HVV!;4&H"&,PB,W7;/X& MR^F84!Z"'\AO*M420$DLXFRLX%,>'X#;A=*F4E5[>)GI?:!;^93@\; 1-T*
M9GKXN:VG7.JVXS@01\:=<<')K@8-O-058+VPO(O &MM.#'8$'Z)2=3H1XD9Q-M.LGF-4)TZW2-]T9="X&.88\KG+K&G:?(P:/CEJETRTHA;)<$Z#PMHB(=/ M7$%08G$$?
MXR:+Q(48)4^G(309PD8=*84*40#4REFI+L.%[X:36MZLF7)0O[MCB-AVGRG[&0W2=A1T#G9D/26]/-Y'06R(PLOTQK4;G?$$U'1'FF.NF[GH./ 76IQ[-0=FA0YY\RJ_ MIH&C"!DRG+5+
(#@*I+++A3*7L F2ASO8S@Z(:!=YP_PJ$"A5AUD MC.@BC$ZHJ!'+*\Q<&?FB?J"18DR$8*?4&,$%3->V2E%%($VB!9;0>1DN[C*(1 ME,"TU2D67S2"&9B&&F:M1B/PPS)0""5NE:*/1G
%4Y,M"G&2Q3R-8@B7JCB@:,@0K_7@P4M551HU@A.8@JY$>5(CV HU#(+ MH!H"L4*EUSU0@N8$JJ3%;!+=A)-X'EM!:5UX1%W@U@@I8$FLSX(55'M8(M"H"*J8I%9N50\
f__U,$,WL/OC9\9O[80AIK/6;7C%F8^/C[^F%]S39 ^+%+ M_JB-CW^JBE#_*?-^Q%%//4)8FN#_,>>WNR E,,\3:C)\WAZ0GQ-_907]*O?
M#W&258BX0YD7A.E/,'1$\],Y/V!FB'@VDQ47+-R3<>C$2R+8%3;\9 X%LN]- M*-QZ8$@0 &ZQV";"G$?8,4 X9>EE*8'F,Y%WQ/PN^:#?R"6^4QC5KGF:$%X6:
MA]MV,\=916\5/EN|)N3/6 U[Q0S9'Z1GB. M*>J=P+3.R{5L*(@!ZFH 2@7E.6# PY.1&2I1:L.;+V7:;X>M]BH1P+/GB1 M *4KWP*2!XC6KF!_,6V8?(Y?WL+&QJ7(=,D?
[PUK:RI)9%YDCW68@_"+-A3 M.B AXWD],%$RAX+9N-!$R1GL\N;/=0PM4OUK2C,7L_MW0LB=\]0]NF>/A%1] MX3'PQUNT]J5IS>!/?XEO7@R$:
{;N/L5QFCTE\2ZHJV;US8']05#H@;EG\5AK M6U\ER%OO/GN1S]EO8X#>3:9)UM@@_ENI.9*W=TI5^H3B?>*|'8*M%S*8A'CL
MM%LNK);-33!OE'BL>UNV_YZT>1,65VI*_D0BS\XL2R2@R"\!,@+6;;],WM& M618BOQ91Q&R3,QJ,X"Z47QA#X6R<1";N^6YD^7GS PG +>EL40D>G>>2HNT?
M]_'GJ+L+2DV3O[4>$WPWWZ[777?C?)>0N(F_CDA:0FUM';(X&,R!QGCXX&C M-$5H_89(@8YH_QEY*?X;K=41%49>'Q\>*\N"9Q\@A 2,2$14KKK]W07#+/(
M8KR=N@9*6:*=@U3&4&L;;Q\NS?]<[JZE:(5/GN>D%\\!_LJOB.P+^:MW_*]| M5#F-2/AF&> I!9W$,J#N:,;$,%()CXFVY41;#T!=2[1>=ZI F",R;I#B.+,_M"V_HIXBCTD<)_=39=\T,*AJ:
^0:E34&I.Y*-184[31OK +5M*;IEB+06^@5 MK]9MG-*:>J35#U.0X RUAF)2&['AVGV+$K0E+C-Q:-_0+*O@$&UU@TA6H?\2 M-RS75/-CW%^UN%=L!X@@&A W=+D*!
M(QW=OO""MQ'W9J_"<-.#S(5P?- ?6&=Q]AXKCT_^ZX 1$,!\4*P,3\V;.M-@'&YP/.H:JRH\"WX8C&.\"U/!\RPHT\B1%*KXI2Z1@.%PMCB!#=&FT86,VET3:Q29"CQ,4(NX0
M.A@P09_>RA<&&5#I+!EAB.I9TN"+)(YGAZCH66R_I.,(4-(S9'R!'+WKRGPP0I5@=P+2ZO -1P([G[MDUEF<@ZD =WX:(HKTH[(<;WWD?SMX(;]N-[G2(DB!@.(7&]QI(P-B?@CU_+I
MZ]1^6EKW$(?X&-*B^1G0C'Y&"\?>R3%2*@63K*:%%OM:)P7.OZ#L0'HYOZ,T M0ZBQVYM3?W U3%P20.,G_"'"JU[A3_L M9U75&R$%8]:[E\2+4BR*DTLES T? MGF@-J,>GM3#?
J/Y[TJ15VM*3G?33+7?9=9;@:_\^/<8XR=/U:];HK%T6 M7W4=E-$.7(KMLM-9--XJB^]LUAHYR))\3;8^QMM4V'4GR MAH%)$+CLDZ},>V[\X02NL!A;L>=">MV#3<,E;]3@VL!
{4_%0Y6<;*\T M>_ >^%B]3ULML9B@,(?:TW (WEX]TA@O/A(JE=8>\YQ8%C!/ \I>SRM/KS$ M:\J3[<$[$UKSU@D3@ U^4+/ V/C"]SA##W%R[VT/+"H=' Z+WWR+ MJ"286O
MG.=H1C*SFUH?N;QANH^;!7;'2=GBKDPB4%Y$>_;KH(2Y$K,T\R(_B/8L$!17 ML,>YR$Z*AF)W.6DDA=E $/N%"-/L/!8 HY8T>=SHD5AW7/^04M/LRUWDX[U MA>0R#
{QP"@+1!MMD#3U95?^1R75?RG&5_]W(2GWV]9G&:NMW.;!1WK/4Q\:?MC+M0VH#?Q$?#0NXH_!R#>A77WS%Y&[@P9R,'6T9P:OH&PAP%78I?UK2M0?B@
M43)\MT7^A3DTO)',EU=[787>]#8D+HC?*]""PE,RIE) HL94.'#:"'CRIA8 MH.#]<1T_ZGSE4K?13/*&S KJ++/8&&7'&KF+'+>:<";P4V%M8>8-3Y# >A2'E@"+,3M:T/(2CG
MUGL+,B\LKG1%#U*[P[7D5S'.J#OJ+,J#HP4.(O\I]"+B)E6G/QHXE..XR0K M&7J]*^K8I,2@1J&9XP_5L\+D)MH.!*3[$:?<]0>;BY]>O>-G@ESY\X7XQ,V] M49MK,?RT+
(W91*0HNYDIWEZ7X/-MXY^[/6;A7N, ^=7"2^FM[#UOE+:"'?O_\],1'O>H2NB% 28 _M/S8?>MP:1F"XT0"#PAI&8+B5^#[F+Y5%9PB<<Q.P^DHK&$$AGL-,"BL M802&![T4-
FXY=Y-@)M)FI6F9 ^27>]T&_$L+3(<{ @=822:.QXOT+:_.CM)RXOC MJ.;85BA$ /V$=*XD,M=&;*6,+QO+=RYCP*FM:479*3]L:^3?108FR6=<)\'$||=Q1(';O? %)<<_BQ \|ZA
M%UN'4=R_3]>D,;K]#'I"HPJ*[G'/NH[_ GK!\DD[$/JF],I&'S3@$O9=X.[M;.(P?(@3]J.AMX+SL3D@K_"\FL=;^1WW4++4(1."R)#&+E?NZDNL^Q&YHYT MNYAV5]@NP2
75%+$%1:)GG@G5E*UFT?$-%86EGDI\'JW*,!T\,CNE#7QO^$2 MVU)Z#0(K_5Y$C$1^%8_P$I-_4C[WP/)W#3[DW67TA1R2D,I,?AGS4 M_33F\U,H%5V/PB78N>N9&W +R]GGAWB1-
!0 MP.07W4.C6!QN4,QJOT_0WLO0)$_P^/W.I0BE,NY+?WI&"+9@5+UP4W.[C.8% MMT'M_<]BV"'^'?D*LI;]-E*?O*E?KA>_<%@H6JH=7!*IY?@AR1?(4@J!Q MD(7ISFE-
+@2/BJ"ZUD,R(^X-/,_7BNS)I9[H$O.=P+ZJW#-U*-VUGLNTKSKT M^@HN%+2Q];+K.B[UK;,ZL&7OL/7>A"3"P/,2,L%^Q >'>5@3LC%M<&^/&:B M/Z_U*(P^) ,'?
*TX5WS1H3L7BMR0>F'O4#B:ST56 ^U8F@RY#8#8)!0[', MUWH6UMQ]H[#H:VTH84M^O2"T^LJ;CK]7#[V>CD2 /[?2R.YK[7;"Y1[Q8CR
M7HX$P+V2CAF?:257]I7W\,=]LU!4=DV7TJZ,A9?2KG!+N\(C"G?-KFUS[+-MN)@&?8]#O$R()9"B+Y(>)UCAR],2(1;PA$38^GT>)[X)-MTM\?$D1,.BC!*L[4Y\W\[CQ0RFYM-
MT5:GUW25Q=$E>9^)7/B927?AU'B<$X M!T,R-6B$+]F0-;@(M[X"QI(X;$R!>8*RA8"(_H-Z&O@\-KC?D?9]F
MM1Y'3_$:H;#F0@KR6QUH5HZ.FN(ULEO=;@MNG9X)B6W.ZYT)A2.4%!E**;-MTT,>T7;0B_]L\9^YZ#];A71=Q&E;7-(Y!W!D)R=:. PU6FP\=1NG&68 7HA2ID. /\
!;EC%/_$RF+?:BQ5[DHKUH]/%65P=?D9P"N,X.Y$9X49FK\36. MWFEVC9D^"ZKEL8PZD]1) M;_-=5EO.7FM[4L3PUF9X,,*"IP!.1W5_,SRB1GE >.>CM+D9'DZ;=<,[']7]-M+?
ZQO3_F0I2;NG%B[OB_P,:0,9>S5'+0V)-R4#(5=CWE 4A8HPX& Z[SL$X M[!|RC4!V33B.>\)<0]<$G4"N-QO>V?9SK>7U;,M1$KK3M59H _$T6#J?ORJG -MH\XXC]DHG@E2UK
T/-8/S(.MX#3-I18WR$?H2*CHE@AZ21;@/S[A&2A)2A/3KUY"!0U^H47U1>!Z&I90(*E0 MH&_X_4HWS]|40H(Z<^SEEX5>FI:E?{4GR!BH^?H]8^D#I2N)"\2_70!3A9?"+P-I%\=-
B/_'S+-8T+Y[@=/GCE[##X;VV:LH56I&0F_/' M6P.AE"]$VVZ/L?A^CF/QZO.-/%$W&IXHA36,P'"K 0:%-8S <*6':M.XXB2V$Y M7?!?8<2SR->:,ZU:JR)@L:)W(A2^,UV6&FYTHPDV19!F
X=:.R@QR#]K7KUBM-%2I64!X^0M G*A851V//Y;&B8J5 MUK78N W^G[_J +GGPG+I&.WBY$B?E'.O\C5F/?A?HOT&I5@-; QYB)-[.WO8 MH+N%QOF.T-*%T);1#?S:Y
=;O.TBX\H*80XC.M5FB+\?_Z+ M]T.,D])*$FJ6?XIC^6*#N:A[P'F0L]QZ ^_G+CG=GSAMMGN_6SNUIA957+E"%Q_G7M%5L M24;)T*8;(HDWOR#IBX5X3W;S%?

*$N"6NDQ6T7';C${6*ZH^RQ(,R_4W+0*%U" M]S_(X>=!>B#(7._NT"N7,0W.LT?O)&'L*8:V|0L/I"!29:{O(!!&5\)YT$.5X M>^55C:/T!F'-!Q7CL!Q-C*WX68L3+%|C19BJ?A@N$O.$-*>B00E;0'I0"M+'3T'V#(P0<7GW!;<# /4)7/7$:X@!PJ8! U3';J>-# 6%PP MS%>,APINUM\9RS6'#H.N%K\9RC@'[MH@FT_!T^6HQ:*EV+4VJ$*.6O*?I7CC%Z_TXU4-\/BITW$&L]!*B]R=XY=[V_.MO.'V?-;M'0ECB%A#!5;GR;=9GF'ZOSUXR9[K4F0.M,;QSYB*]T7(7>9EN2@D M@SD4S.;%<0Z=OGJD2*48 L$,S1Y_*FLT+,$)T5Y-[C\!TE]WV" Mf+%45">./13(/2 !$R5EKW<-8A?O)/D+ 9B95F(-]@7F JE3>V5Z#D@<4'MPAN]< >Y3UPO.XEE#DQ.C]&OAPT*OS8Y+W%#!*0A.:8=[L31AD0:C2(a;TWD!`M4" <*G[.$N[G%W0GLYWQ6)&9DKD?B2 A[@W9<>A5Y!RV6@X9 ?KO!5,J=CW@ M2D'=43-R0$:,=MK@OE"NQZ"--P>T3$.N!Z IH$'2N*0QVF'KA=L\K*(W3(4[MU-698KQ@1&O-16D$LO1;Y.4^ZC2TDE&+++4' #7CNRS(^E%&;N*/WE-D\2>B*U7/9!&\[1IVB05B>' M]D-KFBDQX*-=(X+LB(?(O);XIPSD'X.O%?RR)#|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}@0R@ >^N8A "(]^NR6U<8"%NA2="]5N,N%WU)U92;*WV"UCUX MRA-,/BDBXF/U9^=,"G49ZGCW$R5VME,S3 M"$GDA' Y$^/SNJF\D(-M331D@A2,6DC\B3G8!F^%R"OY83A"!PA+03E/]..5.D[6 O6*;4]YD)GA24Z&=GL"K+'=Z MK 6LGYZ,\UMXAA(+6.UU,+VO@-$T8<)-6*PP(./G9])(:JK%\% 9KS43,*FI M@-YC.6^IY,LLM9AU!LATA@HY'FN&S;8A9]\;>]?U@+&;):V-60'016%YMR2O!6;]+,.\ZOBIVP+13[86002X+'0@7F 3DEDW!_WZ($0 MMV0M\DBP0)2<#.L66_5WRV)IS@"95T=IVTIU>]FJf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`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`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|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|E"S8IJ69+B_>#*\M[:RLN#_T [,ZZ@ZV;KC2=L> M(QH)Y? 0'7ZG/-'5]2N)=T.5;C[_<8U)M6I4;"H\R"\UF-=)DH3(Y &78-R-M:\&]E'DCP\1W>(N2G#TE\Y)8U[,Y\)G7566'>Z6&QVE#\)_]O#@43!PR/@B/ M]_!Z?S6J0S%^A?+ZR:BA_1 ,KG]? 2T#E,TPIT#92O7 M3NC0\A;,L99/$. 7#0?2[0%OIO_\?U\!+ P04 "_@V=9E8]H0)8) . M50 #P '-G;'0M97@S,5\O+FAT;>U<;6 ,;.!+ ^?/LK>"FZUP*68\=)MRMG M"Z2IBPUP;+M)>NA]I*51S"LE;DG*+XO]\3=#2GZ)G<;IT\1N%;!-) TY,Q3G MX3-#2<<#F\I7/[*C ? 8?[-C*ZR$5[U/0:?=;!_O^T,4V"\ECOLJGC!C)Q)^ MVTNYOA)9R'AAU3]%FBMM>6;].8|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|0T?=MH'6ZRPITO91[VXR!C/)]S(K"X ;>76316**;DD@ XP]P_6$1%+^&5P<3_LT>'Y&8U"E=,&*,D@@$CHJ4A2C MT$5+,"5E.#[1(@]F"_INU'X&&LA-R(!5&8HJ-F2P,"3M !TT.D3.0^BUA(U)# M;!:S_F1^&&IPJ,'A/L&AL\O@ "P1&88?1? (LW']{#"B,E_7<=9'A HUQ+[? MD46RH$490WHNMAH(!\(MW!B1!"8$,E+,.T*(,5'---5H:NV)5@R0*B0(($0HG MI5-GG#T1-P.62#4R%7YHN,)YK#DJXG32VXU6-N9@P%&;G;W219 IH|SC_N M7^'=D $:)6K4VQSU#6<]2X7(.+3 #5OO7KBF!K4S,B4.H)!%XZ-#C€'$-_M#[<=0T1?@DM+ /WNX_09D#B)L!'*M(HCQOM&'/ M$)}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|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{JS29AK[N1M89Y8) M:P&6Z>2L;*0PFB2!1*"&KI97"%@XR0V11/Q-R<<:^>&O4[!#NO+/'9;N[_# M!A,.3&QXZ#/=/Z&W0BBC)1 .,,>1]BS=.YRB"DBG^QAC[R*,'U&R<68+A?F MWDJKWQ#9"!6K+0>_S[N"_O$$"QJ8LK_[$;1*H6$91$$'=<5Y(2NDF@ ^'0^5)[I\ ?$1H5>D&F;@NG: < M[S]:F=_LX^IZ7SN+WJ/"SI0I=C4742#W\F]1)GJ+8^]#_$D M+R%P$OF_Z3#W\GU0U=>IHU?0.,^ W]&K\6G8+B,@$(U=A74Z#W:F]1)GJ+8^ M[#K

0001531177 srt:MaximumMember sght:TwoThousandTwentyOneEmployeeStockPurchasePlanMember 2023-07-01 2023-09-30 0001531177 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0001531177 sght:TwoThousandTwentyOneEmployeeStockPurchasePlanMember 2023-07-01 2023-09-30 0001531177 us-gaap:RestrictedStockMember 2024-09-30 0001531177 us-gaap:IPOMember 2024-09-30 0001531177 srt:MinimumMember sght:TwoThousandTwentyOneEmployeeStockPurchasePlanMember 2024-01-01 2024-09-30 0001531177 sght:TwoThousandTwentyOneEmployeeStockPurchasePlanMember 2021-07-31 0001531177 us-gaap:RetainedEarningsMember 2023-09-30 0001531177 us-gaap:AdditionalPaidInCapitalMember 2024-06-30 0001531177 sght:HerculesCreditAgreementMember 2023-12-31 0001531177 sght:DryEyeMember 2024-01-01 2024-09-30 0001531177 us-gaap:CostOfSalesMember 2024-01-01 2024-09-30 0001531177 sght:JeremyBHaydenMember 2024-09-30 0001531177 sght:HerculesCreditAgreementMember 2024-01-01 2024-01-31 0001531177 us-gaap:RestrictedStockUnitsRSUMember 2024-07-01 2024-09-30 0001531177 us-gaap:CommonStockMember 2024-09-30 0001531177 us-gaap:SupplyCommitmentMember 2022-01-01 2022-12-31 0001531177 2023-12-31 0001531177 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0001531177 us-gaap:CommonStockMember 2024-01-01 2024-09-30 0001531177 us-gaap:CommonStockMember 2024-07-01 2024-09-30 0001531177 sght:SurgicalGlaucomaMember 2024-01-01 2024-09-30 0001531177 srt:MaximumMember sght:TwoThousandTwentyOneEmployeeStockPurchasePlanMember 2023-01-01 2023-09-30 0001531177 sght:DryEyeMember 2023-01-01 2023-09-30 0001531177 us-gaap:ConstructionInProgressMember 2023-12-31 0001531177 us-gaap:RetainedEarningsMember 2024-06-30 0001531177 sght:DryEyeMember 2024-07-01 2024-09-30 0001531177 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2024-07-01 2024-09-30 0001531177 sght:TwoThousandAndTwentyOnePlanMember 2024-01-01 0001531177 sght:HerculesCreditAgreementMember sght:TrancheTwoLoansMember 2024-01-31 0001531177 us-gaap:CostOfSalesMember 2023-07-01 2023-09-30 0001531177 us-gaap:USTreasurySecuritiesMember 2023-12-31 0001531177 us-gaap:CostOfSalesMember 2024-07-01 2024-09-30 0001531177 sght:HerculesCreditAgreementMember 2024-09-30 0001531177 sght:HerculesCreditAgreementMember 2024-09-30 0001531177 us-gaap:FurnitureAndFixturesMember 2023-12-31 0001531177 us-gaap:SupplyCommitmentMember 2024-09-30 0001531177 srt:MinimumMember sght:TwoThousandTwentyOneEmployeeStockPurchasePlanMember 2023-01-01 2023-09-30 0001531177 us-gaap:AdditionalPaidInCapitalMember 2024-01-01 2024-09-30 0001531177 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2024-09-30 0001531177 sght:MidcapCreditFacilityAgreementsMember 2024-09-30 0001531177 us-gaap:FairValueMeasurementsRecurringMember 2023-01-01 2023-12-31 0001531177 2024-06-30 0001531177 us-gaap:CommonStockMember 2023-01-01 2023-09-30 0001531177 us-gaap:CostOfSalesMember 2023-01-01 2023-09-30 0001531177 us-gaap:EmployeeStockOptionMember 2024-01-01 2024-09-30 0001531177 srt:MaximumMember 2023-07-01 2023-09-30 0001531177 us-gaap:WarrantMember 2023-01-01 2023-09-30 0001531177 2023-07-01 2023-09-30 0001531177 us-gaap:ConstructionInProgressMember 2024-09-30 0001531177 srt:MinimumMember 2023-07-01 2023-09-30 0001531177 2024-11-01 0001531177 us-gaap:AdditionalPaidInCapitalMember 2023-12-31 0001531177 sght:JeremyBHaydenMember 2024-07-01 2024-09-30 0001531177 sght:CommonStockAvailableForFutureGrantMember 2024-09-30 0001531177 us-gaap:ToolsDiesAndMoldsMember 2023-12-31 0001531177 us-gaap:AdditionalPaidInCapitalMember 2024-09-30 0001531177 us-gaap:ResearchAndDevelopmentExpenseMember 2024-01-01 2024-09-30 0001531177 us-gaap:ResearchAndDevelopmentExpenseMember 2023-07-01 2023-09-30 0001531177 us-gaap:CommonStockMember 2024-06-30 0001531177 sght:TwoThousandAndTwentyOnePlanMember 2023-12-31 0001531177 us-gaap:EmployeeStockOptionMember 2023-01-01 2023-09-30 0001531177 us-gaap:RestrictedStockMember 2024-01-01 2024-09-30 0001531177 srt:MaximumMember sght:TwoThousandTwentyOneEmployeeStockPurchasePlanMember 2024-07-01 2024-09-30 0001531177 sght:SurgicalGlaucomaMember 2023-01-01 2023-09-30 0001531177 sght:SharesAvailableForFuturePurchaseUnderESPPMember 2024-09-30 0001531177 sght:CommonStockOptionsIssuedAndOutstandingMember 2024-09-30 0001531177 us-gaap:RetainedEarningsMember 2024-01-01 2024-09-30 0001531177 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2023-01-01 2023-09-30 0001531177 sght:TwoThousandTwentyOneEmployeeStockPurchasePlanMember 2024-07-01 2024-09-30 0001531177 us-gaap:ResearchAndDevelopmentExpenseMember 2023-01-01 2023-09-30 0001531177 us-gaap:RetainedEarningsMember 2023-06-30 0001531177 us-gaap:CommonStockMember 2023-06-30 0001531177 srt:MinimumMember sght:TwoThousandTwentyOneEmployeeStockPurchasePlanMember 2024-07-01 2024-09-30 0001531177 us-gaap:RestrictedStockUnitsRSUMember 2023-07-01 2023-09-30 0001531177 us-gaap:RestrictedStockMember 2023-12-31 0001531177 sght:RestrictedStockUnitsOutstandingMember 2023-12-31 0001531177 sght:TwoThousandTwentyOneEmployeeStockPurchasePlanMember 2023-01-01 0001531177 us-gaap:AdditionalPaidInCapitalMember 2023-06-30 0001531177 us-gaap:RetainedEarningsMember 2023-12-31 0001531177 2023-06-30 0001531177 us-gaap:WarrantMember 2024-01-01 2024-09-30 0001531177 us-gaap:ComputerEquipmentMember 2023-12-31 0001531177 srt:MaximumMember sght:TwoThousandTwentyOneEmployeeStockPurchasePlanMember 2024-01-01 2024-09-30 0001531177 us-gaap:RetainedEarningsMember 2024-07-01 2024-09-30 0001531177 us-gaap:RestrictedStockUnitsRSUMember 2024-09-30 0001531177 sght:RestrictedStockUnitsOutstandingMember 2024-09-30 0001531177 sght:TwoThousandTwentyOneEmployeeStockPurchasePlanMember 2024-01-01 2024-09-30 0001531177 us-gaap:RetainedEarningsMember 2023-07-01 2023-09-30 0001531177 2023-01-01 2023-09-30 0001531177 2022-12-31 0001531177 sght:SharesAvailableForFuturePurchaseUnderESPPMember 2023-12-31 0001531177 us-gaap:LeaseholdImprovementsMember 2024-09-30 0001531177 us-gaap:ResearchAndDevelopmentExpenseMember 2024-07-01 2024-09-30 0001531177 2024-09-30 0001531177 sght:TwoThousandTwentyOneEmployeeStockPurchasePlanMember 2023-01-01 2023-09-30 0001531177 us-gaap:CommonStockMember 2022-12-31 0001531177 us-gaap:CommonStockMember 2023-07-01 2023-09-30 0001531177 us-gaap:ComputerEquipmentMember 2024-09-30 0001531177 srt:MaximumMember 2023-01-01 2023-09-30 0001531177 sght:MidCapFinancialServicesMember 2024-01-01 2024-09-30 0001531177 sght:CommonStockOptionsIssuedAndOutstandingMember 2023-12-31 0001531177 sght:CommonStockAvailableForFutureGrantMember 2023-12-31 0001531177 sght:TwoThousandTwentyOneEmployeeStockPurchasePlanMember 2024-09-30 0001531177 us-gaap:FurnitureAndFixturesMember 2024-09-30 0001531177 srt:MinimumMember sght:TwoThousandTwentyOneEmployeeStockPurchasePlanMember 2023-07-01 2023-09-30 0001531177 us-gaap:RetainedEarningsMember 2023-01-01 2023-09-30 0001531177 us-gaap:ToolsDiesAndMoldsMember 2024-09-30 0001531177 sght:DryEyeMember 2023-07-01 2023-09-30 0001531177 sght:MidcapTermLoanMember 2023-12-31 0001531177 us-gaap:CommonStockMember 2023-09-30 0001531177 sght:HerculesCreditAgreementMember sght:LendersMember 2024-01-31 0001531177 sght:SurgicalGlaucomaMember 2024-07-01 2024-09-30 0001531177 us-gaap:CommonStockMember 2023-12-31 0001531177 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2023-07-01 2023-09-30 0001531177 us-gaap:AdditionalPaidInCapitalMember 2024-07-01 2024-09-30 0001531177 sght:SeniorSecuredTwoThousandNineteenTermLoanMember sght:MidCapFinancialServicesMember 2024-09-30 0001531177 sght:HerculesCreditAgreementMember 2024-01-22 0001531177 sght:HerculesCreditAgreementMember 2024-01-31 0001531177 sght:TwoThousandAndTwentyOnePlanMember 2023-01-01 0001531177 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2024-01-01 2024-09-30 0001531177 us-gaap:SupplyCommitmentMember 2024-01-01 2024-09-30 0001531177 sght:TwoThousandAndTwentyOnePlanMember 2024-09-30 0001531177 us-gaap:RestrictedStockUnitsRSUMember 2023-01-01 2023-09-30 0001531177 2024-01-01 2024-09-30 0001531177 us-gaap:AdditionalPaidInCapitalMember 2023-07-01 2023-09-30 0001531177 srt:MinimumMember 2023-01-01 2023-09-30 0001531177 srt:MaximumMember 2024-09-30 0001531177 us-gaap:RestrictedStockUnitsRSUMember 2024-01-01 2024-09-30 0001531177 us-gaap:AdditionalPaidInCapitalMember 2023-01-01 2023-09-30 0001531177 sght:MidcapTermLoanMember 2024-09-30 0001531177 sght:TwoThousandTwentyOneEmployeeStockPurchasePlanMember 2024-01-01 0001531177 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2024-09-30 0001531177 us-gaap:RetainedEarningsMember 2022-12-31 0001531177 sght:SurgicalGlaucomaMember 2023-07-01 2023-09-30 0001531177 us-gaap:AdditionalPaidInCapitalMember 2023-09-30 0001531177 sght:HerculesCreditAgreementMember sght:LendersMember 2024-01-01 2024-01-31 0001531177 us-gaap:FairValueMeasurementsRecurringMember 2024-01-01 2024-09-30 pure shares iso4217:USD shares sght:Segment iso4217:USD sght:Vote false 0001531177 --12-31 Q3 10-Q true 2024-09-30 2024 false 001-40587 SIGHT SCIENCES, INC. DE 80-0625749 4040 Campbell Ave Suite 100 Menlo Park CA 94025 877 266-1144 Common Stock, par value $0.001 per share SGHT NASDAQ Yes Yes Non-accelerated Filer true true false false 50754616 118564000 138129000 824000 1186000 12929000 14289000 6091000 7849000 2885000 2604000 140469000 162871000 1448000 1640000 1100000 1458000 580000 682000 143597000 166651000 1297000 1731000 7889000 4528000 4613000 3774000 0 2219000 13799000 12252000 34152000 31708000 689000 2476000 48640000 46436000 0.001 0.001 10000000 10000000 0 0 0 0 0 0 0.001 0.001 200000000 200000000 50398148 50398148 49131363 49131363 50000 49000 429358000 414956000 -334451000 -294790000 94957000 120215000 143597000 166651000 20157000 20009000 60792000 62305000 3250000 2677000 9068000 9105000 16907000 17332000 51724000 53200000 4746000 4239000 13698000 14129000 23390000 26504000 76629000 85235000 28136000 30743000 90327000 99364000 -11229000 -13411000 -38603000 -46164000 1454000 1897000 4628000 5499000 1151000 1432000 3501000 4057000 0 0 -1962000 0 26000 -11000 -25000 -34000 -10900000 -12957000 -39463000 -44756000 166000 78000 198000 100000 -11066000 -13035000 -39661000 -44856000 -0.22 -0.22 -0.27 -0.27 -0.79 -0.79 -0.92 -0.92 50340603 50340603 48671049 48671049 49911655 49911655 48538517 48538517 50136131 50000 424973000 -323385000 101638000 38936 77000 77000 223081 4308000 4308000 -11066000 -11066000 50398148 50000 429358000 -334451000 94957000 49131363 49000 414956000 -294790000 120215000 194119 233000 233000 840376 1000 -1000 -20000 -20000 609000 609000 232290 450000 450000 13131000 13131000 -39661000 -39661000 50398148 50000 429358000 -334451000 94957000 48649343 49000 407146000 -271064000 136131000 60738 117000 117000 12138 0 0 3856000 3856000 -13035000 -13035000 48722219 49000 411119000 -284099000 127069000 48298138 48000 399271000 -23924300 160076000 163940 288000 288000 181607 1000 1000 -222000 -222000 78534 661000 661000 11121000 11121000 -44856000 -44856000 48722219 49000 411119000 -284099000 127069000 -39661000 -44856000 536000 455000 550000 452000 13131000 11121000 -68000 416000 -105000 219000 481000 743000 -23000 -66000 1033000 0 -1427000 2187000 -1863000 3345000 280000 -517000 35000 444000 -41000 841000 3360000 -1851000 418000 -3089000 -1524000 242000 -18892000 -40700000 248000 527000 -248000 -527000 -34526000 0 35375000 0 238000 0 450000 289000 -20000 -222000 232000 661000 -425000 728000 -19565000 -40499000 138129000 185000000 118564000 144501000 3023000 3167000 43000 81000 609000 0 Note 1. Company and Nature of Business Description of Business Sight Sciences, Inc. (the “Company”) was incorporated in the State of Delaware in 2010 and is headquartered in Menlo Park, California. The Company is an ophthalmic medical device company focused on the development and commercialization of surgical and nonsurgical technologies for the treatment of prevalent eye diseases. The Company’s mission is to develop transformative, interventional technologies that allow eyecare providers to procedurally elevate the standards of care — empowering people to keep seeing. The Company’s product portfolio aligns with its two reportable operating segments: Surgical Glaucoma and Dry Eye. The products for the Surgical Glaucoma segment include the OMNI® Surgical System (“OMNI”), which is an implant-free, handheld, single-use, therapeutic technology that enables ophthalmic surgeons to perform a comprehensive procedure (i) indicated in the United States to reduce intraocular pressure in adult patients with primary open-angle glaucoma, and (ii) CE Marked for the catheterization and transluminal viscodilation of Schlemm’s canal and cutting of the trabecular meshwork to reduce intraocular pressure in adult patients with open-angle glaucoma; and the SION® Surgical Instrument (“SION”), a bladeless, manually operated device used in ophthalmic surgical procedures to excise trabecular meshwork. The product portfolio for the Dry Eye segment consists of the TearCare® System ("TearCare") for ophthalmologists and optometrists. TearCare is a proprietary, interventional, dry eye device designed to melt and facilitate the comprehensive removal of meibomian gland obstructions and restore gland functionality and healthy oil production for adult patients with evaporative dry eye disease due to meibomian gland dysfunction (“MGD”) when used in conjunction with manual expression of the meibomian glands, enabling clearance of gland obstructions by physicians to address the leading cause of dry eye disease. Significant Risks and Uncertainties Since inception, the Company has incurred losses and negative cash flows from operations. As of September 30, 2024, the Company had an accumulated deficit of $334.5 million since inception and recorded a net loss of $39.7 million for the nine months then ended and expects to incur additional losses in the future. If the Company’s revenue levels from its products are not sufficient or if the Company is unable to secure additional funding when desired, the Company may need to delay the development of its products, scale back its business and operations, or change its business strategy. The Company believes that its existing sources of liquidity will satisfy its working capital and capital requirements for at least 12 months from the issuance of its unaudited condensed consolidated financial statements. Any failure to generate increased revenue, achieve improved gross margins, or control operating costs could require the Company to raise additional capital through equity or debt

financing. Such additional financing may not be available on acceptable terms, or at all, and could require the Company to modify, delay, or abandon some of its planned future expansion or expenditures or reduce some of its ongoing operating costs, which could harm its business, operating results, financial condition, and ability to achieve its intended business objectives. -334500000 -39700000 Note 2. Summary of Significant Accounting Policies Basis of Presentation The condensed consolidated financial statements and accompanying notes thereto are unaudited and have been prepared in accordance with accounting principles generally accepted in the United States of America ("US GAAP") applicable to interim periods and pursuant to the instructions to Form 10-Q and Article 10 of Regulation S-X. The Company's condensed consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries, Sight Sciences UK, Ltd and Sight Sciences GmbH. All intercompany balances and transactions have been eliminated in consolidation. The unaudited condensed consolidated financial statements have been prepared on a basis consistent with the audited consolidated financial statements. In the opinion of management, the unaudited condensed consolidated financial statements reflect all adjustments, which include only normal recurring adjustments, necessary for the fair presentation of the Company's financial information contained herein. The condensed consolidated balance sheet as of December 31, 2023 is derived from the Company's consolidated audited financial statements as of that date. These interim condensed consolidated financial statements do not include all disclosures required by US GAAP and should be read in conjunction with the Company's audited consolidated financial statements and the accompanying notes thereto for the fiscal year ended December 31, 2023, which are contained in the Annual Report. The Company's results of operations for the nine months ended September 30, 2024 are not necessarily indicative of the results to be expected for the year ending December 31, 2024 or for any other interim period. Use of Estimates The preparation of the unaudited condensed consolidated financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent liabilities at the date of the financial statements, and the reported amounts of revenues and expense during the reporting period. The most significant estimates related to the provision for credit losses, inventory excess and obsolescence, determination of the fair value of stock option grants, and provisions for income taxes and contingencies. Management evaluates its estimates and assumptions on an ongoing basis using historical experience and other factors, including the current economic environment, and makes adjustments when facts and circumstances dictate. These estimates are based on information available as of the date of the financial statements. Actual results could differ from these estimates and such differences could be material to the Company's financial position and results of operations. New Accounting Pronouncements Accounting Standards Recently Adopted During the nine-month period ended September 30, 2024, there were no significant Accounting Standard Updates ("ASUs") issued that were adopted. Accounting Standards Not Yet Adopted In November 2023, the Financial Accounting Standards Board ("FASB") issued ASU No. 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures. The ASU updates reportable segment disclosure requirements, primarily through requiring enhanced disclosures about significant segment expenses and information used to assess segment performance. The ASU is effective on a retrospective basis for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024, with early adoption permitted. The Company is currently evaluating the impact of adopting this ASU on its disclosures. In December 2023, the FASB issued ASU No. 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures. The ASU includes amendments requiring enhanced income tax disclosures, primarily related to standardization and disaggregation of rate reconciliation categories and income taxes paid by jurisdiction. The guidance is effective for fiscal years beginning after December 15, 2024, with early adoption permitted, and should be applied either prospectively or retrospectively. The Company is currently evaluating the impact of adopting this ASU on its disclosures. As of September 30, 2024, there are no additional ASUs issued and not yet adopted that are expected to have a material impact on the Company's financial statements and related disclosures. Basis of Presentation The condensed consolidated financial statements and accompanying notes thereto are unaudited and have been prepared in accordance with accounting principles generally accepted in the United States of America ("US GAAP") applicable to interim periods and pursuant to the instructions to Form 10-Q and Article 10 of Regulation S-X. The Company's condensed consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries, Sight Sciences UK, Ltd and Sight Sciences GmbH. All intercompany balances and transactions have been eliminated in consolidation. The unaudited condensed consolidated financial statements have been prepared on a basis consistent with the audited consolidated financial statements. In the opinion of management, the unaudited condensed consolidated financial statements reflect all adjustments, which include only normal recurring adjustments, necessary for the fair presentation of the Company's financial information contained herein. The condensed consolidated balance sheet as of December 31, 2023 is derived from the Company's consolidated audited financial statements as of that date. These interim condensed consolidated financial statements do not include all disclosures required by US GAAP and should be read in conjunction with the Company's audited consolidated financial statements and the accompanying notes thereto for the fiscal year ended December 31, 2023, which are contained in the Annual Report. The Company's results of operations for the nine months ended September 30, 2024 are not necessarily indicative of the results to be expected for the year ending December 31, 2024 or for any other interim period. Use of Estimates The preparation of the unaudited condensed consolidated financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent liabilities at the date of the financial statements, and the reported amounts of revenues and expense during the reporting period. The most significant estimates related to the provision for credit losses, inventory excess and obsolescence, determination of the fair value of stock option grants, and provisions for income taxes and contingencies. Management evaluates its estimates and assumptions on an ongoing basis using historical experience and other factors, including the current economic environment, and makes adjustments when facts and circumstances dictate. These estimates are based on information available as of the date of the financial statements. Actual results could differ from these estimates and such differences could be material to the Company's financial position and results of operations. New Accounting Pronouncements Accounting Standards Recently Adopted During the nine-month period ended September 30, 2024, there were no significant Accounting Standard Updates ("ASUs") issued that were adopted. Accounting Standards Not Yet Adopted In November 2023, the Financial Accounting Standards Board ("FASB") issued ASU No. 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures. The ASU updates reportable segment disclosure requirements, primarily through requiring enhanced disclosures about significant segment expenses and information used to assess segment performance. The ASU is effective on a retrospective basis for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024, with early adoption permitted. The Company is currently evaluating the impact of adopting this ASU on its disclosures. In December 2023, the FASB issued ASU No. 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures. The ASU includes amendments requiring enhanced income tax disclosures, primarily related to standardization and disaggregation of rate reconciliation categories and income taxes paid by jurisdiction. The guidance is effective for fiscal years beginning after December 15, 2024, with early adoption permitted, and should be applied either

prospectively or retrospectively. The Company is currently evaluating the impact of adopting this ASU on its disclosures. As of September 30, 2024, there are no additional ASUs issued and not yet adopted that are expected to have a material impact on the Company's financial statements and related disclosures. Note 3. Fair Value Measurements The Company reports all financial assets and liabilities and nonfinancial assets and liabilities that are recognized or disclosed at fair value in the financial statements on a recurring basis. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. The authoritative guidance establishes a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to measurements involving significant unobservable inputs (Level 3 measurements). The three levels of the fair value hierarchy are as follows: Level 1—Inputs are quoted prices (unadjusted) in active markets for identical assets or liabilities that the Company has the ability to access at the measurement date. Level 2—Inputs are observable, unadjusted quoted prices in active markets for similar assets or liabilities, unadjusted quoted prices for identical or similar assets or liabilities in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the related assets or liabilities. Level 3—Inputs are unobservable inputs for the asset or liability. The level in the fair value hierarchy within which a fair value measurement in its entirety is based on the lowest-level input that is significant to the fair value measurement in its entirety. The Company's cash and cash equivalents included Level 1 investments in treasury securities of $100.5 million and $129.1 million as of September 30, 2024 and December 31, 2023, respectively. These securities are classified as held-to-maturity and all have been purchased with original maturities of 90 days or less. Held-to-maturity debt securities are recorded at amortized cost in the financial statements.</p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:98.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:31.549%;box-sizing:content-box;"></td> <td style="width:1.16%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:13.937000000000001%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.16%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:13.937000000000001%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.16%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:13.998000000000001%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.16%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:13.937000000000001%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="14" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">September 30, 2024</p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="vertical-align:top;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">Amortized Cost</p></td> <td style="vertical-align:top;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="vertical-align:top;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">Unrealized Gains</p></td> <td style="vertical-align:top;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td colspan="2" style="vertical-align:top;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">Unrealized Losses</p></td> <td style="vertical-align:top;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="vertical-align:top;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">Aggregate Fair Value</p></td> <td style="vertical-align:top;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">U.S. treasury securities</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 100,488 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">24</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> (1 </td> <td style="white-space:nowrap;vertical-align:bottom;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 100,511 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> </table> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:98.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:31.626%;box-sizing:content-box;"></td> <td style="width:1.347%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:14.017%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.02%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:13.670000000000002%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.387%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:15.037%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.02%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:12.874%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word,"> <td style="vertical-align:bottom;text-align:left,"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="14" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> December 31, 2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left,"> </td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:top;border-bottom:0.5pt solid #000000;text-align:left;"> Amortized Cost </td> <td style="vertical-align:top;border-bottom:0.5pt

solid #fffff03;text-align:left;"> </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td colspan="2" style="vertical-align:top;border-bottom:0.5pt solid #000000;text-align:left;"> Unrealized Gains </td> <td style="vertical-align:top;border-bottom:0.5pt solid #fffff03;text-align:left;"> </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> </td> <td colspan="2" style="vertical-align:top;border-bottom:0.5pt solid #000000;text-align:left;"> Unrealized Losses </td> <td style="vertical-align:top;border-bottom:0.5pt solid #fffff03;text-align:left;"> </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td colspan="2" style="vertical-align:top;border-bottom:0.5pt solid #000000;text-align:left;"> Aggregate Fair Value </td> <td style="vertical-align:top;border-bottom:0.5pt solid #fffff03;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> U.S. treasury securities </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">129,113</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 28 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">—</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 129,141 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr></table> The Company measures the fair value of outstanding debt for disclosure purposes on a recurring basis. As of September 30, 2024 and December 31, 2023, total debt of $34.2 million and $33.9 million is reported at amortized cost, respectively. This outstanding debt is classified as Level 2 as it is not actively traded. The amortized cost of the outstanding debt approximates the fair value. The Company measures the fair value of the unissued common stock warrants to be issued pursuant to the Hercules Loan Agreement (as defined in Note 5, Debt) using the Black-Scholes option pricing method. These are classified as Level 3 liabilities, with an overall value of less than $0.1 million as of September 30, 2024. The unissued warrants are remeasured at each reporting date following execution of the Hercules Loan Agreement. See Note 5, Debt, and Note 7, Stockholders' Equity, for additional information regarding the common stock warrants. </p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">The financial statements as of September 30, 2024 and December 31, 2023 do not include any assets or liabilities that are measured at fair value on a nonrecurring basis. </p> 100500000 129100000 These securities are classified as held-to-maturity and all have been purchased with original maturities of 90 days or less. Held-to-maturity debt securities are recorded at amortized cost in the financial statements.<p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:98.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:31.549%;box-sizing:content-box;"></td> <td style="width:1.16%;box-sizing:content-box;"></td> <td style="width:1.16%;box-sizing:content-box;"></td> <td style="width:13.937000000000001%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.16%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:13.937000000000001%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.16%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:13.998000000000001%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.16%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:13.937000000000001%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:8pt;background-color:#fffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="14" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">September 30, 2024</p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #fffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> </tr> <tr style="height:8pt;background-color:#fffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="vertical-align:top;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">Amortized Cost</p></td> <td style="vertical-align:top;border-bottom:0.5pt solid #fffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="vertical-align:top;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">Unrealized Gains</p></td> <td style="vertical-align:top;border-bottom:0.5pt solid #fffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="vertical-align:top;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">Unrealized Losses</p></td> <td style="vertical-align:top;border-bottom:0.5pt solid #fffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="vertical-align:top;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">Aggregate Fair Value</p></td> <td style="vertical-align:top;border-bottom:0.5pt solid #fffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">U.S. treasury securities</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 100,488 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 24 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td

style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">(1</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">)</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 100,511 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr></table>   <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:98.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:31.626%;box-sizing:content-box;"></td> <td style="width:1.347%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:14.017%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.02%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:13.670000000000002%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.387%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:15.037%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.02%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:12.874%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="14" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> December 31, 2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:top;border-bottom:0.5pt solid #000000;text-align:left;"> Amortized Cost </td> <td style="vertical-align:top;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td colspan="2" style="vertical-align:top;border-bottom:0.5pt solid #000000;text-align:left;"> Unrealized Gains </td> <td style="vertical-align:top;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> </td> <td colspan="2" style="vertical-align:top;border-bottom:0.5pt solid #000000;text-align:left;"> Unrealized Losses </td> <td style="vertical-align:top;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td colspan="2" style="vertical-align:top;border-bottom:0.5pt solid #000000;text-align:left;"> Aggregate Fair Value </td> <td style="vertical-align:top;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> U.S. treasury securities </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">129,113</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 28 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">—</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 129,141 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> </table> 100488000 24000 1000 100511000 129113000 28000 0 129141000 34200000 33900000 100000 Note 4. Balance Sheet Components Property and Equipment, Net Property and equipment, net consist of the following (in thousands):   <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:63.013%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:16.124%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.46%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:14.402999999999999%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:left;"> As of September 30, </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:left;"> As of December 31, </td> <td style="vertical-align:bottom;text-align:left;"> </td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Tools and equipment </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> <span style="color:#000000;white-space:pre-

wrap;min-width:fit-content;">1,991 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">2,010</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Computer equipment and software</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">37</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">37</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Furniture and fixtures</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">286</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">323</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Leasehold improvements</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">38</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">1,071</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">859</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">3,423</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">3,267</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Less: Accumulated depreciation</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">(1,975</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">)</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">(1,627</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">)</p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Property and equipment, net</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 1,448 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 1,640 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr> </table> Depreciation expense was $0.1 million and $0.4<span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New

Roman;min-width:fit-content;"> million for the three and nine months ended September 30, 2024, respectively. Depreciation expense was $0.2 million and $0.5 million for the three and nine months ended September 30, 2023, respectively. </p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">Accrued and Other Current Liabilities</p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">Accrued and other current liabilities consist of the following (in thousands):</p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p><table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"><tr style="visibility:collapse;"><td style="width:63%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:14.62%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:1.44%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:15.940000000000001%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td></tr><tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"><td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td><td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">As of September 30,</p></td><td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td><td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">As of December 31,</p></td><td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td></tr><tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"><td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td><td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">2024</p></td><td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td><td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">2023</p></td><td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td></tr><tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"><td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Accrued expenses</p></td><td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 2,447 </td><td style="white-space:nowrap;vertical-align:bottom;"> </td><td style="white-space:pre-wrap;vertical-align:bottom;"> </td><td style="white-space:nowrap;vertical-align:bottom;"> $</p></td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">1,639</p></td><td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td></tr><tr style="height:10pt;background-color:#ffffff;word-break:break-word;"><td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Current portion of lease liabilities</p></td><td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">519</p></td><td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">573</p></td><td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td></tr><tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"><td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Short-term interest payable</p></td><td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">311</p></td><td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">375</p></td><td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td></tr><tr style="height:10pt;background-color:#ffffff;word-break:break-word;"><td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Other accrued liabilities</p></td><td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">1,336</p></td><td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">1,187</p></td><td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td></tr><tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"><td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Total accrued and other current liabilities</p></td><td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td><td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 4,613 </td><td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td><td style="white-space:pre-wrap;vertical-align:bottom;"> </td><td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $ </td><td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 3,774 </td><td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td></tr></table> Other Noncurrent Liabilities Other noncurrent liabilities consist of the following (in thousands): <p

style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:64.8%;box-sizing:content-box;"></td> <td style="width:1.44%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:12.4%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.44%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:15.92%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:left;"> As of September 30, </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:left;"> As of December 31, </td> <td style="vertical-align:bottom;text-align:left;"> </td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Noncurrent portion of lease liabilities </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">614</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 914 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Other noncurrent liabilities </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 75 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 38 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Long-term interest payable </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 1,524 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Total other noncurrent liabilities </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">689</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 2,476 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr> </table> Property and equipment, net consist of the following (in thousands): <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:63.013%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:16.124%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.46%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:14.4029999999999999%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:left;"> As of September 30, </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:left;"> As of December 31, </td> <td style="vertical-align:bottom;text-align:left;"> </td> </tr> <tr style="height:8pt;background-color:#ffffff;word-break:break-word;"> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:left;"> 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:left;"> 2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times

New Roman;margin-bottom:0;text-align:center;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Tools and equipment </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">1,991</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 2,010 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Computer equipment and software </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 37 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 37 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Furniture and fixtures </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 286 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 323 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Leasehold improvements </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 38 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 38 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Construction in process </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 1,071 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 859 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 3,423 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 3,267 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Less: Accumulated depreciation </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> (1,975 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> (1,627 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;">) </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Property and equipment, net </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">1,448</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 1,640 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-

size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </td> </tr> </table> 1991000 2010000 37000 37000 286000 323000 38000 38000 1071000 859000 3423000 3267000 1975000 1627000 1448000 1640000 100000 400000 200000 500000 Accrued and other current liabilities consist of the following (in thousands): <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:63%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:14.62%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.44%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:15.940000000000001%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:left;"> As of September 30, </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:left;"> As of December 31, </td> <td style="vertical-align:bottom;text-align:left;"> </td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Accrued expenses </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">2,447</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 1,639 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Current portion of lease liabilities </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 519 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 573 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Short-term interest payable </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 311 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 375 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Other accrued liabilities </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 1,336 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 1,187 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Total accrued and other current liabilities </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">4,613</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 3,774 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr> </table> 2447000 1639000 519000 573000 311000 375000 1336000 1187000 4613000 3774000 Other noncurrent liabilities consist of the following (in thousands): <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:64.8%;box-sizing:content-box;"></td> <td style="width:1.44%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:12.4%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.44%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:15.92%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;text-align:left;"> <span style="white-space:pre-

wrap;min-width:fit-content;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:left;"> As of September 30, </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:left;"> As of December 31, </td> <td style="vertical-align:bottom;text-align:left;"> </td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Noncurrent portion of lease liabilities </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">614</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 914 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Other noncurrent liabilities </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 75 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 38 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Long-term interest payable </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 1,524 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Total other noncurrent liabilities </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">689</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 2,476 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr> </table> 614000 914000 75000 38000 0 1524000 689000 2476000 Note 5. Debt Hercules Capital Loan Agreement In January 2024, the Company entered into a Loan and Security Agreement (the “Hercules Loan Agreement”), with Hercules Capital, Inc. (“Hercules”) and certain of its affiliates (collective with Hercules, the “Lenders”), which provides for a senior secured term loan facility in the aggregate principal amount of up to $65.0 million. An initial tranche of $35.0 million (the “Initial Loan”) was funded under the Hercules Loan Agreement on January 22, 2024. In addition to the Initial Loan, the Hercules Loan Agreement provides for additional tranches as follows: $5.0 million available in a single draw through December 15, 2024, $10.0 million available to draw upon the achievement of certain performance milestones through September 15, 2025, and $15.0 million available for the Company to draw on through the interest-only period in increments of $5.0 million, subject to the sole approval of Hercules' investment committee (such tranche loans together with the Initial Loan, the “Term Loans”). The Hercules Loan Agreement includes a maturity date of July 1, 2028, with an interest only period running for the first 30 months of the agreement term, extendable for an additional six months for a total of 36 months upon the achievement of certain milestones. The Term Loans accrue interest at a floating annual rate of the greater of 10.35% or the Wall Street Journal prime rate plus 2.35%, with the interest rate under the Term Loans equal to 10.35% at September 30, 2024. The final payment fee is set at <span style="font-size:10pt;font-family:Times New

Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">5.95% of the funded balance, which is recognized as a debt discount and is being accreted into the amortization of debt issuance costs using the effective interest rate method over the term of the loan. In conjunction with the funding of the Initial Loan, the Company issued warrants to the Lenders to purchase up to an aggregate of 135,686 shares of its common stock at an exercise price of $5.159 per share, which were recorded and classified as equity. Each warrant is exercisable for a period of seven years from the date of issuance. See Note 7, Stockholders' Equity, for additional information regarding these common stock warrants. The obligations under the Hercules Loan Agreement are guaranteed by the Company and its future subsidiaries, subject to exceptions for certain foreign subsidiaries. The obligations under the agreement are secured by substantially all of the Company's assets, including its material intellectual property. Additionally, the Company is subject to customary affirmative and negative covenants, including covenants that limit or restrict the ability of the Company to, among other things, incur indebtedness, grant liens, merge or consolidate, make investments, dispose of assets, make acquisitions, pay dividends or make distributions, repurchase stock and enter into certain transactions with affiliates, in each case subject to certain exceptions. The Company is also subject to certain minimum cash and revenue covenants under the Hercules Loan Agreement. The Company was in compliance with all covenants as of September 30, 2024. MidCap Loan Agreement The Company had credit and security agreements with certain entities affiliated with MidCap Financial Services (such entities collectively, "MidCap"), which provided for a $35.0 million senior secured term loan (the "MidCap Term Loan"). In January 2024, the Company terminated the Amended and Restated Credit and Security Agreement (Term Loan) (the "MidCap Term Loan Agreement") evidencing the MidCap Term Loan and paid off in full the secured obligations thereunder in connection with its entry into the Hercules Loan Agreement. The Company recorded a loss on debt extinguishment of $2.0 million during the nine months ended September 30, 2024. The commitment obligations under the MidCap Term Loan Agreement were guaranteed by the Company's current and future subsidiaries, subject to exceptions for certain foreign subsidiaries, and secured by substantially all assets of the Company, including material intellectual property. The MidCap Term Loan Agreement had a maturity date of November 1, 2025, and principal payments under the Term Loan were scheduled to commence in December 2024. In addition, the MidCap Term Loan Agreement included a stated floating interest rate that was reserve-adjusted Secured Overnight Finance Rate, plus 7.00%, and a provision for a final payment fee of 6.0% of the $35.0 million MidCap Term Loan balance, which was recorded as a long-term interest payable as of December 31, 2023. </p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">Maturities Schedule</p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">Long-term and short-term debt as of September 30, 2024 and December 31, 2023, respectively, was as follows (in thousands):</p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p><table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"><tr style="visibility:collapse;"><td style="width:64.46%;box-sizing:content-box;"></td><td style="width:1.76%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:13.06%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:1.76%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:14.96%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td></tr><tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"><td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td><td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">As of September 30,</p></td><td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td><td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">As of December 31,</p></td><td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td></tr><tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"><td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td><td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">2024</p></td><td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td><td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">2023</p></td><td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td></tr><tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"><td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Hercules Initial Loan</p></td><td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 35,000 </td><td style="white-space:nowrap;vertical-align:bottom;"> </td><td style="white-space:pre-wrap;vertical-align:bottom;"> </td><td style="white-space:nowrap;vertical-align:bottom;"> $ </td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td><td style="white-space:nowrap;vertical-align:bottom;"> </td></tr><tr style="height:10pt;background-color:#ffffff;word-break:break-word;"><td style="white-space:pre-wrap;vertical-align:top;"> MidCap Term Loan </td><td style="white-space:pre-wrap;vertical-align:bottom;"> </td><td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td><td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> — </td><td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td><td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td><td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td><td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 35,000 </td><td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td></tr><tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"><td style="white-space:pre-wrap;vertical-align:top;"> Total principal payments due </td><td style="white-space:pre-wrap;vertical-align:bottom;"> </td><td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td><td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 35,000 </td><td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td><td style="white-space:pre-wrap;vertical-align:bottom;"> </td><td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td><td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-

align:center;"> 35,000 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Less: unamortized discount and debt issuance costs </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> (848 </td> <td style="white-space:nowrap;vertical-align:bottom;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> (1,073 </td> <td style="white-space:nowrap;vertical-align:bottom;">) </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Total amounts outstanding </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 34,152 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 33,927 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Less: current portion </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> (2,219 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;">) </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Long-term debt, net </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">34,152</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 31,708 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr> </table> The repayment schedule relating to the Hercules Initial Loan as of September 30, 2024, is as follows (in thousands):   <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:80%;box-sizing:content-box;"></td> <td style="width:2.1%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:15.9%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Amount </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> 2024 (remainder) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> 2025 </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> 2026 </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 6,680 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> 2027 </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 17,294 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Thereafter </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid

#000000;text-align:center;"> 11,026 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #fffff03;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"> Total principal payments </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">35,000</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Final fee due at maturity</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">2,083</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #fffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Total repayments</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 37,083 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #fffff03;"> </td> </tr> </table> 65000000 35000000 5000000 10000000 15000000 5000000 2028-07-01 30 months P36M 0.1035 0.0235 0.1035 0.0595 135686 5.159 P7Y 35000000 2000000 0.07 0.06 35000000 Long-term and short-term debt as of September 30, 2024 and December 31, 2023, respectively, was as follows (in thousands): <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:64.46%;box-sizing:content-box;"></td> <td style="width:1.76%;box-sizing:content-box;"></td> <td style="width:1.1%;box-sizing:content-box;"></td> <td style="width:13.06%;box-sizing:content-box;"></td> <td style="width:1.1%;box-sizing:content-box;"></td> <td style="width:1.76%;box-sizing:content-box;"></td> <td style="width:1.1%;box-sizing:content-box;"></td> <td style="width:14.96%;box-sizing:content-box;"></td> <td style="width:1.1%;box-sizing:content-box;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:left;"> As of September 30, </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:left;"> As of December 31, </td> <td style="vertical-align:bottom;text-align:left;"> </td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #fffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #fffff03;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Hercules Initial Loan </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">35,000</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> MidCap Term Loan </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #fffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 35,000 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #fffff03;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Total principal payments due </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 35,000 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #fffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 35,000 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #fffff03;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Less: unamortized discount and debt issuance costs </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> (848 </td> <td style="white-space:nowrap;vertical-align:bottom;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;">

 </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> (1,073 </td> <td style="white-space:nowrap;vertical-align:bottom;">) </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Total amounts outstanding </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 34,152 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 33,927 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Less: current portion </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> (2,219 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;">) </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Long-term debt, net </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">34,152</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 31,708 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr> </table> 35000000 0 0 35000000 35000000 35000000 848000 1073000 34152000 33927000 0 2219000 34152000 31708000 The repayment schedule relating to the Hercules Initial Loan as of September 30, 2024, is as follows (in thousands): <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:80%;box-sizing:content-box;"></td> <td style="width:2.1%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:15.9%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Amount </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> 2024 (remainder) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">—</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">2025</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">—</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">2026</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">6,680</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">2027</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">17,294</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Thereafter</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">11,026</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Total principal payments</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 35,000 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"> Final fee due at maturity </td> <td style="white-space:pre-wrap;vertical-

align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 2,083 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #fffff03;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Total repayments </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 37,083 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #fffff03;"> </td> </tr> </table> 0 0 6680000 17294000 11026000 35000000 2083000 37083000 Note 6. Commitments and Contingencies Operating Lease Obligations The Company's leases include facility leases and equipment leases. In determining the present value of lease payments, the Company uses its incremental borrowing rate based on the information available at the lease commencement date if the rate implicit in the lease is not readily determinable. The Company's incremental borrowing rate represents the interest rate that the Company would expect to incur at lease commencement to borrow an amount equal to the lease payments on a collateralized basis with similar terms and payments, in an economic environment where the leased asset is located. In determining the lease term, the Company includes all renewal options that are reasonably probable to be executed. The Company leases its corporate headquarters in Menlo Park, California. The lease commenced in August 2021 and was originally for a term of 37 months from the commencement date. In December 2023, the Company entered into an amendment to the lease, extending the lease term an additional 26 months. Upon signing the amendment, the Company recorded an aggregate lease right-of-use ("ROU") asset and lease liability of $1.2 million. The lease ROU asset and corresponding liability were estimated using a weighted-average incremental borrowing rate of 11.40%. Total base rent for the remaining 34 months under the amended lease agreement is approximately $1.5 million. During the fourth quarter of 2022, the Company entered into a supply agreement that was expected to last approximately 18 months. In January 2024, the term was extended through December 31, 2024. The supply agreement contained provisions that, when evaluated, indicated an embedded lease was present within the agreement and the Company recorded an aggregate lease ROU asset and lease liability of $0.7 million. The lease ROU asset and corresponding lease liability were estimated using a weighted-average incremental borrowing rate of 10.75%. Total base rent under the agreement is approximately $0.7 million. The Company recognizes rent expense on a straight-line basis over the noncancelable lease term. The Company's rent expense was $0.2 million and $0.3 million for the three months ended September 30, 2024 and 2023, respectively. The Company's rent expense was $0.6 million and $0.9 million for the nine months ended September 30, 2024 and 2023, respectively. As of September 30, 2024, the weighted average remaining lease term for the leases was 2.0 years. Operating lease expense and supplemental cash flow information related to operating leases for the three months ended September 30, 2024 and 2023 were as follows (in thousands):   <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:51.83%;box-sizing:content-box;"></td> <td style="width:1.36%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:8.862%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.36%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:8.502%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:8.862%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.36%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:8.862%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Three Months Ended
September 30, </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #fffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Nine Months Ended
September 30, </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #fffff03;text-align:left;"> </td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #fffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #fffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #fffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #fffff03;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> <span style="color:#000000;white-space:pre-wrap;min-

width:fit-content;">Operating lease expense </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">196</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 288 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">587</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 869 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Cash paid for operating leases </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 162 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 295 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 582 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 885 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> </table> Aggregate future minimum lease payments as of September 30, 2024, under these noncancelable operating leases were as follows (in thousands): <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:78.496%;box-sizing:content-box;"></td> <td style="width:1.98%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:16.203%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.32%;box-sizing:content-box;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:left;"> As of September 30, </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;text-align:left;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> 2024 (remainder) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">158</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">2025</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">618</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">2026</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">497</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Total future minimum lease payments</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 1,273 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Less: imputed interest </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-

align:left;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> (140 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Present value of future minimum lease payments </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">1,133</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Less: current portion of operating lease liability</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">(519</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">)</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Noncurrent portion of lease liabilities</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 614 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> </tr> </table> Legal Proceedings On September 16, 2021, the Company filed suit in the U.S. District Court for the District of Delaware (C.A. No. 1:21-cv-01317) (the "Court") alleging that Ivantis, Inc. ("Ivantis") directly and indirectly infringes the Company's U.S. Patent Nos. 8,287,482, 9,370,443, 9,486,361, and 10,314,742 by making, using, selling, and offering for sale the Hydrus® Microstent. The Company's complaint seeks money damages and injunctive relief. On January 24, 2022, Ivantis asserted counterclaims requesting declaratory judgments that the Company's asserted patents-in-suit are not infringed and/or invalid. On August 1, 2022, the Company filed an amended complaint alleging that Alcon Inc., Alcon Vision, LLC and Alcon Research, LLC (collectively, "Alcon") infringe the four originally asserted patents by making, using, selling, and offering for sale the Hydrus® Microstent, and that all defendants also infringe U.S. Patent No. 11,389,328. The defendants asserted counterclaims requesting declaratory judgments that the Company's asserted patents-in-suit are not infringed and/or are invalid. In September 2022, Ivantis and Alcon filed petitions with the U.S. Patent Office seeking inter partes review of U.S. Patent Nos. 8,287,482, 9,370,443, 9,486,361, and 10,314,742 (IPR2022-01529, IPR2022-01530, IPR2022-01533, IPR2022-01540), each of which the U.S. Patent Office denied for raising prior art references and invalidity arguments that were cumulative of those previously considered by the U.S. Patent Office. On April 26, 2024, at the conclusion of a five-day jury trial, the Company was awarded a positive jury trial verdict of $34 million, comprised of $5.5 million in lost profits damages and $28.5 million in royalty damages for commercial sales of the Hydrus Microstent for the period between its commercial launch through trial. The patents at issue were U.S. Patent Nos. 8,287,482, 9,370,443, and 11,389,328. The parties have submitted their post-trial briefings and the Court will hold an in-person hearing in December 2024 to hear the parties' oral arguments on these briefings. The Court will enter its final judgement after the hearing, with such entry currently expected in late fourth quarter 2024 or in first quarter 2025. The Court's final judgment will be subject to appeal. The Company is presently unable to predict the outcome of this lawsuit or to reasonably estimate the potential financial impact of the lawsuit on the Company, if any. In addition to the foregoing, from time to time, the Company is subject to legal claims, regulatory matters and contingencies in the ordinary course of business. Accruals for these matters are reflected in the financial statements based on management's assessment, including the advice of legal counsel, of the expected outcome of these matters. Liabilities for estimated losses are accrued if the potential losses from any legal proceedings, regulatory matters or contingencies are considered probable and the amounts can be reasonably estimated. Significant judgment is required in both the determination of probability of loss and the determination as to whether the amount can be reasonably estimated. Accruals are based only on information available at the time of the assessment due to the uncertain nature of such matters. As additional information becomes available, management reassesses potential liabilities related to legal claims, regulatory matters and contingencies, and may revise its previous estimates, which could materially affect the Company's results of operations in a given period. Except as described above, as of September 30, 2024 and December 31, 2023, the Company was not a party to any legal proceedings, regulatory matters, or other disputes or claims which, if determined adversely, would, individually or taken together, have a material adverse effect on the Company's business, financial condition, operating results, liquidity, or future prospects. Indemnification In the normal course of business, the Company enters into contracts and agreements that contain a variety of representations and warranties and provide for general indemnifications. The Company's exposure under these agreements is unknown because it involves claims that may be made against the Company in the future, but that have not yet been made. To date, the Company has not paid any claims or been required to defend any action related to its indemnification obligations. However, the Company may record charges in the future as a result of these indemnification obligations. The Company indemnifies each of its directors and officers for certain events or occurrences, subject to certain limits, while the director is or was serving at the Company's request in such capacity, as permitted under Delaware law and in accordance with its certificate of incorporation and bylaws. The term of the indemnification period lasts as long as a director or officer may be subject to any proceeding arising out of acts or omissions of such director or officer in such capacity. The maximum amount of potential future indemnification is unlimited; however, the Company currently holds director and officer liability insurance. This insurance allows the transfer of risk associated with the Company's exposure and may enable it to recover a portion of any future amounts paid. The Company believes the fair value of these indemnification obligations is minimal. Accordingly, the Company has not recognized any liabilities relating to these obligations as of September 30, 2024 and December 31, 2023. P37M 26 1200000 0.114 P34M 1500000 P18M 700000 0.1075 700000 200000 300000 600000 900000 P2Y Operating lease expense and supplemental cash flow information related to operating leases for the three months ended September 30, 2024 and 2023 were as follows (in thousands): <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:51.83%;box-sizing:content-box;"></td> <td style="width:1.36%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:8.862%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.36%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:8.502%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:8.862%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.36%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:8.862%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Three Months Ended
September 30, </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Nine Months Ended
September 30, </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2024

</td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Operating lease expense </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">196</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 288 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">587</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 869 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Cash paid for operating leases </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 162 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 295 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 582 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 885 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> </table> 196000 288000 587000 869000 162000 295000 582000 885000 Aggregate future minimum lease payments as of September 30, 2024, under these noncancelable operating leases were as follows (in thousands):   <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:78.496%;box-sizing:content-box;"></td> <td style="width:1.98%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:16.203%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.32%;box-sizing:content-box;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:left;"> As of September 30, </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> 2024 (remainder) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 158 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> 2025 </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 618 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> 2026 </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> <span style="color:#000000;white-space:pre-

wrap;min-width:fit-content;">497 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Total future minimum lease payments </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">1,273</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Less: imputed interest</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">(140</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">)</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Present value of future minimum lease payments</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 1,133 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Less: current portion of operating lease liability </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> (519 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Noncurrent portion of lease liabilities </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 614 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> </tr> </table> 158000 618000 497000 1273000 140000 1133000 519000 614000 Note 7. Stockholders' Equity Common Stock The Company's certificate of incorporation provides for 200,000,000 authorized shares of common stock, par value $0.001 per share, and 10,000,000 authorized shares of preferred stock, par value $0.001 per share. The holders of common stock are entitled to receive dividends whenever funds are legally available, when and if declared by the board of directors. As of September 30, 2024, no dividends have been declared. Each share of common stock is entitled to one vote. At September 30, 2024 and December 31, 2023, the Company had reserved common stock for future issuances as follows: <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:66.673%;box-sizing:content-box;"></td> <td style="width:1.28%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:13.383%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.28%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:13.383%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:left;"> September 30, </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:left;"> December 31, </td> <td style="vertical-align:bottom;text-align:left;"> </td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Common stock available for future grants </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 5,956,636 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 6,033,176 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p

style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Common stock options issued and outstanding </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 4,583,289 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 4,980,190 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Restricted stock units outstanding </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 4,574,045 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 2,721,361 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Shares available for future purchase under employee stock purchase plan </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 1,747,250 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 1,488,227 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Total </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 16,861,220 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 15,222,954 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr> </table> Common Stock Warrants In conjunction with the funding of the Initial Loan under the Hercules Loan Agreement, the Company issued common stock warrants to the Lenders to purchase up to an aggregate of 135,686 shares of our common stock at an exercise price of $5.159 per share. Each warrant is exercisable for up to seven years from the date of issuance. The warrants are classified as equity. During the nine months ended September 30, 2024, the fair value of the issued warrants recorded was $0.6 million, which was calculated using the Black-Scholes option pricing model. These warrants were recorded at fair value upon their issuance in additional paid-in capital in the condensed consolidated balance sheet. The issued warrants are not remeasured after the issuance date. If the additional Term Loans are funded, the Company will be obligated to issue to the Lenders additional warrants to purchase common stock in an amount equal to 2.0% of the funded balance of each tranche, divided by the exercise price on the date the Company draws funds from such tranche, or the issuance date. The exercise price will be calculated using the five-day volume-weighted average stock price as of such date. The unissued warrants do not meet the requirements for classification in equity, and are recorded as liabilities in other noncurrent liabilities in the financial statements. The fair value of the unissued common stock warrants was calculated using the Black-Scholes option pricing method and they were recorded at fair value upon the funding of the Hercules Loan Agreement. The unissued warrants are remeasured at each reporting date after the issuance date. According to the fair value measurement criteria, the unissued warrants are considered Level 3 liabilities, with an overall value of less than $0.1 million as of September 30, 2024. 200000000 0.001 10000000 0.001 0 1 At September 30, 2024 and December 31, 2023, the Company had reserved common stock for future issuances as follows: <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:66.673%;box-sizing:content-box;"></td> <td style="width:1.28%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:13.383%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.28%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:13.383%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:left;"> September 30, </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:left;"> December 31, </td> <td style="vertical-align:bottom;text-align:left;"> </td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> <span

style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Common stock available for future grants </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 5,956,636 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 6,033,176 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Common stock options issued and outstanding </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 4,583,289 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 4,980,190 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Restricted stock units outstanding </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 4,574,045 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 2,721,361 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Shares available for future purchase under employee stock purchase plan </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 1,747,250 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 1,488,227 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Total </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 16,861,220 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 15,222,954 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr> </table> 5956636 6033176 4583289 4980190 4574045 2721361 1747250 1488227 16861220 15222954 135686 5,159 600000 0.02 100000 Note 8. Equity Incentive Plans 2011 Stock Option Plan and 2021 Incentive Award Plan In 2011, the Company established its 2011 Stock Option Plan (the “2011 Plan”) that provided for the granting of stock options to employees and nonemployees of the Company. In July 2021, the board of directors and stockholders adopted and approved the 2021 Incentive Award Plan, (the “2021 Plan”). Under the 2021 Plan, the Company has the ability to issue incentive stock options (“ISOs”), nonqualified stock options (“NSOs”), stock appreciation rights, dividend equivalent rights, restricted stock awards, and restricted stock unit awards (“RSUs”). Options under the 2021 Plan can typically be granted for periods of up to ten years. For stock options granted to a grantee who, at the time the option is granted, owned stock representing more than 10% of the voting power of all classes of stock of the Company (or any parent or subsidiary of the Company), the term of the stock option may be granted for periods of up to five years. The ISOs and NSOs will be granted at a price per share not less than the fair value at the date of grant. The exercise price of a stock option granted to a 10% stockholder shall be not less than 110% of the grant date fair value of the shares. Options granted to new hires generally vest over a four-year period, with 25% of the shares vesting on the first anniversary of the grant date and the remaining shares vesting in 36 equal monthly installments thereafter; options granted as merit awards generally vest in 48 equal monthly installments following the grant date. RSUs granted generally vest over a four-year period with straight-line vesting in equal amounts (either in annual or quarterly installments). The Company initially reserved 5,200,000 shares of common stock for future issuance under the 2021 Plan. This initial reserve is subject to annual increase on the first day of each calendar year beginning on January 1, 2022 and ending on and including January 1, 2031. These annual increases are equal to the lesser of (i) 5% of the aggregate number of shares of common stock outstanding on the final day of the immediately preceding calendar year and (ii) such smaller number of shares of common stock as determined by the Board, subject to certain limitations. Pursuant to the evergreen provision, the initial share reserve was increased by 2,456,568 shares and 2,414,907 shares on January 1, 2024 and 2023, respectively. The 2011 Plan was superseded by the 2021 Plan at the time of the initial public offering of the Company’s common stock, which closed on July 15, 2021, and no further grants have been made under the 2011 Plan from the date the 2021 Plan became effective. The terms under the 2011 Plan are consistent with those described above for the 2021 Plan. As of September 30, 2024 and December 31, 2023 there were 5,956,636 shares and 6,033,176 shares, respectively, of

common stock available for issuance under the 2021 Plan. Stock Option Awards The following table summarizes stock option activity under the 2021 Plan during the periods presented: <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:38.732%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:11.618%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.4%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:10.678%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:13.897%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.4%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:12.278%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Number of
Shares </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Weighted-Average Exercise Price </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Weighted-Average
Contractual
 Term (in years) </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Average Intrinsic Value
(in thousands) </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Balances as of December 31, 2023 </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 4,980,190 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">9.00</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">7.4</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 5,924 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Grants </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 7,377 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 4.43 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Forfeited/cancelled </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> (210,159 </td> <td style="white-space:nowrap;vertical-align:bottom;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 10.15 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;">

(194,119 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 1.20 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Balances as of September 30, 2024 </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 4,583,289 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">9.28</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">7.0</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 6,558 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Vested and exercisable as of September 30, 2024 </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 3,163,058 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">9.32</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">6.4</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 4,635 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Vested and expected to vest as of September 30, 2024 </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 4,583,289 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">9.28</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">7.0</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 6,558 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr></table> During the three months ended September 30, 2024 and 2023, the Company recorded stock-based compensation expense of $1.9 million and $2.1 million related to stock option awards, respectively. During the nine months ended September 30, 2024 and 2023, the Company recorded stock-based compensation expense of $5.7 million and $6.6 million related to stock option awards, respectively. The weighted-average grant-date fair values of options granted during the nine months ended September 30, 2024 and 2023 was <span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$2.71 and $6.92 per share, respectively. <span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times

*New Roman;min-width:fit-content;">The aggregate intrinsic value of options exercised was $0.2 million and $0.8 million during the three and nine months ended September 30, 2024, respectively. The aggregate intrinsic value was calculated as the difference between the exercise prices of the underlying options and the estimated fair value of the common stock on the date of exercise. As of September 30, 2024, the unrecognized stock-based compensation expense relating to unvested options was $8.1 million, which is expected to be recognized over a weighted-average period of 1.3 years. Determination of Fair Value The Company estimated the grant date fair value of stock options using the Black-Scholes option-pricing model, which requires the use of highly subjective and complex valuation assumptions to determine the fair value of stock-based awards, including the option's expected term, the expected volatility of the underlying stock, the risk-free interest rate, and the expected dividend yield. For the purposes of the Black-Scholes valuation model, the Company used the simplified method for determining the expected term of the granted options. The simplified method was used since the Company does not have adequate historical data to utilize in calculating the expected term of options. The fair value for options granted was calculated using the following weighted average assumptions: <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:99.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:29.568%;box-sizing:content-box;"></td> <td style="width:1.659%;box-sizing:content-box;"></td> <td style="width:15.914%;box-sizing:content-box;"></td> <td style="width:1.959%;box-sizing:content-box;"></td> <td style="width:15.914%;box-sizing:content-box;"></td> <td style="width:1.2%;box-sizing:content-box;"></td> <td style="width:15.914%;box-sizing:content-box;"></td> <td style="width:1.959%;box-sizing:content-box;"></td> <td style="width:15.914%;box-sizing:content-box;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="3" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Three Months Ended
September 30, </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td colspan="3" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Nine Months Ended
September 30, </td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2023 </td> </tr> <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:top;"> Expected term (in years) </td> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;text-align:left;"> N/A </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> 5.99 - 6.01 </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> 6.13 </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> 5.60 - 6.07 </td> </tr> <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:top;"> Expected volatility </td> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;text-align:left;"> N/A </td> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;text-align:left;"> 79.82% </td> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;text-align:left;"> 61.67% </td> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;text-align:left;"> 78.53% - 79.82% </td> </tr> <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:top;"> Risk-free interest rate </td> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;text-align:left;"> N/A </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> 4.04% </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> 4.28% </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> 3.48% - 4.04% </td> </tr> <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:top;"> Dividend yield </td> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;text-align:left;"> N/A </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> - </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> - </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> - </td> </tr>*

</table> Restricted Stock Units RSUs are share awards that entitle the holder to receive shares of common stock upon vesting. The RSUs cannot be transferred, and the awards are subject to forfeiture if the holder's employment terminates prior to the release of the vesting restrictions. The RSUs generally vest either (i) annually over a four-year period with straight-line vesting in equal amounts, or (ii) quarterly over a four-year period with straight-line vesting in equal amounts, in each case provided the holder provides continuous services to the Company. The fair value of the RSUs is equal to the closing price of the Company's common stock on the grant date. The following table summarizes restricted share award activity: <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:84.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:57.249%;box-sizing:content-box;"></td> <td style="width:1.6%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:18.056%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:2.08%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:17.017%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Number of
Shares </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Weighted-Average Grant Date Fair Value Per Share </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Outstanding, December 31, 2023 </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 2,721,361 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">7.61</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Grants</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">2,949,065</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">4.46</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Forfeited/cancelled</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">(213,175</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">)</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">6.54</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Vested</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">(883,206</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">)</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">7,58</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Outstanding, September 30, 2024</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">4,574,045</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 5.62 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> </table> During the three months ended September 30, 2024 and 2023, the Company recorded stock-based compensation expense of $2.2 million and $1.6 million, respectively, related to the RSUs. During the nine months ended September 30, 2024 and 2023, the Company recorded stock-based compensation expense of $6.9 million and $4.2 million, respectively, related to the RSUs. As of September 30, 2024, there was $21.2 million of total unrecognized stock-based compensation expense relating to the RSUs that is expected to be recognized over a weighted-average period of 2.7 years. <p

style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">Employee Stock Purchase Plan In July 2021, the board of directors and stockholders adopted and approved the 2021 Employee Stock Purchase Plan (the "ESPP"). The Company initially reserved 850,000 shares of common stock for future issuance under the ESPP. This initial reserve is subject to annual increase on the first day of each calendar year beginning on January 1, 2022 and ending on and including January 1, 2031. These annual increases shall be equal to the lesser of (i) 1% of the aggregate number of shares of common stock outstanding on the final day of the immediately preceding calendar year and (ii) such smaller number of shares of common stock as determined by the Board, subject to certain limitations. Pursuant to the evergreen provision, the initial share reserve was increased by 491,313 and 482,981 shares on January 1, 2024 and 2023, respectively. The Company has two offering periods annually, running for six months, with the first offering period beginning in the second quarter, and the second offering period beginning in the fourth quarter. The purchase of shares for participants in the ESPP occurs at the conclusion of each offering period. During the nine months ended, September 30, 2024, participants in the ESPP purchased 232,290 shares for a total of $0.5 million. As of September 30, 2024, the Company has collected payroll withholdings of $0.4 million in the current offering period for the purchase of shares under the ESPP. The Company recorded stock-based compensation expense associated with the ESPP of $0.1 million for both the three months ended September 30, 2024 and 2023. The Company recorded stock-based compensation expense associated with the ESPP of $0.5 million and $0.4 million for the nine months ended September 30, 2024 and 2023, respectively. As of September 30, 2024, there were 1,747,250 shares of common stock available for issuance under the ESPP. The fair value of shares to be issued under the ESPP was estimated using the Black-Scholes valuation model with the following assumptions for the three and nine months ended September 30, 2024 and 2023: <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:26%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:18%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:17%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:18%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:17%;box-sizing:content-box;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="3" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Three Months Ended
September 30, </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td colspan="3" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Nine Months Ended
September 30, </td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2023 </td> </tr> <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:top;"> Expected term (in years) </td> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;text-align:left;"> 0.49 - 0.50 </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> 0.48 - 0.50 </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> 0.49- 0.50 </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> 0.48 - 0.50 </td> </tr> <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:top;"> Expected volatility </td> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;text-align:left;"> 100.00% - 197.51% </td> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;text-align:left;"> 66.72% - 97.38% </td> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;text-align:left;"> 100.00% - 197.51% </td> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;text-align:left;"> 66.72% - 97.38% </td> </tr> <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:top;"> Risk-free interest rate </td> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;text-align:left;"> 5.37% -

5.40% </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> 4.62% – 5.32% </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> 5.37% – 5.40% </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> 4.62% – 5.32% </td> </tr> <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:top;"> Dividend yield </td> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;text-align:left;"> – </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> – </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> – </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> – </td> </tr> </table> Stock-Based Compensation The following is a summary of stock-based compensation expense by function (in thousands): <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"><tr style="visibility:collapse;"> <td style="width:41.76%;box-sizing:content-box;"></td> <td style="width:1.38%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:11.34%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.38%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:11.08%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.38%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:11.34%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Three Months Ended
September 30, </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Nine Months Ended
September 30, </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Cost of goods sold </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">83</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 77 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">283</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 206 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Research and development </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 588 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 549 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> <span style="white-space:pre-wrap;min-width:fit-

content;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 1,787 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 1,664 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Selling, general and administrative </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 3,637 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 3,230 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 11,061 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 9,251 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Total stock-based compensation expense </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">4,308</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 3,856 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">13,131</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 11,121 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr> </table> 5200000 annual increases are equal to the lesser of (i) 5% of the aggregate number of shares of common stock outstanding on the final day of the immediately preceding calendar year and (ii) such smaller number of shares of common stock as determined by the Board, subject to certain limitations 2456568 2414907 5956636 6033176 The following table summarizes stock option activity under the 2021 Plan during the periods presented: <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:38.732%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:11.618%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.4%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:10.678%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.4%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:13.897%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:12.278%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Number of
Shares </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Weighted-Average Exercise Price </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Weighted-Average
Contractual
 Term (in years) </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Average Intrinsic Value
(in thousands) </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Balances as of December 31, 2023 </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 4,980,190 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 9.00 </td>

<td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 7,4 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">5,924</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Grants</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">7,377</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">4,43</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Forfeited/cancelled</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">(210,159</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">)</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">10.15</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word,"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Exercised/released</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">(194,119</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">)</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">1.20</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Balances as of September 30, 2024</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">4,583,289</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 9.28 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 7.0 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 6,558 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Vested and exercisable as of September 30, 2024 </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"><p

style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 3,163,058 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">9.32</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">6.4</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 4,635 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Vested and expected to vest as of September 30, 2024 </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 4,583,289 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">9.28</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">7.0</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 6,558 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> </table> 4980190 9 P7Y4M24D 5924000 7377 4.43 210159 10.15 194119 1.2 4583289 9.28 P7Y 6558000 3163058 9.32 P6Y4M24D 4635000 4583289 9.28 P7Y 6558000 1900000 2100000 5700000 6600000 2.71 6.92 200000 800000 8100000 P1Y3M18D The fair value for options granted was calculated using the following weighted average assumptions: <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:99.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:29.568%;box-sizing:content-box;"></td> <td style="width:1.659%;box-sizing:content-box;"></td> <td style="width:15.914%;box-sizing:content-box;"></td> <td style="width:1.959%;box-sizing:content-box;"></td> <td style="width:15.914%;box-sizing:content-box;"></td> <td style="width:1.2%;box-sizing:content-box;"></td> <td style="width:15.914%;box-sizing:content-box;"></td> <td style="width:1.959%;box-sizing:content-box;"></td> <td style="width:15.914%;box-sizing:content-box;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="3" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Three Months Ended
September 30, </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td colspan="3" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Nine Months Ended
September 30, </td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2023 </td> </tr> <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:top;"> Expected term (in years) </td> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;text-align:left;"> N/A </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> 5.99 – 6.01 </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> 6.13 </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> 5.60 – 6.07 </td> </tr> <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:top;"> Expected volatility </td> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;text-align:left;"> N/A </td> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;text-align:left;"> 79.82% </td> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;text-align:left;"> 61.67% </td> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;text-align:left;"> 78.53% – 79.82% </td> </tr> <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:top;"> Risk-free interest rate </td> <td style="vertical-

align:bottom;"> </td> <td style="vertical-align:bottom;text-align:left;"> N/A </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> 4.04% </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> 4.28% </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> 3.48% – 4.04% </td> </tr> <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:top;"> Dividend yield </td> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;text-align:left;"> N/A </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> – </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> – </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> – </td> </tr>
</table> P5Y11M26D P6Y3D P6Y1M17D P5Y7M6D P6Y25D 0.7982 0.6167 0.7853 0.7982 0.0404 0.0428 0.0348 0.0404 The following table summarizes restricted share award activity:
 <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:84.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;">
<td style="width:57.249%;box-sizing:content-box;"></td> <td style="width:1.6%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:18.056%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:2.08%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:17.017%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Number of
Shares </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Weighted-Average Grant Date Fair Value Per Share </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Outstanding, December 31, 2023 </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 2,721,361 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 7.61 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Grants </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 2,949,065 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 4.46 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Forfeited/cancelled </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> (213,175 </td> <td style="white-space:nowrap;vertical-align:bottom;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 6.54 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Vested </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> (883,206 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 7.58 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Outstanding, September 30, 2024 </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 4,574,045 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-

wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 5.62 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> </table> 2721361 7.61 2949065 4.46 213175 6.54 883206 7.58 4574045 5.62 2200000 1600000 6900000 4200000 21200000 P2Y8M12D 850000 491313 482981 232290 500000 400000 100000 100000 500000 400000 1747250 The fair value of shares to be issued under the ESPP was estimated using the Black-Scholes valuation model with the following assumptions for the three and nine months ended September 30, 2024 and 2023:   <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:26%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:18%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:17%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:18%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:17%;box-sizing:content-box;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="3" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Three Months Ended
September 30, </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td colspan="3" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Nine Months Ended
September 30, </td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:top;"> Expected term (in years) </td> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;text-align:left;"> 0.49 - 0.50 </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> 0.48 - 0.50 </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> 0.49 - 0.50 </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> 0.48% - 0.50 </td> </tr> <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:top;"> Expected volatility </td> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;text-align:left;"> 100.00% - 197.51% </td> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;text-align:left;"> 66.72% - 97.38% </td> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;text-align:left;"> 100.00% - 197.51% </td> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;text-align:left;"> 66.72% - 97.38% </td> </tr> <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:top;"> Risk-free interest rate </td> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;text-align:left;"> 5.37% - 5.40% </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> 4.62% - 5.32% </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> 5.37% - 5.40% </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> 4.62% - 5.32% </td> </tr> <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:top;"> Dividend yield </td> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;text-align:left;"> - </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> - </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> - </td> </tr> </table> P0Y5M26D P0Y6M P0Y5M23D P0Y6M P0Y5M26D P0Y6M P0Y5M23D P0Y6M 1 1.9751 0.6672 0.9738 1 1.9751 0.6672 0.9738 0.0537 0.054 0.0462 0.0532 0.0537 0.054 0.0462 0.0532 <span

style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following is a summary of stock-based compensation expense by function (in thousands): <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:41.76%;box-sizing:content-box;"></td> <td style="width:1.38%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:11.34%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.38%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:11.08%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:11.34%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.38%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:11.34%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Three Months Ended
September 30, </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Nine Months Ended
September 30, </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Cost of goods sold </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">83</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 77 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">283</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 206 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Research and development </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 588 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 549 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 1,787 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 1,664 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Selling, general and administrative </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 3,637 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 3,230 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 11,061 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-

wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 9,251 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Total stock-based compensation expense </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">4,308</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 3,856 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">13,131</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 11,121 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr> </table> 83000 77000 283000 206000 588000 549000 1787000 1664000 3637000 3230000 11061000 9251000 4308000 3856000 13131000 11121000 Note 9. Net Loss per Share Attributable to Common Stockholders Basic net loss per share is computed by dividing the net loss by the weighted-average number of common shares outstanding for the period. As the Company reported a net loss for the three and nine months ended September 30, 2024 and 2023, basic net loss per share is the same as diluted net loss per share for each of the reported periods. The following table sets forth the computation of basic and diluted net loss per share attributable to common stockholders for the periods presented (in thousands, except share and per share data): <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:42.388%;box-sizing:content-box;"></td> <td style="width:1.54%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:10.862%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.54%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:10.862%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.54%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:10.862%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.54%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:10.862%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:top;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Three Months Ended
September 30, </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Nine Months Ended
September 30, </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:top;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:top;"> Numerator: </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Net loss attributable to common stockholders </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> (11,066 </td> <td style="white-space:nowrap;vertical-align:bottom;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;">

</td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">(13,035</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">)</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> (39,661 </td> <td style="white-space:nowrap;vertical-align:bottom;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">(44,856</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">)</p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Denominator:</p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Weighted-average shares of common stock
  outstanding—basic and diluted</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">50,340,603</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">48,671,049</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">49,911,655</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">48,538,517</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Net loss per share attributable to common
  stockholders—basic and diluted</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">(0.27</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">)</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> (0.79 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> (0.92 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;">) </td> </tr> </table> The following potentially dilutive issued and outstanding securities were excluded from the computation of diluted net loss per share attributable to common stockholders for the period presented because including them would have been antidilutive as a result of the net loss position: <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:63.32%;box-sizing:content-box;"></td> <td style="width:1.46%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:14.88%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.46%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:14.88%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:top;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> September 30, </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> December 31, </td> <td style="vertical-align:bottom;"> </td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;

family:Times New Roman;margin-bottom:0;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Stock option awards </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 4,583,289 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 4,705,390 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Restricted stock units </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 4,574,045 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 1,853,657 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Common stock warrants </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 135,686 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Total </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 9,293,020 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 6,559,047 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr> </table> The following table sets forth the computation of basic and diluted net loss per share attributable to common stockholders for the periods presented (in thousands, except share and per share data): <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:42.388%;box-sizing:content-box;"></td> <td style="width:1.54%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:10.862%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.54%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:10.862%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.54%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:10.862%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.54%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:10.862%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:top;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Three Months Ended
September 30, </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Nine Months Ended
September 30, </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:top;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:top;"> Numerator: </td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-

align:left;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Net loss attributable to common stockholders </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">(11,066</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">)</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> (13,035 </td> <td style="white-space:nowrap;vertical-align:bottom;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">(39,661</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">)</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> (44,856 </td> <td style="white-space:nowrap;vertical-align:bottom;">) </td> </tr> <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:top;"> Denominator: </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Weighted-average shares of common stock
 outstanding—basic and diluted </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 50,340,603 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 48,671,049 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 49,911,655 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 48,538,517 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Net loss per share attributable to common
 stockholders—basic and diluted </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">(0.22</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">)</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> (0.27 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> (0.79 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-

top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> (0.92 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;">) </td> </tr> </table> -11066000 -13035000 -39661000 -44856000 50340603 50340603 48671049 48671049 49911655 49911655 48538517 48538517 -0.22 -0.22 -0.27 -0.27 -0.79 -0.79 -0.92 -0.92 The following potentially dilutive issued and outstanding securities were excluded from the computation of diluted net loss per share attributable to common stockholders for the period presented because including them would have been antidilutive as a result of the net loss position: <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:63.32%;box-sizing:content-box;"></td> <td style="width:1.46%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:14.88%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.46%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:14.88%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:top;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> September 30, </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:top;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Stock option awards </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 4,583,289 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 4,705,390 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Restricted stock units </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 4,574,045 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 1,853,657 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Common stock warrants </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 135,686 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Total </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 9,293,020 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 6,559,047 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr> </table> 4583289 4705390 4574045 1853657 135686 0 9293020 6559047 Note 10. Segment Information The Company has two reportable operating segments which are determined on the basis of the product portfolio: Surgical Glaucoma and Dry Eye. The operating and reportable segments were determined based on how the Company's Chief Executive Officer, its Chief Operating Decision Maker ("CODM"), views and evaluates the Company's operations. The CODM allocates resources to and evaluates the financial performance of each operating segment primarily based on gross profit and gross profit margin. The Surgical Glaucoma segment includes sales of the Company's OMNI Surgical System and SION Surgical Instrument for use in minimally invasive glaucoma procedures. The Dry Eye segment includes sales of the Company's TearCare System and related components. The following table summarizes select operating results information for each reportable segment (in thousands): <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:99.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:41.268%;box-sizing:content-box;"></td> <td style="width:1.58%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:11.102%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.58%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:11.102%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.58%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:11.102%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.58%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:11.102%;box-sizing:content-box;"></td> <td

style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:top;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Three Months Ended
September 30, </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Nine Months Ended
September 30, </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:top;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:top;"> Revenue </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Surgical Glaucoma </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">18,632</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 18,425 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">57,132</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 57,158 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Dry Eye </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 1,525 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 1,584 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 3,660 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 5,147 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"> Total </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 20,157 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> <span

style="white-space:pre-wrap;min-width:fit-content;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 20,009 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 60,792 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 62,305 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:top;"> Cost of goods sold </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Surgical Glaucoma </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 2,453 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 2,002 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 7,084 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 6,808 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Dry Eye </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 797 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 675 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 1,984 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 2,297 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"> Total </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 3,250 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 2,677 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 9,068 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 9,105 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:top;"><p

style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Gross profit </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Surgical Glaucoma </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 16,179 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 16,423 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 50,048 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 50,350 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Dry Eye </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 728 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 909 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 1,676 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 2,850 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"> Total </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 16,907 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 17,332 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 51,724 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 53,200 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Operating expenses </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 28,136 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 30,743 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> <span style="min-width:fit-

content;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 90,327 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 99,364 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Loss from operations </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> (11,229 </td> <td style="white-space:nowrap;vertical-align:bottom;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> (13,411 </td> <td style="white-space:nowrap;vertical-align:bottom;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> (38,603 </td> <td style="white-space:nowrap;vertical-align:bottom;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 1,454 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 1,897 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 4,628 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 5,499 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Interest expense </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> (1,151 </td> <td style="white-space:nowrap;vertical-align:bottom;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> (1,432 </td> <td style="white-space:nowrap;vertical-align:bottom;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> (3,501 </td> <td style="white-space:nowrap;vertical-align:bottom;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> (4,057 </td> <td style="white-space:nowrap;vertical-align:bottom;">) </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Loss on debt extinguishment </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> (1,962 </td> <td style="white-space:nowrap;vertical-align:bottom;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times

*New Roman;margin-bottom:0;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Other income (expense), net </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 26 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> (11 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> (25 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> (34 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;">) </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Loss before income taxes </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">(10,900</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">)</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> (12,957 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">(39,463</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">)</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> (44,756 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;">) </td> </tr> </table> The Company does not allocate any income and expenses beyond revenue and cost of goods sold to the reportable operating segments in its reporting to the CODM. No asset information is provided for reportable operating segments because they are not reviewed by the CODM on a segment basis. Substantially all of the Company's revenue is generated from sales in the United States. 2 The following table summarizes select operating results information for each reportable segment (in thousands): <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:99.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:41.268%;box-sizing:content-box;"></td> <td style="width:1.58%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:11.102%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.58%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:11.102%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.58%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:11.102%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.58%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:11.102%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:top;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Three Months Ended
September 30, </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Nine Months Ended
September 30, </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:top;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:top;"> Revenue </td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-*

align:left;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Surgical Glaucoma </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">18,632</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 18,425 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">57,132</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 57,158 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Dry Eye </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 1,525 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 1,584 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 3,660 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 5,147 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"> Total </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 20,157 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 20,009 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 62,305 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word,"> <td style="vertical-align:top;"> Cost of goods sold </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-

indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Surgical Glaucoma </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 2,453 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 2,002 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 7,084 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 6,808 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Dry Eye </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 797 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 675 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 1,984 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 2,297 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"> Total </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 3,250 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 2,677 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 9,068 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 9,105 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:top;"> Gross profit </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Surgical Glaucoma </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 16,179 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 16,423 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> <span style="color:#000000;white-space:pre-wrap;min-width:fit-

content;">50,048 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 50,350 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Dry Eye </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 728 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 909 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 1,676 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 2,850 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"> Total </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 16,907 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 17,332 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 51,724 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 53,200 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Operating expenses </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 28,136 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 30,743 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 90,327 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 99,364 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Loss from operations </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> (11,229 </td> <td style="white-space:nowrap;vertical-align:bottom;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> (13,411 </td> <td style="white-space:pre-wrap;vertical-align:bottom;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> (38,603 </td> <td style="white-space:nowrap;vertical-align:bottom;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> (46,164 </td> <td style="white-

space:nowrap;vertical-align:bottom;">) </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Investment income </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 1,454 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 1,897 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 4,628 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 5,499 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Interest expense </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> (1,151 </td> <td style="white-space:nowrap;vertical-align:bottom;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> (1,432 </td> <td style="white-space:nowrap;vertical-align:bottom;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> (3,501 </td> <td style="white-space:nowrap;vertical-align:bottom;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> (4,057 </td> <td style="white-space:nowrap;vertical-align:bottom;">) </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Loss on debt extinguishment </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Other income (expense), net </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 26 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> (11 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> (25 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> (34 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;">) </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Loss before income taxes </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double

#000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">(10,900</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">)</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> (12,957 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">(39,463</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">)</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> (44,756 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;">) </td> </tr> </table> 18632000 18425000 57132000 57158000 1525000 1584000 3660000 5147000 20157000 20009000 60792000 62305000 2453000 2002000 7084000 6808000 797000 675000 1984000 2297000 3250000 2677000 9068000 9105000 16179000 16423000 50048000 50350000 728000 909000 1676000 2850000 16907000 17332000 51724000 53200000 28136000 30743000 90327000 99364000 -11229000 -13411000 -38603000 -46164000 1454000 1897000 4628000 5499000 1151000 1432000 3501000 4057000 0 -0 -1962000 0 26000 -11000 -25000 -34000 -10900000 -12957000 -39463000 -44756000 Trading Plans Our directors and officers may enter into trading plans or other arrangements with financial institutions to purchase or sell shares of our common stock, which plans or arrangements are intended to comply with the affirmative defense provisions of Rule 10b5-1 of the Exchange Act or which may represent a non-Rule 10b5-1 trading arrangement as defined under Item 408(a) of Regulation S-K. Set forth below is a summary of the adoption, modification, and termination activity of our directors and executive officers in respect of their Rule 10b5-1 trading plans during the quarter ended September 30, 2024: <table style="border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;"> <tr style="visibility:collapse;"> <td style="width:22.222%;box-sizing:content-box;"></td> <td style="width:1.111%;box-sizing:content-box;"></td> <td style="width:17.778%;box-sizing:content-box;"></td> <td style="width:1.111%;box-sizing:content-box;"></td> <td style="width:18.889%;box-sizing:content-box;"></td> <td style="width:1.111%;box-sizing:content-box;"></td> <td style="width:18.889%;box-sizing:content-box;"></td> <td style="width:1.111%;box-sizing:content-box;"></td> <td style="width:17.778%;box-sizing:content-box;"></td> </tr> <tr style="height:36pt;white-space:pre-wrap;word-break:break-word;"> <td style="padding-left:0.04in;vertical-align:bottom;border-bottom:1pt solid #000000;padding-right:0.04in;text-align:left;"> Name & Title </td> <td style="padding-left:0.08in;vertical-align:bottom;border-bottom:1pt solid #ffffff03;padding-right:0.08in;"> </td> <td style="padding-left:0.04in;vertical-align:bottom;border-bottom:1pt solid #000000;padding-right:0.04in;text-align:left;"> Adoption Date </td> <td style="padding-left:0.08in;vertical-align:bottom;border-bottom:1pt solid #ffffff03;padding-right:0.08in;"> </td> <td style="padding-left:0.04in;vertical-align:bottom;border-bottom:1pt solid #000000;padding-right:0.04in;text-align:left;"> Termination Date </td> <td style="padding-left:0.08in;vertical-align:bottom;border-bottom:1pt solid #ffffff03;padding-right:0.08in;"> </td> <td style="padding-left:0.04in;vertical-align:bottom;border-bottom:1pt solid #000000;padding-right:0.04in;text-align:left;"> Contract End Date </td> <td style="padding-left:0.08in;vertical-align:bottom;border-bottom:1pt solid #ffffff03;padding-right:0.08in;"> </td> <td style="padding-left:0.04in;vertical-align:bottom;border-bottom:1pt solid #000000;padding-right:0.04in;text-align:left;"> Aggregate Shares Covered (in ones) </td> </tr> <tr style="height:30pt;background-color:#cceeff;white-space:pre-wrap;word-break:break-word;"> <td style="text-indent:6.75pt;padding-left:0.04in;vertical-align:bottom;padding-right:0.04in;"> Jeremy B. Hayden, Chief Legal Officer </td> <td style="padding-left:0.08in;vertical-align:bottom;padding-right:0.08in;"> </td> <td style="padding-left:0.04in;vertical-align:bottom;padding-right:0.04in;text-align:left;"> August 28, 2024 </td> <td style="padding-left:0.08in;vertical-align:bottom;padding-right:0.08in;"> </td> <td style="padding-left:0.04in;vertical-align:bottom;padding-right:0.04in;text-align:left;"> August 25, 2025 </td> <td style="padding-left:0.08in;vertical-align:bottom;padding-right:0.08in;"> </td> <td style="padding-left:0.04in;vertical-align:bottom;padding-right:0.04in;text-align:left;"> August 25, 2025 </td> <td style="padding-left:0.08in;vertical-align:bottom;padding-right:0.01in;text-align:left;"> </td> <td style="padding-left:0.08in;vertical-align:bottom;padding-right:0.04in;text-align:left;"> 48,000 </td> </tr> </table> true true true Jeremy B. Hayden Chief Legal Officer August 28, 2024 August 25, 2025 August 25, 2025 48000

M3(D&9[!N M R1.D<13)L((# MP%IA3DY.);W0M1H0G]9@T.N3! '$3 6D QHT&<$(!% "$@-Y5PJUIC*B N]"S7H0Y"A F/17CJ # M"8B?BR!G?I8^"'?MRE974>I12%J$NW;-
'5<.)#POSJ/.;$H= 5C'J'+M170C MTXP(X((Z&+PF@%0FH]LID'W4>1Y\4#P-T;-5X,*GH0<-L0 >5?4U*"<^$J&(M/+D2"/ M+!%;WAO(! >#4C.A\7<+7<]$@55>,>Z5R7*.Z$ B?@G(B0Z4N36,O
M@'_ZUFV038CP_B83+T$3GUO ?(^_MRQ$2.XK%/$@G2 BO>49F6CY.2\;FI6#?:,8V@OT:M0+[M#;PK;D+D33]9!7(M+D7X2^!G6+E27\C7H3@GWGT!0A9X[];.M%*7%2*@RI8X(X%PP1
MPM3QYXU0S.,\@^'OI/!1O;K= B'RSCP !!"*62H_I!*MA4R:/: T9S7VF\4Z M;VP4-Z+TNP_F^54%U/2Z7]\Y'+KOJO%+O5 5P/S+/<^UFSUG@Z,1I#@:; M3/ 4U_1 U?W@I2Z(6T]\-]RY
@$&+Y^5\7(WNVQK<2]VL4OOD8M=GM3-X]5_M?:OM%U"+^]-T]"_+6M1FU+).DX]\V.C=7RG#H,2@!!@H/7:,U.F!$IINC#S_M(\PC#_+(H[M_CQ5U5EP0_E7W-
_EZ+I^;+/1T$W>CEK#^S!T#G^4^>V;L=W MILS)M3:.+;N_QNI5W MR+S>)2L'<*G,L3170&65JNS_K@.KET5RV:?"O;B=?A0'67V_5O+=!I??M =E M!RK:@O>E@0IGXZT9U%5"M1
96V_=8=E];77[V"B.&C1)W1U6=0#N5GIEU9JE M134#!1L(5!;5PIBJ+608B)'I[H8#=LLV4"+,"Z4;'KOO* MPB=!FN9XE*]3.^N'V],/7=WHM%55^BKZ84F8RYIBIU-A0\5C&^]ZP-(NI]>H
MG&Y)2<]1$9=[]U)CY-4-S5= 4HDO[LI'2D1"SLUG,^ AU=0OQE;!"#W727R; M37!5E4EC4V<?ITS&P_#3/M>L/I=7#L(9S<+Y0[6L?!19&1S8Z#=3/6G^8X,/T@_ME82H7O"P2. V7F$Q0Q,58&E.-
ZZ,L/6D1PW9\.7F]E("[EF"C*7O@\40Y;S6 M$9;IO4KO9W\W67G?*UEYOQ59>4S]JZA_5=:B!FZSVO4P]VE%2I+C#4.+C;!1 MEF,[7E"92$:.)MCT9=$A^US.D!AL:(?M.
[>F"_>O&];Q<(>2\E\FLZG>M)7 M-#YU[6ZY+"4V4]-U6][A_:V]WRQ>.1'K*Q- 0!9]"DS1D])/58=[.9V%\5QJ MI<6:@2E6HL!]2\3=RC61>"7=PEG5CK!ZWGK78RQ8WD2>+C1:GBZL7H?^W[O
M'U)MN6?N[P$ N&\N]]\T;/V0*1" _)^]MI+MW +3AMJR/Z%=]0Y\!BSW;8\1V MW/;8V6&;X=CR 6%LPDAS%7E:,I&G"6DB;]0UDA*OI)K"PP,0!)/:GL!D< ' M4"4K# :,G4"K=HI'(L4P2@P^V4K
KP&FP.*7[<.A"FR5PTR;DQ?=+I=.;Z]F+ M&SS,4VH-^OYPZRI '5ZY#HCPY4S;!K51+2420DG55-YG$#)Z_@UW(0(%"<]RI M^:H(".OX]]F@T2]?;Q=47EAUAW.IE0&@&&55^: S4F=8FFK@7\
M'Q'E>'CJWA-8)[F[20R3)4T70."+KB18D@@4Y6T09[B+>(T\4 H]-T.0M^V/ M[O>$)BU%W2%DKID7XS&8IR2VSK#51=%'ZT^]\;O !TE9)*:=Y1RD(2M$JIX MIV.$-[6D.\'T)0N)KN\CFILF >61
K$"HLW >L#WDK%B;'DQ> _Q1(?PJCIW1!72;H6A*B0E0:$C0N!'4,L,M$^ZC(MD-Z'_HLX(IZ18SCHC(:]ALU5SAGS ORW4G/P>V56F;-TZU<\X#PC0%>+LE1Q MQ3B!K**O@6T$S!Z!C31*8N'#-
*9TT9:.XS0/LV 62OV6."DN=4C%5-WLD)(> MJJ[R,FI7X"E'REC]M9:/X]U6.5!TFH]2F L>_:*4]MELV+$0^D0 NNKZIEOE M6+LWFU8[F@;5&W($>=MR.$2R 'PYAH/)5$S=
[53<060^UUBZ0KRK6+>XJ:.* MG2,)1"OKOB3@F+^2?RM6Q%C< P?:=X0?%XY%A=1W:+27/?U7KI2<@OKR..!M M)2Y@HO#-C0A"8]#'X>8VP)LI%;OEQ&EC8I&ZMY/P-B-O6Z8- ."FMF,,&IQ+
M1A<4X)V9DD8;YOE TR;75NQ& 7^49G>N.2Y;E@MG<;K_O.! GTQF6\75%P5 MW>1OT.((KBA5CD*DVA6.OBJO/F_R'VUO67U&SZ4-I%^P(R;$!%*WL8@@@I7" M3^'??
B)NX7D0;]>3!XSM'\]G)]9P8LV6)\I:T.;&&$VOV2K]EIY28]M=H\;^ M:;=68CH:?PCE^4S;%*:!/*F*\;FPTT.Y 84PI*PBAH5$3H%582H*(YZU=V M=?"SO5J4H/11RA^]G=ZM1LKHRCMU%64CGL
N4C=*]4@66)V%P^=M392"7?-/ M5&&U1$QC#&VC+P6T5_RU$8C_5;THE2Y-SC())C091\;@)I\&WOY^+2GP75QF MN2QHM=5:*:.ER_K?W(X[C;1S\!6FTZ^#WTQ M:94:DCRB"Z>1D-
R6M@IL3&,"!"U(3$15@R4-[HSYH%2[+,X4<;@]\5C?%#2 MOLI%*,^=3#Z\BZN<,!@P]]'TVDG$6AR(=V4:H)%L"OP5X)_ G^ZW7>6ULK^ M(M72T"\0FI0,;PQ,$]08?
<%E=9M#G*Q:A596=9(=*:A " _(U*H2N:!W^E$ MCV5>NI64]8 !,Y&@ZZ4(.17NE[@(&VEM>M%WVG:[=F_04X&BPB5:]W-BED49 MO4*7B=1@TNX.D;K4TTWK"U"
F0NN7#]3TI8A17@Z17\PW@$_1]Y\@9R!+ MD_*%V68L@@1 (T M;"_ Q5'I__LS'N4ZQ\ELH"/.N9!AH,*4)@3124@%9XZ:H6NA:>:,EHD(H-' MXU0V73]=D@FY]/%H1)C&JWX*A!U.\VGI<3-AI?
(@']5!IG:5@*"C#_4 .N$+ M7&LAN?9P.22G8S@%6E'LOMBX4B#50C(F'![Z0TR-%U.59*((&? N4PDX?P Q MDW8!FD7+U@XHH[JA$GA'3(")QZ6EL!A=6JQ3JSO-[W71]< 8OKA4@]Z\-UFZ MU2&

]>+PAA(\%QI\0=_(1.OURF>W9!C4WU$S#319GJLE_.:75$:V\)A0\<5\ M'#HC'O;J^&LQ]_>U;-SB#>KPK4>]J4 MG?&8,JYR$'!D@^GS] IIW#6I4"T@-3&2%2T1I1\,GWO UB]@7=U_ M+-H$TI2P9&(MTRI*I()'E2'5U:$>=#&GJ@301%<9.W=] (3 .D]S(1O'4U>5O MAVQEJ?2;K=:[)L*(=HL7>=ZE?'M@100OQ:((KA=F45\Z;JQ3!&8HIF$R9-*.] M/(127A*G;4//3!
<=>B>A7DL\R;ZX+L%)4PR+X4RV%[:]* C"61KV&O44[NA0,JK0K)X.VF[.,'LKQ4$ETCVO!>C= 18W(VT+P%O=1W8CPWBFJGEE!+LE M0N)D@AGQ#@KD_=&?(/T%!B M$"B9RKX6$=6;-'30PDIIJT1E]Q:1G7-+.'XM.=[M:1C)1+A$/ MK6:IJ#HX8115>5_O0)#:HX8115)*3"S.\[]I E%ZG,\R&?@31DH1R,:9I/9K$M*R^WQ'Y\5C],&-'RY.^S]!.JZ)OL)V\3,;..2(=4!")UZ'Z1>&*=Y8IQ)E1G MMHZJ*2*POZ_1$R7C6$D@3=#^1B1!#,M07I>Q*BB@J9\B[L?8J;(KC,I2DE*M5Y47)%X^19>49ZJ,8#YD8L*I5*$1)E?1-S"E0'G&8,?P8/Z9^]=]1T%ISW6[
M$%!4YOCEC0CSBKMFJ:>)VM9$DN(#D_.QI!=L"D'%)2JH!:E"^Z:F%_62IZ M@E/Rl6!!29'8D%;/4:U2_8)"{)4S5?ZF:H4*:EV4:&4>P-(@?,5(%FZX??,& M[A@R/D55CC2:C#DC6-1GO-V69P WP$*]DM'$ZL250U/A5^B]>DR*K."GF4PJ M%#,!(0'$DD?&<UR8RTZV%JE+PROQP=*!H*BFAI)&"*3".EX=^!;2PXLU&0H%' M5;N>U*33E_,W,ZJ, [(&&]@B1QS0T Y\$TSA6-
1,5\'2/MJDOT_8/TF(E<<>MQ:77W1P[D"EE:QGB7D'*V%>!&O8(7=Y&6/C@ [Y,X0K;19!31.*Z"&]V^Q!3ZS,(CCQ-39'6ITB$3^>!Y26N\G\N_7]&@S_(1_*4G M19& ?VB\D'BP9>$N:<$/S*1D*:,7H-)@LK%2:%27@97Z*JHA]"6-I(88,[?[-M1(G)[42I>3N)E^],JSM" HVT6XP&^@-1-J:.MLU.%_'MXRTS).JZ#E&VUBB!5 M"OR]ZZ85ZJ"?T@471[:F5%X:H)L9]O!T@=>>'1&<0G.F%RE2NX,_W()YBU)5.
MW.UZ);7U1PO,Y#-,5J F14HN*88PZS"H!\,.10W34P(;U !WJIRC?.2E5@4^OY M'E.Y3(SFD952M7NK!T<(,$=/L:\K"SDU63.^BN@D,AZ_"@=8@?_2,YM;X+8S5!1EZIV/P$G\(-0_[T?K(:UG,TI2W/9FJY322(8M-(8?O?=5S*P%!.?8I,_[-XJ^V MWUAG(]7F-9$"TA~4A!UV1:/=/9,J\;O=!25?):A^N=.=M\'Z>F]-)98>UEZB MS8SB52JG7UNDI,T#* [*K:0.:\X5YTM1J7(F,-WGI.$R?\S+F?(&
<+$]FH'H*_=0E"HQ+L4Z("R&&/ MS-F3#RF30([B:NZ-A&KSU(<+<@L5@(I.D9BS?-#$&=~:9J"K$"&V2C#'R*C?*F%"P"]RKQ2:=*+*0ZA,$O5#VS>/D!^VF+?6&WM9$]Y*I"__G/
M(/B33+_*:,&?N#]T\ ?EH7%Q3^=SY>_OS;ESWB\A_6Q1^_7?[X]NGGQ>4? MK^"D*GV-[3]#L'O"/W5_;JP^W(_SVS+=$3'9>C):1O$/[8;&Z2R7ET>8M(Y=5\= MW3@9,9>\?'/5> IPF*>\(F&++!-
%4! M>Y4V)U4+!_2%^ #?]8,\':/ZF.*&NT UM[FZ*B6A'(VHZ$1AZI*6,DBBQ!'F MJDER 2$9N[)!19*F7;GG3"> 8K;MN=8C+HJ[8=5TRU/:M/X6W\)N),2#4S&W M'P@)5=Z-6A E6306F.^]9B
M+-6N%1X#:EF -=WIVA>2;%6[U!YC;;B667EX-5"!!:DNAZ>ML;U.0NO?P5^ D0Y0U\XNM5*V[!O<&\@+ER:;+ M@ZFFX;A.O+U6XW^+CN_9)=$@@[/BG)VG[*?.M
KJVE.X3DM3M\'>QIG(%M#6Z8<**J9I@YY;F6^P_Z1W8))9Z$\/!H)Y1A5<] MT=NJ6]?5OE\1SIB2.^B]2FZ6/RLD*D7%@9EOO BJU.$/D31{GJME*:Q][;50V'FCB7_(:K:N28@MND.3!]3Z :GN-
$&D"EB.^] N358Z%VB:#;?7 M&^U%RZY@.D+%536.BI-Z[%5S"](U50[;B+GZ7T.1>[2?.=G4'R_S&6AY!&) MJF(7I1Y6%%Q:"PSK!1$U_YG&H(?1SS-. SAU;.7VZ.M9.P/)BKZJE4N;(@T0-
LXG"!&P2A-V?DVOX\M^5GD!*4U4_O5DT#*O5?EI< MWO*1=E*X[O.U7E\7LW7!Z$%&X 5:[HLTK0U2A?*$P3!IF2O&K3;&BXM@5%A M:]?.@9I=I]@*F5?#=PA42];+AHI$U\4@C&8XYSJ-[CYIJ!
<7'"'Z_]:RHI5ND:T.W ZZN>5>PCL"ODJ1:/<-MK6-%$3LN2=F,Y"67A5E. P00:8H-+7 M3(EF?7.O0:.@\]((/STBA]G_A7GZL+<3]&@(H@-AI9-@C'E F#)A+O"N9KE4 MLV*\N.C?6B$^?4-
$E>\)=3+I32(P>LYZHK80IY>I84>6IKP5C](BW(C1(=E M.[>Q*]:J 0TQ=L+3ZJ3-(B&^Y GT7+1Z$K1N%("FHP0I9:MWMD3MI-4GO<* M3/(I9OK^Q9O A@:);Y]4!RG=V;>@%'.+=:7*MP*!@
-*W:0*\B+4?R@4E15 MC%OB7CW!T> W>GEAS!%%$LL<'K(1EI:B?%,X0WV55L7K%2=*Y]*+565:2[^Z 2=4M[2)PK4#K,BOK /V:E# [@ZV=?[M"]3EIW.M8 HQ6!P TKQ.5J*:ZQA*C>N
M6)9N^Z5^K1N_XTL18]..:/#(&F@^)63Q#]S>Q"?S\.C!7)13HN4(E,.866B7:]MG0BZ+6B0JOFQCJ:I7&/=*:?(Z:4VSFB4B:1(>_]G MG@0I&'JZ:S&I$,H' Z+G"FPCO-HC117=&+*]]\1?0:AI
MD_&'BC%H)2*.806INF44I/I(;X\N/0&)*:T\C.$X08L=Z5P@,!-=KG11,R\\ M 2@YM6),&?D88:,T>^74+?>\|'%2] A_R-,FG4*CY]VUL-LE3.A23
MCDVS@9.8Z;.,UW$4]4LUJQ4ID+Q.WP2+XZCMN]ORR=Z@[NVQ]NL]-&/+A/*%ZS)T$_MR/%V-,%:=E4C']"LNPG&=8S"]J_;T7E.M=!!5 M-7%%\ZDL=*LZ^5=2 $P#YJP^:>V'C#& 4A)
H73.D8$BBDG^*R?K+YWDRCI.M.ZGNK-64'"S-742Z?Y7Q=M2YW"X;6]1V!H8N-L8VC8W4S>H8O PJ5ZT:Y5;. M)36E6&A+5& /VU)WHM&U$WCM-K^UA!5-
14S%LOHB$=4H)N*DD)A.CNJ_ &ND%=\X$ZR>,W M;R_4":KHC%WW1))5IYR0RBE)]'F?E844: PS1$GX8[RJA8R6VBG:54]%89+5 MK$Y]:JM\'W3J2$T464CDZO03XI)9T8UA01)7)ZLL0^_
)":)QF$OU^6HI/IJ7 MEQ4L. 4H*:,2/BT3&RSR95%Z 76LGI>2?AD_5&H*M1:X7A0YFP1QE/9+K1E M>]_ NNTN-MP$>5Y>C+<1(H@CIY]#G=MWI-&BD.%
(JDLA08]W9;62LOF2Y*Y&H72WC\B;I4[,EUNGU?>6%%C-C]!T3@7*E\)W>H*Z^>4>H698]!D>H5S\SE!FL)!4_C(BGA_MX=M'9S9F%15]*G6JM%6
8)FU_R'K26C,"6P4.Q*DCT0P@#9A"W1+>VJLF<3" MOS>*4=GMIG5NX)OH%#>).)%2EH/2Q O\-KJ+):TN*?E/+51>)K"[$(:7.<+/5 #U86R$BQ8(9-,VEH9FC9):#GE2JJ*XMA<_MP:N"-
$K&H+IGT!AS+ M5H1IL"C*C=!),'E3'7O&'ZOYGU=-O6K_EB+(DKKEZ*LAX51_L1$SQ4MJ%K?$)-9;6 MM!J<=0\)%I"E%3A06G>*PX0Q^F,P+8#N!5*Y.T+?[J9T8,W#:%+7CT%9
MDUZ>FCN5S%2O,1LP9J2NGJ"U_Y*@;F1(D[^PF\I>=<[LO2D1ENXD\FZ"-J7.9 M=00M78$5.F-V74X9&L:"2DJY1O3JVQX.]T(C"F
MLZX_A7O5E6KH()%C:GFW'$18W@5;Z9_J9QCY+OBA#&8^]'10TAUL'<7-565^ M*$H@$T]=16@J3711=AGQM,CR*T)N\ZP._%R1#6'2?DW>_V8 Q5.T/SU;6;!U MZZ/$ 5NWSR N5@GNA-
GP3\R,BF<8+=6=%];P$FQ-021:6 $T67R@](=*.IB M[E(GL9A' 36MUC\-2UR!DE4!2]!D7K4GW_TRJ%@@K^<"_L)Y[V(PH>JH_6* MA ,5XUA\"=-Z9*K&K\>DDM7D_0!$4M%$0:<(3SG-
ISH0J92@:HA:]+14 MAK]A8"W J \D<3',TM8:GW:GX,$TZI4%OLAS$H7[DZ0I;.W7FG'DM:/\@2G6" M?8W8BA2V%:,6PYN?3FC5(UGT9*CMG@\S5/(1\PZ,> RJN20:8;2 L>D:+L12 MU5 >P9M
6[E;1BAVEB91-C&KW#M8)'/8"WFY90Z$3LJLL(:B21O+38(T+ /N M=2&0,L#*A'C'!OGR58H$+Y\1H=2TRL&% /EU;@'(,68O^OG3:>K.@'0) M> 5]

MQ9F_-5M_*VDSNYE_]^O=\<^]+'_UZ3C MONT *^G6>;RD] 73YT1*U";7873AN$]W&(H?PVT@]+0='T8&ZMA7-0Z"VGVE MQFIF#G#.3*$E> F 'Y0SE%%\VX1:4 ;W2_C=HV_'5JFZ"2K8A-_\ 03_\8K-MM@PDJ#ZTG,B%GG=XA<2/Z@{}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`Z3>\:.BXVO<-8/BD#!MO=#*0;A$-M##*\"[\'!_^OJ=A[F,E,S $XR*GG2FW@P:=R*0=#$_&FMX)\$-TJ^&%T0+T,],'H8V'4V!5=3HW]]>H-MV_;HU>^E#HF7 =D-B-6N17{X"]D8^C]S7@.6H^-=.X^X!WH(0!>HW0" X>?C MDX_')W]D'-=1,\'N0Y@X1" /59)&&*>7(M:,>(5D.^.$FE[3GT1K&*^1^Q\Y M!] PH^XGT"$C4QP5OR:8:KR> FJ3#1RZA:.TWTX2U@!F9) 'RHD?&2=I?+QV MG*WX1D@2R]_D'XOXQ=_.7Z06^BH^AUA-XPH1XL->#7E.(S]OWS7M}?[L<3)M$E;H5:,&K'<(@% P_8&8!6M^=WD3D0W('DWZ2/+ M<9M6T.R8HT=N LI%RF_\! ,8!U=Z_,4/.5040?#KV%,>G>B]'+5[I M<!!"%J}[[*+_6<0I&$K]>HZFF#P MXKMQ-OB\!56$[J'42/.>8NXKV+N@OJ,' CTOZO9,?>8X>P(1V-1!LEJB, .W=N M>R06! R&H TJ@5D/+<>+/OI65Y2>BF&T#3F$$%,ES^!,C:;M2\Q>:\23_#0% M-V$ZSAE5^M:X^]AKE+>.CX8V!NOW&*K\=XEZ6/L M> SX8RB+NT?F,DZ?0NPJ>*7L8WSM@]N8>Q%VUL6S6]OUK'6(BBOE92/>;.Y;" MV(W\K9KIUJJGU_6;VIL47H_/5,5UG__RP+6M$I4IB9FfV?PQ2M5,_P8MM]? M.1ATL;=XQI&SQN(O|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sG8/3H80.7=A9^P\N-*7E=[6F/>Y,9SU2M)FUQ M9:,U9VN/X60=P6DIQ#WAWSWMAS*B@(Q+8GP^U'8P)I M@-T10_5MQ]=LA!*6UWON/@7;^XP1PBW^Y;S]L)G5QMGDE=5:$6"& M4AQ]=7>'6;A!{_=K=S^CMW$.@M3W*][TF)\CH].1P]PUQI+X]AU^3.O3EGYC M46;Y;KT'FEI/S^;?Y;WHT7$]4:< (==VL36TGL M.;#"8_\+1-M DTKA_^R\ M0H3%D 3^1A+S.]'KZC7?^?$_+B..>V2HFQ]7\R6^C-9.(."=SNB8(?$]1R__MW=)!(:N2;^=+/W "UW=(IN,JH'%-!Z&9,4;,5?SE"M#9+DA({U$"I6C\K6T[U M^O6=WQ?3]83 ;MNW;S3@SH5WVE# M9\!NL>F*]V_L-Y${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{/)VCR/ @(KO M0^)U)/;VZ#BMDR=#>[_$6,DFW^?D;2*A'<2K$T%718]NL_D<3D>W+"G!)Q]. M? SJA]CGT/-7/OU4JD%R[6TGX"VNOYSK.GAY=5 _"[/;T&L9Q2K]6?.MP98 M#_XW$F<^L=Z9 ,1S73<_"&<18"VUH2?7]MTY(,;$#+.O4G5=I;VQWGH,JD_M_TZ=B*XVV4QU]=T+1R? FI_9WPROZ%KL%Y, (OP7_[&V_Y_ %0]_EDI&5K\ MA=*RZ5,91-_^'$J-KEK\VP2URKVUR2E<_A>O9"E/_?B)A_6R.1+#^N$1!BW6RVFA^%T8&U<&+*#T(/@%=[C*,/M4X%/HP/ M-[\)W#,M>GHW[K\C8Y5([G^AG)\][^8\/%#R#_"LK_#.7\3)G_#R[UVPV4-MOGHN,=V#XE?0KDD'M%S$B!4WXIA7YEOCP-W=0-!&>^QX6P_IS,D=A Q.p&:1X MD-J1=U)T*?;1*+/F#&M M5[P9;_D5ZDQ%*\#(1@CM+R1F"X\Y) &][>&MXZ]\5[AMBO9QN44?PII]^V4; M!E>@*CCD-GTDOKMU837/E!PPMWG6%!%O:SEB3N>+",>#&(DH#.B/ MO-1)?!O2&=OQ_^UZP^]9@S0MS/ZXS)Z""O5TMM:CISOU>%;.+#72[EY[#LDS M1 X4O'L*8!D'#FVK++P7A2%1#4_3V ^@:#LO?.8+U;"VC_[49_%U06BPLX-R MXO0[2S##]]8_K2-GT_ZM'D[G*[RX183DB'=WE0.C)OMI00_,@I5D]\BUW9@-/I3]BYXE] MU>S =ZGO!,Y87E9Q-MNW.WSMW6V=)F$#'8NY./CP]^4E$'.YM.S>N3R'1!,=[-K BX

>NY!L!_BSM98?TN)(2^F>"/@T+!V=/LL6<,_6/K$TIA#OT,_""! MH/FK:Q+SNL>$N.^K>+PIO;ZI-20,CL8K+$GHIFE46-(E=:&4A!!=N+56F>C2 M>FVQ!!) 38ATI2I$U?!TN2"'%,,: (]Q9')* <@/E9"S#[^D3I?OTE8LS"DQ9 M.0S[UHF6$<,"]5C.DROVIR=]7!A4G @]VPBH.B,:*4LEM!]*X4!'U+U1"TM M;U4-']8R/W5$QA-[+.AKN$W-!ND=2(L%0T]"^-DN?H4AE2\"+O['#W[+H[O M0^(M'N,D&+!'$$U.ER"?KC;'WT%>4G MK 0*QNZO1WV. Y +-(9 M5 &*$L#9+EY?TGL,6W1P>+. 3![$438PU)63(T %N<*578@+GOU.B/V?#X64 ML2](4IG;GAT.1B/!K%.26(8+053^%.2>O4 T1%04WW?W MUIZ] |@=OO4P9)>,O-)CXL+^7^G3D3GD.SN.12C&U3\]39!$&4W$BRV"/XSK6DU68QOED4*;//#A(ETS:WFQXASMW;(]'8.M7 MIIC+TOH97+8.PQZ.,4 ^,!5/OC@ (O'*OU!;'GHH4RI'B&&$*.0* MNB9O.]:$TB_5'E_5W*AYRCTGJ&M^+&4R6YVFF] @.1,N_(!STLBAWVX6#D25 M #L8@2-,AQ(QU#89&'+,3$]#AM0]U DV%L+X '=5{[XR.Z]80GI=@Z1X"Z02[? X\M%WK1*K,\ )6.+T7Z(U2!879VD=0@$D>7T1THW.9S M,9$C5/H.?VQK/-G/N*#R/&++)'O;O#"..!OS_K% 0&HKO M?L]DCMGC5/T[/&=OPN1O.+G#.K@. $^2BTD/$/$K.'>H![DS2B-C4*X*>V!3 MEM .)RAGZDC,/GM_%,.^[5FN/6]D ^LZ/<@,4Y0HT@4@.;SP"E1=.W-T-@/8.*^W,H/H4DG3K,*+F2T^"DG]!PZ!<.04+O()03RH<@X0Y""'|AW M$K011*\P||K+ $(F#G.G3Y+3S0_R!*MV1T MD20\(WD4OP265C@AER1[E%71M.2EX!ZPDM]K@<'"9RZOL_K0DT(%(HHUG-UT MEO >[^&#V.'[.+C$7*8 4S[3C:RTP. M!OQM!BD&%YD" #79WU%%=H>=*#:. M, IS"'27S3'P9_0"E+.@Y4K![Q#6XYB_UH=MEH;Z(\)<'$N\ ME;D)2:KRJ2 ETBD0FT9%,B5?2:?I7$>QC.,3S8ME$9@+.5!$:.$0@G#*&;\] M 4A1XVB\#H/U.9P8[":16;$LN6V&0 PL+E.S67UN0Z* RFFI$.ZWX6+/>8!.M"0426"R \"\YDD M>[A>V:99C=2$<52GEE4XP8O8R&:>4/E7PBVIMK#IRB. M]|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¥L=*VD1.K[2 M&'T0YV 04$^G!*3$_%$AZV(.$]B! UBV"A*(Q$>"YH4>)>2'[*D,S+%D!\1F M:T_H%8@492EI>D9Q#O0*4C*KCR%016$7402#GNRY (;WU7#N:Q$F9L1_T#@N7ZA@I>*]]<[R-L"ML+'A+<,(3O@5$%/M]XQA.8HTU<% MXC$SB=;A?<:=4"7&T]ATVH4:NE:L[X-2=Z^+QG9;N;IPF6#8@-.UD<@PEX_M,2B7]X |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

*8KG6V'+25DYP7*Q""%4#L7 F[WG9-6[V*XJ#))7*0)-^]E?G%Y3Z MNPAE5)D|\>TD1X3Y|K&RLDK:U56)*R$BL*.#;,[O`5] 7_=]P>Y$$E>VF;^G$ MEBN3<4B_UDLN@58!&2PC!\ PP;T]P R^&4_Y5@$SZI1-U@@SNRWEAT)RE$ MAH%V2+3M"Q#\'Z\4O2'"%DFNT<(> 5Q3N]25!O MX\3$N?8-V-!W2#KO6A,GI@T1"&$0>NE^F=(R;\H7R9SEGV)# MJ]&8-U-*C2'"=X)A51/E(L%;$:NVERCSTY!8G.UVC;23$Z0I3&TPH^P_NZO MT3)&S1O^@.XNDVOL6;@JZRWH@!7&<&H8?MJ^FEBFL+,9?XL#E)+C3A)&Y>JB M42_[Q-%0\K-7+XQ@:Z3)]441[C?2R:KQR9]=7C_;Y"S((]W3DTBOM8*?W378:WY5T8(ZQ9]&10UP6<6%=1 MK@NM!2];3$US)\B1A>_-5BL@FN3.D/'PK7^K2?[/:K|TRJ'[!*1IS MXW"VM'=BM;GO#G3_)_PEM>=5WM()(H02H]1$NXB|K QJE^Y'?1>G-MM5!*X$ MT"G/8"?5-A4V5S1*ZF'#.+&JL.&>V(;3O.5HFME?O7)[467Y*RU%]@!A@A$O M D;P5O$X7*^N HA0-Z1T$X_T"2=6O832 .=M&241HDQ2!D6V(;J-X 31A4Z@ M=U83[_2W.'G,4$H>[8@*@7_&7\"]R)6]904OSBQO6\ED#D]TTW5U@E"+M$V13X] /C/$2)*; QQ6U!AP5-[M5MOI.4$@T<&?Vl7TY[J:3OZ'.18(=%56 A@I8&A/V3_1YG2M%F?_Z+MP^4 M-KNDC?V)/CZ%3%)2<("HQ"YJH[NJEQ/$E8YD*"\ 6C?=#YR25SQ_K0-[_U6)_N.YP1#-D^I M>$ON(=A$&1&N:`^\$03*U[ `!|@1{4G3Y#MXH;TM_BW?FRIVZA$<"_^YP*N1 M>M%-'*"W_X4J=^D;,,%>3 JJCUBE@1-3%ATYI4YWCCPP2;_#-X\;+6/'VUQ! M[2,X073?-_;K)%VA$/P_V4VLCL$?X3-.L*\9V5QXN"XHBH(N1,N\MQ/$"L^X M;6]FBJ;VI8SR4;1+J(51+R?6]+FE[E,$P!X\@?/]#8X?PMK+$G*0:9BJV>8T M&WRW+U:P)3O4^^H_0!86T4#.%D M^3UN[&*33DZl`T00;U"1V]#)KQR#=0=B7.0I](`MQT^#OE"T?LW^3BDCW4G.GNI-5-;*B9UP7^0>DON.60<$.$VVE)KF3I#SB-UJ ME%U7TY$UXES=W:+K>5DCJ4QA;/SH\N>K4*FWVA!&5D(QYENB+,RL?VB++'0 MMJD.&L"}M;OR4K *X?V7W|FA+UL:4,G2)"9N_3Z>$JP+HIBJ1+3WL1)XHH) M.D>%-EM2V=@)4@":R/= 19+]CVS.,KK,>CI!L.@!,_N.S'A!T3KH"S?>;[MN\IN FY#!3X_5.3EMO6R+[O49QLI\&.)TU9+?SFQ"IP1 /5L[SXNQ,3?D0O MH T^H"T$7\4O6EPG15LW"!FNYC8U;\=X.6I\Q G646QZEKR@=H$C6YO=/R3F0VB NR49:E7D2_$] %B=!L{^3$]MZA'*): MB/LY0,Y[+EL&K]:%>G3FY^$KB=N6+:=Y; OKB&5]V*$T)+#$P39_K26BZ]HY ML5H'"T>.&\%W9$:>\)[67MQ\<*_ESI,.38 ?1?T'<&-FQ]U(C& (-L8TQN3! M%?RD3PG\D^#?&^_V-/VV$XR6V:5@,$_">JR\8=M[.4%<]0;1.HH439T@ U\- MF-/Y'K3R'/85/NY;F*8"#4C7W@F"9-NGJ`_`;^7,_1_D)=*>)SOI^>TZAA.$ MF]_U.OVV^RA.$"\KP9L5^6L&R?>:? O95HZ]AX'O;ELP+62,GUH8EYZC\ <+/-M3DQ7,(`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`CO'e"B M:2A$F%B3G>;"""#$Q'-1 ;!1>10GB/_52T-8$E*17GGV-%LY,7E(U,'-0WU M$BH)) <33PUZ!M$\M;=V<(*_T>Y"R,QW\^,WV;A!$,NVOND$]2)L[04[M>4M]`M?*0-[0K[-/_] 0PQB1U0_=&Y%T$NWN,:H,ST+,04/.K0WPF' MN8.)"2555K]DF1/3YW$("5=OJ8ZC@0K0]W"'"]{,QD3`1(05=:WFA&F)P)UAU MQ<-J.63)X2OV.GPC^7*:O 1E.R>(N4^359BK%/CR5T0$;,*.13Y!)3I^2Q\G".-R MZSD)Q?-SB;,@!%O&{!FDA\V@GQL$0J9EAN4 GNEELGO.5[N(YU43K^5-72"|`:L+@54U\30&72S?_V6T/DL +QO\39;.:+$FK6^G6?>2%36\ M"GX1WZ>A'!UGZCG8WRVBf%26O^1_;D9)=.MNGUPQ@A'"&.{0}U|'}.%FT-R) M8\.20FC2I](;UVSEQ.2U#PA\VRQ7ZTH9G09P@N1&H18!+TVZU:A@_(E0M9TC^M2DYAlO9=(A0&^83UR%`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`_`;^7,_1_D)=*>)SOI^>TZAA.$ MF]_U.OVV^RA.$"\KP9L5^6L&R?>:? O95HZ]AX'O;ELP+62,GUH8EYZC\ <+/-M3DQ7,(`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`CO'e"B M:2A$F%B3G>;"""#$Q'-1 ;!1>10GB/_52T-8$E*17GGV-%LY,7E(U,'-0WU M$BH)) <33PUZ!M$\M;=V<(*_T>Y"R,QW\^,WV;A!$,NVOND$]2)L[04[M>4M] M:

*--YDAUQ1,G!*X{1$_4.8:$,-!8+&^ I M%[4-VHP;@X[#OSA#T0M>@?FB@&%K*\S*+N_)@]HUVK&=A;?;>M0.)A],W.75X<,>H MR1P7*%RQ2PGSS_<7D9>U)\&V]'+C"!L P+51?*

_HL'K8MV,\?S#Q.V^#M-&H MM48#]-/WY.G=;++O#AX^HY9M5_&Z(I@F2 JY.YWJ;_&XAZFH2X^>,@P]B1) M@6DFHIX)E2G/IPW8LI/O7AK MVR@[>YJ*

^$H39U=/++NJVH3;Z.O!QG?_!X?<8!9U<7&RQGZ>+T)1=]B0\" @>5DUV_X@"[\"@T I;\AQ!%)14=$ MID&>0R'TZB4,_X7W"<):,+#T_'5Y?!OZ>&\.!7$LL_"@':7"S\$<-I^@RF1 [Q8W=3<;,|>+,76+E%C8 R[.]3-_,K':1R.= MA>M_5)$RQ#]/10KS/ N]#(Y98."O1:#6S/38>PX$@C4L7S",;KTC[Z(@K#? M:W.#;"G_+ XNPVB'14]'IT:WT1P@_RS.PP F%[IB(^_O4A)G??

7F1SN\P;ZQ MZ(%SO^.1W%V+3XSP(3?$<)>]%0=OMED8T(=O)'.=QFV M K+L+ A"2K# LTN4>V%T9& ! @M5[!Y8 #ER_0!>*5YR%:WMU?,5S8E;;",*

*MKH<[>>85<5O@HEVNGO#D,H\@AVJI,>AHC:B;^Z46]:S\W3ZN'(T7*Q$;.*= MW\=>;;OJ;+2[1M[6E;(E3 A3.OXK6KLT??V95;8?.'*O5Y)Q>14VG%]B6_ @ MW[\"VC]PA<_O-COR6@3%V/0O1IX;=+1;!dZYS+2RN-G.E>.DG;:\ MK=6I8\O:2_?\"O=BOM3MW90$LOB_X<[PI'T:&2M;@E8/G%Y(*15^*M>)%W=$YB<9G\)L9F+()G$L6T*

*MJVW'<\%*TVI]BFI)KU7#Q'RKU,"6&TDG'X^C-[T911% M8^:DM!2H:I/(8!,SXZ0Y,>2P]-P&31MF%@QJ]2MHSNWL&*4UNRJ,,KA93YIK MHQF$]>VH6)*39FZ'=XDB/>,*

W46/!P'CW+8G3^+A3C,&-$8VR<=>3V9)EES M!;PS=8A+2VHFO;.V-VOUEOH8T>S+A5 #B6E:7;ES=$}!F66M[Z!>RJL_*R4E# M:Y-

N+YM=F[RF@W6Q0D0$]_]0(E4]3>UQ'|NNWP%)]#I)+Y/=<{[:18S!V0/R M4?BJV?R&G6V6]/$1"C)(]GA<)VG^A-(-['T%/>KV;K@6HNY>45U6W'.S\.2T M792%YFMT=-PM$CY\TZB,LX.ID);,+OQ=LE\-RLP>I=.KH/4L MRQ 1+Z"Q%{]DSBM%F_6&%+#C6_-UA)?PL;XCHE3TW^7N,,,.GI EG:BN9M ME.DZVR=:/,#-F6K=C-W&L)U''2Y[W33)GQ886D[5;8V;TD?WF_>UOP?+:..?/_M:;O8)X343L_(Z?ZD71U=#_MD]+B)&@K6"+?=K?VGL(U5)B]9&^V[>:.HfA. M;C\R'=CX,AVD\PU8[^D465EQLLSDDZZK?5 #\<(V 31HM+>_-L(%!+GSE?'9*

M]DK()O5C9S)^5)-AP6,PN,$G^AB,3*59/#MTLZZD/#0S76;!3,6-4TW-,C8J M9LUPM$NO/ZBX9Y\;>+DT<-)EE-2\6#FF455C]1TATRTJ**$C'6*

*MEU'&8&_*TE??'I]2PO:]@AJ#C@/G?BN.[-D&\@QJLS3HX * /"G^E0%(CI^&-MSR@XW^7?XC#+=BA0L-VP\\"L+WBW7#VM$?^*,!>.IB9;!O/.\PLW.UG_P'NT*

MR7NTR7O'@W=.N_G@^OX"?M#6-W%#O7-X".%BZB,[:33>;?9S!]_>=%"[I\CM M0\,T?SK=Z!A]8,PO IRK.+EH%GL0>Z66L99C@5NFH?_HNA>[^$R(SWL6@Z7 MN?"R-9X6_*

=@IE^]",E+B6LZ6$36P-I"Z.'6V(26U+N0+B7GI*O[%ZJW$-GJYR6Z.%P>!>8OC#75)8= M9&A'&/VBB]AN##P[#"$5[-*D$7M"YC^(KU3+S(R4L,U'W1X\H/,_YQL\AX M*

_49WQJ+JG,LB6D+XFKO=SHFA;I6C49%.G4LX"$T*Y&7.@5E%D\<[?!V%=VA M#_M/?7.>6,R"DZP=\ZV!O\(W"Y%QA.\?[^)1 QZ.7DK_^X(XLR 5D37.\!7/ M=$%B],+EK.UC2.CI'EDP

M-6T:F4E/>P"I_AH%.ZB9KIZFYB7,N+LU 1^2),HNX?:.@Z])%.C?152MK4U_MV:>L;\OKR3!CVRPY2?4M%%PB?&WA^5& AVV$&!7,HO1843CY!E5P9[#A;>;#

*M,?=8<2FFHMWZJM;N25RLNW05M=#%WGO@+HW#'# &X^ Z?(,_Z:60IH,U(FZQ M[H[66"3>;+9I\DJ%@)8*70^+9X)$&)(RD3>T4"3*]'1HN|AA=9EKQ;4]65]U*

MM@[JJA'O1'5P%@SLJD$:<5%D_BRXV,&\$!FHU&YGP.1!E>,!^CQGIX% MGP^]7H;3SP=U9KOK.QU%DL[MD>9 0;ITE>;-M,/T1V*@C9*OD^1>=!2,T^\V MG4XBSRG _FF-4)GD;)TL'C3F;W3I1\Y_6!V.GBQ[UYC3=1PJ8HJ W^%)FX< M^]$LG2H[QK!F7E'ZG:R;*"C>SK$1D^Y0@-F\S-CI:.CE*3+%SA-UTGV3D&K^"4Y9! M7;S;,#N,[[#6P<;O??*

*VI!R@=145C>VM+@C5KD>NI9-#HH-?&\(_&8L16=\3 M5T8T&V$6?M;1&-MV(\S"R66)NUVNJ#%\/RZEEXRV!*I+'071+([Z;XVZ;X O*^K%Q^7RE7SM&PA 7%JRRW M!'H,-#*

UM8M'/V-U8[>Z_)=;.,:A7NDC26T^"@+PR\'ET;#HJ91M2T[IN M2Z!Z=ENVHKK#B6H0?>3HNR%,,70]$PS,YS!I2"TXEC@2BG.V_3DE];,32P0OTU#'OO2\%GKCV?

*MR,V5EQ11$]#,_^]G+YDKB%RPA-K!=6A.8%8T'9O03UEK]-5K&Z#;Q8@UGY0WM ML3*,T7)56VAUDKNRN5,$W,*Y3_6[HJV;O1R_R,NRY8H90LOT 62I#MI8V=XM*

M$K3+H>MA#UW @VP&8L"A%ZNX.QF'@E#U5)CT-%>P.7!4ILO6OYN+W6:78DZ ML VQB2.U!6]I,,%Q4K9T2G5^]MW"SVYPG:9!QR;7A;?%O^2]T1Q=BV(E!<'CZGCRM*

*MDUWFQ<$=WMHY0O$3UAU!55.K=!U'L+8 OWH'"Z_![RSM:R7-+1W=BE;EZ\H MC4$I8.9U_*3>TQ6.?'+#=;>WAZ_>UOX17O'!1O3A0KA;5@HM7;#3CE+O.9/5,5&:QX>"2,85XF?*I MYB*)\<'(P\;KC4XV=AQC^]TJ!40*]OSER8>M;NUQFD?:QRFK\,)'17E&8DU9;LTL>UAZT>V, H4*K,^DY6HU]>6*A**U^(MHK$3DR_%_#G6T_%&N0[?4" :U09$&0SB1C*X/+&W2)8W2[H=*

\K$)2 "?9)N MP2Q%XNPL@%YD$E=5LD_6MIKG>NH;JC4QME(R1)>"">NJ<,D]YBQVF3]% MLU(`M%_,Y"PXJ4VDKM56K&==GC2#%"FKW7V-_S>O&4]?

*K;BCI\Z4UAS1RGUF8,_,0Q!ITE(%;-VNR:*SX)T] MJU3<;#+U:A,,T6>P5DLN2]39+'AD@&I6>C7,TV\GP3-=VF[%H:!P%L_Z-=CN MU6V^+>@2CV>OJX9,,_?=(66;^4FS*

MK9W!_S&+HDRUOO5"2!=O4- UV82X2Y' 5F%B6_>SI?=' S M,^2?4IC+=+!9\,?($&Q' 3KU.H$=S] .9V@6Q?],/2_2QZXQ.'1D&ZD5$FJ4 M0H=`NHN:<0HSY(Y6'AE ?"L..\>?

*O\^"/6D2IHT'X)#C!TV]C3I #S*_3PCOC6V5RT& M?0R6N'O8.EQT.HQ'_E!UVJZ[KJJ4/,EO%%Z=Q [3@VQROIWVD_%!7CN!QW/D MTH%;K IQRAEWVBJ8@S!.\I_*^?2:3N,._)-*

BLG(NS M617:+P\TF9.QVIEG-=1ASK-WL\)4LLF.Z>=WXT+#/D.P9,[+V1L:!X S<|Z] MFQ^FQYBC/G(.O;^O\/_\?D((6<>_34=A#/ MP?EU%@>/ZR3-.>\N4>Z%4;5EL"1=O%$4*::1:(H3F!6%#=+6UGE:T\LX3?G_H M;(^JILD:)75;KWB,@M@<V_M+K/DQIG$*1Z2('O2K'$,Z=4U]APDCZ1ZSZ H/S]3;L7H!:)>GCU(LR36P>6$A*

M'1!X.P_^N((5Y2Z'6J62B;DP"JI/DGO140HFA4AZ# ^K0V4F#0F0?$_?4?2*OB9QOE9YE?N- M>1RL@%5[^IX,P0$^U!$1#AB<@Y%.!AO8^RJ9Q?YLA;4/U?1->PWM)88+K&!(

M&08D\]1;+6PX\'RBJ 6&5ESMT5K! -AUY0R>VL,'&=$BK,O-#],^W9N,,'IRA MLGMO%OC>(W&SN#IG8V".Q41ZC\T"SK*=C<;W_F5@&@WXI=(_1H';<|$S9L C

*MA4XT&|RX{M)K)&@XEYT]959-=A8'%UA-",,7/ B6X&=!$%**;V*'O0[.4K7 MSRVFXX5,#O!K=IDFLDS:U)YV4)N--DA2T=C:Y $8CH PYE>O\'96*R%9F[V] MM4O3U|)?*

*W=ZB=9EEY9>W\$=H"=`UV-P5T>6WZ?)*BRK#@\&_5&KNP'Z9SU M,2U.?;N-A 3*QCM(8_]]M9(.$N1MUS=>G&@F+/08-A)9FDN3M:@ M^=@UCF84W./C/!+%#!>B.*

*HCLT#ONP)>'=#N^FR%2;Y8BK(AS[=WZ:'IOFNZFJ M*9)\F5!<3"Q'6Y*$YJI/3&TV'"\P_ ^P5GRC0 MT@I.?5&F:W7K^YZP,"0="@G8>IP5U7G68E ,-KXU%M$Y%-5LI616VXQW7&@%*

*M8G9]8QU(T'Z,CDQI?XOI *QTMRA_=#@?RO:#9V3@0QKZ,,;O\5A1>M4|\VL MH|W.L8,.9+G;X^ ^\F)XC=;CF(SQJ8&7F3M5H&P-,22DJAMU'N,/JY?9K,/ MLV4OU(T;D'O*

*R1RN'N_OU?/N.L3 %"" J#._S3H.S6^4AIA9A^("'#;&V!P' M(UHBHPY>B"{CC;(^YP.L3XHM_8Q;)$ 997L-Y(4X^>V)HAXVX#C57QZGSLMM1-O"]S".T?\P= MJ/$"S8*Y!EO2T:!\UCXCU-*

*}>AY-6]PEO.I3^?)A4L|6$W0BX'=P:.PUV7KI^Q MA>$ JOW))T6-Z,4N1*ZA;Y@G8HRX,#&XHS]H^>1PS+%7C?TJ_,TE_>]VMVU M/T:*D(.>#CO;M=.C:,!V.ET%PW@==WGI(*-);X8;V.*

YAF=XO8O97D]#8R3 M_?_M?6N3X[B1X%_9F.^V;IS>]2/.%Z%Z]=1%=ZM"5=T3^VF"}4(2.RBRS$=5 MR[_^) 47P (4 "1H!BQZ^EN 2 RD4CD.P$2K#0:5?Q0)C+>7,:=BO]KRGY,*

M+N!NI-_-1#8>A$Q MP]^'Z!U%XDB5@1EP0_"N,39_=/;W_8^W(*&#BT0U$6ZTK&^O%4-YOP3AL:TA MUC;Z'6MR0;07[+,YPO8VA3RM/<9^F'3QRA

*2CB.BRLB$2C/G6$Z4..]&B'WV M6-T!DL_LEH:=`Y=^ADL_PR7C9GJQB.X,;QX#N(]8=V+,"A9[#E4: RU5<|[F M!H6DL-)MG&9I3Q))!Q++++ES4]*C^\H& _=<*85Y'669,L]L"*MPCYZ0-*

*6G_& M;*X(QAX\+9\.(C&?;OUN!O3/I]BRE9[K-19:P_;= MCIOG;P/M8$5SW+.@-!E$45ZE/C/=UA3AMW0K=I4M=BAA;FBTB2Q.14[>*OY5 MHXRF%?3:4IGZBF0\E*[_SL ,N$\%CWV?*

\CW(JX=<=1.B]+$T{G=*^`]$?)[{"F=]Z8J/OD1^["6717 MG.P,ZTN<$2_%1H%.YN>_-#X4%N6!N7/X3&<=3!R?>A'N,X,S$5FF:'ZNK^8:(MW%[5Y=Y@9J>;"TA_=RF#-

*Bs5U243[U"Z30)Z+]U>*CPZD)CIWN5@B@.?DCC5 M'EH@^!)^"))&YX/K9LYY?]!*L(Y8 M"!K0!?.OK/+K'7[_4#:J8WMO#6B@%MU/+H*4OO2,P-"!Y(VA2+RK*&]AI@"+*

*MQBBXJS@%5DAYM|N0^IT+E67@\|0.TJ2$<8G%=G M[]41<[/&"B<2KVH[W(FN%PY4=&]-#T>S1H.Q<#[6HV6N'!,X?#)#L26*8K"# M Z\"97KB"!VJQP;N!)34)&84Y%44MS*C*?*

*%B,F>-TB&!!WY.6M4&'V),]+. M52!2GIO)1_5>154Z)G&V@(DB>>Z=B)82>8+LA2LIXVB4E;2\9";(M%I)\;$# ,)"%8])"(3RJGH){#.76F"FA"0_7CA3JOG**G]9",IAT9:+NI^N' MH|\.,3+*

*KJ12*K_,#8GS4111?6E-L":TF:A<>B4'9# QSD0AU.54C.3:5;Z^ MY3F.D,7]^I5QS-O5ZR9XQGQ?W//GQ?LRC;(!0@%"XLV+;EWS+YL3J0]^-R*

M8N9(="965D>UV$[&BU42J9D5FJ_<&C+N/HQ(#ZWP/??.'9-BG)>;6B%[49CU M$C^$+2HY_%B%XXIU8;ZL!H[=-G4Y/ MDT;Z0=?259-55H);BN5J>^&,BOT^,[9/6+!/)N&I4M^T?

KG!]\RY]$UKL-Q-.M'(8/<4)^-/2 M3<7\93KX?X\ MQ[9SF;'Z0HX(F65BC T1L MIN#=MB?T4B-L,#:U33@K9C;TY#;,F4 Q[WX0 M+L5"=3?*

\]A<'D5;QL=%2!!#O$B:#UE,DONH=&ERR:3M*I6,]M+\+5?I^>.MO9>A203#\?N9VQ%,Q7:E/S|C!%O@+1=N:FZ'T;C@-]B]_WEG$2O,RIF79+-.@)BKAX)-6UC)P:O>1#^K,W&X0!*

*(E-75VC&TC(MQ>U M:NC]D*HIL+PJ #6U4<&B5]&Z!9BV,2 >+D<"2K86EL%9:E#HD:RGCE2^CCOF M2'%GK:>P"(?*)V6BZ-2\+Y9KH]'.X/>EX10$B5&:'RS'!4J:9&8X:#VCOQ=G*

*M%-&(%5@YO[G8.7_[LYE[-5-+"! Q1CG#8V&=QF09,XDC2[LL;Z+) !DL)Z-7 M"AF1..3U"!8A8|KDH^7TG!(U%#.N%NX(T6@B2N4RT0\39IR&,YHU*YEK.2>X*

MNK4H76WID@SGK=.6L;9<1K Z]04Y>28:M,[R4=[">73^Y,#,A(3331<7NZIL8.53HB2S!?M622+[_AO0R[B4V]UPE,<8L)NI":Z0PYO 'K[1M1IIDC4WB*

*MOJ4;O'_Y;4,0R[{"G5\GW=87|T=P5{ ;"T(N6[X#WPL2XR|15]?1>&JB]?/D5>7UEJ!UP6 &9(+;B*8UF]IQ3X MX&@@&|&+WM8!9DPD3M:@0T<+17(G!:,"IB!*

*[USQ^%2YV.>CZYI16W6*9E#KTU;.M?9LU*NR55EH2N.W=>K;R?AVI2X[4-]\Z"LOUT&!XF2[@'KK?G:GU$Z1%*;HY M/>31EOR#DT[WQ?O+0,HJI.LBGPU$>?*

("X7SZ43GDNR,7R67HA2ILN-/\[.EC?X$<0BTV$5^?7H M'87Q&\%ER0N%0.C,M'=S48B7VY=)07B+*_^(E6E"($2,'8LT\H^.MN[,VARL\TTW<#3R'5X$RHZJN\#RN*

*KU79UH'=]Z+B3P0Q)X2H0Y8K1.]XV M=F5RE9(2KZ2]L#+R%&51$Y97'AHAV_>"?Z,4TUV6!-M*BQ2_K=X(]S+<)X M>CD@_(F?R;3%RC<7*_HO5?*

$A(DFIT_(.CL0&O&B,K7M:QR|T[1%,ST3E;^__M6+;@6K:*/>_/" RP[3&+$0Z"$<[<[6U7$I^<>70^/T,$,UH=3(SC_@[@HIG+

*M.&NN%/E2N;M&/@47<:.IHRAY8(TX.Y^WZ3.HI'*2RC#D)6",G2%M-!,M?_O+ MK)'<*4Q!G\8[+):<@VCLX7]X:S,\&&&3%0"GH[J_&1Y1HX \O/-1VMP,#Z?] MM,,[']7|S?"*

(9O'V_/9W(%9T8,&WZN+=-?62->FTZYC9YIZ)=76^>DC(=XWI M=.V.5^&<7D(%0)R"8U>%WR5W[GWIF'XJ/?U 1(;D"KM_7%X+(%>@:YU>FNY< M[?IQ$"QK-X5EI=[*

.4>]"WA2^\&\&7QWAWZ<1;NR'C'|%V>8GP4QSBB$OHA#C%BTMJ>1(XI+[:TWN%3",8DGR$(R^)\"YJ MVA"U7\@P%@[9QM W"H&!H:N:!P)EL##E_L(F.'7&\.#.TQT.Y,R:%Z9*]V*

M;[BK@"$[$2M@CP6S]1*YDINO1ENN/,@_9$TSU1>R5V@N]-"T]KPH/@C%0, ^]?48/=B6!/#[FE=< M=A^DK_/-B;V *,G>X!?MY2E4W%]81;$]."F%< W&V&,7L,(?)$RPY8^WF!\|*

MCA.]SS?'T<'%->RSH.83*CA_/%PL]V6&@F*]H"9OP6!5FZ>?ZFDLK?-MF6/D*MYJN(H*:[CS_!12M1#!#]QB!X6C>3#%&X## IKP#!ZHT.K50[M/5K^5;@9J-7^LSEYA*

)^%8CD^IGU*DKT#/W_TRH:P_S:]-=7\%1+%LUO^*<-M915_=Q=Y5T$Q*H^%A)Y_)9Y:\%@G]87[T=PS(^K*.J]L/DCT;DK.Q#^(^F!Q(%8Q\l.HD486JIA M81CL4NX6-!]E+:1V%*

*<;9;7';<9).8">5GQ_PC/8$M8VG:#[O4PG;!KW%6#2) M]@.O$W>XO?SG.C&LV!*1L\H|TZ+1X M6N_6XATHXSV&Y3F87/(0YS<>]M##X%.WN8->D=1CH;DRI\PBW%Z="">%TR:B*

MF_DUR ZW>9K%1_SJ4<.N0-IB0#_^2_>#S%,2BO9B^OTP6>LVBAAW!M:%X6C>9\MD?)3HK2*]G+RJ%MK3_%L9^N(A]K^.\!9E'/<>@/G*#$1(_*0,#<D-C[D^O M<)NFU3LH$_#-*

*G&.,.8BCM5MCK&WU4T+R9I,8:QP#%X_U$L*VA[>K/8PW3_,! MU@L_A5Z.91M/$*S+'FF:,%D,^O-0,K#,5,V(ODM.]R?$1V_K=VM(/4NF59]T M#@;]X^QO>,#P%&NDM6T_T]*#A89*

=O,5\6X ;Z3%;6.E"V^G/'?NEMNC[/%6 M_""EY!1NH[N?Y##SX/T0)"YWMVA5R['\9QGC[Y)^6*%EQ&%+(-M"MKCDJ:Y+|*PV/#4[G;PR A-*

]RH,V"KVKE%ZY]SCU^6UTE9LHD#MNPZZDU$9 M6\375LRN TGC#3W,("8VK[\"E0)EN8FJEG)]!#%QYH60$,,T>-1Q-!Q]^2IH M1D7E9D@;Z945X-

3%K;2P/M>,89R+7LFU=N8]TF;&7448^6Q H0"#SY;R.5;1 M&&-8%,\EH/Y2C#'J,&N-9IX-C3'MJ29BF&>$L8XI5VN,,, M+,?R_6%;G5T MZ1K+TP8,U!?1'&OT935H#?*

*1TPI;JD2)]2.7Q?DPAX+9N##_MAS/8WN8Q.RQ8X1f?_]-7CW33%$,@F*$YX -_*BNT1$$-\/X@:\A\2;PHQ0R^_MM@J0YV7W@)^/:/L0YGCNH$B265/V3T+L:_V$]H+N|W&('ZW5/D'4-R*

JW,X> M"N0>D$HI)663+HQG8A?Q)/D%+,9[9?@-]FL>)*S?R1MM;?L,2A8<"&^T/>RW M905A###5K*)2-#R4C<(?K[R"!A1=,EX_1KW'R.Y8[MUU\\L?IWDM\\L+L=.<= M/2Q$"?

*@>:YQ/N,R24B[GK(T'VX)&-^9MFI3!\B9,D_B!RH?>&>,P\Y?R'.6J8: